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I. THE STRUCTURE AND FUNCTION OF THE SKIN, HAIR 
AND NAILS 
 
The skin is one of the largest organs in the body.  It has a surface area of 1.8 m2 
and makes up approximately 16% of our body weight. More importantly, the skin 
is a window through which the physician can "see" the entire body.  
The skin is often referred to as the "integumentary system" composed of epithelial, 
mesenchymal, glandular and neurovascular components. Specifically, the 
integumentary system consists of the skin and its derivatives such as: sweat glands, 
sebaceous glands, nails, hair, and arrector pili muscles. Also included in the system 
are the mammary glands and the teeth. 
 
The skin can also be divided into three main functional areas: 
1) Epidermis: the major protective layer derived from ectoderm.  
2) Dermis: the major support layer derived from mesoderm. 
3) Skin Appendages: cells derived from both ectoderm and mesoderm: 
          - Eccrine Sweat Gland 
          - Apocrine Sweat Gland 
          - Sebaceous Gland 
          - Hair Follicle 
          - Nails 
Based on the thickness of the epidermis, skin can also be classified as thick or thin: 
1) Thick skin covers our palms and soles.  It has sweat glands, but lacks hair 
follicles, arrector pili muscles, and sebaceous glands. 
2) Thin skincovers most of the rest of the body. It contains hair follicles, arrector 
pili muscles, sweat glands, and sebaceous glands.    
 
1. The Microstructureof the Skin 
 
The skin is conventionally divided into several layers (Fig.1.1). Its two main layers 
are the epidermis and the dermis. The tissue immediately below the dermis is 
called the subcutis, although in certain sites (e.g. the scrotum) the skin lies directly 
on the muscle. The subcutis (Fig.1.4) consists largely of fat transversed by nerves 
and blood vessels. 
 
1.1. The Epidermis 
The epidermis is a stratified squamous epithelium that mainly serves as a 
protective barrier. The epidermis is about 0.1 mm thick, but on the palms and soles 
the thickness can be greater (0.8-1.4 mm). It has four well-defined layers 
(Fig.1.2). The principal cell of the epidermis is known as a “keratinocyte” but the 
epidermis contains also melanocytes, Langerhans’s cells and Merkel cells.  
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Keratinocytes are produced by cell division in the deepest basal layer of the 
epidermis, the so-called stratum basale. In the process ofmaturation and 
differentiation they move progressively to the skin surface finally producing the 
surface layer of cells which is called the hornylayer orstratum corneum. These 
horny cells or corneocytes are then shed from the skin surface.The process of 
differentiation involves also two transitional phases, recognized as producing the 
prickle cell (spinous) layer and the granular cell layer respectively.  
The keratinocyte “transit” time, from the beginning of normal differentiation to the 
final shedding from the surface, is in the order of 50-70 days. The loss of cells 
from the surface is matched by production in the basal layer so that epidermis 
thickness is constant.  
 
 
Fig.1.1. Microstructure of the Skin 
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Fig.1.2. Four Main Layers of the Epidermis 
  
 
 
 
1) BASAL CELL LAYER (STRATUM BASALE)  
The basal cell layer is composed of columnar cells which are anchored to the 
basement membrane - a multilayered structure with anchoring fibrils extending 
into the superficial dermis. Interspersed among the basal cells are 
melanocytes.These large dendritic cells derived from the neural crest make up to 5-
10% of the layer and are most numerous on the face and other exposed areas of the 
skin. They are responsible for melanin pigment production which is synthesized 
from tyrosine in melanosomes - cytoplasmatic organelles of melanocytes. The 
melanosomes migrate along the dendrites of the melanocytes, and are transferred 
to the keratinocytes in the prickle cell layer. 
 
Merkel cells, although present in only very small numbers, can also be found in 
this layer and are closely associated with specialized nerve endings within the 
epidermis. Merkel cells have a role in sensation. Neuropeptide granules, 
neurofilaments, and keratin can be seen in their cytoplasm. 
 
2) PRICKLE CELL LAYER (STRATUM SPINOSUM) 
 
Daughter basal cells migrate upwards and differentiate into polyhedral cells in this 
layer.  Desmosomes (intercellular bridges) interconnect these polyhedral cells and 
give rise to the "prickles/spines"seen at light microscope level. The desmosomes 
themselves are stabilized within the cells by tonofilaments. Scattered throughout 
the prickle cell layer are Langerhans’ cells. These dendritic cells originate in the 
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bone marrow and migrate to the epidermis where they are the first line of 
immunological defense against environmental antigens.Langerhans’ cells are 
responsible for the uptake of such antigens and their presentation to 
immunocompetent lymphocytes. 
3) GRANULAR CELL LAYER (STRATUM GRANULOSUM)  
In this layer, cells become flattened and lose their nuclei.  Their cytoplasm contains 
numerous darkly staining particles known as keratohyalin granules. Also present in 
the cytoplasm of cells in the granular layer are organelles known as lamellar 
granules (Odland bodies). These contain lipids and enzymes, and they discharge 
their contents into the intercellular spaces between the cells of the granular layer 
and stratum corneum - providing the equivalent of “mortar” between the cellular 
“bricks” and contributing to the barrier function of the epidermis.  
 
4) HORNY LAYER (STRATUM CORNEUM) 
 
This layer is composed of sheets of overlapping polyhedral cornified cells 
calledcorneocytes which aredevoid of nuclei and cytoplasmic organelles. The 
corneocytes are keratinized dead cells that are gradually abraded by daily wear and 
tear. Adjacent corneocytes overlap at their margins, and this locking together of 
cells, together with intercellular lipid, forms a very effective barrier. The stratum 
corneum varies in thickness according to the region of the body. This layer is 
thickest on the palms and soles. The flattened corneocyte develops a thickened cell 
envelope. Its cytoplasm is replaced by keratin tonofibrils in a matrix formed from 
keratohyalin granules. The membrane-coating granules produce lipid glue that 
keeps the cells stuck together. This forms the hydrophobic barrier membrane that 
protects the skin and prevents water loss. 
 
1.2. The Dermis 
The dermis is a layer of connective tissue lying beneath the epidermis (Fig.1.3). 
Itcontains numerous specialized structures and forms the bulk of the skin. The 
dermal thickness varies being thinnest (0.6 mm) on the eyelids and thickest (3 mm 
or more) on the back, palms, and soles.    
The dermis and the epidermis interdigitate via downward epidermal projections 
(rete ridges), and upward dermal projections (dermal papillae).The main 
component of the dermis is a network of interlacing fibers, mostly collagen but 
with some elastin. They are embedded in a matrix of mucopolysaccharides 
(glycosaminoglicans) which impart movement to some dermal structures. Collagen 
fibers make up 70% of the dermis and give structural toughness and strength. 
Elastin fibers are loosely arranged in all directions and give elasticity to the skin. 
They are most prevalent near hair follicles and sweat glands and less so in the 
papillary dermis. The papillary part of the dermis is composed of loosely 
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interwoven collagen. Found deeper is the thicker reticular dermis with its coarser 
and horizontally running bundles of collagen. 
The main cellular elements of the dermis are fibroblasts, mast cells and 
macrophages. 
Fibroblasts synthesize the connective tissue matrix of the dermis and are usually 
found in close proximity to collagen and elastin fibers. 
Mast cells are specialized secretory cells present throughout the dermis but more 
numerous around blood vessels and appendages. They contain granules whose 
contents include mediators such as histamine, prostaglandins, leukotrienes and 
eosinophil and neutrophil chemotactic factors. 
Macrophages are phagocytic cells that originate in the bone marrow. They act as 
scavengers of cell debris and extracellular material 
The dermis is also richly supplied with blood vessels, lymphatics, nerves and 
sensory receptors. 
 
Fig.1.3.The dermisis a layer of connective tissue lying beneath the epidermis 
 
 
 
                 
 
 
1.3. The Basement Membrane Zone 
 
The basement membrane zone, also called the dermo-epidermal junction, is the 
narrow, but multilayered, structure lying between the epidermis and the dermis and 
supplies the cohesion between these two layers. This cohesion may be damaged by 
genetic defects in the proteins involved (as in some forms of epidermolysis 
Rete ridges 
 
Dermal papillae 
11 
 
bullosa) or by acquired disease processes, such as bullous pemphigoid. A further 
degree of stability is provided by the corrugations of the basement membrane zone, 
in which the rete ridges of the epidermis interdigitate with dermal papillae. This 
occurs less often with age. 
 
1.4. TheSubcutis 
Beneath the dermis, a layer of subcutaneous fat separates the skin from underlying 
fascia and muscle (Fig.1.4). This subcutaneous layer consists of loose connective  
tissue and fat transversed by nerves and blood vessels. It can be up to 3 cm thick 
on the abdomen.  
 
Fig.1.4.The subcutis consists of loose connective tissue and fat transversed by 
nerves and blood vessels 
 
           
 
2. Appendageal Structures 
 
Three important components of the skin are conventionally considered as 
“appendages” of the epidermis:  
1) hair follicles and their sebaceous glands 
2) eccrine and apocrine sweat glands  and  
3) the nails.  
All lie within the dermis or the subcutis, but connect with the surface. 
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2.1. Hair Follicles and Sebaceous Glands (or Pilosebaceous Units) 
Hairs grow out of tubular invaginations of the epidermis known as follicles, and a 
hair follicle and its associated sebaceous glands are referred to as a “pilosebaceous 
unit». There are three types of hair seen in humans: terminal, vellus and lanugo. 
Fine, soft lanugo hair is present in utero and is shed by the eighth month of fetal 
life. Fine, downy vellus hair covers most of the body except those areas occupied 
by terminal hair. Thick and pigmented terminal hair occurs on the scalp, eyebrows 
and eyelashes before puberty. After puberty, under the influence of androgens, 
secondary sexual terminal hair develops from vellus hair in the axillae and pubic 
region, and on the trunk and limbs in men. 
The growth of each hair is cyclical. Periods of active growth alternate with resting 
phases. After each period of active growth (anagen) there is a short transitional 
phase (catagen), follows by a resting phase (telogen), after which the follicle 
reactivates, a new hair is produced and the old hair is shed. The duration of anagen 
in a scalp follicle is genetically determined and ranges from 2 to more than 5 years. 
In pubic or eyebrows hair anagen lasts a few months. Scalp hair catagen lasts about 
2 weeks and telogen from 3 to 4 months. The hair cycle occurs in different hair 
follicles asynchronously, i.e., at a given time, each individual hair follicle is at a 
different stage of the hair cycle. At any one time approximately 85% of scalp hairs 
are in anagen, 1% in catagen and 14% in telogen. The average number of hairs 
shed daily is 100. 
Hair follicles extend into the dermis at an angle. A small bundle of smooth muscle 
fibers, the arrector pili muscle, extends from just beneath the epidermis and is 
attached to the side of the follicle at an angle. Arrector pili muscles are supplied by 
adrenergic nerves, and are responsible for the erection of hair during cold or 
emotional stress ('goose flesh'). The sebaceous gland is attached to the follicle just 
above the point of attachment of the arrector pili. At the lower end of the follicle is 
the hair bulb, part of which, the hair matrix, is a zone of rapidly dividing cells 
which is responsible for the formation of the hair shaft. Hair pigment is produced 
by melanocytes in the hair bulb. Cells produced in the hair bulb become densely 
packed, elongated and arranged parallel to the long axis of the hair shaft. They 
gradually become keratinized as they ascend in the hair follicle and as the hair 
shaft matures and grows. 
 
Ultimately the hair shaft consists of the following tubular layers (Fig.1.5): 
– thecortex, which is more or less equivalent to the prickle cell layer of the 
epidermis, but within which keratinization is further advanced. It is mainly 
composed of keratinized spindle-shaped cells 
– the cuticle, a thin layer of overlapping keratinized cells whose free margins point 
towards the tip of the hair 
– the medulla, present on terminal hairs, which is a central core, consisting of 
specialized cells which contain air spaces 
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Fig.1.5.The Hair Shaft 
 
 
Covering the cortex is the cuticle, a thin layer of cells which 
overlap like the tiles on a roof. 
 
Terminal hairs (as that of scalp) have a central core known 
as the medulla. 
 
The main part of each hair fiber is the cortex. 
The cross-sectional shape of hair varies with body site and with race. African hair 
is distinctly oval in cross-section, and pubic, beard and eyelash hairs are oval in all 
racial types. The form of scalp hair also differs among human races (e.g., the 
peppercorn pattern in black Africans). The average rate of growth of human scalp 
hair is 0.37mm per day. In women scalp hair grows faster and body hair grows 
more slowly than in men. The rate of growth of body hair is undoubtedly increased 
by androgens, since it can be reduced by treatment with antiandrogenic steroids. 
Sebaceous glands 
Sebaceous glands are found everywhere on the skin apart from the hands and feet. 
They are particularly numerous and prominent on the head and neck, the chest, and 
the back. Sebaceous glands are part of the pilosebaceous unit, and their lipid-rich 
product (sebum) flows through a duct into the hair follicle. They are holocrine 
glands – sebum is produced by disintegration of glandular cells rather than an 
active secretory process. Modified sebaceous glands which open directly on the 
surface are found on the eyelids(Meibomian glands), lips, nipples, glans penis and 
prepuce(Tyson's glands), and the buccal mucosa (Fordyce spots). 
 
Sebaceous glands are prominent at birth, under the influence of maternal 
hormones, but atrophy soon after, and do not enlarge again until puberty. 
Enlargement of the glands and sebum production at puberty are stimulated by 
androgens. Growth hormone and thyroid hormones also affect sebum production.It 
should be noted that: (1) sebum production is low in children; (2) in adults, sebum 
production is higher in men than in women; (3) in men, sebum production falls 
only slightly with advancing age, whereas in women it decreases significantly after 
the age of 50. 
 
2.2. Sweat Glands 
Generalized sweating is the normal response to exercise or thermal stress by which 
human beings control their body temperature through evaporative heat loss. Failure 
of this mechanism can cause hyperthermia and death.Human skin possesses two 
kinds of sweet glands: eccrine and apocrine. 
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Eccrine sweat glands 
Humans have over 2 million eccrine sweat glands distributed over nearly the entire 
body surface (except labia minora and glans penis). They are more numerous in 
such sites as the forehead, axillae, palms and soles. A person can perspire as much 
as several liters per hour and 10 liters per day, which is far greater than the 
secretory rates of other exocrine glands such as the salivary and lacrimal glands 
and the pancreas.  
Each eccrine sweat gland consists of a secretory coil deep in the dermis, and a 
duct which conveys the secreted sweat to the surface. Eccrine sweat glands are 
innervated by the sympathetic nervous system, but the neurotransmitter is 
acetylholine. The secretory activity of the human eccrine sweat glands consists of 
two major functions:  
(1) secretion of an ultrafiltrate of a plasma-like precursor fluid by the secretory 
coil in response to acetylcholine released from the sympathetic nerve endings, and  
(2) reabsorption of sodium in excess of water by the duct, thereby producing a 
hypotonic skin surface sweat.  
Under extreme conditions, where the amount of perspiration reaches several liters 
a day, the ductal reabsorptive function assumes a vital role in maintaining 
homeostasis of the entire body.  
In addition to the secretion of water and electrolytes, the sweat glands serve as 
excretory organ for heavy metals, organic compounds, and macromolecules. The 
sweat is composed of 99% water, electrolytes, lactate (provides an acidic pH to 
resist infection), urea, ammonia, proteolytic enzymes, and other substances.  
There is a hypothalamic preoptic sweat center that plays an essential role in 
regulation of body temperature. Sweat secretion on palms and soles is more or less 
continuous (perpetual sweating) when humans are awake. In contrast, those glands 
on the general skin surface respond predominantly to thermal stimuli (thermal 
sweating). Both types of sweating can be inhibited by atropine as all sweat glands 
in different areas of the body are stimulated by the same sympathetic cholinergic 
mechanism. Sweating induced by emotional stress (emotional sweating) can occur 
over the whole skin surface, but usually it is confined to palms, soles, axillae, and 
the forehead. 
 
Apocrine sweat glands 
 
The term “apocrine glands”was given to sweat glands present in the axillae and 
anogenital area which are under the control of sex hormones, mainly androgens. 
Specialized apocrine glands include the wax glands of the ear and the milk glands 
of the breast.  
Apocrine glands are also composed of a secretory coil and a duct, but the duct 
opens into a hair follicle, not directly onto the surface of the skin. But 
nowadays by electron microscopy, these apocrine glands (apocrine = apical part of 
the cell is destroyed during the process of secretion) proved to be merocrine in 
nature (merocrine = no destruction of the cell during the process of secretion).  
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The "apocrine" sweat of humans has been described as milky (because it is mixed 
with sebum due to shared duct) and viscid, without odour when it is first secreted. 
This oily secretion of apocrine glands contains protein, carbohydrate, ammonia and 
lipid. These glands become active at puberty, and secretion is controlled by 
adrenergic nerve fibers.Pungent axillary body odour (axillary bromhidrosis) is the 
result if the action of bacteria on apocrine secretion. 
 
2.3. Nails 
The nail acts as a protective covering to the end of the digit and assists in grasping 
small objects. It is a transparent plate of keratin derived from an invagination of 
epidermis on the dorsum of the terminal phalanx of a digit (Fig.1.6). 
Thenail plate is roughly rectangular and flat in shape but shows considerable 
variation in different persons. It is the product of cell division in thenail matrix, 
which lies deep to the proximal nail fold, but is partly visible as the pale “half-
moon“ (lunula) at the base of the nail. 
Thelunula is the most distal portion of the matrix and determines the shape of the 
free edge of the nail plate. The nail plate is firmly adherent to the underlying nail 
bed. The pink color of the nail bed results from its extensive vascular network and 
can be seen because of the transparency of the plate.  
As the nail plate emerges from the matrix, its lateral and proximal borders are 
enveloped by folds of the skin termed the lateral and proximal nail folds. 
The extension of the horny layer of the proximal nail fold onto the nail plate is 
called the cuticle.It forms a seal between the nail plate and proximal nail fold, 
preventing penetration of extraneous material.  
The skin underlying the free end of the nail is referred to as the hyponychium and 
is contiguous with the skin on the tip of the finger.  
Nail growth is continuous throughout life, but is more rapid in youth than in old 
age as well as during pregnancy, in case of nail biting, trauma andduring regrowth 
after avulsion. The average rate of growth of fingernails is approximately 1 mm 
per week, and the time taken for a fingernail to grow from matrix to free edge is 
about 6 months. Toenails grow at one-third the rate of fingernails, and take about 
18 months to grow from matrix to free edge. 
 
Fig.1.6.The Nail 
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Many factors affect nail growth rate. It is increased in psoriasis, and may be 
speeded up in the presence of inflammatory change around the nail. A severe 
systemic upset can produce a sudden slowing in nail growth, causing a transverse 
groove in each nail plate. These grooves, known as Beau’s lines, subsequently 
become visible as the nails grow out. 
Nail growth may also be considerably slowed in acute viral infections such as 
mumps and measles, in starvation, some types of anemia as well as in the digits of 
a limb immobilized in plaster.  
 
3. TheFunctionsof the Skin 
 
The complex organization and structure of the skinobviously point out to the fact 
that the skin performs several important (sometimes vitally important) 
physiological functions. Some of its functions are as follows: 
 
 Box 1.1.  The functions of the Skin 
 
 
 
 
 
 
Barrier function 
The outer layers of the epidermis consist of several overlapping plates of keratin. 
These are surrounded by a thin film of lipid that is dispersed across the surface of 
the cells by the Odland bodies (or membrane-coating granules), which become 
visible under electron microscopy on the prickle cell layer. The envelope thus 
produced is both strong and flexible, providing a semi-permeable barrier to the 
outside world. Thus, the skinis structured to prevent loss of essential body fluids, 
and makes diffusion of water into the environment very difficult. In the absence of 
a stratum corneum we would all lose significant amounts of water to the 
environment, and rapidly become dehydrated. The stratum corneum is also quite an 
effective barrier to the penetration of external agents and protects the body against 
the entry of toxic environmental chemicals. However, the barrier capacity of 
considerably reduces if the stratum corneum is hydrated, or its lipid content is 
reduced by the use of lipid solvents. 
The skin: 
• acts as a barrier to physical agents 
• protects against mechanical injury 
• prevents dehydration of body through fluid loss 
• reduces the penetration of UV radiation 
• helps regulate body temperature 
• provides a surface for grip 
• acts as a sensory organ 
• acts as an outpost for immune surveillance 
• plays a role in Vitamin D production 
• has a cosmetic association 
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One aspect of the skin’s barrier function deserves a special mention: the role of 
melanocytes and melanin in the prevention of damage by ultraviolet radiation. 
Melanocytes produce melanin granules at a genetically predetermined rate and 
transport them into the cytoplasm of surrounding keratinocytes. Melanin absorbs 
ultraviolet radiation and thus protects the nuclei of the basal and spinous cells from 
DNA damage. In the lower layers of the epidermis, the melanin granules are 
arranged as a shield or umbrella over the nuclei of the basal and spinous cells. In 
the outer layers, melanin granules are scattered throughout the cells. 
Immunological surveillance 
The skin is and important site of immunological activity and partof the innate 
immunity of the body against invasion by microorganisms. The dryness and 
constant desquamation of the skin, its normal flora, fatty acids of sebum and the 
lactic acid of sweat, all represent natural defense mechanisms against invasion by 
microorganisms. 
A variety of the skin cells and chemical messengers (or cytokines) produced by 
these cells are involved in recruiting and stimulating both cellular and humoral 
responses: 
Box 1.2 Skin cells involved in recruiting and stimulating both cellular and 
humoral responses 
 
 
 
 
 
 
 
 
 
 
 
 
 
These functions are important   in dealing with infection and tumour cells. 
Dysregulation leads to allergic contact dermatitis and, probably, to atopic 
dermatitis, psoriasis and many other skin disorders. Defective function, in patients 
receiving immunosuppressive drugs for example, increases the risk of infection 
and tumour formation. 
 
 
• Langerhans cells (Fig. 1.7) present in the epidermis have an 
antigen-presenting capacity and might play an important role in 
delayed hypersensitivity reactions. They also play a role in 
immunosurveillance against viral infections.  
• Epidermal keratinocytes interact with neighboring 
Langerhans cells and secrete a number of immunoregulating 
cytokines, and epidermotropic T-cells forming the skin immune 
system: SALT (skin associated lymphoid tissue). 
• Mast cells in the dermis aid the process by releasing 
vasoactive chemicals that help in the recruitment of cells. 
• Tissue macrophages are recruited by vessel dilatation and 
release of chemical attractants. 
• So-called adhesion molecules assist by binding the surface 
markers on immunologically competent cells. 
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Fig.1.7 Langerhans Cells. 
 
 
Langerhans cells form a network in the epidermis. In this section, the Langerhans 
cells have been stained with a monoclonal antibody to HLA-DR 
 
Temperature regulation 
The skin is a vital part of the body's temperature regulation system, protecting us 
against hypothermia and hyperthermia, both of them may be fatal.The body core 
temperature is regulated by a temperature-sensitive area in the hypothalamus, and 
this is influenced by the temperature of the blood which perfuses it. The response 
of the skin to cold is vasoconstriction and a marked reduction in blood flow, 
decreasing transfer of heat to the body surface. The response to hear is 
vasodilatation, and increase in skin blood flow and loss of heat to the environment. 
Perspiration helps to cool the body by evaporation of sweat. These 
thermoregulatory functions are impaired in certain skin diseases - patients 
suffering from exfoliative dermatitis (erythroderma) radiate heat to their 
environment because their skin blood flow is considerably increased and they are 
unable to control this by vasoconstriction. In a cold environment their central core 
temperature drops, in spite of producing metabolic heat by shivering, and they may 
die of hyperthermia. 
 
Sensation 
The skin is also a huge sensory receptor, perceiving heat, cold, pain, light touch 
and pressure and even tickle. The same nerve fibers that carry pain also carry the 
sensation of itch. This sensation, which is unique to the skin, causes considerable 
distress when it becomes persistent and severe.Parts of the skin are considered as 
erogenous zones. The skin is very rich in nerve endings, especially on the fingers, 
toes, lips (and tongue) and this allows us to localize sensations very accurately. 
 
Biochemical reactions 
The skin is involved in several biochemical processes but actively participate in 
vitamin D and androgen metabolism. A vital part of vitamin D metabolism takes 
place in the epidermis: exposure to ultraviolet radiation, largely in the basal and 
prickle cell layers, converts 7-dehydrocholesterol to vitamin D3, vial a peculiar 
molecule, previtamin D3. Without this natural process, vitamin D3 deficiency 
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leads to impaired intestinal calcium and phosphate absorption, which results in 
osteomalacia and rickets. 
There is no doubt that androgen metabolism also takes place within the skin,with 
the conversion of testosterone to 5α-dihydrotestosterone by the enzyme 5α-
reductase.The skin also contains receptors for other steroid hormones (oestrogens, 
progestogens, and glucocorticoids) and for vitamin A. 
 
Social signalling and aesthetic function 
In addition to all above-mentioned mechanistic functions, the skin plays and 
essential aesthetic role in social interaction and sexual attraction.It is an organ of 
emotional expression and a site for the discharge of anxiety. The presence of facial 
blemishes, such as a port-wine stain, or even essentially physiological 
“abnormalities”, such as male balding, excessive hairiness or body ordour, can 
cause major misery. The skin has great psychological importance at all ages. 
Caressing favors emotional development, learning and growth of newborn infants. 
The signs of skin aging, such as wrinkliness of the face or greying of the hair, are 
often not accepted by some people as a part of life but also serve for them as a 
cause of anxiety. 
 
Medical and legal importance of dermatoglyphics 
The fingers and toes, and the palms and soles are interestingly characterizes by 
remarkable whorled ridge and furrow patterns, known as dermatoglyphics. These 
characteristic elevated ridge patterns are unique to each individual. The term 
dermatoglyphics is applied to both the configurations of the ridges, and also to the 
study of fingerprints. The ridge patterns of fingerprints are important both from 
legal and medical point of view, characteristic dermatoglyphic abnormalities 
frequently accompany many chromosomalaberrations. 
 
4. Hypersensitivity Reactions of the Skin 
 
Hypersensitivity refers to an inappropriate or exaggerated adaptive immune 
response that results in tissue damage. There are four main types of 
hypersensitivity reactions: 
 
Type 1 (Immediate) 
IgE is bound to the surface of mast cells via Fc-receptors. Upon binding antigen 
(pollen, food, etc.), the IgE molecules group together and become cross-linked 
which causes mast cell degranulation and release of inflammatory mediators 
(histamine, prostaglandins, leukotrienes, etc.).The response occurs within 
minutes and can range from skin urticaria to anaphylaxis. There is also a delayed 
component that is recognized.  In addition, other factors, besides IgE, can cause 
mast cell degranulation. 
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Type 2 (Antibody-Dependent Cytotoxicity) 
 
Antigens on target skin cells or structures attractantibodies. In turn, killer T cells 
and complement activation are induced and produce cytotoxic effects. This can 
lead to lysis of keratinocytes and intraepidermal blisters. Other examples of type II 
reactions are hemolytic anemia, transfusion reactions, and certain autoimmune 
reactions. 
 
 
Type 3 (Immune Complex Disease) 
In the blood, antigen and antibodies form immune complexes. These immune 
complexes are deposited in the walls of vessels, especially the small vessels of the 
skin.Vascular damage results as these immune complexes induce complement, 
platelet aggregation, and lysosomal enzyme release from polymorphs. This 
reaction is seen in systemic lupus erythematosus and dermatomyositis, microbial 
infections such as infective endocarditis. 
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Type 4 (Cell-Mediated or Delayed) 
Antigen is presented to T-cells by antigen presenting cells (APC). Released 
cytokines activate T-cells and amplify the reaction by recruiting more T-cells and 
macrophages to the site of action.Tissue damage results which is maximal at 48-
72 hours. This reaction is seen in allergic contact dermatitis, and the tuberculin 
reaction to intradermally administered antigen. Leprosy and tuberculosis are 
granulomatous variants of the Type IV reaction.  
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II. Dermatologic Terminology 
 
An understanding of the basic lesions that occur on the skin is essential to the 
discipline of dermatology. Lesions are divided into the general categories of 
primary and secondary. Primary lesions are those that are directly associated with 
the disease process and usually appear early in the course of the disease. Those 
appearing later are called secondary lesions and may be a result of the ongoing 
disease process and changes to the primary lesions.A morphological classification 
of dermatological lesions is most helpful to the identification of the diseases 
present. 
 
1. Primary Lesions 
– Macule - circumscribed area of skin, up to 1.0 cm, with a change from 
normal skin color, which is neither raised above nor depressed below the 
surrounding skin. Examples: freckles, flat nevi. Patch - a flat, circumscribed, 
discoloration of skin or mucous membrane greater than 1.0 cm in diameter. 
Examples: vitiligo, solar lentigines.This term does not include purpura. 
Purpura:larger (greater than 4 mm), circumscribed deposits of blood or blood 
products in the skin. Example: bruises.Pinpoint(up to 4 mm),circumscribed, non-
palpablehemorrhagic macules representingsmall deposits of blood or blood 
pigments are called petechiae. 
Box 2.1. Possible colours and their common causes: 
 
Colour Possible  cause 
Red Hyperemia (erythema), teleangiectases (small dilated vessels), 
leakage of blood (purpura, petechiae, ecchymosis, suggillation) 
Blue Cyanosis, hematoma (back eye), dermal melanin, 
Brown Dermal and epidermal melanin, hemosiderin, 
White Anemia, vasoconstriction, loss of melanin 
Yellow Caronenoids, bile, solar elastosis 
Gray-black Epidermal melanin, heavy metals, tar, dithranol, foreign bodies 
 
• Papule- a discrete solid area of skin that is elevated by palpation above the 
surrounding skin and less than 1 cm in diameter. Variations include acuminate, 
keratotic, flat-topped, follicular, umbilicated, pedunculated, necrotic and others. 
Examples: elevated nevi, warts, lichen planus.  
• Plaque - similar to a papule but greater than 1.0 cm in diameter.Often 
formed by the confluence or coalescence of papules. Secondary features may 
include, among others, atrophy, lichenification or hyperkeratosis. Examples: 
psoriasis, mycosis fungoides. 
• Nodule - discrete, solid, palpable, round or oval (elipsoidal) lesion of the 
skin measuring between 1.0 cm and 2.0 cm in diameter (or long axis). Applies to 
processes involving any or all levels of the skin, and is a general term for any 
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mass, benign or malignant. Nodule is the deepest primary lesion.Examples: 
nodular basal cell carcinomas, xanthomas. 
• Vesicle - a circumscribed fluid-filled lesion less than 1.0 cm in diameter that 
is usually elevated above the surrounding skin.May be described as solitary, 
grouped, umbilicated, dyshidrotic, spongiotic, multilocular or unilocular. 
Examples: herpes simplex, herpes zoster, contact dermatitis. 
• Bulla - a circumscribed fluid-filled lesion greater than 1.0 cm in diameter 
that is usually elevated above the surrounding skin. May attain diameters of several 
cm and are described as tense, or flaccid. Examples: pemphigus vulgaris, bullous 
pemphigoid, second-degree burns. 
• Pustule - discrete elevated vesicle or bulla of the skin, usually small, 
containing purulent exudate composed of inflammatory leukocytes (pus), with or 
without cellular debris. May be superficial, deep-seated, follicular, grouped, etc. 
and may arise secondarily from a vesicle. Examples: acne, impetigo. 
• Wheal (urtica, hive) - an evanescent, round or irregular, often flat-topped 
elevation of skin with a pale red color, arising from edema in the superficial 
dermis. May vary from 2-3 mm to 10 or more cm in diameter, with round or 
arcuate configurations.Should be distinguished from angioedema, a massive edema 
involving the entire dermis and subcutaneous tissues. Examples: hives, insect bites.  
 
2. Secondary Lesions 
 
• Erosion - a superficial denudation of the skin, usually implying the loss of 
the epidermis. 
• Ulcer - loss of skin tissue or substance from the surface downward, leaving 
an uncovered or denuded wound that is slow to heal.  
• Scale - a thin flake of epithelium (mostly composed of corneocytes) which is 
separated from the underlying intact skin proper 
• Crust - dried surface fluid, often serous in nature, with or without tissue 
debris. 
• Scale-crust – a combination of scale (cornified cells, usually parakeratotic 
ones) and crust (serum that contains blood cells, ether red, white, or both) 
• Fissure - a vertical splitting or separation of the skin. 
• Scar - a hard plaque of dense fibrotic tissue covered by a thin epidermis. A 
mark of injury from any sort of process (physical or pathologic). 
• Excoriation - a scratch mark, often with denudation of the skin to form a 
small ulcer.Exposure of the corium by mechanical removal of the epidermis. 
• Lichenification - a thickening of the skin surface and an increase of skin 
markings, usually seen with chronic coalescence of papular lesions, especially 
atopic eczema.  
 
3. Special Lesions and Conditions of the Skin 
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• Atrophy: thinning of the epidermis leaving an easily wrinkled and/or shiny 
surface. Atrophy may also apply to dermal and/or subcutaneous tissue, with or 
without changes in the epidermis. 
• Horn: projection of keratin 
• Burrows: small and short or long and tortuous tunnels in the epidermis. 
Examples: small and short burrows (scabies); long and tortuous burrows (creeping 
eruptions). 
• Milia (Whiteheads): whitish papules, 1-2 mm in diameter with no visible 
opening onto the skin surface. Examples: healed burns, healed bullous disease 
states, face of newborn babies. 
• Comedones (Blackheads): plugs of whitish or blackish sebaceous and 
keratinous material lodged in the pilosebaceous follicle usually seen on the face, 
the chest and/or back. Example: acne. 
• Cysts: elevated, circumscribed, encapsulated lesions; in dermis or 
subcutaneous layer; filled with liquid or semi-solid material. Examples: acne, 
epidermal inclusion cysts. 
• Tumor: a term used by some for a "nodule" greater than 1.0 cm in diameter. 
Applies to processes involving any or all levels of the skin, and is a general term 
for any mass, benign or malignant. Examples: neurofibromas, large basal cell 
carcinomas and xanthomas. 
• Telangiectasias: dilated superficial blood vessels that appear as fine 
irregular red lines. Example: spider angiomas. 
• Sclerosis:clinically, a condition of hardness of the skin (morphea). 
• Sinus: an epithelium-lined channel in the skin that opens on the surface, 
usually through and infundibular ostium. In contrast to a fistula that is open on 
both ends a sinus is open at one end only. 
• Necrosis: death of skin that appears black or dark green or purple in color.  
• Wet/Oozing: the water barrier of the skin has been damaged and there is 
enough flow of fluid from below to keep the surface of the lesion wet. 
• Maceration: softened, wettened epidermis 
 
4. Descriptive terms necessary for an accurate diagnosis 
 
Eruption character 
 
• Vegetating: a lushly growing, proliferating, process, usually with elevated 
or exophytic features.  
• Eczematous: This term is used to describe inflammatory conditions of the 
skin, which appear erythematous and scaly with ill-defined borders. Examples: 
atopic dermatitis, irritant dermatitis, tinea.  
• Papulosquamous: This term is used to describe conditions, which manifest 
themselves as papules or plaques with scales. Examples: psoriasis, lichen planus, 
pityriasis. 
Eruption surface: smooth, rough, warty, papillary, granular, lichenoid, dry, moist, 
scaly, crusted, erosive, ulcerative, atrophic, shiny, necrotic, elevated. 
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Eruption texture:soft, firm, fragile, tense, elastic, movable. 
Eruption shape: round, oval, polygonal, irregular, linear, circinate: arched or 
rounded border, annular: circular or ring-shaped, discoid, nummular: disk or coin-
shaped, serpiginous: winding, twisting (snake-like), iris or cockade (target-like). 
Eruption colour: colored, depigmented, hyper- or hypopigmented, pale, anemic 
Eruption distribution: localized, widespread, diffuse, centrifugal, linear (following 
a line), symmetrical, asymmetrical, grouped, isolated from each other, lines of 
Blaschko (invisible under normal conditions): following embryologic skin lines, 
reticular (net-like), herpetiform (arranged in clusters, grape-like), zosteriform: 
following a dermatom, disseminated (randomly distributed). 
Eruption progress: rapid, gradual, with or without recurrence. 
Eruption border: sharp (well-circumscribed) or vague (blurred). 
Number ofEruptions: single or multiple 
 
5. Characteristics of Individual Lesions 
 
Macule:flat, nonpalpable circumscribed area of change in the skin.  Macules are < 
1-2 cm in size. 
1. Macules may be the result of (A) hyperpigmentation (e.g. brown as in 
melasma), (B) depigmentation (e.g. vitiligo),(C) vascular dilation (e.g. erythema). 
A B C 
 
 
2. Multiple well-defined macules of various shapes and sizes. In this case, the 
macules blanch upon pressure(diascopy) and thus are due to inflammatory 
vasodilation. 
 
 
 
Papule: small solid elevation of skin generally < 5 mm in diameter.  The majority 
of the papule elevation projects above the plane of the surrounding skin.   
Papules may be flat-topped, as in lichen planus; or dome shaped, as in xanthomas; 
or spicular, if related to hair follicles.  
1. Papules may result from (A) dermal metabolic deposits, (B) localized dermal 
cellular infiltrates, (C) localized hyperplasia of dermal or epidermal cellular 
elements.  
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2. Two firm dome-shaped papules - dermal melanocytic nevi. 
3. Multiple well-defined and coalescing papules - lichen planus.  
 
 
1.           2.     3.  
 
 
Nodule: palpable, solid, round, or ellipsoidal lesion.Its depth of involvement 
and/or palpability differentiate it from a papule rather than its diameter (although 
nodules are usually larger than papules: > 5 mm diameter). Nodules can involve 
any layer of the skin and can be edematous or solid. Based on the anatomical 
component(s) involved, there are five types of nodules: epidermal, epidermal-
dermal, dermal, dermal-subdermal, and subcutaneous. 
1. Nodule can be located in (A) the dermis and subcutaneous layer or in (B) the 
epidermis. 
2. Firm well-defined nodule with a smooth and glistening surface through which 
dilated capillaries (telangiectasia) can be seen; there is central crusting due to 
tissue breakdown and thus ulceration - nodular basal cell carcinoma  
3. Multiple nodules varying in size - melanoma metastases. 
 
 
1.            2. 3.  
 
Vesicle (blister): circumscribed, elevated lesion that is < 5 mm in diameter 
containing serous (clear) fluid. A vesicle/bulla is the technical term for blisters. 
Vesicle walls can be so thin that the contained serum, lymph, blood, or 
extracellular fluid is easily seen.  Fluid can be accumulated within or below the 
epidermis. 
Bulla: A vesicle with a diameter > 5 mm.  
1. (A) subcorneal vesicle - fluid just below stratum corneum, (B) spongiotic 
vesicles - intercellular edema. 
2. Multiple translucent subcorneal vesicles, extremely fragile leading to crushing 
(arrows). 
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1.           2.  
 
 
3. (A) acantholytic vesicles - cleavage within epidermis due to intercellular 
attachment loss, (B) Balloondegeneration of epidermal cells in certain viral 
infections leads to vesicles. 
4.Herpes zoster  
 
 
3.           4.  
 
5. Subepidermal vesicles due to changes in dermal-epidermal junction 
6. Multiple subepidermal vesicles.  Vesicles have arisen on normal or 
erythematous skin. Some vesicles have collapsed and crusted. 
     
5.           6.  
 
Pustule: superficial, elevated lesion that contains pus (pus in a blister). Pustules 
may vary in size and shape. The color may appear white, yellow, or greenish-
yellow depending on the color of the pus. Pus is composed of leukocytes with or 
without cellular debris.  It may also contain bacteria or may be sterile.  
1. A pustule is basically a papule containing pus.  
2. Superficial, subcorneal pustules - pustular psoriasis. 
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1.           2.  
 
Cyst: an epithelial lined cavity containing liquid or semisolid material (fluid, cells, 
and cell products). A spherical or oval papule or nodule may be a cyst if, when 
palpated, is resilient (feels like an eyeball).  
1. Most common are (A) epidermal cysts, lined by squamous epithelium and 
produce keratinous material. (B) Pilar cysts, lined by multilayered epithelium 
which does not mature through the granular layer.  
2. Bluish, resilient cyst filled with mucous material - adnexal tumor (cystic 
hidradenoma). 
 
1.           2.  
 
Plaque: palpable, plateau-like elevation of skin, usually more than 2 cm in 
diameter and rarely more than 5 mm in height.Often formed by a convergence of 
papules, as in psoriasis. 
1. Plaques occupy a relatively large surface area in comparison with its height 
above the skin.  
2. Well-defined, reddish, scaling plaques. 
 
1.     2.         
 
Wheal:transitory, compressible papule or plaque of dermal edema.  
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1. The papule or plaque is usually rounded or flat-toped, and evanescent, 
disappearing within hours. The borders of a wheal are sharp, but not stable and can 
move from involved to adjacent uninvolved areas over hours.The epidermis is not 
affected. Wheals can be pale red or white (especially in the center) if edema is 
sufficient to compress superficial vessels. Wheals are a common allergic reaction.  
2. A wheal may be large coalescing plaques as in this allergic reaction. 
3. An eruption of wheals is termed urticaria and usually itches. 
 
 
1.           2.           3.  
 
Scale: accumulation or abnormal shedding of horny layer keratin (stratum 
corneum) in perceptible flakes. The change may be primary or secondary.  Scales 
usually indicate inflammatory change and thickening of the epidermis.  The may 
be fine, as in pityriasis; white and silvery, as in psoriasis; or large and fish-like, as 
in ichtyosis. 
1.(A) Parakeratotic scale (with retained nuclei) can be seen in psoriasiform 
epidermal hyperplasia.(B) Actinic keratosis is a densely adherent scale with gritty 
feel due to a localized increase in stratum corneum.  
2. Typical psoriasis scaling 
3. Scales may build up to form an asbestos-like layer covering the underlying 
lesion. 
 
1.           2.   3.  
 
Ulcer: circumscribed area of skin loss extending through the epidermis and at least 
part of the dermis (papillary).  
1. Basically, it's a "hole in the skin". Ulcers usually result from the impairment of 
vascular and nutrient supply to the skin.  
2. Gigantic ulcer, red granulating base with punched out borders. 
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1.           2.  
 
Crust: dried serum, blood, or pus on the surface of skin. 
1. May be thin, delicate, and friable or thick and adherent. Crusts are yellow, if 
from serum; green or yellow-green if from pus; or brown or dark red if formed 
from blood. Characteristic of pyogenic infections. 
2. Crusts that occur as honey-coloured, delicate, glistening particulates are typical 
of impetigo. 
 
1.           2.  
 
Erosion: moist, circumscribed, usually depressed lesion due to loss of all or part of 
the epidermis.  
1. Often results from eruptions of vesicles and bullae. Seen in infection from 
herpes viruses and in pemphigus. 
2. Toxic epidermal necrosis causes erosion. 
 
1.           2.  
 
Excoriation: linear or punctate superficial excavations of epidermis caused by 
scratching, rubbing, or picking.  
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Lichenification: chronic thickening of the skin along with increased skin 
markings.Results from scratching or rubbing.1. Note the increased skin markings.  
 
1.  
 
Atrophy: paper-thin, wrinkled skin with easily visible vessels. Results from loss 
of epidermis, dermis or both.Seen in aged, some burns, and long-term use of 
highly potent topical corticosteroids. 
1. (A) Dermal atrophy manifests as a depression in the skin.  (B) Epidermal 
atrophy manifests as thin almost transparent skin; may not retain normal skin lines. 
2. Dermal and epidermal atrophy. There is loss of normal skin texture, thinning 
and wrinkling. 
 
1.        2.  
 
Scar: replacement of normal tissue by fibrous connective tissue at the site of injury 
to the dermis. Scars may be hypertrophic, atrophic, sclerotic or hard due to 
collagen proliferation. Reflects pattern of healing in the affected area. 
1. (A) Hypertrophic or (B) atrophic scar.2. Hypertrophic scar. 
 
1.           2.  
 
 
6. Specific symptoms in dermatology 
 
Nikolsky’s sign:a clinical dermatological sign, named after the Russian physician 
Pyotr Nikolsky (1858-1940). The sign is positive when slight rubbing of the skin 
results in exfoliation of the outmost layer. Nikolsky’s sign is almost always present 
32 
 
in toxic epidermal necrosis (TEN), pemphigus vulgaris, epidermolysis bullosa, 
staphylococcal scaled-skin syndrome (SSSS). It is useful in differentiation between 
pemphigus vulgaris (where it is present or positive) and bullous pemphigoid 
(where it is absent). 
Asboe-Hansen sign: also known as “indirect Nikolsky’s sign” or “Nikolsky’s sign 
II”. It refers to extension of a blister to adjacent unblistered skin when pressure is 
put on the top of the bulla. 
Koebner phenomenon: this “isomorfic response means the appearing of specific 
skin lesions on the site of skin injury. As a rule, lesions have linear distribution. 
The most common skin disorders with Koenbner phenomenon are psoriasis, lichen 
nitidus, vitiligo, lichen sclerosus, Kaposi sarcoma, warts. Warts and molluscum 
contagiosum lesions can be spread in linear patterns by self-scratching (“auto-
inoculation”). 
Auspitz sign: used in the psoriasis diagnosis. It is performed by scraping a psoriatic 
plague with the slides, when the scales exfoliate, pointed bleeding is quickly 
produced. 
Wickham net: there are whitish lines visible in the papules of lichen planus, 
typically the macroscopic appearance of the histologic phenomenon of 
hypergranulosis. 
Dennie-Morgan fold: also known as Denni-Morgan line or an infraorbital fold. It 
is a fold or line in the skin below the lower eyelid caused by edema in atopic 
dermatitis. The presence of Dennie-Morgan fold is used as a diagnostic marker for 
allergy. 
“Apple-jelly” symptom: Diascopic examination of granulomas (tubercules) gives 
an apple-jelly appearance (yellow-brownish colour of grains). This symptom is 
positive in cutaneous tuberculosis (lupus vulgaris) and in sarcoidosis of the skin. 
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III. DIAGNOSING SKIN DISEASE 
 
 
1. Dermatological Diagnosis 
 
A dermatological diagnosis is a short statement about a disease state or condition. 
The facts on which a diagnosis of a skin disease is made must always come first 
and foremost from the patient and there is no substitute for talking to and 
examining patients. The process of identifying skin diseases consists of (1) taking 
a history, (2) examining the patient, and (3) performing investigations where 
necessary. 
 
2. Dermatological History –Taking 
 
Box 3.1.The essentials of dermatological history-taking are as follows: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chief complaint 
• What is the main reason for the patient’s visit? 
• The duration of the disease? 
• What factors provoke the disease? (stress, infection, drugs, food, allergies or others) 
• What is the course of the disease (relapses and remissions)? 
Present condition 
• What symptoms (itch, pain, bleeding, numbness or burning sensation, just a cosmetic 
defect)?  
• Intensity of pathologic sensations? What effect do they have on the patient’s daily 
activities and self-image, work, school, sleep, self-confidence, personal relationships? 
• Are there systemic symptoms (e.g. high fever, fatigue, joint or/and muscle pain, 
insomnia)? 
• How did the lesion progress? (What factors aggravate the disease? Does it worsen at 
night?)  
• How does the lesion spread? (Is it spreading? Does it occur and disappear rapidly?) 
Past history 
• Past skin disease, significant allergies, general disorders (diabetes, TB) 
Family history/close contacts 
• Any skin disease (some disorders are infectious; others have strong genetic 
backgrounds)? 
• Any allergies or atopic diseases (e.g. hay fever, asthma)? 
Occupation and hobbies 
• Exposure to material in the workplace or at home 
Therapy 
• Medical,systemic and topical, this includes over the counter products and those 
recommended by non-medical health professionals, e.g. pharmacists, specialist nurses 
• Alternative/complementary therapy, exposure to cosmetics and toiletries 
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– As with any other specialty, the first thing to establish is the presenting 
complaint. Questions should be asked to define and qualify it, establish whether 
there are any other linked problems, and to assess its severity. 
– There are important genetic aspects to many skin diseases. 
– Some skin diseases are infectious or contagious. 
– Special attention should be paid to itch which is one of the most specific 
symptoms of skin diseases. 
– Itchy patients can be divided into two groups: those with a rash and those 
without it; it is important to establish from the beginning whether the itch preceded 
or followed any skin changes.  
The distribution of itch may be important, e.g. in dermatitis herpetiformis, itch 
affects the extensor aspects of the forearms and lower legs and the lower back and 
scalp, scabies seldom affects the scalp and face in adults. 
The time when itch is worse may be significant, e.g. itch may be a problem only 
when the patient is at rest, be worse at night (it characteristically is in scabies), 
result in loss of sleep (a frequent problem in atopic dermatitis) or be present 
constantly (as it is when a feature of systemic disease).  
The intensity of itch may be judged to some extent by the presence of secondary 
skin lesions caused by scratching (excoriations and bruising) 
In should be kept in mind that patients frequently use multiple creams and 
ointments on their skin - these may have been prescribed by their doctor; already 
present in the house for other problems or other people; bought “over the counter” 
at a pharmacy; lent by friends and family; supplied by alternative/complementary 
practitioners; be part of a cosmetic/toiletryregimen. 
 
 
3. Examination of the Skin 
 
The next step in making a dermatological diagnosis is to examine the patient. 
 
It is considered “the best practice” to examine the whole skin every time.In reality 
this can be hard on both patient and doctor, especially if the problem is a solitary 
wart on the thumb. However, as a general rule, and especially with inflammatory 
dermatoses and conditions with several lesions, it is important to have an overall 
look at the sites involved. 
It is critical to palpate skin lesions as well as to inspect them – not only does this 
provide useful information but it also indicates to the patient that the doctor, at 
least, is not repelled or frightened by their rash. 
It should be noted that skin diseases are dynamic. Some lesions in any rash will be 
very early, some very late and some at various intermediate evolutionary stages. 
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The fundamental elements of a good dermatological examination are: 
 
1. Site and/or distribution of the problem 
2. Characteristics of individual lesions 
3. Examination of “secondary” sites 
4. “Special” techniques 
 
Box 3.2. Key elements in examination of the skin: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Box 3.3. Examples of secondary examination techniques that can aid diagnosis 
 
 
 
 
 
 
 
 
 
 
 
 
1. Establish the site and distribution of the lesions 
e. g. psoriasis has a predilection for knees, elbows, scalp and lower back; eczema 
favours the flexures in children; acne occurs predominantly on the face and upper 
trunk; basal cell carcinomas are more common on the head and neck 
 
2. Note the characteristics of the individual lesion(s) 
• The type (see “Characteristics of Individual Lesions”) 
• The size, shape, outline and border (lesions may be various shapes, e.g. round, oval, 
annular, linear or irregular; straight edges and angles may suggest external factors; the 
border is well-defined in psoriasis, but blurred in most patches of eczema) 
• The colour(s): red, purple, brown, slate-black, etc. 
• Surface features: It is helpful to assess whether the surface is smooth or rough, and to 
distinguish crust (dried serum) from scale (hyperkeratosis); some assessment of scale 
can be helpful, e.g. ” silvery’ in psoriasis 
• The texture - is the lesion superficial and therefore largely epidermal, or is it deep? 
Use your fingertips on the surface; assess the depth and position in or beneath the skin: 
lift scale or crust to see what is underneath; try to make the lesion blanch with pressure 
 
3. Examine secondary sites (using appropriate secondary techniques – see Box 3.3) 
• The nails - in psoriasis, alopecia areata, fungal infections 
• The umbilicus – in psoriasis 
• The finger-webs and wrists – in scabies 
• The toe-webs – in fungal infections 
• The mouth – in lichen planus 
• The male genitalia – in scabies 
 Scratching, rubbing or prodding the skin to elicit whealing in: 
dermographism, mastocytosis  - Darier sign 
 Application of ice, warm water, pressure, etc. to elicit whealing in physical 
urticaria  
 Scraping a psoriatic plaque to elicit 
capillary bleeding – Auspitz sign 
 Easy stripping of the epidermis in 
pemphigus and toxic epidermal necrolysis – Nikolsky’s sign 
 Blanching a spider angioma with a fine point 
 Diascopy (pressure with a glass slide) in  
cutaneous granulomas, especially cutaneous tuberculosis 
 Wood’s light examination for fluorescence in some fungal infection and for 
enhancing the visibility of pale patches in tuberous sclerosis 
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4. Special Investigations 
Inevitably, history and examination alone will not always provide all the 
information required. There are some skin disorders in which further investigation 
is nearly always necessary: either to confirm a diagnosis with important prognostic 
or therapeutic implications (e.g. blistering disorders), or to seek an underlying 
associated systemic disorder (e.g.in generalized pruritus). As with all other 
specialties, dermatology has developed a number of special techniques for 
advancing the diagnostic information available on an individual patient. Many of 
these have been used for a long time. Some are much more recent. 
 
Table 3.1 Investigational Techniques 
 
Investigational 
techniques 
Potential value 
Blood tests For a wide range of underlying systemic abnormalities, for indirect 
immunofluorescence in immunological disorders and, increasingly, for 
genetic analysis 
Swabs: 
bacteriological→ 
viral→ 
To ascertain nature of infecting organisms, antibiotic sensitivity 
To ascertain nature of infecting organism 
Wood’s light Some disorders/features are easier to see 
Skin scrapes or nail 
clippings 
To obtain material for inspection for fungi, mites, molluscum bodies, 
giant cells (in herpes virus infections); to set up cultures for fungi 
Skin Biopsy: 
light microscopy→ 
 
immunofluorescence→ 
 
electron microscopy→ 
culture→ 
 
in-situ hibrisization→ 
Pathological interpretation, including special stains and 
immunohistochemistry as necessary 
Bullous disorders; cutaneous and systemic lupus erythematosus; 
vasculitis 
Especially useful in congenital and acquired blistering diseases 
The organisms causing TB, leishmaniasis, and some rare organisms 
are more easily, or can only be cultured from skin biopsies 
Sybtyping human papilloma virus 
Patch tests  For evidence of contact allergy 
Dermatoscopy Useful in distinguishing benign from malignant skin lesions 
 
4.1. Scrapings/Cippings/Smear Preparations 
Material from the skin, hair or mails can be examined directly under the 
microscope and/or sent for culture. This is particularly useful in suspected fungal 
infection, or in a search for scabies mites. 
 
Diagnosis of fungal infections 
Potassium hydroxide (KOH) is used for observation and detection of fungi and 
mites. The scales are placed on a microscopic slide with some drops of 20% KOH 
solution and covered with a coverslip. The slide is heated on a hot plate at 70oC to 
80oC for 5-10 minutes. The horny cell layers are hydrolyzed and the fungal 
elements can be seen as mycelial strands crossing cell boundaries. Scabies mites, 
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egg, egg cases or immature forms are also easily seen under low power. Nail 
clippings can also be treated this way. 
Microscopy of hair may also provide information about fungal infections, may 
reveal structural hair shaft abnormalities in certain genetic disorders, and can be 
useful in distinguishing some causes of excessive hair loss. 
 
Cytologial diagnosis (Tzank test) 
Scrape/smear preparations are also uses as a diagnostic aid for the cytodiagnosis of 
suspected viral blisters and pemphigus, using a “Tzank preparation”. 
Herpes infection diagnosisis conducted by applying a slide glass to the bottom of 
erosion or the content of a vesicle and staining the adherent cellular components in 
Giemsa for observation under a light microscope. Ballooning keratinocytes 
produced by viral infection are observed. They look like multinuclear giant cells 
(“Tzank cells”). 
Pemphigus diagnosis is conducted by applying a slide glass to the bottom of a 
blister and staining the adherent cellular components in Giemsa for observation 
under a light microscope. Acantolytic cells called Tsanck cells are observed in 
pemphigus. The term “acantolytic cell” refers to a epithelial cell that has 
undergone dyshesion (i.e. separation from another epithelia cell) by dissolution of 
intercellular bridges and has consequently become round. 
 
4.2. Wood’s Light 
A Wood’s light is a nickel oxide-filtered ultraviolet light source emitting 
ultraviolet light in the wavelength of 360 nanometers which is used to highlight 
three features of skin disease (see Table 4.2): 
1) Certain organisms which cause scalp fungal infection (ringworm) produce 
green fluorescence (useful in initial diagnosis and helpful in assessing therapy). 
2) The organism responsible for erythrasma fluoresces coral-pink. 
3) Some pigmentary disorders are more clearly visible – particularly the pale 
patches of tuberous sclerosis and café-au-lait marks of neurofibromatosis. 
4) Wood’s light can also be used to induce fluorescence I the urine in some of 
the porphyrias. 
 
Table 3.2 Wood’s Light Examination in Different Skin Disorders 
 
Disease Coloration 
Fungal infection 
Tinea capitis associated with Microsporum species and favus Green 
Pityriasis versicolor Brownish-yellow 
Bacterial infection 
Erythrasma Coral-pink 
Pigmentary disorders 
Vitiligo 
Tuberous sclerosis 
Café-au-late marks 
Bright white or 
more clearly visible 
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4.3. Dermatoscopy 
Dermatoscopy (also known as dermoscopy or epiluminiscence microscopy) is the 
examination of skin lesions with a dermatoscope. This traditionally consists of a 
magnifier (typically x10), a non-polarized light source, a transparent plate and a 
liquid medium between the instrument and the skin, and allows inspection of skin 
lesions unobserved by skin surface reflections. This instrument is useful in 
distinguishing benign from malignant (cancerous) lesions, especially in the 
diagnosis of melanoma. 
 
4.4. Direct Immunofluorescence (DIF) 
DIFinvolves the overlay of fluorescein-conjugated antibodies (IgG, IgM, 
IgA),complement (C3) and fibrinogen onto frozen sections of tissue obtained from 
patients. Biopsy specimens for direct immunofluorescence in immunobullous 
diseases should be taken from perilesional normal-appearing skin within a few 
millimeters from the edge of the blister. However, when a biopsy specimen is 
needed for diagnosis of connective tissue disease or vasculitis, a lesional biopsy is 
optimal. 
 
Table 3.3.Direct Immunofluorescence in Some Inflammatory Skin Disorders 
 
Skin disease Deposition Site of deposition 
Pemphigus vulgaris IgG, complement C3 Intercellular (around keratinocytes 
of stratum spinosum) 
Bullous pemphigoid IgG, complement C3 Linear in the epidermal basement 
membrane 
Dermatitis herpetiformis IgA Granular deposition on the papillar 
layer in derma 
Lupus erythematosus IgG, IgM Linear on the basement membrane 
and around hair follicles 
Vasculitis IgM, IgG, C3, 
fibrinogen 
Strong dermal blood vessels 
 
4.5. Indirect Immunofluorescence 
Indirect immunofluorescence studies involve the detection of circulating 
autoantibodies in the patient’s serum which target specific antigens in the patient’s 
skin or mucosa. The technique for indirect immunofluorescence is helpful in 
immunobullous diseases. It includes incubation of patient’s serum which contains 
the antibodies with frozen sections of epithelial substrate. The substrate is usually a 
monkey esophagus, but a pig esophagus also may be. The rat bladder is used to 
rule out paraneoplastic pemphigus. After washing, the fluorescence-labeled animal 
anti-IgG-conjugate binds to the patient’s circulating IgG, which is already bound to 
the target antigen on the epithelium surface. 
Note: the serology tests are also used in dermatology for the detection of 
antibodies to syphilis and HIV. 
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4.6. Skin Biopsy 
Biopsy of skin lesions is useful to establish or confirm a clinical diagnosis. In some 
cases, such as skin cancers, bullous disorders and infections, such as tuberculosis 
and leprosy, it is critical to have confirmation of a clinical diagnosis.In others 
biopsy is necessary because clinical information alone has not provided all the 
answers. In case of a biopsy a piece tissue is removed surgically for histologic 
examination and sometimes for other tests (e.g. culture for organisms). 
 
Indications for biopsy: 
– You cannot make a diagnosis; 
– The disorder does not respond to treatment; 
– The disorder is unusual or severe; or 
– You are just not sure. 
 
Biopsy technique selection 
Six major methods are employed to biopsy skin: curettage, snip or scissors biopsy, 
shave biopsy, punch biopsy and excision in toto. 
Curettage is frequently used to remove clinically benign lesions; a curette 3-5 mm 
in diameter is held like a pencil and drawn with pressure under the lesion (if 
epidermal) or through the lesion (e.g. presumed basal cell carcinoma). 
Snip or scissors biopsy is an efficient technique for assessing pedunculated 
lesions as well as removing benign growth (e.g. acrochordons, filiform warts). 
Shave biopsy usually provides a specimen consisting of epidermis, papillary 
dermis and, sometimes, reticular dermis (particularly in elevated lesions). It is a 
popular biopsy technique for ”planing” popular, clinically benign lesions (e.g. 
irritated or unwanted compound and dermal melanocytic nevi, fibrous papules of 
the nose) where histological confirmation is desired, also a useful procedure for 
diagnosing superficial carcinomas, lentigo maligna. 
Punch biopsy supplies a cylindrical to conically shaped specimen consisting of 
epidermis, dermis and, sometimes, subcutaneous fat. The volume of tissue sample 
correlates with the size of the punch biopsy instrument. In general, its diameter 
varies from 2 to 6 mm and the wider the diameter, the greater the likelihood of 
obtaining subcutaneous fat. Punch biopsy is much quicker than 
incisional/excisional biopsy, but produces small samples and is only appropriate 
for diagnosing biopsies or removing tiny lesions. 
Incisional biopsy removes a wedge of tissue from the center or edge of a lesion 
and is the best option for obtaining deep subcutaneous fat or fascia for histological 
examination. It is also used to sample a significant portion of large-sized tumours. 
Excisionin toto removes the entire lesion and includes epidermis, dermis and 
subcutaneous fat. For these reasons, it is often the biopsy of choice for a presumed 
invasive cutaneous melanoma. 
Site preparation and anesthesia 
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It is important to choose an appropriate area from which to take the sample. The 
skin lesion(s) should be fully formed. Late lesions should be avoided. In some 
situations (e.g. dermatitis herpetiformis and bullous pemphigoid), it is important to 
sample early lesions because the classic histology may be altered by the passage of 
time. 
Marking the site, cleansing the skin, and draping are important prior to performing 
local anesthesia. Local anesthesia is adequate for all skin biopsies. The agent 
generally used is lidocaine, either at a 1% or 2% concentration. Epinephrine may 
be added to the lidocaine in order to reduce bleeding and prolong anesthesia, but it 
is avoided in patients who have a proclivity for cardiac arrhythmias. Topical agents 
include eutectic mixture of local anesthetics (e.g. EMLA with lidocaine and 
prilocaine), tetracaine, liposome-encapsulated tetracaine, and liposome-
encapsulated lidocaine. 
 
Specimen handling 
Transportation of the biopsy specimen to the laboratory differs according to the 
processing and type of examination required. Most specimens are placed in 10% 
formalin, but, occasionally, special carrier media are necessary, e.g. Michel’s 
medium for direct immunofluorescence. Fresh tissue specimens for direct 
immunofluorescence, immunoperoxodase, culture for bacteria, mycobacteria or 
fungi are sent on saline-moistened gauze and either promptly delivered to the 
laboratory or packed in ice; the laboratory must be on reasonable proximity and 
have the capability of processing the tissue immediately. For culture for viruses 
viral transport medium is necessary. 
 
Hemostasis 
All methods of biopsy require attention to hemostasis of the wound bed. For small-
diameter, superficial wounds, compression alone may be used. Styptics such as 
aluminum chloride hexanydrate (DrysolTM, Xerac ACTM) and ferric subsulfate 
(Monsel’s solution) are frequently used. Punch biopsy sites are usually closed 
primarily and the suturing itself creates sufficient hemostasis. Wounds created 
during incisional biopsy or excision in toto may require electrocoagulation for 
hemostasis before closure. 
 
4.7.Patch Test 
The patch test is the most frequent test for detection of specific substance causing 
allergic inflammation of the skin. A patch test relies on the principles of a type IV 
hypersensitivity reaction. 
The general rules for patch testing: 
– Complete healing or remission need to be achieved before patch testing 
– Avoid patch testing on markedly tanned persons 
– Do not test pregnant women 
– The preferred site is the upper back 
– Clip hair one or two days before testing 
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– Patients should be informed as to the aim of the test; about avoidance of 
showers, wetting the test site, irradiation and excessive exercise, and about 
symptoms such as itch and discomfort. 
The standard patch test technique involves application of the test allergen strips to 
the skin under occlusion for 48 hours. Interpretation of results is performed at the 
3d-4thdays and and the 7th day after occlusion (i.e. 1, 2 and 5 days after the removal 
of the patch test strips). 
 
Table 3.4.Scoring of Patch Test Reactions 
 
Score Interpretation 
- Negative reaction 
?+ Doubtful reaction: faint erythema only 
+ Weak (non-vesicular reaction; erythema, slight infiltration 
++ Strong (edematous or vesicular) reaction; erythema, infiltration, vesicles 
+++ Extreme (bullous or ulcerative) 
IR Irritant reaction of different types 
NT Not tested 
 
4.8. Other  SkinTests 
Stripping test is a variant of patch testing consisting of “stripping” the stratum 
corneum before applying the allergen in the usual way to suppress the skin barrier. 
Open test. Skin allergens are dropped onto the volar forearm and allowed to 
spread freely. No occlusion is used. 
Semi-open test is a variant of the open test covered by a non-occlusive tape. It is 
thus “half-way” between open testing and conventional patch testing. 
Repeated open application test. Allergens are applied twice daily for 7 days to 
the outer aspect on the upper arm, antecubital fossa or back skin (scapular area). A 
positive result (eczematous dermatitis) may appear on the 2-4 days but it is 
recommended to extend the application beyond 7 days so as not to miss late-
appearingreaction. 
Prick test is a test method for detecting immunoglobulin E (IgE)-mediated allergy. 
Drops of allergen solution are applied to the volar aspect of the forearm or to the 
upper part of the back. When drops of allergen solutions are applied to the skin, 
they are pierced with a special lancet for penetration of allergens into epidermis. 
No bleeding may occur. Conventional time reading is 15-20 min. Prick testing of 
allergen needs the concomitant use of controls, positive and negative. Histamine 
chlorhydrate solution and codeine phosphate solution (9%) are used as positive 
controls. Saline and/or vehicle of the allergens is used as a negative control. 
Scratch test is a common method for detecting immediate allergy. It is still used 
when only non-standardized allergens are available. A scratch of approximately 5 
mm long is made with a blood lancet and bleeding is avoided. The back and arms 
are the preferred test sites. Scratch testing of allergens needs the concomitant use 
of controls, positive and negative. 
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IV. BASICS OF MEDICAL THERAPY IN DERMATOLOGY 
 
Medical treatment in dermatology consists of: topical therapy, systemic therapy, 
phototherapy and surgical procedures. 
 
1. Topical Therapy 
 
The advantage of direct delivery and reduced systemic toxicity make topical 
treatment quite attractive.All topical agents are “held” in a base of some kind, the 
so-called “vehicle”, which allows the patient to apply the material to the skin 
surface. 
 
1.1. Vehicles 
Cream – a semi-solid emulsion of oil-in-water; contains a preservative to prevent 
overgrowth of microorganisms. It is stabilized by an emulsifier and contains 
mostly water, so mostly evaporates. As the proportion of oil increases, the 
preparation approaches the consistency of ointment, which is the most lubricating 
vehicle. Creams are not greasy and easy to remove. Effects of creams are cooling, 
vasoconstrictive, anti-inflammatory. They are often used for dry skin lesions. 
Creams are more superficial comparing with ointments. 
Gel – a semi-solid transparent non-greasy emulsion. Gels are aqueous preparations 
that liquefy on contact with the skin and leave a uniform film on drying. They are 
well-tolerated in hair-bearing regions. 
Lotion – a liquid vehicle, aqueous or alcohol based (in the latter case it is used 
especially on the scalp to avoid matting of the hair), which may contain a salt 
solution. Lotions evaporate and cool the skin. They are useful for inflamed and 
exudative conditions. 
Ointment –is a topical vehicle of semi-solid grease or oil with little or no water. 
Ointments are occlusive and allow for high transcutaneous penetration of the active 
drug. They are stable for a long period of time. An ointment is the best therapeutic 
option in the treatment of thick infiltrates of the skin (plaques), because they can 
penetrate to the deep layers of the skin. Ointments rehydrate, moisturize, but 
because of the greasiness they are difficult to remove. 
Paste – an ointment with a high proportion of powder which gives a stiff 
consistency.  Pastes can be applied to well-demarcated lesions.  Due to its ointment 
base, they are difficult to remove. 
Powders promote drying and are especially useful in intertriginous areas but in the 
wet areas powder can form clumps. They are used in subacute processes without 
weeping. 
Aerosols and sprays act in a manner similar to lotions and gels. Active ingredients 
are incorporated into aqueous phase. A convenient delivery system usually allows 
for easy dispersion over the skin surface. Aerosols are also particularly useful on 
the erosive and ulserative lesions. 
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Solutions possess anti-inflammatory and cooling effects. The main indication for 
solutions in dermatology is wet dressings in acute exudative skin surface (eczema, 
pyoderma). 
 
Box 4.1.The vehicle is prescribed according to the stage of the inflammation 
process 
 
Acute inflammation (weeping, bright erythema, edema, erosion) → sprays, wet-drying 
bandages, solutions 
Acute inflammation without weeping (hyperemia, swelling) → creams, lipocreams, pastes, 
aerosols 
Subacute inflammation (light swelling and hyperemia, mild itching) → creams, lipocreams, 
pastes, ointments 
Chronic inflammation (lichenification, infiltration) → hot compresses (occlusion), ointment, 
keratolytic and keratoplastic ointments 
Hyperkeratosis (palms and solves) → keratolytic ointment under occlusion 
 
In general terms, the greasier a base is the more occlusive it is. This also generally 
implies a greater degree of emolliency or moisturizer effect, as it prevents water 
loss to a greater degree. On the other hand, a lighter cream is much easier to use 
and is much more cosmetically acceptable to most patients.  
Some of the more modern oily creams aim to achieve a balance between these two 
extremes, by providing a higher degree of occlusion and emolliency with a lower 
and more acceptable degree of "greasiness". Some agents designed purely to be 
emollients contain additional elements (such as urea, allantoin, or aloe vera) which 
are claimed to increase the moisturizing effects 
 
1.2. Quantities Required 
A useful guide is the fingertip unit (FTU) which equals ½ g. One FTU is the 
amount of topical agent that can be applied to the terminal phalanx of the index 
finger.The whole body requires 20-30 g of ointment per single dose. 
 
Table 4.1 Ointment per Single Dose In an Adult 
 
Body part Quantity 
Face or neck 1g 
Trunk (each side) 3g 
Arm 1 ½ g 
Hand ½ g 
Leg 3 g 
Foot 1 g 
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Table 4.2 Overview of Topical Medications 
 
Drug Pharmacology Indications 
Antibiotics Resistance and sensitization are potential 
problems.  Bacitracin, chlortetracycline, 
gramicidin, mupirocin, neomycin, 
polymixin, sodium fusidate.   
Metronidazole is used for rosacea. 
Acne, folliculitis, 
impetigo, infected 
eczema, rosacea. 
Antifungals Polyenes, imidazoles (more than 20), 
allylamines,hydroxypyridones,morpholines, 
benzylamin 
Fungal infections of the 
skin, candidiasis. 
Antiseptics Chlorhexidine, iodine compounds, 
potassium permanganate, silver nitrate. 
Skin sepsis, leg ulcers. 
Antivirals Acyclovir, penciclovir, docosanol Herpes simplex and 
zoster. 
Coal tar Presumed anti-inflammatory and anti-
proliferative effects. 
Eczema, psoriasis. 
Corticosteroids Anti-inflammatory, anti-proliferative, 
vasoconstrictive effects; different strengths 
available. 
Eczema, discoid lupus 
erythematosus, lichen 
planus, lichen sclerosus, 
mycosis fungoides, 
photodermatoses, 
pityriasis rosea, psoriasis.  
Dithranol Anti-proliferative effect Psoriasis. 
Topical 
immunomodulators 
Modulate immune function: tacrolimus and 
pimecrolimus 
Atopic dermatitis 
Retinoids                                                                            Chemically related to vitamin A: tretinoin 
adapalen, isotretinoin, tazaroten 
Moderate and mild forms 
of acne, actinic keratosis, 
plan warts, photoaging 
Vitamin D 
analogues 
Inhibit keratinocyte proliferation and 
promote differentiation:calcipotriol, 
tacalcitol. 
Psoriasis 
Keratolytics Salicylic acid, benzoyl peroxide Acne, scaly eczemas 
Diphencyprone Induces allergic contact dermatitis  
Parasiticidals Malathion, permethrin, carbaryl for lice. 
Benzyl benzoate, lindane, malathion, 
permethrin for scabies. 
Lice, scabies 
   
 
1.3.Topical Corticosteroids 
Topical corticosteroids are undoubtedly the mainstay of the treatment of all the 
eczema/dermatitis group of conditions and of many other inflammatory dermatoses 
(e.g. lichen planus and lupus erythematosus). They also have a valuable role in 
psoriasis, especially on certain sites. However, topical corticosteroids need to be 
handled with care. They have the potential to cause significant skin atrophy if they 
are applied to the same area of skin repeatedly over many weeks or months. They 
reduce the skin’s resistance to superficial infections. They can inhibit the pituitary-
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adrenal axis if sufficient quantities are applied to lead to significant systemic 
absorption. 
It is important to appreciate that topical corticosteroids are by no means “all the 
same”:some are much stronger than others (Table 4.3). Furthermore, several 
factors increase the potential for atrophogenicity and absorption: 
The base – ointments>creams>gels>lotions. 
The site of application – the face and flexures are much more vulnerable. 
The size of the patient – children have a higher surface-area-to body-mass ratio and 
are more susceptible to absorption of steroids. 
The use of occlusive dressings over the steroids (especially polythene). 
Table 4.3 Steroid Potency 
Potency Examples 
Mild Hydrocortisone 
Moderately potent Alcometasone dipropionate 
Hydrocortisone with urea 
Potent Betametasone valerate 
Fluocinolone acetonide 
Fluocinonide 
Hydrocortisone butyrate 
Very potent Clobetasol propionate 
The most appropriate topical steroid for a givensituation should be determined by 
the type and severity of the condition being treated, the sites affected, and the age 
of the patient. In general, a severe dermatosis should be treated with a potent 
steroid, and a mild condition with a weak steroid. In the case of a chronic 
dermatosis subject to periodic exacerbations a mild to moderate potency steroid 
can be used when the condition is quiescent, and a potent preparation when it 
worsens. 
There are regional variations in the absorption of topical steroids through the skin 
and their potential for local adverse effects. These variations are determined by the 
thickness of the stratum corneum, occlusion, for example in the flexures where 
skin surfaces are in apposition, and the vascularity of the area. Most facial 
dermatoses should only be treated with mild topical steroids, although a few 
conditions such as discoid lupus erythematosus will require potent preparations. 
Skin diseases affecting the axillae, groins and submammary areas should also be 
treated with mild topical steroids. Conversely, dermatoses of the palms and soles, 
where the stratum corneum is extremely thick, require potent steroids, and a 
greater benefit is often obtained if polythene occlusion is used to enhance 
penetration. 
There is a greater risk of adverse systemic effects from the use of topical steroids 
in children because of the high ratio of skin surface area to body volume, 
particularly in infants. For this reason mild topical steroids should be used in small 
children. The skin of the elderly is thin and potent steroids will amplify this change 
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– their use over long periods of time should therefore be avoided or carefully 
supervised. 
Side effects of steroid topical application 
Skin atrophy. Repeated use of topical steroids in the same area can cause thinning 
of the epidermis and changes in the connective tissue of the dermis. The skin 
becomes lax, wrinkled, and shiny with visible teleangiectasias, hypopigmentation, 
and prominence of underlying veins. In most cases the atrophy is reversible once 
topical steroid use is stopped, but it may take month for the skin to “thicken” back 
up. 
Tachyphylaxis. Tachyphylaxis is the tolerance which the skin develops to the 
vasoconstrictive action of topical steroids. After repeated use of topical steroids the 
capillaries of the skin do not constrict as well requiring higher doses or more 
frequent application of the steroid. The ability of the blood vessels to constrict 
returns 4 days after stopping therapy. 
Steroid rosacea. This is a side effect commonly observed in fair-skinned people 
who already have rosacea. A typical example occurs when a person uses a very 
mild steroid on the face to counteract the facial flashing and teleangiectasia. This 
gives pleasing results, but tolerance develops causing the person to use a higher 
strength steroid. At this point any attempt to cut down on the steroid application or 
stop altogether causes intense facial redness and pustules. 
Striae – stretch marks. Repeated use of topical steroids in arrears where skin 
touches skin such as the groin and armpits can result in striae,or stretch marks. 
Stretch marks from topical steroids are permanent and irreversible. It is 
recommended to progressively decrease the steroid potency until topical steroid 
therapy in these areas can be terminated.  
Alteration of infection. Because topical steroids change the way the immune 
system functions, they can inhibit the skin’s ability to fight off bacterial or fungal 
infections. A typical example of this is seen when someone applies a topical 
steroid to an itchy groin rush. If this is a fungal infection, the rash gets redder, 
itchier and spreads more extensively than a typical fungal infection. The resulting 
rash is a bizarre pattern of widespread inflammation with pustules called tinea 
incognito. 
Topical steroid allergy.Some people may be allergic to a component of a topical 
steroid base or vehicle. People who have chronic skin conditions and use multiple 
prescriptions or over the counter topical steroids are at higher risk of developing 
allergies to topical steroids. 
Systemic side effects. As long as the doses of steroids are appropriate, systemic 
side effects are rare. However, when strong steroids are applied on a large area for 
a long period or when they are used in occlusive therapy, side effects similar to 
those caused by steroid systemic administration may be produced (e.g. iatrogenic 
Cushing’s syndrome). 
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1.4. Topical Retinoids 
There is now consensus that topical retinoids should be used as the first-line 
therapy, alone or in combination, for mild-to-moderate inflammatory acne and are 
also preferred agents for maintenance therapy. Their effectiveness is well 
documented, as they target the abnormal follicular epithelial hyperproliferation, 
reduce follicular plugging, microcomedones and both non-inflammatory and 
inflammatory acne lesions.  
Tretinoin, adapalen, isotretinoin, taxaroten are effective comedolytic agents. 
Topical tretinoin is also effective in actinic keratosis, and plane warts.  
Isotretinoin and tazaroten were found to improve photoaging skin changes. 
Epidermal melasma, actinic lentigines, superficial post-inflammatory 
hyperpigmentation also respond to topical tretinoin, either alone or in combination 
with hydroquinolone and hydrocortisone. 
 
Table 4.4Topical Retinoids 
 
Substance Vehicles Indication 
Adapalen 0,1% gel, solution, cream Mild/moderate acne 
Alitretinoin 0,1% gel AIDS-related Kaposi’s sarcoma 
Bexaroten 0,1% gel Cutaneous T-cell lymphoma 
Isotretinoin 0,05% gel; 0,05%, 0,1% cream Mild/moderate acne, photoaging 
Tazaroten 0,05%, 0,01% gel Psoriasis, mild/moderate acne 
Tretinoin 0,025%, 0,1%,0,05%, 0,1%, 0,4% cream 
0,025% gel, 0,05%, 0,1%, 0,2%  solution, 
0,1% ointment 
Mild/moderate acne, photoaging 
Cosmetic indications 
Tretinoin 0,025% cream  Inflammatory rosacea 
 
1.5. Topical Antifungal Agents 
There is a wide variety of topical antifungal agents but there is no truly effective 
topical agent for onychomycosis, although nail vanishes (ciclopirox 8% and 
amorolfin) are now available for treatment of onychomycosis. The spectrum of 
action of topical anifungal agents is shown in Table 4.5. 
Table 4.5. Topical Antifungal Agents and Their Spectrum of Action 
Agent Spectrum of action 
Dermatophytes Yeasts Molds 
Polyenes 
- Amphotericin B +   
- Nystatin +   
- Natamycin + + + 
Imidazole (more than 20) + + + 
Allylamines 
- Naftifin +   
- Terbinafine +   
Hydroxypyrudones 
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- Ciclopirox + + + 
Morpholines 
- Amorolfin +   
Benzylamine 
- Butenafin +   
Others 
- Tolnaftat +   
- Clioquinol +   
- Undecylenic acid +   
- Iodoquinol +   
 
1.6. Topical Immunomodulators 
Two agents that modulate immune function after topical application are tacrolimus 
and pimecrolimus. They have been primarily introduced for the treatment of atopic 
dermatitis. Both exert their effect predominantly by calcineurin inhibition, which 
alters T-cell reactivity. They have both been shown to be effective in atopic 
dermatitis, and successful use in other disorders is being reported. They have the 
obvious advantage of not being corticosteroids and therefore avoiding steroid side-
effects, notably cutaneous atrophy.  
1.7. Other Topical Dermatological Preparations 
Salicylic acid 
Salicylic acid “softens” keratin and helps to remove scale from psoriasis and from 
very scaly disorders, especially in the scalp. It is therefore often added to mixtures 
of tar and steroids. Salicylic acid in higher concentrations is also used to treat viral 
warts. 
Tar and dithranol 
Tar is soothing to itchy, inflamed skin. It is also a valuable adjunct in the 
management of psoriasis, where it seems to augment the effects of ultraviolet 
radiation. Dithranol is a strange material, originally isolated from Goa powder, 
which can return psoriatic skin to normal. It can cause quite nasty burns, however, 
and it also oxidizes to a brownish purple dye. It is used in creams and ointments 
and in a complicated, stiff paste known as Lassar’s paste. 
Vitamin D analogues 
Vitamin D analogies are relatively new, but have quickly found and important 
place in the management of plaque psoriasis. Reports of improvement have also 
been recorded on other hyperkeratotic disorders such as pityriasis rubra pilaris, 
ichthyosis, porokeratosis and epidermal nevi. 
Diphencyprone 
There are good studies that have shown that the application of agents that induce 
allergic contact dermatitis can encourage regrowth in alopecia aerated, although 
the percentage of those who derive persisting benefit is small. Diphencypron 
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appears to have replaced some of the earlier alternatives because it is safer (not 
oncogenic). 
 
2. Systemic Therapy 
 
Systemic therapy is reserved for more serious condition and infections (see Box 
4.1). 
  
Box 4.1 Systemic therapy 
Group Drug Indications 
Antiandrogens Cyproterone Acne (only in females)  
Antibiotics Various Acne, rosacea, skin sepsis, 
bacterial infections 
Antifungals Griseofulvin 
Ketoconazole 
Itraconazole 
Terbinafine 
Fungal Infection 
Fungal Infect., candidiasis 
Fungal Infect., candidiasis 
Fungal Infection 
Antihistamines H1- Blockers Eczema, urticaria 
Antileprotic Dapsone Dermatitis herpetiformis, 
leprosy, vasculitis 
Antimalarials Hydroxychloroquine Lupus erythematosus, 
polymorphic light eruption, 
prophyria cutanea tarda 
Antivirals Acyclovir 
Famciclovir 
Herpes simplex/zoster 
Herpes zoster, genital herpes 
simplex 
Corticosteroids Prednisolone usually Bullous disorders, connective 
tissue disease, vasculitis 
Cytotoxics/ 
immunosuppressives 
Methotrexate 
Hydroxyurea 
Azathioprine 
Cyclosporin 
Gold 
Psoriasis, sarcoidosis 
Psoriasis 
Bullous disorders, chronic 
actinic dermatitis 
Psoriasis, atopic eczema 
Bullous disorders, lupus 
erythematosus 
Retinoids Acitretin 
Isotretinoin 
Keratinization disorders 
Acne 
Monoclonal antibodies 
(Biologics) 
Infliximab 
Etanercept 
Psoriasis with or without 
arthropathy 
 
2.1. Systemic Antifungal Agents 
The prescription of systemic antifungals depends on their spectrum of action (see 
Table 4.7 and Table 4.8). Main indications for systemic antifungal drugs are 
• chronic recurrent tinea disorder such as tinea pedis: dyshydrotic and 
hyperkeratotic forms, 
• spreadinglesions in tinea capitis, 
• acute tinea inflammation (vesicles, papules, pustules) as in tinea ungum 
(total dystrophic, proximal forms). 
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Table 4.7 Systemic Antifungals and Their Spectrum of Action 
 
Agent Spectrum of action 
Dermatophytes Yeasts Molds 
Griseofulvin +++ - - 
Terbinafine +++ ++ - 
Itraconazol +++ +++ +++ 
Ketaconazol ++ + - 
Fluconazol ++ +++ - 
 
 
Table 4.8  Antifungalsfor Systemic Use 
 
Drug Mechanism of action Indications 
Terbinafine Inhibits sterol biosynthesis by 
blocking squalene peroxidase 
causing accumulation of squalene 
and cell death 
Primarily dermatophytes (tinea 
corporis, tinea capitis, tinea pedis, 
tinea ungum) 
Griseofulvin Binds to tubulin, interfering with 
microtubule function thus inhibiting 
mitosis. The micronized forms are 
better absorbed and distributed 
Dermatophyte infections (tinea 
capitis), not effective against yeasts 
and molds. Griseofulvin is still the 
only agent approved for tinea 
capitis in children, it has been 
replaced in most of its other uses by 
the more effective imidazoles. 
Itraconazole Inhibits cytochrome P450 –
dependent synthesis of ergosterol, a 
key component of fungal cell walls. 
Because of its ability to inhibit 
cytochrome P450, caution should be 
used when considering interactions 
with other medications 
Effective against dermatophytes, 
molds and many yeasts. Excellent 
against Candida albicans and 
Candida krusei; moderately 
effective against other Candida 
species, cutaneous mycoses, 
including onychomycoses, mycoses 
in HIV/AIDS, mucocutaneous and 
systemic candidiasis, recurrent 
vaginal candidiasis, aspergillosis, 
soft tissue mycotic infections. 
Fluconazole Inhibits cytochrome P450 –
dependent synthesis of ergosterol, a 
key component of fungal cell walls 
 Effective against dermatophytes and 
yeasts; not molds. Effectiveness 
reduced against Trichophyton 
mentagrophytes, Candida glabrata 
and Candida guilliermondii. Useful 
for candidiasis in almost all settings 
from acute vaginal to HIV/AIDS to 
chronic mucocutaneous candidiasis, 
dermatophytes infections, including 
onycomycosis 
Ketoconazole Structurally similar to imidazole, and 
interferes with the fungal synthesis 
of ergosterol, a constituent of fungal 
cell membranes 
Inhibits growth of dermatophytes 
(tinea criris, tinea corporis, tinea 
pedis) and yeast species such as 
Candida albicans 
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2.2. Antihistamines 
There are several types of antihistamine agents that bind to histamine receptors to 
inhibit their functions, H1-receptor inhibiting drugs, widely used in dermatological 
treatment, are extremely effective in the treatment of allergic inflammatory skin 
disorders. Antihistamines suppress the histamine-induced wheal response 
(swelling) and flare response (vasodilatation) by blocking the binding of histamine 
to its receptors on nerves, vascular smooth muscle, glandular cells, 
endothelium,and mast cells. They exert a competitive antagonism to histamines. 
Itching and sneezing are suppressed by antihistamine blocking of H1-receptors on 
nasal sensory nerves. 
In common sense, the term antihistamines refers only to H1-antagonists, also 
known as H1-antihistamines. Sedation is a common side effect of first-generation 
antihistamines, such as diphenhydramine and doxylamine, which are also used to 
treat insomnia. However, second-generation antihistamines, such as loratadine, 
cetirizine, fexofenadine do not cross the blood-brain barrier, and as such do not 
cause drowsiness and also they have a long serum half-life. 
The main indications for H1-antihistamines in skin are suppression of pruritus in 
urticaria and atopic eczema, both of which are associated with increased mast cell 
numbers and tissue histamine levels. 
 
Table 4.9 Systemic Antihistamines 
 
First generation (sedative) Second generation (non-sedative) 
Brompheniramine Cetirizine hydrochloride 
Chlorpheniramine Fexofenadine hydrochloride 
Clemastine Loratadine 
Cycloheptadone hydrochloride Desloratadine 
Dyphenhydramine Levocabastine 
Hydroxyzine hydrochloride Mizolastine 
Promethazine hydrochloride Acrivastine 
Promathazine teoclate Levocetirixine dihydrochloride 
Trimeprazine  
 
2.3. Antileprotics 
Dapsone is used extensively as a first line agent in leprosy.It also has important 
effects on several other diseases with no apparent common features (apart, perhaps, 
from the pathological involvement of polymorphs).It is a sulfone drug and sulfones 
are related to the sulfonamide family. 
Dapsone has anti-inflammatory and immunomodulatory effects, which are thought 
to come from the drug's blockade of myeloperoxidase. This is thought to be its 
mechanism of action in treating dermatitis herpetiformis. 
Dapsone is also useful in such diseases as linear IgA bullous dermatosis, bullous 
eruption of systemic lupus erythematosus and erythema elevatum diutinum, other 
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autoimmune bullous diseases (e.g. pemphigus foliaceus, bullous pemphigoid) and 
selected vasculitic syndromes.  
 
2.4. Antimalarials 
The most common antimalarials are chloroquine and hydroxychloroquine. The 
mechanism of action of the antimalarials is not well known. They exert various 
anti-inflammatory effects and they decrease platelet aggregation. The antimalarials 
are a second line therapy for cutaneous lupus erythematosus, after topical 
intralesional corticosteroids. They are especially useful in patients with widespread 
discoid lesions and in those with annular or papulosquamous lesions of subacute 
cutaneous lupus erythematosus. Other diseases are polymorphous light eruption, 
sarcoidosis, lichen planus.  
 
2.5. Antiviral Agents 
The systemic antiviral drugs are acyclovir, valacyclovir, cidofovir, famcyclovir, 
foscarnet sodium injections, gancycloivir.Acyclovir, valacyclovir and famcyclovir 
are all effective against herpes labialis when used intermittently or suppressively, 
and they are all effective in treating herpes zoster. 
Intravenous acyclovir is used in immunocompromised patients with disseminated 
HSV or VZV and in patients with severe herpes zoster. 
Famcyclovir is indicated for herpes zoster primarily or recurrent genital herpes, 
herpes suppression in immunocompetent patients and recurrent herpes simplex in 
HIV-infected patients. 
Foscarnet is an intravenous antiviral used for CMV retinitis or CMV skin infection 
in HIV-infected patients and for acyclovir-resistant herpes simplex infections. 
 
2.6. Cytotoxic/Immunosuppressive Agents 
Methotrexate 
Methotrexate (MTX) is and antimetabolite and a folic acid antagonist. It was first 
developed as an anticancer drug. MTX inhibits the synthesis of DNA, RNA, 
thymidylates, and proteins.Besides, it inhibits enzymes involved in purine 
metabolism, leading to accumulation of adenosine. MTX also exertsinhibition 
of T-cell activation and suppression of intercellular adhesion molecule expression 
by T cells, as well as selective down-regulation of B cells. Its use in severe, 
debilitating or recalcitrant, psoriasis is well established, where it is one of the most 
reliable agents available. MTX is also used in pityriasis rubra pilaris, pytiriasis 
lichenoides et varioliformis acuta (PLEVA), lymphomatoid papulosis, Reiter’s 
disease, dermatomyositis and sarcoidosis, in certain types of vasculitis, 
neutrophilic and immunobullous dermatoses, in particular bullous pemphigoid. 
The drug is associated with some side effects, notably marrow suppression and 
liver fibrosis, but these can generally be avoided if patients are monitored properly. 
Avoidance of alcohol and awareness of drug reactions is important. 
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Azatioprine 
Azatioprine exerts moderately potent anti-inflammatory and immunosuppressive 
effects. It should be reserved for more serious, life-threatening or recalcitrant 
dermatoses after other therapies have failed. The active metabolite of azathioprine 
(6-thioguianine) inhibits purine metabolism and cell division. It has also other 
activities, which are not well understood, such as suppression of T-cell function 
and B-cell antibody production. It also decreases the number of Langerhangs cells 
in the skin and inhibits their ability to present antigen. 
Azatioprine is most often used as a corticosteroid-sparing agent in the treatment of 
immunobullous diseases such as pemphigus vulgaris, bullous pemphigoid and 
cicatrical pemphigoid, cutaneous vasculitis, severe, recalcitrant atopic dermatitis 
and chronic actinic dermatitis in adults, connective tissue diseases such as systemic 
lupus erythematosus and dermatomyositis, it may improve the cutaneous 
manifestations as well. There may be a delay of 4-6 weeks in the onset of full 
clinical benefits. 
 
Cyclosporine 
Cyclosporine is a cyclic peptide of 11 amino acids, and has clinical 
immunosuppressive effects. Two forms are available, the original preparation 
(Sandimmune) and a predigested microemulsion (Neoral) that is more completely 
and consistently absorbed.  
Cyclosporine binds to cyclophilin a member of the family of intracytoplasmatic 
proteins and the inhibitory action of thiese complex results in a decrease on the 
number of CD4+ and CD8+ (cytotoxic) T-cells in the epidermis. 
Cyclosporine is best used on a short-term basis (< 6-12 months) to control flares of 
psoriasis and to provide an alternative to the patient’s current regimen. It is 
reasonable to use cyclosporine as a sequential therapy with acitretin, methotrexate 
or other systemic therapies. After psoriasis clearance has been initiated by 
cyclosporine, the alternative medicine may be started and advanced to the 
therapeutic dose. At the same time, cyclosporine may be weaned by 1 mg/kg/day 
each month until the patient is receiving acitretin or methotrexate alone. 
Cyclosporine can be beneficial for patients with psoriasis who have failed or 
cannot tolerate other therapies and for those with widespread atopic dermatitis, 
severe pyoderma gangrenosum. 
 
2.7. Retinoids 
The retinoids are a class of chemical compounds that are related chemically to 
vitamin A. Retinoids include naturally occurring molecules and synthetic 
compounds that have specific biologic activities resembling those of vitamin A or 
bind to the nuclear receptors for retinoids. 
There are three generations of retonoids: 
• First generation retinoids include retinol, retinal, tretinoin (retinoic acid), 
isotretinoin, and alitretinoin. 
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• Second generation retinoids include etretinate and its metabolite acitretin. 
• Third generation retinoids include bexaroyene, tazarotene and adapalene. 
 
The biological functions and actions of retinoids: 
1. Reproduction, embryonic growth and morphogenesis 
2. Modulation of proliferation and differentiation of epithelium. 
3. Decreae in sebaceous gland size (isotretinoin) 
4. Immunological and anti-inflammatory effects 
5. Tumor prevention and treatment 
6. Effect on extraxellular matrix components. 
Systemic treatment with acitretin is effective in several disorders of keratinization. 
Darier’s disease, ichtyosis vulgaris, congenital ichtyosis (particularly dry lamellar 
type, various types of palmoplantar keratoderma, and also erythrokeratoderma 
figurate variabilis today represent standard indication for oral acitretin treatment. 
Oral acitretin belongs nowadays to the mainstream systemic antipsoriatic 
treatment, particularly in severe pustular and erythrodermic types of the disease. It 
acts on a pathological epidermis to reduce proliferation and stimulate 
differentiation. Acitretin is usually prescribed in combination with other modalities 
(mild corticosteroids, dithranol, tar, vitamin D derivatives) and/or with 
phototherapy (Re-PUVA). Palmoplantar pustulosis, psoriasis of nails, HIV-
associated psoriasis significantly improve under systemic acitretin. In pityriasis 
rubra pilaris, a beneficial effect can be expected under systemic acitretin, 
especially on juvenile type of the disease. 
Oral isotretioin is only one drug currently available that affects all four pathogenic 
factors of acne, directly suppressing abnormal desquamation of sebaceous follicle 
epithelium and sebum production. The basic patterns of use of retinoids are 
described in Table 4.10. 
Contraindications: pregnancy, breast-feeding 
Pregnancy is recommended to be excluded in female patients two weeks prior to 
commencement of isotretinoin, and patients should use two simultaneous forms of 
effective contraception at least one month prior to commencement, during and for 
at least one month following isotretinoin therapy, women of childbearing age 
should either abstain from sexual intercourse or use 2 effective methods of birth 
control for at least 1 month before, while taking and for 3 years after taking 
acitretin. 
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Table 4.10 Retinoids in Dermatology 
 
Retinoids Skin disorder Clinical forms 
Isotretinoin Acne Nodulocystic 
Severe scarring 
Severe acne-associated 
psychological distress 
Isotretinoin Rosacea Nodulocystic 
Papulo-pustular 
Acitretin 
Etretinate 
Psoriasis Palmo-planter puslular 
Pustular generalized 
Erythrodermic 
Psoriasis of nails 
Acitretin Lichen planus Oral and skin forms 
Etretinate Cutaneous T-cell lymphoma Sezary syndrome with no 
organ involvement 
Bexaroten Early Ia,IB, IIA stages 
Alitretinoin Sarcoma Kaposi  
 Epithelium tumor  
Acitretin Ichtyosis Lamellar ichtyosis 
X-linken ichtyosis 
Epidermolytic ichtyosis 
Ichtyosis vulgaris 
Acitretin 
Isotretinoin 
Darier’s disease  
Etretinate Pityriasis rubra pilaris  
Acitretin 
Etretinate 
Lichen sclerosus and 
atrophicus 
Genital region localization 
Alitretinoin Chronic hand eczema 
Seborrhea 
 
 
2.8. Biologics 
Biologics are novel compounds composed of antibodies or other peptides that act 
through one of three mechanisms: inhibiting inflammatory cytokine signaling 
(typically tumor necrosis factor or TNF), inhibiting interleukins, T-cell activation, 
or depleting B-cells. They are being used more frequently to treat a multitude of 
systemic inflammatory conditions. In the past ten years biologic drugs have 
emerged as an important advance in the treatment of inflammatory diseases such as 
rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic 
arthritis, plaque psoriasis, Chron’s disease and ulcerative colitis. 
Biologics are divided into three groups: 
1. Recombinant human cytokines and growth factors (interferon-α [INF-α], 
interferon-γ [INF-γ], interleukin 1 receptor antagonist [IL1Ra], interleukin 2 [IL-
2], interleukin 4 [IL-4], interleukin10 [IL-10], interleukin 11 [IL-11],granulocyte 
macrophage colony stimulating factor [GV-GSF], platelet derived growth factor 
[PDGF]. 
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2. Monoclonal antibodies 
– Anti TNF-α: infliximab, adalimumab,certolizumab,golimumab 
– Anti-LFA1: efalizumab 
– Anti-CD20: rituximab 
– Anti-IL-12 and anti-IL-23 monoclonal antibody: ustekinumab 
– Anti-CD2 antibody: siplizumab 
– Anti-CD4 antibody: orthoclome (OKTcdr4a) 
– Anti-CD25 antibodies: basiliximab, daclizumab 
– Anti-CD80r: galiximab (IDEC 114) 
– Anti-IgE: omalizumab 
3. Fusion antibody proteins (chimeric proteins) 
– Etanercept 
– Alefacept 
– Abatacept 
Infliximab (a chimeric monoclonal anti-TNF antibody), adalimumab (a fully 
human anti-TNF monoclonal antibody) and etanercept (a recombinant soluble 
decoy TNF-receptor) exert therapeutic effects via the suppression of TNF-α, a 
cytokine released by macrophages that is central to cell-mediated immunity. 
Ustekinumab is a fully human monoclonal antibody that binds with high 
specificity and affinity to the cytokines interleukin -12 and IL-23 thereby 
suppressing IL-12 and IL-23-mediated inflammation associated with psoriasis. 
 
3. Phototherapy and Photochemotherapy 
 
Phototherapy is nowadays one of the main methods used in dermatology. It can be 
used alone or in combination with oral and/or topical treatment. The action of 
ultraviolet radiation is exploited for the treatment of many diseases. The detection 
of the type of skin isvery important in the appointment of phototherapy. The 
classification of skin types known as the Fitzpatrick skin type (or phototype) 
depends on the amount of melanin pigment in the skin (see Table 4.11) and helps 
the doctor to prescribe phototherapy. 
 
Table 4.11 Skin Types 
 
Skin Type Typical features Tanning ability 
I Pale, white skin, blue/hazel eyes, 
blond/red hair 
Always burns, does not tan 
II Fair skin, blue eyes Burns easily, tans poorly 
III Darker white skin Tans after initial burn 
IV Light brown skin Burns minimally, tans easily 
V Brown skin Rarely burns, tans darkly easily 
VI Dark brown or black skin Never burns, always tans darkly 
 
Dermatologists have been used various forms of light treatment for years in the 
management of psoriasis, eczema and vitiligo. The range of conditions for which 
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various regimens are used has increased significantly over the last few years and 
now includes, paradoxically, some of the photodermatoses. 
Ultraviolet light is divided to three wavelength ranges. From longest to shortest, 
they are UVA (320 nm till 400 nm), UVB (290 nm till 320 nm), und UVC (200 nm 
to 290 nm). The shorter wavelength the lower is the penetration and the greater the 
energy of light. UVA and UVB directly or indirectly damage DNA by exciting UV 
light absorbing molecule or they produce free radicals that injury cells. 
The following types of phototherapy are used for dermatological purposes: 
• UVB-therapy 
• UVA1 long wave therapy 
• Photochemotherapy (PUVA) 
• Photodynamic therapy 
• Laser therapy 
 
3.1. UVB-Therapy 
UVB-therapy (290 nm till 320 nm) is the type of immunosuppressive therapy that 
inhibits the function of Langerhance cells. Narrowband UVB-therapy (311 nm) 
is thought to be more effective than broadband UVB in the treatment of skin 
diseases. Indications forUVB therapy are vitiligo, psoriasis, pityriasis lichenoid 
chronica, atopic dermatitis, lichen planus, alopecia areata, pruritus, mycosis 
fungoides.  
UVB (290-320 nm) is given 3 times a week. The initial dose is determined from 
the patient’s skin type or minimal erythema dose (MED). With each visit, the 
scheduled dosage is increased. Commonly, 10-30 treatments are the normal course. 
UVB can be used in children and pregnant women. Side effects include acute 
sunburn and increase risk of skin cancer. 
 
3.2. UFA 1 Long Wave Therapy (340 nm-400 nm) 
Unlike UVB radiation that can penetrate at the most into the papillary dermis, 
longer wavelengths in the UVA region have the capacity to reach the subcutis as 
well. Accordingly, as well as due to its lesser antiproliferative activity, UVB has 
not been established in the treatment of sclerotic disorders excerpt foe occasional 
cases of graft-versus-host disease (GvHD). 
UVA 1 irradiation has been shown to initiate atopic cell death in dermal T-
lymphocytes and dermal immunoregulation. Besides, UVA1 irradiation induces 
the formation of several cytokines and soluble factors, e.g. interleukin-1 and/or 
interleukin-6 stimulating the synthesis of collagenase. Indications for UVA1 long 
wave phototherapy are lupus erythematosus, scleroderma, exacerbated atopic 
dermatitis, cutaneous T-cell lymphoma, parapsoriasis or mucinosis follicularis, 
polymorphic light eruption, actinic prurigo, cutaneous porphyrias. 
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3.3. Photochemotherapy (PUVA) 
UVA alone has minimal effect, thus it is used in combination with photosensitizing 
psoralens given topically or systemically. PUVA stand for Psoralens plus 
UltraViolet A. Commonly, oral 8-methoxypsoralens is taken 2 hours before UVA 
(320-400 nm).  The psoralen is photoactivated, which results in DNA cross-
linking, inhibition of cell division, and suppression of cell-mediated immunity. 
Like UVB, the initial dose of UVA is determined by MED or skin type; and 
dosage is increased a scheduled visits. PUVA is usually given 2-3 times per week 
for 15-25 treatments. PUVA can be combined with acitretin (RePUVA) but not 
methotrexate. Bath PUVA, bath containing a psoralen, is an alternative to systemic-
side effects of oral psoralens.Local PUVA, topical psoralen, may be effective in 
psoriasis and dermatitis involving the hands or feet. PUVA may be given 
for psoriasis, mycosis fungoides, atopic eczema, polymorphic light eruption or 
vitiligo.  Acute side effects include pruritus, nausea, erythema; long-term side-
effects of premature skin ageing and skin cancer depend on the number and total 
dose of UVA.  Cataracts are possible and UVA-opaque sunglasses must be worn 
for 24 hours after taking psoralen. 
 
3.4. Photodynamic Therapy 
Photodynamic therapy (PDT) is used clinically to treat a wide range of medical 
conditions, including age-related macular degeneration and malignant cancers, and 
is recognizedas a treatment strategy which is both minimally invasive and 
minimally toxic. PDT uses exogenously administered or endogenously formed 
photosensitizers activated by light to induce cell death via formation of sunlight 
oxygen and other free radicals. 
Photodynamic therapy is a 2-step procedure. In the first step, the photosensitizer is 
administered to the patient by one of several routes (e.g. topical, oral, intravenous), 
and it is allowed to be taken up by the target cells. The second step involves the 
activation of the photosensitizer in the presence of oxygen with a specific 
wavelength of light directed toward the target tissue. Because thephotosensitizer is 
preferentially absorbed by hyperproliferative tissue and the light source is directly 
targeted on the lesional tissue, photodynamic therapy achieves dual selectivity, 
minimizing damage to adjacent healthy structures. For dermatological purposes, 
incoherent lamps or light emitting diode arrays can be used for lightactivation. 
The basis of PDT is the interaction of light with photosensitive agents to produce 
an energy transfer and a local chemical effect. Beyond direct phototoxic effects on 
target tissue, photodynamic therapy with various photosensitizers has been shown 
to modify cytokine expression and induce immune-specific responses. 
Immunologic effects include the production of interleukin-1 beta, interleukin 2, 
tumor necrosis factor-alpha, and granulocyte colony-stimulating factor. 
Photodynamic therapy generally has a low potential for causing DNA damage, 
mutations, and carcinogenesis. Photosensitizers used for PDA are 5-aminolevulinic 
acid (ALA), methyl ester of ALA. Indications for PDT in dermatology are basal 
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cell carcinoma, Bowen disease, squamous cell carcinoma, actinic keratosis, 
malignant melanoma, mycosis fungoides, Kaposi sarcoma. Non-tumoral 
applications of ALA-PDT are psoriasis, acne vulgaris, viral warts, alopecia areata, 
photoaging. 
 
3.5. Laser Therapy 
Laser – Light Amplification by Stimulated Emission ofRadiation – produces high 
energy radiation. 
Lasers used in dermatology emit specific wavelengths within the UV (10-400 nm), 
visible (400-720 nm) and infrared (IR) (720 -1 000 000 nm) portions of the 
electromagnetic spectrum. By the active medium type lasers are divided into solid 
(ruby, neodymium), gas (He-Ne, CO2), semiconductor (or diode), liquid (for 
inorganic and organic dyes), metal-vapor lasers (the most common: a copper vapor 
or gold). 
In dermatology, lasers of the two types are used: low-intensity lasers – for laser 
therapy and high intensity ones – for laser surgery. 
Low-intensity laser radiation has the following effects: anti-inflammatory, 
antioxidant, anesthetic, immunomodulatory, and used to treat atopic dermatitis, 
psoriasis, alopecia areata. The penetration of the laser radiation depends on 
wavelengths, decreasing from the long to the short wave radiation. 
High-intensity is obtained using CO2-laser, Er: YAG laser and argon laser.CO2-
laser is used mainly in dermatology and cosmetology for laser removal 
(destruction) of nevi, warts, tumors, scars and for dermabrasion.  
Relative contraindications for the use of laser therapy are cancer, diabetes mellitus, 
hypertension, hyperthyroidism, arrhythmias. 
 
4. Basic Surgical Procedures 
 
Excisional Biopsy. Excision axis depends on skin creases/Langer’s lines and its 
margins on the lesion.  Once the skin is numbed with local anesthetic, the skin is 
incised vertically down to the subcutaneous fat with the scalpel, in a smooth 
continuous manner to complete both arcs of the ellipse.  Using simple interrupted 
skin sutures, the wound is apposed and slightly everted. Absorbable subcutaneous 
sutures are used for big excisions. 
Incisional Biopsy.Performed for diagnostic purposes.  The technique is 
comparable to an excision, but less tissue is taken. 
Punch Biopsy. A punch (normally about 4 mm in diameter) is twisted into the 
skin: resulting cylinder of skin is removed and the defect cauterized or sutured. 
Shave Biopsy. Used for benign lesions, usually intradermal nevi or seborrheic 
keratosis. The lesion is shaved parallel to and slightly above the skin’s surface.  
Cautery may be used to achieve hemostasis. Skin tags are removed by using 
scissors to snip them off followed by cauterization to any bleeding points. 
Curettage.After local anesthetic, the lesion is removed by a gentle scooping 
motion with the curette. The base is then cauterized. Curettage may be used in 
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seborrheic keratosis, pyogenic granulomas, keratoacanthomas, single facial viral 
warts, but not nevi. 
Cautery.Provides hemostasis and destroys tissue. The classic cautery machine has 
an electrically heated wire and is self-sterilizing. Silver nitrate sticks or 35% 
aluminum chloride in 50% isopropyl alcohol provide chemical cautery.  
Cryotherapy.Liquid nitrogen (- 196 °C) is delivered by cotton wool bud or spray 
gun and injures cells by ice formation. After immersion into liquid nitrogen, the 
cotton wool bud is applied to the lesion for 10-15 seconds until a thin frozen halo 
appears at the base. The spray gun is used at a distance of 10 mm for a similar 
amount of time.  Longer freezing times are given for malignant tumors. Blisters 
may develop within 24 hours. These are punctured and a dry dressing applied. Side 
effect may include hypopigmentation of pigmented skin, ulceration (especially on 
the lower legs of the elderly). Treatment may be repeated in 4 weeks if warranted. 
Cryotherapy may be used for viral warts, seborrheic keratosis, molluscum 
contagiosum, intraepidermal carcinoma. 
Mohs’ Surgery.Excision of malignant tumor which is mapped and 
microscopically examined to define its extent and the completeness of the 
excision.   
Dermabrasion. A rotating mechanical head wounds the skin down to the dermis. 
Laser (Light Amplification by Stimulated Emission of Radiation). High 
intensity light energy is applied to the tissue. Laser surgery is a rapidly changing 
field in which new types of lasers, as well as the conditions amenable to treatment, 
are continually being introduced.  Lasers vary from a continuous-wave carbon 
dioxide laser to a short-pulsed pigment Q-switched ruby laser.Uses for lasers are 
equally varied and include: port wine stain nevi, telangiectasia, viral warts, some 
tumors, and tattoos. 
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V. FUNGAL INFECTIONS 
 
1. Introduction 
 
Fungi are amongst the most successful and widely distributed of microorganisms 
with habitats ranging from lakes to the Arctic wastes. They are classified as a 
separate kingdom of living organisms and have several distinct structural and 
physiological features: unicellular or filamentous growth; saprophytic or parasitic 
existence; a polysaccharide-based cell wall; and single or multiple nuclei. 
Fungal cells may also be specialized for certain functions, chiefly propagation as 
spores, but also for penetration of underlying structures, such as plant cells or 
hairs. The basic fungal cell is illustrated in Fig. 5.1. 
 
 
 
Fig. 5.1.Fungal Cell 
 
Fungi are divided into five phyla: chytridiomycetes, zygomycetes, ascomycetes, 
ascomycetes, basidiomycetes and imperfect fungi, which have no known sexual 
stage. Many of the pathogenic fungi belong to the last group. 
There are three main ways in which fungi cause disease, although these 
mechanisms cannot be completely separated in every case: 
1.  Allergy. Generally this follows inhalation of fungi. For instance between 4% 
and 15% of respiratory allergic diseases, such as asthma, may be caused by fungi. 
 
62 
 
2.Toxins. The effects of the fungal toxins to be described such as the ergot 
alkaloids from the ergot of rye, Claviceps purpurea, or muscarine from the 
toadstool, Amanita muscaria, have been known for centuries. More 
pharamacologically active toxins, such as the aflatoxins, ochratoxins or 
trichothecenes, have been discovered more recently bit they may also cause human 
disease, for example hepatic necrosis. These toxins may be produced in small but 
significant levels in contaminated grain. 
3. Invasion of tissue – the mycosis. Skin disease ascribed to fungi generally 
follows tissue invasion either from the external surface or by implantation via a 
superficial injury or following internal dissemination from a deep focus of 
infection. 
They are known respectively as the superficial, subcutaneous and systemic 
mycosis (see Table 5.1). Immunological reactions due to the presence of fungi may 
contribute to the pathology of fungal disease. This can occur either at the site of the 
infection, for instance in the formation of granulomas, or by transepidermal 
elimination, or at a distance, by causing skin diseases, such as erythema nodosum, 
urticaria or vesicular eczema (pompholix). Few mycotoxins affect the skin but 
some trichothecenes may cause epidermal necrosis. 
 
Table 5.1.Types of Fungal infections – the Mycosis 
 
Superficial mycosis 
 
Dermatophyte or ringworm infections 
Malasseziainfections (pityriasis versicolor, Malassezia folliculitis) 
Superficial candidosis 
Others: infections dues to Scyralidum 
             white piedra 
             black piedra 
             tinea nigra 
Subcutaneous mycosis 
 
Mycetoma 
Chromoblastomycosis, phaeohyphomycosis 
Sporotrichosis 
Others; lobomycosis 
             subcutaneous zygomycosis 
Systemic mycosis 
 
Infections caused by endemic respiratory pathogens: 
          histoplasmosis 
          coccidioidomycosis 
          blastomycosis 
          paracoccidioidomycosis 
Rare: infections due to Penicillinum marneffei 
Infections due to opportunistic fungi: 
Candidosis 
          Aspergillosis 
          Zygomycosis 
          Cryptomycosis 
Rare: infections due to: 
          Fusarium 
          Hansenula 
          Trichosporon 
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2. Pathogenesis 
 
Skin invasion 
Certain fungi are able to penetrate keratinized cells by producing enzymes such as 
keratinases. Trichophyton mentagropjytes, for instance, has at least two enzyme 
isotypes. In addition, hyphae are able to “squeeze” between keratinocytes. Other 
fungi which cause skin disease have not been shown to produce keratin-splitting 
enzymes. Candida albicans elaborates a proteinase which is important for 
determining virulence and strains which do not produce this enzyme are less 
virulent in experimental infections. Malassezia species produce lipases which may 
aid the digestion of fats in sebum. Fungi which cause nail disease do not all 
produce keratinases and some appear to be able to invade the nail plate only if 
there is a pre-existing abnormality, such as peripheral vascular disease. 
   The process of invasion of skin depends on a number of factors: 
1. Survival of infective spores (arthtospores) in the environment before 
transmission. Many dermatophytes survive for over two years in shed skin scales. 
2. Adhesion of fungal cells to the skin scales. This depends on a time – 
dependent physicochemical bond between a fungal cell-wall receptor and 
keratinocytes or mycosal cells. 
3. Skin surface factors such as pH and carbon dioxide tension. 
The defenses against fungi invading skin are shown in Table 5.2. 
 
Table 5.2.The Defenses Against Fungi Invading Skin 
 
Non-immune mechanisms 
Serum inhibitory factors including unsaturated transferring 
Fatty acids in sebum 
Increased epidermal cell turnover 
Phagocytosis by neutrophils and macrophages 
Immune mechanisms 
T-lymphocutes activation – via cytokines, e.g. gamma interferon, TNF (tumor necrosis factor) 
(Possible role for antibody in opsonization and secretory IgA in mucosal candidosis) 
 
The way in which lymphocytes activation leads to elimination of fungi in 
epidermis is unknown but cytokine-mediated cooperation between neutrophils and 
macrophages and increased epidermal cell turnover are involved. 
Small changes in host defense are important for allowing organisms to invade the 
skin or mucous membranes (see Table 5.3). This means that although not all fungi 
should be regarded as opportunistic pathogens, changes in host resistance will 
make a difference to the outcome and clinical presentation of most fungal 
infections. 
The existence of a pre-disposing factor in the host will not necessarily lead to an 
increased frequency of infection as this also depends on exposure to the infecting 
organisms. In AIDS, for instance, oropharingeal candidosis is very common as 
Candida is normally an oral commensal, but dermatophytosis does not have an 
increased incidence, presumably as the frequency of exposure does not increase. 
64 
 
However, clinical manifestations of dermatophytosis in AIDS patients often differ 
to those seen in other groups. 
 
Table 5.3 Factors Associated with Fungal Infections 
 
Factor Infection 
Age – infancy, old age 
Pregnancy 
Epithelial abnormalities 
 
Endocrine disease 
 
 
 
Antibiotic therapy 
 
 
Immunosuppression (drugs,congenital, 
cancer) affecting: 
neutrophils 
 
 
 
T-lymphocytes 
 
 
 
Zinc deficiency 
 
Iron deficiency 
Candidosis 
candidosis 
candidosis 
dermatophytosis 
candidosis 
dermatophytosis 
pityriasis versicolor 
zygomycosis 
candidosis 
aspergillosis 
 
 
 
candidosis 
aspergillosis 
zygomycosis 
 
most except 
aspergillosis 
zygomycosis 
 
candidosis 
 
candidosis 
 
The reasons for increased incidence of infection in the presence of certain 
predisposing factors are varied. 
Antibiotics reduce the local bacterial flora, which compete for adherence sites. 
Diabetes mellitus increases levels of available sugars in tissues and reduces 
phagocytes efficiency. 
Smoking reduces ciliary clearance of inhaled fungal particles. 
 
3. Epidemiology 
 
The spread of fungal infections depends on a number of factors: 
presence of the organism 
its survival in a form suitable for infection 
route of entry. 
There are two main sources of infection in man: endogenous and exogenous. The 
endogenous infections are caused by fungi which are part of the resident 
microflora such as Candida and Malassezia yeasts. Infection then follows some 
change in the host which allows the fungus to change from saprophyte to parasite. 
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The other fungal pathogens are exogenous organisms. Dermatophytes may 
originate from one of three main sources: animals (zoophilic), soil (geophilic) and 
other humans (antropophilic). All the subcutaneous pathogenic fungi are soil or 
plant organisms; the world distribution of infections depends on their distribution 
in nature. 
Whether one of these organisms causes infection depends on host susceptibility 
which, in turn, is largely determined by the immune status of the host or the 
presence of other risk factors, i.e. sources of infection (see Table 5.4). 
Genetic susceptibility has been proposed in those infections where fungi invade 
without underlying host predisposition. The best evidence for this comes from only 
one disease, tinea imbricata, a dermatophyte infection caused by fungi called 
Trichophyton concentricum. This is based on a population genetic analysis of the 
prevalence of infection in families in the highlights of Papua New Guinea. 
 
Table 5.4Sources of Fungi 
 
Organism Source 
Dermatophytes 
Madurella mycetomatis 
Sporothrix schenckii 
Histoplasma capsulatum 
Coccidioides immitis 
Aspersillus 
 
Zyhomycetes 
Rhizopus rhizopodiformis 
Cryptococcus neoformans 
humans, soil, animals 
plants, thorns 
plants, moss, soil 
soil (bird and bat excreta) 
new world semi-dessert soil 
building work, AC systems, hospital 
equipment, e.g. ventilators, plants 
building work, compost heaps 
dressing packs, bandages 
soil, pigeon excreta, red gum trees 
 
The procedures for investigating the epidemiology of fungal disease are simple 
(see Table 5.5). 
 
Table 5.5 Investigation of the Epidemiology of Mycoses 
 
Superficial mycoses 
• Presence of cases 
• Culture to confirm source 
• (Wood’s light – dermatophytes only) 
Subcutaneous mycoses 
• Presence of cases 
• Culture of cases and environmental sources 
• (Skin testing – for delayed-type hypersensitivity- sporothrichosis only) 
Systemic mycoses 
• Presence of cases 
• Autopsy findings or surgical removal of pulmonary nodules 
• Skin testing (histoplasmosis, coccidioidomycosis, paracoccidioidomycosis) 
• Environmental sampling – choose suitable sites 
5. Superficial Fungal Infections 
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The superficial fungal infections (mycoses) are the commonest of the human 
fungal infections and they include derpatophytosis or ringworm, superficial 
Candida and Malassezia infections as well as rare conditions such as tinea nigra 
and black or white piedra. Superficial infections rarely involve deep tissue except 
in candidosis – although even here most infections arising on the skin or oral 
mucosa will never invade more deeply. 
 
5.1. Dermatophyte Infections 
The dermatophyte or ringworm fungi are hyphal organisms which invade the 
stratum corneumof the epidermis and keratinized tissues such as hair or nail 
derived from it. The dermatophytes affecting man belong to three genera - 
Trichophyton, Microsporum and Epidermophyton. They can be divided into those 
infections which are spread from man to man (anthropophilic), animal to man 
(zoophilic) or soil to man (geophilic). The commonest of these organisms is 
Trichopyton rubrum followed by T. violaceum, T. interdigitale/mentagrohytes, 
Microsporum canis and M. audoinini. However, this pattern differs in different 
countries. For instance, the order of frequency most often seen in the United 
Kingdom and Europe is shown in Table 5.6. However, with specific infections 
such as tinea capitis the causes of disease in different countries are strikingly 
different, as shown in Table 5.7. 
 
Table 5.6 Dermatophytes in the UK and Europe in Order of Frequency of 
Isolation 
 
Frequent isolates Infrequent isolates 
Microsporum canis 
Trichophyton rubrum 
T. interdigitale 
Epidermophyton floccosum 
T. verrucosum 
T. mentagrophytes (animal source) 
T. erinacei 
T. soudanense 
T. viloaceum 
N. equinum 
M. gypseum 
 
Table 5.7Main Casual Agents for Tinea Capitis in Different Geographic Areas 
 
Europe North America Africa India 
M. canis 
T. tonsurans 
T. tonsurans 
M. canis 
M. audouinii 
T. violaceum 
T. soudenense 
M. audouinii 
M. canis 
T. yaoundei 
N. violaceum 
 
Dermatophyte infections occur in any patient irrespective of age or sex. Generally 
scalp infections are not seen in adults except rarely in women, and tinea pedis is 
uncommon under the age of ten. 
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Epidemiology 
Animal or zoophilic infections are usually sporadic and restricted to the areas 
where the host animal is found. Microsporum canis, the cat and dog ringworm, is 
the commonest of the zoophilic infections world-wide and spread occurs directly 
from an infected animal, and possibly from furniture, floors and carpets in the 
home of an infected animal. Anthropophilic dermatophytes are more common in 
the community and in some cases there is evidence to support the existence of 
localized epidemics of infection where there are appropriate conditions for 
transmission. These are seen in swimming baths, school changing areas and 
industrial shower rooms or areas where infected skin scales can be shed on wet 
floors. Spread of dermatophyte infections has led to a heavy rate of infection in 
coal miners in Europe where, in some mines, the infection rate is 35% or more. 
Bacterial infection is also common in this group and may follow dermatophytosis. 
Tinea capitis, a childhood infection, is often a sporadic infection caused 
predominantly by zoophilic organisms such as Microsporum canis. However, in 
some parts of Europe, Asia and Africa, certain urban areas in the USA as well as 
other parts of the world, epidemics of this infection have been described affecting 
large numbers of children and caused by anthropophilic organisms. Transmission 
can occur following a short contact with an infected child. 
Nail infections caused by dermatophytes are common in the community. Studies 
from the United Kingdom suggest that about 2.7% of the population have 
onychomycosis, with an incidence of infection approaching 5 per 1,000 each year. 
At least 50% of these do not present for treatment. 
 
Pathogenesis 
The initial infection probably follows contact with an infected desquamated scale 
or hair. The process of skin invasion is initiated by adherence of the atmosphere to 
the stratum corneum. It then germinates and penetrates keratinocytes. 
 
Pathology 
Most dermatophyte infections are confined to the stratum corneum or specialized 
keratin structures such as hair or nail. In the skin the infection seldom passes the 
granular layer unless there is hair follicle invasion, in which case fungal fragments 
are surrounded by phagocytes or giant cells in the dermis in the vicinity of a 
destroyed follicle. In many infections the main feature is a lymphohistiocytic 
infiltrate around the upper dermal blood vessels, the fungus in the upper layers of 
the epidermis only being visible with special strains such as Periodic Acid Schiff. 
In more inflammatory lesions, the early phase, there is a dense neutrophil 
accumulation around hair follicles. 
 
Clinical features 
The archetypical lesion of a dermatophyte infection is the ringworm or tinea 
circinata. This is a round scaly lesion whose rim is more inflamed and scaly than 
the center. Typically this form occurs in infections of the body, tinea corporis. 
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Dermatophyte infections are normally called “tinea” followed by the appropriate 
part of the body involved (in Latin). Other forms include tinea pedis, tinea 
corporis, tinea cruris, tinea capitis and tinea facei. Nail infections, tinea 
unguium, are also called onychomycosis due to dermatophytes. Tinea incognito 
describes an atypical dermatophyte infection often located on the face and usually 
associated with the inappropriate use of topical corticosteroids as therapy. 
 
5.1.1. Tinea pedis 
 
Tinea pedis is the commonest dermatophyte infection most often caused by 
anthropophilic fungi such as Trichophyton rubrum and T. interdigitale 
(mentagrophytes). The earliest lesion develops with scaling and itching between 
the toes, particularly the lateral third and fourth interdigital spaces; this may spread 
to the undersurface of the toes. 
– Blisters are generally only seen with T. interdigitale. 
– In T. rubrum infections, the soles are often covered with a dry scaly rash – 
“dry” or “moccasin” – type dermatophytosis  
– In chronic cases,erosion of the skin of the toe webs may enlarge with the 
appearance of a greenish discolouration due to Gram negative bacteria such as 
Pseudomonas 
Various causes of interdigital scaling are shown in Table 5.8. 
 
Table 5.8Causes of Interdigital Scaling 
 
 Dermatophyte Candida Gram- 
negative 
Erythrasma Staphylococcus 
Aureus 
Symptomps itch, scaly soggy, 
eroded 
sore, 
eroded 
scaly itchy 
Site lateral toe 
webs 
lateral toe 
webs 
lateral toe 
webs 
lateral toe 
webs 
first toe web 
Colour red/white white green/white red/white red 
Spread soles, nail no spread no spread no spread dorsum 
 
5.1.2. Tinea cruris 
 
Tinea cruris presents with scaling in the groin extending onto the upper surface of 
the thigh and around the perineum; it is mainly seen in adult men. The infection is 
generally bilateral and itchy. There is often a raised margin and the infection may 
extend around the natal cleft to the perineum. Other causes of groin rash include 
erythrasma (a bacterial infection) and candidosis. In erythrasma the skin is 
uniformly affected with fine wrinkles and scales and has a light red/brown colour. 
The presence of papules or pustules outside the border (satellite pustules) is 
characteristic of Candida infection. A summary of the causes of scaling in the 
groin is given in Table 5.9. Flexural psoriasis may also produce scaling in this area 
with erythematous and soggy skin, but usually there are psoriatic lesions 
elsewhere, e.g. around the umbilicus. 
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Table 5.9Causes of Scaling in the Groin 
 
 Dermatophyte Candida Erythrasma 
Symptoms Itch Itch +/- Itch +/- 
Signs Scaling 
prominent rim 
Satellite pustules Uniform fine 
scaling 
Colour Red Deep red Brown/red 
Spread Perineum 
nails 
feet 
Perineum 
 
axillae 
 
5.1.3. Tinea corporis 
 
Tinea corporis may either be caused by zoophilic fungi or anthropophilic 
organisms, and more rarely by geophilic fungi. Lesions are annular, often irregular 
and may be multiple. The edge in at least one area is clearly seen and the hair 
follicles are prominent. Generally, in infections caused by zoophilic 
dermatophyrtes the lesions are more inflamed and itch severely; with 
anthropophilic fungi such as Trichophyton rubrum the lesions are often large, have 
a poorly defined border and there is less erythema or scaling.Tinea corporis is 
often confused with other annular lesions such as eczema, annular erythemas, 
psoriasis, and granuloma annulare. 
The distinguishing features of tinea corporis are: 
• Annular shape – the edge is more distinct than the rest of the lesion in at 
least one area 
• Scaling is more obvious at the edge 
• Itch 
• Hair follicles within the margin are often prominent 
 
5.1.4. Tinea capitis (scalp ringworm) 
 
Tinea capitis usually presents in childhood with patches of scalp-hair loss and 
scaling. There is a background of erythema, although in some children this is 
minimal. The intensity of inflammation varies although the zoophilic fungi usually 
produce more crusting and oozing.  At its most extreme this type of inflammatory 
lesion affecting a hear-baring area is boggy and pustular, a kerion, which is an 
inflammatory response to the dermatophyte itself rather than a secondary bacterial 
infection. Hair loss is seldom permanent unless an extensive kerion forms and even 
then there is a surprising degree of recovery. The severity of itching is very 
variable. 
There are three main patterns of scalp infection which are generally classified by 
the way in which the dermatophytes form spores after invading the hair shaft: 
ectothrix, endothrix and favic. These patterns, in part, determine the site of 
breakage of hairs and the clinical appearances. They are best determined by careful 
microscopic examination of infected hairs. 
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Table 5.10Types of Tinea Capitis 
 
 Ectothrix Endothrix Favic 
Clinical erythema, scaling often less 
inflammation 
mixed, crusting 
Level of hair break 1-3 mm above scalp scalp level may not break 
Source animals or children children children 
Commonest in Europe,  
urban tropics (some) 
USA, rural tropics 
Europe (some) 
sporadic 
Hair changes spores outside hair spores in hair all spaces in hair 
 
It is possible to form some preliminary understanding of the likely source of 
infection by the clinical and microscopic features which will focus the subsequent 
investigation. The final decision will rest on the results of culture. In Europe, for 
instance, the commonest organism is Microsporum canis, a cause of ectothrix 
infection while in many cities in the USA Trycophyton tonsurans is the dominant 
fungus. 
Favus is now a rare infection seen in small foci in the USA, North Africa and the 
Middle East. It is caused by Trichophyton schoenleinii. It is clinically important as 
it may 
• present with multiple crusts or scutula in the scalp 
• cause scarring alopecia 
• affect adults (mainly women) in addition to children. 
Some preliminary help with the diagnosis can also be obtained by shining a filtered 
ultra-violet light on lesions – Wood’s light. Microsporum but not Trychophyton 
species fluoresce green when viewed with this lamp in a completely darkened 
room. In favus, hairs have a dull yellowish fluorescence. Wood’s light can also be 
used to select infected hairs for culture. Features of tinea capitis associated with 
different organisms are shown in Table 5.11. 
Scalp scaling without hair loss occurs in a number of conditions. In children, 
seborrhoeic dermatitis, psoriasis or pityriasis amantiacea may appear similar. In the 
last of these conditions large numbers of thick scales are present around hairs. In 
alopecia areata where there arepatches of hair loss there is usually no scaling and 
small numbers of broken tapering hairs (exclamatory mark hairs) can be seen. 
 
Table5.11 Features of Tinea Capitis 
 
Organism Hair invasion Wood’s light Source Common in 
M. canis Ectothrix positive cat, dog Europe, cities 
M. audouinii Ectothrix positive Human Africa 
M. ferrugineum Ectothrix positive Human SE Asia 
T. violaceum Endothrix negative Human India, Middle East, Africa 
T. tonsurans Endothrix negative Human USA, Mexico 
T. soudanense Endothrix negative Human Africa 
T. verrucosum Ectothrix negative Cattle Europe 
T. schoenleinii Favic yellow Human sporadic 
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5.1.5. Tinea manuum 
 
Dry-type dermatophytosis affecting the palms caused by Trichophyton rubrum 
may accompany foot infections. The palm is covered with fine scales and there 
may be involvement of the finger nails; itching is generally minimal. The 
involvement of one hand and both feet is typical and suggestive of this condition 
although bilateral palmar infections may also occur. Other dematophytes may 
affect the palm or dorsum of the hand, particularly if there is a disease of 
keratinization such as palmar/plantar keratoderma. This form of infection has to be 
distinguished from eczema and psoriasis. 
 
Table5.12 Hand Disease and Dermatophytosis 
 
 Dermatophytosis Psoriasis Hand eczema 
Site may be unilateral Bilateral Bilateral 
Other sites Feet 
Groin 
Elbows 
Scalp 
anywhere 
Nails thick, broken 
onycholysis 
Pitted 
Onycholysis 
transverse ridges 
Itch Yes usually not Yes 
 
5.2. Candida Infections 
Infections caused by yeasts of the genus Candidaare common and although they 
most frequently affect the mucous membranes or skin they may also produce 
systemic infections. The principal pathogen is Candida albicans although other 
species, such as Candida tropicalis, C.parapsilosis, C. krusei and C.glabrata may 
also cause human infections. C. albicans forms filaments or hyphae during the 
process of tissue invasion. The disease caused by these fungi is called either 
candidosis or candidiasis.There aretwo distinct forms of candidosis – superficial 
or deep. Superficial candidosis principally affects the sites of carriage of the 
organism such as the mouth or the vagina; sometimes it affects the skin or the 
nails. Infections of the skin generally involve body fold areas. 
Candida species are normal commensals in the mouth, gastrointestinal tract and 
vaginal mucosa. They are less commonly isolated from the skin. Superficial 
Candida infections may occur in any part of the world although there are some 
differences. Interdigital candidosis is more common in the tropics whereas 
onychomycosis without paronychia due to Candida is mainly seen in colder 
climates. Factors predisposing to candidiasis are shown in Table 5.3 and generally 
it is possible to find an underlying reason for infection. The most common 
exception is vaginal candidosis where most women with the infection have no 
detectable predisposition. Although it may affect all ages, infants and elderly are 
particularly susceptible to superficial candidosis and this probably reflects 
immaturity or senescence of immune responsiveness. 
The process of infection by Candida starts with adherence of commensal 
organisms to mucosalcells or keratinocytes. Spread from other patients or sources 
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is not necessary as most infections are endogenous; the key event appears to be a 
change in the level of resistance in the host. Adherence probably involves the 
interaction of a fungal cell wall polysaccharide with a human receptor site on an 
epithelial cell. Adherence is a prerequisite for the germination of yeasts to produce 
germ tubes and hyphal elements which can penetrate tissue. 
 
Pathology 
In the early stages of Candida invasion the main changes are the infiltration of the 
epithelium by neutrophils with some hyper- and parakeratosis. There is an upper 
dermal infiltrate of lymphocytes and plasma cells. Dysplastic changes of the 
epithelium may develop in some chronic infections of the oral mucosa raising the 
possibility that persistent oral candidosis, either on its own or in combination with 
some other factor, such as smoking, may lead to the development of oral squamous 
carcinomas. 
 
5.2.1. Candidosis of skin and flexures 
 
Candida is an important cause of skin inflammation in intertriginous areas.It is 
also frequently isolated from intertrigo in the infra-mammary folds, axillae, and 
groin, where the presence of small “satellite” pustules around the edge of the 
characteristic glazed erythema of intertrigo should raise suspicion. 
The skin can be indirectly involved in vaginal Candida infection when there is 
spread of infection to the vulva and perineum. In this case a prominent red rush in 
the groin and on the upper surface of the thighs may appear with satellite pustules 
and papules. The same can occur in other sites, such as under the breasts and in the 
umbilicus. In some cases there is no underlying skin abnormality although groin 
candidosis in males and females is more common in diabetics. Eczema or psoriasis 
affecting the skin flexures may be accompanied by secondary candidosis. 
Skin can be affected by Candida infectionin the finger or toe web spaces. This type 
of interdigital candidosis is commonerin hot climates. It may be the commonest 
type of foot infection in army groups in the tropics. Lesions are with soggy looking 
skin which is superficially eroded. Between the toes Candida may be a secondary 
invader in a lesion primarily caused by a dermatophyte. 
Candida infection of the skin sometimes accompanies nappy dermatitis in 
infants. Nappy rush in infants is a form of irritant eczema which can be 
secondarily infected with, amongst other organisms, C. albicans. The presence of 
yeasts may be suspected by the appearance of satellite pustules and this is 
confirmed by culturing the organisms from swabs of the area.Generalized 
cutaneous candidosis is rarely seen in newly born infants where the mother has a 
vaginal Candida infection prior to delivery. The baby’s skin is covered with 
multiple pustules against a background of erythema. 
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5.2.2. Oral andoropharyngeal candidosis 
 
Oral candidosis or thrush is a common infection of the elderly, denture wearers, 
infants and the immunocompromised patient. It is the commonest infectious 
complication of AIDS. There are a number of different clinical types of 
oropharyngeal candidosis (see Table 5.13). 
 
Table 5.13 Clinical Types of Oropharyngeal Candidosis 
 
CLINICAL TYPES OF OROPHARYNGEAL CANDIDOSIS 
– Acute oral candidosis 
– Chronic oral candidosis 
– Mediam rhomboid glossitis – a form of localized candidosis on the dorsal surface 
of the tongue 
– Secondary candidosis – secondary to some other abnormality such as oral ulcers 
– Angular cheilitis due to Candida 
– Candidaoesophagitis 
 
These different forms are largely distinguished by their chronicity and clinical 
appearances and can be further subdivided. 
Acute pseudomembranous candidosis present with white plaques on the 
epithelium which is inflamed. The scattered nature of these appearances is 
suggestive of the speckling on a thrush’s breast. This may present as an acute 
infection in infants, the elderly or in patients who are immunocompromised such 
as those with AIDS. In the latter the condition is often persistent and refractory to 
therapy – chronic pseudomembranous candidosis. 
In some patients plaques are not formed but the mucosal surface appears red and 
glazed, acute erythematous candidosis also known as acute atrophic oral 
candidosis. In patients presenting with inflammatory changes and oral discomfort 
associates with dentures, denture sore mouth, persistent erythema associated with 
Candida is a common feature – chronic erythematous candidosis. While this is 
related to the presence of Candida, treatment of the yeast alone will not control the 
condition and the addition of oral antiseptics is usually necessary, suggesting that 
oral bacteria may also play a role. 
In smokers chronic candidosis may have additional features such as the appearance 
of a white plaque which cannot be detached on the tongue and other areas of the 
mouth – chronic plaque-like candidosis (Candidaleikoplakia). Histologically it 
contains epithelial atypia and, in some patients, oral carcinomas have developed. A 
few patients with chronic oral Candida infection may develop a pebbly appearance 
on the mucosa, chronic nodular candidosis. 
Any of the above changes can be accompanied by splitting at the corners of the 
mouth, angular cheilitis, which in these cases may be due to Candida infection. 
This is an important and common sign of candidosis and it can be spotted easily 
(see Table 5.14). 
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Table5.14 Angular Cheilitis 
 
Causes Appearances 
Candida 
 
Staphylococcus aureus 
 
 
Avitaminosis 
erythema, cracking, oral candidosios 
 
erythema, cracking, no oral candidosis, often eczema 
elsewhere 
 
erythema, cracking no oral candidosis 
NB. Secondary candidosis may accompany angular cheilitis due to iron deficiency 
Median rhomboid glossitis takes the form of a chronic lozenge shaped area of 
Candida infection on the dorsal surface of the tongue. 
In most patients the main focus of infection is on the buccal mucosa, but in 
severely infected individuals there is involvement of the tongue or pharynx, as well 
as the oesophagus. Oesophageal candidosis is mainly seen in patients with AIDS, 
leukemia or chronic mucocutaneous candidosis. While it may present with 
retrosternal pain on swallowing it is often silent. Secondary oral infections due to 
Candida may occur in patients with epithelial abnormalities such as hyperkeratosis 
or ulceration in lichen planus, pemphigus and white sponge naevus. 
 
5.2.3. Vaginal candidosis 
 
Vaginal Candida infection is normally caused by C. albicans although other 
Candida species such as C. glabrata or C. tropicalis have also been cultured. It can 
occur in pregnant women or diabetics but one of the features of this condition is 
that there is usually no underlying abnormality to be found.  Theories about the 
causes of vaginal candidosis abound from the use of tampons and tightly fitting 
underwear to immunological deficiencies. Generally, however, no consistent 
predisposing causes can be found and severely immunocompromised women do 
not usually show a higher frequency of persistent vaginal infection than 
appropriate control groups. The main clinical forms of vaginal candidosis are 
shown in Table 5.15. 
 
Table5.15Clinical Forms of Vaginal Candidosis 
 
Clinical Forms of Vaginal Candidosis 
– Acute (pseudomembranous or erythematous) vaginal candidosis 
– Chronic relapsing vaginal candidosis 
– Persistent vaginal candidosis 
 
The symptoms of all forms of candidosis are similar with the appearance of itching 
and discharge. Vaginal pain and dispareunia may also occur. The clinical 
appearances are varied but the main variations are presence or absence of soft 
white plaques (thrush). The course of infection is unpredictable and although most 
women have a single episode of infection others have either recurrent attacks or 
persistent thrush. No clear reasons for this have been found although those with 
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recurrent symptoms have been found to have a higher frequency of familiar 
atopoic diseases such as hay fever or asthma suggesting that sensitization might 
play a role in the development of symptoms. Women on high dose oestrogen 
replacement therapy may also have more frequent episodes of vaginal candidosis. 
Secondary candidosis may occur in those with underlying mucosal disease such as 
pemphigoid, lichen planus or Bechcet’s syndrome. 
 
5.2.4. Chronic mucocutaneous candidosis 
 
The rare syndrome of chronic mucocutaneous candidosis usually presents in 
childhood or infancy with oral, nail and cutaneous candidosis which recurs despite 
treatment. Other chronic skin infections such as warts (papilloma viruses) and 
dermatophytes may also appear. An adult form also exist. A classification of 
chronic mucocutaneous candidosis is shown in Table 5.16. 
 
Table 5.16 Classification of Chronic Mucocutaneous Candidosis (CMC) 
 
Childhood onset Adult onset 
Inherited CMC – autosomal recessive type 
Inherited CMC – autosomal dominant type 
CMC associated with polyendocrinopathy 
(usually hypoparathyriodism, hypoadrenalism 
or hypothyroidism) 
Idiopathic CMC 
– CMC associated with thymoma 
– CMC associated with systemic lupus 
erythematosus 
 
 
 
The oral lesions are usually of the chronic pseudomembranous type or plaque 
types. The skin may be covered with crusted plaques – the so called Candida 
granuloma- particularly where the infection has spread to the face or scalp. The 
finger nail changes affect the nail plates,nail folds and periungual skin, all of which 
may be severe dystrophic. 
A large number of immunological abnormalities have been thought to be 
associated with this condition but with few exceptions these may alter over time 
and with therapy. For this reason it is likely that the real defect, or defects, in most 
patients with this condition remains unknown and the immunological investigation 
of children with this abnormality is not necessary unless they have very extensive 
infection or as history suggestive of abnormal responses to other infections, such 
as chicken pox or boils. Here it is with excluding functional leucocyte 
abnormalities such as chronic granulomatous disease although such patients 
usually have a history of internal infection. With the exception of bronchiectasis 
most patients with CMC do not have internal disease, although the severely 
affected patient may later develop systemic infection such as tuberculosis. A 
suggested plan of investigations in suspected cases of CMC is shown in Table 
5.17. 
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Table 5.17 Suggested Plan of Investigations in Suspected Cases of CMC 
 
Suggested plan of investigations in suspected cases of CMC 
– Genetic history (in CMC associated with polyendocrinopathy inheritance is also 
autosomal recessive 
– Endocrine screen (thyroid, parathyroid, adrenal, autoantibodies) 
– In severe cases immunological work up – T lymphocyte and phagocyte functional assays 
– In adults – chest X-ray to exclude thymoma 
– Many patients with CMC develop a spontaneous remission as they get older while others 
deteriorate. As there is a wide range of clinical expression in this syndrome all patients should be 
followed up closely. 
 
5.3. Malassezia Infections 
Malassezia (lipophilic) yeasts are skin-surface commensals which have also been 
associated with certain diseases, the commonest of which are pityriasis versicolor, 
Malassezia folliculitis, seborrhoeic dermatitis and dandruff. In addition, these 
organisms can rarely cause systemic infections, usually in neonatal infants 
receiving intravenous lipid infusions. 
The taxonomy of the Malassezia (formerly Pityrosporum) yeasts is in the process 
of revision and they have been regrouped on the basis of DNA content.  
Within the genus Malassezia, however, there are yeast with different shapes and 
site preferences on human skin. Some are round and are most common on the 
trunk; others are oval and are more common on the scalp. In addition, the 
formation of short stubby hyphae by round yeasts on the skin surface is a feature of 
the development of pityriasis versicolor and this form is described as Malassezia 
furfur. Occasionally oval yeasts without hyphae have been found to cause 
pityriasis versicolor. 
 
5.3.1. Pityriasis versicolor 
 
The pathogenesis of pityriasis versicolor is still ill-understood. The disease occurs 
in young adults and older individuals but is less common in childhood. Pityriasis 
versicolor is a common disease in the tropics and elsewhere in otherwise healthy 
patients, and there is no evidence of immunosuppression in these groups. However 
it has also been associated with Cushing’s syndrome and immunosuppression 
associated with transplantation, but not with AIDS. The pigmentary changes which 
characterize this infection are thought to follow the inhibition of melanin formation 
by substances, such as azelaic acid, produced by yeasts enzyme activity. 
The rush consists of multiple hypo- or hyperpigmented, occasionally red, macules 
which are distributed across the upper trunk and back; with time these coalesce. 
The lesions are asymptomatic and scaly. Patients usually notice this infection 
because of its unsightly appearance. In the tropics fear of other conditions such as 
leprosy may bring the patients to see a doctor. 
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Lesions can also be highlighted by shining a Wood’s light on the area. They 
fluoresce with a yellowish light, although this is generally a weak response and 
complete darkness as well as powerful light source are necessary. 
 
5.3.2. Malassezia folliculitis 
 
A second condition associated with Malassezia yeasts is an itchy folliculitis on the 
back und upper trunk which often appears after a summer holiday and sun 
exposure. Malassezia folliculitis is a clinically distinct condition most often seen in 
teenagers or young adult males. Lesions are itchy papules and pustules which are 
often widely scattered on the shoulders and back. The condition has to be 
distinguished from acne as it does not respond to the same range of treatment (see 
Table 5.18). 
 
Table 5.18 Differential Diagnosisof Malassezia Folliculitis and Acne 
 
 Malassezia folliculitis Acne vulgaris 
Comedones No Yes 
Itch Yes Seldom 
Facial lesions  
precipitated by sum 
exposure 
Rare 
 
Common 
Common 
 
Uncommon 
Response to: 
1) antibiotics 
2) azoles 
 
No 
Yes 
 
Yes 
No 
 
5.3.3. Malassezia yeasts and seborrhoeic dermatitis 
 
Lipophilic yeasts of the genus Malassezia are part of the normal skin flora and 
therefore any evidence that they are either directly or indirectly implicated in the 
pathogenesis of common skin diseases such as dandruff or seborrhoeic dermatitis 
is difficult to assess. However: 
– Malassezia yeasts are found in large quantities in the scales of seborrhoeic 
dermatitis and dandruff. 
– Most patients with seborrhoeic dermatitis or dandruff respond to treatment 
with azole antifungal agents and this coincides with the disappearance of the 
yeasts. 
– In animals it is possible to induce similar skin scaling by the application of 
Malassezia yeasts. 
– Patients with seborrhoeic dermatitis have significantly raised levels of 
antibody to these organisms 
Seborrhoeic dermatitis is one of the earliest and most consistent abnormalities seen 
in patients with AIDS but is also common in perfectly healthy individuals. The 
relationship between infantile seborrhoeic dermatitis and these organisms is less 
well established although heavy colonization with Malassezia has been 
documented in association with cradle cap eczema of the scalp. 
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The main clinical feature of seborrhoeic dermatitis is erythema together with 
greasy scales in the scalp, eyebrows and eye lashes, in the nasolabial folds, behind 
the ears and over the sternum. 
 
5.4. Rarer Superficial Infections 
White piedra is a chronic infection of the hair shaft caused by the yeast, 
Trichosporom beigelii. It is generally sporadic and rare and the infection is mainly 
seen in genital hair. It may also affect the axilla and scalp. The lesions are soft 
yellowish nodules around the hair shafts, trichomycosis axillaries where hairs in 
the axillae are covered with a soft yellowish coating is caused by a bacterial 
infection associated with sweating. 
Back piedra caused by Piedra hortae is a rare infection confined to the tropics. 
Here scalp hairs are surrounded by a dense black concretion to produce a small 
nodule. 
Tinea nigra is an infection of palmar or plantar skin caused by the black yeast, 
Phaeoannelomyces werneckii. It is mainly seen in the tropics but can present in 
Europe and the United States. The main differential diagnosis is an acral melanoma 
as it presents as a flat pigmented mark on the hands or feet. If the lesion is scraped 
with a glass slide it can be shown to be scaly. Lesions are usually solitary. 
Alternaria species cause a rare form of skin granuloma often presenting with 
ulceration in normal or immunocompromised patients. The lesions are most often 
located over exposed sites such as the dorsum of the hands. 
Scopulariopsis brevicaulis causes a form of onychomycosis and may occasionally 
be isolated from toe-web spaces. The onychomycosis is generally confined to the 
great toe nail which develops a light tan discoloration. 
Other fungi may also be isolated from dystrophic nails. These include species of 
Fusarium, Aspergillus and Pyrenochaet. Generally they are secondary invaders of 
already dystrophic nails. 
 
5.5. Deep Mycosesand the Skin 
 
While the commonest fungal infections affecting the skin are those caused by 
superficial pathogens, mycoses affecting the subcutaneous tissue or those 
disseminated from deep foci, such as the lung, may also involve dermis and 
epidermis. 
 
5.5.1. Subcutaneous Mycoses 
The subcutaneous mycosis or mycoses of implantation may all affect the skin in 
the course of their evolution. In most cases they develop following traumatic injury 
and inoculation of the infective organisms. They are sporadic, mainly occur in the 
tropics and subtropics and chiefly affect manual workers.The main infections are: 
– mycetoma 
– chromoblasomycosis and pjaeohyphomycosis 
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– sporotrichosis 
– rarer infections such as lobomycosis and subcutaneous zygomycosis. 
 
5.5.1.1. Mycetoma (Madura foot) 
 
Mycetoma is a chronic subcutaneous infection caused by fungi (eumycetoma) or 
filamentous bacteria, (actinomycetes, actinomycetoma). The characteristic of this 
infection is the formation of large granules or grains of filaments within abscesses. 
The latter drain through sinuses onto the skin or affect the bone causing chronic 
osteomyelitis. A key step in the diagnosis is to distinguish between fungal and 
actinomycete causes, as the latter are treatable with chemotherapy whereas the 
former generally require surgery. Patients usually come from the tropics. The 
features of mycetoma are summarized in Table 5.19. 
 
Table 5.19 Summary of the Features of Mycetoma 
 
Origin of patients Central and northern South America, Africa, 
Middle East, India and Pakistan 
Clinical features Chronically swollen limb with draining sinuses 
Symptoms Pain just before dermal abscess ruptures 
Characteristics Small but visible black, white or red grains in 
discharge from sinuses 
Tests Direct microscopy, histopathology, culture, X-ray 
(lytic bone lesions) 
 
Organisms causing mycetoma include 
– Fungi – Madurella mycetomatis (black grains), M.grisea (black grains), 
Pseudallescheria boydii (white/yellow grains) 
– Actinomycetes – Actinomadura madurae (white/yellow grains), Streptomyces 
somaliensis (white/yellow grains), Nocardia species (grains only visible with 
microscope). 
 
5.5.1.2. Chromoblastomycosis (chromomycosis) 
 
Chromoblastomycosis is a chronic infection affecting the dermis and the epidermis 
caused by pigmented or dematiaceous fungi. The characteristic feature is the 
presence of thick-walled, pigmented, rounded cells (muriform or sclerotic cells) in 
skin scrapings or biopsy material. It occurs as a rare, sporadic infection in humid 
parts of the tropics. The skin is involved by a verrucous lesion which spreads 
slowly on exposed sites such as the lower legs or hands. Occasionally lesions are 
flat, plaque-like and atrophic. The main organisms involved are Fornasecaea 
pedrosoi, Cladosporium carrionii, and F. compacta. The disease features are 
summarized in Table 5.20. 
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Table 5.20 Summary of the Featues of Chromoblastomycosis 
 
Origin of patients Central and South America, Africa, South-East Asia, Japan 
Clinical features Warty growth or atrophic annular plaques 
Characteristics Pigmented muriform cells in skin scales or in biopsy 
Tests Direct microscopy, histopathology, culture 
 
Another infection caused by pigmented fungicalled phaeohyphomycosis presents 
a subcutaneous cyst. These are generally diagnosed after surgical excision and are 
found in certain numerous pigmented hyphae in an inflammatory cyst wall. 
 
5.5.1.3. Sporotrichosis 
 
Sporotrichosis is the infection caused by Sporothrix schenckii, a dimorphic fungus 
found in soil and plant debris. Infections occur over a wide geographic range in the 
tropics and subtropics including the United States. Although it most commonly 
presents as a skin infection – cutaneous sporotrichosis – systemic sporotrichosis – 
presenting with lung lesions or arthritis may also occur. The organism gains entry 
through traumatic injury. Infections occur sporadically, although certain 
occupational groups, such as those who handle plant materials or soil (gardeners, 
packers, florists) may be infected. The clinical lesions are of two types. Fixed 
lesions are solitary granulomas which ulcerate and are often confined to the face or 
exposed areas. They most resemble cutaneous leishmaniasis. Lymphangitic lesions 
spread along the course of lymphatics with the appearance of a chain of secondary 
nodules. These resemble either Mycobacterium marinum (fish-tank granuloma) 
infections or leishmaniasis. A summary of the features of sporotrichosis is given in 
Table 5.21. 
 
Table 5.21 Summary ofthe Features of Sporotrichosis 
 
Origin of patients USA and Central/South America, South 
Africa, Japan, Australia, rare in Europe 
Clinical features Fixed type – solitary granuloma/ulcer 
Lymphangitic type – primary granuloma with 
secondary nodules along lymphatics 
Characteristics Few organisms on biopsy. Single fungal cell 
surrounded by eosinophilic “star” – asteroid 
body (haematoxylin/eosin stain) 
Tests Culture, histopathology 
 
Other subcutaneous fungal infections are rare. They include lobomycosis, a rare 
infection seen in Central and South America which resembles an inflammatory 
keloid scar. Cutaneous zygomycosis (phycomycosis) occurs on Africa or Latin 
America and presents with woody swelling of the faceor limbs. 
81 
 
Most subcutaneous mycoses are chronic infections and may present years after the 
patient hasleft an endemic area. They should, therefore, be considered as potential 
causes of illness in immigrants from tropical countries. 
 
5.5.2. Systemic Mycoses 
Systemic fungal infections sometimes present with skin lesions and, when this 
occurs, their recognition may simplify the diagnostic process. There are two main 
groups of fungi which cause systemic disease. 
The respiratory pathogens include: Histoplasma capsulatum (histoplasmosis), 
Histoplasmacapsulatum var. duboisii (African histoplasmosis), Coccidioides 
immitis (coccidioicomycosis), Blastomyces dermatitidis (blastomycosis), and 
Paraccoccidioides brasilienis (paracoccidioidomycosis). Primary infection in all 
cases usually occurs in the lungs and the majority of patients inhaling the 
organisms manage to control the infection, the only evidence of exposure being a 
positive skin test. Alternatively the lesions may be walled-off in lung granulomas 
or produce chronic pulmonary infiltrates or cavitation; they may disseminate to 
other sites including the skin. This may occur rapidly with the eruption of multiple 
skin or mucous membrane lesions particularly in the immunocomprimised patient 
with defective T lymphocyte-mediated immunity. Features of the skin 
complications of these infections are shown in Table 5.22.  
 
Table5.22Features of the Skin Complications of Systemic Fungal Infections 
 
Disease Endemic area Superficial lesion Skin and underlying 
disease 
Histoplasmosis Worldwide not 
Europe 
oral ulcers 
skin papules, ulcers 
erythema 
multiforme 
chronic disseminated 
AIDS 
 
acute  
pulmonary disease 
African histoplasmosis Africa skin ulcers, 
abscesses, papules 
disseminated 
Coccidioidomycosis USA 
Central/South 
America 
skin granulomas 
erythema nodosum 
disseminated 
primary infection 
Blastomycosis USA, Canada, 
Africa 
Plaques disseminated 
Paracocidioidomycosis Central/South 
America 
mucosal ulcers 
papules 
chronic disseminated 
acute disseminated 
Candidosis Worldwide folliculitis 
nodules, abscesses 
iv drug abusers 
neutropenics 
Aspergillosis Worldwide Abscesses chronic granulomatous 
disease 
Mucormycosis Worldwide skin necrosis Burns 
Fusarium Worldwide necrotic papules neutropenia 
Cryptococcosis Worldwide papules, ulcers, 
abscesses 
AIDS, lymphoma, 
transplant patients 
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Rarely direct inoculation of these organisms into the skin as a result of a laboratory 
accident may produce a local granuloma with peripheral lymphadenopathy which 
usually resolves without treatment. 
The systemic opportunistic fungal pathogens such as Aspergillus enter via 
various routes from the lungs to the gastrointestinal tract. They less commonly 
disseminate to the skin; but they may involve this site in specific circumstances. 
Skin lesions occur in about 15% of cases of disseminated cryptococcosis caused by 
Cryptococcus neoformans, which is now an important systemic mycosis, occurring 
in between 3% and 13% of AIDS patients. Where appropriate, biopsy of a skin 
lesion may provide the diagnosis. 
 
5.5.6. Use of the Laboratory 
 
The laboratory diagnosis of fungal infections depends on four different 
approaches: direct microscopy, culture, serology and histopathology. For most 
superficial mycoses the first two are quite sufficient to establish the identity of the 
organism. 
 
5.5.6.1. Taking Specimens 
For most skin lesions the edge or active margin is the site most likely to contain 
viable fungi. If the lesion is a blister, the roof will contain the fungal cells. 
Appropriate material can be taken by scraping the lesion gently with a solid scalpel 
such as a banana-shaped scalpel, a disposable scalpel or even a glass slide. In any 
case care must be taken to avoid cutting into the skin; the object is to remove the 
easily detachable superficial scales. 
Swabs from the mouth or vagina are taken directly from lesions and should be sent 
to the laboratory as soon as possible. Skin scales are best sent either in disposable 
packs or folded in dark paper. Dermatophytes will survive for several months in 
this material. 
Specimens can be viewed directly by the clinician using a microscope. Material is 
mounted in 5-10% potassium hydroxide (KOH) which softens the keratinized 
cells. Generally the higher the concentration of KOH, the quicker the softening 
will be, although the stronger solutions are more caustic. For nails, material may 
take one hour to soften and the process can be hastened by gentle warming of the 
glass slide. Certain fungi such as Malassezia yeasts as well as some nail pathogens 
can be stained with a mixture of Parker ink and KOH (50:50), which colours these 
organisms blue. Other staining procedures are available such as Gram stains of 
smears and the use of calcoflour white, a fluorescent brightener which accentuates 
the fungal cell walls under fluorescent illumination. The nigrosin or India ink 
satins may also be applied to skin smears for Cryptococcus although this is 
designed principally for cerebrospinal fluid examination. 
The use of direct microscopy can be practiced on the office or consulting room and 
can be applied to different materials from skin to sputum. One area of immediate 
use is, in the diagnosis of mycetomas, where a grain obtained by gently opening an 
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unruptured sinus with a sterile needle can be examined with KOH. If filaments can 
be distinguished under high-power magnification, the infection is fungal, whereas 
if they cannot be seen it is likely to be caused by an actinomycete. 
 
5.5.6.2. Culture Techniques for Fungi 
Generally, the methods used to culture fungi in the laboratory are simple; fungi are 
seldom fastidious organisms. The following points are worth remembering. 
Failure to grow fungi is common with certain materials such as nail samples. This 
is probably due to the fact that fungi in the distal nail segment are not viable. Try 
to take material as near to the proximal edge of the nail as possible. 
Most yeasts grow quickly – within two to four days – although Cryptococcus is 
often slower on primary isolates. Drematophyte identification is usually complete 
within fourteen days. However, more exotic fungi may have to be passed on to a 
reference laboratory. A delay in reporting the result does not necessarily mean that 
the specimen has been lost. 
It is almost impossible to examine skin scales or recover fungi if they are heavily 
coated with medication. This should be removed with an alcohol swab before 
taking the skin scraping. 
If a systemic pathogen is suspected, warn the laboratory. Some of these fungi (e.g. 
Histoplasma capsulatum and Coccidioides immitis) are potentially infectious to 
laboratory staff. 
 
5.5.6.3. Serodiagnosis in Mycology 
Serology, the detection of antibody responses, is helpful in some situations. 
Serology has no value for the diagnosis of superficial infections. 
 
Table 5.23 Use of Serodiagnosis in Mycology 
 
Infection Test and value 
Mycetoma Immunodiffusion – poor diagnostic use 
Histoplasmosis Immunodiffusion, complement fixation- useful 
Coccidioidomycosis Immunodiffusion, complement fixation- useful  
Cryptomycosis Latex agglutination for antigen – very useful 
Systemic candidosis Numerous tests, mainly of research use only 
Aspergillosis Numerous tests, poor results in immunodeficient 
 
5.5.6.4. Histopathology 
The recognition of fungi in tissue is an important part of the diagnosis of fungal 
infections. Histopathology is not very useful in the diagnosis of superficial 
infections. Fungi generally stain poorly with hematoxylin and eosin satin and 
special stains, such as periodic acid-Schiff and methenamine silver (Grocott), 
are used.The former stains fungal cell walls red/pink, the latter black. The 
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mucicarmine stain is specific for the cryptococcal capsule which it stains pink. A 
guide to recognition of some pathogens is given in Table 5.24. 
 
Table 5.24 Recognition of Pathogens 
 
Description Diagnosis 
Epidermis 
Non-pigmented hyphae, no yeasts 
Pigmented hyphae 
Yeasts, mycelium plus pseudomycelium 
Yeasts, oval/round yeasts with/without short hyphae 
– cell wall thick at bud site 
 
Dermatophyte or Hendersonula 
Tinea nigra 
Candidosis 
 
Malassezia 
 
Dermis 
Yeasts with large capsule, pleomorphic 
Yeasts, mycelium plus pseudomycelium 
Small oval yeasts, intracellular, no hyphae 
Large yeasts with broad base to buds 
Large round structure  
(spherule) filled with endospores 
Large yeasts with multiple buds (cartwheel) 
Few pleomorphic yeasts – asteroid bodies 
Large amorphous structure with filaments up to 1-2 
μm surrounded by neutrophils 
Pigmented thick walled rounded cells with septa, in 
dermis or epidermis 
 
Cryptococcosis 
Candidosis 
Histoplasmosis 
Blastomycosis 
Coccidioidomycosis 
 
Paracoccidioidomycosis 
Sporotrichosis 
Mycetoma 
 
Cromoblastomycosis 
 
5.5.7. Therapy 
The treatment of superficial fungal infections depends on three different 
approaches: 
• The use of topical broad-spectrum substances analogues to antiseptics 
• The removal of the site of the infection, the stratum corneum, with 
keratolytic compounds 
• The use of specific antifungal drugs 
 
5.5.7.1. Antifungal Antiseptics 
Most of these compounds fall into one or two groups. The first are dyes with weak 
antifungal activity, such as gentian violet or brilliant green. Castellani’s paint 
which contains magenta and resorcinol is a further example. The second group 
contains substances such as 2% selenium sulphide and 20% sodium hyposulphite, 
both of which are used in the treatment of pityriasis versicolor. 
All these compounds are cheap but can be messy to apply and are generally slower 
in action than specific antifungal drugs. Selenium sulphide is also an irritant and 
can stain the skin. 
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5.5.7.2. Keratolytics 
The keratolytics work by removing the stratum corneum, the principal site of the 
fungal infection in superficial mycoses. The best-known example is salicylic acid. 
The combination of 3% salicylic acid and 6% benzoic acid to form Whitfield’s 
ointment is a useful preparation which is effective against dermatophytes. It is a 
potential irritant and in sensitive areas such as the groin should be used as a half 
strength preparation. One of the disadvantages of Whitfield’s ointment is that it is 
thick and sticky to apply, although there is at least one version available in some 
parts of the world where the combination is formulated in a cream base. 
 
5.5.7.3. Antifungal Compounds 
The modern antifungal drugs comprise three main families and a large number of 
compounds which make up a miscellaneous group of drugs. The first of the major 
antifungal families discovered was the polyene group which are all derived from 
Streptomyces species; the main polyene drugs in use today are amphotericin B, 
nystatin and natamycin. Amphotericin B is used widely for systemic mycoses, but 
is associated with significant renal toxicity. Recently a number of lipid associated 
amphotericin B formulations, including a liposome, have been produced in which 
the risk of renal damage appears to be much reduced. 
The large azole family has two components: the imidazoles amd the triazoles. 
They are all synthetic drugs with a common mode of action. Examples of 
imidazoles include miconazole, econazole and ketokonazole; examples of triazoles 
include itraconazole and fluconazole. 
The third group,the allylamines, are also synthetic drugs. An example of this 
group is terbinafine. There is also a large miscellaneous group of antifungal 
compounds, the commonest of which are griseofulvin, tolnaftat, amorolfine, 
cyclopiroxolamine and flucytosine. 
The modes of action of these drugs are different (see Fig. 5.2). Most affect the 
integrity of the cell membrane. Antifungals which block other processes include 
flucytosine (RNA and DNA synthesis) and nikkimycins and echinocandins (cell 
wall synthesis). Most antifungal drugs, in laboratory tests, are inhibitory to the 
growth of fungi (fungistatic) at concentrations achievable at the sites of infection 
whereas a few are able to destroy the organisms (fungicidal). The difference may 
be important clinically where host resistance is impaired or otherwise ineffective. 
Antifungal compounds than inhibit fungicidal action may also cure infection with 
shorter courses of drug therapy than those required for fungistatic compounds. The 
uses of various antifungal drugs are shown in Table 5.25. 
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Fig 5.1 The modes of action of polyenes, azoles, allylamines and griseofulvin 
 
 
 
Table 5.25 The Uses of Various Antifungal Drugs 
 
Drug Fungal affected Formulation  (dose) Side effects 
Aphotericin Candida, most 
systemic 
topical, iv iv: pyrexia, malaise, 
renal failure, anemia 
Nystatin Candida Topical skin staining 
Natamycin Candida, 
Dermatophyte 
Topical - 
Clotrimazole most superficial Topical -* 
Miconazole most, not Aspergilli topical,iv iv: tachycardia, 
anaphylaxis* 
Econazole most superficial Topical -* 
Ketoconazole most superficial, some 
systemic,  
not Aspergilli 
topical, oral oral: hepatitis*, 
androgen blockade, 
nausea 
Fluconazole most 
superficial/systemic 
not Aspergilli 
oral, iv nausea 
Intraconazole most 
superficial/systemic 
Oral nausea 
Griseofulvin dermatophytes Oral nausea, headache, 
photosensitivity 
Terbinafine dermatophytes, 
sporotrichosis 
dermatophytes 
Candida 
Malassezia 
Oral 
 
 
topical 
 
nausea, abdominal 
pain 
 
- 
Flycytosine Candida 
Cryptococcus 
oral, iv agranulocytosis, 
resistance 
Amorolfine most superficial Topical - 
Tolnaftate dermatophytes Topical - 
Cyclopiroxolamine most superficial Topical - 
* most topical azole antifungals may occasionally cause allergic contact dermatitis 
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5.5.7.4. The Management of Specific Fungal Diseases of the Skin 
5.5.7.4.1. Dermatophytosis 
 
Topical therapy 
The simple principle of the therapy is that if theinfection is not widespread or 
involves hair or nails, topical therapy is generally used. For most superficial 
infections caused by dernatophytes a topical imidazole, tolnaftate, terbinafine, 
amorolfine or cyclopiroxolamine is adequate. 
The minimum treatment period has never been clearly established. Generally, the 
specific antifungal agents clear tinea cruris/corporis within two weeks; Whitfield’s 
ointment takes about four weeks. Terbinafine is effective after seven day’s therapy 
and there is evidence that even shorter period of one or two days may be effective 
in many patients. 
In tinea pedis of the dry type, most topical agents take four weeks to produce a 
remission and the relapse rate is high. Topical therapy is not indicated for 
treatment of scalp infections; in nail disease there is some evidence that some 
topical agents, such as tioconazole, amorolfime and cycloporoxolamine, may 
produce recoveries although success rates are comparatively low. 
 
Oral Therapy 
Griseofulvin is used for dermatophytosis of the skin, dry-type infections, and 
scalp and nail disease. The dose of griseofulvin is 10 mg/kg daily. For certain scalp 
infections, such as those caused by Microsporum canis, griseofulvin is an 
appropriate therapy. It should be given for at least six weeks in tinea capitis. 
Long-term success rates in onychomycosis affecting the toe nails are less than 40% 
after twelve months of therapy, although the results in finger nail infections are 
considerably better. In the treatment of the nail disease and dry-type Trichophyton 
rubrum infections, remission rates are lower than with oral azoles, ketoconazole 
and intraconazole, or terbinafine. 
Ketoconazole is helpful in dermatophytosis. However, in view of the rare 
complication of hepatitis in 1:10.000 cases it has largely been superseded by 
itraconazole even though the main risk of this complication followed long-term 
therapy for nail disease. 
Fluconazole is available in a few countries for the treatment of dermatophytosis in 
doses of 50-100 mg daily. The use of intermittent doses of 150-300 mg weekly is 
under investigation for the treatment of onychhomycosis. 
Itraconazole is given in doses of 100 mg daily for tinea cruris/corporis (two 
weeks) and tinea pedis (four weeks). At higher doses shorter periods of treatment 
appear to be effective, e.g. 400 mg daily for one week in tinea pedis (dry type). In 
nail disease a treatment regimen of 200 mg daily for three months is used. An 
alternative regimen of 400 mg daily for one week of each month for two months 
(finger nails) or three months (toe nails) is under evaluation. 
Terfinafine is used in doses of 250 mg daily for a wide range of dermatophyte 
infections. Oral terbinafine produces better results than griseofulvin in the 
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treatment of nail disease where the optimum time for therapy is about three months 
for toe-nail infection and six weeks for finger-nail infection. For tinea 
cruris/corporis and dry-type foot infections it is given orally for two weeks. Shorter 
treatment periods are also under evaluation, such as 250 mg daily for tinea 
corporis. In addition it is available for use in children with dermatophytosis at 
doses of 62.5 mg (for children under 20 kg) and 125 mg (20-40 kg). This includes 
tinea capitis where four weeks therapy is as effective as six weeks of griseofulvin. 
One feature of this drug, which is fungicidal, is the very low relapse rate at long-
term assessment (e.g. six months) after therapy. 
 
5.5.7.4.2. Candidosis 
Most superficial Candida infections respond to topical nystatin, azoles, terbinafine 
or amorolfine. In oral infections topically applied nystatin lozenges or suspension 
and amphotericin B lozenges are useful for uncomplicated infections, although the 
taste of the medication is bitter. Micomazole oral gel is better tolerated by infants. 
When treating patients with oral candidosis associated with dentures, these should 
be removed overnight and cleaned with saline or a disinfectant before they are 
replaced. For infection in the immunocompromised it is often necessary to use an 
orally absorbed drug, such as ketoconazole, fluconazole or itraconazole. In AIDS 
patients the dose of itraconazole (200 mg) and ketoconazole (400 mg) is double of 
that normally used as absorption may be impaired. If possible, treatment is stopped 
in AIDS patients after achieving remission and recurrences are retreated as 
necessary. Continuous therapy is best avoided. 
For vaginal infections, topically applied azoles are available, usually in tablet form, 
for single-dose vaginal use, for example clotrimazole, sulconazole, econazole and 
miconazole. Longer topical regimens can also be used. Where topical therapy is 
unacceptable, oral therapy with a single dose of fluconazole 150 mg or 
itraconazole 400 mg given in one day can be used. There is no magic answer to 
chronic or relapsing vaginal candidosis. In all cases it is important to confirm 
that the recurrence of symptoms really is accompanied by the presence of Candida. 
Longer-term therapy with a course of oral fluconazole or itraconazole over two to 
three weeks followed by topical therapy with clotrimazole or even betadine once or 
twice weekly over three months may occasionally bring  halt to repeated episodes 
of infection. 
For paronychia, topical azoles are helpful if applied in solution from and over 
three to four months or until the nail fold becomes less swollen. Similar results can 
be obtained with oral azoles, such as ketoconazole or itraconazole. The latter are 
the only effective therapies for genuine nail-plate invasion due to Candida. 
In the rare cases of chronic mucocutaneous candidosis, remission should be 
induced using ketoconazole, fluconazole or itraconazole. If possible it is best to 
treat relapses when they occur by using intermittent azole therapy for three or 
seven days if there is a severe clinical relapse. 
Resistance to ketoconazole and fluconazole has been described where the drug has 
been given for a period of several months in the face of continuing infection. This 
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appears to be a problem where either drug has been given for long periods in 
patients with immunological deficiencies such as AIDS or chronic mucocutaneous 
candidosis. 
 
5.5.7.4.3. Pityriasis versicolor  
Pityriasis versicolor responds well to selenium sulphide given for at least two 
weeks, most topical azoles, amorolfine or topical terbinafine for one or two weeks, 
and oral ketoconazole (400 mg as a single dose, or five days of 200 mg daily). 
Itraconazole (200 mg for seven days) is also effective, ketoconazole shampoo is 
effective if given for two to three application only. There are three potential 
problems in the management of this infection 
– Relapse occurs very frequently particularly in patients living in the tropics 
– Patients often believe that they are still infected because the skin discoloration 
takes several months to revert to normal. They need to be reassured that this is the 
normal course and that they do not need more treatment. 
– Because of the thickness of the Malassezia cell wall, organisms persist on the 
skin surface for up to four weeks after the yeasts have been killed. Direct 
microscopy of the skin is a poor guide in the early phases to successful treatment. 
 
5.5.7.4. Malassezia folliculitis 
Malassezia folliculitis is difficult to treat. Oral ketoconazole or ketoconazole 
shampoo are the most effective approaches although itraconazole is an alternative 
(seven to ten days). Unfortunately topical therapies seldom work well. 
 
5.5.7.4. Seborrhoeic dermatitis 
While conventional therapy with low-to-medium strength topical corticosteroids or 
tar-based preparations may be helpful, most patients with seborrhoeic dermatitis 
respond well to topical azolesor terbinafine or oral azole therapy. The combination 
of an azole with hydrocortisone may be helpful. Relapse is frequent whatever the 
therapy used. Treatments for specific superficial mycosis are summarized in Table 
5.26. 
 
Table 5.26 Treatments Commonly Used for Specific Superficial Mycoses 
 
Dermatophytosis (wide range of choice but not nystatin) 
Interdigital tinea pedis most topical antifungals; azoles and 
allyaminesare probably faster than rest 
Dry-type tinea pedis usually oral antifungal:  
terbinafine (2 weeks), 
itraconazole (4weeks), 
griseofulvin (4-8 weeks) 
Tinea corporis, minor infections as with interdigital tinea pedis 
Tinea corporis, extensive infections terbinafine, itraconazole (2-3 weeks); 
griseofulvin (4-12 weeks) 
Tinea capitis griseofulvin (10-15 mg/kg daily) for at least 6 
weeks; in some countries, terbinafine 125 mg 
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daily for 4 weeks 
Tinea cruris topical antifungals, griseofulvin, terbinafine, 
itraconazole (2 weeks) 
Onychomycosis terbinafine, griseofulvin, itraconazole; topicals 
are usually less active – tioconazole, 
amorolfine 
Candidosis 
Cutaneous candidosis topical nystatin, azoles, terbinafine, amorolfine 
Vaginal candidosis single-or multiple-dose topical azole pessaries 
or vaginal tablets; in severe infections – 
fluconazole, itraconazole 
Oral candidosis topical nystatin, amphotericin B, miconazole; 
in severe infections – fluconazole, 
ketyoconazole. itraconazole 
Pityriasis versicolor topical ketoconazole shampoo, other azole 
creams, terbinafine, selenium sulphide; in 
severe infections – oral 
itraconazole/ketoconazole 
 
5.5.7.4. Subcutaneous mycoses 
Mycetoma–eumycetoma: Only infections due to Madurella mycetomatis respond 
in about 50% of cases to ketoconazole 200 mg daily. For other cases a trial of 
chemotherapy with griseofulvin or itraconazole can be givem but usually radical 
surgical removal is the only alternate. In these circumstances it may be preferable 
to do nothing unless the lesion is very large or painful. 
Mycetoma-actinomycetoma: Therapy with a sulphonamide, dapsone (100 mg 
daily) or cotrimoxazole is useful. In extensive cases, rifampicim or streptomycin 
may have to be used as well; alternatives include amikacin and imipenem. 
Chromomycosis: itraconazole 100 mg daily sometimes with flucytosin 30-35 
mg/kg qid for a patient with normal renal function is effective. Alternatives include 
amphotericin B plus flucytosine on its own, thiabendazole and the application of 
heat. 
Sporotrichosis: potassium iodide in saturated solution of 1 ml ds increased 
dropwise per dose to 406 ml tds is the standard approach. If the dose is increased 
too rapidly patients may develop severe nausea and salivation due to iodism. The 
drug may be given in milk. Alternatives include itraconazole in a dose of 100 mg 
daily and terbinafine in a dose of 250 mg daily. Treatment takes at least six weeks 
but the length of therapy should be guided by clinical response. 
 
5.5.7.4  Systemic mycoses 
Considering the therapy of systemic fungal infections there are some general 
principles which should be understood. 
– For most systemic mycoses, particularly those in severely ill patients, 
intravenous amphotericin B still remains the therapy of choice in doses of 0.6 – 1.0 
mg/kg daily. 
– Fluconazole (oral or intravenous) is used for some forms of systemic 
candidosis, such as peritonitis, systemic candidosis in the non-neutropenic and 
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oropharyngeal candidosis. It can be used for cryptococcal meningitis in the AIDS 
patient, either as the primary therapy or as a continuous suppression after 
remission to prevent relapse. It can also be used for cutaneous cryptococcosis 
where there is no evidence of deep infection. 
– Itraconazole (oral) is an alternative drug in histoplasmosis, blastomycosis and 
some forms of cryptococcosis. It is also used for certain Aspergillus infections, 
such as those occurring in the transplant patient. 
– New developments include liposomal and lipid complexed forms of 
amphotericin B, which at present are reserved for severely ill neutropenic patients 
or those who have failed on other therapies. Also terbinafine is being investigated 
in some forms of systemic mycosis, such as aspergillosis. 
 
5.8. Onychomycosis 
 
5.8.1. Definition and Prevalence 
Onychomycosis is one of the commonest dermatological conditions.Recent 
mycological surveys indicate its prevalence between 7% and 10% both in Europe 
and the USA. Onycomycosis is an infection of the nail apparatus by fungi that 
include dermatophytes, nondermatopyte moulds and yeasts (mainly Candida 
species). The toenails are affected in 80% of all cases of onychomycosis; 
dermatopyte infection, mostly due to Trichophyron rubrum, is the cause in over 
90% of cases. 
Onychomycoses are classidied clinically as  
– distal and lateral subungual onychomycosis (DLSO),  
– superficial white onychomycosis (SWO),  
– proximal subungual onychomycosis (PSO),  
– candidal onychomycosis and  
– total distrophic onychomycosis (TDO) 
 
5.8.2. Distal and Lateral Subungual Onycomycosis 
Distal and lateral subungual onycomycosis (DLSO) accounts for the majority of 
cases and is almost always due to dermatophyte infection. It affects the 
hyponychium, often at the lateral edges initially, and spreads proximally along the 
nail bed resulting in subungual hyperkeratosis and onycholysis although the nail 
plate is not initially affected. DLSO may be confined to one side of the nail or 
spread sideways to involve the whole of the nail bed, and progresses relentlessly 
until it reaches the posterior nail fold. Eventually the nail plate becomes friable and 
may break up, often due to trauma, although nail destruction may be related to 
invasion of the plate by dermatophytes that have keratolytic properties. 
Examination of the surrounding skin will nearly always reveal evidence of tinea 
pedis. Toenail infection is an almost inevitable precursor of fingernail 
dermatophytosis, which has a similar clinical appearance although nail thickening 
is not as common. 
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5.8.3. Superficial White Onychomycosis 
Superficial white onychomycosis (SWO) is also nearly always due to a 
dermatophyte infection, most commonly T. mentagrophytes. 
It is much less common than DLSO and affects the surface of the nail plate rather 
than the nail bed. Discoloration is white rather than cream and the surface of the 
nail plate is noticeably flacky. Onycholysis is not a common feature of SWO and 
intercurrent foot infection is not as frequent as in DSLO. 
 
5.8.4. Proximal Subungual Onychomycosis 
Proximal subungual onychomycosis (PSO)without evidence of paronychia is an 
uncommon variety of dermatopyte infection often related to intercurrent disease. 
Immunosuppressed patients, notably those who are human immunodeficiency 
virus-positive, may present with this variety of dermatophyte infection; conditions 
such as peripheral vascular disease and diabetes also may present in this way. 
Evidence of intercurrent disease should therefore be considered in a patient with 
PSO. 
 
5.8.5. Candidal Onychomycosis 
Infection of the nail apparatus with Candida yeasts may present in one of four 
ways: (I) chronic paronychia with secondary nail dystrophy; (II) distal nail 
infection; (III) chronic mucocutaneous candidiasis; and (IV) secondary candidiasis. 
Chronic paronychia of the fingernails generally occurs in patients with wet 
occupations. Swelling of the posterior nail fold occurs secondarily to chronic 
immersion in water or possibly due to allergic reactions to some foods, and the 
cuticle becomes detached from the nail plate thus losing its water tight properties. 
Microorganisms, both yeasts and bacteria, enter the subcuticular space causing 
further swelling of the posterior nail fold and further cuticular detachment, i.e. a 
vicious circle. Infection and inflammation of the area of the nail matrix eventually 
lead to a proximal nail dystrophy. 
Distal nail infection with Candida yeasts is uncommon and virtually all patients 
have Raynaud’s phenomenon or some other form of vascular insufficiency. It is 
unclear whether the underlying vascular problem gives rise to onycholysis as the 
initial event or whether yeast infection causes the onycholysis. Although candidal 
onychomycosis cannot be clinically differentiated from DLSO with certainty, the 
absence of toenail involvement and typically a lesser degree of subungual 
hyperkeratosis are helpful diagnostic features. 
Chronic mucocutaneous candidiasis has multifactorial etiology leading to 
diminished cell-mediated immunity. Clinical signs vary with the severity of 
immunosuppression, but in more severe cases gross thickening of the nails occurs, 
amounting to Candida granuloma. The mucous membranes are almost always 
involved in such cases. 
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Secondary candidal onychomycosis occurs in other diseases of the nail apparatus, 
most notably psoriasis. 
 
5.8.6. Total Dystrophic Onychomycosis 
Any of the above varieties of onychomycosis may eventually progress to total nail 
dystrophy where the nail plate is almost completely destroyed. 
 
5.8.7. Diagnosis 
Although 50% of all cases of nail dystrophy are fungal in origin it is not always 
possible to identify such cases accurately. Treatment needs to be administered 
long-term and enough time must elapse for the nail to grow out completely before 
such treatment can be designated as successful. Toenails take around 12 months to 
grow out and fingernails about 6 months. This is far too long to await the results of 
therapeutic trial and, in any case, treatment is not always successful. If the 
diagnosis is not confirmed, and improvement does not occur, it is impossible to tell 
whether this represents treatment failure or an initial incorrect diagnosis. Although 
the cost of diagnostic tests may be deemed high at times of budgetary constraint, 
the cost is always small relative to inappropriate and unnecessary treatment. 
Laboratory diagnosis consists of microscopy to visualize fungal elements in the 
nail sample and culture to identify the species concerned. The success or otherwise 
of such tests depends upon the quality of the sample, the experience of the 
microscopist and the ability of the laboratory to discriminate between organisms 
that are likely pathogens, organisms growing on the nail as saprophytes, and 
contamination of the culture plate. 
Given that dermatophyte onychomycosis is primarily a disease of the nail bed 
rather than of the nail plate, subungual debris taken from the most proximal part of 
the infection is likely to yield the best results. In DSLO material can be obtained 
from beneath the nail: a small dental scraper is most useful for this purpose. If the 
nail is onycholytic, then this can be cut back and material can be scraped off the 
underside of the nail as well as from the bed. As much material as possible should 
be submitted to the laboratory because of the relative paucity of fungal elements 
within the specimen. In SWO, the surface of the infected nail plate can be scraped 
and material examined directly. PSO is rare and again should be scraped with a 
scalpel blade. However, punch biopsy to obtain a sample of the full thickness of 
nail together with the nail bed may be necessary. Some of the material obtained is 
placed on a glass slide and 20% potassium hydroxide added. Fifteen to 20 minutes 
should be allowed to elapse before examining the sample by direct microscopy. 
The addition of Parker’s blue/black ink may enhance the visualization of the 
hyphae. An inexperienced observer may very well misdiagnose cell walls as 
hyphae and care should be taken to examine all of the specimens as fungal 
elements within the material may be very scanty.  
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The remaining material should be cultured on Saboraud’s glucose agar, usually 
with the addition of an antibiotic. The culture plate is incubated at 28oC or at least 
3 weeks before it is declared negative, as dermatophytes tend to grow slowly. 
Direct microscopy can be carried out by the clinician. However, nail microscopy is 
difficult and should only be carried out by those who do it on a regular basis. 
Fungal culture should always be carried out in a laboratory experienced in 
handling mycology specimens, because of potential pitfalls in interpretation of 
cultures. It must be remembered that the most common cause of treatment failure 
is incorrect diagnosis, which is usually made on clinical grounds alone. This 
should not be further compounded by incorrect laboratory interpretation of results. 
Histology is almost never required and its use is usually confined to other causes of 
nail dystrophy. Such dystrophies, notably psoriasis, regularly yield Candida yeasts 
on culture but they are rarely casual in etiology of fungal nail infection. 
 
5.8.8. Reasons for Treatment 
Although dermatophyte onychomycosis is relentlessly progressive there remains a 
view among some practitioners that it is a trivial cosmetic problem that does not 
merit treatment. In the elderly the disease can give rise to complications such as 
cellulites and therefore further compromise the limb in those with diabetes or 
peripheral vascular disease. While these complications may not be common they 
are certainly serious. The high prevalence of the disease is the result of heavy 
contamination of communal bathing places by infected users; disinfecting the 
floors of such facilities is very difficult because fungal elements are protected in 
small pieces of keratin. It is therefore logical to try to reduce the number of 
infected users by effective treatment and thus reduce the disease prevalence. 
Finally, onychomycosis is a surprisingly significant cause of medical consultation 
and of absence from work. 
Onychomycosis should not therefore be considered a trivial disease, and there is a 
sound case for treatment on the grounds of complications, public health 
considerations and effects on the quality of life. 
 
5.8.9. Treatment 
Both topical and oral agents are available for the treatment of fungal nail infection. 
The primary aim of treatment is to eradicate the organism as demonstrated by 
microscopy and culture. Clinical improvement and clinical cure are secondary end-
points based on a strict scoring system of clinical abnormalities in the nail 
apparatus. It must be recognized that successful eradication of the fungus does not 
always render the nails normal as they may have been dystrophic prior to infection. 
Such dystrophy may be due to trauma or non-fungal nail disease; this is 
particularly likely in cases where yeasts or non-dermatophyte moulds (secondary 
pathogens and saprophytes respectively) are isolated. 
Invariably mycological cure rates are about 30% better than clinical cure rates 
which are often below 50%. This suggests that eradication of the organism does 
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restore the nail to its previous state prior to infection even though that state may 
not be completely ”normal” as defined by a scoring system. 
Systemic therapy is almost always more successful than topical treatment, which 
should only be used in SWO, possibly very early DSLO or when systemic therapy 
is contraindicated. 
 
5.8.9.1. Topical therapy 
 
There are several topical antifungal preparations available both as prescription-
only medicines and on an over-the-counter basis. The active antifungal agent in 
these preparations is an imidazole, an allylamine or a polyene, or a preparation that 
contains a chemical with antifungal, antiseptic and sometimes keratolytic 
properties such as benzoic acid, benzoyl peroxide, salicylic acid or an undecenoate. 
Products that are specifically indicated for nail infection are available as a paint or 
lacquer that is applied topically.  
There are no published studies on the efficacy of salicylic acid and methyl 
undecenoate in fungal nail infection and their use cannot be recommended. 
Amorolfine nail lacquer has been shown to be effective in around 50% of cases of 
both fingernail and toenail; infection where only cases with infections of the distal 
portion of the nail were treated. While it is clearly possible to achieve clinical and 
mycological cure with topical nail preparations, these cure rates do not compare 
favourably with those obtained with systemic drugs. Currently, topical therapy can 
only be recommended for the treatment of SWO where the infection is confined to 
the distal edge of the nail. 
A combination of topical and systemic therapy may improve cure rates still further 
or possibly shorten the duration of therapy with the systemic agent. 
Although there are no studies comparing one topical preparation with another in a 
properly controlled fashion, it is likely that amorolfine nail lacquer is the most 
effective preparation of those available. 
 
5.8.9.2. Systemic therapy 
The three drugs currently listed for general use in onychomycosis are listed in 
Table 5.27. 
 
Table5.27 Systemic Agents for Onychomycosis with Major Advantages, and 
Strength of Recommendation and Quality of Evidence Grading 
 
Drug Advantages Disadvantages Main drug interactions 
Griseofulvin Licensed in both 
adults and 
children, 
inexpensive, 
extensive 
experience 
Lengthy treatment 
necessary in both 
fingernail and toenail 
infection: poor cure 
rates; high relapse 
rates; no pediatric 
formulation currently 
available: 
Warfarin, cyclosporine, oral 
contraceptive pills 
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contraindicated in 
lupus erythematosus, 
porphyria and severe 
liver disease 
Terbinafine* Fungicidal: high 
cure rates 
(compared with 
griseofulvin); 
good compliance 
No suspension 
formulation: 
idiosyncratic liver and 
skin reactions; 
reversible taste 
disturbance in 1:400 
patients 
Plasma concentrations 
reduced by rifampicin, 
increased by cimetidine 
Intraconazole Active against 
Candida 
albicans: pulse 
treatment 
regimens are 
possible 
Less effective in 
dermatophyte 
onychomycosis than 
terbinafine; monitoring 
of liver function 
required for treatment 
durations of longer than 
1 month; 
contraindicated for 
children under 12 years 
of age and in 
pregnancy 
Enhanced toxicity of 
anticoagulants (warfarin), 
anti-histamines  
(terfenadine and astemizole), 
antipsychotics (sertindole), 
anxiolytics (midazolam), 
digoxin, cisapride, 
cyclosporine and simvastadin 
(increased risk of myopathy); 
reduced efficacy of 
itraconazole with 
concomitant use of H2 
blockers, phenytoin and 
rifampicin 
*Terbinafine has better cure rate and lower relapses rate than intraconazole for dermatophytes 
 
Griseofulvin 
Griseofulvin is weakly fungistatic, and acts by inhibiting nucleic acid synthesis, 
arresting cell division and inhibiting cell wall synthesis. It is available in tablet 
form and is licensed for use in children with onychomycosis at a recommended 
dose for age group of 1 month and above of 10 mg/KG daily. It requires to be 
taken with fatty food to increase absorption and aid bioavailability. In adults the 
recommended dose is 500 mg daily given for 6-9 months in fingernail infection 
and 12-18 months in toenail infection. Mycological cure rates in fingernail 
infection are reasonably satisfactory at around 70% but griseofulvin is a 
disappointing in toenail disease where cure rates of only 30-40% can be expected. 
It is generally recognized than 500 mg daily is too small a dose for nail infection 
and 1 g daily is most often prescribed, but there is no evidence that this improves 
cure rates in toenail infection. Although the cost of griseofulvin is very low, its 
poor cure rate, often necessitating further treatment, suggests that its cost/efficacy 
ratio is relatively high. Both direct and historical comparison with studies of the 
newer antifungal agents terbinafine and itraconazole suggest that griseofulvin is no 
longer the treatment of choice for dermatophyte onychomycosis. 
Side effects include nausea and rashes in 8-15% of patients. In adults, it is 
contraindicated in pregnancy and the manufacturers caution against men fathering 
a child for 6 months after therapy. 
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Terbinafine 
Terbinafine, an allyamine, inhibits the enzyme squalene epoxidase thus blocking 
the conversion of squalene epoxide in the biosynthetic pathway of ergosterol, an 
integral component of the fungal cell wall. Its action results in both a depletion of 
ergosterol, which has a fungistatic effect, together with an accumulation of 
squalene, which appears to be directly fungicidal. The minimum inhibitory 
concentration (MIC) of terbinafine is very low, approximately 0.004 μg mL-1.. This 
is equivalent to the minimal fungicidal concentration (MFC), demonstrating that 
this drug is truly fungicidal in vitro. It is the most effective currently available 
antidermatophyte agent in vitro and clinical studies strongly suggest that this is 
also the case in vivo. 
 
Itraconazole 
Itraconazole is active against a range of fungi including yeasts, dermatophytes and 
some non-dermatopyte moulds. It is not as active in vitro against dermatophytes as 
terbinafine, its MIC being 10 times greater. Although it is generally felt to be a 
fungistatic agent it can achieve fungicidal concentrations, although its MFC is 
about 10 times higher than its MIC. 
Both terbinafine and itraconazole persist in the nail for a considerable period and 
elimination follows from the plasma. This property has given rise to a novel 
intermittent (“pulsed”) treatment regimen using itraconazole in nail infection. 
Terbinafine vs. itraconazolein dermatophyte onychomycosis. Both of these drugs 
have been shown to be more effective than griseofulvinin dermatophyte 
onychomycosis and therefore the optimum choice of treatment lies between 
terbinafine and itraconazole. 
Terbinafine is licensed at a dose of 250 mg daily for 6 weeks and 12 weeks in 
fingernail and toenail infection, respectively. Itraconazole is licensed at a dose of 
200 mg daily for 12 weeks continuously or alternatively at a dose of 400 mg daily 
for 1 week per month. It is recommended that two of these weekly courses, 21 
days apart, are given for fingernail infections and three courses for toenail disease. 
 
Treatment of yeast infections 
Most yeast infections can be treated topically, particularly those associated with 
paronychia. Antiseptics can be applied to the proximal part of the nail and allowed 
to wash beneath the cuticle, thus sterilizing the subcuticular space. Ideally, such 
antiseptics should be broad spectrum, colourless and non-sensitizing. An imidazole 
lotion alternative with antibacterial lotion is usually effective. 
Itraconazole is the most effective agent for the treatment of candidal 
onychomycosis where the nail plate is invaded by the organism. It is used in the 
same dosage regimen as for dermatophytes, i.e. 400 mg daily for 1 week per month 
repeated 2 months in fingernail infection. Candida infection of toenails is much 
less common but can be treated as above using three or four pulses. 
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Treatment of non-dermatophyte moulds 
Many varieties of saprophytic moulds can invade diseased nail. Scopulariopsis 
brevicaulis is the commonest of these and may be a secondary pathogen. Its 
response to systemic antifungal agents is variable, although terbinafine is probably 
the drug of choice in that the primary nail disease is quite likely to be a 
dermatophyte infection that is masked by the Scopulariopsis. There is little 
categorical evidence to support the choice of one drug. In the USA and Europe 
cyclopriox nail laquer has its advocates. Nail avulsion followed by an oral agent 
during the period of regrowth is probably the best method of restoring the nail to 
normal. 
 
8.9.3. Treatment failure 
 
Although terbinafine is demonstrably the most effective agent in dermatophyte 
onychomycosis a consistent failure rate of 20-30% is found in all studies. If the 
most obvious causes of treatment failure, notably poor compliance, poor 
absorption, immunosuppression, dermatophyte resistance and zero nail growth are 
excluded, the commonest cause of failure is likely to be kinetic. Subungual 
dermatophytoma has been described and it is likely that this tightly packed mass of 
fungus prevents penetration of the drug in adequate concentrations. In such cases 
partial nail removal is indicated. It is best demonstrated that cure rates of close to 
100% can always be achieved if all affected nails are avulsed under ring block 
prior to commencement of treatment. However, this is neither feasible, nor 
necessary in most cases and the best approach is to try to identify those individual 
nails that are likely to fail and to remove the offending area. 
Reports of long-term follow-up of treated patients have recently been presented, 
suggesting that positive mycology at 12 and 24 weeks after commencement of 
therapy are poor prognostic signs and may indicate a need for retreatment or for a 
change of drug. However, this work remains to be confirmed. 
Cure rates, both short- and long-term, may be influenced by correction of 
associated orthopedic and podiatric factors to avoid, as much as possible, trauma 
that particularly affects the great toenails. 
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VI. INFLAMMATORY DERMATOSES 
 
6.1. Ezematous Inflammation and Its Stages 
 
Eczema asa clinical descriptive term describes a proress that is clearly superficial 
in form and that, early, is erythematous, papulo-vesicular, oozing and crusting and, 
late, red-purple, scaly, lichenified and possibly pigmented. Epithelial disruption 
and non-sharp margination are its characteristics. 
Eczema can be defined histologically by the presence of a predominantly 
lymphohistiocytic infiltrate around the upper dermal blood vessels, associated with 
varying degrees of spongiosis and acanthosis. 
The terms eczema and dermatitis are regarded as synonymous. 
 
Table 6.1 Stages of Eczematous Inflammation 
 
Stage Morphology of 
Lesions 
Symptoms Examples Treatment 
Acute Vesicles, blisters, 
intense red 
Intense itch, 
stinging, 
burning 
Acute contact 
dermatitis, acute 
nummular eczema, 
stasis dermatitis, 
pompholyx 
Cold wet 
compresses, 
steroid, 
antihistamine, 
antibiotics 
Subacute Red, scale, fissuring, 
parched appearance, 
scalded appearance 
Slight to 
moderate 
itch, 
stinging, 
burning 
Contact allergy, 
irritation, atopic 
dermatitis, stasis 
dermatitis, nummular 
eczema, asteatotic 
eczema 
Topical 
steroid, 
emollients, 
antihistamine, 
antibiotics 
Chronic Thickened skin, 
lichenified excoriation, 
fissuring 
Moderate to 
intense itch 
Atopic dermatitis, 
lichen simplex 
chronicus, fingertip 
eczema, hyperkeratotic 
eczema 
Topical 
steroid, 
antihistamine, 
antibiotics, 
emollients 
 
6.2. Dyshidrotic Eczema 
 
Background: Dyshidrotic eczema is a recurrent or chronic relapsing form of 
vesicular palmoplantar dermatitis of unknown etiology. Dyshidrotic eczema also is 
termed pompholyx, which derives from cheiropompholyx, which means "hand and 
bubble" in Greek.  
The etiology of dyshidrotic eczema is unresolved and believed to be multifactorial. 
It is considered a reaction pattern caused by various endogenous conditions and 
exogenous factors.  
Pathophysiology: Several hypotheses exist for the pathophysiology of dyshidrotic 
eczema. The original hypothesis of sweat gland dysfunction is not valid, since 
vesicular lesions are not associated with sweat ducts. Patients usually do not have 
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hyperhidrosis. Dyshidrotic eczema may be associated with atopy. Of patients with 
dyshidrosis, one half have atopic dermatitis. Exogenous factors (e.g. contact 
dermatitis to nickel, balsam, cobalt; sensitivity to ingested metals; dermatophyte 
infection; bacterial infection) may trigger episodes. These antigens may act as 
haptens with a specific affinity for palmoplantar proteins of the stratum lucidum of 
the epidermis. The binding of these haptens to tissue receptor sites may initiate 
pompholyx. Emotional stress and environmental factors (e.g. seasonal changes, hot 
or cold temperatures, and humidity) reportedly exacerbate dyshidrosis.  
Controversy exists concerning whether a distant fungal infection can cause palmar 
pompholyx as an "id reaction". The finding that one third of pompholyx 
occurrences on the palms resolve after treatment for tinea pedis supports this 
hypothesis.  
Causes: The cause of dyshidrotic eczema is unknown. The condition often appears 
related to other skin diseases (e.g. atopic dermatitis, contact dermatitis, allergy to 
ingested metals, dermatophyte infection, bacterial infection, environmental or 
emotional stress). Several factors may participate in causing dyshidrotic eczema 
and pompholyx.  
Atopy: As many as 50% of patients with dyshidrotic eczema have reportedly had 
personal or familial atopic diathesis (eczema, asthma, hayfever, allergic sinusitis). 
Serum immunoglobulin E (IgE) level frequently is increased, even in patients who 
do not report a personal or familial history of atopy. Occasionally, dyshidrotic 
eczema is the first manifestation of atopic diathesis. Nickel sensitivity: this may be 
a significant factor in dyshidrotic eczema. 
Low-nickel diets: these have reportedly decreased the frequency and severity of 
pompholyx flares. A high palmoplantar perspiration rate has been suggested to 
result in a local concentration of metal salts that may provoke the vesicular 
reaction.Contact allergy has been documented in 30% of patients with dyshidrotic 
eczema.“Id”- reaction: dyshidrotic eczema outbreaks are not always associated 
with exposure to sensitizing chemicals or metals. Controversy surrounds the 
possible existence of an “id- reaction”, which is a distant dermatophyte infection 
(tinea pedis, kerion of scalp) triggering a palmar pompholyx reaction (also termed 
pompholyx dermatophytid). 
Fungal infection: pompholyx occasionally resolves when a tinea pedis infection is 
treated, then relapses when the fungal infection recurs, supporting the existence of 
this reaction pattern. Of patients who have a vesicular reaction to intradermal 
trichophyton testing, fewer than one third have experienced a resolution of 
pompholyx after treatment with antifungal agents. 
Emotional stress: this is a possible factor in dyshidrotic eczema. Many patients 
report recurrences of pompholyx during stressful periods. Improvement of 
dyshidrotic eczema using biofeedback techniques for stress reduction supports this 
hypothesis. 
Other factors: isolated reports of other possible causative factors exist, such as 
aspirin ingestion, oral contraceptives, cigarette smoking, and implanted metals. 
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Age: Dyshidrotic eczema affects individuals aged 4-76 years; mean age is 38 
years. After middle age, the frequency of episodes tends to decrease.  
History: Patients complain of pruritus of hands and feet with sudden onset of 
blisters. Burning pain or pruritus occasionally may be experienced before blisters 
appear. Episodes vary in frequency from once per month to once per year. Patients 
may report a variety of factors that possibly are related to eruptions: 
Emotional stress 
Personal or familial atopic diathesis (e.g. asthma, hay fever, sinusitis) 
Certain work exposures (e.g. cobalt) and/or recreational exposures 
Recent exposure to contact allergens (e.g., nickel, balsams, paraphenylenediamine, 
chromate, sesquiterpene lactones) before condition flares 
Exposure to contact irritants before condition flares 
Recent exposure to costume jewelry (patients with palmar pompholyx and allergic 
to nickel) 
Recent treatment with intravenous immunoglobulin therapy 
Physical: Symmetric crops of clear vesicles and/or bullae on the palms and lateral 
aspects of fingers characterize dyshidrotic eczema. Feet, soles, and the lateral 
aspects of toes also may be affected.In mildly affected patients, vesicles are present 
only on the lateral aspects of fingers and, occasionally, involve feet and 
toes.Vesicles are deep seated with a tapioca-like appearance, without surrounding 
erythema.May become large, form bullae, and become confluent. Typically resolve 
without rupturing, followed by desquamation. Hands are involved solely in 80% of 
patients, feet solely in 10%, and both hands and feet are involved in 10% of 
patients.With long-standing disease, patients' fingernails may reveal dystrophic 
changes (e.g. irregular transverse ridging, pitting, thickening, 
discoloration).Interdigital maceration and desquamation of the interdigital spaces 
often are present, despite the possible absence of a dermatophyte infection.Vesicles 
and/or bullae may become infected secondarily, and pustular lesions may be 
present. Cellulitis and lymphangitis may develop. 
Complications. Secondary bacterial infection of vesicles or bullae can result in 
cellulitis, lymphangitis, and septicemia (rare).Dystrophic nail changes may develop 
with transverse ridging, thickening, discoloration, and pitting of nails. 
Lab Studies. Diagnosis usually is made clinically. Bacterial culture and sensitivity 
exclude secondary infection. Blood tests usually are not ordered; however, IgE 
commonly is elevated. Use patch testing to exclude allergic contact dermatitis. 
Procedures. Perform potassium hydroxide wet mount preparation to exclude 
dermatophyte infection.Punch biopsy for hematoxylin and eosin staining usually is 
not necessary. Punch biopsy for periodic acid-Schiff staining may help exclude 
dermatophytosis in patients with unresponsive disease.Use punch biopsy for direct 
immunofluorescence to exclude bullous pemphigoid. 
Histologic Findings: Spongiosis with an epidermal lymphocytic infiltrate and 
intraepidermal vesicles or bullae are not associated with sweat glands.  
Medical Care: Some mildly affected patients experience spontaneous resolution 
within 2-3 weeks. Biofeedback therapy for stress reduction has succeeded in some 
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patients. Outpatient care is multifaceted. The following treatment is appropriate if 
bullae are present. Use compresses with Burow solution (10% aluminum acetate).  
Apply in a 1:40 dilution bid/tid until bullae resolve (usually, within a few days).  
Drain large bullae with a sterile syringe, and leave the roof intact. Prescribe 
systemic antibiotics that cover Staphylococcus aureus and group A 
streptococci.Topical corticosteroids are the mainstay of treatment. Prescribe class I 
steroids bid/tid for up to 2 weeks, then class II or III steroids. Ointments penetrate 
skin better than creams; patients may prefer creams during the day. Topical 
antipruritics with pramoxine are useful. 
Prescribe systemic corticosteroids. Prescribe either oral prednisone or 
intramuscular (IM) betamethasone sodium phosphate and betamethasone acetate 
suspension for severe episodes. Tapering of prednisone can follow IM treatment.  
IM triamcinolone acetonide (Kenalog) may be administered; its anti-inflammatory 
activity lasts 4-6 weeks. 
For severe refractory pompholyx, prescribe azathioprine. Azathioprine has been 
used in refractory disease.  
Consider measuring thiopurine methyltransferase levels, which may help guide 
azathioprine therapy.  
Methotrexate at low doses and cyclosporine also have been successful in case 
reports. 
Hand and/or foot UV-A therapy (alone or with oral or topical psoralen) improves 
the eruption and pruritus when administered 2-3 times per week. The dose 
typically starts at 0.5 J per treatment and is increased by 0.5 J at every other or 
every third treatment. 
Nickel chelators, such as disulfiram (Antabuse), occasionally are used in nickel-
sensitive patients who demonstrate a positive oral provocation test. 
Diet.For nickel-sensitive patients, consider a low-nickel diet for 3-4 weeks. The 
diet regimen only rarely is successful and is difficult for patients to follow.The diet 
requires avoiding foods rich in nickel, such as canned foods, foods cooked in 
nickel-plated utensils, herring, oysters, asparagus, beans, mushrooms, onions, corn, 
spinach, tomatoes, peas, whole grain flour, pears, rhubarb, tea, cocoa, chocolate, 
and baking powder.For cobalt-sensitive patients, consider a low-cobalt diet that 
avoids apricots, beans, beer, beets, cabbage, cloves, cocoa, chocolate, coffee, liver, 
nuts, scallops, tea, and whole grain flour. 
Prevention. Advise patients to avoid known contact irritants or allergens. Advise 
patients to reduce stress (may help some patients). Advise patients to follow a hand 
care regimen. Advise regular prophylactic use of emollients. 
Prognosis: dyshidrotic eczema follows a chronic intermittent course. Fewer 
episodes occur after middle age. 
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6.3. Nummular Dermatitis 
 
Synonyms and related keywords: discoid eczema, nummular eczema 
 
Background: Nummular (meaning coin-like) dermatitis is an idiopathic disease 
that manifests as discrete round plaques. These plaques can be dry or exudative. It 
is a chronic condition with relapse and recurrence often at the same sites. Lesions 
wax and wane with changes in environmental conditions; it worsens in the winter, 
in low relative humidity, and in the presence of heaters. Nummular dermatitis is 
usually diagnosed clinically, and it is distinguished from generalized patchy 
dermatitis, which has ill-defined borders.  
Causes.The etiology has not been clearly elucidated, but it appears to be 
multifactorial.Local trauma, irritating conditions, and venous stasis may play a role 
in the pathogenesis. Xerosis may also play a role. Venous insufficiency (and 
varicosities) may be related to involvement in affected lower 
extremities.Autoeczematization (lesional spread from the initial focal site) may 
account for multiple plaques.Lymphocytes are predominately CD8+ in the 
epidermis and CD4+ in the dermis. Mast cell–derived interleukin 4 (IL-4) appears 
to be involved in activation of the T- lymphocytes. 
Age.The incidence peaks in the sixth and seventh decades. Another common 
population who may have nummular dermatitis is persons with atopic dermatitis 
who are in their second and third decades. Nummular dermatitis is rare in children.  
History.Plaques may develop central clearing that resembles tinea corporis, which 
tends to be less vesicular, has a narrower border, and is duller in color.Contact 
dermatitis may have a pattern that approximates the way the offending agent came 
in contact with the skin, such as a linear pattern. It may become chronic in the 
setting of repeated exposure, such as with chromate and formaldehyde. The patient 
may recall contact to an allergen, such as poison ivy. 
Psoriasis is often found on the extensor surfaces, especially at the joints, and it may 
have larger plaques, it is scalier, and it has a less pronounced irritation. 
Lichen simplex chronicus often occurs on the lower legs, the neck, the scalp, or the 
scrotum; it is lichenified (thickened by chronic scratching) and does not have a 
clear border. 
Stasis dermatitis may occur simultaneously on the lower extremities, and venous 
stasis may lead to the concomitant development of both conditions. 
Physical: Diagnosis is usually based on the characteristic clinical appearance; a 
biopsy sample typically reveals a spongiotic reactive pattern.  
Distinguishing between forms of dermatitis (e.g. xerotic eczema, atopic dermatitis, 
and nummular dermatitis) may be difficult, but, fortunately, it is not necessary to 
make proper treatment decisions. Lesions begin as papules or vesicles that coalesce 
to form confluent plaques with an erythematous base.Early lesions may be 
exudative and crusted, and, because of the moist environment, the lesions often 
become colonized by staphylococci and it increases the severity and the duration of 
the lesion.Secondary frank infection may occur, necessitating systemic antibiotics. 
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Late lesions are dry, scaly, and often excoriated secondary to moderate 
pruritus.Patients may report a burning sensation. The lower extremities and the 
dorsum of the hands are the most frequently affected areas, though the arms, the 
trunk, and the thighs may also be affected.Irritant hand dermatitis may present as a 
nummular pattern. Plaques may be single or multiple; symmetric bilateral 
involvement may occur. 
Lab Studies: Tinea corporis should be excluded by scraping and microscopic 
analysis of a potassium hydroxide (KOH) preparation. 
Procedures: A skin biopsy may be performed. While nonspecific, excluding other 
papulosquamous diseases listed in the differential diagnosis may be useful. 
Histologic Findings: Biopsy findings mirror the evolution of the lesion. In the 
early stages, a nonspecific infiltrate is present with spongiosis, vesicles, and a 
predominant lymphocytic infiltrate. Eosinophils may be observed in the papillary 
dermis. Chronic lesions demonstrate epidermal hyperplasia, hyperkeratosis, and a 
pronounced granular cell layer. The papillary dermis may be fibrotic, with a 
perivenular infiltrate of lymphocytes and monocytes.  
Medical Care.Emollients and topical class I-III topical steroids may be used. Bed 
rest and isolation from stress-provoking stimuli may be beneficial.Oral or 
parenteral steroids may be used as a temporizing measure in severe flares, followed 
by topical therapy.Oral antibiotics, such as dicloxacillin, cephalexin, or 
erythromycin, should be used in cases of secondary infection.A potent-to-
intermediate potency steroid may be applied sparingly 2-4 times daily to the 
affected areas. Once lesions improve, a lower potency steroid is prescribed to 
avoid skin atrophy. Usually, a more effective treatment is a combination of a 
topical antibiotic and a steroid ointment applied twice daily. This therapy decreases 
inflammation and colonization by staphylococci. Nighttime pruritus may be treated 
with sedating oral antihistamines.  
Activity.Activities that lead to perspiration and increased skin temperature may be 
irritating.Heat, drying conditions, and irritating activities should be avoided. 
Sunlight may be beneficial. 
Chronic disease.Chronic lesions may be treated with tar ointments in addition to 
steroids, although patients may be resistant to this therapy because it is time 
consuming and messy.  
Severe disease.Severe or generalized flares may be treated with tap water–
moistened dressings on top of the steroid ointment. Oral or parenteral steroids may 
be used as a temporizing measure in severe flares, followed by topical therapy. 
Oral antibiotics, such as dicloxacillin, cephalexin, or erythromycin, should be used 
in cases of secondary infection. 
Prevention.Temperature and humidity extremes can worsen lesions. Bathing is 
permissible, but hot water should be avoided. Patients should use mild, nondrying 
cleansers. Patients should be encouraged to use non-soap cleansers only for control 
of body odor and cleanliness (e.g. on the groin, axillae, and feet).Oil additives may 
be used in bathing water.To avoid drying of the lesions, an emollient should be 
used immediately after bathing.The skin may be patted dry, and the emollient 
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should be applied before the skin dries out completely.Creams are better emollients 
than lotions and should be encouraged. Clothing should be loose to avoid 
overheating, and irritating fibers, such as wool, should be avoided.A room 
humidifier is useful particularly when a heater or air conditioning is used. 
Prognosis: Inform patients that the lesions tend to be persistent, are difficult to 
treat, and can reoccur in the same location. 
 
6.4. Vesicular Palmoplantar Eczema 
 
Synonyms and related keywords: pompholyx, dyshidrotic eczema, vesicobullous 
dermatitis, dyshidrosis, chronic relapsing vesiculosquamous eczema 
 
Background: Vesicular palmoplantar eczema is a term used to describe a group of 
diseases characterized by vesiculobullous eruption involving mainly the hands and 
feet. Clinical presentations vary from acute explosive dermatitis to more chronic 
relapsing and remitting disease patterns. Although considerable overlap exists in 
the various forms of vesicular palmoplantar eczema, the disease can be divided 
into 4 distinct categories: pompholyx, subacute or chronic relapsing 
vesiculosquamous eczema, chronic vesiculohyperkeratotic or hyperkeratotic 
eczema, and “id- reactions”.  
Pompholyx may be further subdivided into vesicular and bullous forms in which 
patients present with acute eruptions of blisters over their palms and soles. 
Chronic vesiculosquamous eczema, also called dyshidrotic eczema, was initially 
thought to be caused by abnormal function of the sweat glands. This association 
has since been disproved, but the term dyshidrotic eczema is still used. Patients 
with this variant present with vesicles involving the inner sides of the fingers. The 
chronic hyperkeratotic variety involves mainly the central palms, where it causes 
thickening and fissures. This category is notoriously the most difficult to treat. An 
“id-reaction” refers to vesicular eruption of the hands, caused by a distal focus of 
infection, with fungal infections being the most common. Despite the wide range 
of clinical presentations, all 4 types are histologically characterized by features of 
dermatitis, such as spongiosis and exocytosis.  
Causes: The etiology of hand eczema is unknown, but most observers suggest that 
intrinsic changes in the skin are responsible for this condition. However, several 
exogenous factors have been implicated in the causation of the disease.  Coexisting 
atopy is common in patients with palmoplantar eczema. This is by no means the 
only causal relationship because many patients have no history of atopy.Emotional 
stress may also trigger episodes. Seasonal changes seem to be directly related to 
relapses, as episodes are most common in the spring and summer months. Warm 
weather has been known to initiate episodes.Although dysfunction of the sweat 
glands is no longer accepted as the cause of dyshidrotic eczema, increased 
sweating seems to exacerbate the condition. Photosensitivity to ultraviolet A 
(UVA)-1 has been reported as an etiologic factor in a small subset of patients with 
eczema. Therefore, worsening of the disease in summer months may be due to the 
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increase in exposure to sunlight. UVA-therapy is a widely accepted form of 
treatment for palmoplantar eczema. Sensitivity to certain metals, particularly 
nickel, has been linked to the condition. Other exogenous factors include balsams 
and various allergens in general. Drugs responsible for inducing episodes include 
oral contraceptive pills and aspirin. Palmoplantar eczema occurring after 
intravenous immunoglobulin therapy is reported. Bacterial infections play a role in 
both causation and in secondarily infecting lesions. Fungal infections are most 
commonly implicated in “id-reactions”. Cigarette smoking may reduce the efficacy 
of topical therapy with psoralen and UVA (PUVA). 
Pathophysiology.Vesicular palmoplantar eczema is often thought to have an 
unidentified intrinsic cause. Although many etiologic factors are described, the 
underlying pathology is unknown. Similarly, though certain triggers have been 
associated with the development or worsening of symptoms, how these triggers 
cause flares has not been elucidated.  
The disease results in histologic evidence of dermatitis, such as spongiosis, which 
is often accompanied by lymphocytic infiltrates.  
Age.Pompholyx most commonly occurs in patients aged 20-40 years, but it may 
occur in individuals of any age. Onset in patients younger than 10 years is unusual.  
The frequency of recurrent episodes of pompholyx decreases after middle age, 
though this is not true of chronic vesicular and hyperkeratotic variants.  
History: The severity of symptoms varies, ranging from mild discomfort to acute 
severe episodes. Patients rarely require hospitalization. Itching, burning, and 
prickling sensations of the palms and soles precede the eruption of 
vesicles.Thereafter, small (1- to 2-mm) vesicles form, most commonly on the 
lateral sides of the fingers. In pompholyx, the central areas of the palms and soles 
may or may not be involved.Large vesicles can develop on the palms and soles and 
may coalesce to form confluent bullae.The lesions last for 2-3 weeks, after which 
spontaneous resolution generally occurs. Occasionally, large bullae may need to be 
aspirated. This phase is followed by desquamation.Palmoplantar eczema typically 
recurs, and episodes are more frequent during the spring and summer than in the 
fall and winter.The chronic hyperkeratotic variety results in severe itching 
accompanied by thickening and fissuring of the palm. This effect may decrease the 
mobility of the affected hand. 
Physical: Clinical signs depend on the stage of disease. An absence of erythema is 
often an important clinical feature in the acute and chronic forms. Acute episodes 
are characterized by a sudden onset of small, clear vesicles or bullae that are said 
to be sago-like or tapioca-like in appearance.Vesicles and/or bullae are 
accompanied by severe, occasionally painful pruritus.Small vesicles may enlarge 
or become more confluent and present as large bullae (especially on the palms and 
soles).Vesicles and bullae subsequently dry out and resolve, usually without 
rupturing.In most individuals, desquamation occurs 2-3 weeks after the onset of 
vesicles and bullae.In some patients, a milder recurrence follows the initial severe 
episode. Secondary infections, such as impetigo, cellulitis or lymphangitis, are 
possible in patients with recurrent hand eczema.Secondary nail changes 
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(e.g.dystrophic nails, irregular transverse ridging, pitting, thickening, 
discoloration) can also occur.Subacute vesicular eczema tends to have a chronic 
relapsing course with more vesiculation and more erythema in the acute phases 
than in later phases.Residual erythema or some dryness or scaling occurs in the 
less-active phases. Fissures are common and painful sequelae. A form of 
microvesicular palmar eczema also occurs in association with dry nummular 
(discoid) eczema.Hyperkeratotic palmar eczema is characterized by highly itchy, 
hyperkeratotic palms. Fissures in the folds of the hands and fingers are common 
and painful. Fissures can limit the use of the hands.Typically, chronic eczema 
affects the central area of the palm or the palmar aspect of the hands and 
fingers.Only occasionally are vesicles visible on clinical examination, but 
spongiosis is found on histology.When they occur on the hands, id reactions 
typically involve the lateral sides of the fingers. These reactions often resolve when 
the primary infection is treated. 
Lab Studies.The diagnosis of palmoplantar eczema is essentially a clinical one, 
and laboratory tests are not routinely performed. However, laboratory studies may 
be helpful in excluding other disorders.Elevated serum immunoglobulin E levels or 
positive results on prick tests may suggest an atopic tendency. Skin scrapings can 
indicate the presence of a fungus. Skin swabs may exclude bacterial infection. 
Procedures.Perform patch tests to exclude contact dermatitis or a systemic 
reaction to contact allergen.Perform biopsy to distinguish eczema from psoriasis or 
some forms of palmoplantar hyperkeratoses. 
Histologic Findings: Histologic features vary according to the stage of the 
evolution of disease. Usually, evidence suggests intracellular edema or spongiosis, 
lymphocytic infiltration of the epidermis, and intraepidermal vesicles or bullae in 
acutely affected persons. In chronically affected persons, spongiosis is present and 
often associated with epithelial proliferation and/or hyperkeratosis or psoriasiform 
epidermal hyperplasia. Dermis is often edematous, with a mixed perivascular 
inflammatory cell infiltrate.  
Medical Care: Several modalities of therapy are available for the treatment and 
control of palmoplantar eczema. Therapy should be chosen according to the type 
and severity of the condition. Whenever possible, eliminate known triggers. If 
pruritus is a problem, antihistamines (e.g. hydroxyzine) can relieve some 
symptoms.  
Topical therapy includes high-potency glucocorticoids, Burow solution (aluminum 
acetate 1%, or potassium permanganate solution (1:8000 dilution), tacrolimus, 
and/or PUVA. Topical high-potency glucocorticoids, such as betamethasone 
valerate and clobetasol propionate are first-line of therapies. Application of these 
medications under plastic and vinyl occlusion enhances their efficacy. However, 
this method may predispose the patient to secondary bacterial infection; therefore, 
it should be used only intermittently and in the absence of coexisting infection. 
Acute, severe episodes of pompholyx benefit from rest, and bland applications 
with wet soaks and compresses and with drying agents such as Burow solution. 
Occasionally, large blisters may need to be aspirated. Newer agents, such as topical 
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tacrolimus, are just as effective at mometasone furoate in the treatment of chronic 
relapsing eczema of the hands. These topical immunosuppressants may be used as 
steroid-sparing agents to treat resistant palmar eczema, with minimal systemic 
absorption or effect. Use of other agents should be considered when plantar 
eczema is being treated, as this therapy is less effective on the soles of the feet than 
on the hands. 
Systemic therapy includes steroids, immunosuppressive agents (eg, azathioprine, 
cyclosporine), retinoids (including acitretin), and/or PUVA. Consider the use of 
systemic glucocorticoids or intralesional steroids in acute episodes when local 
therapy fails. These agents are not helpful for long-term treatment because of a 
potential for severe adverse effects. Cyclosporine, mycophenolate mofetil, and 
methotrexate either alone or in combination with steroids may be used for severe, 
recalcitrant cases. These agents have also been tried as steroid-sparing agents in 
chronic relapsing eczema. For hyperkeratotic eczema, consider the use of aromatic 
retinoids, such as acitretin, which help control hyperkeratosis. These agents are 
best used in relatively low doses because of adverse effects. Therapy may need to 
be continued indefinitely in cases of hyperkeratotic eczema and is often 
accompanied by topical occlusive therapy, with combined or alternating steroids 
and keratolytics (5-20% salicylic acid) or tar preparations. 
Other treatment options include treatment with intradermal injections of 
botulinum toxin A, X-ray therapy, and disulfiram (Antabuse).  
Prevention. Elimination of known exacerbating factors, though often difficult to 
accomplish, is crucial in preventing relapses.Patients with established nickel 
sensitivity may benefit from nickel-free diets. 
 
 
6.5. Asteatotic Eczema 
 
Synonyms and related keywords: asteatotic dermatitis, eczema craquelé, eczema 
craquelatum, xerotic eczema, winter itch, etat craquelé 
 
Background: First described by Brocq in 1907, using the term eczema craquelé, 
asteatotic dermatitis is characterized by pruritic, dry, cracked, and polygonally 
fissured skin with irregular scaling. It most commonly occurs on the shins of 
elderly patients, but it may occur on the hands and the trunk. In 1971, Domonkos 
described the appearance of this dermatitis as cracked porcelain. The pattern of 
cracking has been likened to a crazy pavement pattern. In 1999, Fitzpatrick likened 
asteatotic eczema to a dried-up riverbed. According to Caplan, superficial bleeding 
and fissures can occur as the epidermis loses water, as it splits, and as it cracks 
deeply enough to disrupt papillary dermal capillaries. The inflammation can be 
associated with asymmetric leg edema. Eczema with increased lichenification 
occasionally supervenes as patients rub and scratch the pruritic areas. The eruption 
can be generalized or localized. Generalized asteatosis is a distinct entity and 
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should provoke a search for possible associated diseases. Guillet divides the 
localized forms into 4 types:  
– Asteatotic eczema of the lower extremities in elderly persons secondary to 
aging, dehydrated skin, and malnutrition  
– Cracked erythema secondary to irritant contact dermatitis from soaps or 
detergents  
– Eczema craquelé in areas in which corticosteroid therapy was discontinued  
– Asteatotic eczema in neurologic disorders  
Pathophysiology: Initially, excess water loss from the epidermis results in 
dehydration of the stratum corneum with upward curling of corneocytes. The outer 
keratin layers require 10-20% water concentration to maintain their integrity. A 
significant decrease in free fatty acids in the stratum corneum is present in people 
with asteatotic dermatitis. Stratum corneum lipids act as water modulators, and 
cutaneous loss of these lipids can increase transepidermal water loss to 75 times 
that of healthy skin. Elderly persons with decreased sebaceous and sweat gland 
activity, patients on antiandrogen therapy, people using degreasing agents, and 
people bathing without replacing natural skin emollients lost to bath water are at 
risk for asteatotic eczema.  
When the stratum corneum loses water, the cells shrink. A significantly decreased 
cellular volume can stress the skin's elasticity, creating fissures. Edema in the 
dermis leads to additional stretch on the overlying epidermis. Fissures rupture 
dermal capillaries, causing clinical bleeding. The disruption of cutaneous integrity 
can result in inflammation with risk of infection. Transepidermal absorption of 
allergens and irritants is increased as the epidermis is damaged, increasing 
susceptibility to allergic contact dermatitis and irritant contact dermatitis. Allergic 
contact dermatitis and irritant contact dermatitis may cause a persistent and 
possibly more extensive dermatitis despite therapy. Furthermore, low 
environmental humidity contributes to xerosis, creating a clinical picture of 
asteatotic dermatitis in some dermatologic conditions, such as atopic dermatitis.  
Causes.Multiple etiologic factors may coexist to cause asteatotic dermatitis, 
including the following:  
 
• Xerosis and friction 
• Frequent or prolonged bathing in hot water, use of soap on the involved site, and infrequent use 
of emollients for water retention in the stratum corneum 
• Degreasing agents (Solvents, Cleansers) 
• Decreased sebaceous and sweat gland activity in elderly persons 
• Decreased keratin synthesis in elderly persons 
• Low environmental humidity and cold winds that increase the loss of water by convection 
• Radiation 
• Long-term malabsorption of essential fatty acids, including linoleic acid and linolenic acid 
• Nutritional deficiencies (Zinc deficiency; Essential fatty acid deficiency, such as linoleic acid 
deficiency or linolenic acid deficiency) 
• Atopy 
• Ichthyosis 
• Thyroid disease - Myxedema and other thyroid diseases with diminished sweat and sebaceous 
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gland activity 
• Neurologic disorders - Decreased sweating in denervated areas 
• Drugs - antiandrogen therapy and diuretic therapy 
•Malignancies - malignant lymphoma, gastric adenocarcinoma, glucagonoma, 
angioimmunoblastic lymphadenopathy, breast cancer, large-cell lung carcinoma, and colorectal 
carcinoma 
 
Age.The median patient age at presentation is 69 years. Asteatosis can also occur 
in young people.  
History.During the winter months, an elderly person classically presents with 
pruritic and dry skin with dermatitis on the pretibial areas. Sometimes, the 
dysesthesia may be described as a pinprick or biting sensation.Asking the patient 
about pertinent controllable factors, such as the following, is important. Frequency 
of bathing, showering, and cleansing, and which soaps and cleansers are in contact 
with the skin. If the eruption persists despite therapy, behavioral changes, and 
treatment compliance, allergic contact dermatitis and irritant contact dermatitis and 
internal malignancy may require investigation. 
Physical. Primary lesions: slightly scaly, inflamed, curvilinearly cracked and/or 
fissured skin most commonly involves the pretibial areas, but it may also occur on 
the thighs, on the hands, and on the trunk.Secondary lesions: excoriated, 
erythematous, edematous patches may result from rubbing or scratching.Bleeding 
fissures secondary to the disruption of dermal capillaries have been described in 
exaggerated eczema craquelé, which begins as superficial cracks in the epidermis. 
Generalized lesions: generalized or extensive asteatotic dermatitis presents with 
primary lesions and secondary excoriations. 
Lab Studies. Appropriate laboratory studies are indicated for identified or 
suspected associated diseases. 
Histologic Findings. Spongiosis and a varying amount of inflammatory dermal 
infiltrate similar to that of mild, subacute eczema are seen.  
Medical Care. Patients should follow the methods listed below to improve the 
condition. Take short baths with decreased water temperature. Eliminate or reduce 
the use of soap on the involved areas. Avoid harsh skin cleansers. Apply 
petrolatum-based emollients following bathing, and use moisturizing agents 
liberally.Apply topical steroid ointments with or without polyethylene occlusion. 
Use humidifiers. 
Topical steroid ointments with 24- to 48-hour occlusion with polyethylene or 
Unnaboot are the treatment of choice for the rapid resolution of asteatotic 
dermatitis. Many patients heal with mild topical steroids (class III-VI) alone, 
depending on the severity of the dermatitis, the patient's compliance with 
treatment, and the reduction in the use of soap and hot water to the involved areas. 
The liberal use of moisturizers, especially petrolatum-based preparations, alone or 
in combination with topical steroids for mild cases of asteatotic dermatitis is 
recommended. 
Prognosis. Asteatotic dermatitis responds well to therapy; however, if the 
causative factors are not eliminated, recurrences are common. 
111 
 
 
6.6.Stasis Dermatitis 
 
Synonyms and related keywords: venous eczema, chronic venous insufficiency 
 
Background.Stasis dermatitis is a common inflammatory skin disease that occurs 
on the lower extremities in patients with chronic venous insufficiency. The 
condition typically affects middle-aged and elderly patients. It rarely occurs before 
the fifth decade of life, except in patients with acquired venous insufficiency due to 
surgery, trauma, or thrombosis. Stasis dermatitis is usually the earliest cutaneous 
sequela of venous insufficiency, and it may be a precursor to more problematic 
conditions, such as venous leg ulceration and lipodermatosclerosis.  
Causes (pathophysiology).Stasis dermatitis occurs as a direct consequence of 
venous insufficiency. Disturbed function of the 1-way valvular system in the deep 
venous plexus of the legs results in backflow of blood from the deep venous 
system to the superficial venous system, with accompanying venous hypertension. 
This loss of valvular function can result from an age-related decrease in valve 
competency. Alternatively, specific events, such as deep venous thrombosis, 
surgery (e.g. vein stripping, harvesting of saphenous veins for coronary bypass), or 
traumatic injury, can severely damage the function of the lower-extremity venous 
system. The mechanism by which venous hypertension causes the cutaneous 
inflammation of stasis dermatitis has been extensively studied for decades. Several 
theories have been proposed.  
The earliest theories regarding the cause of cutaneous inflammation in venous 
insufficiency centered on oxygen perfusion of lower-extremity tissues. Originally, 
an incompetent venous system was thought to lead to pooling of blood in the 
superficial veins, with reduced flow and therefore reduced oxygen tension in the 
dermal capillaries. This pooling hypothesis led to the term stasis dermatitis. It was 
believed that the decreased oxygen content of pooled blood led to hypoxic damage 
to the overlying skin.  
The hypoxia/stasis theory was refuted by evidence that instead of pooled, stagnant 
blood with low oxygen tension, leg veins in patients with venous insufficiency 
have increased flow rates and high oxygen tension. Arteriovenous shunting could 
have accounted for these findings, but no evidence of shunting in patients with 
venous insufficiency was found. The complete lack of evidence to support a 
hypoxia/stasis theory has led many investigators to advocate the abandonment of 
the term stasis dermatitis.  
Subsequent research focused on the role of lower-extremity microcirculation in the 
pathogenesis of skin damage due to venous insufficiency. In the 1970s and 1980s, 
increased venous hydrostatic pressure was found to be transmitted to the dermal 
microcirculation; this leads to increased permeability of dermal capillaries.  
This increased permeability enables macromolecules, such as fibrinogen, to leak 
out into the pericapillary tissue; then, polymerization of fibrinogen to fibrin results 
in the formation of a fibrin cuff around dermal capillaries. It has been hypothesized 
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that this fibrin cuff serves as a barrier to oxygen diffusion, with resulting tissue 
hypoxia and cell damage. Subsequently, the phenomenon of fibrin cuff formation 
was found in more severe disease, such as venous ulceration. Fibrin cuffs are not 
found in ulcers due to causes other than venous hypertension. Decreased cutaneous 
fibrinolytic activity has been proposed to contribute to the formation of fibrin 
cuffs. The role of the fibrin cuff in causing skin changes of venous insufficiency 
has been questioned during the past decade. Specifically, the fibrin cuff has not 
been found to significantly decrease oxygen diffusion.  
An alternate theory has emerged, implicating leukocyte trapping as a pathogenesis 
of stasis dermatitis. Venous hypertension has been shown to result in leukocyte 
sequestration in the microcirculation, with increased contact of leukocytes with the 
capillary endothelium. This leukocyte trapping may very well result in the release 
of inflammatory mediators, which further derange microvascular permeability and 
function. In addition, sludging of leukocytes may block dermal capillaries, leading 
to tissue ischemia. This is an attractive hypothesis; unlike previous theories, the 
leukocyte trapping hypothesis provides a direct link between dysfunctional venous 
circulation and cutaneous inflammation.  
Frequency. Although not nearly as prevalent as skin cancer, dermatophytosis, or 
xerosis, stasis dermatitis affects a significant proportion of the elderly population. 
Age. The risk of developing stasis dermatitis steadily increases with each passing 
decade; when considering only adults older than 70 years, the prevalence of stasis 
dermatitis may be greater than 20%.  
History. Patients with stasis dermatitis typically present with an insidious onset of 
pruritus affecting 1 or both lower extremities.The medial ankle is most frequently 
involved, with symptoms progressing to involve the foot and/or the calf.The 
patient may offer a prior history of dependent leg edema. Factors that worsen 
peripheral edema (eg, congestive heart failure, long-standing hypertension with 
diastolic dysfunction) are often found in patients with stasis dermatitis. 
Physical: Physical examination reveals erythematous, scaling, eczematous patches 
affecting the lower extremity. The medial ankle is most frequently and severely 
involved because of the fact that the medial ankle represents a watershed area with 
relatively poor blood flow compared with the rest of the leg. In advanced cases of 
stasis dermatitis, the inflammation may encircle the ankle and extend to just below 
the knee; this is sometimes referred to as stocking erythroderma. The dorsal part of 
the foot may be involved in severe cases.Involved skin in stasis dermatitis may 
exhibit the same changes as seen in other eczematous conditions.Severe, acute 
inflammation may result in exudative, weeping patches and plaques.Secondary 
infection can cause typical honey-colored crusting due to bacteria or 
monomorphous pustules due to cutaneous candidiasis.In long-standing lesions, 
lichenification and hyperpigmentation may occur as a consequence of chronic 
scratching and rubbing. In addition to lichenification and hyperpigmentation, 
chronic stasis dermatitis can show changes, such as skin induration, which may 
progress to lipodermatosclerosis with the classic inverted champagne bottle 
appearance.Another unique feature sometimes seen in chronic stasis dermatitis is 
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the development of violaceous plaques and nodules on the legs and dorsal part of 
the feet. These lesions frequently undergo painful ulceration and can be clinically 
indistinguishable from classic Kaposi sarcoma. This clinical appearance has led 
this entity to be called pseudo–Kaposi sarcoma or acroangiodermatitis.Stasis 
dermatitis frequently occurs along with a background of skin changes that are 
typical for patients with venous insufficiency.These skin changes include edema, 
varicosities, hyperpigmentation, atrophic patches (atrophie blanche), and diffuse 
red-brown discoloration representing deep dermal deposits of hemosiderin (from 
degraded, extravasated erythrocytes).These chronic changes persist regardless of 
the activity of stasis dermatitis. 
Complications. Complications of chronic stasis dermatitis include cellulitis and 
non-healing venous ulcers.Direct consequences of stasis dermatitis include an 
increased incidence of allergic contact dermatitis, lower-extremity ulceration, 
lipodermatosclerosis, and id reaction (autoeczematization). 
Lab Studies. Blood tests are generally not helpful in the management of stasis 
dermatitis, except in a patient where cellulitis and/or sepsis are suspected. An 
exception is the patient with stasis dermatitis due to venous thrombosis; patients 
with venous thrombosis need a thorough hematologic workup to rule out 
underlying hypercoagulability states. 
Imaging Studies. Radiologic/Doppler studies. In patients with acute new-onset 
stasis dermatitis or in a young patient, investigating the dynamics of the deep 
venous circulation is prudent.Venous Doppler studies may reveal deep venous 
thrombosis or severe valve damage due to past thrombosis. Of course, the 
consequences of an unrecognized acute or subacute deep venous thrombosis may 
be catastrophic. 
Histologic Findings. Skin biopsy of stasis dermatitis, although rarely indicated, 
shows an acute or subacute dermatitis. Acute lesions may exhibit a superficial 
perivascular lymphocytic infiltrate, epidermal spongiosis, serous exudate, scale, 
and crust. Chronic lesions may show epidermal acanthosis with hyperkeratosis. 
The dermis is characterized by deep dermal aggregates of siderophages due to 
uptake of hemosiderin from degraded erythrocytes. Dermal capillaries are 
frequently dilated; long-standing lesions show intimal thickening of small 
arterioles and venules along with dermal fibrosis.  
A special consideration in chronic stasis dermatitis where biopsy may be necessary 
is the development of acroangiodermatitis (pseudo–Kaposi sarcoma). The 
violaceous plaques and nodules of acroangiodermatitis may be clinically 
indistinguishable from classic Kaposi sarcoma, especially when occurring in an 
elderly man. Biopsy samples show changes typical of stasis dermatitis, along with 
a proliferation of capillaries and fibroblasts. However, the vascular slits and the 
atypical endothelial cells that are seen in classic Kaposi sarcoma are absent. 
Medical Care. Compression therapy. Although extensive work has been 
completed in the study of treatment of venous ulcers, no large, well-controlled 
trials examine the treatment of stasis dermatitis. The overall mainstay of treatment 
has always been aimed at lessening the clinical impact of the underlying venous 
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insufficiency, which is typically accomplished with compression therapy. 
Assessing the patient's peripheral arterial circulation (clinically or with a Doppler 
study) before recommending compression therapy is important; adding 
compression to a leg with compromised arterial circulation could increase 
claudication and put the patient at risk for ischemic damage. Compression is 
generally accomplished by means of specialized stockings that deliver a controlled 
gradient of pressure (measured in mm Hg) to the affected leg. More aggressive 
compression can be performed by using elastic wraps; compression (Unna) boots; 
and more sophisticated devices, such as end-diastolic compression boots. Frequent 
leg elevation is a necessary adjunct to leg compression. Counseling patients that 
compression therapy must be maintained on a lifelong basis is important. 
Topical therapy. Topical treatment of stasis dermatitis has much in common with 
the treatment of other forms of acute eczematous dermatitis. Weeping lesions can 
be treated with wet-to-damp gauze dressings soaked with water or with a drying 
agent, such as aluminum acetate. Topical corticosteroids are frequently used for 
reducing inflammation and itching in acute flares; mid-potency corticosteroids, 
such as triamcinolone 0.1% ointment, are generally effective. Be wary of the use of 
high-potency topical corticosteroids in stasis dermatitis because the chronically 
inflamed skin can increase the risk of systemic absorption and because steroid-
induced cutaneous atrophy can predispose the patient to ulceration. Systemic 
corticosteroids are not part of stasis dermatitis treatment, although they may be 
required in very severe cases of widespread autoeczematization. 
Prevention/management of infection. Be wary of infection in stasis dermatitis; 
this becomes more problematic when using topical corticosteroids, which make the 
patient more susceptible to infection. Open excoriations and erosions should be 
treated with a topical antibiotic, such as bacitracin or polysporin. Obvious 
superficial impetiginization should be treated with topical mupirocin or a systemic 
antibiotic with activity against Staphylococcus and Streptococcus species (e.g. 
dicloxacillin, cephalexin, cefadroxil, levofloxacin). Expanded coverage may be 
necessary in patients who are immunocompromised. Suspected deep cellulitis 
should always be treated with oral or intravenous antibiotics. Necrotizing fasciitis 
would be a rare complication but is a surgical emergency. 
Complications of treatment. The development of contact dermatitis is especially 
problematic in the treatment of patients with stasis dermatitis. All of the above-
mentioned topical treatments, including bacitracin and topical corticosteroids, have 
been reported to cause contact sensitization in patients with stasis dermatitis. 
Consider contact dermatitis in any patient with stasis dermatitis who becomes 
clinically worse despite appropriate topical treatment.  
Long-term management. Patients with chronic, quiescent stasis dermatitis can be 
treated with bland topical emollients to maximize epidermal moisture. Plain white 
petrolatum is an inexpensive occlusive moisturizer that is very effective and, 
importantly, does not contain any contact sensitizers. 
Recent new theories regarding the pathogenesis of cutaneous inflammation in 
venous insufficiency have led to the investigation of systemic therapies, which 
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have been hypothesized to have beneficial modulating effects on neutrophil 
function. Treatments, such as prostaglandin E1 (PGE1) and pentoxifylline, have 
been studied in the treatment of venous ulcers; it is hypothesized that these 
medications decrease cytokine-mediated neutrophil activation, leading to reduced 
inflammation. However, even if these systemic therapies are proven unequivocally 
effective, it is unlikely that their use will extend beyond the scope of treatment of 
recalcitrant venous ulcers. 
Consultations.Uncomplicated stasis dermatitis is usually managed in the 
dermatologist's office. A consultation with a vascular surgeon may be required, 
especially when an underlying surgically correctable vascular abnormality is 
suspected.A consultation with a hematologist may be needed when treating a 
patient with stasis dermatitis due to deep venous thrombosis; cases such as these 
may be secondary to congenital or acquired hypercoagulable states. 
Patient Education.Patients should be educated regarding the underlying cause of 
their condition and the permanent nature of venous valvular insufficiency. 
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VII. Erythema Multiforme and Stevens-Johnson syndrome 
 
Synonyms and related keywords: EM, Stevens-Johnson syndrome, SJS, 
erythema multiforme major, EM major, erythema multiforme minor, EM minor, 
herpes-induced EM major, herpes-associated erythema multiforme, herpes-
associated EM, drug-induced SJS, drug-induced Stevens-Johnson syndrome 
 
Background: Erythema multiforme (EM) is an acute self-limited eruption 
characterized by a distinctive clinical eruption, the hallmark of which is the iris or 
target lesion. EM may present within a wide spectrum of severity. EM minor 
represents a localized eruption of the skin with mild or no mucosal involvement, 
corresponding to the initial description of von Hebra. EM major and Stevens-
Johnson syndrome (SJS) are more severe mucosal and skin diseases and are 
potentially life-threatening disorders.  
Recently, international collaborators have suggested that EM and SJS could be 
separated as 2 distinct clinical disorders with similar mucosal reactions but 
different patterns of cutaneous lesions. The clinical pictures are as follows:  
– Mucosal erosions plus typical or raised atypical targets and epidermal 
detachment involving less than 10% of the body surface. The lesions are usually 
located on the extremities and/or the face. This characterizes herpes-induced EM 
major.  
– Mucosal erosions plus widespread distribution of flat atypical targets or 
purpuric macules and epidermal detachment involving less than 10% of the body 
surface. The lesions may be present on the trunk, the face, and the extremities. 
These are characteristic findings of drug-induced SJS.  
Pathophysiology: The pathophysiology of EM is still not completely understood; 
however, herpes-associated EM (HAEM) appears to represent the result of a cell-
mediated immune reaction associated with herpes simplex virus (HSV) antigen. 
The immunologic reaction affects HSV-expressing keratinocytes. Cytotoxic 
effector cells, CD8+ T lymphocytes in the epidermis, induce apoptosis of scattered 
keratinocytes and lead to satellite cell necrosis. Neighboring epidermal cells are 
human leukocyte antigen DR (HLA-DR) positive. A relationship exists between 
human leukocyte antigen (HLA) types A33, B35, B62 (B15), DR4, DQB1*0301, 
DQ3, and DR53 and recurrent EM. HLA-DQ3 has been proven to be especially 
related to recurrent EM, and it may be a helpful marker for distinguishing HAEM 
from other diseases with EM-like lesions.  
Frequency: The exact incidence of EM is unknown; as many as 1% of 
dermatologic outpatient visits are for EM.  
Mortality/Morbidity: Most cases of EM minor subside completely within 2-3 
weeks without any complications. The mortality rate of EM major is reportedly 
less than 5%, and clearing requires a longer time than EM minor. EM major 
usually takes 3-6 weeks to heal.  
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Age: The highest incidence is in the second to fourth decades of life, with 20% of 
cases occurring in children and adolescents.  
Causes.Many suspected etiologic factors have been reported to cause EM (and 
many were published at a time when a distinction between EM major and SJS was 
not made). They are listed below. EM and SJS are both caused by drugs, but 
infectious agents are considered to be the major cause of EM. Today, EM minor is 
regarded as being triggered by HSV in nearly 100% of cases; many instances of 
idiopathic EM minor may be precipitated by subclinical HSV infection. A herpetic 
etiology also accounts for 55% of cases of EM major. Among the other infections, 
Mycoplasma infection appears to be a common cause. Drugs are reported in many 
documented cases of SJS and EM major. Sulfa drugs are the most common 
triggers. A slow acetylator genotype is a risk factor for sulfonamide-induced SJS. 
Prophylactic anticonvulsants after surgery for a brain tumor combined with cranial 
irradiation may result in life-threatening SJS.  
Infections. Bacterial - Bacille Calmette-Guérin (BCG) vaccination, borreliosis, 
catscratch disease, diphtheria, hemolytic streptococci, legionellosis, leprosy, 
Neisseria meningitidis, Mycobacterium avium complex, pneumococcus, Proteus 
species, Pseudomonas species, Salmonella species, Staphylococcus species, 
syphilis, tuberculosis, tularemia, Vibrio parahaemolyticus, Vincent disease, 
Yersinia species, rickettsial infections, Mycoplasma pneumonia.Chlamydial - 
Lymphogranuloma venereum, psittacosis.Fungal - Coccidioidomycosis, 
dermatophytosis, histoplasmosis.Parasitic - Trichomonas species, Toxoplasma 
gondii.Viral - Adenovirus, coxsackievirusB5, cytomegalovirus, echoviruses, 
enterovirus, Epstein-Barrvirus, hepatitisA, hepatitisB, hepatitisC, herpessimplex, 
influenza, measles, mumps, paravaccinia, parvovirusB19, poliomyelitis, vaccinia, 
varicella-zoster, variola. 
Drugs. Antibiotics - penicillin, ampicillin, tetracyclines, amoxicillin, cefotaxime, 
cefaclor, cephalexin, ciprofloxacin, erythromycin, minocycline, sulfonamides, 
trimethoprim-sulfamethoxazole, vancomycin. Anticonvulsants - barbiturates, 
carbamazepine, hydantoin, phenytoin, valproic acid.Antipyretics - analgesics, 
especially aspirin.Antituberculoids - rifampicin, isoniazid, thiacetazone, 
pyrazinamide.Others - acarbose, albendazole, allopurinol, arsenic, bromofluorene, 
chinine, cimetidine, clofibrate, corticosteroids, diclofenac, didanosine, 
dideoxycytidine, diphosphonate, estrogen, etretinate, fluconazole, griseofulvin, 
gabapentin, granulocyte-macrophagecolony-stimulatingfactor, hydralazine, 
indapamide, indinavir, lamotrigine, methazolamide, mefloquine, methotrexate, 
meprobamate, mercurials, minoxidil, nifedipine, nevirapine, nitrogenmustard, 
nystatin, nonsteroidalanti-inflammatorydrugs (NSAIDs), phenolphthalein, 
piroxicam, pyritinol, progesterone, potassiumiodide, sulindac, suramin, saquinavir, 
thiabendazole, thiouracil, terbinafine, theophylline, verapamil. 
Contactants - ammoniated mercury, budesonide, bufexamac, capsicum, 
chloromethylnaphthalene, desoximethasone, dinitrochlorobenzene (DNCB), 
disperse blue 124, diphenylcyclopropenone, fire sponge (Tedania ignis), isopropyl-
p-phenylenediamine of rubber, nitrogen mustard, oxybenzone, phenylbutazone, 
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poison ivy, proflavin, resin, rosewood, sesquiterpene lactones in herbal medicine, 
triamcinolone acetonide. Immunologic disorders - transient selective C4 
deficiency of infancy. Mechanical factors– tattooing. Foods - salmon berries. 
Physical factors - radiotherapy, cold, sunlight. Others - collagen diseases, 
vasculitides, non-Hodgkin lymphoma, leukemia, multiple myeloma, myeloid 
metaplasia, polycythemia. 
History.The prodromal symptoms are mild or absent in EM minor and may 
present as a mild nonspecific upper respiratory infection. The abrupt onset of a 
rash usually occurs within 3 days, starting on the extremities symmetrically with 
centripetal spreading. 
– In EM major, 50% of patients have nonspecific prodromes, including 
moderate fever, general discomfort, cough, sore throat, vomiting, chest pain, and 
diarrhea. These symptoms are usually present for 1-14 days preceding the eruption. 
The lesions begin on the acral areas and spread similarly to the distribution of EM 
minor. 
– Prominent mucosal involvement may occur in EM major. Erosions of the 
oral mucosa may result in difficulty in eating, in drinking, and in opening the 
mouth. Eye involvement may cause lacrimation and photophobia. Genital lesions 
are painful and may result in urinary retention. 
– Skin tenderness is absent with an occasional mild burning sensation and 
itching. 
– A localized form of EM has been reported at the site of marrow aspiration. 
– One half of children who are affected have a history of herpes labialis or 
herpes genitalis. While the onset usually precedes EM by 3-14 days, it may still be 
present at the onset of EM. HAEM can be precipitated by exposure to the sun. 
Physical: The hallmark of EM is a target lesion with variable mucous membrane 
involvement.  
Skin lesion. The initial lesion is a dull red macule or urticarial plaque expanding 
slightly to a maximum of 2 cm over 24-48 hours. In the center, a small papule, 
vesicle, or bulla develops, flattens, and then may clear. The intermediate ring 
develops and becomes raised, pale, and edematous. The periphery gradually 
changes to become cyanotic or violaceous and forms a typical concentric target 
lesion.Some lesions are atypical targets that consist of only 2 concentric 
rings.Polycyclic or arcuate lesions may occur.The Koebner phenomenon may be 
observed.The Nikolsky sign is negative. 
Skin distribution. The lesions appear predominantly on the extensor surfaces of 
the acral extremities and spread centripetally. The palms, the neck, and the face are 
frequently involved. Lesions of the soles and flexural aspects of the extremities are 
less frequent. A zosteriform distribution has been observed. 
Mucosal lesions. Mucosal involvement is present in as many as 70% of patients 
with EM. The degree is usually mild with limitation to one mucosal surface.Oral 
lesions are the most common, with the lips, the palate, and the gingiva often 
affected. More severe erosions of at least 2 mucosal surfaces are seen in EM major 
and are characterized by a hemorrhagic crusting of the lips and ulceration of the 
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non-keratinized mucosa. Extensive painful mucosal involvement with few or no 
skin lesions may be seen.Eye involvement is usually mild and may present as red 
conjunctivae, chemosis, and lacrimation.The genital areas may have painful, 
hemorrhagic bullae and erosions.Mucosal lesions usually heal without sequelae. 
The mucosal involvement in SJS is more severe and extensive than in EM 
major.Generalized lymphadenopathy often accompanies EM major. 
Complications.Most patients have an uncomplicated course, with the exception of 
hosts who are immunocompromised and those with secondary bacterial infections 
of the skin or the mucosa.Severe oral involvement may be accompanied by 
difficulty in consuming food and fluid and can result in dehydration. Ocular 
complications may manifest as purulent conjunctivitis, dry eyes, anterior uveitis, 
panophthalmitis, scarring of the conjunctivae, symblepharon, and 
blindness.Vaginal and urethral lesions are infrequent. The erosions may cause 
urinary retention and phimosis. Hematocolpos is the result of genital lesions in 
teenage females. Severe scarring of the genitourinary tract may cause vaginal and 
urethral stenosis. 
Lab Studies.Complete blood count; electrolyte levels; BUN determination; 
erythrocyte sedimentation rate (ESR); liver function tests; and cultures from blood, 
sputum, and erosive areas are indicated in severe cases of EM major. In severe 
cases, elevated ESR, moderate leukocytosis, and mildly elevated liver 
transaminase levels may be found.Specific HSV antigens have been detected 
within keratinocytes by immunofluorescence study. The HSV DNA has been 
identified primarily within the keratinocytes by polymerase chain reaction 
amplification. 
Procedures.A histopathologic examination of a cutaneous punch biopsy should be 
performed to confirm the diagnosis and to rule out the other differential diagnoses. 
Histologic Findings: The early lesion of EM is characterized by infiltration of 
lymphocytes at the dermal-epidermal interface with accompanying exocytosis and 
spongiosis in the epidermis. Individual eosinophilic necrotic keratinocytes may be 
scattered and surrounded by lymphocytes (satellite cell necrosis). The dermal 
changes include edematous papillary dermis, ectatic and swollen endothelial cells 
of the vessels, and extravasation of the red blood cells.  
As lesions progress, partial-to-full-thickness epidermal necrosis, intraepidermal 
vesiculation, subepidermal blisters due to spongiosis, ballooning, vacuolar 
degeneration of the junctional zone, and severe papillary edema occur. 
Lymphohistiocytes (CD4+ more than CD8+ T lymphocytes) with a few neutrophils 
and occasional eosinophils comprise the dermal inflammatory infiltrate. Recently, 
an observation revealed that acrosyringeal keratinocyte necrosis and dermal 
inflammation containing eosinophils may occur in drug-related cases. 
Medical Care: Identification of the cause should be made if possible. If a drug is 
suspected, it must be withdrawn. Infections should be appropriately treated after 
cultures and/or serologic tests have been performed. For all forms of EM, 
symptomatic treatment, including oral antihistamines, analgesics, local skin care, 
and soothing mouthwashes, is of great importance. Topical steroids may be 
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considered.A liquid diet and intravenous fluid therapy may be necessary. Oral 
antacids may be helpful for discrete oral ulcers.Electrolytes and nutritional support 
should be started as soon as possible. The use of liquid antiseptics, such as 0.05% 
chlorhexidine, during bathing is preferable. Topical treatment, including that for 
genital involvement, may be performed with a gauze dressing or a hydrocolloid. 
Local supportive care for eye involvement is important and includes topical 
lubricants for dry eyes, sweeping of conjunctival fornices, and removal of fresh 
adhesions. 
Systemic corticosteroids are controversial, and some believe they may predispose 
to complications. Beneficial effects of hemodialysis, plasmapheresis, cyclosporin, 
immunoglobulin, levamisole, thalidomide, dapsone, and cyclophosphamide have 
been documented in case reports.The most severe cases should be managed in 
intensive care or burn units. 
Consultations.Obtain a dermatologic consultation for diagnosis and management. 
Consult an internal medicine specialist or a pediatric specialist for evaluation of the 
underlying causes of disorders and systemic sequelae.Obtain an early 
ophthalmologic consultation for evaluation and management of ocular 
involvement.EM major may require hospitalization for the treatment of 
complications and sequelae. 
Prevention.Sulfonamide-containing ointments should be avoided.Prophylaxis for 
recurrence of HAEM should be considered in patients with more than 5 attacks per 
year.Low-dose acyclovir (200 mg qd to 400 mg bid) can be effective for 
recurrence of HAEM, even in subclinical HSV infection. In children, the dosage of 
10 mg/kg/d may be considered.Prophylaxis may be required for 6-12 months or 
longer. If unresponsive, continuous therapy of valacyclovir (500 mg bid) has been 
reported to be effective. 
Prognosis. In EM minor, the lesions ultimately subside within 2-3 weeks without 
scarring. The recurrence of EM minor is common and varies between 1 and 10 
times per year.EM major has a mortality rate of less than 5%. It usually takes a 
more protracted course than EM minor; clearing may require 3-6 weeks. Skin 
lesions usually heal with hyperpigmentation and/or hypopigmentation. Scarring is 
usually absent, except after secondary infection.Healing of the mucosal areas is 
usually complete. Scars and strictures of the esophageal, urethral, vaginal, and anal 
mucosa rarely occur.Severe eye complications may result in permanent blindness. 
 
 
8. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis 
 
Synonyms and related keywords: erythema multiforme, EM, SJS, TEN 
 
Background: Toxic epidermal necrolysis (TEN) is an acute dermatologic disease, 
the presentation of which may constitute a true emergency. The disorder is 
characterized by widespread erythematous macules and targetoid lesions; full-
thickness epidermal necrosis, at least focally; and involvement of more than 30% 
of the cutaneous surface. Commonly, the mucous membranes are also involved. 
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Nearly all cases of TEN are induced by medications, and the mortality rate can 
approach 40%.  
Stevens-Johnson syndrome (SJS) may also present as a dermatologic emergency 
characterized by purpuric macules and targetoid lesions; full-thickness epidermal 
necrosis, although with lesser detachment of the cutaneous surface; and mucous 
membrane involvement. As with TEN, medications are important inciting agents, 
although Mycoplasma infections may induce some cases. The mortality rate is 
much lower and approaches 5% of cases.  
Erythema multiforme (EM) is generally a far more benign process characterized by 
target or targetoid lesions, with or without blisters, in a symmetric acral 
distribution. Oral lesions are common. Severe presentations may have widespread 
involvement of the mucous membranes and epidermal detachment with a loss of 
less than 10% of the cutaneous surface. Most cases are secondary to prior infection 
with a herpes virus. The condition generally has low morbidity and no mortality 
and is often recurrent. SJS may have features of both EM and TEN, which has led 
to confusion in nosology.  
SJS and TEN may represent a spectrum of a single disease process. Some evidence 
suggests that EM may be an entirely distinct disorder. This article discusses SJS 
and TEN.  
Pathophysiology: SJS and TEN are often drug induced, but the pathophysiologic 
mechanism is unknown. A number of theories have been proposed that may have 
implications for treatment. Patients and their first degree-relatives may have 
genetic defects in their metabolic pathways that lead to the accumulation of toxic 
metabolites. For example, patients with sulfonamide-induced TEN have been 
shown to have a slow acetylator genotype, resulting in increased production of 
sulfonamide hydroxylamine via the P-450 pathway. These drug metabolites may 
have direct toxic effects or act via a hapten-mediated mechanism to break self-
tolerance to endogenous proteins.  
Apoptosis of keratinocytes has been proposed secondary to a cell-mediated 
cytotoxic reaction. Keratinocyte apoptosis is rare in the healthy epidermis, but it 
has been shown to be increased in TEN. In 1997, Inachi et al demonstrated 
perforin-mediated apoptosis in patients with SJS. Perforin, a pore-making 
monomeric granule released from natural killer cells and cytotoxic T lymphocytes, 
kills target cells by forming polymers and tubular structures not unlike the 
membrane attack complex of the complement system.  
A second proposed mechanism of apoptosis involves interaction between a cell-
surface death receptor, such as Fas, and its receptive ligand, to form a Fas ligand 
(FasL). In 1998, Viard et al demonstrated high concentrations of soluble Fas ligand 
(sFasL) in TEN sera. In vitro, target cell death was blocked by a FasL-blocking 
antibody and by antibodies present in pooled human intravenous immunoglobulin 
(IVIG). An open trial of IVIG in 10 patients with TEN resulted in a halt of 
progression within 24-48 hours, with no mortality.  
Mortality/Morbidity: SJS may prove fatal in roughly 5% of patients; TEN may 
prove fatal in as many as 40% of patients. Sepsis and respiratory distress are the 
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most common complications and ultimately the direct causes of death. Important 
prognostic factors include the percentage loss of body surface area (BSA), age, 
persistent neutropenia (defined as neutropenia lasting >5 d), hypoalbuminemia 
(usually <2 g/dL), and persistent azotemia. Among 247 French patients, only 1 out 
of 70 died when BSA involvement was less than 10%. In contrast, the mortality 
rate was 11% for patients with 10-30% BSA involvement and 35% for patients 
with BSA involvement exceeding 30%.  
While some patients rapidly progress to lose very large areas of the epidermis in a 
matter of days, the process suddenly ceases in others and re-epithelialization 
begins a few days later. Predicting the course of disease in a given patient at the 
initial presentation is not possible. Re-epithelialization is usually complete within 3 
weeks, but pressure and mucosal areas may remain eroded and crusted for 2 weeks 
or longer.  
Survivors of SJS/TEN may experience numerous long-term sequelae; the most 
disabling are those of the eye. Cicatrization of conjunctival erosions may lead to 
inverted eyelashes, photophobia, a burning sensation in the eyes, watery eyes, a 
sicca-like syndrome, and corneal and conjunctival neovascularization. As many as 
40% of survivors of TEN have residual potentially disabling lesions that may cause 
blindness.  
Cutaneous lesions may resolve with a patchwork of hyperpigmentation and 
hypopigmentation. Fingernails and toenails may regrow abnormally. Lesions of the 
genitourinary system may lead to phimosis or vaginal synechiae.  
Age: TEN occurs in all age groups, including newborns. Because drug exposure 
increases with age, SJS and TEN occur more frequently in the older population. 
Also, adults might be metabolically more susceptible to such drug reactions than 
children. However, only 54% of cases of SJS could be attributed to drugs, and 
some cases of EM, which typically affects younger patients, were likely included 
in the analysis. Lastly, HIV infection is associated with TEN. 
 
Causes: Most cases of SJS/TEN are drug induced. In establishing a drug exposure 
timeline, agents administered within 1-3 weeks are most suspect, although longer 
or shorter times do not necessarily rule out a particular medication. A case-control 
study of 245 patients and 1,147 control subjects in Europe identified potential drug 
triggers.  
For medications used on a short-term basis, the relative risk was greatest for 
trimethoprim-sulfamethoxazole and other sulfonamide antibiotics, chlormezanone, 
aminopenicillins, quinolones, and cephalosporins.  
Among drugs used long term, the greatest risk of SJS/TEN was seen in the first 2 
months of use. The agents posing an increased risk were carbamazepine, 
phenobarbital, phenytoin, valproic acid, oxicam non-steroidal anti-inflammatory 
drugs, allopurinol, and corticosteroids. The greatest excess risk was 4.5 cases per 
million users in 1 week for sulfonamides.  
Epidemiologic studies in France have shown a greater risk of TEN in patients 
infected with HIV, especially those with acquired immune deficiency syndrome 
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(AIDS). In the greater Paris area, 15 cases of AIDS-associated TEN occurred over 
a 6-year period, whereas 0.04 cases would be expected in the general population. 
This finding may be due to the increased use of sulfonamides in patients infected 
with HIV and abnormal patterns of production or detoxification of drug 
metabolites.  
TEN has been reported in patients with systemic lupus erythematosus, but these 
limited cases may be a mere coincidence. Infections with herpesvirus, Mycoplasma 
pneumoniae, or Yersinia have also been reported in patients with SJS, but these 
patients may have had EM. Other reported associations include leukemia, 
lymphoma, ulcerative colitis, and Crohn disease. 
History.Constitutional symptoms, such as fever, cough, or sore throat, may appear 
1-3 days prior to any cutaneous lesions.Patients may complain of a burning 
sensation in their eyes, photophobia, and a burning rash that begins symmetrically 
on the face and the upper part of the torso.Delineation of a drug exposure timeline 
is essential, especially in the 1-3 weeks preceding the cutaneous eruption. 
Physical.Primary lesions.The initial skin lesions of SJS/TEN are poorly defined 
erythematous macules with darker purpuric centers. The lesions differ from classic 
target lesions of EM by having only 2 zones of color: central dusky purpura or a 
central bulla, with surrounding macular erythema. A classic target lesion has 3 
zones of color: central dusky purpura or a central bulla, a surrounding edematous 
pale zone, and a surrounding macular erythema.Lesions, with the exception of 
central bullae, are typically flat. Lesions of EM are more likely to be palpable.Less 
frequently, the initial eruption may be scarlatiniform. Flaccid blisters are typically 
present with full-thickness epidermal necrosis.Non-denuded areas have a wrinkled 
paper appearance. Nikolsky sign is easily demonstrated by applying lateral 
pressure to bullae.Arrangement: individual macules are found surrounding large 
areas of confluence.Distribution: lesions begin symmetrically on the face and the 
upper part of the torso and extend rapidly, with maximal extension in 2-3 days. In 
some cases, maximal extension can occur rapidly over hours. Lesions may 
predominate in sun-exposed areas. Full detachment is more likely to occur in areas 
subjected to pressure, such as the shoulders, the sacrum, or the buttocks.Painful 
edematous erythema may appear on the palms and the soles. The hairy scalp 
typically remains intact, but the entire epidermis, including the nail beds, may be 
affected. 
A recent classification proposes that epidermal detachment in SJS is limited to less 
than 10% of the BSA. Overlapping SJS/TEN has more extensive confluence of 
erythematous and purpuric macules, leading to epidermal detachment of 10-30% of 
the BSA. Classic TEN has epidermal detachment of more than 30%.An uncommon 
form of TEN (TEN without spots) lacks targetoid lesions, and blisters form on 
confluent erythema. Greater than 10% epidermal detachment is required for 
diagnosis of these cases.In contrast, bullous EM, which has been previously 
grouped with SJS, may have epidermal detachment of less than 10% of the BSA, 
but typical target lesions or raised atypical targets are localized primarily in an 
acral distribution. 
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Secondary lesions: areas of denuded epidermis are dark red with an oozing 
surface. 
Mucous membranes: mucous membrane involvement is present in nearly all 
patients and may precede skin lesions, appearing during the prodrome.Painful oral 
erosions cause severe crusting of the lips, increased salivation, and impaired 
alimentation. Involvement of the genitalia may lead to painful micturition. Lesions 
have been reported in the oropharynx, the tracheobronchial tree, the esophagus, the 
GI tract, the genitalia, and the anus. Intact expectorated cylindrical casts of 
bronchial epithelium have been reported. Patients may develop a profuse protein-
rich diarrhea. Internal involvement is not necessarily limited to patients with 
extensive cutaneous involvement. 
Ocular lesions: ocular lesions are especially problematic because they have a high 
risk of sequelae. Initially, the conjunctivae are erythematous and painful. The lids 
are often stuck together, with efforts to loosen them resulting in tearing of the 
epidermis. Pseudomembranous conjunctival erosions may form synechiae between 
the eyelids and the conjunctivae. Keratitis, corneal erosions, and a sicca-like 
syndrome may develop. 
Complications.Ocular complications must be taken seriously. Failure to lyse 
adhesions and treat keratitis and corneal erosions can result in blindness. Even 
meticulous ophthalmologic care can still eventuate long-term sequelae. 
Cicatrization of conjunctival erosions may lead to inverted eyelashes, photophobia, 
a burning sensation in the eyes, watery eyes, a sicca-like syndrome, and corneal 
and conjunctival neovascularization. As many as 40% of survivors of TEN have 
residual potentially disabling lesions that may cause blindness. 
TEN and SJS may result in cutaneous scarring, especially in the setting of 
impetiginization and inadequate wound care. Such scarring may eventuate in 
cosmetically problematic healing and, if severe, may lead to contractures and 
functional impairment. Lesions of the genitourinary system may lead to phimosis 
or vaginal synechiae. Ideally, patients are cared for in a burn unit, where 
meticulous wound care can be provided. 
Lab Studies.The initial laboratory workup includes a CBC count, a chemistry 
profile, liver enzyme studies, renal function studies, prothrombin time, activated 
partial thromboplastin time, and cultures of blood and areas of denuded skin. 
Imaging Studies.A baseline chest radiograph should be obtained because 
tracheobronchial involvement and respiratory distress are frequent complications. 
Procedures.Bronchoscopy may be considered to verify involvement of the 
respiratory tract, but further epithelial trauma may be induced.Similarly, an upper 
GI series, esophagogastroduodenoscopy, and colonoscopy may be needed to 
confirm involvement of the GI tract. 
Histologic Findings: Diagnosing SJS/TEN and ruling out staphylococcal scalded 
skin syndrome or a blistering disorder are important because the prognosis and the 
course differ markedly. To this end, routine or fresh-frozen section specimens of 
sloughed epidermis should be obtained for histologic examination. Full-thickness 
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epidermal necrosis is consistent with TEN/SJS, whereas a subcorneal split is 
consistent with staphylococcal scalded skin syndrome.  
A biopsy sample of fully developed lesions reveals full-thickness epidermal 
necrosis with involvement of the sweat ducts, relative sparing of the hair follicles, 
and little alteration of the dermis. Immunofluorescence study results are negative. 
Medical Care: Patients with SJS/TEN should be treated in an ICU or burn unit 
under the coordinated care of an ICU team and consultants. Hospitalization should 
be considered for patients with an initially benign presentation of SJS because 
predicting which patients will progress to more severe manifestations or TEN is 
not possible. The broad principles of management are fluid replacement, 
nutritional supplementation, sterile technique, and wound care. Studies have shown 
that early care by or transport to a burn center significantly reduces the mortality 
rate.  
The first step in medical treatment is withdrawal of causative drugs. Retrospective 
studies have indicated that early withdrawal decreases the mortality rate. 
Implicated medications are listed above. 
The use of corticosteroids in the management of the SJS/TEN spectrum is one of 
the most controversial areas in dermatology. Administration early in the course of 
disease has been advocated, but multiple retrospective studies demonstrate no 
benefit or higher rates of morbidity and mortality.  
A number of studies support the use of IVIG in the treatment of TEN. The authors 
recommended early infusion of IVIG at a total dose of 3 g/kg over 3 consecutive 
days (1 g/kg/d for 3 d).  
An open study from the trauma literature demonstrated the efficacy of 
cyclosporine. All patients in the cyclosporine group survived versus 50% surviving 
in the cyclophosphamide group. Given a mortality rate of approximately 30% in 
patients not infected with HIV with TEN, cyclosporine may prove to be a life-
saving therapy, but randomized controlled trials are needed to make definitive 
recommendations.  
Fluid replacement: fluid rehydration is essential because epidermal loss results in 
massive fluid shifts and dehydration.  
Nutritional supplementation: aggressive nutritional support should be initiated 
because protein losses through denuded skin are massive, predisposing the patient 
to complications and retardation of re-epithelialization.  
Sterile technique. Epidermal loss predisposes patients to infection and sepsis.  
Sterile technique is essential to prevent complications from endogenous and 
exogenous sources. Silver sulfadiazine must be avoided because sulfonamides are 
a frequent inciting drug in TEN. Broad-spectrum prophylactic antibiotics are not 
recommended. 
Wound care. Debridement of all necrotic epidermis with replacement by using 
biologic dressings, such as collagen-based substitutes or porcine xenografts, is 
recommended. Some physicians use biologic dressings only on denuded skin, 
leaving necrotic intact epidermis in place. Adhesive tapes should be avoided 
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because further skin loss may occur at the site of application. Oral care and 
application of antiseptics may be necessary. 
Consultation with an ophthalmologist is essential. Frequently applied eye drops 
may be necessary with daily blunt disruption of synechiae. Eye drops must not 
contain sulfonamides because they are frequently implicated in TEN.  
Other supportive treatment. Because epidermal slough leads to massive heat loss, 
the environmental temperature should be increased to 30-32°C. Heated antiseptic 
baths, heat shields, infrared lamps, and air-fluidized beds may decrease heat losses. 
As a caveat, air-fluidized beds can pose an evaporative effect, and fluid status 
should be corrected prior to use. 
Consultations.Obtain an early consultation with a dermatologist because the 
prognosis and the course differ markedly for TEN/SJS and other diseases in the 
differential diagnosis.Consultation with an ophthalmologist is essential because 
early lesions may be subclinical.Consultation with a pulmonologist is prudent 
because interstitial edema may be evident on chest radiographs prior to the 
appearance of clinical symptoms.Consultation with a GI specialist is appropriate in 
cases of suspected involvement of the GI tract. 
Prognosis: The prognosis is largely a function of the degree of skin sloughing. As 
the percentage of skin sloughing increases, the mortality rate dramatically worsens. 
In some patients for unknown reasons, the disease process simply stops 
progressing and rapid epithelialization ensues. For patients experiencing sloughing 
over a large area of their skin surface, the mortality rate is much higher. 
If a causative drug can be identified, early discontinuation is essential. Early 
discontinuation is associated with improved survival, especially for short-acting 
medications. Patients exposed to causative drugs with long half. 
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VII. ATOPIC DERMATITIS AND RELATED DISORDERS 
 
7.1. Atopic Dermatitis 
Synonyms and related keywords: AD, eczema, immunologic skin disorder. 
Background: Atopic dermatitis (AD) is a chronically relapsing skin disorder with 
an immunologic basis. The clinical presentation varies from mild to very severe. In 
the worst cases, AD may interfere with normal growth and development. 
Treatment consists of adequate skin hydration, avoidance of allergenic precipitants, 
topical anti-inflammatory medications, systemic antihistamines, and antibiotic 
coverage of secondary infections. Although often used interchangeably, the terms 
eczema and AD are not equivalent. Eczema is a reaction pattern with various 
causes, the most common pediatric cause being AD. Other causes of eczematous 
dermatitis include allergic contact dermatitis, irritant contact dermatitis, seborrheic 
dermatitis, nummular eczema, dyshidrotic eczema, asteatotic eczema, and lichen 
simplex chronicus. Eczematous reactions can be classified as acute, subacute, or 
chronic, depending on historical and physical characteristics.  
Pathophysiology.The etiology of AD remains unclear. Histologically, AD has 
been shown to be a complex inflammatory process involving mast cells, 
lymphocytes, and infiltrating leukocytes. One causative theory is that AD results 
from a hyperactive T helper cell 2 (Th2) and down-regulation of T helper cell 1 
(Th1) activity. Th2 cells normally secrete interleukin (IL)–4, IL-5, and IL-13, of 
which IL-4 and IL-13 serve to promote the synthesis of immunoglobulin E (IgE) 
from B lymphocytes and to activate the vascular endothelium. IL-5 enhances 
eosinophil-mediated responses. This theory is supported by the frequent 
occurrences of elevated serum IgE levels and peripheral blood eosinophilia in AD 
patients. Furthermore, evidence is accumulating that administration of IL-2 or 
gamma-interferon, the cytokines of the Th1 immune response system, to atopic 
patients results in improvement in disease severity.  
Another theory is that AD may be a result of problems with fatty acid metabolism. 
Specifically, deficient levels of omega-6 fatty acids have been observed in the 
blood and adipose tissues of individuals affected by AD as well as in the breast 
milk of mothers of some affected infants. Infants fed formula, which has a 
relatively low yield of omega-6 fatty acids in comparison with breast milk, have a 
higher incidence of AD than infants fed human milk. Furthermore, prostaglandin 
E1 (PGE1) and prostaglandin E2 (PGE2), major metabolites of omega-6 fatty acid 
biosynthesis, have been shown to suppress synthesis of IgE and are necessary for 
the optimal stimulation of Th1 cell activities by thymic hormones.  
Frequency: AD occurs in approximately 10-15% of children. Areas in the 
Western Hemisphere have prevalence estimated at 10%, while areas in Asia have 
much lower disease prevalence. Interestingly, populations that migrate from areas 
of low prevalence to areas of higher prevalence have shown an increased incidence 
of AD, bolstering the idea of strong environmental influences in the development 
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of AD. Children with concurrent asthma or hay fever have a 30-50% incidence of 
developing AD. 
Age: AD may occur in people of any age, but it often starts in infants aged 2-6 
months. Seventy-five percent of individuals experience marked improvement in 
the severity of AD by age 10-14 years, but the remaining 25% continue to have 
relapses during their adult life.  
Cause.The etiology of AD appears to be linked both to genetic causes and to 
environmental agents. The prevalence of AD in children with 1 affected parent is 
60% and rises to nearly 80% for children of 2 affected parents. Additionally, nearly 
40% of patients with newly diagnosed cases report a positive family history for 
AD in at least 1 first-degree relative. Much higher concordance of AD exists in 
monozygotic twins than in dizygotic twins. 
Environmental allergens repeatedly have been shown to trigger exacerbations of 
AD in susceptible individuals. Contact irritants, climate, sweating, aeroallergens, 
microbial organisms, and stress/psyche are common culprits. 
Contact irritants (eg, soaps, solvents, wool clothing, mechanical irritants, 
detergents, preservatives, perfumes) compromise the integument, creating 
inflammation, irritation, and a portal of entry for further environmental insult. 
These surface irritants, along with the macerative effects of sweating and the 
drying effects of low humidity, lower the pruritic threshold. A vicious cycle of 
itching and scratching ensues, in which added cutaneous damage caused by 
scratching further lowers the pruritic threshold and subsequently causes increased 
itching. 
Aeroallergens (eg, house dust mite, molds, pollen, dander) induce peripheral 
eosinophilia and elevate serum IgE levels. These early effects lead to increased 
histamine release from IgE-activated mast cells and elevated activity of the T-
helper cell–mediated immune system. The increased release of vascular mediators 
(eg, bradykinin, histamine, slow-reacting substance of anaphylaxis [SRS-A]) 
induces vasodilation, edema, and urticaria, which in turn stimulate pruritus and 
inflammatory cutaneous changes. 
Microbial agents (e.g.S. aureus, Malassezia yeasts, Candida organisms, 
Trichophyton dermatophytes) act in 2 different ways to promote the flares of AD. 
The microorganisms directly invade the skin, creating local injury and 
inflammation, and they induce a systemic allergic response to specific antigens, 
causing a rise in serum IgE and enhanced activity of the immune system. 
Food allergy is implicated in one third to one half of children with AD. The most 
common food allergens are egg, soy, milk, wheat, fish, shellfish, and peanut, 
which together account for 90% of food-induced cases of AD in double-blind 
placebo-controlled food challenges. Fortunately, many food allergies fade in 
intensity after age 1 year, eliminating the need for long-term restrictive diets. 
Stress may trigger AD at the sites of activated cutaneous nerve endings, possibly 
by the actions of substance P, vasoactive intestinal peptide (VIP), or via the adenyl 
cyclase–cyclic adenosine monophosphate (cAMP) system. 
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History.Diagnostic criteria for AD have been proposed by Hanifin and Rajka 
(1980). Appropriate cases must have at least 3 major characteristics and at least 3 
minor characteristics. 
 
Major characteristics include the following: 
– Pruritus  
– Typical morphology and distribution (i.e. flexural lichenification and linearity in adults, 
facial and extensor involvement in infants and young children)  
– Chronic or chronically relapsing dermatitis  
– Personal or family history of atopy (eg, asthma, allergic rhinoconjunctivitis, AD) 
 
Minor characteristics are as follows: 
– Xerosis (dry skin)  
– Ichthyosis/palmar hyperlinearity/keratosis pilaris  
– Hand and/or foot dermatitis  
– Cheilitis  
– Nipple eczema  
– Susceptibility to cutaneous infection (eg, with Staphylococcus aureus, herpes simplex 
virus [HSV], other viruses, warts, molluscum, dermatophytes)  
– Erythroderma  
– Perifollicular accentuation  
– Pityriasis alba  
– Early age of onset  
– Impaired cell-mediated immunity  
– Recurrent conjunctivitis  
– Orbital darkening  
– Infraorbital fold (e.g. Dennie pleat, Morgan fold)  
– Anterior neck folds  
– Keratoconus  
– Anterior subcapsular cataracts  
– Sensitivity to emotional factors  
– Food intolerance  
– Pruritus with sweating  
– Intolerance of wool  
– White dermographism  
– Immediate type I skin test response  
– Elevated total serum IgE  
– Peripheral blood eosinophilia 
 
Most atopic children relate a history notable for intense pruritus and dry skin. The 
quality of the pruritus is referred to as a spreading itch. Affected children often 
have a lowered itch threshold, resulting in increased levels of cutaneous reactivity 
in response to stimuli. Patients may succumb to a vicious itch-scratch-itch cycle, in 
which pruritus stimulates a bout of scratching. This, in turn, increases skin 
inflammation and triggers a greater sensation of itching, thus exacerbating flares. 
Altered cell-mediated immunity has been noted in patients with AD. This is 
observed clinically as a history of repeated unusual cutaneous infections (e.g. 
eczema herpeticum, warts, molluscum, dermatophytes). 
Physical: Three classes of skin lesions exist. 
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– Acute - Intensely pruritic erythematous papules and vesicles overlying 
erythematous skin; frequently associated with extensive excoriations and erosions 
accompanied by serous exudates  
– Subacute - Erythema, excoriation, and scaling  
– Chronic - Thickened plaques of skin, accentuated skin markings 
(lichenification), fibrotic papules (prurigo nodularis); possible coexistence of all 3 
types of lesions in chronic AD 
Typical locations of lesions by age.Non-mobile infant - face and scalp. Crawling 
infant - extensor surfaces of extremities, trunk, face, and neck. Older child and 
adolescent - wrists, ankles, antecubital fossae, popliteal fossae, and neck. Adult - 
may be limited to hand and foot eczema. 
Associated findings in AD include keratosis pilaris; accentuated palmar creases; 
lichenification; atopic pleats; allergic shiners; transverse nasal crease; pallor 
around the nose, mouth, and ears; white dermographism; cataracts; and 
keratoconus. 
Keratosis pilaris, or plucked chicken skin, consists of large cornified plugs in the 
upper part of hair follicles and produces a stippled appearance of the skin on the 
outer aspects of the arms and legs and on the buttocks and trunk. 
Hyperlinear palms are usually present at birth and persist throughout life. These 
consist of an increased number of fine lines and accentuated markings on the 
palms. 
Lichenification of the wrists, ankles, popliteal fossae, or antecubital fossae is 
characteristic of chronic AD. It is observed as thickened, leathery, hyperpigmented 
patches of skin with a deepening of normal skin creases. 
Atopic pleats, also referred to as Morgan-Dennie folds, Morgan folds, Dennie 
pleats, or mongolian lines, are skin folds observed just below the lower lid of both 
eyes and are retained throughout life. 
Allergic shiners are violet-gray infraorbital discolorations caused by underlying 
vascular stasis. Increased pressure on nasal and paranasal venous plexuses causes 
edema in these areas, leading to development of atopic pleats and allergic shiners. 
A prominent transverse nasal crease is a common sign of concurrent allergic 
rhinitis and, along with allergic shiners and atopic pleats, may be a clue to the 
diagnosis of an atopic diathesis. 
Dermographism is a normal reaction in 5% of the population. After a firm pointed 
instrument is stroked against the skin, the path of the instrument is observed as a 
red line followed by an erythematous flare that ultimately develops into a wheal. 
This response occurs within 3 minutes of the insult. White dermographism is a 
paradoxical reaction wherein the initial red line is replaced within 10 seconds by a 
white line and an absence of a wheal. This reaction can be observed in AD and 
allergic contact dermatitis. 
Atopic cataracts affect 4-12% of patients with AD and occur much earlier in life 
than senile cataracts. They typically are bilateral, central, and shield-shaped, and 
they mature rapidly. Because patients generally are asymptomatic, diagnosis is 
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usually made by slit lamp examination. Incidence of cataracts in atopic patients 
appears to be unrelated to the use of topical steroids. 
Keratoconus is an elongation of the corneal surface that is thought to be caused by 
long-term eye rubbing and may be a degenerative change in the cornea. 
Keratoconus affects approximately 1% of children with AD and generally can be 
alleviated with the use of contact lenses. 
Complications.The most common complication of AD is secondary infection. 
Staphylococcus species and group A beta-hemolytic streptococci are the most 
frequent organisms cultured from skin lesions. Superinfected eczematoid lesions 
appear as erythema associated with serous or purulent exudates and crusting. 
Greasy moist scales on the surface of the lesions and small pustules at the 
advancing edges may be present. Always consider infection in acute flares of 
chronic AD or in cases that are unresponsive to appropriate therapy. 
Osteomyelitis has been described in patients with superinfected AD. Topical 
antibiotic therapy is useful for localized infections; however, systemic treatment is 
preferred for recurrent or widespread infections. The agent of choice is penicillin G 
if group A streptococci is the known infectious organism. Use erythromycin or a 
semisynthetic penicillin (e.g. nafcillin, oxacillin, dicloxacillin), if S. aureus is a 
possible cause. Hospitalization and use of intravenous antibiotics are indicated in 
cases of invasive infection (e.g. osteomyelitis). Perform urinalysis and closely 
observe patients for symptoms for at least 7 weeks after treatment in endemic areas 
because systemic antibiotic treatment does not prevent postinfectious 
glomerulonephritis after a cutaneous infection with nephritogenic M strains of 
streptococci. 
Less commonly, patients with AD may develop an explosive vesicular eruption 
known as Kaposi varicelliform eruption or eczema herpeticum. Vesicles and 
pustules typically are umbilicated and initially confined to eczematous skin but 
may later spread to normal skin. Later in the course of the disease, erosions may be 
commonplace and confluent, resulting in denuded areas. Tzanck smear of vesicles 
or a viral culture confirms the diagnosis. Treatment is with acyclovir (if mild, 
administer 25-30 mg/kg/d, up to 200 mg 5 times per d orally; if severe, administer 
5 mg/kg 8h or 1.5 g/m2/d IV). 
Lab Studies: No definitive laboratory tests to diagnose AD exist. Elevated serum 
IgE levels and peripheral blood eosinophilia occur in most individuals with AD, 
and these findings may be useful in confirming the atopic status of suspected cases. 
The presence of serum IgE directed against the cell wall of S aureus is observed in 
hyper-IgE syndrome and AD. Common infections that mimic or complicate AD 
can be tested for as follows: conduct a Tzanck smear for HSV, a potassium 
hydroxide (KOH) preparation for dermatophytes, and a Gram stain for bacterial 
infections. 
Other Tests.Prick skin testing to common allergens can help identify specific 
triggers of AD. For accuracy, antihistamines must be discontinued for 1 week and 
topical steroids for 2 weeks prior to testing. Although used most often in young 
children with moderate-to-severe disease, false-negative and false-positive test 
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results are not uncommon in children younger than 8 years. If positive, these tests 
do not necessarily indicate clinically significant triggers. Prick skin tests only 
indicate that the patient has been sensitized to the particular antigens. For example, 
most children shown to have multiple food allergies by skin tests only demonstrate 
clinically detectable allergic reactions to 3 or fewer foods when tested by double-
blind randomized provocative testing. 
Radioallergosorbent test (RAST) and enzyme-linked immunosorbent assay 
(ELISA) in vitro tests identify serum IgE directed toward specific allergens. As 
with prick skin tests, these diagnostic methods show a poor predictive value for 
clinically significant food allergies and may produce false-positive results when 
the patient's serum contains elevated IgE levels. 
Histologic Findings. Acute eczematous lesions show histologic markings of 
hyperkeratosis, parakeratosis, and acanthosis with a decreased or absent granular 
cell layer. Important features in histologic diagnosis include spongiosis 
(accumulation of fluid in the intercellular and intracellular areas) and exocytosis 
(infiltration of leukocytes through the epidermis). Chronic eczematous lesions 
display hyperkeratosis with areas of parakeratosis and papillomatosis (upward 
proliferation of dermal papillae).  
Treatment. The most fundamental and important step in combating AD is 
rehydration of the stratum corneum. Adequate rehydration preserves the stratum 
corneum barrier, minimizing the direct effects of irritants and allergens on the skin 
and maximizing the effect of topically applied therapies, thus decreasing the need 
for topical steroids. 
Lukewarm soaking baths lasting 20-30 minutes are ideal. Very hot water should be 
avoided to prevent both vasodilation, which can trigger pruritus, and the damage to 
the skin barrier caused by scalding.  
Small amounts of bath oils or emulsification agents may be used for added 
hydration benefits in older children and adolescents. Bath oils or emulsification 
agents result in slippery conditions; warn patients and parents of the resultant risks 
of trauma and drowning after a fall.  
Recommended soaps are mild and unscented with a neutral pH. Examples include 
Dove, Oil of Olay, Caress, Camay, Aveeno, and Purpose. Even these mild soaps 
are often too drying for atopic skin. If the children are prepubertal, bathing in water 
alone may be preferable. Postpubertal patients need to use soap in the axillae and 
groin but do not need it elsewhere.  
If soaps are too irritating to the skin, hydrophobic lotions and creams, such as 
Cetaphil, Diprobase, and Unguentum Merck, may be used. These agents have 
excellent cleansing properties and low potential for irritation. They should be 
applied without water and rubbed gently over the skin surface until a light foaming 
occurs. A soft cotton cloth or tissue can then be applied to wipe away the agent, 
leaving behind a protective film of stearyl alcohol and propylene glycol.  
Baby shampoo may be used to manage scalp dermatitis.Baths should be followed 
by the immediate application of an occlusive emollient over the entire skin surface 
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to retain moisture in the epidermis. If an emollient is not applied within 3 minutes 
of leaving the bath, evaporation causes excess drying of the skin. 
Frequently recommended emollients are hydrophobic and ointment-based; these 
include Vaseline petrolatum jelly, Crisco, vegetable oil, Aquaphor, and Elta. 
Occasionally, parents may find these agents too greasy for everyday use, and 
cream-based alternatives may be offered. Common creams are DML Forte, 
Moisturel, Aveeno, Curel, Purpose, Dermasil, Neutrogena, and Eucerin. This latter 
group of moisturizers is less effective because of the weaker occlusive effects of 
creams as compared to ointments; thus, they should be used only if the ointment-
based emollients are not well tolerated.  
Urea, alpha-hydroxy acid, and lactic acid preparations have also been shown to 
soften and moisturize dry skin.  
For children with repeated cutaneous infections, adding 2 teaspoons of household 
bleach (eg, Clorox) per gallon of bath water can help reduce incidence of such 
infections. During acute AD exacerbations, pouring 1 cup of table salt into the bath 
may ameliorate the stinging effect these children frequently experience while 
bathing.  
Wet dressings are very useful for diverse types of atopic dermatitic flares. They 
can be used on dry lichenified lesions to improve hydration and increase the 
penetration of topical corticosteroids; they also work well to dry weeping or oozing 
lesions via evaporation.  
Burow solution 1:40 is a commonly used wet dressing because it is germicidal and 
directly suppresses weeping lesions by precipitation of protein. Place the dressing 
over the affected skin site, periodically rewetting the compress. In severe cases, a 
topical corticosteroid may be applied after the compress for enhanced penetration 
and action of the medication. A final benefit of wet dressings is to provide a 
physical barrier against scratching.  
Seek psychological counseling, biofeedback, relaxation techniques, massage 
therapy, and behavioral modifications if emotional stressors are a contributing 
factor to AD. 
Ultraviolet light may benefit some patients. Ultraviolet light in the UVB range may 
provide control and eliminate or markedly reduce the need for steroids. The new 
narrow band units are especially effective. Ultraviolet light in the UVA range has 
been used alone, in combination with oral psoralen administration (PUVA), or 
with high-dose UVA 1 units. PUVA is not indicated in young patients and may 
lead to skin cancer with long-term treatments. UVA 1 is an evolving technology 
that is not yet standardized or readily available enough to recommend. A small 
number of patients develop erythema or disease flares with light treatment. 
Topical corticosteroids are the mainstay of treatment of AD. Topical steroids 
should be applied only to areas of acute exacerbations, whereas emollients should 
be used over the remainder of the skin. The absorption of topical steroids is much 
better through hydrated skin; thus, the ideal time for application is within 3 
minutes of taking a bath. Formulations of steroids in ascending order of 
occlusiveness are lotions, creams, gels, and ointments.  
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– Lotions contain water and may be drying because of the evaporative effect; 
thus, they are used mostly in scalp and beard areas where drying effects are not as 
problematic. Lotions containing alcohol may cause a burning sensation upon 
application. Lotions may contain preservatives, solubilizers, and fragrances that 
can irritate the skin.  
– Creams generally are tolerated well but are less moisturizing than ointments. 
Creams are popular for cosmetic appearance and are more convenient during hot 
weather because they do not occlude eccrine sweat glands as much as ointments 
and gels. As with lotions, creams may contain preservatives, solubilizers, and 
fragrances that can irritate the skin.  
– Gels are highly occlusive, but the propylene glycol base is irritating to the 
skin and promotes dryness. Therefore, gels, similar to lotions, are used mostly in 
scalp and beard areas where the drying effects are not as problematic. They are 
very effective in the management of acute weeping or vesicular lesions of AD.  
– Ointments are the most moisturizing steroid vehicles, but occlusiveness may 
not be tolerated well because of interference with sweat gland function and 
resultant development of sweat retention dermatitis, especially in warm humid 
climates. Ointments work the best on thickened lichenified plaques of AD. 
Systemic corticosteroids have been used in severe chronic AD, but usage has been 
limited in the pediatric population because of the risk of severe adverse effects, 
including growth retardation and immune suppression.  
Pramoxine is a topical antipruritic agent and can be found as Prax, Pramosone, or 
PrameGel. Oral antihistamines are effective as systemic antipruritics, sedatives, 
and mild anxiolytics. These are beneficial especially at nighttime because pruritus 
usually is worse at night. Use diphenhydramine, hydroxyzine, or doxepin.  
Coal tar topical preparations have antipruritic and anti-inflammatory effects. They 
work as disinfectants and astringents and help to correct abnormal keratinization 
by decreasing both epidermal proliferation and dermal infiltration. They are 
effective as second-line agents for subacute, chronic, and lichenified AD.  
Topically applied tacrolimus has proven to be an effective new therapy for AD. It 
is a nonsteroidal alternative that is especially useful when treating facial and 
intertriginous dermatitis. It does not lose efficacy, even after a year of continuous 
treatment.  
Systemic cyclosporine can dramatically reverse severe flares of AD. Because of 
adverse effects, this treatment should be limited in duration. Once control is 
obtained, alternative maintenance therapy should be instituted.  
Experimental treatments for AD have included trials of gamma-interferon and IL-
2; both are inhibitors of Th2-cell functions and have been promising. Oral 
mycophenolate mofetil, an inhibitor of purine synthesis, has also recently been 
shown in 2 small series to be an effective alternative form of treatment for severe 
disease. 
Topical corticosteroids. In older children and adolescents, treat mild cases of AD 
with a low-potency (class VI or VII) topical steroid twice a day to decrease 
inflammation. Examples include hydrocortisone cream or ointment, 1% and 2.5%. 
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For moderate cases of AD, intermediate-potency steroids (class III, IV, V) may be 
used for brief periods (<2 weeks) to control an eczematous flare. Subsequently, 
low-potency steroids can be used to maintain remission.  
For severe cases of AD, pulse therapy with high-potency topical steroids (class II) 
or PO steroids may be beneficial in adolescents. Remember to only use class VII 
steroids on the face, axillae, groin, and intertriginous areas because of increased 
absorption. For mild AD in infants, class VI or VII topical steroids should be 
effective. If the infant has more severe AD, a moderate-potency steroid can be 
prescribed for up to 1 week and then tapered down to a lower-potency medication 
for maintenance therapy. In general, do not treat infants with topical steroids in the 
high-potency classes (class II or above) without a referral to a dermatologist.  
Antimicrobials. Antistaphylococcal antibiotics (e.g. topical mupirocin or 
bacitracin, first-generation cephalosporins, macrolides, penicillinase-resistant 
extended-spectrum penicillins such as oxacillin or dicloxacillin if resistant strains 
of S aureus are encountered, amoxicillin-clavulanate) are helpful in secondary 
bacterial infections. Herpes simplex superinfections (eczema herpeticum) should 
be suspected if vesicles are present or if no improvement is observed with PO 
antibiotics. Tzanck smear of the base of vesicles is positive in 70% of cases. Treat 
with PO or IV acyclovir for 10 days. Varicella infections may become severe in the 
setting of AD, and early treatment with acyclovir is recommended. Counsel all 
children with AD as to the benefits of vaccination against varicella. Treat 
dermatophyte infections with topical or PO antifungals, such as topical 
ketoconazole cream or shampoo.  
Immunomodulators. Topical tacrolimus has been shown to diminish pruritus and 
inflammation markedly within 3 days of initiating therapy and to have persistent 
effects after 3 weeks of treatment in adults with moderate-to-severe AD. The only 
common adverse effect is a local burning sensation upon application.  
PO cyclosporine (5 mg/kg/d adult dose) has proven beneficial in patients with 
severe AD refractory to treatment with topical steroids. Discontinuation of 
cyclosporine frequently results in rapid relapse of skin disease. Significant adverse 
effects (eg, nausea, abdominal discomfort, hypertrichosis, paresthesias, 
hypertension, hyperbilirubinemia, renal impairment) have diminished enthusiasm 
for this drug.  
Diet. Earlier claims that breast-feeding may help to prevent AD recently have been 
modified because of studies depicting no significant difference in the prevalence of 
AD between breast-fed and formula-fed children. However, a substantial amount 
of evidence indicates that the child who is breast-fed until age 2 years experiences 
a delayed age of onset of the disease but that the severity and duration of AD once 
onset occurs are similar for children in both groups. 
Many physicians are currently advocating elimination of specific commonly 
allergenic foods during the first 1-2 years of life in children with acute AD. The 
short list includes cow's milk, eggs, tomatoes, citrus fruits, chocolate, wheat 
products, spiced foods, fish, nuts, and peanut butter. These foods may be 
reintroduced after controlling the initial acute flare of AD, or parents may elect to 
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wait until after the child is aged 2 years because food reactivity diminishes 
markedly with age. 
For children older than 5 years, nutritionally adequate elimination diets are the goal 
if double-blind placebo-controlled trials indicate a clinically significant food 
allergy. However, most skin tests, RAST, and ELISA tests that reveal positive 
results against food allergens are not borne out to cause disease flares in clinical 
trials; thus, elimination diets are only rarely indicated. 
Chinese herbal teas have been shown to be efficacious in inducing remission in 
some children and patients with recalcitrant disease. Because these teas can contain 
up to 10 different herbs, which have various anti-inflammatory, antihistaminic, or 
immunosuppressant activities, these effects have not yet been specifically linked to 
any one ingredient. Reports exist of liver, kidney, and cardiac damage as well as 
hypersensitivity; thus, risks and benefits need to be further evaluated. 
Activity. In the subgroup of children with AD who also experience respiratory 
allergies to animal allergens, parents should consider removing animals from the 
home or confining them to areas of the house where susceptible children do not 
come into contact with their dander or saliva.Prohibit smoking in the home and 
other areas that are frequented by children with allergies.Implement dust mite and 
mold control measures for allergic children. Counsel parents to use dust mite–
proof plastic cases around pillows, mattresses, and box springs. Wash bedding in 
hot water weekly to remove offending agents. For children who have tested 
positive for sensitivity to house dust mite by skin test, natamycin spray and benzyl 
benzoate (Acarosan) may be helpful in controlling mites in carpets and drapes. 
Avoid irritants that trigger the itch-scratch-itch cycle (e.g, soaps, detergents, 
chemicals, abrasive clothing, extremes of temperature and humidity).Use pH-
neutral minimally defatting soaps (e.g. Dove). Avoid excessive drying of the skin 
with alcohol-containing astringents. Launder new clothes before wearing to 
remove manufacturing chemicals. Use liquid detergent rather than powder 
detergent and add a second rinse cycle to remove all residual detergent. Wear loose 
fitting open-weave cotton or cotton-blend clothing; avoid wool. Use a humidifier 
in the winter to prevent excessive skin dryness and an air conditioner in the 
summer to prevent sweating and associated macerative effects on the skin. 
Decreased humidity indoors helps prevent the growth of mold. 
Prevention. Prevention of acute flares and the subsequent development of chronic 
lesions of AD are indicators of successful treatment for this disease. Maintenance 
of adequate hydration of the stratum corneum, avoidance of known or probable 
allergens and irritants, rapid self-treatment with the proper class of topical steroids, 
and judicious use of complementary therapies (eg, antipruritics, stress relievers, 
antibiotics) are the cornerstones of ensuring a high quality of life unimpeded by the 
more severe aspects of this disease. 
Prognosis: Twenty to 40% of atopic children remain atopic as adults. Many 
children outgrow severe AD and only experience itchy or inflamed skin if exposed 
to exogenous irritants as adults. 
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7.2. Contact Dermatitis, Allergic 
 
Synonyms and related keywords: contact hypersensitivity 
 
Background: The term contact dermatitis sometimes is used incorrectly as a 
synonym for allergic contact dermatitis (ACD). Contact dermatitis is inflammation 
of the skin induced by chemicals that directly damage the skin and by specific 
sensitivity in the case of ACD. ACD is inflammation of the skin manifested by 
varying degrees of erythema, edema, and vesiculation. It is a delayed type of 
induced sensitivity (allergy) resulting from cutaneous contact with a specific 
allergen to which the patient has developed a specific sensitivity.  
Pathophysiology: Most chemicals able to provoke ACD have small molecules 
(<500 d). Approximately 3000 chemicals are well documented as specific causes 
of ACD. The small chemical molecules responsible for ACD must bind to carrier 
proteins on Langerhans cells, which are situated within the suprabasilar layer of the 
epidermis. Langerhans cells are the antigen-presenting cells within the skin. 
Langerhans cells interact with CD4+ T cells (helper T cells).  
Cytokines also play an important role in ACD because they regulate accessory-
adhesion molecules, such as intercellular adhesion molecule 1. Interleukin 8 may 
be a cytokine indicating ACD, not irritant contact dermatitis. Langerhans cells can 
migrate from the epidermis to the regional draining lymph nodes. Sensitization to a 
chemical requires intact lymphatic pathways. The initial sensitization typically 
takes 10-14 days from initial exposure to a strong contact allergen such as poison 
ivy. Some individuals develop specific sensitivity to allergens (eg, chromate in 
cement) following years of chronic low-grade exposure associated with chronic 
irritant contact dermatitis resulting from the alkaline nature of cement. Once an 
individual is sensitized to a chemical, ACD develops within hours to several days 
of exposure. CD4+ CCR10+ memory T cells persist in the dermis after ACD 
clinically resolves.  
Age: ACD may occur in neonates. In elderly individuals, the development of ACD 
may be delayed somewhat, but the dermatitis may be more persistent once 
developed.  
Causes: Approximately 25 chemicals appear to be responsible for as many as one 
half of all cases of ACD.  
– Poison ivy is the classic example of acute ACD. ACD from poison ivy is 
characterized by linear streaks of acute dermatitis that develop where plant parts 
have been in direct contact with the skin. 
– Nickel is the leading cause of ACD in the world. ACD to nickel typically is 
manifested by dermatitis at the sites where earrings or necklaces containing nickel 
are worn or where metal objects containing nickel are in contact with the skin. 
Nickel may be considered a possible occupational allergen. Workers in whom 
nickel may be an occupational allergen primarily include hairdressers, retail clerks, 
caterers, domestic cleaners, and metalworkers. Individuals allergic to nickel 
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occasionally may develop vesicles on the sides of the fingers (dyshidrotic hand 
eczema or pompholyx) from nickel in the diet. 
– Allergy to 1 or more chemicals in rubber gloves is suggested in any 
individual with chronic hand dermatitis who is wearing them, unless patch testing 
demonstrates otherwise. ACD to chemicals in rubber gloves typically occurs 
maximally on the dorsal aspects of the hand. Usually, a cutoff of dermatitis occurs 
on the forearms where skin is no longer in contact with the gloves. Individuals 
allergic to chemicals in rubber gloves may develop dermatitis from other exposures 
to the chemicals (e.g. under elastic waistbands). 
– Individuals allergic to dyes and permanent press and wash-and-wear 
chemicals added to textiles typically develop dermatitis on the trunk, which occurs 
maximally on the lateral sides of the trunk but spares the vault of the axillae. 
Primary lesions may be small follicular papules or may be extensive plaques. 
Individuals in whom this ACD is suggested should be tested with a series of textile 
chemicals, particularly if routine patch testing reveals no allergy to formaldehyde. 
New clothing is most likely to provoke ACD, since most allergens decrease in 
concentration in clothing following repeated washings. 
– Preservative chemicals added to cosmetics, moisturizers, and topical 
medications are major causes of ACD. The most widely used preservatives include 
parabens, which are not a frequent cause of ACD despite their wide use. The risk 
of ACD appears to be highest to quaternium-15, followed by ACD to 
isothiazolinones (Kathon CG). 
– Formaldehyde is a major cause of ACD. Certain preservative chemicals 
widely used in shampoos, lotions, other moisturizers, and cosmetics are termed 
formaldehyde releasers. 
– Individuals may develop allergy to fragrances. Fragrances are found not 
only in perfumes, colognes, aftershaves, deodorants, and soaps, but also in 
numerous other products, often as a mask to camouflage an unpleasant odor. 
Unscented products may contain fragrance chemicals used as a component of the 
product and not labeled as fragrance. Individuals allergic to fragrances should use 
fragrance-free products. Unfortunately, the exact chemicals responsible for a 
fragrance in a product are not labeled. Four thousand different fragrance molecules 
are available to formulate perfumes. The fragrance industry is not required to 
release the names of ingredients used to compose a fragrance, even when 
individuals develop ACD to fragrances found in topical medications. Deodorants 
may be the most common cause of ACD to fragrances because they are applied to 
occlude skin..  
– Massage and physical therapists and geriatric nurses are at higher risk of 
occupational ACD to fragrances. 
– In the last decade, it has become clear that many individuals with chronic 
dermatitis develop allergy to topical corticosteroids. Most affected individuals can 
be treated with some topical corticosteroids, but an individual can be allergic to all 
topical and systemic corticosteroids. Budesonide and tixocortol pivalate are useful 
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patch test corticosteroids for identifying individuals allergic to topical 
corticosteroids. 
– The risk of allergy to neomycin is related directly to the extent of its use in a 
population. The risk of allergy to neomycin is much higher when it is used to treat 
chronic stasis dermatitis than when it is used as a topical antibiotic on cuts and 
abrasions in children. Assume that individuals allergic to neomycin are allergic to 
chemically related aminoglycoside antibiotics (e.g. gentamicin, tobramycin). 
Avoid these drugs both topically and systemically in individuals allergic to 
neomycin. 
– Avoid topical use of benzocaine. Benzocaine is included in most standard 
patch test trays. Individuals allergic to benzocaine may safely use or be injected 
with Xylocaine, which does not cross-react with benzocaine. 
– Many individuals complain of adverse reactions to sunscreens, but many of 
these individuals are not allergic to the sunscreen materials. They may be allergic 
to preservatives in these products or may have nonspecific cutaneous irritation 
from these products. 
– Occasionally, individuals develop photo ACD. ACD may be accentuated by 
ultraviolet (UV) light, or patients may develop an allergic reaction only when a 
chemical is present on the skin and when the skin is exposed sufficiently to 
ultraviolet light A (UV-A; 320-400 nm). 
History.A detailed history, both before and after patch testing, is crucial in 
evaluating individuals with ACD. Potential causes of ACD and the materials to 
which individuals are exposed should be patch tested. Patients with ACD require a 
much more detailed history compared to those with most other dermatologic 
disorders.  
History is equally important after patch testing. Only history and questioning can 
determine whether the materials to which a patient is allergic are partly or wholly 
responsible for the current dermatitis. A positive patch reaction may indicate only 
sensitivity and not the cause of current dermatitis.  
Preexisting skin diseases. Individuals with stasis dermatitis are at high risk for 
developing ACD to materials and agents applied to the areas of stasis dermatitis 
and leg ulcers. Neomycin is an important cause of ACD in these individuals 
because it is used frequently despite the lack of documentation of its efficacy in the 
treatment of stasis ulcers. Individuals with otitis externa frequently are allergic to 
topical neomycin and topical corticosteroids. Individuals with pruritus ani and 
pruritus vulvae may become sensitized to benzocaine and other medications 
applied to chronic pruritic processes. Women with lichen sclerosus et atrophicus 
frequently develop ACD, complicating the severe chronic vulvar dermatosis. Patch 
testing these patients may provide important information that can help in the 
management of recalcitrant and difficult-to-manage dermatosis. 
Atopic dermatitis. Patients with a history of atopic dermatitis are at increased risk 
for developing nonspecific hand dermatitis and irritant contact dermatitis. Patients 
with a history of atopic dermatitis do not appear to be at an increased risk for 
ACD, despite the wide range of topical medications and moisturizers used by 
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individuals with chronic atopic dermatitis. Patients with atopic dermatitis are at 
lower risk of ACD to poison ivy. Some European studies indicate that patients with 
atopic dermatitis may have increased incidence of ACD to nickel. 
Onset of symptoms. Individuals with ACD typically develop dermatitis (within a 
few days of exposure) in areas that were exposed directly to the allergen. Certain 
allergens (eg, neomycin) penetrate intact skin poorly, and the onset of dermatitis 
may be delayed up to a week following exposure.A minimum of 10 days is 
required for individuals to develop specific sensitivity to a new contactant. An 
individual who never has been sensitized to poison ivy may develop only a mild 
dermatitis 2 weeks following the initial exposure but typically develops severe 
dermatitis within 1-2 days of the second and subsequent exposures. Remember that 
removing the poison ivy allergen from the skin is difficult, and unless an individual 
washes exposed skin within 30 minutes of exposure, ACD will develop. The 
hallmark of the diagnosis of poison ivy is linear dermatitic lesions.  
The possibility of an external cause of dermatitis always must be considered if the 
dermatitis is linear or sharply defined. The immediate onset of dermatitis following 
initial exposure to material suggests either a cross-sensitization reaction, prior 
forgotten exposure to the substance, or nonspecific irritant contact dermatitis 
provoked by the agent in question. 
Eyelid dermatitis. Individuals may develop dermatitis on eyelids and other 
exposed skin following exposure to airborne allergens. 
Contact urticarial. Immediate reactions, i.e. visible lesions developing less than 30 
minutes after exposure, indicate contact urticaria (not ACD), particularly if 
urticarial in appearance and if associated with other symptoms such as distant 
urticaria, wheezing, ophthalmedema, rhinorrhea, or anaphylaxis. 
Rubber latex currently is the most important source of allergic contact urticaria. 
The term hypoallergenic may refer to gloves that do not contain sensitizing 
chemicals added to rubber latex but may not indicate whether the gloves are rubber 
latex free. Some individuals may have delayed specific contact sensitivity to 
rubber latex, but contact urticaria to rubber latex is much more common than ACD 
to latex. Individuals with hand dermatitis, hospital workers, children with spina 
bifida, and atopic individuals are at increased risk of developing contact urticaria to 
rubber latex. Individuals may have ACD to chemicals added to rubber gloves and 
have contact urticaria to latex. Individuals wearing rubber gloves should be 
evaluated carefully for both possibilities.  
Rare reports exist of immediate anaphylactic reactions to topical antibiotics (e.g. 
bacitracin). 
Occupational dermatitis. Contact dermatitis is 1 of the 10 leading occupational 
illnesses. It may prevent individuals from working. The hands are the sites exposed 
most intensely to contact allergens and irritants, both at work and at home. The 
hands are crucial for performing many work-related tasks. ACD in response to 
workplace materials may improve initially on weekends and during holidays, but 
individuals with chronic dermatitis may not demonstrate the classic history of 
weekend and holiday improvement. Irritant contact dermatitis is more likely if 
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multiple workers are affected in the workplace. Most allergens rarely sensitize a 
high percentage of the population. 
Hobbies. Hobbies may be the source of ACD, eg, woodworking with exotic 
tropical woods or processing film using color-developing chemicals that may 
provoke cutaneous lesions of lichen planus from direct skin exposure. 
Medications. Self-prescribed and physician-prescribed medications are important 
causes of ACD. The workplace nurse may dispense ineffective and sensitizing 
topical preparations, such as Merthiolate, which may change a simple abrasion into 
a severe case of ACD. Individuals may develop allergy to preservatives in 
medications and/or to the active ingredients in topical medications, especially 
neomycin and topical corticosteroids. 
Iatrogenic adverse effects. Chronic use of systemic corticosteroids to treat ACD 
may produce severe morbidity. Individuals with ACD should not receive chronic 
systemic corticosteroids or immunosuppressives, unless extensive patch testing 
and evaluation have failed to identify remedial causes of the severe dermatitis. 
Chronic widespread use of potent topical corticosteroids may produce local skin 
atrophy and systemic adverse effects. 
Physical.Acute ACD is characterized by pruritic papules and vesicles on an 
erythematous base. Lichenified pruritic plaques may manifest chronic ACD. 
Occasionally, ACD may affect the entire integument (i.e. erythroderma, exfoliative 
dermatitis). The initial site of dermatitis often provides the best clue regarding the 
potential cause of ACD.  
Hands. Hands are an important site of ACD, particularly in the workplace. 
Common causes of allergic dermatitis on the hands include the chemicals in rubber 
gloves. 
Perianal. ACD is frequent in the perianal area as a result of the use of sensitizing 
medications and remedies (eg, topical benzocaine). 
Otitis externa. Topical medications are important causes of ACD in cases of otitis 
externa. 
Airborne ACD. Chemicals in the air may produce airborne ACD. This dermatitis 
usually occurs maximally on the eyelids, but it may affect other areas exposed to 
chemicals in the air, particularly the head and the neck. 
Ophthalmologic. Allergy to chemicals in ophthalmologic preparations may 
provoke dermatitis around the eyes. 
Hair dyes. Individuals allergic to hair dyes typically develop the most severe 
dermatitis on the ears and adjoining face rather than on the scalp. 
Stasis dermatitis and stasis ulcers. Individuals with stasis dermatitis and stasis 
ulcers are at high risk for developing ACD to topical medications applied to 
inflamed or ulcerated skin. The chronicity of this condition and the frequent 
occlusion of applied medications contribute to the high risk of ACD to medicament 
(e.g. neomycin) in these patients. Individuals may develop widespread dermatitis 
from topical medications applied to leg ulcers or from cross-reacting systemic 
medications administered intravenously. For example, a patient allergic to 
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neomycin may develop systemic contact dermatitis if treated with intravenous 
gentamicin. 
Erythema multiforme. Erythema multiforme (EM) is a severe cutaneous reaction 
with targetoid lesions that occurs primarily after exposure to certain medications or 
is triggered by infection, most commonly by herpes simplex virus. Rare cases of 
EM have been reported after ACD resulting from exposure to poison ivy, tropical 
woods, nickel, and hair dye. 
Complications.Occasionally, ACD is complicated by secondary bacterial 
infection, which may be treated by the appropriate systemic antibiotic.Darkly 
pigmented individuals may develop areas of hyperpigmentation or 
hypopigmentation from ACD. Occasionally, they may develop depigmentation at 
sites of ACD to certain chemicals. 
Lab Studies: Potassium hydroxide preparation and/or fungal culture to exclude 
tinea are often indicated for dermatitis of the hands and feet. 
Procedures.Patch testing. Patch testing is required to identify the external 
chemicals to which the person is allergic. The greatest quality-of-life benefits from 
patch testing occur in patients with recurrent or chronic ACD. Patch testing is most 
cost effective and reduces the cost of therapy in patients with severe ACD.Patch 
testing must be performed by health care providers trained in the proper technique. 
Most dermatologists can perform patch testing using the TRUE test (consult the 
Physicians' Desk Reference), which can identify relevant allergies in as many as 
one half of affected patients. More extensive patch testing is indicated to identify 
allergies to chemicals not found in the TRUE test. Such testing typically is 
available only in a limited number of dermatology offices and clinics.Individuals 
with suspected ACD without positive reactions on the TRUE test or with chronic 
dermatitis or relapsing dermatitis, despite avoiding chemicals to which they are 
allergic (identified on TRUE test), need additional patch testing. Many individuals 
have more than 1 contact allergy and may be allergic to 1 or more chemicals found 
on the TRUE test and on special allergen trays or series. Testing to more allergens 
increases accuracy of the diagnosis of ACD. Selection of allergens for testing 
requires consideration of the patient's history and access to appropriate 
environmental contactants. 
Certain chemicals (e.g. neomycin) typically produce delayed positive patch test 
reactions at 4 days or later following initial application. A tendency exists for 
elderly patients to manifest positive patch test reactions later than younger patients. 
Do not perform patch testing on patients taking more than 15 mg per day of 
prednisone. Oral antihistamines may be used during the patch test period if 
required. 
Angry back syndrome or excited skin syndrome: If a patient has a large number of 
positive patch test reactions, retesting the patient sequentially to a small series of 
these allergens may be necessary to exclude nonspecific false-positive reactions. 
The syndrome most likely occurs in individuals who have active dermatitis at the 
time of patch testing or who have a strong positive patch test reaction, both of 
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which may induce local skin hyperreactivity in the area where patches were 
applied. 
– Repeat open application test. For individuals who develop weak or 1+ 
positive reactions to a chemical, the repeat open application test (ROAT) is useful 
in determining whether the reaction is significant. ROAT is most useful when an 
individual has a 1+ reaction to a chemical found in a leave-on consumer product. 
For example, an individual with a weak reaction to a preservative found in a 
moisturizer may apply the moisturizer twice a day for a week to the side of the 
neck or behind an ear. If the individual applies it twice a day for a week without 
developing clinical dermatitis, the 1+ reaction likely was not meaningful. 
Conversely, if the individual develops dermatitis following a few days of repeated 
application of the suspected product, then the weak patch test reaction is highly 
relevant. 
– Dimethylgloxime test. The dimethylgloxime test is a useful and practical 
way to identify metallic objects that contain enough nickel to provoke allergic 
dermatitis in individuals allergic to nickel. Dermatology staff may test suspected 
metal products in the office, or the individual may purchase a test kit and test 
objects at home or at work, particularly jewelry or metallic surfaces. Other 
chemical tests are available for other suspected allergens (eg, formaldehyde, 
chromate). Occasionally, chemical analyses may be necessary to determine 
whether a material contains a suspected allergen or to identify new unknown 
allergens. 
Skin biopsy may help exclude other disorders, particularly tinea, psoriasis, and 
cutaneous lymphoma. Skin biopsy of skin lesions of the palms and soles has 
several potential pitfalls, which include the following: the stratum corneum and 
epidermis are particularly thick on the palms and soles. This makes the histologic 
diagnosis of psoriasis more difficult and increases the possibility that the biopsy 
specimen will lack sufficient dermis for optimal diagnosis.  
An overly deep skin biopsy of the thenar area can cut the motor nerve, which is the 
recurrent branch of the median nerve. A biopsy from the sole may leave a chronic 
painful scar on which the patient must walk. 
Histologic Findings.Histology of ACD is similar to that found in other forms of 
eczematous dermatitis. A pattern of subacute chronic dermatitis or acute dermatitis 
may be seen. The inflammatory infiltrate in the dermis predominately contains 
lymphocytes and other mononuclear cells. Epidermal edema (i.e. spongiosis and 
microvesicle formation) may be seen, but these changes may be absent in long-
standing dermatitis in which thickening of the epidermis (acanthosis) with 
hyperkeratosis and parakeratosis may be seen in the epidermis and stratum 
corneum. ACD is provokes atypical T-cell infiltrates, simulating mycosis 
fungoides. 
Medical Care.The cause of ACD must be identified; otherwise, the patient is at 
increased risk for chronic or recurrent dermatitis.  
The goal of pharmacotherapy is to reduce morbidity and to prevent complications. 
Topical glucocorticosteroids are the mainstay of therapy. When choosing a topical 
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glucocorticosteroid, match the potency to the location of the dermatitis and the 
vehicle to the morphology (ointment for dry scaling lesions; lotion or cream for 
weeping areas of dermatitis).  
For severe acute ACD (e.g. rhus dermatitis, erythroderma), systemic 
glucocorticosteroids or other immunosuppressive medications may be needed.  
In some cases, ACD may prove persistent despite avoidance of the allergen. In 
some of these cases (eg, nickel), ingestion of minute amounts of the allergen is 
believed to drive the process, and chelation therapy with disulfiram can be 
beneficial. In other instances, the cause of persistence remains enigmatic; many 
allergens penetrate through rubber gloves. PUVA can be helpful in these cases.  
Symptomatic treatment. Cool compresses with saline or aluminum acetate solution 
are helpful for acute vesicular dermatitis (e.g. poison ivy). Some individuals with 
widespread vesicular dermatitis may obtain relief from lukewarm oatmeal baths. 
Sedating oral antihistamines may help diminish pruritus. Patients should avoid 
using topical antihistamines, including topical doxepin, because of the apparently 
high risk of iatrogenic ACD to these agents. 
Corticosteroids. Topical corticosteroids are the mainstay of treatment, with the 
strength of the topical corticosteroid appropriate to the body site. For severe ACD 
of the hands, 3-week courses of class I topical corticosteroids are required, while 
class 6 or class 7 topical corticosteroids typically are used for ACD of 
intertriginous areas. Acute severe ACD, such as acute severe ACD to poison ivy, 
often needs to be treated with a 2-week course of systemic corticosteroids. Most 
adults require an initial dose of 40-60 mg. The oral corticosteroid is tapered over a 
2-week period, but a complicated tapering regimen probably is not necessary given 
the short duration of systemic corticosteroids. The systemic corticosteroids must be 
administered for 2 weeks, because shorter courses are notorious for allowing 
poison ivy dermatitis to relapse. Long-acting triamcinolone acetonide (Kenalog) 
40-60 mg may be used in place of oral prednisone in these cases. 
Topical immunomodulators. Topical immunomodulators (TIMs) are approved for 
atopic dermatitis and are prescribed for cases of ACD when they offer safety 
advantages over topical corticosteroids. TIMs do not cause cutaneous atrophy or 
glaucoma or cataracts when applied near the eye. Pimecrolimus (Elidel cream) is a 
topical treatment often helpful for ACD of the face. Tacrolimus (Protopic 0.1% 
ointment) appears to be the most helpful TIM for ACD of the hands.  
Psoralen plus UV-A. Individuals with chronic ACD that is not controlled well by 
topical corticosteroids may benefit from psoralen plus UV-A (PUVA) treatments. 
Immunosuppressive agents. Rarely, chronic immunosuppressive agents, such as 
azathioprine (Imuran) or cyclosporine (Neoral), are used in recalcitrant cases of 
severe chronic widespread ACD or severe hand dermatitis that prevents the 
individual from working or performing daily activities. Biologicals active on T 
cells may be helpful in the future. 
Disulfiram. Occasionally, an individual who is highly allergic to nickel with 
severe vesicular hand dermatitis benefits from treatment with disulfiram 
(Antabuse). The chelating effect of disulfiram is helpful in reducing the body's 
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nickel burden. Alcohol ingestion may produce severe adverse reactions in patients 
taking disulfiram. 
Consultations.Many primary care physicians treat individuals with typical poison 
ivy dermatitis who respond well to a 2-week treatment course using topical or 
systemic corticosteroids and subsequently avoid poison ivy and related plants. 
Acute dermatitis that resolves with short-term treatment does not require further 
evaluation. Individuals with chronic dermatitis, particularly if it possibly is related 
to work, require detailed history and patch testing to standard screening sets and 
additional allergens as indicated by history, occupation, hobbies, and results on 
initial patch testing.  
Diet.Some chemicals tested by the TRUE test may be present in the diet. 
Individuals with severe dermatitis, particularly if it is a disabling vesicular 
dermatitis of the hands, may be treated with diets low in minerals and chemicals to 
which the individual is allergic. A low-nickel diet is the most common, but 
published diets are available that are low in chromate, cobalt, or balsam of Peru. 
These diets may be attempted for the occasional allergic patient with severe 
chronic vesicular dermatitis.  
Activity.Individuals with severe acute ACD may be incapacitated temporarily and 
unable to work. Most individuals with ACD may require light duties or restrictions 
of duties. They should avoid further contact with the chemicals to which they are 
allergic or chemicals that cross-react with these materials. Patients also should 
minimize exposure to irritant chemicals, particularly if the dermatitis is active or 
recently resolved. They should use mild cleansing agents on the skin, such as 
Aquanil, Cetaphil cleanser, or Oilatum-AD, and should apply bland protective 
emollients, such as SBR Lipocream, Cetaphil cream or Neutrogena hand cream, to 
help minimize relapse of ACD or development of irritant contact dermatitis of 
ceramide cream (e.g. Impruv). 
Prevention. To prevent recurrence of ACD, instruct patients thoroughly 
concerning allergen(s) and the types of products likely to contain allergen(s). For 
many patients with allergic reactions to fragrances, preservatives, vehicles, and 
medicaments, reading cosmetic labels and package inserts of topical/systemic 
medicaments may be sufficient to avoid allergens. For patients allergic to nickel, 
the dimethylgloxime test can alert them the presence of the metal. For many other 
patients with allergic reactions to chemicals that are unlikely to be labeled on 
consumer products (e.g. rubber accelerators), suitable allergen alternatives (e.g. 
gloves specifically known to be accelerator free) must be provided by the 
practitioner.Many cases of ACD, especially of the hands, occur in the occupational 
setting. Proper worker education and hygiene may prevent allergic reactions. For 
example, glutaraldehyde is a known sensitizer with widespread use as a cold 
sterilizing agent in medicine and dentistry. Needless cases of ACD to this biocide 
occur because of the lack of proper education regarding the appropriate use of 
gloves and other barriers to cutaneous contact.Advise patients to avoid identified 
chemicals to which they are allergic to minimize the risk of relapse, the risk of 
chronic contact dermatitis, and the risk of adverse effects from chronic use of 
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nonspecific suppressive treatments (eg, topical and systemic corticosteroids, 
cyclosporine). 
Prognosis. Individuals with ACD may have persistent or relapsing dermatitis, 
particularly if the material(s) to which they are allergic is not identified or if they 
continue to practice skin care that is no longer appropriate (i.e. they continue to use 
harsh chemicals to wash their skin, they do not apply bland emollients to protect 
their skin).The longer an individual has severe dermatitis, the longer it is believed 
it will take the dermatitis to resolve once the cause is identified.Some individuals 
have persistent dermatitis following ACD, which appears to be true especially in 
individuals allergic to chrome.A particular problem is neurodermatitis (lichen 
simplex chronicus), in which individuals repeatedly rub or scratch an area initially 
affected by ACD. 
 
7.3. Contact Dermatitis, Irritant 
 
Synonyms and related keywords: non-allergic contact dermatitis, ICD 
 
Background: Irritant contact dermatitis (ICD) is inflammation of the skin 
typically manifested by erythema, mild edema, and scaling. ICD is a nonspecific 
response of the skin to direct chemical damage that releases mediators of 
inflammation predominately from epidermal cells. A corrosive agent causes the 
immediate death of epidermal cells as manifested by chemical burns and cutaneous 
ulcers.  
ICD remains understudied compared to allergic contact dermatitis. Most articles on 
contact dermatitis concern allergic contact dermatitis. This largely reflects the fact 
that with patch testing, a specific hypersensitivity and a probable cause of 
dermatitis can be identified in most cases of allergic contact dermatitis. No 
diagnostic test exists for ICD. The diagnosis rests on the exclusion of other 
cutaneous diseases (especially allergic contact dermatitis) and on the clinical 
appearance of dermatitis at a site sufficiently exposed to a known cutaneous 
irritant.  
In the consumer world, the term hypoallergenic is used widely, although no Food 
and Drug Administration–approved definition of hypoallergenic exists. A necessity 
exists for hypoirritating cleansers, cosmetics, moisturizers, and protectants; 
however, no standard method exists to identify products that are of great use to 
individuals with susceptible skin (e.g. atopic dermatitis, facial skin of individuals 
with rosacea).  
The hands are the most important sites of ICD. Most occupational skin disorders 
are ICD resulting from repeated workplace exposure of the hands to soaps, 
cleansers, and solvents.  
Pathophysiology.A wide range of chemicals with sufficient concentration or 
duration of exposures are capable of acting as cutaneous irritants. Common 
cutaneous irritants include detergent and water. Most cases of housewife's eczema 
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are ICD resulting from repeated skin exposure to low-grade cutaneous irritants, 
particularly soaps, water, and detergents.  
Cumulative ICD from repeated mild skin irritation from soap and water is 
common. For example, hand-washing frequency of more than 35 times per shift 
was associated strongly with occupational hand dermatitis in intensive care unit 
workers (odds ratio=4.13).  
Solvents are another major cause of cutaneous irritation because they remove 
essential fats and oils from the skin, which increases transepidermal water loss and 
renders the skin susceptible to the increased direct toxic effects of other previously 
well-tolerated cutaneous exposures.  
Microtrauma also may produce skin irritation. A common example is fiberglass, 
which may produce pruritus with minimal visible inflammation in susceptible 
individuals. Many plant leaves and stems bear small spicules and barbs that 
produce direct skin trauma.  
Skin irritation predisposes the skin to develop sensitization to topical agents. An 
exacerbation of ICD may reflect development of allergic contact dermatitis to 
topical creams, medications, or rubber gloves.  
The pathogenesis of ICD involves resident epidermal cells, dermal fibroblasts, 
endothelial cells, and various leukocytes interacting with each other under the 
control of a network of cytokines and lipid mediators. Keratinocytes play an 
important role in the initiation and perpetuation of skin inflammatory reactions 
through the release of and responses to cytokines. Resting keratinocytes produce 
some cytokines constitutively.  
A variety of environmental stimuli (eg, ultraviolet light, chemical agents) can 
induce epidermal keratinocytes to release inflammatory cytokines (interleukin 1, 
tumor necrosis factor alpha), chemotactic cytokines (interleukin 8, interleukin 10), 
growth promoting cytokines (interleukin 6, interleukin 7, interleukin 15, 
granulocyte-macrophage colony-stimulating factor, transforming growth factor), 
and cytokines regulating humoral versus cellular immunity (interleukin 10, 
interleukin 12, interleukin 18). Intercellular adhesion molecule 1 promotes the 
infiltration of leukocytes into the epidermis in cutaneous inflammatory reactions, 
including ICD.  
Significantly increased numbers of dividing keratinocytes are present 48 and 96 
hours after exposure to the anionic emulsifying agent sodium lauryl sulfate (used 
in medicated shampoos, skin cleansers, acne treatments, and toothpastes and as an 
experimental irritant).  
All irritants provoke a similar pattern of cellular infiltration in the dermis; the 
densities of most of the cell types rise in proportion to the intensity of 
inflammation. Within the epidermis, marked differences exist in the patterns of 
cellular infiltration among different irritants.  
Causes.Almost any material may be a cutaneous irritant with sufficient exposure 
in time and/or concentration.  
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Dry air. Dry air renders the skin more susceptible to cutaneous irritants. 
Sufficiently dry air alone may provoke ICD. Most cases of winter itch are a result 
of dry skin from the drier air found during sustained periods of cold weather. 
Water. Continual exposure to water may produce maceration or repeated 
evaporation of water from the skin may produce cutaneous irritation by desiccation 
of the skin. Even distilled water experimentally provokes increased CD11c+ cells 
and neutrophils in the epidermis. 
Solvents. Many individuals are exposed to solvents, particularly at work. Solvents 
such as alcohol or xylene remove lipids from the skin, producing direct ICD and 
rendering the skin more susceptible to other cutaneous irritants, such as soap and 
water. 
Alcohol. ICD from alcohol most often is cumulative. Manual workers may wash 
their hands inappropriately with solvents to remove oil, grease, paints, or other 
materials; thus, they develop ICD. Inappropriate skin cleansing is a primary cause 
of ICD in the workplace. Washing facilities and methods must be inspected when 
investigating the workplace for 1 or more cases of occupational ICD. The irritating 
agents include aromatic, aliphatic, and chlorinated solvents, as well as solvents 
such as turpentine, alcohol, esters, and ketones. Some organic solvents produce an 
immediate erythematous reaction on the skin and remove lipids from the stratum 
corneum. 
Metalworking fluids. Neat oils most commonly produce folliculitis and acne. They 
may cause ICD (but rarely allergic dermatitis). Water-based metalworking fluids 
often cause ICD in exposed workers; surfactants in these fluids are the main 
culprit. 
Cumulative ICD. This is common in many occupations that often are termed wet 
work. Health care workers wash their hands 20-40 times a day, producing 
cumulative ICD. Similar exposures occur among individuals who wash hair 
repeatedly or in cleaners or kitchen workers. 
Microtrauma. Many plant leaves and stems bear small spicules and barbs that 
produce direct skin trauma. 
Fiberglass. Fiberglass produces direct damage to the skin, usually manifested by 
pruritus that may result in excoriation and secondary skin damage. Cutaneous 
irritation primarily is caused by fiberglass with diameters exceeding 4.5 m. 
Controversy surrounds whether individuals with dermatographism are more 
susceptible to fiberglass dermatitis. Most workers with ICD resulting from 
fiberglass develop hardening, in which they tolerate further cutaneous exposure to 
fiberglass. 
Mechanical trauma. Pressure produces callus formation. Pounding produces 
petechia or ecchymosis. Sudden trauma or friction produces blistering in the 
epidermis. Repeated rubbing or scratching produces lichenification. 
Rubber gloves. Some rubber gloves may provoke direct cutaneous irritation. Many 
workers complain of irritation from the powder in rubber gloves. Remember that 
gloves compromised by a hole may allow an irritant to enter; occlusion 
dramatically increases skin damage from the irritant. Occlusion accentuates the 
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effects, good or bad, of topical agents. Kerosene may produce skin changes similar 
to that of toxic epidermal necrolysis following occluded cutaneous exposure. 
Excessive amounts of ethylene oxide in surgical sheets also may produce similar 
changes. 
Sodium lauryl sulfate. This chemical is found in some topical medications, 
particularly acne medications, and also is a classic experimental cutaneous irritant. 
Hydrofluoric acid. A hydrofluoric acid burn is a medical emergency. Remember 
that onset of clinical manifestations may be delayed after the acute exposure 
(crucial to diagnosis). Unfortunately, hydrofluoric acid burns are most frequent on 
the digits where the pain is most severe and management is most difficult. 
Alkalis. Skin surfaces normally have an acidic pH and alkalis (eg, many soaps) 
produce more irritation than many acids. 
History.A detailed history is required because the diagnosis of ICD rests on the 
history of exposure of the affected body site to the cutaneous irritant. Patch testing 
also is used in severe or persistent cases to exclude allergic contact dermatitis as a 
component of the individual's cutaneous manifestations.  
Primary subjective symptoms include the following. History of sufficient 
exposure to a cutaneous irritant is noted. Onset of symptoms occurs within minutes 
to hours of exposure in simple acute ICD. The onset of signs and symptoms may 
be delayed by weeks in cumulative ICD.Pain, burning, stinging, or discomfort 
exceeding pruritus early in the clinical course occur. 
Less important subjective criteria include the following. Onset of dermatitis 
within 2 weeks of exposure. Reports of many other coworkers or family members 
affected. Occupational ICD typically affects workers who are new to a job, who 
are constitutionally more susceptible to ICD, or who have not learned to protect 
their skin from cutaneous irritants. 
Individuals with history of atopic dermatitis (especially of the hands) are more 
susceptible to ICD, particularly of the hands. 
Other causes of contact dermatitis (particularly allergic contact dermatitis) must be 
excluded by history and/or patch testing to the relevant allergens. 
Physical. Proposed the primary diagnostic criteria for ICD as follows: 
Macular erythema, hyperkeratosis, or fissuring predominating over vesiculation 
Glazed, parched, or scalded appearance of the epidermis 
Healing process beginning promptly on withdrawal of exposure to the offending 
agent 
Patch testing negative and includes all possible allergens 
Minor objective criteria include the following: 
Sharp circumscription of the dermatitis 
Evidence of gravitational influence such as a dripping effect 
Lower tendency for the dermatitis to spread than in cases of allergic contact 
dermatitis 
Morphologic changes suggesting small differences in concentration or contact time 
producing large differences in skin damage 
Other criteria include the following: 
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ICD may be manifested by vesicles, particularly on the hands. 
Dyshidrotic eczema or pompholyx is a morphologic term describing deep-seated 
vesicles on the sides of the fingers and, to a lesser extent, on the palms. The 
identical morphology may be produced by contact allergens. ICD has much less 
tendency to form vesicles. 
Individuals may develop a habit of continuing to rub a site initially affected by 
ICD and may develop secondary neurodermatitis or lichen simplex chronicus 
(lichenification), which may be accepted as a sequela of an occupational injury. 
Complications. ICD increases the risk of sensitization to topical medications. Skin 
lesions may become colonized secondarily and/or infected, particularly by 
Staphylococcus aureus.Secondary neurodermatitis (lichen simplex chronicus) may 
develop in individuals with ICD, particularly in those with workplace exposures or 
under psychologic stress.Postinflammatory hyperpigmentation or 
hypopigmentation may occur in areas affected by ICD or persist after resolution of 
ICD in individuals with more pigmented skin.Scarring may occur after corrosive 
agent exposure, excoriation, or artifact, causing ulceration. 
Lab Studies. A bacterial culture can be obtained in cases complicated by 
secondary bacterial infection.A KOH examination may be performed and samples 
for mycology may be obtained to exclude superficial tinea infections or candidal 
infections, depending on site and morphology of lesions.Findings of significantly 
elevated serum immunoglobulin E occasionally are useful to substantiate an atopic 
diathesis in the absence of a personal or family history of atopy. 
Procedures. Patch testing can be performed to diagnose contact allergies, but no 
patch test exists that proves that a cutaneous irritant is responsible for a particular 
case of ICD. Diagnosis rests on exclusion of allergic contact dermatitis and history 
of sufficient exposure to a cutaneous irritant.Skin biopsy can help exclude other 
disorders, such as tinea, psoriasis, or cutaneous T-cell lymphoma. All clinical cases 
of dermatitis are similar histologically. Skin biopsy of skin lesions of the palms 
and soles has several potential pitfalls. The stratum corneum and epidermis are 
particularly thick on the palms and soles. This makes the histologic diagnosis of 
psoriasis more difficult and increases the possibility that the biopsy specimen lacks 
sufficient dermis for optimal diagnosis. An overly deep skin biopsy of the thenar 
area can cut the motor nerve, which is the recurrent branch of the median nerve. A 
biopsy from the sole may leave a chronic painful scar on which the patient must 
walk. 
Histologic Findings: The histopathology of acute experimental ICD has been 
studied to a greater extent than chronic ICD, which is the primary clinical 
complaint. Cellular changes seen in the skin vary according to the chemical nature 
and concentration of the irritant applied, duration of exposure, severity of ensuing 
response, and time of sampling for acute ICD. Many primary irritants cause overt 
necrosis if applied in a sufficiently high concentration for sufficient time.  
Most histologic examinations of ICD reveal some degree of intercellular edema or 
spongiosis in the epidermis. Spongiosis usually is less pronounced than that seen in 
allergic contact dermatitis reactions. Parakeratosis also is observed widely in ICD 
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reactions. The histology of chronic ICD is one of hyperkeratosis with areas of 
parakeratosis, moderate-to-marked epidermal hyperplasia (acanthosis), and 
elongation of the rete ridges. 
Consultations.Multidisciplinary consultations may be required when many 
workers become affected with ICD in a workplace. Identifying and remediating the 
causes of widespread ICD interfering with workplace productivity and worker 
quality of life is important.Any patient with hydrofluoric acid burn should be 
evaluated as a medical emergency by a physician experienced in the management 
of hydrofluoric exposures and burns. Consider regional intravenous infusion of 
calcium gluconate as a therapeutic option in hydrofluoric acid burns to forearm, 
hand, or digits when topical therapy fails. 
Further Outpatient Care.Individuals with ICD frequently are seen, particularly 
from the workplace. Identifying and minimizing exposure to cutaneous irritants at 
home and work is crucial.Advise individuals to use bland emollients after washing 
hands with soap and before sleep. Recommend mild skin cleansers (eg, Aquanil, 
Cetaphil cleanser, Oilatum AD, Neutrogena cleanser) in place of soap on affected 
areas.Instruct individuals to refrain from the use of inappropriate solvents (eg, 
gasoline) or abrasives (eg, pumice stone) to cleanse hands; these directly defat or 
traumatize the skin. 
ICD does not respond as well to topical corticosteroids as allergic contact 
dermatitis, probably because the clinical pathophysiology often is different.  
ICD often responds better to treatment with bland topical steroid preparations (eg, 
fluocinolone or amcinonide ointment) rather than products such as Diprolene 
cream (betamethasone valerate in an augmented base containing propylene glycol). 
Propylene glycol is a rare allergen but a frequent cutaneous irritant, especially 
when the skin is more susceptible to irritants. 
Prognosis. Prognosis is good for nonatopic individuals in whom ICD is diagnosed 
and managed promptly.Individuals with atopic dermatitis remain highly 
susceptible to ICD and may find that the tasks of many common occupations (e.g. 
nursing, hairdressing) produce too much direct skin inflammation to continue with 
these careers. 
 
7. 4. Drug Eruptions 
 
Synonyms and related keywords: adverse cutaneous drug reactions, cutaneous 
reaction to drugs, drug-induced cutaneous reactions, mucocutaneous drug reactions 
 
Background: Drug eruptions can mimic a wide range of dermatoses. The 
morphologies are myriad and include morbilliform, urticarial, papulosquamous, 
pustular, and bullous. Medications can also cause pruritus and dysesthesia without 
an obvious eruption.  
A drug-induced reaction should be considered in any patient who is taking 
medications and who suddenly develops a symmetric cutaneous eruption. 
Medications that are known for causing cutaneous reactions include antimicrobial 
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agents, non-steroidal anti-inflammatory drugs (NSAIDs), cytokines, 
chemotherapeutic agents, anticonvulsants, and psychotropic agents.  
Prompt identification and withdrawal of the offending agent may help limit the 
toxic effects associated with the drug. The decision to discontinue a potentially 
vital drug often presents a dilemma.  
Pathophysiology: Drug eruptions may be divided into immunologically and non-
immunologically mediated reactions.  
Immunologically mediated reactions 
Coombs and Gell proposed 4 types of immunologically mediated reactions, as 
follows:  
• Type I is immunoglobulin E (IgE)–dependent reactions, which result in 
urticaria, angioedema, and anaphylaxis.  
• Type II is cytotoxic reactions, which result in hemolysis and purpura.  
• Type III is immune complex reactions, which result in vasculitis, serum 
sickness, and urticaria.  
• Type IV is delayed-type reactions with cell-mediated hypersensitivity, 
which result in contact dermatitis, exanthematous reactions, and photoallergic 
reactions. 
Insulin and other proteins are associated with type I reactions. Penicillin, 
cephalosporins, sulfonamides, and rifampin are known to cause type II reactions. 
Quinine, salicylates, chlorpromazine, and sulfonamides can cause type III 
reactions. Type IV reactions, the most common mechanism of drug eruptions, are 
often encountered in cases of contact hypersensitivity to topical medications, such 
as neomycin. Sulfonamides are most frequently associated with toxic epidermal 
necrolysis (TEN).  
Although most drug eruptions are type IV hypersensitivity reactions, only a 
minority is IgE-dependent. That is, antibodies can be demonstrated in fewer than 
5% of cutaneous drug reactions. Type IV cell-mediated reactions are not dose 
dependent, they usually begin 7-20 days after medication, they may involve blood 
or tissue eosinophilia, and they may recur if drugs chemically related to the 
causative agent are administered.  
Non-immunologically mediated reactions 
Non-immunologically mediated reactions may be classified according to the 
following features: accumulation, adverse effects, and direct release of mast cell 
mediators, idiosyncratic reactions, intolerance, Jarisch-Herxheimer phenomenon, 
overdosage, or phototoxic dermatitis. (Symptoms of Jarisch-Herxheimer reactions 
disappear with continued therapy. Drug therapy should be continued until the 
infection is fully eradicated.)  
An example of accumulation is argyria (blue-gray discoloration of skin and nails) 
observed with use of silver nitrate nasal sprays.  
Adverse effects are normal but unwanted effects of a drug. For example, 
antimetabolite chemotherapeutic agents, such as cyclophosphamide, are associated 
with hair loss.  
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The direct release of mast cell mediators is a dose-dependent phenomenon that 
does not involve antibodies. For example, aspirin and other NSAIDs cause a shift 
in leukotriene production, which triggers the release of histamine and other mast 
cell mediators. Radiographic contrast material, alcohol, cytokines, opiates, 
cimetidine, quinine, hydralazine, atropine, vancomycin, and tubocurarine also may 
cause release of mast-cell mediators.  
Idiosyncratic reactions are unpredictable and not explained by the pharmacologic 
properties of the drug. An example is the individual with infectious mononucleosis 
who develops a rash when given ampicillin.  
Imbalance of endogenous flora may occur when antimicrobial agents preferentially 
suppress the growth of one species of microbe, allowing other species to grow 
vigorously. For example, candidiasis frequently occurs with antibiotic therapy.  
Intolerance may occur in patients with altered metabolism. For example, 
individuals who are slow acetylators of the enzyme N-acetyltransferase are more 
likely than others to develop drug-induced lupus in response to procainamide.  
Jarisch-Herxheimer phenomenon is a reaction due to bacterial endotoxins and 
microbial antigens that are liberated by the destruction of microorganisms. The 
reaction is characterized by fever, tender lymphadenopathy, arthralgias, transient 
macular or urticarial eruptions, and exacerbation of preexisting cutaneous lesions. 
The reaction is not an indication to stop treatment because symptoms resolve with 
continued therapy. This reaction can be seen with penicillin therapy for syphilis, 
griseofulvin or ketoconazole therapy for dermatophyte infections, and 
diethylcarbamazine therapy for oncocerciasis.  
Overdosage is an exaggerated response to an increased amount of a medication. 
For example, increased doses of anticoagulants may result in purpura.  
Phototoxic dermatitis is exaggerated sunburn response caused by the formation of 
toxic photoproducts, such as free radicals or reactive oxygen species.  
Mortality/Morbidity: Most drug eruptions are mild, self-limited and usually 
resolve after the offending agent has been discontinued. Severe and potentially 
life-threatening eruptions occur in approximately 1 in 1000 hospital patients. 
Mortality rates for erythema multiforme (EM) major are significantly higher. 
Stevens-Johnson syndrome (SJS) has a mortality rate below 5%, whereas the rate 
for TEN approaches 20-30%; most patients die from sepsis.  
History: The first step is to review the patient's complete medication list, including 
over-the-counter supplements. Document any history of previous adverse reactions 
to drugs or foods. Consider alternative etiologies, especially viral exanthems and 
bacterial infections. Exanthematous eruptions in children are more likely to be due 
to a viral infection than another infection; however, most such reactions in adults 
are due to medications.  
Note any concurrent infections, metabolic disorders, or immunocompromise (e.g., 
due to HIV infection, cancer, chemotherapy) because these increase the risk of 
drug eruptions. Immunocompromised persons have a 10-fold higher risk of 
developing a drug eruption than the general population. Although HIV infection 
causes profound anergy to other immune stimuli, the frequency of drug 
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hypersensitivity reactions, including severe reactions (e.g., TEN), is markedly 
increased in HIV-positive individuals. Patients with advanced HIV infection (CD4 
count <200 cells/µL) have a 10- to 50-fold increased risk of developing an 
exanthemata’s eruption to sulfamethoxazole.  
Note and detail the following:  
– All prescription and over-the-counter drugs including topical agents, 
vitamins, and herbal and homeopathic remedies 
– The interval between the introduction of a drug and onset of the eruption 
– Route, dose, duration, and frequency of drug administration 
– Parenterally administered drugs, which are more likely than oral agents to 
cause anaphylaxis 
– Topically applied drugs, which are more likely than other drugs to induce 
delayed-type hypersensitivity reactions 
– Multiple courses of therapy and prolonged administration of a drug, which 
can cause allergic sensitization 
– Any improvement after drug withdrawal and any reaction with re-
administration 
Physical: Although most drug eruptions are exanthematous, different types of drug 
eruptions exist. With every drug eruption, it is important to evaluate for certain 
clinical features that may indicate a severe potentially life-threatening drug 
reaction, such as TEN or hypersensitivity syndrome. Such features include the 
following: mucous membrane erosions, blisters (blisters herald a severe drug 
eruption), Nikolsky sign (epidermis sloughs off with lateral pressure), confluent 
erythema, angioedema and tongue swelling, palpable purpura, skin necrosis, 
lymphadenopathy, high fever, dyspnea, or hypotension  
Appreciating the morphology and features of drug eruptions is important. This can 
help the clinician determine the causative medication and the most appropriate 
treatment. 
Acneiform - inflammatory papules or pustules that have a follicular pattern; 
localized primarily on the upper body; in contrast to acne vulgaris, comedones are 
absent in acneiform eruptions. 
Acral erythema (erythrodysesthesia) - relatively common reaction to chemotherapy 
characterized by symmetric tenderness, edema, and erythema of the palms and 
soles; thought to be a direct toxic effect on the skin; often resolves 2-4 weeks after 
chemotherapy is discontinued. 
Acute generalized exanthematous pustulosis (AGEP) - acute-onset fever and 
generalized scarlatiniform erythema with many small, sterile, nonfollicular 
pustules; clinical presentation is similar to pustular psoriasis, but AGEP has more 
marked hyperleukocytosis with neutrophilia and eosinophilia; most cases are 
caused by drugs (primarily antibiotics) often in the first few days of administration; 
a few cases are caused by viral infections, mercury exposure, or UV radiation; 
resolves spontaneously and rapidly, with fever and pustules lasting 7-10 days then 
desquamation over a few days. 
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Dermatomyositis-like - cutaneous findings of dermatomyositis (e.g., Gottron 
papules), but patients tend to lack muscle involvement, associated malignancy, and 
antinuclear antibodies; improvement is usually noted after the drug is withdrawn 
EM - includes a spectrum of diseases, e.g., EM minor and EM major; many 
categorize SJS and TEN as EM major and differentiate them by body-surface 
involvement. 
EM minor - overall, a mild disease; patients are healthy; characterized by target 
lesions distributed predominantly on the extremities; mucous membrane 
involvement may occur but is not severe; patients with EM minor recover fully, 
but relapses are common; most cases are due to infection with herpes simplex 
virus, and treatment and prophylaxis with acyclovir is helpful. 
SJS - characterized by widespread skin involvement, large and atypical targetoid 
lesions, significant mucous membrane involvement, constitutional symptoms, and 
sloughing of 10% of the skin; may be caused by drugs and infections (especially 
those due to Mycoplasma pneumoniae). 
SJS/TEN overlap - epidermal detachment involves between 10-30% of body 
surface area. 
TEN - severe skin reaction; prodrome of painful skin (not unlike sunburn) quickly 
followed by rapid, widespread, full-thickness skin sloughing; affects 30% or more 
the total body surface area; secondary infection and sepsis are major concerns; 
pneumonia may develop due to aspiration of sloughed mucosa; most cases are due 
to drugs; the risk of TEN in HIV-positive patients is 1000-fold higher than the 
general population. 
Erythema nodosum - tender, red, subcutaneous nodules, typically on the anterior 
aspect of the legs; lesions do not suppurate or become ulcerated; a reactive process 
often secondary to infection, but it may be due to medications, especially oral 
contraceptives and sulfonamides. 
Erythroderma - widespread inflammation of the skin; may result from an 
underlying skin condition, drug eruption, internal malignancy, or 
immunodeficiency syndrome; lymphadenopathy is often noted, and 
hepatosplenomegaly, leukocytosis, eosinophilia, and anemia may be present 
Fixed drug eruptions - lesions recur in the same area when the offending drug is 
given; circular, violaceous, edematous plaques that resolve with macular 
hyperpigmentation is a characteristic; lesions occur 30 minutes to 8 hours after 
drug administration; perioral and periorbital lesions may occur, but the hands, feet, 
and genitalia are the most common locations 
Hypersensitivity syndrome - potentially life-threatening complex of symptoms 
often caused by anticonvulsants; patients have fever, sore throat, skin rash, 
lymphadenopathy, hepatitis, nephritis, and leukocytosis with eosinophilia; usually 
begins within 1-3 weeks after new drug is started, but it may develop 3 months or 
later into therapy; aromatic anticonvulsant drugs cross-react (phenytoin, 
phenobarbital, carbamazepine); valproic acid is a safe alternative. 
Leukocytoclastic vasculitis - most common severe drug eruption seen in clinical 
practice; blanching erythematous macules quickly followed by palpable purpura; 
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fever, myalgias, arthritis, and abdominal pain may be present; typically appears 7-
21 days after the onset of drug therapy; laboratory evaluation to exclude internal 
involvement is mandatory. 
Lichenoid - appears similar to lichen planus and may be severely pruritic; eruption 
may include eczematous or psoriasiform papules. 
Lupus - drug-induced systemic lupus erythematosus (SLE), which produces 
symptoms identical to those of SLE with skin findings being uncommon, or drug-
induced subacute cutaneous lupus erythematosus (SCLE), which is characterized 
by an– annular psoriasiform, non-scarring lesions in a photodistributed pattern 
Morbilliform or exanthematous - the most common pattern of drug eruptions, 
quintessential drug rash; exanthem is typically symmetric, with confluent 
erythematous macules and papules that spare the palms and soles; typically 
develops within 2 weeks after the onset of therapy. 
Pseudoporphyria - largely a drug-induced condition, but it can also occur with use 
of tanning beds and hemodialysis; patients have blistering and skin fragility that is 
clinically and pathologically identical to that of porphyria cutanea tarda, but 
hypertrichosis and sclerodermoid changes are absent, and urine and serum 
porphyrin levels are normal; treatment is sun protection and withdrawal of 
medication. 
Serum sickness and serum sickness–like - type III hypersensitivity reaction 
mediated by the deposition of immune complexes in small vessels, activation of 
complement, and recruitment of granulocytes; cutaneous signs typically begin with 
erythema on the sides of fingers, hands, and toes and progress to a widespread 
eruption (most often morbilliform or urticarial); viscera may be involved, and 
fever, arthralgia, and arthritis are common; serum sickness–like reaction has a 
clinical presentation similar to that of serum sickness, without the immune 
complex deposition; renal involvement is rare; serum sickness–like reactions 
usually occur antibiotic therapy, especially with cefaclor. 
Sweet syndrome (acute febrile neutrophilic dermatosis) - tender, erythematous, 
papules and plaques most often on the face, neck, upper trunk, and extremities; 
surface of lesions may become vesicular or pustular; systemic findings are 
common and include fever (most often), arthritis, arthralgias, conjunctivitis, 
episcleritis, and oral ulcers; laboratory evaluation usually reveals elevated 
sedimentation rate, neutrophilia, and leukocytosis; Sweet often occurs in 
association with cancers, inflammatory disorders, pregnancy, and medication. 
Urticarial - usually occurs as small wheals that may coalesce or that may have 
cyclical or gyrate forms; lesions usually appear shortly after the start of drug 
therapy and resolve rapidly when the drug is withdrawn; giant urticaria easily 
mistaken for EM. 
Vesiculobullous - can resemble pemphigus, bullous pemphigoid, linear IgA 
dermatosis, dermatitis herpetiformis, herpes gestationis, or cicatricial pemphigoid; 
most causative drugs have a thiol group, disulfide bonds, or sulfur-containing rings 
that are metabolized to thiol forms; thiol-induced pemphigus tends to resemble 
pemphigus foliaceus or pemphigus erythematosus; non-thiol eruptions may 
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resemble pemphigus vulgaris or pemphigus vegetans; mucosal findings may be 
most common with non-thiol drugs; direct and indirect immunofluorescence may 
be positive in drug-induced pemphigus and bullous pemphigoid; eruptions usually 
resolve after the inducing drug is discontinued, but D-penicillamine–induced 
pemphigus may take months to resolve and corticosteroids are often needed. 
Lab Studies.History and physical examination are often sufficient for diagnosing 
mild asymptomatic eruptions.Severe or persistent eruptions may require further 
diagnostic testing. Biopsy can be helpful in confirming the diagnosis of a drug 
eruption (e.g., by showing eosinophils in morbilliform eruptions or numerous 
neutrophils without vasculitis in Sweet syndrome).CBC count with differential 
may show leukopenia, thrombocytopenia, and eosinophilia in patients with serious 
drug eruptions.Serum chemistries may be useful. Liver involvement leading to 
death can occur in hypersensitivity syndromes. Special attention should be paid to 
the electrolyte balance and renal and/or hepatic function indices in patients with 
severe reactions, such as SJS, TEN, or vasculitis.Antibody and/or immunoserology 
tests may be ordered. Antihistone antibodies are noted in drug-induced SLE, 
whereas anti-Ro/SS-A antibodies are most common in drug-induced SCLE.Direct 
cultures may be needed to investigate a primary infectious etiology or secondary 
infection.Urinalysis, stool guaiac tests, and chest radiography are important for 
patients with vasculitis. 
Imaging Studies.Chest radiography, along with urinalysis and stool guaiac tests, is 
important for patients with vasculitis. 
Other Tests.Rechallenge tests by means of skin prick or patch testing to confirm 
the causative agent is of limited value.Skin tests may be hazardous to patients who 
have had severe reactions. With the possible exception of AGEP, patch tests have a 
low sensitivity and specificity and are not useful. 
Histologic Findings.In some cases, biopsy may be helpful in establishing a 
diagnosis of a drug reaction. Histopathology of an exanthematous drug eruption 
may show both superficial and deep perivascular inflammatory cell infiltrates. 
Eosinophils in the infiltrate suggest such a drug eruption.In patients with Sweet 
syndrome, biopsy reveals edema of the superficial dermis and a dense infiltrate of 
neutrophils. Leukocytoclasia may be present, but vasculitis is absent.  
Histopathology of TEN shows subepidermal split, full-thickness epidermal 
necrosis and a sparse perivascular lymphocytic infiltrate. 
Medical Care.The ultimate goal is always to discontinue the offending medication 
if possible. Individuals with drug eruptions are often the most ill patients taking the 
most medications, many of which are essential for their survival. However, all 
nonessential medications should be limited. Once the offending drug has been 
identified, it should be discontinued promptly. Knowledge of the common eruption 
inducing-medications may help in identifying the offending drug.It is possible to 
treat the patient through morbilliform eruptions (i.e., continue medication even in 
patients with a rash). The eruption often resolve, especially if the individual is 
being treated with antihistamines. Most believe that exanthematous drug eruptions 
are not a precursor to severe reactions, such as TEN. Nevertheless, all patients with 
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severe morbilliform eruptions should be monitored for mucus-membrane lesions, 
blistering, and skin sloughing. 
Treatment of a drug eruption depends on the specific type of reaction. Therapy for 
exanthematous drug eruptions is supportive. First generation antihistamines are 
used around the clock. Mild topical steroids (hydrocortisone or desonide) and 
moisturizing lotions are also used, especially during the late desquamative phase. 
Severe reactions, such as SJS, TEN, and hypersensitivity reactions, warrant 
hospital admission. TEN is best managed in a burn unit with special attention 
given to electrolyte balance and signs of secondary infection. Because adhesions 
can develop and result in blindness, ophthalmologic evaluation is mandatory. Also, 
there is mounting evidence that intravenous Ig (IVIG) may improve outcomes for 
TEN patients. 
Hypersensitivity syndrome, a systemic reaction characterized by fever, sore throat, 
skin rash and internal organ involvement, is potentially life threatening. Timely 
recognition of the syndrome and immediate discontinuation of the anticonvulsant 
or other offending drug is crucial. Patients may require liver transplantation if the 
drug is not stopped in time. Treatment with systemic corticosteroids has been 
advocated. 
Therapy for most drug eruptions is mainly supportive. Morbilliform eruptions are 
treated with oral antihistamines and topical steroids. IVIG may be an effective 
treatment for TEN. Prednisone may be used in the treatment of hypersensitivity 
syndrome with heart and lung involvement, severe serum sickness–like reaction, 
and Sweet syndrome. 
Prognosis. Full recovery without any complications is expected for most drug 
eruptions. Even after the responsible agent is discontinued, drug eruptions may 
clear slowly or worsen over the next few days. The time required for total clearing 
may be 1-2 weeks or longer.Patients with exanthematous eruptions should be 
counseled to expect mild desquamation as the rash resolves.Patients with 
hypersensitivity syndrome are at risk of becoming hypothyroid, usually within the 
first 4-12 weeks after the reaction.The prognosis for patients with TEN is guarded. 
Scarring, blindness, and death are possible. 
 
159 
 
7.5. Urticaria 
 
Urticaria is characterized by transient itchy pale dermal swellings secondary to the 
release of histamine and possibly other vasoactive agents from mast cells. 
ETIOLOGY. The release of histamine and possibly other vasoactive mediators 
from mast cells leads to a sudden increase in vascular permeability allowing the 
escape of fluid from the circulation into the tissues. Mast cells may degranulate in 
response to a number of stimuli including physical, chemical, pharmacological and 
immunological. 
Different mechanisms may be operating in different types of urticaria. The type I 
hypersensitivity is mediated through the IgE attached to the mast cell which will 
degranulate on exposure to the specific antigen. Patients suffering from this type of 
allergic urticaria frequently have a personal or family history of atopy.  
Mast cells can also degranulate by other non - immunological stimuli. Certain 
drugs, for example morphine, codeine, ethanol, polymyxin B, and bacterial, plant 
or intervertebrate toxins can stimulate mast cells to degranulate directly.  
Other drugs like salicylates and NSAIDs, on the other hand, act on the must cell 
through its action on the cyclo-oxygenase pathway. It has been postulated that food 
additives such as tartazine, azo dyes, benzoates and sulphites can provoke urticaria 
through a similar mechanism.  
Recently some research workers have demonstrated the presence of IgG auto-
antibodies directed against IgE receptor Fc epsilon RI of mast cells and basophils 
in some patients with chronic idiopathic urticaria, which can activate the mast cells 
to degranulate. This autoimmune hypothesis of idiopathic chronic urticaria has led 
to the use of various immune therapies for treatment of the condition. 
Vasodilatation, dermal edema and a mild perivascular infiltration of lymphocytes 
and eosinophils are seen in a typical lesion of urticaria. However in a small number 
of patients repeated biopsies may show a predominance of neutrophils and 
eosinophils infiltrate and absence of endothelial damage, representing a late phase 
reaction. This picture would suggest that other cellular elements and mediators 
may operate in the pathogenesis of urticaria in some cases. 
 
CLASSIFICATION OF URTICARIA 
Various types of classification exist; the following classification adopts a more 
practical approach (see Box 7.1) 
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Вох7.1 Clinical Classification of Urticaria and Angioedema 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table7.1 Common Causesof Urticaria 
 
Drugs Salicylates, penicillin, ACE inhibitors, NDSAID, allopurinol and 
many others 
Foods Fish, nuts, egg, strawberries, milk, cheese, wine and may others 
Food additives Azo dyes, benzoates, sulphites and yeast 
Infections Hepatitis B, infectious mononucleosis, candidosis and focal sepsis 
Inhalants Grass pollens, moulds, housedust mites, etc. 
Infestation Enterobius, filariasis, ascariasis 
Immune complex  Transfusion reaction, drugs 
 
CLINICAL FEATURES 
The lesions in urticaria are usually not difficult to recognize. They are intensely 
itchy, with a white palpable center of edema and a variable halo of erythema. The 
size and shape can be highly variable and individual lesions usually last for several 
hours except in urticarial vasculitis and angioedema where the lesion may persist 
longer. Frequently patients do not have any lesion during the visit to the clinic and 
one hat to rely on the description from the patient to diagnose a prior attack of 
urticaria. 
The history is very important for the diagnosis of different types of urticaria in 
particular for physical urticaria. The frequency, duration, severity, and timing of 
the attacks may give clues to the diagnosis and are essential; for subsequent 
management. A thorough food and drug history should be elicited. The 
characteristic rash of physical urticaria,if present on examination, together with the 
typical history would usually allow the diagnosis to be made. In case of doubt, 
simple tests can be done to confirm the diagnosis (Table 7.2). 
After making the diagnosis, one should always try to look out for any underlying 
causes and associated involvements. Focal sepsis, such as dental abscess and 
Ordinary urticaria 
 Acute (up to 6 weeks of continuous activity) 
 Chronic (6 weeks or more of continuous activity) 
 Episodic (intermittent) 
Physical urticaria (reproducibly induced by the same physical stimulus) 
 Aquagenic urticaria 
 Cholinergic urticaria 
 Cold urticaria 
 Delayed pressure urticaria 
 Dermographism 
 Localized heat urticaria 
 Solar urticaria 
 Vibratory angioedema 
Angioedema (without wheals) 
Contact urticaria (induced by biological or chemical skin contact) 
Urticarial vasculatis (defined by vasculitis on skin biopsy) 
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urinary tract infectionhave been reported to cause chronic urticaria. Urticaria can 
also be the presenting symptom of connective tissue diseases and other features of 
the disease would usually be evident. Acute urticaria can be just part of the 
manifestation of serum sickness with systemic symptoms like fever, arthritis and 
nephritis. Similarly systemic symptoms are also seen in patients with urticarial 
vasculitis. 
 
Table7.2 Tests for Physical Urticaria 
 
Cholinergic urticaria Exercise test, whole body warming 
Dermographism Light stroke on the skin, dermographometer 
Cold urticarial Ice cube test 
Solar urticarial Phototesting 
Aquagenic Water at 25o C compresses 
 
INVESTIGATION 
In most patients suffering from urticaria, the correct diagnosis can be made after 
history taking and physical examination. A complete blood counts and ESR is 
adequate for the majority who has no other abnormal physical finding. Other 
investigations should be done when necessary. 
1) complete blood count and ESR:look for eosinophilia 
2) liver function test 
3) complement C3 and C4 
4) C1 esterase inhibitor level 
5) investigation underlying infections: chest radiograph, urine for 
culture, stool for ova, throat swab, HbsAg, viral study etc. 
6) ANF, RF etc. In suspected connective tissue disease 
7) Skin biopsy: urticarial vasculitis, urticaria pigmentosa 
8) RAST: controversial as to its usefulness 
9) Skin prick test: useful for contact urticaria. Difficult to interpret for 
chronic idiopathic urticaria   
 
Acute Urticaria 
The cause of the cute attack is often obvious and there may be a history of similar 
attack. Initial investigations should include the differential white cell count and 
ESR measurement. The presence of eosinophilia points to parasitic infestation. 
Other possible causative factors listed above should be sought for. 
Since the casual factor can usually be withdrawn, subsequent attack can be avoided 
ad long-termed treatment is usually not required. Challenge test is not advisable 
since acute urticaria is frequently IgE mediated and there is a definite risk of 
anaphylaxis during the test. Though the prognosis is good in most cases, those with 
persistent symptoms for weeks may actually be suffering from chronic idiopathic 
urticaria with an acute onset. 
Most of these acute episodes can be successfully controlled with antihistamine. In 
acute urticaria of serum sickness type hypersensitivity, a short course of systemic 
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steroid may be necessary. Parenteral adrenaline is lifesaving in case of anaphylaxis 
and bronchial constriction. Resuscitation procedures should be carries out as 
indicated. 
 
Chronic Idiopathicurticaria 
Chronic idiopathic urticaria is defined as urticaria lasting longer than 6 weeks, for 
which no obvious cause can be found. This is the commonest type of urticaria in a 
dermatology clinic. Although symptomatic relief can be achieved with drug 
therapy, a certain percentage of patients may suffer from continuous symptoms for 
years without true emission. 
Numerous factors have been suggested for causing this disease including sea food, 
azo dyes, food preservatives, candida in their gut and trace of penicillin in dairy 
product. Some patients may benefit from elimination of one of these factors, but 
for most others the cause of the disease remains obscure. Recently autoimmune 
etiology has also been proposed. 
By definition, no obvious etiological factor is apparent and special investigations 
are nearly always unhelpful. For most patients with chronic idiopathic urticaria, a 
complete blood count, ESR for screening may be adequate. Stool for ova is 
indicated if there is eosinophilia. Other tests detailed above should be performed 
for individual patient as directed by the history and examination. Prick test and 
intradermal skin test are often positive but are difficult to interpret. Challenge tests 
with food coloring agents and preservatives, if available, are helpful in the 
management. 
Although no underlying cause can be found, for the majority of patients their 
symptoms can be well controlled by drug with minimal disturbance to their daily 
life. Depending on the patient’s tolerance, a sedating or non-sedatingantihistamine 
can be prescribed during daytime. Because most patients have more severe attack 
at night time, an additional nocturnal dose of mere sedating drug like promethazine 
is helpful. The patient should be encouraged to keep a food diary. Food containing 
tartrazine dye and preservatives as well as drugs that known to aggravate urticaria 
should be avoided. In suitable cases, elimination diet can be carried out with the 
help of a dietitian.  
Tolerance to antihistamine therapy may develop in a patient whose symptoms are 
previously under control. This tolerance cannot be overcome by increasing the 
dosage or by changing to another antihistamine. The cause of tolerance is thought 
to be due to the down regulation of the H1 receptors. Ketotifen and sodium 
cromoglycate can be tried and responsiveness to antihistamine may return. 
Hospital admission may be required for alternative therapy in different cases. 
 
Cholinergic Urticaria 
A common condition in young adults with intensely itchy and short-lived eruption 
developing in response to sweating, exercise, emotion and hot foods. It is 
postulated that an increase in blood temperature triggers a neural reflex which 
releases acetylcholine from sympathetic nerve endings, in turn activate the mast 
163 
 
cell to degranulate. Characteristic small wheals, less than 2 mm in diameter with 
surrounding red halo are more profuse on the upper trunk and proximal parts of the 
upper limbs. Thus it is also called micropapular urticaria. Associated systemic 
symptoms include faintness, headache, wheezing and palpitation. 
Diagnosis is established from the history and the findings of characteristic rash 
during an attack. The rash can also be brought up on exercise or whole body 
warming. These lesions can often be reproduced by intradermal injection of 
cholinergic drugs, e.g., metholyl or acetylcholine. 
Treatment is unsatisfactory. Patients, especially those with associated systemic 
symptoms, should be told to avoid situations that can precipitate an attack. Some 
patients improve with antihistamine therapy. This can be taken regularly or at 
times when they anticipate attacks. Fortunately for most patients the condition 
tends to improve spontaneously. 
 
Pressure Urticaria 
This rather rare condition is not a true urticaria. Delayed cutaneous erythema and 
edema and subcutaneous edema occur in response to the sustained application of 
pressure to the skin. The lesions itch and burn. They appear between 30 min to 9 
hours after the stimulus. A large proportion of these patients have associated 
chronic idiopathic urticaria. 
The lesions characteristically occur after certain activities: sitting on hard chairs, 
carrying bags, leaning against furniture, wearing seat belts and lying on hard 
mattresses. Swelling of the feet and hands, often indistinguishable from 
angioedema occurs after walking, jogging, running, climbing ladder and using a 
screwdriver. During severe attacks, arthralgia and a flu-like illness may accompany 
the rash. 
The pathogenesis of pressure urticaria is not known. Histamine is probably not an 
important mediator of this disease and treatment with antihistamine is useless. 
Other forms of treatment including the use of NSAIDs and colchicine have been 
tried with varying results. Systemic steroid is an effective agent bit is limited by its 
side effects. 
 
Symptomatic Dermographism 
Dermographism means whealing after direct pressure on the skin. The patient 
notices that the skin itches with linear wheals appearing after scratching. The 
itching and whealing reach their maximum in 5-10 minutes after the stimulus and 
disappear 30-60 minutes later. It is an exaggerated response of the skin to trauma. 
Lesions frequently appear in areas where clothing is tight and at sites of scratching. 
Patients can be of any age group but young adults are more often affected. No 
associated systemic disease has been recognized and no increased incidence in 
patients with chronic idiopathic urticaria is noted. The diagnosis can be confirmed 
by using the more sophisticated dermographometer. Any patient who itches and 
wheals at or below a stroking pressure of 3.5x105 Pa has symptomatic 
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dermographism. The tendency to dermographism may last for years but ultimately 
improve in most cases, 
 
Solar Urticaria 
Solar urticaria is a rare photodermatosis of unknown etiology. It is occasionally 
associated with polymorphic light eruption, other urticarias, lymphocytoma cutis 
or lupus erythematosus. It may also be systematic of porphyria cutanea tarda. 
Patients notice erythema, burning and urticarial wheals within minutes following 
exposure to sunlight or other visible light source. Wheals can develop anywhere on 
the body, mostly in the sun exposed skin. If the whole body is irradiated, severe 
generalized solar urticaria can occur with hemodynamic disturbance. The action 
spectrum of solar urticaria is broad, ranging from UVC, UVB, and UVA to visible 
spectrum. The diagnosis can be confirmed by phototesting with monochromator on 
areas of the body that are normally covered e.g. the buttock. If monochromator is 
not available, lesions of solar urticaria can be reproduced outdoor by direct 
exposure to sunlight or visible light. 
Avoidance of sunlight is essential in the management. The body should be covered 
with clothing and the patient should be advised to use an appropriate sunscreen. 
Antihistamines can produce symptomatic relief. Other treatment modalities that 
have been used include hardening with UVB, UVA, or visible light, PUVA, and 
plasmapheresis. 
 
Cold Urticaria 
Patients with cold urticaria develop whealing on exposure to cold. Wheals 
typically appear on exposed areas on a cold day. Handling of cold objects also 
causes immediate local reaction. There may be swelling of the mouth and 
esophagus after drinking cold water. If whealing is extensive, cold urticaria may be 
associated with systemic symptoms like faintness, wheezing and palpitations. 
Diagnosis is established by placing an ice cube (wrapped in plastic bag) on the skin 
for 30 seconds to 10 minutes. Wheals form on rewarming. In some cases, water at 
7oC is more effective in bringing out the wheal. 
It is important to warn patients against swimming in cold water or immersing in 
cold water as syncope may occur. Antihistamine treatment is partially effective in 
suppressing symptoms. Cyprohepatidine is generally considered to be the drug of 
choice. Salbutamol and aminophylline can relieve the pruritus of cold urticaria. 
Unlike antihistamines these drugs act by suppressing histamine release from skin 
mast cells. Doxepin and ketotifen may also be useful. 
Desensitization to cold has a place in the management of this condition. This 
should be carried out in the hospital under antihistamine cover. The procedure 
begins with putting one limb in water at 15oC for 5 min, hourly at first and then at 
longer intervals up to 24 hours. Other limbs and the face can then be treated. The 
exposure needs to be repeated indefinitely at 24 hours intervals to maintain the 
effect. 
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It should be remembered that occasionally cold urticaria is secondary to the 
presence of cryoglobulin, cold hemolysin and cryofibrinogen in the circulation. 
 
Aquagenic Urticaria 
This is a rare type of physical urticaria in which brief contact of the skin with water 
of any temperature causes an immediate urticaria eruption at the site of contact, the 
morphology of which closely resembles that of cholinergic urticaria. This 
condition may persist for many years. Acquagenic pruritus is a related but distinct 
condition in which brief contact of skin with water evokes intense local pruritus 
without any skin lesion. Patients with this disorder, which is probably quite 
common in the elderly, are often wrongly labelled as psychoneurosis or senile 
pruritus. Complete blood count should be checked as this condition may be 
symptomatic of polycythemia rubra vera. Both disorders involve histamine release 
from skin mast cells and respond well to antihistamine. UVB therapy is also 
helpful. 
 
Vibratory Angioedema 
Vibratory angioedema is an acute short-lived itchy swelling of the skin that occurs 
within minutes of application of a vibratory stimulus to the skin. This condition is 
rare and is probably genetically transmitted. It is benign and the familiar form is 
not associated with any other physical urticaria. Affected patients generally limit 
their activities to avoid symptoms. The lesions tend to appear after low frequencies 
vibration (about 10 Hz) like handling a power lawn mower and running, and 
wheals can be seen within minutes after the stimulus and disappear within an hour. 
Clapping and riding a motor bike may also produce lesions. The severity of 
symptoms is proportional to the intensity of the provoking stimulus. If the stimulus 
is sufficiently strong, facial and/or generalized erythema may occur. Systemic 
symptoms like headache and dizziness are also reported. Treatment with 
antihistamine is usually effective. 
 
Angioedema 
This is a variant of urticaria where massive edema involves subcutaneous tissues 
rather that the dermis. It may involve any part of the body surface like the lips, 
eyelids, tongue and larynx. This condition can be associated with urticaria of any 
cause. The hereditary form is caused by a quantative or functional deficiency of C1 
esterase inhibitor and is inherited as an autosomal dominant trait. An acquired 
form of C1 esterase inhibitor may develop in patients with lymphoproliferative 
disorders and systemic lupus erythematosus.  
 
Hereditary Angioedema 
In hereditary angioedema attacks are infrequent in childhood, common in 
adolescence and early adult life and may subside later. It is precipitated by trauma 
and the lesions may affect the skin, mucosal surface and intestine. Subcutaneous 
swelling is not itchy and typically persisted for a few days. Intestinal edema may 
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cause symptoms simulating acute abdomen. Laryngeal edema may lead to upper 
airway obstruction and death. The C2 and C4 level are low in between attacks and 
C3 is normal. There is a low C1 esterase inhibitor level. In acute airway 
obstruction, subcutaneous adrenaline may be lifesaving. Fresh frozen plasma 
should be administered by intravenous infusion or, alternatively a purified C1 
esterase inhibitor concentrate can be given. For long term management attenuated 
androgens stanozolol or danazol can be used for prophylaxis. They act by 
stimulating hepatic synthesis of C1 inhibitor. Antifibrinolytic agents like 
tranexamin acid and epsilon aminocaproic acid are less effective as prophylaxis but 
can be tried in patient who cannot tolerate androgenic steroids. 
 
Contact Urticarias 
Contact urticaria is a local immediate or delayed erythema or urticarial reaction at 
the site of epidermal or mucosal contact with a causative agent. It may be 
associated with generalized cutaneous reactions, rhinitis, asthma, or anaphylaxis. It 
is commonly an IgE mediated immediate reaction and non-immunological 
mechanism is also possible. 
Probably the most important cause of contact urticaria is natural rubber latex 
present in gloves and other rubber products. Latex contact urticaria symptoms vary 
from mild itching to bronchial asthma, anaphylaxis, and death. Up to ten allergenic 
proteins have been isolated from latex. Small molecular weight chemicals may 
cause contact urticaria. Chemicals like ethylene oxide isocyanates, chloramines-T, 
epoxy resins and nickel sulphate can act as hapten and initiate IgE-mediated 
allergies. This can be confirmed by using skin prick testing. 
 
Urticariapigmentosa 
This condition is in fact not urticaria but is a disorder of mast cell proliferation 
commonly seen in early childhood. Clinically there are multiple guttate or larger 
pigmented macules on the trunk and limbs of the baby and urticated lesion may 
appear on rubbing the pigmented lesions. The biopsy of the skin shows increase in 
the number of mast cells. 
 
THERAPEUTIC MODALITIES FOR URTICARIA 
 
Antihistamines. This group of drugs has H1 receptor blockers action and is the 
mainstay of therapy for urticarias. There are many antihistamines available. While 
the classical ones have been used for many years and are effective and cheap, they 
have more anticholinergic action and can cause more sedation. The newer 
antihistamines are more expensive and less sedating. In general there is little 
difference in the efficacy between the two groups of antihistamines and there are a 
lot of individual variations in response to treatment 
As a guideline one should prescribe an antihistamine that one is familiar with and 
gradually titrate the dosage according to the response. It is worthwhile to switch to 
an antihistamine of another class if the response to the first choice is not 
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satisfactory when the maximum dosage has already been given. Alternatively, in 
order to select out the most suitable agent for the patient, an antihistamines self-
assessment questionnaire can be employed. 
The classical antihistamines (see Table 7.3) can be grouped into 6 classes 
according to their chemical structures, but the introduction of the newer drugs has 
greatly complicated this. 
 
Table7.3 Commonly Used “Classical” Antihistamines 
Class Generic name Usual Adult Dose 
Ethanolamines Dimenhydrinate 
Diphenhydramine 
50-100 mg qid 
25-50 mg qid 
Alkylamines Chlorpheniramine  
Dexrochlorpheniramine 
Pheniramine 
4 mg tid 
2-3 mg tid 
75 mg bid 
Phenidenes Mebhydrolin 50-100 mg tid 
Phenothiazimes Promethazine 
Trimeprazine 
Mequitazine 
10-25 mg bid 
10-30 mg qid 
5 mg bd 
Piperazines Hydroxzine 10-25 mg tid 
Piperidines Cyproheptadine 
Azatadine 
4 mg tid 
1-2 mg tid 
 
Unwanted effects are common with these antihistamines, the commonest being 
sedation, dizziness, fatigue, insomnia and dry mouth. Paradoxical increase 
irritability may be seen in children. Alcohol can potentiate the sedative effect and 
patient should be advised to abstain from drinking while on antihistamine therapy. 
The anticholinergic action may cause urinary retention and precipitate glaucoma. 
All antihistamines are not proven safe in pregnancy and one should balance the 
risk and the possible benefit before prescribing antihistamines to pregnant woman. 
Newer antihistamines should always be avoided. 
 
Table7.4 Low SedatingAntihistamines 
 
Usual adult dosage Onset Duration of action 
Terfenadine 60 mg bd 12-2 hours > 12 hours *1 
Astemazole 10 mg daily Days  4 weeks *2 
Loratadine 10 mg daily 1-2 hours 24 hours 
Cetirizine 10 mg daily 1-2 hours 24 hours 
Acrivastine 8 mg tid 30 minutes 12 hours 
Notes:  
1. Fatal ventricular arrhythmia has been reported with larger than normal dose, in patients with 
liver disease and when it is administered with erythromycin or ketoconazole 
2. Very long duration of action. Ventricular arrhythmia reported. Cautious in the elderly. 
Weight gain may occur during prolonged therapy. 
 
168 
 
Other antihistamines and related drugs 
Ketotifen: antihistamine-like drug with mast cell stabilizing effect, worth a try in 
difficult urticaria and when tolerance to antihistamine therapy appears. Adult 
dosage 1-2- mg bd. 
Oxatamide: properties comparable to ketotifen, dosage is 30 mg bd. 
Doxepin: tricyclic antidepressant with antihistamine activity. Suitable for 
administration at night. There is drug interaction with MAOIs, and can cause 
cardiac arrhythmia. Dosage: 10 mg nocte. 
 
H2-Receptor Blockers 
The exact mode of action of H2 antagonist in urticaria is still uncertain. In many 
stubborn cases addition of an H2 antagonist with an antihistamine may be helpful, 
but there is no ground to give an H2 antagonist alone. Cimetidine: 400 mg bd. 
Ranitidine: 150 mg bd. 
 
Beta-stimulants 
This is considered as a second line treatment for patients with resistant chronic 
urticaria and antihistamine tolerance. They act directly on the mast cell and prevent 
degranulation. Although they are effective, their use is limited by their side effects, 
including tremors and tachycardia. Salbutamol: 2-4 mg tid. Terbutalin: 0.5 mg tid. 
 
Calcium Channel Blocker 
Only nifedipine is useful for stubborn urticaria. It acts by stabilizing mast cell and 
inhibit degranulation. Side effects include hypotension and flushing attacks. 
Nifedipine: 5-10 mg tid. 
 
Anabolic steroid 
This has been used in patients suffering from hereditary angioedema. It is also used 
in cholinergic urticaria. Danazole: 100-600 mg daily. Stanozolol: 2-5 mg daily. 
 
Systemic corticosteroid therapy 
This is an effective form of therapy for urticaria but long term therapy should be 
used only in exceptional cases because of its side effects. Systemic steroid therapy 
is indicated for anaphylaxis and acute urticaria of serum sickness. For chronic 
urticaria, this should be avoided unless it is given for a short duration to tie over an 
acute episode. 
 
Mast Cell-Stabilizing Agents 
Disodium cromoglycate which stabilizes mast cell membrane has been found to be 
useful in atopic asthma when administered via an inhaler. Because the drug is not 
absorbed in the gastrointestinal tract they are generally not effective for patients 
with chronic urticaria. However, it may be helpful in cases of urticaria caused by 
food allergy. Two antihistamine, ketotifen and oxatamide, have additional mast 
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cell stabilizing effect but it is not certain whether this additional property is of any 
clinical significance. 
 
Immune Modulation 
Based on the autoimmune hypothesis for chronic idiopathic urticaria, various 
immune modulation therapies have been investigated for treatment of the 
condition: plasmapheresis, cyclosporine and intravenous immunoglobulin. These 
modalities are still experimental and not yet suitable for routine clinical 
application. 
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VIII. PAPULOSQUAMOUS DISEASES 
8.1 Psoriasis 
Introduction. Psoriasis is one of the most common clinical dermatological 
conditions and recent evidence points to an etiology encompassing systemic, 
“immunologic”, autoimmune and genetic elements. It is important to recognize 
that psoriasis is a term that embraces a spectrum of disease, ranging from localized 
plaques to more severe generalized involvement, with or without psoriatic arthritis 
and the associated manifestations of other autoimmune diseases. However, all 
patients, regardless of the severity of their condition, may suffer from a reduced 
quality of life, particularly in relation to work and social/personal interactions. 
Epidemiology. Psoriasis is a common chronic inflammatory disease that affects 
approximately 2% of the population. Although all races are affected, there is 
considerable interracial variation. For example, psoriasis is relatively common in 
white people, but appears to be very uncommon in native American Indians and in 
Japanese people. Prevalence appears to be highest in Scandinavian countries and 
northern Europe. Men and women are affected equally. The usual age of onset is 
20-35 years, with 75% of all cases occurring for the first time before the age of 40 
years. However, psoriasis can occur at any age. 
Based on the age of onset, human leukocyte antigen (HLA) association and disease 
course, two types of chronic plaque psoriasis have been described. 
– Type I, the commonest form, occurs in young adults with a high probability 
of a positive family history. Affected individuals tend to have more severe disease 
that runs a more irregular course. 
– Type II psoriasis has a peak incidence between 50 and 60 years of age. In 
these individuals, a positive family history is very uncommon and the disease tends 
to be mild and localized. 
– Approximately 80% of patients with type I psoriasis are HLA-Cw6 positive, 
compared with only 20% of those with type II psoriasis. 
Although psoriasis is rarely fatal, it severely affects a patient’s quality of life, in 
terms of both psychological and physical well-being. Studies comparing psoriasis 
with other important chronic diseases have shown that the impact of psoriasis on 
the patient’s quality of life is at least as great as that of ischemic heart disease, 
diabetes and chronic obstructive airways disease. Psoriasis is therefore a disease of 
major socioeconomic importance.  
Genetics. The role of genetic predisposition in determining whether an individual 
develop psoriasis is at least as great as in many other chronic inflammatory 
diseases, including inflammatory bowel disease and multiple sclerosis. Many 
investigators are now using modern molecular genetics technology to try to 
unravel the genes that cause psoriasis. Such studies hold great promise for the 
development of highly specific treatments and new diagnostic and prognostic aids. 
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Numerous chromosomal loci have been discovered for psoriasis. However, only 
30% of patients have a family history of the disease and it is not yet known how 
psoriasis is inherited. In some families, psoriasis appears to behave like an 
autosomal dominant disease, whereas in other cases there is little or no family 
history. It has been suggested that psoriasis may represent a spectrum of disease in 
which different genes, working either alone or in concert (polygenic disease), are 
important in different families. 
Environmental factors also play a key etiologic role. For example, in 60% of 
patients with guttate psoriasis the disease was precipitated by systemic, usually 
upper respiratory tract, streptococcal infection. Other important environmental 
factors include drugs, particularly lithium and antimalarias, and physical or 
psychological stress. Excessive alcohol intake is also associated with disease 
deterioration and makes management more difficult. 
 
Pathopysiology. Psoriasis is characterizes by bright red, elevated, scaly plaques. 
These clinical features mirror the characteristic pathophysiological events that 
occur in lesional skin. 
Epidermal hyperproliferation. There is an increase in the number of proliferating 
keratinocytes in the basal layer of the epidermis. This, together with loss of 
differentiation, is responsible for the thick, silvery scale seen clinically. The 
growth rate of the psoriatic epidermis is up to 10 times that of normal epidermis. 
Expansion of the dermal vasculature. The blood vessels in the upper dermis 
become dilated and hyperpermeable, and actively increase in number. This 
expansion of the dermal vasculature accounts for the vivid red color of active 
plaques. 
Accumulation of inflammatory cells. These cells - neutrophils and T-lymphocytes 
in particular – accumulate in both the dermal and epidermal layers of the skin. 
Primary pathophysiological event. Most evidence indicates that lymphocytes play 
a key role in the disease process, and that the epidermal proliferation and loss of 
differentiation are secondary, a consequence of the release of mediators from 
infiltrating lymphocytes. Indeed, it has been postulated that psoriasis is an 
autoimmune disease. The observation of an increased prevalence of psoriasis 
among patients with other organ-specific inflammatory diseases, such as ulcerative 
colitis and Chrohn’s disease is consistent with this hypothesis. 
Immunologic aspects. Evidence that psoriasis is primarily an immunologic 
disease comes from many different sources. In evolving lesions, lymphocytes 
infiltrate early into the skin, prior to epidermal and other changes. Psoriasis is 
associated with certain HLA antigens, particularly HLA-Cw6 and HLA-B57, 
which are cell-surface molecules critical to the regulation of T-lymphocyte 
function.  
Considerable progress has been made in identifying the precise lymphocytes that 
cause the disease. However, the antigens- foreign or auto – to which these 
lymphocytes are responding are currently unknown. 
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Box 8.1 Key Points – Epidemiology and Pathophysiology 
 
 
 
 
 
 
 
 
 
Clinical Presentation 
Chronic plaque psoriasis (psoriasis vulgaris) accounts for approximately 85% of all 
cases of psoriasis. The majority of patients develop clinical signs of psoriasis 
before the age of 35 years, with about 10% of patients developing the condition 
during childhood. A history of long-standing “dandruff” scaling in the ears, 
pruritus ani or vulvae, arthralgias or the presence of other autoimmune disease, 
such as inflammatory bowel disease, diabetes or thyroid disease, may be clues to a 
diagnosis of psoriasis. There is no blood test specific to psoriasis 
Table 8.1 Important Factors in Patient’s History 
Medical history 
• Persistent scaling in the ears 
• Concomitant or previously diagnosed autoimmune disease 
• Joint problems 
• Long-standing “dandruff” 
• Pruritus ani or vulvae 
Family history 
• Psoriasis 
• Rheumatoid disease 
Precipitating factors 
• Antecendent infections (particularly streptococcal) 
• Physical trauma 
• Emotional or metabolic stress 
Drugs likely to exacerbate psoriasis 
• Antimalarials (e.g. chloriquine) 
• Interferons 
• Lithium 
• Systemic glucocorticoids 
Clinical manifestations 
Psoriasis exhibits a range of histological features. All lesions show varying 
 Psoriasis affects approximately 2% of the population; however, there is 
considerable interracial variation in prevalence. 
 The usual age of onset is 20 – 35 years. 
 There is a family history of psoriasis ion 30% of patients. 
 There is growing evidence that psoriasis is primarily an immunologic T-cell-
driven disease. 
 Important environmental triggers include infection, drugs, and physical and 
psychological stress. 
 Three key events characterize the pathophysiology of psoriasis: epidermal 
hyperproliferation, angiogenesis and accumulation of inflammatory cells. 
 The impact of psoriasis on the patient’s quality of life is similar – physically 
and emotionally – to that of ischemic heartdisease, diabetes or chronic 
obstructive airways disease. 
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degrees of three cardinal characteristics: 
• Scaling 
• Thickening (induration) 
• Inflammation (redness). 
Вох 8.2 Histological Features of Psoriasis 
 
 
 
 
 
 
 
 
The classic symmetry, silvery scale and vivid reddish-purple color allow psoriasis 
to be easily differentiated from other skin disorders in the majority of cases. 
Shape of lesions. Classically, a psoriatic lesion is oval-shaped (discoid), although 
atypical lesions featuring linear, annular or geographic “map-like” configurations 
may be present. Other morphological variants, which can coexist in one patient, 
include: 
• Guttate lesions (predominantly on the trunk) 
• Flexural forms (body folds) 
• Erythrodermic psoriasis (total body erythema and scaling) 
• Pustular psoriasis (localized or generalized) 
• Localized variants, such as palmar-plantar forms. 
Guttate lesions, approximately 1 cm in diameter, often follow a streptococcal 
infection in younger patients. Multiple “drop-like” lesions occur and are typically 
distributed on the trunk; they may develop rapidly over a period of a week. Larger 
plaques may be seen in areas such as the lumbar-sacral region, and frequently 
involve the natal cleft with extensionto perianal areas. 
Flexural forms(inverse psoriasis), commonly seen in obese patients, occur in 
normal body folds, such as under the breasts, and in the inguinal and axillary 
regions. 
Erythrodermic psoriasisis relatively uncommon. It involves the entire body 
surface and may be precipitated by inappropriate use of systemic glucocorticoids, 
infections or even phototherapy or sunburn. Patients are febrile, and often have 
high white-cell counts and problems with temperature control. Associated ankle 
edema is common. Frequently cardiac and renal decompensation is seen, 
particularly in the elderly. 
 Parakeratosis: retention of nuclei in the stratum corneum 
 Suprapapillary thinning: only a few layers of epidermal cells are 
observed above the dermal papillae 
 Papillary elongation: increased lengthening of the papillary folds 
 Increased prominence of the papillary аcantosis: thickening of the 
epidermis vasculature 
 Squirting papillae: neutrophils noted in the dermal papillae and frequency 
in the adjacent epidermis. This may even produce microabscesses in the 
more inflammatory or pustular variants 
 Chronic perivascular inflammatory response noted in the dermis 
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Pustular psoriasiscan appear as two forms. The first form occurs in association 
with erythrodermic psoriasis, in which multiple tiny pustules. With or without 
coalescence, are scattered throughout the inflamed body surface. The second is a 
more localized form in which multiple small pustules, often on an erythematous 
and hyperkeratotic base, are present on the palms and soles; this is sometimes 
referred to as palmar-plantar pustulosis. 
Distribution of psoriatic lesions is highly symmetrical in most cases, except when 
modified, for example, by chronic scratching on the back or sides of the scalp. 
Regions commonly involved include the thicker areas of the skin, such as the 
scalp, elbows, knees, sacral area and knuckles on the hand dorsa. Although 
psoriasis is normally considered to be a non-itchy condition, the majority of 
patients quickly develop the habit of scratching, leading to a marked increase in 
thickening (lichenification) of individual plaques. Similarly, day-to day trauma 
may modify lesions in areas such as the hands and feet. 
Secondarily candidiasis in body folds can also modify psoriasis, as can concurrent 
disease such as human immunodeficiency virus (HIV) infection, which frequently 
results in a more inflammatory form of psoriasis, often with severe facial 
involvement. 
Color of lesions. Psoriasis lesions are usually a more vivid purplish-red color than 
most other dermatoses, such as eczema. Even in early lesions, gentle scratching of 
the affected skin will elicit the classic silvery scale. Gentle detachment of the 
overlying silvery scale will produce fine, pinpoint bleeding on the surface of the 
skin; this is known as the Auspitz sign and is highly diagnostic. 
Sites of disease involvement. For diagnosis, the whole body surface should be 
evaluated. Similarly, the total skin area should be assessed when deciding on 
appropriate treatment. 
Scalpinvolvement may range from a moderate degree of silvery scale, resembling 
seborrheic dermatitis, to thick well-circumscribed plaques, covering major portions 
of the scalp surface. The patient’s habitual scratching will often modify the 
psoriasis to produce asymmetric plaques, particularly on the sited and the posterior 
scalp. Extension beyond the scalp fringes onto the forehead, temples, sideburns 
and nape of the neck is common. 
Ears. The retroauricular folds, which extend into the scalp margin, are a common 
site of involvement, often producing secondary fissuring. Psoriasis is also one of 
the most common causes of otitis externa, with a classic silvery scale on an 
erythematous base extending into the ear canal. Wafting of the scale down the ear 
canal may produce a pseudo-membrane, which may impair hearing with time. 
Face. Involvement of the face is not uncommon. Scaling, erythema and even 
plaque formation may be noted in the eyebrows, together with scaly erythema 
around the sides of the nose, scalp and sideburn fringes, which extend onto the 
forehead and temple regions. In addition, men frequently develop psoriasis within 
the beard region, particularly the sides of the neck, because of shaving trauma. 
Trunk. Individual discoid plaques are usually seen in this region. There is great 
variation in size and shape, but larger plaques are often noted in the lumbar-sacral 
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area. Involvement of the umbilicus and gluteal cleft is common. Lesions in the 
folds of the breasts are also common – usually the classic silvery scale is not seen, 
but a distinct erythema is present. In the flexures, secondary candidiasis, with 
development of pustules peripheral to the well demarcated erythematous areas, is a 
common sequels. 
Extremities.Localized discoid plaques are common on the elbows and knees. 
Symmetrical discoid plaques, ranging in size and number are particularly 
prominent on the distal portions of the extremities, particularly the shins and ulnar 
surface of the arms. 
Hands and feet. Two main forms of psoriasis occur at these sites 
• The hyperkeratotic variant has localized well-circumscribed or more diffuse 
erythematous silvery plaques, with or without fissures. There is frequent 
involvement of the palmar surface and sides of the fingers 
• The pustular variant has multiple tiny pustules (0.1-0.3 cm in diameter), 
with or without associated erythema, scaling or crusting of the intervening skin. 
These pustules are sterile and are caused by accumulation of polymorphonuclear 
leukocytes within the epidermis. 
Genitalia are frequently involved. In men, a well-circumscribed, thin, 
erythematous lesion is seen on the glans penis, usually with minimal associated 
silvery scale because of the thinness of the skin in this region. In women, a similar, 
well-circumscribed, purplish-red erythema is noted enveloping the vaginal 
opening. The pubic region is often involved in both sexes. Direct extension of 
disease from the natal cleft may involve perianal skin and cause pruritus ani. 
Nails. Involvement of the nails can take several forms. 
Pitting describes discrete, well-circumscribed depressions of about 1 mm in 
diameter on the nail surface. This may involve only a few nails or the majority of 
the fingernails and to a lesser degree, the toenails. 
Onycholysis is a separation of the nail from the nail bed at its free edge. It produces 
a white to yellowish discoloration of the distal nail plate, ranging from 1-2 mm at 
the distal free edge to involvement of the entire nail. 
Subungual hyperkeratosis. Silvery white crusting and debris are seen underneath 
the free edge of the nail in association with some degree of thickening of the nail 
plate. 
“Oil-drop sign” refers to the well-circumscribed, usually circular, light pink-to-red 
color change seen on the surface of the nail, separate and distinct from 
onycholysis. 
 
Koebner phenomenon, also known as isomorphic response, describes induction 
of psoriasis as a result of trauma at sites of previous non-involvement. It occurs at 
scratches, surgical incisions, body-piercing sites and scars, and with friction from 
clothing or jewelry, such as rings, watches and earrings. 
Psoriatic joint disease. On clinical and radiological evaluation, approximately 
25% of patients have confirmed psoriatic arthritis. Many more complain of mild 
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arthralgias. Five major pattern of psoriatic arthritis are recognized, with 
overlapping clinical expressions frequently seen: 
• Distal interphalangeal involvement 
• Symmetrical polyarthritis, indistinguishable from rheumatoid arthritis 
• Asymmetrical oligoarthritis 
• Psoriatic spondylarthropathy 
• Arthritis mutilans, a rare variant that is most likely to affect the hands and 
feet 
• Patients with the most common form – distal interphalangeal disease – 
frequently have concomitant nail disease, often localized to the same digits as the 
joint disease. 
Box 8.3 Key Points – Clinical Presentation 
 
 
 
 
 
 
 
DISEASE MANAGEMENT 
The overall goals of any treatment program for psoriasis must be to: 
• improve the patient’s quality of life 
• achieve long-term remission and disease control 
• reduce individual drug toxicity 
• carefully evaluate individual treatments and monitor their cost-effectiveness 
Available Treatments 
Treatments available for psoriasis include a wide range of topical therapies, 
phototherapy (including photochemotherapy) and a variety of systemic agents, 
some with potentially significant side effects (see Table 4). Many factors influence 
the choice of therapy for an individual (see Table 5). Approximately 70% of 
patients with psoriasis can be managed using topical therapy alone. 
 
• Medical history, family history and physical examination are all 
important in establishing the diagnosis of psoriasis 
• Psoriasis is a clinical diagnosis; there is no blood tests specific 
for this  disease  
• Chronic discoid plaque psoriasis is the most common subtype of 
psoriasis 
• The scalp, elbows, knees and sacrum are the areas most 
commonly affected by psoriasis 
• Psoriasis can sometimes be triggered by infection, trauma, stress 
or medications 
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Table 8.2 Conventional Psoriasis Therapies 
Level 1 
Topical 
therapies 
Level 2 
Photo 
therapies 
Level 3  
Systemics 
(high efficacy, 
high toxicity) 
Level 4 
Systemics 
(moderate 
efficacy, 
moderate 
toxicity) 
Level 5 
Systemic 
therapies 
(moderate 
efficacy, high 
toxicity 
Emollients 
Keratolytics 
Dithranol 
Vitamin D3 
analogs 
(calcipotrien) 
Corticosteroids 
Coal tar 
Topical retinoids 
(Tazarotene) 
Sunlight 
UVB 
UVB+ coal tar 
UVB+anthralin 
UVB 
narrowband 
Psoralen+UVA 
Psoralen+UVA
+UVB 
Acitretin 
Methotrexate 
Cyclosporine 
Sulfasalazine 
Hydroxyurea 
Calcitrol 
Antibiotics 
Azathioprin 
6-thioguanine 
Tacrolimus 
 
Box 8.4 Factors to Consider When Treating Psoriatic Patients 
 
 
 
 
 
Before beginning therapy, the patient should have a realistic expectation of the 
outcome. In practice, this means explaining that treatment will be lengthy and is 
not curative, and that the psoriasis is likely to relapse if therapy is discontinued. In 
addition, it is crucial to spend sufficient time explaining practical aspects, such as: 
 
• Precisely what a treatment is designed to achieve and how 
• Where and for how long therapy should be applied 
• Any local side effects, such as irritation, staining or smell. 
 
Topicaltreatments 
Topical therapy remains the mainstay in the management of psoriasis as the 
majority if patients achieve adequate control of their lesions with topical agents. 
Besides, topagents are prescribed as a rule in patients who are treated with 
systemic agents. 
• Patient’s perception of disease severity 
• Objective measures of the pattern, extent and severity of disease 
• Amount of time the patient is able to devote to therapy 
• Previous treatments for psoriasis 
• Coexistent medical problems 
• Other drug therapy 
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Table 8.3 Topical Therapies for Chronic Plaque Psoriasis 
Agent Efficacy Relapse rate Side effects Cosmetic 
problems 
Emollients + + - + 
Keratolytics + + + + 
Coal tar ++ + + ++ 
Dithranol +++ + + ++ 
Corticosteroids 
(potent/very potent) 
+++ ++ ++ - 
Vitamin D3 
analogs(Calcipotriol) 
+++ + + - 
Topical retinoids 
(Tazarotene) 
++ + ++ + 
-     little or none 
+++ very great or frequent (or in case of side effects and cosmetic problems, severe) 
 
Emolients. According to the classic textbook description psoriasis does not itch. 
However, a recent survey suggests that itching is a prominent and troublesome 
symptom in more than 60% of patients with psoriasis. Regular use of an emollient, 
particularly in colder months can alleviate pruritus, reduce scale and enhance 
penetration of concomitant topical therapy. 
Keratolytic agents. Agents such as salicylic acid and urea are often included in 
topical psoriasis preparations, especially in case of prominent hyperkeratosis; they 
reduce scale and enhance penetration id other active agents. Both salicylic acid in 
concentrations of 10% on an ointment or propylene glycol 50% in water under 
plastic occlusion are effective keratolytic approaches. 
Coal tar. Crude coal tar is effective in the treatment of psoriasis. Especially in 
itchy, unstable psoriasis, tar treatment can be very effective with a pronounced 
antipruritic effect. In patients with pustular psoriasis and erythrodermic psoriasis, 
the concentration of coal tar should be low to avoid irritation. In view of the 
staining by tar, this treatment only is successful if careful instruction is guaranteed. 
Coal tar should be avoided during pregnancy and lactation. 
Dithranol (anthralin). Dithranol has been used in the treatment of psoriasis for 
more than 80 years. It includes a cascade of free radicals, which is reputed to be 
the antipsoriatic action. Dithranol is indicated in patients with chronic plaque 
psoriasis and in general for those patients whose psoriasis cannot be controlled by 
vitamin D3 and corticosteroid treatments. Dithranol is contraindicated in patients 
with pustular erythrodermic and unstable relapsing psoriasis as patients with these 
conditions may respond with severe irritation which can be problematic to manage. 
The clinical efficacy of dithranol approaches that of major treatments such as 
PUVA and systemic treatments provided that treatment is performed adequately at 
an in-patient department. Prescription as a cream for short contact treatment and 
application by the patients at home is less effective. Side effects are the staining of 
skin, which reaches a maximum 48-73 hours after application. In view of side 
effects but also in view of the need for concentration adjustment up to “minimal 
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irritancy”, dithranol treatment is only effective if the patient is treated at an 
experienced unit under intense supervision. 
Corticosteroids. Since 1963, topical corticosteroids have been an important 
treatment modality for psoriasis. Topical corticosteroids are indicated if fast 
induction of a remission is required. In the case of dermatitis perioralis or atrophic 
changes of the skin due to overtreatment with topical corticosteroids, topical 
steroid treatment is contraindicated. 
The clearing capacity of potent topical corticosteroids is excellent, especially if 
these compounds are prescribed to a patient for the first time. The efficacy of 
topical corticosteroids is enhanced considerably by using occlusion; hydrocolloid 
occlusives are especially well tolerated. The value of topical corticosteroids as a 
maintenance therapy is less convincing as a hazard of long-term corticosteroid 
treatment is atrophy of the skin, resulting in striae, teleangiectasias and purpura. 
Other side effects include hypertrichosis, perioral dermatitis and allergic contact 
dermatitis. Potent topical corticosteroids may also suppress plasma cortisol levels. 
In general, patients should be treated once daily, although intermittent treatment   
(once/twice weekly) has been claimed to be very effective. The application of 
topical corticosteroids over large areas of the skin should be avoided. 
Vitamin D3 analogues. In 1992 calcipotriol was introduced as a treatment for 
psoriasis. In view of the excellent therapeutic efficacy and the limited toxicity, 
calcipotriol has become a frequently used treatment in chronic plaque psoriasis. 
Calcipotriol is now the first line treatment for patients with chronic plaque 
psoriasis. Comparative studies between calcipotriol and other treatment revealed 
that calcipotriol is at least as effective as betamethasone or dithranol outpatient 
treatment. Irritation of the skin is observed in up to 20% of patients, requiring 
discontinuation in only 5% of these. If no bone or kidney disease exists, 
hypercalcaemia will not be observed at weekly doses of less than 100 g calcipotriol 
cream or ointment. 
Calcipotriol cream or ointment is a first line treatment for psoriasis. As a rule twice 
daily application is advised as the most effective dose schedule. Not more than 100 
g of ointment per week should be used. Calcipotriol should not be applied in the 
face and body folds. Children and patients with kidney disorders are more at risk 
of developing hypercalcaemia during treatment with calcipotriol. 
Topical retinoids (tazarotene). Tazaroten is the first retinoid which proved to have 
an antipsoriatic effect following topical application. In concentrations up to 0.1% 
in gel formulation, the compound was effective and showed an acceptable 
tolerability in the treatment of chronic plaque psoriasis. In a comparative study, 
once daily treatment with Tazaroten 0.1% gel approached the efficacy of 
fluocinonide cream with respect to induration and scaling. However fluocinonide 
induced a more substantial reduction of erythema as compared to Tazarotene.  
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Box 8.5Key Points – Topical Therapy 
 
 
 
 
 
 
 
 
 
 
 
 
Photo(chemo)therapy 
Ultraviolet radiation has an important therapeutic effect in psoriasis. Ultraviolet B 
(UVB) radiation (290-320nm) has a substantial photodynamic effect, as the 
radiation penetrates into the dermal-epidermal transition zone. The therapeutic 
efficacy of UVB phototherapy in psoriasis is satisfactory in the majority of 
patients. By contrast, the therapeutic effect of UVA (320-400nm) is limited. 
Although the radiation penetrates into the deeper layers of the skin, the quantum 
energy of UVA radiation it too low for a substantial anti-psoriatic effect. With the 
combination of ultraviolet A and the ingestion or topical application of a psoralen, 
a substantial photodynamic and anti-psoriatic effect can be achieved. Both 
phototherapy with UVB and photochemotherapy require dose management to 
minimize irritation of the skin. 
Phototherapy with UVB is indicated in extensive chronic plaque psoriasis and 
guttate psoriasis. In generalized pustular psoriasis and erythrodermic psoriasis, 
restricted use or caution with respect to phototherapy is advised. 
Although several studies have demonstrated the carcinogenic potential of 
phototherapy in humans, the risk of inducing cancer of the skin with UVB 
treatment is minimal. Contraindications for phototherapy are photodermatoses, the 
ingestion of phototoxic medication, a previous history of skin cancer and actinic 
keratosis as well as previous treatment with X-rays, or arsenic ingestion. A family 
history of melanoma is also regarded as a contraindication for phototherapy. 
Photochemotherapy (PUVA) has a substantially increased anti-psoriatic potential 
compared to phototherapy with UVB. Side effects of photochemotherapy are 
erythema, bullae, burning, nausea, itching, and pigmentations. PUVA-lentigines, 
hypertrichosis and pain. Following long-term treatment with PUVA, multiple 
squamous cell carcinomas have been induced. Contraindications for PUVA are the 
same as for UVB, although the side effects of PUVA are more severe compared 
with UVB. Chronic side effects of PUVA are cataract and hepatotoxicity. 
PUVA treatment is indicated in extensive psoriasis, including generalized pustular 
psoriasis, pustulosis palmoplantaris and erythrodermic psoriasis. In the 
Scandinavian countries, bath-PUVA has already been applied for some years. The 
• Approximately 70% of patients (those with mild or moderate disease) can be 
managed using topical therapy alone. 
• Time spent detailing the practicalities of topical therapy is crucial to achieving a 
successful therapeutic outcome. 
• A wide variety of topical therapies is available; topical corticosteroids and vitamin 
D3 analogs are considered first-line therapy for most patients. 
• Efficacy and cosmetic acceptability are key determinants of patient concordance 
with therapy. 
• Consideration should be given to the body site being treated, since this influences 
which  active ingredient and formulation should be prescribed. 
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psoralen is applied via a bath and patients are subsequently treated with UVA. The 
advantage of bath-PUVA is the reduced occurrence of nausea. The long-term risk 
with respect to the induction of squamous cell carcinomata has been reported to be 
reduced with bath-PUVA compared to systemic PUVA treatment. It is of practical 
relevance that patients using systemic medication with a phototoxic potential 
should refrain from photochemotherapy or alternatively should discontinue the 
phototoxic medication. Patients using immunosuppressive treatment should refrain 
from photochemotherapy as this combination can have a carcinogenic effect. 
Recently, it was demonstrated that patients receiving 250 PUVA treatments or 
more has an increased risk of malignant melanoma. Therefore, the cumulative 
carcinogenic risk of PUVA treatment should not be underestimated. 
Box 8.6 Key Points – Phototherapyandphotochemotherapy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Systemictherapy 
 
In case of recalcitrant manifestations of chronic plaque psoriasis, 
erythrodermicpsoriasis and generalized pustular psoriasis, a systemic treatment 
may be indicated. Methotrexate, acitretin and cyclosporine are the well-established 
treatments for psoriasis. 
Methotrexate is very effective in nearly all forms of psoriasis. Intermittent 
treatment is indicated in order to reduce the toxic potential of this drug. In general, 
the treatment is prescribed according to the following scheme: three ingestions at 
12-h intervals per week. A maximum dose of 15 mg methotrexate per week is 
advisable. According to the literature, however, doses between 22.5 and 30 mg are 
acceptable. Side effects include anorexia, nausea, alopecia, leukopenia, 
thrombocytopenia, megaloblastic anemia. Methotrexate may induce fibrosis and 
cirrhosis of the liver. In women and men who wish to have children in the short-
tern, the mutagenic effect of methotrexate has to be considered. Male and female 
patients must use continuous contraception for at least 6 months after 
discontinuing methotrexate treatment. Contraindications for methotrexate 
• Phototherapy (broad-band UVB and narrow-band UVB) is widely used for extensive 
chronic plaque psoriasis and sebo-psoriasis, and persistent guttate psoriasis. 
• Burnig and, rarely, photosensitive rashes complicate phototherapy in the short term. 
• There is a small increase in the risk of non-melanoma skin cancer with long-tern 
phototherapy. 
• Photochemotherapy (PUVA) is indicated for patients with moderate-to severe 
psoriasis involving more than 10% of the body surface area, and those whose psoriasis 
does not respond to topical therapy. 
• Short-term risks of PUVA include nausea (following oral ingestion of psoralen), 
itching and phototoxic reactions. 
• Long-term risks of PUVA include premature skin aging and skin cancer (non-
melanoma and melanoma). 
• In patients who already have risk factors for skin cancer, phototherapy and 
photochemotherapy should be prescribed only with extreme caution. 
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treatment are substantial lever and kidney diseases, pregnancy, a desire to 
procreate in the short-term, active infections, interaction with other medication, 
bone marrow hypoplasia, peptic ulceration, ulcerative colitis and patient non-
cooperation. During treatment, patients are advised not to take alcohol during the 
days of methotrexate ingestion. Patients should be at the out-patients department at 
4- to 6-week intervals. Before treatment and after the cumulative dose of 1.5 mg 
methotrexate, a liver biopsy is indicated in order to assess the histological 
appearance of the liver. 
Acitretin is a retinoic acid derivative which is indicated as a monotherapy in 
erythrodermic and pustular psoriasis. In the case of chronic plaque psoriasis, this 
treatment is very effective in combination with phototherapy (UVB) or 
photochemotherapy (PUVA). The dose of acitretin varies between 25 and 75 
mg/day. Side effects include dry lips, epistaxis, conjunctivitis, pruritus, skin 
atrophy, alopecia,and dermatitis, decreased visual perception at night, color 
blindness and hyperlipidemia. Incidentally, hepatitis and increased osteophyte 
formation have been recorded. Women, wishing to become pregnant, must not take 
acitretin due to its teratogenic potential. Pregnancy should be excluded before 
initiation of acitretin treatment and for a period of at least 2 years following 
discontinuation of treatment. No restrictions with respect to male patients should 
be given. Contraindications for treatment with acitretin are liver disease, 
hyperlipidemia, pregnancy and the desire to become pregnant. Before treatment 
and at monthly intervals, patients should be seen at the out-patient department, and 
serum triglycerides, serum cholesterol and liver function tests mist be carried out. 
Before treatment and at yearly intervals, X-ray examination of the spine is advised. 
Active questioning of the patients with respect to joint complaints is indicated. 
Cyclosporin is effective in nearly all forms of psoriasis. The dose is between 3 and 
5 mg/kg/day. Side effects are nephrotoxicity, hypertension, gingival hyperplasia, 
tremors, hypertrichoses, headache, diarrhea, general feeling of discomfort and 
nausea. Contraindications are nephrotoxicity, cytotoxicity, and immunosuppressive 
co-medication, X-ray exposure, concurrent photo (chemo) therapy, malignancies, 
active infections, immunodeficiency, organ defects, drug abuse, epilepsy, 
pregnancy, kidney dysfunctions and unmanageable hypertension. The patient 
should be seen once every 4-6 weeks. Kidney functions, blood pressure, liver 
functions and hematological investigations must be carried out during each visit. 
Biological response modifiers. Biological response modifiers are likely to 
revolutionize the treatment of moderate–to-severe psoriasis. They include agents 
that target T-cells and inflammatory cytokines. Biologic agents appear to alleviate 
the skin symptoms of psoriasis, improve patient quality of life, and in some cases 
arrest the progression of joint damage that disables some psoriasis patients. 
Biological modifiers have the advantage over traditional therapies of no apparent 
organ toxicity, including renal toxicity and hepatotoxicity. Individual drugs may 
prove to induce sustained, drug-free remissions in patients with psoriasis. 
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Table 8.4Characteristics of BIological Response Modifiers 
Name Dose regimen Selected side effects Stage of 
developments 
Alefacept 7,5 mg i.v. or 15 mg 
i.m. every week for 12 
weeks 
CD4 suppression; 
must monitor CD4 
weekly 
Moderate-to severe 
psoriasis 
Efalizumab 1 mg/kg s.c. every 
week 
Headache, nausea, 
chills 
Moderate-to severe 
psoriasis 
Etanercept 50 mg s.c. twice a 
week for 12 weeks, 
then 25 mg twice a 
week 
Injection site 
reactions; multiple-
sclerosis-like 
syndrome 
Moderate-to severe 
psoriasis, psoriatic 
arthritis, rheumatoid 
arthritis; ankylosing 
spondylitis 
Infiximab 5 mg/kg i.v. infusion 
at 0.2 and 6 weeks; 
then every 8 weeks 
Infusion reactions, 
reactivation of 
tuberculosis 
Chrohn’s disease, 
rheumatoid arthritis 
Moderate-to severe 
psoriasis, psoriatic 
arthritis 
Studies are underway to determine the optimal ways of combining biological 
agents with traditional therapies such as phototherapy, retinoids, methotrexate and 
topical medication. 
Box 8.7 Key Points – Biological Response Modifiers 
 
 
 
 
 
 
 
Combinationtherapy 
Combination treatment is frequently used in the day to day management of 
psoriasis. Some combinations may have an additive clinical effect. Some 
combinations are useful in reducing the side effects. Table 7 provides an overview 
of recommended and contraindicated combinations. 
• Biological response modifiers (“biologics”) are a new class of drugs, widely available 
for several years, they target specific molecules involved in the immunopathogenesis 
of immune-mediated diseases such as psoriasis, psoriatic arthritis, rheumatoid arthritis 
and Crohn’s disease. 
• The biologics currently available or in clinical trials are all given by injection 
(subcutaneous, intramuscular or intravenous). 
• Evidence to date suggests that biologics do not have toxic effects on internal organs. 
• Some of these agents may offer long-term remissions for patients with psoriasis. 
• Cost and long-tern safety will be important in determining the future role of biologics 
in the treatment of psoriasis. 
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Table 8.5 Combinations in treating psoriasis 
Therapies Topical 
Vitamin 
D 
Topical 
Cortico-
steroids 
Dithra
nol 
Coal 
tar 
UV
B 
PUVA Metho-
trexate 
Cyclo-
sporin 
Acitretin ++ + + + ++ ++ - - 
Cyclosporin ++ + + + - - -  
Methotrexate + + + + - -   
PUVA ++ + + + -    
UVB +/++ + +/++ +/++     
Coal Tar + + +/++ +/++     
Dithranol + +       
Topical 
corticosteroids 
+/++        
- +  =  recommended combination 
- =  contraindicated combination 
- ++ = strongly recommended combination 
 
8.2. Lichen Planus 
 
Background: Lichen planus (LP) is a pruritic, papular eruption characterized by 
its violaceous color; polygonal shape; and, sometimes, fine scale. It is most 
commonly found on the flexor surfaces of the upper extremities, on the genitalia, 
and on the mucous membranes. LP is most likely an immunologically mediated 
reaction.  
Pathophysiology: LP is a cell-mediated immune response of unknown origin. LP 
may be found with other diseases of altered immunity; these conditions include 
ulcerative colitis, alopecia areata, vitiligo, dermatomyositis, morphea, lichen 
sclerosis, and myasthenia gravis. An association is noted between LP and hepatitis 
C virus infection, chronic active hepatitis, and primary biliary cirrhosis.  
Causes: The exact cause of LP is not known. The pathogenesis of LP is 
immunologically mediated. Whether the foreign antigen is a virus or a drug is not 
known. Langerhans cells process antigens, which are then presented to T 
lymphocytes. This stimulated lymphocytic infiltrate is epidermotropic and attacks 
keratinocytes. During this lymphocytotoxic process, the keratinocytes release 
cytokines that attract more lymphocytes. This process has been referred to as the 
lichenoid tissue reaction. Also, recent studies reveal a disruption in the epithelial 
anchoring system.  
Some patients with LP have a positive family history. It has been noted that 
affected families have an increased frequency of human leukocyte antigen B7 
(HLA-B7). Others have found an association between idiopathic LP and human 
leukocyte antigen DR1 (HLA-DR1) and human leukocyte antigen DR10 (HLA-
DR10); thus, LP may be influenced by a genetic predisposition. 
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Mortality/Morbidity: Cutaneous LP does not have a higher risk of skin cancer, 
but ulcerative lesions in the mouth, particularly in men, have a higher incidence of 
malignant transformation. Vulvar lesions in women may also be associated with 
squamous cell carcinoma.  
History: Most cases are insidious. The initial lesion is usually located on the flexor 
surface of the limbs, such as the wrists. After a week or more, a generalized 
eruption develops with maximal spreading within 2-16 weeks.Pruritus is common 
but varies in severity depending on the type of lesion and the extent of 
involvement. Hypertrophic lesions are extremely pruritic.Oral lesions may be 
asymptomatic or have a burning sensation, or they may even be painful if erosions 
are present.In more than 50% of patients with cutaneous disease, the lesions 
resolve within 6 months, and 85% of cases subside within 18 months. On the other 
hand, oral LP had been reported to have a mean duration of 5 years. Large, 
annular, hypertrophic lesions and mucous membrane involvement are more likely 
to become chronic. 
Physical: In addition to the cutaneous eruption, LP can involve the mucous 
membranes, the genitalia, the nails, and the scalp. The clinical presentation of LP 
has several forms: actinic, annular, atrophic, erosive, follicular, guttate, 
hypertrophic, linear, and vesicular. The papules are violaceous, shiny, and 
polygonal; varying in size from 1 mm to greater than 1 cm in diameter. They can 
be discrete or arranged in groups of lines or circles. Characteristic fine, white lines, 
called Wickham stria, are often found on the papules.  
• Mucous membrane involvement is common and may be found without skin 
involvement. Lesions are most commonly found on the tongue and the buccal 
mucosa; they are characterized by white or gray streaks forming a linear or 
reticular pattern on a violaceous background. Oral lesions are classified as 
reticular, plaque-like, atrophic, papular, erosive, and bullous. Ulcerated oral lesions 
may have a higher incidence of malignant transformation in men, but this 
observation may be confounded by other factors, such as smoking and chewing 
tobacco. Lesions may also be found on the conjunctivae, the larynx, the tonsils, the 
bladder, the vulva, and the vaginal vault; throughout the gastrointestinal tract; and 
around the anus. 
• Genital involvement is common in men with cutaneous disease. Typically, 
an annular configuration of papules is seen on the glans. Less commonly, linear 
white striae, similar to the lesions on the vulva and the vagina, can be seen on male 
genitalia. Vulvar involvement can range from reticulate papules to severe erosions. 
Dyspareunia, a burning sensation, and pruritus are common. Vulvar and urethral 
stenosis can also be present. 
• In 10% of patients, ungual findings are present. Most commonly, nail plate 
thinning causes longitudinal grooving and ridging. Hyperpigmentation, subungual 
hyperkeratosis, onycholysis, and longitudinal melanonychia can result from LP. 
Rarely, the matrix can be permanently destroyed with prominent pterygium 
formation. LP has been linked to childhood idiopathic nail atrophy and may 
overlap with twenty-nail dystrophy of childhood. 
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• Patients with a cutaneous eruption may also have follicular and perifollicular 
violaceous, scaly, pruritic papules on the scalp. These lesions can progress to 
atrophic cicatricial alopecia that can appear many weeks after the skin lesions have 
disappeared. Pseudopelade can be a final endpoint. 
• Variations in LP include the following: 
Hypertrophic: These extremely pruritic lesions are most often found on the 
extensor surfaces of the lower extremities, especially around the ankles. 
Hypertrophic lesions are often chronic; residual pigmentation and scarring can 
occur when the lesions eventually clear. 
Atrophic: Atrophic LP is characterized by a few lesions, which are often the 
resolution of annular or hypertrophic lesions. 
Erosive: These lesions are found on the mucosal surfaces and evolve from sites of 
previous LP involvement. 
Follicular: Lichen planopilaris is characterized by keratotic papules that may 
coalesce into plaques. This condition is more common in women than in men, and 
ungual and erosive mucosal involvement is more likely to be present. A scarring 
alopecia may result. 
Annular: LP papules that are purely annular are rare. Annular lesions with an 
atrophic center can be found on the buccal mucosa and the male genitalia. 
Linear: Isolated linear lesions may form a zosteriform lesion, or they may develop 
as a Koebner effect. 
Vesicular and bullous: Most commonly, these lesions develop on the lower limbs 
or in the mouth from preexisting LP lesions. A rare condition, lichen planus 
pemphigoides, is a combination of both LP and bullous pemphigoid. 
Guttate: These discrete lesions can range from 1 mm to 1 cm in diameter. They 
almost never become chronic. 
Actinic: Subtropic or actinic LP occurs in regions, such as Africa, the Middle East, 
and India. This mildly pruritic eruption usually spares the nails, the scalp, the 
mucous membranes, and covered areas. Lesions are characterized by nummular 
patches with a hypopigmented zone surrounding a hyperpigmented center. 
Complications.Oral ulcerations have the potential to become malignant. 
Malignant transformation has been reported in ulcerative oral lesions in 
men.Infection, osteoporosis, adrenal insufficiency, bone marrow suppression, renal 
damage, hyperlipidemia, and growth retardation in children may occur due to 
medication. Alopecia is often permanent. Hypertrophic lesions may leave residual 
hyperpigmentation. Vulvar lesions can be pruritic and painful. 
Lab Studies.Direct immunofluorescence study reveals globular deposits of 
immunoglobulin M (IgM) and complement mixed with apoptotic keratinocytes. 
Histologic Findings.The histopathologic features distinguish LP based on the 
presence of irregular acanthosis and colloid bodies in the epidermis with 
liquefactive degeneration and linear fibrin deposition in the basal layer. The upper 
dermis has a band-like infiltrate of lymphocytes and histiocytes. The inflammatory 
reaction pattern is characteristic. The epidermis is hyperkeratotic with irregular 
acanthosis and focal thickening in the granular layer. Degenerative keratinocytes, 
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known as colloid or Civatte bodies, are found in the lower epidermis. In addition to 
apoptotic keratinocytes, colloid bodies are composed of globular deposits of IgM 
(occasionally immunoglobulin G [IgG] or immunoglobulin A [IgA]) and 
complement. Linear or shaggy deposits of fibrin and fibrinogen and liquefaction 
are in the basement membrane zone.  
The upper dermis has a band-like infiltrate of lymphocytic (primarily helper T) and 
histiocytic cells with many Langerhans cells. The infiltrate is very close to the 
epidermis and often disrupts the dermal-epidermal junction. 
Medical Care.LP is a self-limited disease that usually resolves within 8-12 
months. Mild cases can be treated symptomatically with antihistamines and 
fluorinated topical steroids. More severe cases, especially those with scalp, nail, 
and mucous membrane involvement, may need more intensive therapy. 
The first-line treatments of cutaneous LP are topical steroids, particularly class I or 
II ointments. A second choice would be systemic steroids for symptom control and 
possibly more rapid resolution. Many practitioners prefer intramuscular 
triamcinolone 40-80 mg every 6-8 weeks. Oral acitretin has been tried with some 
success. Many other treatments are of uncertain efficacy because of the lack of 
randomized controlled trials. For LP of the oral mucosa, topical steroids are 
usually tried first. Topical and systemic cyclosporin has been tried with some 
success. Other options include oral or topical retinoids. Even with these effective 
treatments, relapses are common.  
Psoralen with ultraviolet light A (PUVA) therapy for 8 weeks has been reported to 
be effective. Risks and benefits of this treatment should be considered. PUVA is 
carcinogenic. Long-term risks include dose-related actinic degeneration, squamous 
cell carcinoma, and cataracts. A phototoxic reaction with erythema, pruritus, 
phytophotodermatitis, and friction blisters could occur.  
UV-A therapy combined with oral psoralen consists of oral psoralen (0.6 mg/kg), 
1.5-2 hours before ultraviolet light, which usually starts at 0.5-1 J/cm2 and is 
increased by 0.5 J/cm2 per visit. Use of topical ointment at the time of receiving 
UV-A treatment may decrease the effectiveness of PUVA. Precaution should be 
taken for persons with a history of skin cancers or hepatic insufficiency. 
Corticosteroids. These agents have anti-inflammatory properties and cause 
profound and varied metabolic effects. In addition, these agents modify the body's 
immune response to diverse stimuli. Topical steroids may be as effective as 
systemic steroids. Class I or II steroids in ointment form reduce pruritus in 
cutaneous LP, but they have not been proven to induce remission. 
Retinoids. These agents modulate cell proliferation. Isotretinoin (Accutane) - oral 
agent that treats serious dermatologic conditions. Synthetic 13-cis isomer of the 
naturally occurring tretinoin (trans-retinoic acid). Both agents are structurally 
related to vitamin A. Decreases sebaceous gland size and sebum production. May 
inhibit sebaceous gland differentiation and abnormal keratinization. 
Immunosuppressants. These agents modulate the immune system. Cyclosporine 
(Sandimmune, Neoral) - topical treatment under occlusion has been efficacious for 
genital lesions and may be beneficial in hypertrophic lesions. Mouthwash or oil-
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based solutions have been effective for oral LP but seem to be no better than 
corticosteroids. Systemic treatment has been used for severe resistant cutaneous 
disease, oral or ulcerative foot involvement, and lichen planopilaris of the scalp. 
Pediatric population may require higher or more frequent dosing because of 
accelerated clearance; use with extreme caution.  
Antihistamines. These agents can reduce pruritus. Hydroxyzine (Atarax, Vistaril) - 
antagonizes H1- receptors in periphery. Can reduce pruritus and aid in sleep. 
Prognosis: The prognosis for LP is good, as most cases regress within 18 months. 
Some cases recur. 
 
 
8.3. Lichen Simplex Chronicus 
 
Synonyms and related keywords: neurodermatitis circumscripta, circumscribed 
neurodermatitis, lichen simplex chronicus of Vidal, LSC, lichen simplex, 
secondary lichenification, lichen simplex, lichenification. 
 
Background.Lichen simplex chronicus (LSC) is thickening of the skin with 
variable scaling that arises secondary to repetitive scratching or rubbing. LSC is 
not a primary process. Rather, a person senses pruritus in a specific area of skin 
(with or without underlying pathology) and causes mechanical trauma to the point 
of lichenification.  
Pathophysiology.LSC is found on the skin in regions accessible to scratching. 
Pruritus provokes rubbing that produces clinical lesions, but the underlying 
pathophysiology is unknown. Some skin types are more prone to lichenification, 
such as skin that tends toward eczematous conditions (i.e. atopic dermatitis, atopic 
diathesis). A relationship likely exists between central and peripheral neural tissue 
and inflammatory cell products in the perception of itch and ensuing changes in 
LSC. The possible interplay among primary lesions, psychic factors, and the 
intensity of pruritus additively influence the extent and severity of LSC.  
Mortality/Morbidity: No mortality occurs as a result of LSC. Overall, pruritus of 
LSC is mild to moderate, but paroxysms may occur that are relieved by moderate-
to-severe rubbing and scratching. Pruritus is usually described as much worse 
during periods of inactivity, usually at bedtime and during the night. Touch and 
emotional stress also may provoke pruritus, which is relieved by moderate-to-
severe rubbing and scratching. Lesions cause little direct morbidity; however, 
occasionally patients report decreased or interrupted sleep, which affects motor and 
mental functioning. LSC may become secondarily infected after excoriation. LSC 
is often visible enough to cause patients to seek treatment.  
History.Patients with LSC usually describe stable pruritic plaques on one or more 
areas; however, thickening of the skin occurs on any location that the patient can 
reach, including the following: scalp, nape of neck, extensor forearms and elbows, 
vulva and scrotum, upper medial thighs, knees, lower legs, and ankles. Erythema is 
noted most in early lesions. Pruritus is described as worse when patients are still or 
quiet and as much less or nonexistent when patients are active.Pruritus is usually 
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intermittent; the resultant scratching provides temporary relief.Patients may have a 
past medical history of a chronic skin condition or acute trauma. Patients with 
atopic dermatitis may have LSC in areas of former atopic outbreaks. Sites of 
irritant or allergic contact dermatitis, insect bites, or other past minor skin trauma 
sometimes demonstrate pruritus and, subsequently, LSC. Each palm-sized plaque 
may have 3 zones. A 2- to 3-cm wide peripheral zone that is barely thickened may 
have isolated papules. The middle zone has lenticular and hemispheric prurigo 
papules that may be excoriated. The central zone has the greatest thickening and 
pigmentary alteration. 
Physical.One or more slightly erythematous, scaly, well-demarcated, lichenified, 
firm, rough plaques with exaggerated skin lines are noted.Pigmentary changes 
(especially hyperpigmentation) are seen variably as in any dermatitic 
lesion.Rubbing plays a key role in lesion formation and is visualized variably by 
white scratch marks, erosion, and ulceration from deeper scratching.LSC is one of 
the hyperkeratotic processes from which a cutaneous horn may grow.Patients may 
scratch lesions de novo when observed. Some patients may start scratching while 
discussing the itch or describing the lesions. 
Causes. Atopic dermatitis results in a higher probability of developing LSC. Insect 
bites, scars (e.g. traumatic, postherpetic/zoster), acne keloidalis nuchae, xerosis, 
venous insufficiency, and asteatotic eczema are common factors.Psychological 
factors appear to play a role in the development or exacerbation of LSC.Anxiety 
has been reported to be more prevalent in patients with LSC. Neurodermatitis is a 
term formerly used interchangeably with LSC, suggesting a role of anxiety or 
obsession as part of the pathological process of developing lesions.Lithium has 
been linked to LSC in one reported case. LSC was dependent on the administration 
of lithium as evidenced by the observation that the LSC remitted when the 
medication was discontinued and recurred when it was restarted.Some reserve the 
diagnosis of lichen simplex for patients who have no known predisposing skin 
disorder. The term secondary lichenification has been used if the eruption is 
initiated by a primary dermatosis. 
Lab Studies. An elevated serum immunoglobulin E level occasionally supports 
the diagnosis of an underlying atopic diathesis.Perform potassium hydroxide 
examination and fungal cultures to exclude tinea cruris or candidiasis in patients 
with genital LSC. 
Other Tests: Patch testing helps exclude allergic contact dermatitis as an 
underlying primary dermatosis (e.g. allergic contact dermatitis to nickel with 
secondary LSC) or as a factor in chronicity (e.g. allergic contact dermatitis to 
topical corticosteroids used to treat LSC). 
Procedures: Frequently, skin biopsy is performed to exclude other disorders, 
particularly psoriasis or mycosis fungoides in elderly patients. 
Histologic Findings: Histologic examination demonstrates hyperkeratosis, 
acanthosis, spongiosis, and patches of parakeratosis in the epidermis. Epidermal 
thickening of all layers is noted, with elongation of rete ridges and with 
190 
 
pseudoepitheliomatous hyperplasia. Papillary dermal fibrosis with vertical 
streaking of collagen bundles is characteristic.  
A characteristic finding of LSC that is noted on electron microscopy is frequent 
collagen fibers attached to and just above the lamina basalis. 
Medical Care.Treatment is aimed at reducing pruritus and minimizing existing 
lesions because rubbing and scratching cause LSC. Topical steroids are the current 
treatment of choice because they decrease inflammation and itch while 
concurrently softening the hyperkeratosis. Because lesions are by nature chronic, 
treatment most likely is lifelong. On larger and more active lesions, a midpotency 
steroid may be used to treat acute inflammation. Occasionally, occlusion is used to 
increase potency and enhance delivery of the agent. Occlusion also provides a 
physical barrier to the scratching. Midpotency topical steroids are not 
recommended for thin skin (e.g. vulva, scrotum, axilla, face). Direct long-term 
therapy more at daily use of low-potency nontrophogenic topical corticosteroids. 
High-potency topical corticosteroids may be used for 3-week courses on thicker-
skinned areas. 
Oral antianxiety medications and sedation may be considered in certain patients. 
According to individual need, treatment can be scheduled throughout the day, at 
bedtime, or both. Antihistamines such as diphenhydramine (Benadryl) and 
hydroxyzine (Atarax) are common. Doxepin (Sinequan) and clonazepam 
(Klonopin) may be considered in appropriate cases.Other topical medications 
reported to decrease pruritus include doxepin cream and capsaicin cream. Both 
topical and systemic immunomodulators, such as topical tacrolimus, may be used 
in directing the changes in cellular activity that induce itching and inflammation. 
Prevention.Direct patients to stop scratching. LSC is worsened or improved 
depending on the patient's ability to stop scratching.Extremes of temperature 
and/or humidity, psychic stress, and exposure of previously affected or predisposed 
areas to cutaneous irritants and allergens provoke relapse.Discussing individual 
ways to change habitual scratching is helpful. 
Prognosis.Lesions may clear completely. Pruritus may resolve, but some mild 
scarring and pigmentary changes remain after successful treatment.Relapse is more 
likely in periods of psychic stress or if previously affected skin is stressed by 
extremes of heat or humidity or by skin irritants or allergens.In patients who do not 
comply with the treatment regimen and scratching cessation, lesions will not 
improve. 
 
 
8.4. Pityriasis Rosea 
 
Synonyms and related keywords: PR, benign papulosquamous disease, herald 
spot, herald patch 
 
Background: Pityriasis rosea (PR) is a common benign papulosquamous disease 
that was originally described by Camille Melchior Gibert in 1860. Pityriasis 
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denotes fine scales, and rosea translates as rose colored or pink. PR can have a 
number of clinical variations. Its diagnosis is important because it may resemble 
secondary syphilis.  
Pathophysiology: PR has often been considered to be a viral exanthema. Its 
clinical presentation supports this concept. PR has been linked to upper respiratory 
infections, it can cluster within families and close contacts, and it has an increased 
incidence in individuals who are immunocompromised. As with viral exanthemas, 
the incidence may increase in the fall and the spring. A single outbreak tends to 
elicit lifelong immunity.  
Immunologic data suggest a viral etiology. Increased amounts of CD4 T cells and 
Langhans cells are present in the dermis; this observation may indicate viral 
antigen processing and presentation. Also, anti-immunoglobulin M (IgM) to 
keratinocytes has been found in patients with PR; this finding may be associated 
with the exanthema phase of the presumed viral infection.  
Despite these tendencies, no single virus has been proven to cause the disease. A 
number of viruses have been studied for links to PR. Picornavirus-like particles 
havebeen seen in the tissue of African green monkeys inoculated from human PR 
lesions. A follow-up study failed to find picornavirus RNA in patients with PR. A 
recent study showed no increase in anti-IgM to parvovirus B19, making this 
etiology less likely. Serology and polymerase chain reaction for viral DNA has 
been negative for Epstein-Barr virus, parvovirus B19, and cytomegalovirus in 
patients diagnosed with PR.  
Other recent work demonstrated human herpesvirus (HHV)–7 viral DNA in both 
the lesions and the plasma in patients with PR. In addition, a separate study found 
HHV-7 DNA in lymphocytes in 75% of patients with PR, compared with 9% of 
controls. Polymerase chain reaction has shown both HHV-7 and HHV-6 DNA in a 
variety of tissues and secretions from patients with PR. In the same study, in situ 
hybridization of lesional lymphocytes showed both HHV-7 and HHV-6 mRNA. 
However, herpesvirus-like particles were not seen via electron microscopy. 
Follow-up studies have not confirmed a herpes etiology, and because HHV-7 is 
frequently found in healthy individuals, its etiologic role is controversial.  
PR commonly develops in children and young adults, although any age group can 
be affected. Most patients are aged 10-35 years.  
Causes.PR may represent a viral exanthema (and at times exanthema). PR-like 
drug eruptions may be difficult to distinguish. Medication-induced eruptions have 
been reported with captopril, metronidazole, isotretinoin, penicillamine, 
levamisole, bismuth, gold, barbiturates, ketotifen, clonidine, and omeprazole. A 
single case has been reported with terbinafine.Certain vaccinations, such as the 
BCG vaccine or the diphtheria vaccine, have been reported to cause similar 
eruptions.Lesions are also thought to be increased in individuals with high stress 
levels. 
History.The history should include questions about close contacts with similar 
eruptions. This finding is uncommon because most cases of PR are sporadic, as PR 
is thought to reflect a weakly contagious disease. A history of medication intake 
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should be obtained because several medications have been shown to cause a 
similar exanthema.  
The disease typically begins with a solitary macule that heralds the eruption (called 
the herald spot/patch), which is usually a salmon-colored macule. This initial 
lesion enlarges over a few days to become a patch with a collarette of fine scale 
just inside the well-demarcated border. 
Within the next 1-2 weeks, a generalized exanthema usually appears, although it 
may occur from hours to months after the herald patch. This secondary phase 
consists of bilateral and symmetric macules with a collarette scale oriented with 
their long axes along cleavage lines. This phase tends to resolve over the next 6 
weeks, but variability is common.Pruritus is common, usually of mild-to-moderate 
severity, and it occurs in 75% of patients. 
Physical.The herald patch is usually a single pink patch, 2-10 cm in diameter, on 
the neck or the trunk with a fine collarette scale. It is observed in more than 50% of 
patients, and it may occur as multiple lesions or in atypical locations.About 1-2 
weeks after the herald patch is seen, the generalized eruption appears, although it 
has been known to occur from hours to 3 months later. It consists of salmon-
colored macules or patches, 0.5-1.5 cm in diameter, with a collarette scale, often 
described as having a cigarette paper–like appearance. The long axes of the lesions 
are oriented in a parallel fashion along cleavage lines, giving the classic Christmas 
tree pattern. These secondary lesions most commonly occur on the trunk, the 
abdomen, the back, and the proximal upper extremities.Pruritus occurs in 75% of 
patients and is severe in 25%. Lymphadenopathy is uncommon. Atypical PR 
occurs in 20% of patients. These variations can be separated into changes in the 
lesions and/or their distribution. Variable distribution can be difficult to 
evaluate.Photosensitivity may occur. Photoexacerbated and photoprotected forms 
have been documented, although photosensitivity is not a classic manifestation of 
the disease.Lesions may be localized to single areas, such as the abdomen, the 
groin, the axilla, the distal extremities, the palms, and the soles. 
An inverse PR may be seen. This form manifests as lesions on the face and the 
distal extremities, and it is more common in children than in adults. The herald 
patch may be the only manifestation of the disease.A unilateral variant in which 
the lesions do not cross the midline has been described.Drug-induced cases are 
frequently observed without the herald patch. Variations in lesion morphology are 
noteworthy. Atypical, large patches tend to be fewer in number. They may 
coalesce to form a variant known as pityriasis circinata et marginata of Vidal. The 
primary lesions may be papules, vesicles, pustules, or urticarial or purpuric 
plaques. PR may first be evident with widespread, intensely pruritic papulovesicles 
in an unusual distribution, such as on the neck and the scalp.Papular PR tends to 
have scaling papules in the normal distribution; this form is more common in 
children than in adults.Erythema multiforme–like plaques may be evident. Oral 
involvement may occur as punctate hemorrhages, ulcers, papulovesicles, bullae, or 
erythematous plaques. Most studies find the incidence to be less than 10%; 
however, one study reported them in as many as 16% of patients.Purpuric PR is 
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seen in both adults and children, and it follows the usual presentation of the 
disease. 
Lab Studies.One must be careful to rule out syphilis. A screening rapid plasma 
reagin (RPR) test or a Venereal Disease Research Laboratory (VDRL) test should 
be ordered for appropriate individuals.One should be aware of the prozone 
phenomenon seen in secondary syphilis and request titration of the RPR test.An 
HIV test should also be considered in these patients. Other laboratory tests are 
usually normal and, therefore, unhelpful. Changes in the white blood cell count 
and differential, as well as increases in erythrocyte sedimentation rate, total serum 
protein level, globulin level, and albumin level, are rarely reported. 
Histologic Findings.A biopsy specimen is helpful to confirm the diagnosis, 
especially in atypical cases. It shows superficial perivascular dermatitis. Focal 
parakeratosis in mounds, hyperplasia, and focal spongiosis are observed in the 
epidermis. The epidermis may show exocytosis with lymphocytes, variable 
spongiosis, mild acanthosis, and a thinned granular layer. In the dermis, 
extravasated red blood cells are a helpful finding along with a perivascular 
infiltrate of lymphocytes, histiocytes, and eosinophils. A number of monocytes are 
also commonly present.  
The herald patch has similar features but has a deeper infiltrate and more 
acanthosis owing to its chronicity. Such variations as dyskeratotic cells in the 
epidermis, multinuclear giant cells, and focal acantholytic dysfunction have been 
observed. These features may closely resemble erythema annulare centrifugum, 
guttate psoriasis, superficial gyrate erythema, and small plaque parapsoriasis. 
Medical Care.The most important part of treating patients with PR is reassurance 
that the rash will resolve. Relief of pruritus is helpful and can be accomplished by 
using topical steroids, oral antihistamines, topical menthol-phenol lotions, and 
oatmeal baths. Systemic steroids are not recommended. Although they suppress 
pruritus, systemic steroids do not shorten the overall disease; in fact, they may 
prolong or exacerbate the disease.Ultraviolet B (UV-B) light therapy, starting at 
80% of the minimum erythrogenic dose, may rapidly relieve pruritus in resistant 
cases. If itching is not controlled, the dose of UV-B light should be increased by 
20% until symptoms decrease. However, a recent study failed to find improvement 
in the pruritus but did note decreased lesion severity with UV-B light therapy. One 
must take into consideration the possibility of postinflammatory pigmentation with 
light therapy.For vesicular PR, a single case was considerably improved with 20 
mg of dapsone twice a day. 
Prognosis: The prognosis for PR is excellent. Patients may return to work or 
school because they are not considered to be contagious. 
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IX. BACTERIAL INFECTIONS 
 
9.1. Ecthyma 
 
Synonyms and related keywords: ulcerative pyoderma, cutaneous pyoderma, 
impetigo, deep impetigo 
 
Background. Ecthyma is an ulcerative pyoderma of the skin caused by group A 
beta-hemolytic streptococci. Because ecthyma extends into the dermis, it is often 
referred to as a deeper form of impetigo. Ecthyma has a predilection for children 
and elderly individuals. 
Pathophysiology. Ecthyma begins similarly to superficial impetigo. Group A beta-
hemolytic streptococci may initiate the lesion or may secondarily infect preexisting 
wounds. Preexisting tissue damage (e.g. excoriations, insect bites, dermatitis) and 
immunocompromised states (e.g. diabetes, neutropenia) predispose patients to the 
development of ecthyma. Spread of skin streptococci is augmented by crowding 
and poor hygiene.  
Causes. Ecthyma can be seen in areas of previously sustained tissue injury (e.g. 
excoriations, insect bites, dermatitis).Ecthyma can be seen in patients who are 
immunocompromised (e.g. diabetes, neutropenia).Important factors contribute to 
the development of streptococcal pyodermas or ecthyma (high temperature and 
humidity, crowded living conditions, poor hygiene).Untreated impetigo that 
progresses to ecthyma most frequently occurs in patients with poor hygiene. 
History. Ecthyma usually arises on the lower extremities of children, persons with 
diabetes, and neglected elderly patients.During wartime in tropical climates, 
ecthymatous ulcers are commonly found on the ankles and dorsa of the feet. 
Physical. Ecthyma begins as a vesicle or pustule overlying an inflamed area of 
skin that deepens into a dermal ulceration with overlying crust.The crust is gray-
yellow and is thicker and harder than the crust of impetigo.A shallow, punched-out 
ulceration is apparent when adherent crust is removed.The deep dermal ulcer has a 
raised and indurated surrounding margin. Ecthyma lesions can remain fixed in size 
(sometimes resolving without treatment) or can progressively enlarge to 0.5-3 cm 
in diameter.Ecthyma heals slowly and commonly produces a scar. Regional 
lymphadenopathy is common, even with solitary lesions. 
Complications. Ecthyma rarely produces systemic symptoms. Invasive 
complications of streptococcal skin infections include cellulitis, erysipelas, 
gangrene, lymphangitis, suppurative lymphadenitis, and bacteremia.Non-
suppurative complications of streptococcal skin infections include scarlet fever and 
acute glomerulonephritis. Prompt antibiotic therapy does not appear to reduce the 
rate of poststreptococcal glomerulonephritis.Possible sequelae of secondary 
untreated S. aureus pyodermas include cellulitis, lymphangitis, bacteremia, 
osteomyelitis, and acute infective endocarditis. Some S. aureus strains produce 
exotoxins that can lead to staphylococcal scalded skin syndrome and toxic shock 
syndrome. 
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Lab Studies. Gram stain and culture of ecthyma lesions reveal gram-positive cocci 
that represent group A streptococci, with or without Staphylococcus aureus. Prior 
group A streptococci infection can be detected by anti-DNase beta testing. 
Histologic Findings. Ecthyma lesions show dermal necrosis and inflammation. A 
deep and superficial granulomatous perivascular infiltrate occurs along with 
endothelial edema. A heavy crust covers the surface of the ecthyma ulcer. 
Medical Care. Medical treatment depends on the progression of the lesions. 
Hygiene is important. Maintain cleanliness by using bactericidal soap and 
frequently changing bed linens, towels, and clothing. Remove crusts and apply an 
antibiotic ointment daily. Consider topical therapy with mupirocin ointment for 
localized ecthyma. More extensive lesions require oral antibiotics; the duration of 
treatment varies because ecthyma may require several weeks of therapy to 
completely resolve.Oral antistaphylococcal agents (e.g. dicloxacillin, cephalexin, 
erythromycin, clindamycin) have been used in the presence of possible secondary 
S. aureus infections. Penicillin should be adequate to treat ecthyma.Consider 
parenteral antibiotics for widespread involvement. 
Prognosis. Ecthyma lesions are slow to heal but do respond to appropriate 
antibiotics over several weeks; prognosis is favorable. 
 
 
9.2. Impetigo 
 
Synonyms and related keywords: impetigo contagiosa, Fox impetigo, impetigo 
bullosa, impetigo contagiosa bullosa, impetigo neonatorum 
 
Background.Impetigo is a highly contagious gram-positive bacterial infection of 
the superficial layers of the epidermis. The 2 forms of the disease, bullous and non-
bullous (crusted) impetigo, are caused by Staphylococcus aureus and group A 
beta-hemolytic streptococci (GABHS). Both organisms can be present at the same 
time. It has been suggested that infection by S. aureus is preceded by a primary 
infection by GABHS.  
Impetigo presents as either a primary pyoderma of intact skin or a secondary 
infection of preexisting skin disease or traumatized skin. Impetigo rarely 
progresses to systemic infection, although poststreptococcal glomerulonephritis is 
a rare complication.  
Bullous impetigo (least common). The causative agent of bullous impetigo is 
gram-positive, coagulase-positive, group II S. aureus, most often phage type 71.  
Approximately 30% of the population is colonized in the anterior nares by this 
bacterium. Some individuals colonized by S. aureus experience recurrent episodes 
of impetigo on the nose and lip. Bacteria can spread from the nose to normal skin 
within 11 days, with impetigo lesions appearing 11 days later.  
A small percentage of individuals are colonized in the axillae, pharynx, hands, and 
perineum. Individuals who are permanent carriers serve as a reservoir of the 
infection for other people. Most healthy persons harbor the organism as an 
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occasional transient part of their microbial flora. Patients with atopic dermatitis 
more commonly have skin colonized by S. aureus.  
The organism often passes from one individual to another through hand contact, 
entering through non-intact skin created by cutaneous diseases (e.g. atopic 
dermatitis, dermatophytosis, varicella, herpes simplex), thermal burns, surgery, 
trauma, radiation therapy, or insect bites. Immunosuppression by medications (e.g. 
systemic corticosteroids, oral retinoids, chemotherapy), systemic diseases (e.g. 
HIV infection, diabetes mellitus), intravenous drug abuse, and dialysis also 
encourage bacterial growth.  
S. aureus produces the extracellular exfoliative exotoxins termed exfoliatins A and 
B. These molecules are superantigens that act locally and activate T lymphocytes. 
The toxins produce a cleavage in the upper epidermis, either within the stratum 
granulosum or immediately below it. Coagulase produces fibrin thrombi that may 
cause the toxins to remain localized within the upper epidermis.  
Non-bullous impetigo. Studies have shown that in industrialized nations, GABHS 
and S. aureus occur with equal frequency as the causative agents for non-bullous 
impetigo. In developing nations, GABHS is the more common cause.  
S. aureus produces bacteriotoxins toxic to streptococci. These bacteriotoxins may 
be the reason that only S. aureus is isolated in lesions that are caused 
predominantly by streptococci. If an individual is in close contact with others (e.g. 
household members, classmates, teammates) who have GABHS skin infection or 
who are carriers of the organism, colonization of normal skin of that individual 
may result. Once the normal skin is colonized, minor trauma, such as abrasions or 
insect bites, may result in the development of impetigo lesions within 1-2 weeks.  
GABHS can be detected in the nose and throat of some individuals 2-3 weeks after 
lesions develop, although they do not have symptoms of streptococcal pharyngitis.  
History. Bullous impetigo begins as a rapid onset of blisters that enlarge and 
rupture. Lesions are asymptomatic. Occasionally, patients complain of pain or 
itching. Individuals with impetigo frequently recall exposure to a person who is a 
known carrier of S. aureus or streptococcal organisms or who has a pyoderma.Hot 
humid weather, participation in contact sports, crowded living conditions, poor 
personal hygiene, or an unhygienic work environment encourage contamination of 
the skin by pathogenic bacteria that can cause impetigo.A compromised immune 
system resulting from disease or disease treatment (e.g. HIV, AIDS, 
posttransplantation, insulin-dependent diabetes, hemodialysis, chemotherapy, 
radiation therapy, systemic corticosteroids), intravenous drug abuse, cutaneous 
conditions (e.g. atopic dermatitis, dermatophytosis, varicella, herpes simplex), 
recent surgical wounds, insect bites, thermal burns, or abrasions creates an 
environment conducive to bacterial infection.Symptoms of a sore throat or fever 
usually are not present. Hot and humid environments with crowded living 
conditions and poor hygiene are associated with non-bullous impetigo. 
Physical.Bullous impetigo. The characteristic lesion is a vesicle that develops into 
a superficial flaccid bulla less than 1 cm in diameter on intact skin, with minimal 
or no surrounding redness. Initially, the vesicle contains clear fluid that becomes 
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turbid.The roof of the bulla ruptures, often leaving a peripheral collarette of scale 
or a tube-like rim at the periphery. A varnish-like crust develops centrally, which if 
removed, reveals a moist red base.Intact bullae usually are not present. When 
present, intact bullae do not demonstrate a positive Nikolsky sign. Lesions of a 
primary skin disease, such as atopic dermatitis or varicella, may be present.Lesions 
may be localized or scattered widely. Lesions often are found on the face but may 
appear anywhere on the body.No regional lymphadenopathy is present. Rarely, 
infants may present with signs of pneumonia, septic arthritis, or osteomyelitis. 
Non-bullous impetigo. The characteristic lesion is a fragile vesicle or pustule that 
readily ruptures and becomes a honey-yellow, adherent, crusted papule or plaque 
of less than 2 cm and with minimal or no surrounding redness.Lesions develop on 
either normal or traumatized skin or are superimposed on a preexisting skin 
condition (e.g. scabies, varicella, atopic dermatitis).Lesions are located around the 
nose, mouth, and exposed parts of the body (e.g. arms, legs), sparing the palms and 
soles.Localized lymphadenopathy usually is present, and nodes may be tender.If 
left untreated, lesions spread by autoinoculation then spontaneously resolve after a 
few weeks. Individual lesions resolve within 10-15 days.Rarely, pedal edema and 
hypertension may be noted in an individual with non-bullous impetigo. Both are 
signs of renal dysfunction most likely resulting from glomerulonephritis.No signs 
of pharyngitis are present. 
Complications.Rarely, lesions resolve with scarring and postinflammatory 
hyperpigmentation or hypopigmentation. Bullous impetigo: cellulitis, 
lymphangitis, bacteremia with subsequent pneumonitis, septic arthritis, 
osteomyelitis, and septicemia may develop.Non-bullous impetigo: acute 
glomerulonephritis develops in 2-5% of individuals with impetigo, most often in 
children aged 2-4 years. Onset usually is 10 days after impetigo lesions first 
appear, but it can occur from 1-5 weeks later. Transient proteinuria and hematuria 
may occur during impetigo and resolve before renal involvement 
develops.Ecthyma, scarlet fever, erysipelas, cellulitis, lymphangitis and, rarely, 
bacterial endocarditis may develop. 
Lab Studies. Impetigo usually is diagnosed clinically. Bacterial culture and 
sensitivity are recommended if standard topical or oral treatment does not result in 
improvement.Urinalysis is necessary to evaluate for acute poststreptococcal 
glomerulonephritis if the patient develops new onset edema or hypertension. 
Hematuria, proteinuria, and cylindruria are indicators of renal involvement.A 
potassium hydroxide wet mount may be performed to exclude bullous 
dermatophyte infection.A Tzanck preparation or viral culture may be performed to 
exclude herpes simplex infection.A bacterial culture of the nares may be obtained 
to determine whether a patient is an S. aureus carrier.If the nares culture is 
negative and the patient has persistent recurrent episodes of impetigo, bacterial 
cultures should be obtained from the axilla, pharynx, and perineum. 
Histologic Findings.Both bullous and non-bullous impetigo show a vesicopustule 
in the upper epidermis, either within the stratum granulosum, above it, or below it. 
Occasionally, gram-positive cocci are found within the vesicopustule.  
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In bullous impetigo, few or no inflammatory cells are present within the bulla. A 
polymorphous infiltrate is present in the upper dermis. In non-bullous impetigo, 
neutrophils are present within the vesicopustule. Epidermal spongiosis with 
neutrophils and a severe dermal infiltrate of neutrophils and lymphoid cells are 
seen. 
Medical care. Topical antibiotics are applied bid/tid. Oral antibiotics with 
appropriate bacterial coverage are used in individuals with extensive impetigo or 
who are refractory to topical treatment. Gentle debridement of lesional crusts with 
a washcloth and antibacterial soap is recommended.  
The goal of pharmacotherapy is to reduce morbidity, to prevent complications, and 
to prevent spread to other individuals. Antimicrobial therapy must cover all likely 
pathogens in the context of the clinical setting. Topical antibiotic ointments active 
against S. aureus and streptococci are used most commonly. Mupirocin applied 
topically has been shown to be as effective as oral antibiotics. At times, systemic 
antibiotic treatment is indicated against gram-positive bacteria for extensive 
cutaneous infections or for cases with systemic manifestations (e.g. septic 
arthritis). Penicillin resistance is common, and penicillinase-resistant penicillins 
are recommended. Erythromycin resistance is present in some geographic areas. 
If pruritus is significant, antihistamines can be prescribed to minimize scratching. 
Avoidance of trauma to the skin may prevent or limit the spread of impetigo by 
autoinoculation. 
Prevention. Treat traumatized skin with an over-the-counter triple-antibiotic 
ointment that contains bacitracin, Polysporin, and neomycin (applied bid).Evaluate 
hospital nursery staff and household members for pyodermas or asymptomatic 
bacterial carrier states.Treat preexisting underlying skin diseases, such as atopic 
dermatitis. Antihistamines and topical steroids help decrease scratching.Teach 
good personal hygiene (e.g. trim nails frequently, keep nails short and clean, wash 
hands frequently).For patients with recurrent impetigo or for S. aureus nasal 
carriers, prescribe 2% mupirocin cream or ointment (Bactroban) inside nostrils tid 
for 5 days each month to reduce colonization in the nose. In addition, encourage 
patients to use antibacterial soap.Patients who are chronic nasal carriers also can be 
treated with rifampin. Advise patients about improving environmental conditions 
through the addition of air conditioning and by keeping surroundings clean. 
Prognosis.Spontaneous healing rarely occurs. If left untreated, some lesions may 
resolve spontaneously, while new lesions appear elsewhere on the body.Resolution 
of lesions usually occurs after 7-10 days of treatment. 
 
 
9.3.Pyoderma Vegetans 
 
Synonyms and related keywords: PV, blastomycosis-like pyoderma, mycosis-
like pyoderma 
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Background: Pyoderma vegetans (PV) is a rare disorder clinically characterized 
by large verrucous plaques with elevated borders and multiple pustules. PV is an 
eruption of multiple pustular ulcerations; it may have a bacterial etiology similar to 
chancriform pyoderma.  
Pathophysiology.The etiology of PV is not known. An immunosuppressive state 
or a dysfunction of the immune system is believed to cause the development of 
vegetations. Diffuse T-cell lymphoma, ulcerative colitis, and HIV infection have 
been associated with this condition.  
Physical: Both clinical and histologic findings are necessary to make the diagnosis 
of PV. At clinical examination, multiple pustules and large verrucous plaques with 
an elevated border are identified.At histologic examination, pseudoepitheliomatous 
hyperplasia is demonstrated. 
Lab Studies. Pathogenic organisms, such as Staphylococcus aureus, are grown 
from wound cultures, and cultures should also be taken for fungi and 
mycobacteria.Direct and indirect immunofluorescence can aid in differentiating PV 
and pemphigus vegetans.Hidradenitis suppurativa may cause an immune complex 
deposition in the skin, which precipitates the PV reaction. This reaction can be 
seen as a nonspecific immunoreactant deposition with direct immunofluorescence. 
Histologic Findings.Two predominant features are found in PV: 
pseudocarcinomatous hyperplasia and numerous abscesses in both the hyperplastic 
epidermis and the dermis. The abscesses can be made up of neutrophils or 
eosinophils. 
Medical Care.No standardized treatment plan is available for PV, although 
antibiotic treatment has often been used with variable results. Topical wound care 
with copper sulfate or aluminum subacetate dressings and intravenous antibiotics 
successfully treated patients with PV.Topical aluminum acetate soaks with 
intravenous ceftriaxone had moderate success at clearing PV in another 
patient.Antibiotic treatment has been successfully supplemented with laser 
debridement or curettage to clear lesions. 
Prognosis.With therapy, the prognosis is good, although this may prove untrue in 
the face of associated medical conditions, such as HIV, diffuse T-cell lymphoma, 
and CML, which must be properly addressed. 
 
 
9.4. Staphylococcal Scalded Skin Syndrome 
 
Synonyms and related keywords: SSSS, exfoliative dermatitis, toxin-mediated 
staphylococcal syndromes, Staphylococcus aureus 
 
Background.Staphylococcal scalded skin syndrome (SSSS) is a toxin-mediated 
type of exfoliative dermatitis. Toxin-mediated staphylococcal syndromes comprise 
a group of blistering skin diseases, ranging in severity from localized bullous 
impetigo to SSSS, in which superficial blistering and exfoliation follow 
widespread painful erythema.  
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Pathophysiology.The disorder is caused by toxigenic strains of Staphylococcus 
aureus, usually belonging to phage group 2 (types 3A, 3B, 3C, 55, or 71). Two 
exotoxins (ET), epidermolytic toxin A (ET-A) and epidermolytic toxin B (ET-B), 
are responsible for the pathologic changes seen in SSSS. Both toxins produce 
blistering by disruption of the epidermal granular cell layer, apparently from direct 
effects on desmosomes; this disruption leads to interdesmosomal splitting. The 
toxins most likely bind directly to the desmosomal protein desmoglein-1, but the 
mechanism of action of the toxin is not fully understood.  
An asymptomatic adult carrier introduces the causative bacteria into the nursery. 
Asymptomatic nasal carriage of S. aureus occurs in 20-40% of healthy individuals, 
with the organism being isolated from the hands, the perineum, and the axillae in a 
smaller proportion of the general population.  
Frequency. SSSS most commonly occurs in infants and in young children, and it 
tends to occur in outbreaks in neonatal nurseries or in day care nurseries. Large 
outbreaks of SSSS in neonatal nurseries have been described, but the occurrence of 
SSSS in adults as a nosocomial infection appears to be exceptional; epidemics 
have never been observed.  
Mortality/Morbidity.Children generally do well and are not as ill as their 
dramatic eruptions might suggest. SSSS is usually associated with a trivial 
infective focus in the conjunctivae or the skin; however, severe infections, such as 
sepsis, do contribute to a low but appreciable fatality rate (3%). Morbidity in the 
occasional child who develops cellulitis, sepsis, and pneumonia can be 
significant.In children, the foci of staphylococcal infections are usually the 
nasopharynx or localized skin infections.Adults with SSSS often have blood 
cultures positive for toxigenic S. aureus, and mortality rates can be high (>50%). 
Age. The disease most commonly affects children younger than 5 years, 
particularly neonates. A decreased ability to achieve renal clearance of toxins and a 
lack of specific immunity (antibody) to the toxins make neonates the group at 
highest risk.Older children and adults may also develop the disease. In such cases, 
renal insufficiency or immunodeficiency (e.g. HIV infection) appears to explain 
the susceptibility to the syndrome. Adults who are affected range in age from 19-
91 years, with one half of the cases occurring in adults older than 60 years. 
History.SSSS originates from a focus of infection that may be a purulent 
conjunctivitis, otitis media, or occult nasopharyngeal infection.It usually begins 
with fever; irritability; and a generalized, faint, orange-red, macular erythema with 
cutaneous tenderness.Periorificial and flexural accentuation may be observed. A 
positive Nikolsky sign (slippage of the superficial layer of the epithelium on gentle 
pressure) can often be elicited at this stage. 
Physical.Within 24-48 hours, the rash progresses from a scarlatiniform to a 
blistering eruption.Characteristic tissue paper–like wrinkling of the epidermis is 
followed by the appearance of large, flaccid bullae in the axillae, in the groin, and 
around the body orifices.Subsequent generalized involvement occurs elsewhere on 
the body, but infection spares the mucous membranes.As sheets of epidermis are 
shed, a moist erythematous base is revealed. Despite the dramatic clinical picture, 
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the entire process usually subsides with superficial desquamation, and healing is 
usually complete within 5-7 days.Cultures obtained from intact bullae are usually 
sterile; this finding is consistent with hematogenous dissemination of a toxin 
produced at a distant focus of staphylococcal infection.An abortive form of SSSS, 
known as the scarlatiniform variant, shows the early erythrodermic and final 
desquamative stages seen in SSSS, but the bullous stage does not occur.Other 
intermediate forms of scalded skin syndrome begin as localized bullous impetigo, 
but they evolve to produce regionally limited bullae and denuded areas that may or 
may not harbor staphylococci. 
Complications.Cellulitis, sepsis, and pneumonia are possible complications that 
may occur in children with SSSS. 
Lab Studies.The definitive diagnosis depends on culture and biopsy results. 
Perform culturing in all patients with suspected SSSS for identification and 
antibiotic sensitivities of the causative organism.Investigate the possibility of a 
staphylococcal carrier in the vicinity. 
Histologic Findings.All forms of scalded skin syndrome are characterized by 
intraepidermal cleavage, with splitting that occurs beneath and within the stratum 
granulosum. The cleavage space may contain free-floating or partially attached 
acantholytic cells. The remainder of the epidermis appears unremarkable, and the 
dermis contains no inflammatory cells. 
Medical Care.Direct the therapy for scalded skin syndrome toward eradication of 
the staphylococcal focus of infection, which generally requires intravenous, 
penicillinase-resistant, antistaphylococcal antibiotics. The current treatment of 
choice is cloxacillin.Oral antibiotic therapy can be substituted within several days 
or sooner. Antibiotics, supportive care, and appropriate attention to fluid and 
electrolyte management because of disrupted epidermal barrier function usually 
ensure rapid recovery.Recognizing the potential for epidemic scalded skin 
syndrome in neonatal care units is important.Identification of health care workers 
colonized or infected with toxigenic S. aureus is an integral part of managing the 
problem.Apply control measures, including strict enforcement of chlorhexidine 
hand washing, administration of an oral antibiotic therapy for workers who are 
infected, and application of mupirocin ointment for eradication of persistent nasal 
carriage. 
Prognosis.The prognosis of the disease is good in children, and the mortality rate 
is low if they are treated.In adult cases of SSSS, the mortality rate is high despite 
appropriate antibiotic therapy. 
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Х. BULLOUS DISEASES 
 
Speaking about bullous dermatoses we refer to a group of severe autoimmune 
conditions with a chronic, partially life-threatening course. The term “bullous” 
comes from the leading symptom of these conditions which is a bulla or a blister 
resulting from pathogenic autoimmune reactions occurring in the epidermis or the 
basal membrane zone. 
 
10.1. Pemphigus Vulgaris 
 
Synonyms and related keywords: PV, bullous disease 
 
Background.Pemphigus is derived from the Greek word pemphix meaning bubble 
or blister. Pemphigus describes a group of chronic bullous diseases, originally 
named by Wichman in 1791. The term pemphigus once included most bullous 
eruptions of the skin, but diagnostic tests have improved, and bullous diseases have 
been reclassified.  
The term pemphigus refers to a group of autoimmune blistering diseases of the 
skin and mucous membranes characterized histologically by intradermal blister and 
immunopathologically by the finding of in vivo bound and circulating 
immunoglobulin G (IgG) antibody directed against the cell surface of 
keratinocytes. The 3 primary subsets of pemphigus include pemphigus vulgaris 
(PV), pemphigus foliaceus, and paraneoplastic pemphigus. Each type of 
pemphigus has distinct clinical and immunopathologic features. PV accounts for 
approximately 70% of pemphigus cases.  
Pathophysiology.PV is an autoimmune, intraepithelial, blistering disease affecting 
the skin and mucous membranes and is mediated by circulating autoantibodies 
directed against keratinocyte cell surfaces. In 1964, autoantibodies against 
keratinocyte surfaces were described in patients with pemphigus. Clinical and 
experimental observations indicate that the circulating autoantibodies are 
pathogenic. An immunogenetic predisposition is well established.  
Blisters in PV are associated with the binding of IgG autoantibodies to 
keratinocyte cell surface molecules. These intercellular or PV antibodies bind to 
keratinocyte desmosomes and to desmosome-free areas of the keratinocyte cell 
membrane. The binding of autoantibodies results in a loss of cell-cell adhesion, a 
process termed acantholysis.  
PV antigen: Intercellular adhesion in the epidermis involves several keratinocyte 
cell surface molecules. Pemphigus antibody binds to keratinocyte cell surface 
molecules desmoglein 1 and desmoglein 3. The binding of antibody to desmoglein 
may have a direct effect on desmosomal adherens or may trigger a cellular process 
that results in acantholysis. Antibodies specific for non-desmosomal antigens also 
have been described in the sera of patients with PV; however, the role of these 
antigens in the pathogenesis of disease is not known.  
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Antibodies: patients with active disease have circulating and tissue-bound 
autoantibodies of both the immunoglobulin G1 (IgG1) and immunoglobulin G4 
(IgG4) subclasses. Disease activity correlates with antibody titer in most patients.  
Complement: pemphigus antibody fixes components of complement to the surface 
of epidermal cells. Antibody binding may activate complement with the release of 
inflammatory mediators and recruitment of activated T cells.  
Disease association: pemphigus occurs in patients with other autoimmune diseases, 
particularly myasthenia gravis and thymoma. 
Frequency.PV is uncommon, and the exact incidence and prevalence depends on 
the population studied. PV has been reported to occur worldwide. PV incidence 
varies from 0.5-3.2 cases per 100,000. PV incidence is increased in patients of 
Ashkenazi Jewish descent.  
Mortality/Morbidity.The mortality rate for PV is approximately 5-15%. 
Complications secondary to the use of high-dose corticosteroids contribute to the 
mortality rate. Morbidity and mortality are related to the extent of disease, the 
maximum dose of systemic steroids required to induce remission, and the presence 
of other diseases. Prognosis is worse in patients with extensive disease and in older 
patients. PV involves mucosa in 50-70% of patients. This may limit oral intake 
secondary to dysphagia. Blistering and erosions secondary to the rupture of blisters 
may be painful and limit the patient's daily activities. Patients with PV typically 
heal without scarring unless the disease is complicated by severe secondary 
infection.  
Age.Mean age of onset is approximately 50-60 years; however, the range is broad, 
and disease onset in older individuals and in children has been described. Patients 
are younger at presentation in India than in Western countries.  
Causes.The cause of PV remains unknown; however, several potentially relevant 
factors have been identified. Genetic factors: predisposition to pemphigus is linked 
to genetic factors. Certain major histocompatibility complex (MHC) class II 
molecules, in particular alleles of human leukocyte antigen DR4 (DRB1*0402) 
and human leukocyte antigen DRw6 (DQB1*0503), are common in patients with 
PV. 
CLINICAL. Mucous membranes: PV presents with oral lesions in 50-70% of 
patients, and almost all patients have mucosal lesions. Mucosal lesions may be the 
sole sign for an average of 5 months before skin lesions develop, or they may be 
the sole manifestation of the disease. 
Skin: most patients develop cutaneous lesions. The primary lesion of PV is a 
flaccid blister, which usually arises on normal-appearing skin but may be found on 
erythematous skin. New blisters usually are flaccid or become flaccid quickly. 
Affected skin often is painful but rarely pruritic. 
Drug-induced PV: drugs reported most significantly in association with PV 
include penicillamine, captopril, and other thiol-containing compounds. 
Physical: Mucous membranes typically are affected first in PV. Mucosal lesions 
may precede cutaneous lesions by months. Patients with mucosal lesions may 
present to dentists, oral surgeons, or gynecologists.  
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Mucous membranes. Intact bullae are rare in the mouth. More commonly, patients 
have ill-defined, irregularly shaped, gingival, buccal or palatine erosions, which 
are painful and slow to heal. The erosions extend peripherally with shedding of the 
epithelium.The mucous membranes most often affected are those of the oral cavity, 
which is involved in almost all patients with PV and sometimes is the only area 
involved. Erosions may be seen on any part of the oral cavity. Erosions can be 
scattered and often extensive. Erosions may spread to involve the larynx with 
subsequent hoarseness. The patient often is unable to eat or drink adequately 
because the erosions are so uncomfortable. 
Other mucosal surfaces may be involved, including the conjunctiva, esophagus, 
labia, vagina, cervix, penis, urethra, and anus. 
Skin: the primary lesion of PV is a flaccid blister filled with clear fluid that arises 
on normal skin or on an erythematous base. The blisters are fragile; therefore, 
intact blisters may be sparse. The contents soon become turbid, or the blisters 
rupture producing painful erosions, which is the most common skin presentation. 
Erosions often are large because of their tendency to extend peripherally with the 
shedding of the epithelium. 
Vegetating PV: Ordinary PV erosions may develop vegetation. Lesions in skin 
folds readily form vegetating granulations. In some patients, erosions tend to 
develop excessive granulation tissue and crusting, and these patients display more 
vegetating lesions. This type of lesion tends to occur more frequently in 
intertriginous areas and on the scalp or face. The vegetating type of response can 
be more resistant to therapy and can remain in one place for long periods of time. 
Nails: acute paronychia, subungual hematomas, and nail dystrophies have been 
reported with PV. 
Pemphigus in pregnancy: Occurrence in pregnancy is rare. When present, 
maternal autoantibodies may cross the placenta, resulting in neonatal pemphigus. 
Neonatal pemphigus is transient and improves with clearance of maternal 
autoantibodies. 
Nikolsky sign: In patients with active blistering, firm sliding pressure with a finger 
separates normal-appearing epidermis, producing erosion. This sign is not specific 
for PV and is found in other active blistering diseases. 
Asboe-Hansen sign: Lateral pressure on the edge of a blister may spread the blister 
into clinically unaffected skin. 
Complications.Secondary infection, which may be either systemic or localized to 
the skin, may occur because of the use of immunosuppressants and the presence of 
multiple erosions. Cutaneous infection delays wound healing and increases the risk 
of scarring.Malignancies resulting from immunosuppressants have been reported. 
Growth retardation has been reported in children taking systemic corticosteroids 
and immunosuppressants.Bone marrow suppression has been reported in patients 
receiving immunosuppressants. Increased incidence is reported of leukemia and 
lymphoma in patients receiving prolonged immunosuppression.Impaired immune 
responsiveness caused by corticosteroids and other immunosuppressive drugs may 
result in the rapid spread of infection. Corticosteroids suppress clinical signs of 
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infection and may allow diseases such as septicemia or tuberculosis to reach an 
advanced stage before diagnosis.Osteoporosis may occur following the use of 
systemic corticosteroids. Adrenal insufficiency has been reported following 
prolonged use of glucocorticoids. 
Lab Studies. To establish a diagnosis of PV, perform the following tests: 
Histopathology from the edge of a blister 
Direct immunofluorescence (DIF) on normal-appearing perilesional skin 
Indirect immunofluorescence (IDIF) using the patient's serum if DIF is positive. 
The preferred substrate for IDIF is monkey esophagus or salt-split normal human 
skin substrate. 
DIF demonstrates in vivo deposits of antibodies and other immunoreactants, such 
as complement. DIF usually shows IgG deposited on the surface of the 
keratinocytes in and around lesions. IgG1 and IgG4 are the most common 
subclasses. Complement components such as C3 and immunoglobulin M are 
present less frequently than IgG. DIF shows intercellular deposition throughout the 
epidermis. This pattern of immunoreactants is not specific for PV and may be seen 
in pemphigus vegetans, pemphigus foliaceus, and pemphigus erythematosus. The 
best location for DIF is normal perilesional skin. When DIF is performed on 
lesional skin, false-positive results can be observed. 
Skin biopsy specimens placed in transport media may yield false-negative results; 
therefore, fresh tissue is the preferred substrate for DIF studies. 
In the patient's serum, IDIF demonstrates the presence of circulating IgG 
autoantibodies that bind to epidermis. Circulating intercellular antibodies are 
detected using IDIF in 80-90% of patients with PV. The titer of circulating 
antibody correlates with disease course. 
Histologic Findings.Histopathology demonstrates an intradermal blister. The 
earliest changes consist of intercellular edema with loss of intercellular 
attachments in the basal layer. Suprabasal epidermal cells separate from the basal 
cells to form clefts and blisters. Basal cells are separated from one another and 
stand like a row of tombstones on the floor of the blister, but they remain attached 
to the basement membrane. Blister cells contain some acantholytic cells. 
Histopathology can help differentiate PV from pemphigus foliaceous, which 
demonstrates a more superficial epidermal cleavage.  
Tzank preparation is a smear taken from the base of a blister or oral erosion that 
contains acantholytic cells. Blistering is preceded by eosinophilic spongiosis in 
some patients. The superficial dermis has a mild, superficial, mixed inflammatory 
infiltrate, which includes some eosinophils.  
TREATMENT 
Medical Care.The aim of treatment in PV is the same as in other autoimmune 
bullous diseases, which is to decrease blister formation, promote healing of blisters 
and erosions, and determine the minimal dose of medication necessary to control 
the disease process. Therapy must be tailored for each patient, taking into account 
preexisting and coexisting conditions. Patients may continue to experience mild 
disease activity while under optimal treatment.  
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MEDICATION 
The aim of treatment is to reduce inflammatory response and autoantibody 
production. While target-specific therapy is not available, non-target–specific 
treatments currently are used. The most commonly used medications are 
corticosteroids. The introduction of corticosteroids has reduced mortality greatly, 
but significant morbidity remains. Numerous steroid regimens with or without 
immunosuppressive agents have been recommended. Immunosuppressants should 
be prescribed and monitored by physicians familiar with these agents. Wound care 
of erosions includes daily gentle cleaning, application of topical agents to promote 
wound healing, and use of non-adhesive dressings. The goal of wound care is to 
promote healing, minimize trauma to the surrounding skin, and diminish scarring. 
Useful adjuvants in patients with PV with generalized disease unresponsive to 
steroids and/or other anti-inflammatory agents or in patients unable to tolerate 
prednisone. Azathioprine (Imuran) - antagonizes purine metabolism and inhibits 
synthesis of DNA, RNA, and proteins. May decrease proliferation of immune 
cells, which results in lower autoimmune activity. In conjunction with prednisone, 
it is more effective than prednisone alone. May be an effective monotherapy in 
mild cases, although the therapeutic effect is delayed 3-5 weeks. Consider 
withdrawal if there is no improvement within 3 months. 
Consultations.Management of patients with PV requires coordination of care 
between the dermatologist and the patient's primary care physician. An 
ophthalmologist should evaluate patients with suspected ocular involvement and 
those requiring prolonged high-dose steroids.Patients with oral disease may require 
a dentist and/or an otolaryngologist for evaluation and care.Patients on systemic 
steroids should maintain adequate vitamin D and calcium intake through diet and 
supplements. Patients with a history of renal calculi should not receive calcium 
carbonate.Patients receiving long-term systemic corticosteroids may require an 
endocrinologist (prophylaxis or treatment of osteoporosis). 
Diet.No dietary restrictions exist, but patients with oral disease may benefit from 
avoiding foods, such as spicy foods, tomatoes, orange juice, and hard foods that 
may traumatize the oral epithelium mechanically, such as nuts, chips, and hard 
vegetables and fruit.  
Activity.Advise patients to minimize activities that traumatize the skin and that 
may precipitate blistering, such as contact sports. Nontraumatic exercises, such as 
swimming, may be helpful.Dental plates, dental bridges, or contact lenses may 
precipitate or exacerbate mucosal disease. 
Prognosis.The severity and natural history of PV are variable, but before the 
advent of steroids, most patients with PV died. Treatment with systemic steroids 
has reduced the mortality rate to 5-15%.Most deaths occur during the first few 
years of disease, and if the patient survives 5 years, the prognosis is good. Early 
disease probably is easier to control than widespread disease, and mortality may be 
higher if therapy is delayed.Morbidity and mortality are related to the extent of 
disease, the maximum dose of prednisolone required to induce remission, and the 
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presence of other diseases. The outlook is worse in older patients and in patients 
with extensive disease. 
Patient Education. Minimize trauma to the skin because the patient's skin is 
fragile both from the disease and from the use of topical and systemic steroids.The 
patient's understanding of the disease and education is important because of the 
chronic nature of this disorder.Educate patients regarding their medications. They 
should know about dose, adverse effects, and symptoms of toxicity so they can 
report adverse effects to the physician.Educate patients about appropriate wound 
care. 
 
 
10.2. Pemphigus Erythematosus 
 
Synonyms and related keywords: Senear-Usher syndrome, pemphigus 
seborrheic, lupus erythematosus, pemphigus foliaceus 
 
Background: Pemphigus erythematosus, also known as Senear-Usher syndrome, 
is an overlap syndrome with features of lupus erythematosus (LE) and pemphigus 
foliaceus. Pemphigus is demonstrated by acantholysis and immunoglobulin 
deposits in the interkeratinocyte substance. The lupus component is demonstrated 
by circulating antinuclear antibodies (ANA) and sometimes by immunoglobulin 
and complement deposits at the dermoepidermal junction. The disease has a better 
prognosis than pemphigus foliaceus, but it can be chronic.  
Pathophysiology.Patients present with vesiculobullae or superficially eroded 
lesions, which may ooze and crust, particularly in sun-exposed areas, such as the 
face, the upper part of the chest, and the back. Pemphigus may be photoactivated. 
LE is the classic autoimmune disease that demonstrates photosensitivity. It appears 
that a genetic predisposition to autoimmunity combines with a sensitivity to 
ultraviolet light leading to an overlap of these 2 diseases in rare cases.  
Causes. Patients with pemphigus develop an autoimmune response directed 
against desmosomes. In patients with pemphigus foliaceus and its variant, 
pemphigus erythematosus, the target antigen is desmoglein 1. Desmogleins are 
desmosomal proteins important in keratinocyte adhesion. The binding of 
autoantibodies is postulated to result in a cascade of biochemical intracellular 
events that eventuates in the loss of desmosome function.Certain HLA haplotypes 
(A10 or A26, DRw6) are thought to be associated, suggesting a genetic 
predisposition. 
Frequency. The incidence of pemphigus is 0.5-3.2 cases per 100,000 population 
per year. Patients with pemphigus erythematosus comprise only a small subgroup 
of those with pemphigus.  
Morbidity.With timely diagnosis and treatment, the disease typically has a good 
prognosis. Some patients may ultimately develop symptoms classified as criteria 
for systemic lupus erythematosus (SLE) by the American Rheumatism Association 
(ARA).  
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Race.Pemphigus erythematosus, like other variants of pemphigus erythematosus 
and LE, may be increased in patients who express specific human leukocyte 
antigen (HLA) haplotypes. Those identified to have pemphigus erythematosus are 
positive for human leukocyte antigen A10 (HLA-A10) or human leukocyte antigen 
A26 (HLA-A26) and human leukocyte antigen DRW6 (HLA-DRW6).  
History.Onset and progression are typically slow. Although the distribution of the 
lesions should suggest induction by sunlight, the patient may be completely 
unaware of the photosensitive nature of the disorder. 
Physical.Lesions typically involve the scalp, the face, the upper part of the chest, 
and the back.Patients with pemphigus erythematosus classically present with 
small, flaccid bullae with scaling and crusting. Occasionally, the appearance may 
suggest a papulosquamous disorder.Secondary infection may occur, resulting in 
impetiginization, in healing with pigment changes, and in scarring. 
On the face, pemphigus erythematosus presents on the bridge of the nose and on 
the malar areas as in the butterfly distribution seen in LE.With extensive 
involvement, patients may present with an exfoliative erythroderma. 
The skin may be tender. Patients with pemphigus erythematosus do not typically 
develop mucous membrane involvement, which can be seen in some other variants 
of pemphigus.Electrolyte imbalance and loss of temperature control can occur with 
extensive skin involvement. 
Complications.The types of medications used to control severe pemphigus 
erythematosus may lead to serious iatrogenic disorders. 
Lab Studies. Direct immunofluorescence. Linear deposits of immunoglobulin G 
(IgG) and C3 are present in the intercellular space of the epidermis.Granular 
deposits of C3 and IgG at the dermoepidermal junction are present in 80% of 
patients, particularly in biopsy specimens from the face or other sun-exposed areas. 
Immunoelectron microscopy: IgG and C3 deposits are localized to the epidermal 
cell membranes and the upper dermis. 
Patients with pemphigus erythematosus may have other laboratory abnormalities 
suggestive of SLE; these include anemia, lymphopenia, thrombocytopenia, renal 
abnormalities, proteinuria, or a positive rheumatoid factor. 
Procedures.Select an early vesicle or bulla for skin biopsy. Perilesional skin is 
tested on immunofluorescence studies. 
Histologic Findings.Intraepidermal superficial bullae are usually within the 
granular layer or just below it. Acantholysis may occur in the blister floor or roof. 
Old lesions may have follicular hyperkeratosis with acantholysis and dyskeratosis. 
Medical Care.Topical therapy - topical corticosteroids are useful for patients with 
limited diseases or as an adjunct to systemic therapy. Selection of the appropriate 
topical steroid strength and vehicle depends on the body site, the age of the patient, 
and the potential for steroid adverse effects. Use of daily sunscreen and sun 
protection is necessary. 
Systemic therapy - systemic steroids have been the mainstay of therapy for 
widespread pemphigus since their first use in 1950. Prednisone 1-2 mg/kg/d as a 
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single morning dose or as intravenous pulses may control the disease. Appropriate 
monitoring and follow-up care to avoid steroid adverse effects is critical. 
Dapsone is effective in some patients with pemphigus erythematosus. Patients tend 
to respond relatively quickly, with improvement within several weeks. It can be a 
steroid-sparing drug. The possible mode of action is stabilization of lysosomal 
membranes and inhibition of polymorphonuclear leukocyte (PMN) toxicity. The 
recommended dose is 100-200 mg/d. Hemolytic jaundice may result in people with 
G-6-PD deficiency. Other adverse effects include agranulocytosis, leading to 
death, headaches, malaise, hepatitis, hypersensitivity reactions, and neuropathy. 
Caution is required. 
Azathioprine is a potent immunosuppressive agent that has been used as a steroid-
sparing agent. The usual doses are 75-150 mg (2-3 mg/kg/d) combined with 40-80 
mg of prednisone. After initial control of the disease is obtained, tapering to 
maintenance doses of azathioprine is recommended. Patients who are thiopurine 
methyltransferase activity deficient (11% of the population) are at an increased risk 
of bone marrow toxicity with this agent. 
Other useful drugs include the following: tetracycline and niacinamide, 
cyclophosphamide, methotrexate, hydroxychloroquine, plasmapheresis, 
mycophenolate mofetil, extracorporeal photochemotherapy. 
Diet.Patients on long-term glucocorticoids should increase their intake of calcium 
and vitamin D as well as bisphosphates in an effort to prevent osteoporosis.  
Activity.Patients should use appropriate sun-smart behaviors and protective 
clothing to minimize sun exposure that may exacerbate disease activity. Sun 
avoidance and sun protection are recommended. 
Prognosis.The prognosis of pemphigus erythematosus is better than that of 
pemphigus vulgaris. With good dermatologic care, patients with pemphigus 
erythematosus are often able to live normal lives. 
 
 
10.3. Dermatitis Herpetiformis 
 
Background.Dermatitis herpetiformis (DH) is an immune-mediated blistering skin 
disease with an associated, most often asymptomatic, gluten-sensitive enteropathy 
(GSE). Characteristic skin lesions found in patients with DH are extremely itchy 
grouped vesicles most frequently located on extensor surfaces. Skin lesions of DH 
can be treated with dapsone, with relief of symptoms within 24-48 hours of the 
start of therapy. Alternatively, many patients can control the skin disease with a 
gluten-free diet, often without medication. Both the skin and gastrointestinal 
systems are affected.  
History.In 1884, Louis Duhring described DH as a skin disorder accompanied by 
severe itching and burning and characterized by herpetiform inflammatory papules 
and vesicles. The initial description also included patients with other blistering 
disease including pemphigoid. The presence of immunoglobulin A (IgA) deposits 
in the skin of patients with DH confirms the unique nature of the eruption. DH is 
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associated with GSE, and the skin disease can be controlled by strict adherence to a 
gluten-free diet.  
Patients with DH and associated GSE have a granular pattern of IgA deposits, 
while those with a similar clinical eruption and linear IgA deposits do not have 
associated GSE, which confirms that patients with DH have characteristic clinical 
presentation, granular IgA deposits in the skin, and associated GSE.  
Causes.The pathogenesis of DH is associated with the presence of GSE; an 
increased expression of human leukocyte A1 (HLA-A1), human leukocyte antigen 
B8 (HLA-B8), human leukocyte antigen DR3 (HLA-DR3), and human leukocyte 
antigen DQ2 (HLA-DQ2) haplotypes; and granular deposition of IgA at the 
dermal-epidermal junction of the skin.  
Gluten sensitivity. Patients with DH uniformly have associated GSE. GSE in 
patients with DH most often is asymptomatic. Fewer than 10% of patients have 
bloating, diarrhea, or symptomatic malabsorption.  
Mild steatorrhea or other signs of mild malabsorption, such as altered D-xylose 
absorption or iron or folate deficiency, can be demonstrated in 20-30% of patients 
with DH. Patients with DH and no apparent gastrointestinal disease can be induced 
by increased gluten intake, which often is termed latent GSE (celiac disease). 
Gluten is a protein present in barley, rye, and wheat but not in rice. Oats generally 
are well tolerated in moderate amounts. Strict compliance with a gluten-free diet 
results in normalization of the small bowel mucosal changes and control of the 
cutaneous manifestations of DH in most patients. 
The critical role of associated GSE in the pathogenesis of DH is confirmed by the 
fact that resumption of a gluten-containing diet in patients with DH results in the 
return of characteristic skin disease. 
Immunoglobulin A.IgA deposits are found in a granular pattern at the dermal-
epidermal junction in patients with DH. These deposits are present throughout the 
skin. IgA deposits in the skin contain both kappa and lambda light chains, 
indicating that they are polyclonal. Secretory component has not been 
demonstrated in the skin of patients with DH. The IgA-associated protein J chain 
has been found by some workers in cutaneous IgA, suggesting a mucosal origin, 
although this finding has not been documented by other laboratories. Deposits of 
the third component of complement, C3, also may be present in a similar pattern at 
the dermal-epidermal junction. The membrane attack complex, C5-C9, also has 
been identified in perilesional skin, although it may be inactive and not contribute 
to cell lysis. The mechanism whereby IgA binds to the skin of patients with DH is 
unknown. IgA deposits in DH skin have been shown to function in vitro as a ligand 
for neutrophil migration and binding in skin. Neutrophil accumulation in the skin 
of patients with DH is the characteristic histologic finding. Collagenase and 
stromelysin 1 may be induced in basal keratinocytes by cytokines released from 
neutrophils or by contact with keratin from damaged basement membrane matrix. 
Stromelysin 1 may contribute to blister formation. IgA deposits disappear after 
long-term avoidance of dietary gluten, which suggests that IgA plays a critical role 
in the development of skin lesions in patients with DH. Patients with bullous 
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pemphigoid, cicatricial pemphigoid, Henoch-Schönlein purpura, and alcoholic 
liver disease also may have IgA deposits in normal skin; however, the pattern of 
IgA deposits is different than that seen in patients with DH.  
IgA-circulating immune complexes are present in 25-35% of patients with DH, 
although no association with disease severity has been noted. These immune 
complexes also have been noted in patients with isolated GSE and have been 
believed to be related to the presence of the gut disease. IgA antibodies to gliadin 
(a portion of wheat protein), reticulum, and smooth muscle endomysium also have 
been noted in patients with DH and those with isolated GSE. IgA endomysial 
antibodies are most specific for gluten sensitivity and are found in patients with 
DH and those with isolated GSE. The presence of IgA antiendomysial antibodies 
correlates with the extent of the gut disease, and some patients with DH do not 
have detectable IgA antiendomysial antibodies even in the presence of active skin 
disease. The criterion standard for the diagnosis of DH remains the presence of 
granular deposits of IgA in normal-appearing perilesional skin. 
Human leukocyte antigens. A genetic predisposition for DH has been established 
conclusively by HLA studies. Patients with DH have an increased expression of 
the HLA-A1, HLA-B8, HLA-DR3, and HLA-DQ2 haplotypes (see Table 10.1). 
This is identical to the HLA association found in patients with isolated GSE. Most 
persons with these HLA types do not have DH or GSE. The mechanism(s) by 
which HLA association results in the development of disease is unknown. In the 
presence of additional factors (including exposure to gluten), it is hypothesized that 
patients with genetic predisposition, as determined by HLA status, may develop a 
cell-mediated immune response resulting in T-cell activation, elaboration of 
cytokines, and tissue damage in the small bowel mucosa. The mechanism whereby 
this gut mucosal injury results in skin disease in patients with DH and not in those 
with isolated GSE is unknown.  
 
Table 10.1 Associations of Human Leukocyte Antigen and Dermatitis 
Herpetiformis  
HLA DH (%) Control Population (%) 
B8 58-87 20-30 
DR3 90-95 23 
DQ2 95-100 40 
Other associations.Associations of DH include gastrointestinal and autoimmune 
diseases (see Table 10.2). Celiac disease (gluten sensitivity in absence of DH) 
usually involves more severe and widespread intestinal involvement. An increased 
risk is seen of gastrointestinal lymphomas and non-Hodgkin lymphoma. Thyroid 
abnormalities include hypothyroidism, hyperthyroidism, thyroid nodules, and 
thyroid cancer. Gluten-free diet may reduce incidence of DH-associated 
lymphomas. Gastric manipulation (surgery) may induce DH. Several chemicals 
have been associated with induction of DH, including potassium iodide and 
cleaning solutions.  
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Table 10.2 Diseases Associated with Dermatitis Herpetiformis 
 
Autoimmune Gastrointestinal Neoplastic 
Dermatomyositis  Gluten enteropathy  Gastrointestinal 
lymphoma  
Insulin-dependent diabetes 
mellitus  
Gastric atrophy  Non-Hodgkin lymphoma  
Myasthenia gravis  Gastric 
hypochlorhydria  
- 
Rheumatoid arthritis  Pernicious anemia  - 
Sjögren syndrome  -  -  
Systemic lupus erythematosus  -  -  
Thyroid abnormalities  -  -  
 
Physical.Flesh-colored–to–erythematous vesicles appear in a herpetiform pattern, 
symmetrically distributed over extensor surfaces including elbows, knees, 
buttocks, shoulders, and the posterior (nuchal) scalp. 
Erythematous papules and urticaria-like plaques occur less frequently; bullae are 
rare.Patients often present with erosions and crusts in the absence of vesicles. 
Typical symptoms include burning, stinging, and intense pruritus. Patients often 
note stinging or burning of the skin before the appearance of new lesions.Rarely, if 
ever, are patients totally asymptomatic, although the degree of itching experienced 
by patients varies.Oral mucosa lesions occur infrequently in patients with DH. 
Palms and soles usually are spared. DH is a lifelong disease, although periods of 
exacerbation and remission frequently are seen. 
Complications.Complications relate to the gluten-sensitive enteropathy, incidence 
of lymphoma, and potential adverse effects of medications (dapsone). 
Procedures.Light microscopy features are not diagnostic of DH, and direct 
immunofluorescence is required to confirm the diagnosis.Biopsies for direct 
immunofluorescence should be performed on perilesional (normal-appearing) skin, 
since neutrophils may degrade the IgA in active lesions. 
Histologic Findings.Biopsy specimens of lesional skin reveal neutrophils in the 
dermal papillae with fibrin deposition, neutrophil fragments, and edema. 
Eosinophils may be present. Papillary microabscesses form and progress to 
subepidermal vacuolization and vesicle formation. Vesicles form in the lamina 
lucida, the weakest portion of the dermal-epidermal junction.  
Histologic differential diagnosis of early skin lesions includes bullous lupus 
erythematosus, bullous pemphigoid, epidermolysis bullosa acquisita, and linear 
IgA disease. Histologic differential diagnosis of late skin lesions includes bullous 
drug eruption, bullous pemphigoid, erythema multiforme, and herpes gestationis.  
Granular IgA deposits in dermal papillae of perilesional skin observed by direct 
immunofluorescence is the criterion standard of diagnosis. 
Medical Care.Dapsone (diaminodiphenyl sulfone) and sulfapyridine are the 
primary medications used to treat DH. For many years, rapid improvement on 
dapsone was a chief diagnostic criterion of the disease; however, many diseases 
respond to dapsone, and this should not be used as a diagnostic criterion. Dapsone 
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often is used initially; sulfapyridine is substituted in patients unable to tolerate 
dapsone. The mechanism for therapeutic effect of dapsone in DH is unclear. 
Improvement may be dramatic; symptomatic improvement of skin lesions often 
begins within hours. No new lesions form for up to 2 days after a dose of dapsone; 
however, dapsone does not improve gastrointestinal mucosal pathology. 
Other, less effective, treatments for DH include colchicine, cyclosporine, and 
prednisone. Cyclosporine should be used with caution in patients with DH because 
of a potential increase in intestinal lymphoma. 
NSAIDs may exacerbate DH; however, ibuprofen appears to be safe. Iodides may 
elicit or exacerbate DH. 
Consultations.Consider consultation with a gastroenterologist for evaluation and 
recommendation regarding GSE.Consult with a dietitian regarding patients who 
are modifying dietary intake to avoid gluten or institute an elemental diet. 
Diet. Most patients (as many as 80%) respond to gluten-free diet with control of 
their skin disease. Some patients are able to discontinue the use of dapsone totally. 
Compliance with a gluten-free diet requires a motivated patient, and the best 
treatment response occurs with absolute gluten restriction in the diet.Strict dietary 
vigilance may be required for 5-12 months before the dapsone dose can be 
reduced.Gluten-free diet is the only sustainable method of eliminating the disease, 
not only from the skin, but also from the gastrointestinal mucosa.Patients on a 
gluten-reduced diet may experience decrease of symptoms; therefore, diet reduces 
the dosage of dapsone required for disease control.Neither IgA deposition nor 
circulating antibodies correlate with gluten intake in short duration studies; 
however, some studies have suggested a correlation exists with complement 
deposition. Avoidance of dietary gluten for 10 years or more has resulted in loss of 
cutaneous IgA deposits that return upon reinstitution of gluten in the 
diet.Elemental diets may improve the disease within weeks. These diets consist of 
free amino acids, small amounts of triglycerides, and short chain polysaccharides; 
they are marketed by pharmaceutical companies. One report has suggested that this 
improvement may be independent of gluten ingestion; however, this finding has 
not been confirmed. 
Prognosis. DH is an ongoing disease process with variability of severity.Prognosis 
is good for patients who can tolerate dapsone and the few that maintain a gluten-
free diet (in whom the incidence of associated lymphoma may be less). 
 
 
10.4. Bullous Pemphigoid 
 
Background.Bullous pemphigoid (BP) is a chronic, autoimmune, subepidermal, 
blistering skin disease that rarely involves mucous membranes. BP is characterized 
by the presence of immunoglobulin G (IgG) autoantibodies specific for the 
hemidesmosomal BP antigens BP230 (BPAg1) and BP180 (BPAg2).  
Pathophysiology.IgG autoantibodies bind to the skin basement membrane in 
patients with BP. The binding of antibodies at the basement membrane activates 
complement and inflammatory mediators. Activation of the complement system is 
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thought to play a critical role in attracting inflammatory cells to the basement 
membrane. These inflammatory cells are postulated to release proteases, which 
degrade hemidesmosomal proteins and lead to blister formation. Eosinophils are 
characteristically present in human patients' blisters as demonstrated by 
histopathologic analysis, although their presence is not an absolute diagnostic 
criterion.  
The precise role of BP antigens in the pathogenesis of BP is not clear. BPAg1 
(BP230) is an intracellular component of the hemidesmosome; BPAg2 (BP180, 
type XVII collagen) is a transmembranous protein with a collagenous extracellular 
domain. Passive transfer experiments in newborn mice have demonstrated that 
rabbit antibodies against mouse BPAg2 can induce subepidermal blisters similar to 
those observed in patients with BP. Furthermore, anti-BP180 NC16A domain 
autoantibodies purified from patients with BP are capable of inducing dermal-
epidermal separation in cryosections of normal human skin.  
Serum levels of autoantibodies against BPAg2 are reportedly correlated with 
disease activity in some studies. Induction of antibodies against BPAg1 in rabbits 
does not induce primary blistering, but it can enhance the inflammatory response at 
the basement membrane. The role of autoantibodies specific for BP antigens in the 
initiation and the perpetuation of disease is unknown.  
Currently, no active experimental model is available to dissect the induction phase 
of the disease. Nevertheless, the autoantibody response can be induced in healthy 
BALB/c mice by immunizing the mice with synthetic peptides of the mouse type 
XVII collagen NC16A domain, the target region of autoantibodies in human 
patients affected with BP.  
Eotaxin, an eosinophil-selective chemokine, is strongly expressed in the basal layer 
of the epidermis of lesional BP skin and parallels the accumulation of eosinophils 
in the skin basement membrane zone area. It may play a role in the recruitment of 
eosinophils to the skin basement membrane area.  
Causes.The cause of BP is not known; however, several potentially relevant 
factors have been identified.  
Immunogenetics. Immunogenetic analyses have identified that the human 
leukocyte antigen (HLA) haplotype, DQB1*0301, is increased in patients with BP. 
In one study, peripheral blood lymphocytes from patients with BP who are positive 
for HLA-DQB1*0301 proliferated in the presence of the BP180 antigen. In these 
studies, the ability of the patient's T cells to respond to the target BP antigen was 
restricted by the HLA haplotype. This HLA haplotype is postulated to be important 
in the presentation of the target antigen by antigen-presenting cells in the initial 
development of the autoimmune response. 
Age. BP is most common in patients in their fifth to seventh decades of life. 
Investigators have postulated that intrinsic changes in the immune system with 
aging may be a factor in the initiation of an autoimmune response against BP 
antigens.Alternately, repeated trauma to the skin may lead to the development of 
an immune response against normal skin proteins. 
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Epitope spreading. The autoimmune reaction may extend by an immunologic 
phenomenon termed epitope spreading, whereby a relatively restricted immune 
response spreads to involve different sites on the same autoantigen and to involve 
different autoantigens.This phenomenon has been well documented in animal 
models of autoimmune diseases. Epitope spreading may explain the presence of an 
immune response against 2 target antigens (BPAg1 and BPAg2) as well as 
multiple epitopes on the target antigens. 
Complement activation. BP autoantibodies bind to the hemidesmosome/upper 
lamina lucida areas of the skin basement membrane. Complement activation 
follows this binding as detected by direct immunofluorescence (DIF) studies that 
demonstrate in situ deposition of complement components (typically C3) at the 
basement membrane in patients with BP.Complement activation leads to the 
recruitment of inflammatory cells to the basement membrane zone. The enzymes 
released by these inflammatory cells cleave BPAg2 in vitro and are postulated to 
be important in blister formation. 
Chemokines. The histologic hallmark for BP is the prominent eosinophil 
infiltration at the skin basement membrane area. Eosinophil migration and 
activation is likely induced by chemokines.The expression of eotaxin, a chemokine 
associated with eosinophil migration, is increased in the epidermis of BP lesions. 
Similarly, eotaxin expression is increased on endothelial cells in biopsy samples 
obtained from the skin of patients with BP. This increased epidermal and 
endothelial expression of eotaxin may be important in the recruitment of 
eosinophils to the basement membrane in patients with BP.At the skin basement 
membrane, eosinophils can release proteolytic enzyme 92-kD gelatinase, which 
cleaves BPAg2 in vitro.Interleukin 5, an interleukin with eosinophil 
chemoattractant and activation properties, has also been found in the skin of 
patients with BP. It may play a role in eosinophil recruitment to the skin. 
Frequency.BP is uncommon, and its frequency is unknown. Internationally:BP 
has been reported to occur throughout the world. In France and Germany, the 
reported incidence is 6.6 cases per million people per year. In Europe, BP was 
identified as the most common subepidermal autoimmune blistering disease.  
Mortality/Morbidity.BP is a chronic inflammatory disease. If untreated, the 
disease can persist for months or years, with periods of spontaneous remissions 
and exacerbations. In most patients who are treated, BP remits within 1.5-5 years. 
Patients with aggressive or widespread disease, those requiring high doses of 
corticosteroids and immunosuppressive agents, and those with underlying medical 
problems have increased morbidity and risk of death. Because the average age at 
onset of BP is about 65 years, patients with BP frequently have other comorbid 
conditions that are common in elderly persons, thus making them more vulnerable 
to the adverse effects of corticosteroids and immunosuppressive agents.  
BP may be fatal, particularly in patients who are debilitated. The proximal causes 
of death are infection with sepsis and adverse events associated with treatment. 
Patients receiving high-dose corticosteroids and immunosuppressants are at risk 
for peptic ulcer disease, GI bleeds, agranulocytosis, and diabetes.  
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BP involves the mucosa in 10-25% of patients. Patients who are affected may have 
limited oral intake secondary to dysphagia. Erosions secondary to rupture of the 
blisters may be painful and may limit patients' daily living activities. Blistering on 
the palms and the soles can severely interfere with patients' daily functions. BP 
lesions typically heal without scarring or milia formation.  
Age. BP primarily affects elderly individuals in the fifth through seventh decades 
of life, with an average age at onset of 65 years. BP of childhood onset has been 
reported in the literature.  
History.The onset of BP may be either subacute or acute, with widespread, tense 
blisters. Significant pruritus is frequently present. In some patients, the blisters 
arise after persistent urticarial lesions. BP has been reported following several non-
bullous, chronic, inflammatory skin diseases, such as lichen planus and 
psoriasis.BP has been reported to be precipitated by ultraviolet irradiation, x-ray 
therapy, and exposure to some drugs.Drugs associated with BP include 
furosemide, ibuprofen and other non-steroidal anti-inflammatory agents, captopril, 
penicillamine, and antibiotics.BP has been reported to develop shortly after 
vaccination, particularly in children. 
Physical.BP may present with several distinct clinical presentations, as follows: 
generalized bullous, vesicular, vegetative, generalized erythroderma, urticarial, and 
nodular variants.  
Generalized bullous form. The generalized bullous form is the most common 
presentation.Tense bullae arise on any part of the skin surface, with a predilection 
on the flexural areas of the skin. Oral and ocular mucosa involvement rarely occurs 
and, when seen, is of minor clinical significance.The bullae can occur on normal-
appearing, as well as erythematous, skin surfaces.The bullae usually heal without 
scarring or milia formation. 
Vesicular form. The vesicular form is less common.It manifests as groups of 
small, tense blisters, often on a urticarial or erythematous base. 
Vegetative form. The vegetative form is very uncommon, with vegetating plaques 
in intertriginous areas of the skin, such as the axillae, the neck, the groin, and 
inframammary areas.This form of BP closely resembles pemphigus vegetans. 
Generalized erythroderma form. This rare presentation can resemble psoriasis, 
generalized atopic dermatitis, or other skin conditions characterized by an 
exfoliative erythroderma.Patients with this variant may develop vesicles or bullae. 
Urticarial form. Some patients with BP initially present with persistent urticarial 
lesions that subsequently convert to bullous eruptions.In some patients, urticarial 
lesions are the sole manifestations of the disease. 
Nodular form. This rare form, termed pemphigoid nodularis, has clinical features 
that resemble prurigo nodularis, with blisters arising on normal-appearing or 
nodular lesional skin. 
Acral form. In childhood-onset BP associated with vaccination, the bullous lesions 
predominantly affect the palms, the soles, and the face. 
Complications. Secondary infection may occur because of the presence of 
multiple erosions and immunosuppressants used to control the disease. These 
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infections may be either systemic or localized to the skin. Cutaneous infection 
increases the risk of scarring and delays wound healing.Malignancies due to 
immunosuppressants have been reported. Case-control series in patients with BP 
have failed to detect an increased incidence of malignancy in patients with BP 
when compared with age- and sex-matched controls. Bone marrow suppression 
may occur in patients receiving immunosuppressants.Growth retardation may 
occur in children receiving systemic corticosteroids and immunosuppressants. 
Adrenal insufficiency may occur following prolonged use of glucocorticoids. 
Osteoporosis and bone fractures may result following the use of systemic 
corticosteroids. 
Lab Studies. To establish a diagnosis of PB, the following tests should be 
performed: histopathologic analysis from the edge of a blister and DIF studies on 
normal-appearing perilesional skin. If the DIF result is positive, indirect 
immunofluorescence (IDIF) is performed using the patient's serum. The preferred 
substrate for IDIF is salt-split normal human skin substrate. 
Direct immunofluorescence studies. DIF studies demonstrate in vivo deposits of 
antibodies and other immunoreactants, such as complement. DIF tests usually 
demonstrate IgG (70-90% of patients) and complement C3 deposition (90-100% of 
patients) in a linear band at the dermal-epidermal junction. This pattern of 
immunoreactants is not specific for BP and may be seen in cicatricial pemphigoid 
and epidermolysis bullosa acquisita. BP can be differentiated from these conditions 
by incubating the patient's skin biopsy sample in 1 mol/L salt prior to performing 
the DIF technique. This process induces cleavage through the lamina lucida. DIF 
on salt-split skin reveals IgG on the blister roof (epidermal side of split skin) in 
patients with BP, while, in CP and EBA, the IgG localizes to the blister floor 
(dermal side of split skin).The optimal location for DIF testing is normal-appearing 
perilesional skin. False-positive results can be observed when it is performed on 
lesional skin. Rarely, skin biopsy samples placed in transport media may yield 
false-negative results. This observation makes the use of fresh tissue the preferred 
substrate for DIF studies. 
Indirect immunofluorescence. IDIF studies document the presence of IgG 
circulating autoantibodies in the patient's serum that target the skin basement 
membrane component. Seventy percent of patients with BP have circulating 
autoantibodies that bind to split skin. The titer of circulating antibody is not 
correlated with the disease course.IDIF studies can be used to detect the patient's 
IgG circulating autoantibodies that bind to the epidermal roof (upper part) of the 
salt-split skin substrate. 
Other Tests.Experimental procedures available in research laboratories include 
direct and indirect immunoelectron microscopy, immunoblotting, 
immunoprecipitation, and enzyme-linked immunosorbent assay (ELISA). 
Direct and indirect immunoelectron microscopy. Direct and indirect 
immunoelectron microscopy (immunoEM) ultrastructurally localize in vivo–bound 
IgG autoantibodies (direct immunoEM) or the binding site of circulating IgG 
autoantibodies (indirect immunoEM) at the basement membrane.IgG 
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autoantibodies are detected at the hemidesmosome/upper lamina lucida areas of the 
skin basement membrane. 
Immunoblotting. Immunoblotting or Western blotting demonstrates reactivity of 
IgG in the sera of patients with proteins extracted from healthy human skin.The 
sensitivity of immunoblotting varies. In 75% of patients, a reaction occurs with the 
BP230 antigen, while, in 50% of patients, a reaction occurs with the BP180 
antigen. 
Immunoprecipitation. Like immunoblotting, immunoprecipitation demonstrates 
reactivity with BP230 and BP180. Unlike immunoblotting, immunoprecipitation is 
performed with native, rather than denatured, protein and is more sensitive. 
Immunoprecipitation is more difficult to perform and generally less available than 
immunoblotting.In most cases, immunoprecipitation detects autoantibodies 
specific for BP230 and BP180. 
Enzyme-linked immunosorbent assay. The ELISA technique analyzes the BP 
antigen-specific IgG autoantibodies in the patients' sera by using various lengths of 
recombinant proteins of the BPAg1 or BPAg2 antigens. In several reports, ELISA 
has been demonstrated to be highly sensitive and specific, but it remains 
experimental at the present time.ELISAs based on recombinant proteins encoded 
by BP230 and BP180 have been developed. These assays are not commercially 
available, but they offer promise as investigational tools. An ELISA based on 
BP180 demonstrates sera reactivity with more than 90% of patients with BP. 
Histologic Findings.The histopathologic examination demonstrates a 
subepidermal blister. The inflammatory infiltrate is typically polymorphous, with 
an eosinophil predominance. Mast cells and basophils may be prominent early in 
the disease course. Lesional skin biopsy specimens may reveal a predominantly 
neutrophilic infiltrate or minimal inflammation. 
Medical Care. As in other autoimmune bullous diseases, the goal of therapy is to 
decrease blister formation, to promote healing of blisters and erosions, and to 
determine the minimal dose of medication necessary to control the disease process. 
Therapy must be individualized for each patient, keeping in mind preexisting 
conditions and other patient-specific factors. 
Treatment is directed at reducing the inflammatory response and autoantibody 
production. Although target-specific therapy is the "Holy Grail" for 
immunodermatologists, non–target-specific treatments are currently used. The 
most commonly used medications are anti-inflammatory agents (e.g. 
corticosteroids, tetracyclines, dapsone) and immunosuppressants (e.g. azathioprine, 
methotrexate, mycophenolate mofetil, cyclophosphamide). A recent article from 
Europe provided evidence that strong topical corticosteroid treatment may achieve 
disease control while avoiding systemic adverse effects from systemic 
corticosteroids. 
Consultations.Treatment of patients with BP requires coordination of care 
between the dermatologist and the patient's primary care provider. Patients with 
oral disease may require an otolaryngologist and/or a dentist for evaluation and 
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care.An ophthalmologist should evaluate patients with suspected ocular 
involvement and those requiring prolonged high-dose steroids. 
Diet. The lesions may flare in patients with oral disease after eating hard and 
crunchy foods, such as chips, raw fruits, and vegetables.For patients treated with 
systemic corticosteroid for longer than 1 month, a combined supplement of 
calcium and vitamin D should be instituted to prevent osteoporosis.  
Prognosis. Most patients affected with BP require therapy for 6-60 months, after 
which many patients experience long-term remission of the disease. However, 
some patients have long-standing disease requiring treatment for years.Most 
mortality associated with BP occurs secondary to the effects of the 
medications.The population at risk for BP is at an increased risk for comorbid 
conditions, such as hypertension, diabetes mellitus, and heart diseases, which 
treatment may exacerbate. 
Patient Education. Patients should avoid trauma to the skin. Patients' skin is 
fragile from the disease, as well as from the use of topical and systemic 
steroids.Patients should be educated about their disease and treatments, so that they 
can report adverse effects to their physicians. 
Special Concerns. Elderly patients with BP who have other significant health 
problems, such as diabetes mellitus, hypertension, or heart disease, may require 
treatment with a more conservative approach, using topical corticosteroids 
(clobetasol), tetracyclines, and/or low doses of systemic corticosteroids 
(prednisone 10-20 mg/d). In all patients, the goal of treatment is to achieve disease 
control with minimal symptoms and adverse effects from treatment. 
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XI. MYCOBACTERIAL INFECTIONS 
 
11.1. Leprosy 
 
Synonyms and related keywords: Hansen’s disease, Hansen disease, indeterminate leprosy, 
tuberculoid leprosy, borderline tuberculoid leprosy, borderline borderline leprosy, borderline 
lepromatous leprosy, lepromatous leprosy 
 
Background.Leprosy is a chronic granulomatous disease, caused by 
Mycobacterium leprae, which affects principally the skin and peripheral nervous 
system.  
The earliest description of leprosy comes from India around 600 BC. It was then 
described in the Far East around 400 BC. In the fourth century, the disease was 
imported into Europe, where it peaked in incidence in the 13th century. The 
disease has now nearly disappeared from Europe. Affected immigrants spread 
leprosy to North America.  
Leprosy, also known as Hansen's disease, is a chronic infectious disease that 
primarily affects the skin, the peripheral nerves, the upper respiratory tract, and the 
eyes. The causative agent is an acid-fast bacterium, Mycobacterium leprae, first 
identified in 1873 by the Norwegian physician, Gerhard Henrik Armauer Hansen. 
Leprosy was considered a divine curse for sin in the Old Testament and karma in 
Buddhism. The term leprosy originates from the Latin word lepros, meaning 
defilement. The fact that leprosy has been deemed an incurable disease, causing 
severe deformities and disabilities, has resulted in severe stigmatization. This has 
resulted in double suffering by victims, both from the disease itself and from 
public discrimination. Although documented since antiquity, leprosy currently 
remains endemic in some developing parts of the world. 
Armauer Hansen discovered M. leprae in Norway in 1873. It was the first bacillus 
to be associated with human disease. Despite this discovery, leprosy was not 
initially thought to be an infectious disease.  
Animal reservoirs of leprosy have been found in 3 species: 9-banded armadillos, 
chimpanzees, and mangabey monkeys.  
Pathophysiology.The areas most commonly affected by leprosy are the superficial 
peripheral nerves, skin, mucous membranes of the upper respiratory tract, anterior 
chamber of the eyes, and testes. These areas tend to be cooler parts of the body. 
Tissue damage is caused by the degree to which cell-mediated immunity is 
expressed, the extent of bacillary spread and multiplication, the appearance of 
tissue-damaging immunologic complications (i.e. lepra reactions), and the 
development of nerve damage and its sequelae. M. leprae is an obligate 
intracellular acid-fast bacillus with a unique ability to enter nerves.  
Causes.Leprosy is caused by M. leprae, an acid-fast bacillus. Only the 
lepromatous form is thought to be infectious.Exposure to the nasal discharge of 
those that remain untreated for years is thought to be the main cause of 
infection.Most persons are immune to leprosy. Subclinical disease is common in 
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endemic areas, and the infection progresses to clinical disease in only a select 
few.Transmission is not completely understood. In addition to exposure respiratory 
secretions, exposure to insect vectors and infected soil has been suspected as a 
possible mode of transmission. Household contacts of patients are at little risk of 
acquiring the disease. 
Frequency.The worldwide prevalence of leprosy is reported to be 5.5 million 
cases. The majority of affected persons live in the tropics and subtropics. 
Worldwide, 80% of the cases are found in 5 countries: India, Myanmar, Indonesia, 
Brazil, and Nigeria.  
Mortality/Morbidity.If severe and left untreated, leprosy can cause significant 
debilitating deformity. Since 1943, when sulfone was introduced as the first 
effective treatment for leprosy, antibiotic treatment has dramatically improved 
patients' outcomes. Early diagnosis and effective antimicrobial treatment can arrest 
and even cure the disease.  
Race.Leprosy occurs in all races. African blacks report a higher incidence of the 
tuberculoid form of leprosy. People with light skin and Chinese individuals have a 
greater tendency to have the lepromatous type of leprosy. Leprosy is endemic in 
Asia, Africa, the Pacific basin, and Latin America (excluding Chile). It is more a 
rural disease than urban disease.  
Sex.In adults, the lepromatous type of leprosy is more common in men than 
women, with a male-to-female ratio of 2:1. In children, the tuberculoid form 
predominates, and no sex preference exists.  
Age.Leprosy has a bimodal age distribution, with peaks in those aged 10-14 and in 
those aged 35-44 years. The disease is rare in infants. Children appear to be more 
susceptible to disease and tend to have the tuberculoid form.  
The incubation period ranges from 6 months to 40 years or longer. The average 
incubation period is 2-3 years.  
History.Several forms of leprosy range from the mildest indeterminate form to the 
most severe lepromatous type. Symptoms and physical findings vary depending on 
the stage of disease.  
The disease is usually diagnosed on the basis of the following characteristic 
findings: anesthesia of a skin lesion or in the distribution of a peripheral nerve, 
thickened nerves, and typical skin lesions.  
Prodromal symptoms are generally so slight that the disease is not recognized until 
a cutaneous eruption is present. Actually, 90% of patient present with numbness 
first, sometimes years before the skin lesions appear.  
Temperature is the first sensation that is lost. Patients cannot sense extremes of hot 
or cold. The next sensation lost is light touch, then pain, and finally deep pressure. 
These losses are especially apparent in the hands and feet. A hypopigmented 
macule is often the first cutaneous lesion. From this stage, most lesions evolve into 
the lepromatous, tuberculoid or borderline types.  
Physical.Indeterminate leprosy (IL). This early form causes one to a few 
hypopigmented, or sometimes erythematous, macules. Sensory loss is 
unusual.Most cases evolve from this state into one of the other forms, depending 
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on the patient's immunity to the disease. Those with strong immunity may become 
cured of disease. In some, the disease may persist in this indeterminate form. In 
those with weaker immunity, the disease progresses to one of the other forms. 
Tuberculoid leprosy (TT). Skin lesions are few in number. Usually, one 
erythematous large plaque is present, with well-defined borders that are elevated 
and slope down into an atrophic center. The lesions can become arciform or 
annular, and they can be found on the face, limbs or elsewhere, but spare 
intertriginous areas and the scalp.Another presentation involves a large asymmetric 
hypopigmented macule.Both types of lesions are anesthetic and involve alopecia. 
Spontaneous resolution can occur in a few years, leaving pigmentary disturbances 
or scars. Progression can also occur, leading to borderline-type leprosy. In rare 
instances in which a patient is untreated for many years, the lepromatous type can 
develop.Neural involvement is common in TT; it leads to tender, thickened nerves 
with subsequent loss of function. The great auricular nerve and superficial peroneal 
nerves are often prominent. 
Borderline tuberculoid leprosy (BT). Lesions in this form are similar to those in 
the tuberculoid form, but they are smaller and more numerous. The nerves are less 
enlarged, and less alopecia is present.Disease can remain in this stage, convert 
back to the tuberculoid form, or progress. 
Borderline borderline leprosy (BB). Cutaneous lesions consist of numerous, red, 
irregularly shaped plaques that are less well defined than those in the tuberculoid 
type. Their distribution may mimic those of the lepromatous type, but they are 
more asymmetric. Anesthesia is only moderate. Regional adenopathy may be 
present. Disease may remain in this stage, improve or worsen. 
Borderline lepromatous leprosy (BL). Lesions are numerous and consist of 
macules, papules, plaques, and nodules. Annular punched-out-appearing lesions 
that look like inverted saucers are common. Anesthesia is often absent. As with the 
other forms of borderline leprosy, the disease may remain in this stage, improve, or 
regress. 
Lepromatous leprosy (LL). Early cutaneous lesions consist mainly of pale 
macules. Later, infiltrations are present, with numerous bacilli. Macular lesions are 
small, diffuse, and symmetric. The skin texture does not change, and little or no 
loss of sensation occurs. The nerves are not thickened, and sweating is normal. The 
lateral eyebrows are affected by alopecia (i.e. madarosis), which spreads to the 
eyelashes and then the trunk. Scalp hair remains intact. Lepromatous infiltrations 
can be diffuse, nodules (called lepromas), or plaques. The diffuse type results in 
the appearance of a leonine facies. Neuritic lesions are symmetric and slow to 
develop. Eye involvement occurs, causing pain, photophobia, decreased visual 
acuity, glaucoma, and blindness. Testicular atrophy results in sterility and 
gynecomastia. Lymphadenopathy and hepatomegaly can result from organ 
infiltration. Stridor and hoarseness are a result of laryngeal involvement. Nasal 
infiltration can cause a saddle-nose deformity. Aseptic necrosis and osteomyelitis 
can occur with repeated trauma after joint invasion. Brawny edema of the lower 
extremities is a late finding.  
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Complications.Reactional states are the most common complications. These states 
can result in permanent neurologic sequelae, resulting in disability and 
deformity.Lepra type I reactions usually affect patients with borderline disease. A 
downgrading reaction represents a shift toward the lepromatous pole before the 
initiation of therapy. Reversal reactions are shifts toward the tuberculoid pole after 
the initiation of therapy.Lepra type II reactions, or ENL, is an immune complex–
mediated reaction that occurs in patients with the BL or LL forms. The most 
common presenting symptoms are crops of painful erythematous nodules of the 
skin and subcutaneous tissue. The reaction usually manifests after a few years of 
therapy and resolves spontaneously after about 5 years. Associated fever, malaise, 
joint pain, nerve pain, iridocyclitis, dactylitis, and orchitis may be present.A Lucio 
phenomenon is an unusual type II reaction that is sometimes designated a type II 
reaction. It common in Mexico and Central America and is characterized by 
cutaneous hemorrhagic infarcts in patients with diffuse LL. Injuries can result in 
ulcerations, cellulitis, scarring, and bony destruction. Contractures can develop and 
result in fixation. Eye damage can result in lagophthalmos, ectropion, and 
entropion. 
Lab Studies.Tissue smear testing. An incision is made in the skin, and the scalpel 
blade is used to obtain fluid from a lesion. The fluid is placed on a glass slide and 
stained by using the Ziehl-Neelson acid-fast method to look for organisms.The 
bacterial index (BI) is then determined. 
Histamine testing. This test is used to diagnose postganglionic nerve 
injury.Histamine diphosphate is dropped on normal skin and affected skin, and a 
pinprick is made through each site. The site forms wheal on normal skin but not 
where nerve damage exists. 
Methacholine sweat testing. This demonstrates the absence of sweating in leprous 
lesions.It is useful in dark-skinned patients in whom the flare with the histamine 
test cannot be seen. 
Skin biopsy. The skin biopsy sample should be examined for morphologic features 
and the presence of acid-fast bacilli.Biopsy is useful for determining the 
morphologic index (MI), which is used in the evaluation and treatment of patients. 
It is the number of viable bacilli per 100 bacilli in the leprous tissue. 
Sensory testing. Tactile and temperature sensations should be tested.A wisp of 
cotton can be used to test for anesthesia of the lesions. 
Lepromin testing. This test indicates host resistance to M. leprae. It results do not 
confirm the diagnosis, but they are useful in determining the type of leprosy. A 
positive finding indicates cell-mediated immunity, which is observed in TT. A 
negative finding suggests a lack of resistance to disease and is observed in LL. A 
negative result indicates a poorer prognosis. To perform this test, bacillary 
suspension is injected into the forearm. When the reaction is assessed at 48 hours, 
it is called the Fernandez reaction and indicates delayed hypersensitivity to 
antigens of M. leprae or mycobacterium that cross react. When the reaction is read 
at 3-4 weeks, it is called the Mitsuda reaction and indicates that the immune 
system is capable of mounting an efficient cell-mediated response. 
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Polymerase chain reaction (PCR) analysis. PCR can be used to detect and 
identify M. leprae.The technique is used most often when acid-fast bacilli are 
detected but clinical or histopathologic features are atypical. It is not useful when 
acid-fast bacilli are not detectable by means of light microscopy. 
Histologic Findings.In the TT form, well-developed epithelioid granulomas are 
observed in the papillary dermis, often around neurovascular structures. The 
granulomas are surrounded by lymphocytes, which extend into the epidermis. 
Langhans giant cells are common. Dermal nerves are destroyed or swollen because 
of the granulomas. Acid-fast bacilli are not observed.  
In the LL form, a diffuse infiltrate of foamy macrophages is present in the dermis 
below a subepidermal zone of uninvolved papillary dermis (i.e. grenz zone). An 
enormous number of acid-fast bacilli develop within the foamy macrophages, 
singly or in clumps called globi. Lymphocytes are scant, and giant cells are 
typically absent. Numerous bacilli invade the nerves, but these are fairly well 
preserved with little infiltrate. Nodular, or dermatofibroma-like lesions in LL, 
referred to as histoid leprosy, result in a diffuse fascicular arrangement of spindled 
cells in the dermis admixed with foamy macrophages that contain numerous 
bacilli.  
In the BT form, well-developed epithelioid cell granulomas are apparent and 
diffuse, but few or no Langhans giant cells are observed. Few lymphocytes are 
present in the epidermis in this form, compared with the TT form. Bacilli are 
absent or rare, but they can be found in dermal nerves as well as in the arrector 
pilorum. Nerves are moderately swollen.  
In the BB form, diffuse epithelioid granulomas that lack giant cells are observed in 
the dermis below the subepidermal grenz zone. Nerves are slightly swollen, and 
acid-fast bacilli are present in moderate numbers.  
In the BL form, smaller granulomas with some foamy changes and numerous 
lymphocytes are observed. Nerves often have an onion-skin appearance due to 
invasion of the perineurium. A few epithelioid cells may be observed.  
In the IL form, findings are nonspecific. Histiocytes and lymphocytes are scattered, 
with some concentration around dermal appendages and nerves. At times, an acid-
fast bacillus can be observed in a nerve bundle. The number of dermal mast cells 
may be increased.  
Medical Care.The management of leprosy includes chemotherapy to stop the 
infection; treatment to minimize potential physical deformities; and physical, 
social, and psychological rehabilitation. Potential deformities can be prevented by 
educating patients about how to deal with existing nerve damage and by treating 
any sequelae of this damage. Close follow-up is important to ensure patient 
compliance. Monitor for drug resistance and adverse reactions to medications.  
The first-line drugs are dapsone, rifampin, and clofazimine. Other antibiotics 
include minocycline, ofloxacin, and clarithromycin.  
Eyes, nerves, and the nose should be examined at follow-up to ensure the timely 
recognition of reactive disease.The real challenge in managing leprosy is the 
treatment of reactional states. Systemic steroids are effective in reducing 
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inflammation and edema in reversal reactions; thus, they are the most helpful 
medications in preventing nerve damage.Prednisone should be given at a dose of 
40-80 mg/d for 5-7 days and then tapered slowly over 3-6 months. This long 
course is necessary to decrease the severity of disabilities and deformities. 
Clofazimine can also be used as a steroid-sparing agent for reversal reactions. 
Thalidomide is ineffective for the treatment of reversal reactions, but it is highly 
effective with erythema nodosum leprosum (ENL). 
The goals of pharmacotherapy are to reduce morbidity, prevent complications, and 
eradicate the disease. 
For drug treatment purposes, infections are classified as paucibacillary or 
multibacillary. Paucibacillary disease can be treated with a combination of 2 drugs, 
whereas multibacillary disease requires triple-drug therapy. The length of 
treatment depends on the type of disease and the access to medicine. The 
recommendations of the World Health Organization (WHO) and those in the 
United States are both mentioned here. Corticosteroids-- These are important anti-
inflammatory agents used in the treatment of reactional leprosy. Corticosteroids are 
the reliable only in the treatment of reversal reactions. These medications can be 
used to treat leprosy reactions when a risk of neurologic deficits exists or when 
lesions occur in cosmetically important places. They can also be used to treat ENL.  
Surgical Care. Emergency surgery may be necessary if a patient with profound 
nerve inflammation presents with a nerve abscess or loss of nerve function 
secondary to compression.Prompt recognition and surgical drainage of the abscess 
can often restore nerve function.Elective surgery may be required for correction of 
lagophthalmos (i.e. inability to close the eye).Reconstructive surgery can be used 
to repair nasal collapse in LL. Other surgery may be needed to improve function or 
for cosmesis. Contractures can be surgically repaired. 
Consultations.Consultations with an ophthalmologist, plastic surgeon, orthopedic 
surgeon, otolaryngologist, neurosurgeon, and/or neurologist may be necessary. 
Reasons for a consultation with an ophthalmologist consult include the following: 
lagophthalmos, ENL-induced iritis, direct invasion of the anterior chamber of the 
eye by M. leprae, corneal and conjunctival insensitivity, infection or scarring from 
fifth and seventh cranial nerve involvement. 
Rehabilitation medicine, including physical and occupational therapy, can help 
reduce morbidity.Consultation with a prosthetics specialist may also be 
appropriate. 
Activity.Restrictions on activity depend on the extent of nerve damage. In patients 
with bone or joint destruction, weight bearing should be minimized. Patients with 
anesthesia of limbs need to be educated about their condition, and they should 
wear appropriate footwear.Plantar ulceration requires rest and avoidance of weight 
bearing. Weakness or paralysis requires physical therapy to prevent contractures. 
Further Outpatient Care. WHO recommends 2 years of follow-up for 
paucibacillary disease and 5 years of follow-up for multibacillary disease. Patients 
should be monitored for possible lepra reactions.In some regions of the world, self-
administration of medications is difficult. Medical posts or mobile units can be set 
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up for the administration of medications and management of health-related issues. 
Supervision may be required to achieve the maximum benefit from therapy.In 
patients taking dapsone, the complete blood count should be checked at frequent 
intervals early during the therapy and at less frequent intervals later during therapy. 
Sensation and muscle strength in the hands, feet, and eyes should be checked on a 
regular basis. 
Prevention.Household contacts of patients with lepromatous disease should be 
annually monitored for 5 years after diagnosis. Children especially should be 
observed for the development of disease. Dapsone prophylaxis is no longer 
advocated.Attempts have been made to develop a vaccine against leprosy. The 
bacille Calmette-Guerin (BCG) vaccine has variable results in protection. 
Prognosis.The prognosis depends on the stage of disease. In borderline cases, the 
disease has the potential to be down-graded to LL; these patients may have nerve 
damage.Even with corticosteroid treatment, neuritis may not be curable. The 
prognosis also depends on the patient’s access to therapy, the patient’s compliance, 
and the early initiation of treatment. 
Patient Education.Patients first need an explanation of the diagnosis and 
prognosis. Their fears should be addressed because of the cultural stigma 
associated with leprosy.They may need psychological counseling because they 
may have difficulty in coming to terms with the disease or in feeling rejected by 
society.Patients need education on how to deal with anesthesia of a hand or foot. 
They must learn to carefully inspect their extremities for trauma and should be told 
to wear proper footwear.Inspecting limbs and eyes for onset of anesthesia or 
weakness is also important.Physical therapy and occupational therapy are 
important tools in rehabilitation.Patients need to learn how to recognize the onset 
of lepra reactions, and they should be told to seek immediate medical attention if 
these develop.Potential deformities can be prevented by educating patients about 
how to deal with existing nerve damage and by treating any sequelae of this 
damage. 
Medical/Legal Pitfalls.Leprosy is a contagious transmissible disease, and cases 
should be reported to health officials when they are diagnosed.Discrimination 
against patients with leprosy in vocational matters is illegal. 
Special Concerns.Pregnant women have decreased cell-mediated immunity and 
thus have an increased risk of acquiring the infection.If the disease is incubating, 
pregnancy can result in overt expression. They also have an increased incidence of 
type I and II lepra reactions. These events are most likely to occur in the third 
trimester.Congenital disease is rare, but infants born to mothers with leprosy have 
slow growth and a decreased birth weight. They have a high risk of contracting 
disease if the mother has LL. 
 
11.2. Cutaneous Tuberculosis 
 
Synonyms and related keywords:tuberculosis verrucosa cutis, miliary tuberculosis of the skin, 
scrofuloderma, tuberculous gumma, tuberculosis cutis orificialis, lupus vulgaris, erythema 
induratum, papulonecrotic tuberculid, lichen scrofulosorum, cutaneous TB 
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Background.Mycobacterium tuberculosis is the causative agent of tuberculosis 
(TB) and a member of a group of closely related organisms in the M. tuberculosis 
complex: Mycobacterium africanum, Mycobacterium bovis, Mycobacterium 
microti, and M. tuberculosis. In 1882, Robert Koch discovered and isolated the 
tubercle bacillus (M. tuberculosis).  
TB is an ancient disease. Signs of skeletal TB (Pott disease) were evident in 
Europe from Neolithic times (8000 BCE), in ancient Egypt (1000 BCE), and in the 
pre-Columbian New World. TB was recognized as a contagious disease by the 
time of Hippocrates (400 BCE), when it was termed "phthisis" (Greek from 
phthinein, to waste away).  
World incidence of TB increased with population density and urban development 
so that by the Industrial Revolution in Europe (1750), it was responsible for more 
than 25% of adult deaths. Indeed, in the early 20th century, TB was the leading 
cause of death in the US. Neil Finsen won the Nobel Prize in Medicine in 1903 for 
introducing UV light into the treatment of skin TB.  
Microbiology. Mycobacteria are aerobic, non-sporeforming, non-motile, 
facultative, intracellular, curved rods measuring 0.2-0.5 by 2.0-4.0 µm. Their cell 
walls contain mycolic acid-rich long-chain glycolipids and phospholipoglycans 
(mycocides) that protect mycobacteria from cell lysosomal attack and also retain 
red basic fuchsin dye after acid rinsing (acid-fast stain). The Ziehl-Neelson acid-
fast stain, while highly specific for mycobacteria, is relatively insensitive, and 
detection requires at least 10,000 bacilli per mL; most clinical laboratories 
currently use a more sensitive auramine-rhodamine fluorescent stain (auramine O).  
Routine culture uses a nonselective egg medium (Lowenstein-Jensen or 
Middlebrook 7H10) and often requires more than 3-4 weeks to grow because of the 
22-hour doubling time of M tuberculosis. Radiometric broth culture (BACTEC 
radiometric system) of clinical specimens significantly reduces time (10-14 d) for 
mycobacterial recovery.  
DNA probes specific for mycobacterial ribosomal RNA identify species of 
clinically significant isolates after recovery. In tissue, polymerase chain reaction 
(PCR) amplification techniques can be used to detect M.tuberculosis-specific DNA 
sequences and thus, small numbers of mycobacteria in clinical specimens.  
Pathophysiology. Disease transmission.TB is an airborne communicable disease 
that occurs after inhalation of infectious droplets expelled from patients with 
laryngeal or pulmonary TB during coughing, sneezing, or speaking. Each cough 
can generate more than 3000 infectious droplets. Droplets are so small (1-5 µm) 
that they remain airborne for hours. The probability that disease transmission will 
occur depends upon the infectiousness of the tuberculous patient, the environment 
in which exposure takes place, and the duration of exposure. Approximately 20% 
of people in household contact develop infection (tuberculin skin test positive). 
Microepidemics have occurred in closed environments such as transcontinental 
flights and submarines. Tuberculin sensitivity develops 2-10 weeks after infection 
and usually is lifelong.  
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Without treatment, an approximate 10% lifetime chance exists of developing active 
disease after TB infection (5% within the first 2 years, 5% thereafter). Increased 
risk of acquiring active disease occurs with HIV infection (100-fold risk overall, 
10% chance per year), IV drug abuse, diabetes mellitus (3-fold risk), silicosis, 
immunosuppressive therapy, cancer of the head and neck, hematologic 
malignancies, end-stage renal disease, intestinal bypass surgery or gastrectomy, 
chronic malabsorption syndromes, low body weight, and in infants younger than 2 
years.  
Because TB induces a strong immune response, individuals with positive 
tuberculin reactions are at a significantly lower risk of acquiring new TB infection. 
In HIV-infected individuals, active TB more likely occurs from reactivation of 
existing disease than from superinfection with a new mycobacterial strain.  
Pathogenesis.The typical TB lesion is epithelioid granuloma with central caseation 
necrosis. The most common site of the primary lesion is within alveolar 
macrophages in subpleural regions of the lung. Bacilli proliferate locally and 
spread through the lymphatics to a hilar node, forming the Ghon complex. Early 
tubercles are spherical 0.5- to 3.0-mm nodules with 3 or 4 cellular zones 
demonstrating (1) a central caseation necrosis, (2) an inner cellular zone of 
epithelioid macrophages and Langhans giant cells admixed with lymphocytes, (3) 
an outer cellular zone of lymphocytes, plasma cells, and immature macrophages, 
and (4) a rim of fibrosis in healing lesions.  
Initial lesions may heal and the infection becomes latent before symptomatic 
disease occurs. Smaller tubercles may resolve completely. Fibrosis occurs when 
hydrolytic enzymes dissolve tubercles, and larger lesions are surrounded by a 
fibrous capsule. Such fibrocaseous nodules usually contain viable mycobacteria 
and are potential lifelong foci for reactivation or cavitation. Some nodules calcify 
or ossify and are seen easily on chest x-ray. Tissues within areas of caseation 
necrosis have high levels of fatty acids, low pH, and low oxygen tension, all of 
which inhibit growth of the tubercle bacillus.  
If the host is unable to arrest the initial infection, the patient develops progressive 
primary TB with tuberculous pneumonia in the lower and middle lobes of the lung. 
Purulent exudates with large numbers of acid-fast bacilli can be found in sputum 
and tissue. Subserosal granulomas may rupture into the pleural or pericardial 
spaces and create serous inflammation and effusions.  
With the onset of host-immune response, lesions that develop around 
mycobacterial foci can be either proliferative or exudative. Both types of lesions 
develop in the same host, since infective dose and local immunity vary from site to 
site.  
Proliferative lesions develop where the bacillary load is small and host cellular-
immune responses dominate. These tubercles are compact with activated 
macrophages admixed and are surrounded by proliferating lymphocytes, plasma 
cells, and an outer rim of fibrosis. Intracellular killing of mycobacteria is effective, 
and the bacillary load remains low.  
229 
 
Exudative lesions predominate when large numbers of bacilli are present and host 
defenses are weak. These loose aggregates of immature macrophages, neutrophils, 
fibrin, and caseation necrosis are sites of mycobacterial growth. Without treatment, 
these lesions progress and infection spreads.  
Although mycobacteria are spread by blood throughout the body during initial 
infection, primary extrapulmonary disease is rare except in severely 
immunocompromised hosts. Resistant hosts control mycobacterial growth at 
distant foci before development of active disease. Infants, older persons, or 
otherwise immunosuppressed hosts are unable to control mycobacterial growth and 
develop disseminated (primary miliary) TB. Patients who become 
immunocompromised months to years after primary infection also can develop late 
generalized disease.  
The lungs are the most common site for TB disease: 85% of TB patients present 
with pulmonary complaints. Extrapulmonary TB can occur as part of a primary or 
late generalized infection or as a reactivation site that may coexist with pulmonary 
reactivation. The most common sites of extrapulmonary disease are mediastinal, 
retroperitoneal, and cervical (scrofula) lymph nodes, vertebral bodes, adrenals, 
meninges, and the GI tract. Pathology of these lesions is similar to those in the 
lung.  
Cutaneous tuberculosis.Although 1 of 3 individuals on this planet is infected with 
tubercle bacillus, the incidence of cutaneous TB appears low. In areas such as India 
or China where TB prevalence is high, cutaneous manifestations of TB (overt 
infection or tuberculids) are found in fewer than 0.1% of individuals seen in 
dermatology clinics.  
Frequency.The current global burden of TB boggles the mind. In 1997, the 
incidence of new TB patients approached 8,000,000 in addition to more than 
16,000,000 existing patients. Approximately 2,000,000 people died of TB in 1997 
with a global fatality rate of 23% (fatality rates exceed 50% in some African 
countries with high HIV incidence). The estimate of the proportion of TB patients 
with coincident HIV infection is approximately 8%. Among infectious diseases, 
TB is the leading cause of death. TB was responsible for 6% of deaths worldwide. 
Global prevalence of TB currently is greater than 32%. More than 50% of new 
patient occurrences were in 5 Asian countries, i.e. India (largest worldwide patient 
load), China, Indonesia, Bangladesh, and Pakistan.  
Age.Although no age group is exempt, most patients show clinical infection within 
the first 3 decades of life.  
History.The variants of cutaneous TB present as follows:  
Primary-inoculation TB (tuberculous chancre). Primary-inoculation TB results 
from direct introduction of mycobacteria into the skin or mucosa of an individual 
who was not previously infected with TB or was immunized with the M. bovis 
strain bacille Calmette-Guérin (BCG). Since mycobacteria do not penetrate intact 
skin, initiation of infection almost always follows an injury, usually in children. 
Common sites include the face and other exposed skin. Tuberculous chancres are 
reported after ritual circumcision, tattooing, ear piercing, venipuncture, sexual 
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intercourse, tooth extraction, and after ingestion of milk contaminated with M. 
bovis. Primary-inoculation TB also is reported after M.bovis BCG immunotherapy 
for malignant melanoma. After mycobacteria gain entry into the skin, they 
multiply in tissue macrophages and spread to regional lymph nodes. An 
inflammatory papule develops in 2-4 weeks at the inoculation site that breaks 
down into a firm, non-healing, shallow, non-tender, undermined ulcer with a 
granulomatous base. Painless regional lymphadenopathy is evident at 3-8 weeks. 
Numerous bacilli are present at the inoculation site and regional node. This 
ulceroglandular complex is the skin analog to the Ghon complex.  
As with all TB infections, the clinical course depends upon the host-immune 
response. Tuberculin sensitivity usually is coincident with the development of 
lymphadenopathy. Epithelioid granulomas are evident in the skin and lymph 
nodes. Numbers of tubercle bacilli progressively decrease. The primary lesion 
heals with scarring after 1-3 months. With a less effective host-immune response, 
bacterial load remains high and healing is delayed for up to 12 months. Regional 
nodes may suppurate, erode, and perforate the surface of overlying skin 
(scrofuloderma). Latent foci of infection can remain at the site and progress to 
lupus vulgaris or TB verrucosa cutis despite evident tuberculin sensitivity. 
Hematogenous dissemination of mycobacteria from skin can result in TB at other 
sites (particularly bones and joints) or progress catastrophically to acute miliary 
disease with a fatal outcome.  
TB verrucosa cutis. TB verrucosa cutis is an indolent warty plaque that occurs 
after direct inoculation of TB into the skin of individuals previously infected with 
M. tuberculosis or M. bovis. Reinfection TB can result from accidental exposure to 
tuberculous tissue in high-risk groups, such as physicians, pathologists, and 
laboratory workers (anatomists' wart, prosectors' wart, verruca necrogenica). 
Farmers, butchers, and veterinarians contract this form of reinfection TB from 
tuberculous cattle. Individuals, especially children from lower socioeconomic 
groups, also can contract this lesion after contact with tuberculous sputum. In 
countries such as India, walking barefoot and the habit of spitting associated with 
betel leaf (paan) chewing are worth noting.  
Lesions most commonly occur on the hands and, in children, the lower extremities. 
Infection starts as an asymptomatic warty papule often mistaken for verruca 
vulgaris. Slow growth and irregular peripheral extension occur. The lesion may 
show central involution with an atrophic scar or form massive papillary 
excrescence with fissures. Pus and keratinous material may extrude from these 
fissures. Lesions usually are solitary, and regional nodes are not affected unless 
secondary bacterial infection occurs. Lesions may evolve and persist for years. 
Spontaneous resolution with scarring can occur.  
Histology shows pseudoepitheliomatous hyperplasia with marked hyperkeratosis 
and a dense inflammatory infiltrate of neutrophils and lymphocytes. Abscesses 
form in the superficial dermis and epidermis. Epithelioid giant cells occur, but 
typical tubercles and acid-fast bacilli are rare.  
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Miliary TB of the skin. Miliary TB of the skin is a rare manifestation of fulminant 
miliary TB resulting from hematogenous spread of mycobacteria to multiple 
organs, including skin. The initial site of infection usually is pulmonary or 
meningeal. This disease occurs predominantly in children and may be coincident 
with other infections such as measles. Tuberculin sensitivity is absent and bacillary 
load is high, which is consistent with an overwhelming infection. Currently, 
numerous instances of miliary TB of the skin are reported in immunosuppressed 
individuals infected with HIV. Disseminated lesions occur on all parts of the body, 
especially the trunk. Lesions erupt as small (millet-sized) red macules or papules. 
Purpura, vesicles, and central necrosis are common. Histologically, lesions show 
microabscesses with tissue necrosis and nonspecific inflammatory infiltrates. 
Tubercle bacilli are numerous and are demonstrated in tissue and intravascular 
spaces. Affected patients are gravely ill, and the prognosis is poor.  
Scrofuloderma. Scrofuloderma results from breakdown of skin overlying a 
tuberculous focus, usually at a lymph node but also at the skin over infected bones 
or joints. Historically, a high prevalence of scrofuloderma was seen in children 
infected with M. bovis from contaminated milk. The oral or tonsillar primary lesion 
progresses to cervical adenitis, formation of cold abscesses, and secondary 
breakdown of overlying skin. Lesions present as firm, painless, subcutaneous 
nodules that gradually enlarge and suppurate, then form ulcers and sinus tracts in 
overlying skin. Typical ulcers have undermined edges and a floor of granulation 
tissue. Typical tubercles with acid-fast bacilli are found in the lower dermis and 
walls of the ulcer or abscess. Tubercle bacilli usually can be isolated from the 
purulent discharge. Tuberculin sensitivity usually is marked. Spontaneous healing 
can occur but often takes years and is accompanied by the formation of 
hypertrophic scars. Lupus vulgaris may develop in the vicinity of healing 
scrofuloderma.  
Metastatic tuberculous abscess (tuberculous gumma) is a variant of scrofuloderma 
that occurs following hematogenous spread of mycobacteria to skin in tuberculin-
sensitive individuals. Painless, fluctuant, subcutaneous abscesses form singly or at 
multiple sites, then break down into fistulas and ulcers resembling scrofuloderma. 
Typically, these lesions occur in malnourished children or in severely 
immunosuppressed patients.  
TB cutis orificialis. Orificial TB results from autoinoculation of mycobacteria into 
the periorificial skin and mucous membranes in patients with advanced TB. 
Underlying disease can be pulmonary, intestinal, or genitourinary TB. Infectious 
mycobacteria shed from these foci are inoculated into surrounding mucous 
membranes and skin. Patients typically are older men. Tuberculin sensitivity is 
strong. The site of the periorificial lesion often is determined by trauma. 
In orificial TB, the tip and lateral margins of the tongue are affected most 
frequently; however, hard and soft palate lesions also are common. 
Autoinoculation of tooth sockets can occur after extraction. Perianal skin, the 
vulva, the urinary meatus, and the glans penis also are described sites. Lesions start 
as red papules that evolve into painful, soft, punched-out, shallow ulcers. 
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Tubercles with acid-fast bacilli can be found in the deep dermis and ulcer walls. 
Usually, patients that develop orificial TB have severe internal organ disease and 
the appearance of these lesions portends a poor prognosis. 
Lupus vulgaris. Lupus vulgaris is a chronic and progressive form of cutaneous TB 
that occurs in tuberculin-sensitive patients. In most series, it is the most common 
form of cutaneous TB and has the most variable presentation. Lesions appear in 
normal skin as a result of direct extension of underlying tuberculous foci, of 
lymphatic or hematogenous spread, after primary inoculation, BCG vaccination, or 
in scars of old scrofuloderma. Historically, lupus vulgaris was most prevalent in 
northern Europe (cause of lower prevalence in Asian countries is not known), with 
affected females outnumbering males by 2-3:1.Lesions usually are solitary, and 
more than 90% involve the head and neck. Small, sharply marginated, red-brown 
papules of gelatinous consistency (apple-jelly nodules) slowly evolve by peripheral 
extension and central atrophy into large plaques. However, many clinicians in 
Asian countries who see large numbers of this entity have questioned the 
descriptive term "apple jelly nodules," since this is not seen in many pigmented 
patients. Reappearance of new nodules within previously atrophic or scarred 
lesions is characteristic. Cartilage (nose, ears) within the affected area is 
progressively destroyed (lupus vorax); bone usually is spared. Buccal, nasal, and 
conjunctival mucosas may be involved primarily or by extension.  
Clinical variants are numerous and are seen in the following forms:  
Plaque forms: disease extension occurs with little central atrophy. Scaling can 
occur, especially on the lower legs where it may resemble psoriasis. Irregular 
scarring is common and the active edge may be thickened and hyperkeratotic.  
Ulcerating form: scarring and ulceration predominate. Crusts form over areas of 
necrosis. Deep tissues and cartilage are invaded by eventual scarring that produces 
contractures and deformity.  
Vegetative form: this form is characterized by necrosis, ulceration, and 
proliferative and papillomatous granulation tissue.  
Nodular form: this form is characterized by a relative absence of ulceration and 
scarring. Large soft tumors occur, especially on ear lobes. 
Histologically, the most prominent feature is a typical granulomatous tubercle with 
epithelioid cells, Langhans giant cells, and a mononuclear infiltrate. Caseation 
necrosis is minimal, and acid-fast bacilli are rare. Tissue histology varies with 
secondary changes of abscess formation, ulceration, atrophy, and scarring. 
Lesions often persist for years before diagnosis and can be disfiguring. Patients 
with lupus vulgaris and pulmonary TB have a 4- to 10-fold higher mortality than 
with pulmonary TB alone. In long-standing lupus vulgaris, squamous cell 
carcinoma can occur and be confused with the disease itself. 
Tuberculids: tuberculids are symmetric generalized exanthemas in the skin of 
tuberculous patients, possibly resulting from hypersensitivity reactions to tubercle 
bacillus. Typically, patients with tuberculids are in relatively good health and show 
(1) positive tuberculin sensitivity, (2) tuberculous involvement (usually inactive) of 
viscera or lymph nodes, (3) negative staining and culture for pathogenic 
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mycobacteria in affected tissue, and (4) skin lesions that heal with remission or 
treatment of TB. Originally, these exanthemas were believed secondary to 
mycobacterial "toxins"; however, recent opinion and identification of 
mycobacterial DNA by PCR amplification reactions in affected tissue suggest that 
they are manifestations of hematogenous spread of bacilli in patients with 
tuberculin immunity. 
Erythema induratum (Bazin disease). Erythema induratum is a persistent or 
recurring condition associated with past or active TB. Inflammatory cutaneous and 
subcutaneous nodules that may ulcerate and scar occur in the posterior calves of 
women's legs (<10% of affected patients are men). Preexisting erythrocyanotic 
circulatory disease may predispose patients to lesions. Cutis marmorata is 
common, and an increased prevalence is seen during cold weather.  
Lesions arise in small numbers as tender indurated plaques and nodules that may 
progress to ulceration and scarring. In early stages, inflammation occurs in venous 
walls with adventitial thickening and endothelial proliferation. A perivascular 
inflammatory infiltrate also may be present. Septal panniculitis is present, which 
may extend into fat lobules. Fat necrosis and foreign-body giant cells occur, and 
fibrosis and atrophy (wucher atrophy) replace subcutaneous fat. Tubercle bacilli 
are not seen, and mycobacterial cultures usually are negative. Erythema induratum 
often recurs for years.  
Papulonecrotic tuberculid occurs as a chronic and recurrent symmetric eruption of 
necrotizing skin papules appearing in clusters and healing with varioliform scars. 
Tubercle bacilli are difficult to demonstrate, but patients usually have an internal 
focus of TB and are tuberculin sensitive, and skin lesions resolve after anti-TB 
therapy. Recent studies detected TB DNA in these lesions using PCR amplification 
reactions. Lesions appear on the exterior aspects of extremities (knees, elbows, 
buttocks, lower trunk) in a symmetric distribution, often in clusters. Individual 
lesions are asymptomatic, small, dusky red papules with a central punctum or 
crust. Involution is common after 6-8 weeks and leaves pitted scars.  
Histologically, these lesions show a wedge-shaped necrosis of the upper dermis 
extending to and involving the epidermis. Epithelioid cells and, infrequently, 
Langhans giant cells are seen. An obliterative granulomatous vasculitis with fibrin 
present in vessel walls and lumen is typical. 
Lichen scrofulosorum is an eruption of asymptomatic, grouped, closely set, 1-2 
mm, perifollicular, lichenoid papules affecting children and young adults with 
underlying TB. The eruption becomes more extensive for weeks, then slowly 
regresses for months without scarring. Recurrences are possible. The response to 
anti-TB drugs is not as remarkable as that seen in other tuberculids.  
Histologically, tuberculoid granulomas can be seen surrounding hair follicles and 
sweat ducts. Caseation necrosis usually is absent. No acid-fast bacilli are seen.  
Lab Studies. Workup for cutaneous TB forms is directed against the underlying 
systemic disease.Obtain a medical history for symptoms of the disease, TB 
exposure or infection, past TB treatment, demographic risk factors for TB, and 
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medical conditions that increase risk for TB. Perform a physical examination. 
Perform a tuberculin skin test. 
Imaging Studies. Obtain a posteroanterior chest radiograph. 
Other Tests.Obtain specimens for bacteriologic examination: 3 sputum specimens 
on each of 3 consecutive days.Alternatively, obtain specimens for histologic 
examination: acid-fast bacilli in stained tissue or nucleic acid amplification of 
bacterial DNA and RNA.Perform a deep biopsy for suspected lupus vulgaris. 
Medical Care.Isolate patients with possible TB infection in a private room with 
negative pressure (air exhausted to outside or through a high-efficiency particulate 
air filter). Medical staff must wear high-efficiency disposable masks sufficient to 
filter the tubercle bacillus. Continue isolation until sputum smears are negative for 
3 consecutive determinations (usually after approximately 2-4 weeks of treatment). 
Unfortunately, these measures are neither possible nor practical in countries where 
TB is a public health problem.  
Treatment regimens adequate for pulmonary TB also are effective for 
extrapulmonary disease. Treat infants and children with miliary TB, bone or joint 
TB, or TB meningitis for a minimum of 12 weeks.  
Because of increased drug resistance among TB isolates, TB treatment regimens 
must contain multiple drugs to which the isolated bacillus is susceptible. These 
regimens must be taken regularly and for a sufficient period.  
In most patients, initiate anti-TB treatment with a 4-drug regimen and include 
ethambutol or streptomycin in the initial regimen until results of drug susceptibility 
are known or the chance of drug resistance is minimized. Low risk of drug 
resistance may be indicated as (1) less than 4% primary drug resistance to isoniazid 
in the local community, (2) the patient has had no previous treatment with TB 
drugs, (3) the patient is not from a country with high prevalence of drug-resistant 
TB, and (4) the patient has no known exposure to a person with drug-resistant TB.  
Short-course therapy (for drug-susceptible strains in HIV-seronegative patients) 
lasts for 6 months.  
The initial phase of 4-drug treatment is for 2 months. The drugs are used as 
follows:  
  Isoniazid: 5 mg/kg/d in adults; 10-20 mg/kg/d in children, not to exceed 300 mg 
qd  
  Rifampin: 10 mg/kg/d in adults; 10-20 mg/kg/d in children, not to exceed 600 
mg qd  
  Pyrazinamide: 15-30 mg/kg/d in adults and children, not to exceed 2000 mg qd  
  Ethambutol: 15-25 mg/kg/d in adults and children or streptomycin: 15 mg/kg/d 
in adults; 20-40 mg/kg/d in children, not to exceed 1000 mg qd 
If TB isolates are susceptible to isoniazid and rifampin, the second phase of 
treatment consists of isoniazid and rifampin for 4 months.  
Consider directly observed therapy (DOT) for patients with active disease. This 
intermittent treatment under direct observation significantly increases cure rate, 
decreases transmission of disease, and prevents emergence of multidrug resistant 
TB. DOT has been designed to prevent irregularity in drug intake in TB patients.  
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The 4-drug DOT administered daily for 2 months can be followed by treatment 
with isoniazid and rifampin administered 2 or 3 times per week.  
Four-drug DOT can be administered daily for 2 weeks, then 2 times per week for 6 
weeks, followed by isoniazid and rifampin alone 2 times per week for 16 weeks.  
Four-drug DOT can be administered 3 times per week throughout the 6-month 
treatment period.  
Treat drug-resistant strains of tubercle bacilli in consultation with experienced 
physicians. Additional anti-TB drugs and longer treatment intervals often are 
needed. Daily DOT is recommended.  
Drugs used for this variant include kanamycin, amikacin, capreomycin, 
ciprofloxacin, ofloxacin, sparfloxacin, ethionamide, and prothionamide.  
Surgical Care.The role of surgery in cutaneous TB is limited. However, 
hypertrophic and verrucous lesions of lupus vulgaris and TB verrucosa cutis have 
been treated with electrosurgery, cryosurgery, and curettage with 
electrodesiccation as an adjunct measure, with pharmacologic therapy as the 
primary method of treatment. 
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XII. PARASITIC INFECTIONS 
 
12.1. Scabies 
 
Background.Scabies is an intensely pruritic, highly contagious infestation of the 
skin by the arachnid mite Sarcoptes scabiei, variety hominis. Originally, scabies 
was a term used by the Romans to denote any pruritic skin disease. In the 17th 
century, Giovanni Cosimo Bonomo identified the mite as one cause of scabies. The 
name S. scabiei is derived from the Greek words sarx (the flesh) and koptein (to 
smite or cut) and the Latin word scabere (to scratch). Today, the term scabies 
refers to the skin lesions produced by this mite.  
Scabies has played an important role in world history, with epidemics partially 
coinciding with military activities and major social upheavals. Scabies has been 
recognized as a disease for approximately 2500 years. Historically, it was treated 
with topical sulfur, a treatment still in use today.  
Like syphilis, scabies has come to be known as the great imitator. Its spectrum of 
clinical manifestations may lead the practitioner to the wrong diagnosis. The 
phrase "7-year itch" was first used with reference to persistent, undiagnosed 
infestations with scabies, not as a movie title.  
Pathophysiology.The mite, S. scabiei, spreads disease through direct and 
prolonged contact with the host. The mite remains viable for 2-5 days on inanimate 
objects; therefore, transmission through fomites, such as infected bedding or 
clothing, is possible, but less likely. Once bound to their host, 10-15 mites mate on 
the surface of the skin.  
After mating, the male mite dies. The female mite burrows into the epidermis of 
the host using her jaws and front legs, where she lays up to 3 eggs per day for the 
duration of her 30- to 60-day lifetime. An affected host harbors approximately 11 
adult female mites during a typical infestation. The eggs hatch in 3-4 days. The 
larvae leave the burrow to mature on the skin. Fewer than 10% of the eggs laid 
result in mature mites.  
A delayed type IV hypersensitivity reaction to the mites, their eggs, or scybala 
(packets of feces) occurs approximately 30 days after infestation. This reaction is 
responsible for the intense pruritus, which is the hallmark of the disease. 
Individuals who are already sensitized from a prior infestation can develop 
symptoms within hours.  
Scabies is usually transmitted by direct contact with an affected individual. 
Although disputed, some believe one can become infested by indirect contact with 
the personal items or clothing of an affected person because the mite can survive 
away from the skin for 2-5 days. This is much more likely to occur in the 
environment of someone with crusted or hyperkeratotic scabies.  
In 1848, Norwegians Danielssen and Boeck described a highly contagious variant 
of scabies that occurs in immunocompromised patients. Crusted or hyperkeratotic 
scabies, as it has come to be known, is an overwhelming scabies infestation. This 
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rare form of scabies occurs in elderly or mentally incompetent patients. Because of 
an impaired antibody response, these individuals can be infested with thousands to 
a couple million mites.  
Causes.Human scabies is caused by the arachnid itch mite, S. scabiei (var 
hominis). Animals can transmit nonhuman scabies to people. Human infestation 
with animal scabies is known to be self-limiting, and, clinically, burrows are often 
absent. Cases have been documented of transmission from horses, cattle, goats, 
camels, llamas, sheep, foxes, and, most commonly, dogs. In fact, canine scabies is 
known as mange. One of the causative agents of animal scabies is Cheyletiella 
yasguri. 
Frequency. In undeveloped countries, scabies infestation is pandemic, with 
millions affected worldwide.  
Mortality/Morbidity.Scabies is unlikely to cause a long-term disease state in 
healthy individuals. However, without adequate treatment, the lesions and 
associated pruritus may last for weeks to months. Immunocompromised 
individuals are likely to develop crusted scabies, which may be impossible to fully 
eradicate. Those infested may contract secondary bacterial infections via skin 
abrasion due to excessive scratching. These secondary infections may result in 
cellulitis, lymphangitis, and acute glomerulonephritis. Other than deaths related to 
secondary infection, scabies causes no appreciable mortality.  
Age.Disease is more common in children (<15 y), young adults (associated with 
sexual contact), immunocompromised persons, and elderly patients (especially 
those who are institutionalized or bedridden).  
History.Consider the diagnosis of scabies in any patient presenting with a recent 
onset of intense itching, especially at night.An increase in the intensity of the 
pruritus often forces the patient to seek medical attention.Importantly, attempt to 
elicit a history of pruritus in family members, sexual partners, close contacts, and 
pets.Itching usually spares the head and neck but can be localized anywhere else 
on the body. However, in infants and young children, the lesions are localized to 
the face, neck, trunk, palms, and soles. Patients with crusted scabies may itch only 
50% of the time.Tenderness of the lesions suggests secondary bacterial infection. 
Physical.Findings include both primary lesions and secondary lesions. Each 
category has its own distinguishing characteristics.  
Primary lesions. The distribution of lesions is highly characteristic in typical 
scabies in adults.The burrow appears as a straight, curved, or S-shaped line. It is 
usually 2-5 millimeters long, slightly elevated, and pinkish-white. A black dot may 
be seen at one end of the burrow, indicating the presence of a mite. Common 
locations include the webbed spaces of the fingers, flexor surfaces of the wrists, 
elbows, axillae, belt line, feet, and scrotum in men and areolae in women. In 
infants, burrows are commonly located on the palms and soles. 
Vesicles and papules can be seen near burrows or alone. Vesicles appear as 
discrete lesions filled with serous rather than purulent fluid. The individual 
character of the lesion is indicative of scabies rather than other skin disorders, 
which have grouped vesicular manifestations (e.g. poison ivy). Papules rarely 
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contain mites and most likely are due to a hypersensitivity reaction. Papules are 
common on the shaft of the penis in men. (Note: Canine scabies, scabies in humans 
due to the canine mite, usually manifests with vesicles and papules, not the classic 
burrow). Crusted scabies is an atypical form of scabies occurring in 
immunocompromised and institutionalized populations. Lesions are often 
hyperkeratotic, crusted, and cover large areas. Marked scaling is common, and 
pruritus can be minimal. Nail dystrophy and scalp lesions may be prominent. 
Nodular scabies occurs in 7-10% of patients with scabies. Pink, tan, brown, or red 
nodules can be seen. They range from 2-20 millimeters in diameter. The mite is not 
usually present within the nodular lesion. 
Secondary lesions. These are usually the result of excessive scratching. 
Characteristic findings include excoriations, postinflammatory hyperpigmentation, 
generalized eczematous dermatitis, erythroderma, prurigo-like lesions, and 
pyoderma. 
Complications.Treatment failures are uncommon if guidelines are 
followed.Residual pruritus may require antihistamines or a short course of topical 
or oral corticosteroids.Secondary infection may require antibiotics.Scabetic 
nodules may require intranodular corticosteroid injection. 
Lab Studies.The most common and useful technique used to diagnose scabies is 
examination of skin scrapings under light microscopy. A definitive diagnosis is 
made if the scraping contains a mite, larvae, eggs, or fecal pellets. 
Other Tests. Elevated immunoglobulin E titers and eosinophilia may be 
demonstrated in some patients with scabies.Defective immune function, especially 
in individuals with HIV disease, may be associated with hyperkeratotic scabies. 
Procedures. The best sample can be obtained by scraping a burrow or 
unexcoriated papule. Asking the patient to identify an actively pruritic lesion may 
be helpful.A drop of mineral oil is placed on the lesion. Then, a sterile blade is 
used to gently scrape the burrow or papule. The lesion should be scraped 6-7 times, 
and bleeding should be avoided.The skin scrapings are placed on a glass slide and 
examined under a light microscope at 40X magnification.The burrow ink test can 
also be used to make the diagnosis of scabies. The tip of a fountain pen is rubbed 
along the site of a possible burrow. The ink penetrates the burrow, distinguishing it 
from the surrounding tissue. The excess ink is wiped off with an alcohol pad. This 
technique is particularly useful in children and individuals with very few 
burrows.Use of topical tetracycline solution is an alternative to the burrow ink test. 
After application and removal of the excess tetracycline solution with alcohol, the 
burrow is examined under a Wood light. The remaining tetracycline fluoresces a 
greenish color. This method is preferred because tetracycline is a colorless solution 
and large areas of skin can be covered.When diagnosing crusted scabies, 10% 
potassium hydroxide is added to the skin scraping, which permits adequate 
microscopic viewing by decreasing the amount of keratitic debris.A past history of 
scabies is important when diagnosing nodular scabies. 
Histologic Findings.A burrow containing the female mite and ova within stratum 
corneum may or may not be present. An inflammatory infiltrate in the deep and 
239 
 
superficial dermis is composed of lymphocytes, histiocytes, eosinophils, and 
occasional neutrophils. Spongiosis and vesicle formation is present near the mite.  
Crusted scabies also demonstrates an inflammatory infiltrate. However, it is 
coupled with prominent hyperkeratosis and innumerable mites.  
Nodular scabies reveals a dense, mixed, inflammatory cell infiltrate. The infiltrate 
is noted around blood vessels of the dermis and subcutaneous fat. Atypical 
mononuclear cells may be present. Mites are not a common finding. 
Medical Care.Treat with a scabicide. Provide antihistamines to help alleviate 
pruritus. Use appropriate antibiotics for the treatment of secondary infections. For 
crusted scabies, crust and scale removal is necessary for scabicide penetration. All 
family members and close contacts of those diagnosed with scabies must receive 
treatment. Instruct patients to wash bed linens, clothing, and towels in warm water.  
Symptomatic treatment may require oral antihistamines and topical 
antipruritics/anesthetics such as menthol (Sarna lotion) and pramoxine (Prax). 
More severe symptoms may require a short course of topical or oral steroids. 
Secondary infections may require antibiotics. Oral ivermectin can be used in cases 
for which topical therapy is difficult or impractical (e.g. widespread infestations in 
nursing homes). 
Permethrin (Elimite) - 5% cream. DOC, especially for infants >2 months and small 
children. More effective than crotamiton for treating symptoms and reducing 
chances of secondary bacterial infection. Even after successful treatment, 
postscabietic nodules and pruritus may persist for months. Sulfur in petrolatum -  
10% concentration. One of few effective scabicidal treatments that may be used 
safely without fear of toxicity in very small children and pregnant women. 
Crotamiton (Eurax) - 10% lotion or cream. Mechanism of action is unknown. 
Ivermectin (Mectizan, Stromectol) - binds selectively with glutamate-gated 
chloride ion channels in invertebrate nerve and muscle cells, causing cell death.  
Activity.Infected individuals should avoid skin-to-skin contact with uninfected 
individuals. Decontamination of clothing, bed linens, and other personal items 
must coincide with medical treatment. 
Prevention.All household members and close personal contacts older than 2 
months and not pregnant should be treated, regardless of whether they are 
symptomatic.Patients should be reexamined 2-4 weeks after treatment to evaluate 
effectiveness.If itching persists 1 week after the initial treatment, a second 
treatment may be indicated. Rarely, individuals with a history of atopy may require 
a tapered dose of prednisone for the treatment of severe pruritus. Intranodular 
injection of dilute corticosteroids may be indicated with nodular scabies. Because 
of the presence of innumerable mites, crusted scabies may require repeated 
applications of scabicide or oral ivermectin. Importantly, inform patients that the 
resolution of symptoms may require weeks. 
Prognosis.Prognosis is excellent with proper diagnosis and treatment unless the 
patient is immunocompromised or institutionalized. These individuals are at an 
increased risk for crusted scabies, which is associated with a less favorable 
outcome. 
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12.2. Leishmaniasis 
 
Background: Leishmaniasis is a disease caused by protozoa, and it affects as 
many as 12 million people worldwide, with 1.5-2 million new cases each year. The 
global incidence of this infectious disease has increased in recent years because of 
increased international leisure and military related travel, human alteration of 
vector habitats, and concomitant factors that increase susceptibility, such as HIV 
infection and malnutrition. The recent conflicts in Iraq, Kuwait, and Afghanistan 
have led to >600 cases of cutaneous leishmaniasis and 4 cases of visceral 
leishmaniasis (VL) in American soldiers in 2004 alone.  
Transmitted by the bite of a sandfly, the clinical spectrum of leishmaniasis ranges 
from a self-resolving cutaneous ulcer to a mutilating mucocutaneous disease to a 
lethal systemic illness.  
Many Leishmania species transmit the disease, and the clinical spectrum, although 
once believed to be predictable, continues to evolve. Diagnosis may be difficult 
because of the small size of the protozoa sequestered within macrophages of the 
skin, bone marrow, and reticuloendothelial system. Therapy has long been a 
challenge in the more severe forms of the disease and is made more difficult by the 
emergence of drug resistance. No effective vaccine for leishmaniasis is available.  
Pathophysiology.Mammalian reservoirs for leishmanial parasites include rodents, 
canines, equines, monkeys, sloths, and humans. In mammalian hosts, the organism 
exists as a nonflagellated amastigote composed of a large nucleus and a smaller 
kinetoplast that resides in the phagolysosome of the macrophage. The vector 
sandfly, of the genus Phlebotomus in the Old World and of the genus Lutzomyia in 
the New World, ingests the amastigotes when drawing a blood meal from an 
infected host. In the gut of the sandfly, the protozoa multiply and transform into 
flagellated promastigotes.  
The promastigotes migrate to the proboscis of the sandfly and are inoculated into 
the naive host during the insect's next blood meal. The promastigotes enter the new 
host's macrophages, where they transform back into amastigotes, multiply, and 
spread throughout the reticuloendothelial system. Clinical disease is apparent 
within weeks to months after infection.  
Similar to Hansen disease, leishmaniasis is a disease in which the clinical diversity 
reflects a complex interplay between the virulence of the infecting species and the 
host's immune response. At one extreme, localized cutaneous disease demonstrates 
a vigorous immune response, with most cases resolving without intervention. This 
form of disease exhibits a helper T-cell subtype 1 (TH1) immune response, with 
interleukin-2, interferon-gamma, and interleukin-12 as the prominent cytokines 
that induce disease resolution. At the other extreme, with visceral or diffuse 
cutaneous disease, patients exhibit relative anergy to the Leishmania organism and 
have a prominent helper T-cell subtype 2 (TH2) cytokine profile. The 
immunomodulation of leishmaniasis has become an area of intense study in the 
search for new treatments for this disease.  
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Frequency.Leishmaniasis occurs in temperate and tropical climates in all parts of 
the world except Australia and Oceania (Pacific islands of Melanesia, Micronesia, 
and Polynesia). The vast majority of cutaneous cases occur in Afghanistan, 
Algeria, Brazil, Peru, Iran, Iraq, Syria, and Saudi Arabia, whereas most visceral 
cases occur in India, Bangladesh, Nepal, Brazil, and the Sudan. The sandfly vector 
is adept at adjusting to climatic changes and to pressures of human habitation; 
therefore, vigilant epidemiologic tracking is required to monitor new patterns of 
disease prevalence. Most cases of leishmaniasis in the United States are imported 
from elsewhere. Sporadic endemic transmission of cutaneous disease has been 
reported in rural southern Texas. 
Mortality/Morbidity.As many as 90% of localized cutaneous forms of 
leishmaniasis heal spontaneously with scarring. Disseminated, recidivans, and 
post–kala azar forms of cutaneous leishmaniasis can be disfiguring cosmetically 
because of the degree of persistent involvement; however, these forms are not life 
threatening. Mucocutaneous leishmaniasis (MCL) can result in extensive midfacial 
mutilation and, occasionally, death resulting from airway or nutritional 
compromise. VL (kala azar) is a serious potentially lethal systemic illness. 
Epidemics of kala azar in impoverished communities can result in death in the 
majority of untreated patients.  
Age.No specific age susceptibility is known; however, individuals at the extremes 
of age may be less able to mount effective immune response to infection. 
Leishmania infantum produces an infantile form of VL. An apparent predilection 
for the young appears to occur in highly endemic areas because of what may be 
protective immunity protecting adults from reinfection.  
History.The discovery of parasites in lesions of cutaneous or VL was reported in 
the late 1800s and early 1900s. By the mid 1900s, the transmission and life cycle 
of the Leishmania organism had been confirmed scientifically. Since that time, 
many clinical syndromes and numerous (at least 20) morphologically similar 
species and subspecies of the protozoan have been, and continue to be, discovered. 
The taxonomy of Leishmania organisms is complex, and no single categorization 
is generally accepted.  
The 2 simplest and most widely used disease categorization systems are based on 
clinical disease and geographic occurrence.  
Clinical disease. The 3 primary clinical forms of leishmaniasis are cutaneous, 
mucocutaneous, and visceral disease. Cutaneous leishmaniasis can be further 
divided into localized, diffuse cutaneous, recidivans, and post–kala azar dermal 
leishmaniasis (PKADL).  
Geographic occurrence. Old World leishmaniasis is caused by Leishmania species 
found in Africa, Asia, the Middle East, the Mediterranean, and India, and it 
produces cutaneous or visceral disease. New World leishmaniasis is caused by 
Leishmania species found in Central America and South America, and it produces 
cutaneous, mucocutaneous, and visceral disease. 
The following forms of leishmaniasis have been identified:  
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Localized cutaneous leishmaniasis (LCL): crusted papules or ulcers occur several 
weeks to months (and in rare cases) after sandfly bite inoculation on exposed skin. 
Lesions may be associated with sporotrichotic spread and usually heal 
spontaneously. 
Diffuse cutaneous leishmaniasis (DCL): analogous to lepromatous leprosy, 
individuals with DCL cannot mount a cell-mediated immune response to the 
Leishmania parasite. Consequently, patients develop multiple, widespread 
cutaneous papules and nodules, and they are anergic to leishmanin skin testing 
(LST). 
Recidivans cutaneous leishmaniasis (RCL): a relatively uncommon clinical 
variant of leishmaniasis, RCL appears as a recurrence of lesions at the site of 
apparently healed disease years after the original infection. RCL lesions typically 
occur on the face, and RCL presents as an enlarging papule, plaque, or coalescence 
of papules that heals with central scarring. Relentless expansion at the periphery 
may cause significant facial destruction similar to the lupus vulgaris variant of 
cutaneous tuberculosis. 
Post–kala azar dermal leishmaniasis (PKADL): endemic to India and the Sudan, 
this form of leishmaniasis develops months to years after the patient's recovery 
from VL. Cutaneous lesions demonstrate great variability, ranging from 
hypopigmented macules to erythematous papules and from nodules to plaques. As 
in leprosy, the wide clinical spectrum of PKADL reflects the immune response of 
the individual to the Leishmania organism. Lesions may be numerous and persist 
for decades. Isolated parasites from the lesions are identical to those causing the 
original visceral disease. 
Mucocutaneous leishmaniasis (MCL): predominantly a New World disease, this 
form of leishmaniasis may not manifest clinically until years after localized 
cutaneous disease apparently has healed. In a poorly understood manner, certain 
species of Leishmania migrate to the upper respiratory tract where relentless 
destruction of the oropharynx and nose ensues. Gradually, the migration results in 
extensive mid facial destruction and, occasionally, in death. 
Visceral leishmaniasis(VL,kala azar): Leishmania parasites localize to the 
reticuloendothelial system, rather than to the skin, and produce a potentially lethal 
widespread systemic disease. 
Physical: localized cutaneous leishmaniasis usually presents as a nonspecific ulcer 
that can mimic many those of other infectious and noninfectious skin conditions. 
The vast majority of cases heal spontaneously with scarring and never come to the 
attention of clinicians. In both the localized cutaneous and mucocutaneous forms 
of leishmaniasis, cell-mediated immunity to the parasite is vigorous and organism 
density in the skin and/or mucosa is low, especially in long-standing disease. 
Therefore, growing organisms in culture can be difficult, as can finding them in 
pathological specimens. Malnourished individuals are at greater risk of acquiring 
leishmaniasis and respond less well to treatment than those with adequate nutrition.  
Approximately 1-3% of individuals infected by L. brasiliensis, and a smaller 
percentage of individuals infected by L. panamensis and L. guyanensis, develop 
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mucosal metastases several months to years after the apparent resolution of 
cutaneous disease. Without treatment, destruction of the oral and nasopharyngeal 
mucosae is relentless. Symptoms of visceral leishmaniasis can be confused with 
many other infectious diseases; however, in endemic areas, the typical patient has 
wasting and presents with massive splenomegaly, pancytopenia, 
hypergammaglobulinemia, and intermittent fevers (though they are less acutely ill 
than patients with malaria).  
LCL: a typical lesion begins as an inflammatory papule that later progresses to an 
ulcer. This may be associated with sporotrichotic lymphatic spread. In the vast 
majority of cases, the ulcers heal spontaneously with scarring. 
DCL: patients develop hundreds of papules, nodules, and plaques throughout the 
skin in a clinical picture that can be reminiscent of lepromatous leprosy. This form 
of leishmaniasis often is resistant to therapy and may assume a chronic course. 
RCL: typically, psoriasiform plaques occur on the face and progress centrifugally, 
bearing a striking resemblance to lupus vulgaris. Similar to disseminated disease, 
RCL may be resistant to therapy and result in a disfiguring clinical picture. 
PKADL: cutaneous lesions are polymorphous, ranging from hypopigmented or 
erythematous macules to papules and nodules that may coalesce. Similar to DCL, 
PKADL closely resembles lepromatous leprosy. Prolonged intensive treatment is 
required to treat this disfiguring, but usually not lethal, form of leishmaniasis. 
MCL: when left untreated, this form of leishmaniasis gradually spreads and results 
in extensive mid facial mutilation or, in some cases, in death. 
VL: the hallmarks of this form are fever, malaise, hepatosplenomegaly, anorexia, 
wasting, pancytopenia, and hypergammaglobulinemia. Occasionally, the skin 
becomes severely xerotic and hyperpigmented because of melanocyte stimulation. 
This form of leishmaniasis frequently is lethal if not treated. 
Complications.Secondary bacterial infection may occur.Leishmaniasis may be 
disfiguring. 
Causes.In the vast majority of cases, sandfly bites transmit leishmaniasis; 
however, infection may be transmitted via a congenital route or through blood 
transfusions and contaminated needle sticks.  
Cutaneous leishmaniasis 
Localized cutaneous leishmaniasis. Old World: Leishmania major, Leishmania 
tropica, Leishmania aethiopica, and L. infantum. New World: Leishmania 
mexicana, Leishmania venezuelensis, Leishmania amazonensis, Leishmania 
braziliensis, Leishmania panamensis, Leishmania guyanensis, Leishmania 
peruviana, and Leishmania chagasi.  
Diffuse cutaneous leishmaniasis. Old World: L. aethiopica.New World: L. 
mexicana, L. amazonensis, and L. venezuelensis. 
Recidivans cutaneous leishmaniasis. Old World: L. tropica. New World: L. 
braziliensis. 
Post–kala azar dermal leishmaniasis. Old World: Leishmania donovani and L. 
infantum.New World: L. chagasi 
Mucocutaneous leishmaniasis 
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Old World: L. aethiopica (rare) and L. major. New World: L. mexicana, L. 
amazonensis, L. braziliensis, L. guyanensis, and L. panamensis. 
Visceral leishmaniasis 
Old World: L. infantum, L. donovani, and L. tropica (rare; also may produce the 
atypical viscerotropic disease). New World: L. chagasi. 
Other diagnostic considerations 
Differential diagnosis of LCL is extensive and includes impetigo, pyoderma 
gangrenosum, deep fungal infection, mycobacterial infection, sarcoidosis, and 
squamous cell carcinoma. 
DCL and PKADL closely resemble lepromatous leprosy.RCL may mimic 
cutaneous tuberculosis (lupus vulgaris, tuberculosis verrucosa cutis), psoriasis, 
deep fungal infection, or nummular dermatitis.MCL may simulate 
paracoccidioidomycosis, histoplasmosis, syphilis, yaws, rhinoscleroma, squamous 
cell carcinoma, and midline granuloma of the face.VL may be confused with a 
variety of other infectious diseases or febrile systemic illnesses, including 
schistosomiasis, malaria, tropical splenomegaly syndrome, histoplasmosis, 
malnutrition, typhoid fever, brucellosis, miliary tuberculosis, lymphoma, leukemia, 
African trypanosomiasis, and bacterial endocarditis.Coexisting infectious diseases 
and/or nutritional deficiencies may impact the severity and outcome of leishmanial 
infection significantly. In southern Europe, VL is emerging most notably as a 
serious opportunistic infection in individuals with HIV infection. Co-infection by 
HIV and leishmanial organisms is particularly common in southern Europe along 
the Mediterranean where most adult patients (<70%) with visceral leishmaniasis 
are associated with late-stage AIDS. Individuals with HIV infection and 
leishmaniasis have higher parasite loads, poorer responses to skin testing, lower 
responses to pentavalent antimony, and higher posttreatment relapse rates than 
those of their immunocompetent counterparts. 
Lab Studies.Cutaneous lesions. Skin scrapings are obtained from the base of an 
active ulcer or biopsy of the edge of a suspicious lesion or ulcer. Leishmanial 
amastigotes may be identified from cutaneous lesions or in biopsy specimens of 
infected tissue. Finding an organism in a tissue sample depends on the parasitic 
burden, the efficacy of the host's immune response, any coexisting contamination 
of the ulcer, and the age of the lesion (Findings in old lesions are frequently non-
diagnostic.). The parasites consist of a nucleus and a kinetoplast surrounded by a 
cell wall. Visualization of all 3 features (nucleus, cell membrane, and kinetoplast) 
is required to make the diagnosis microscopically. 
Direct visualization of the organism is diagnostic but can be difficult because of its 
small size (2-4 mm) and because of subtle distinguishing characteristics on routine 
hematoxylin-eosin stains. Identification often requires an experienced pathologist 
and lengthy searches by using high magnification, particularly when organisms are 
sparse. Giemsa, Brown-Hopps, Gram, or Leishman stains may enhance 
Leishmania organisms on touch preparations, tissue aspiration, or biopsy samples. 
The diagnostic sensitivity of microscopic identification of leishmanial amastigotes 
is typically 75-85% but may vary widely, depending on the size of the inoculum 
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and observer's experience. The ideal way to microscopically identify the parasite is 
with direct touch preparations from the lesion or biopsy tissue stained with Giemsa 
rather than with routine tissue sections. 
The polymerase chain reaction (PCR) is now routinely used in experienced 
laboratories as a rapid diagnostic technique. Even in remote locations and under 
harsh conditions, this technique has proven its worth, as evidenced by the U.S. 
military's recent experience with leishmania in Iraq. Validated genus-specific PCR 
primers exist, and approval of this assay by the U.S. Food and Drug 
Administration (FDA) is being sought so it can be used in worldwide facilities 
certified by the College of American Pathologists (CAP). Species-specific PCR 
probes allow for rapid speciation in confirmed cases of leishmania and are 
undergoing final validation. FDA approval of these assays might also be sought, 
but cases can be referred to reference labs in the United States for rapid diagnosis 
and speciation. 
In vitro cultures of tissue are regularly obtained to aid in diagnosis and to identify 
Leishmania species. This technique has approximately the same diagnostic 
sensitivity as that of pathologic evaluation, but special laboratory capabilities and 
technical skills are required. These are currently available in only 2 reference 
laboratories in the United States (at the Centers for Disease Control and Prevention 
[CDC] and the Walter Reed Army Institute of Research). The value of this method 
is that the species of the parasite can be identified on the basis of long-standardized 
isoenzyme patterns on cellulose acetate electrophoresis after the parasite is grown 
in vitro. 
In vivo diagnosis of Leishmania organisms can also be achieved by inoculating 
clinical specimens into golden hamsters or certain highly susceptible mouse 
strains. Although results are not available for weeks to months, they are useful in 
diagnosing the disease, especially in difficult cases. 
Mucocutaneous or VL: aspirates or touch preparations of mucosal or visceral 
tissue dermal scrapings may be processed like cutaneous samples are, as described 
above. 
Systemic leishmaniasis: a variety of immunodiagnostic serologic tests have been 
developed to aid in the diagnosis of systemic leishmaniasis. The only serologic 
tests are limited to species of Leishmania that cause visceral disease. Limitations 
include false-negative serologic results due to inadequate titers of antibodies late in 
the course of the disease and false-positive results in the setting of other infectious 
or autoimmune diseases. 
The most promising serologic test to date is an L. chagasi recombinant amastigotes 
K39 (rK39)–based antigen test system that has been used with enzyme-linked 
immunosorbent assay (ELISA), a direct agglutination test (DAT), and even a 
nitrocellulose dipstick test. The degree of conservation of the K39 gene is high 
among isolates of the L. donovani family, including L. chagasi and L. infantum. 
Therefore, this test is useful for most recognized cases of visceral leishmania. 
Assays based on rK39 antigen are highly sensitive and specific and validated in 
several large studies worldwide. 
246 
 
Ancillary tests important in the diagnosis of visceral leishmania include 
determinations of the CBC count with differential; liver function tests; and lipase, 
amylase, gamma globulin, and albumin tests. 
Other Tests. Skin testing: similar to the purified protein derivative (PPD) test, the 
Montenegro LST has been used for decades to determine previous or current 
exposure to Leishmania parasites. LST is not used to distinguish between active 
and resolved disease, but can be useful in evaluating known naive populations that 
become immunologically responsive to leishmanial antigens. LST is not applicable 
to immunologically anergic patients with widely disseminated cutaneous disease. 
Because LST is not standardized, the FDA has not approved it; therefore, LST is 
not available as a diagnostic tool in the United States. 
Parasite speciation: cellulose acetate electrophoresis is a well-standardized method 
for determining the species of parasites grown from clinical samples. Although this 
test is standardized, it requires experience and special facilities, and therefore, it is 
available only in highly specialized diagnostic facilities. 
Procedures.Perform biopsy and obtain dermal scrapings and needle aspirates. 
Obtain bone marrow or splenic aspirates and analyze them for visceral disease. 
Histologic Findings.LCL is characterized by irregular acanthosis, with or without 
epidermal ulceration, and dense dermal infiltrate of mixed inflammatory cells, 
particularly plasma cells, lymphocytes, and histiocytes. Early in the course of 
localized disease, organisms may be numerous and found readily in the cytoplasm 
of macrophages. As the lesion ages and as delayed-type immunity is up-regulated, 
the infiltrate is replaced by noncaseating granulomata in which few or no 
organisms can be seen. Ulcerated lesions are often secondarily infected by bacteria, 
in which case histologic changes may be non-specific. Results with biopsy 
specimens obtained from old (>6 months), partially treated, or low-burden 
infections are frequently non-diagnostic.  
DCL occurs in individuals with poor cellular immunity to Leishmania parasites. 
Histologic diagnosis is straightforward in these cases. The dermis contains sheets 
of macrophages containing great numbers of amastigotes, with few lymphocytes or 
plasma cells.  
PKADL has a variable histology that is determined by the degree of host immunity 
and the parasite load. Granulomatous histology is seen with low numbers of 
organisms, whereas diffuse histiocytic or xanthomatous infiltrates may be seen 
with numerous organisms.  
RCL is usually difficult to confirm because of the rarity of organisms and because 
of its histologic similarity to lupus vulgaris.  
Aspirates from bone marrow, lymph nodes, or the spleen are typically obtained to 
make a histologic diagnosis of kala azar. As with diagnosis with skin samples, 
diagnosis based on these aspirates depends on identification of Leishmania 
parasites, which are usually plentiful in macrophages. 
Medical Care.Tailor treatment to the individual because leishmaniasis is caused 
by many species or subspecies of the Leishmania protozoa, all of which have 
different degrees of virulence and clinical predilections. Consider the clinical 
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pattern of disease, the geographic region in which the infection occurs, the 
immunologic status of the patient, and the previous attempts at treatment when 
therapy is started.  
Although treatment used to be the recommendation for every case of leishmania 
after the infection is identified, this is no longer the conventional practice. 
Treatment must be a balance of risk versus benefit, especially in the case of L 
major, which is generally a self-limited cutaneous illness that heals within 12 
months. For lesions caused by this species, treatment is not generally necessary 
unless the lesion is in a cosmetically or functionally sensitive site. Cases due to L. 
tropica, another Old World species, may have a more chronic course (up to years); 
this organism has been implicated in occasional cases of recidivans or 
viscerotropic leishmaniasis. As such, treatment may need to be more prudent in 
cases caused by this species.  
With New World leishmaniasis, as many as 10% of untreated individuals may 
have recurrences in the form of chronic ulcers, recidivans lesions, or 
mucocutaneous involvement. Multiple treatment options are used throughout the 
world. In addition to parenteral and oral medications, local therapies for some 
forms of cutaneous leishmaniasis include the following: cryotherapy; infiltration of 
sodium stibogluconate 0.3-0.8 mL; intralesional heat therapy with 40-42°C for 12 
hours; and various topical paromomycin preparations, typically 15% with 10% 
urea.  
Surgical excision is usually not recommended because of the risk of relapse and 
cosmetic disfigurement. In some areas of the world (Russia, the Middle East), live 
attenuated L. major promastigotes have been used preemptively to immunize 
against Old World cutaneous leishmaniasis. This practice produces a modified 
form of the disease and results in a scar at the injection site. Immunity to 
subsequent L. major infections usually is good; however, as with natural infection, 
cross-reactive immunity to other Leishmania species does not occur. Many more 
universally useful and cosmetically acceptable Leishmania vaccine formulations 
are under investigation. To date, no vaccines are commercially available.  
Treat malnutrition, concurrent systemic illness (e.g. HIV disease, tuberculosis), or 
local infection (secondary bacterial) accordingly. Despite successful therapy, 
whether the parasites are completely eradicated is unclear because reactivation of 
leishmaniasis with immunosuppression has been reported.  
For 50 years, the mainstay of antileishmanial therapy has been pentavalent 
antimony (sodium stibogluconate or meglumine antimonate). These drugs are not 
marketed in the United States, but they may be obtained through the CDC under an 
investigational new drug application. Cure rates are 90-97% with 1-3 treatment 
courses; however, the drawbacks are considerable. These drugs are expensive and 
difficult to obtain. They must be delivered parenterally, they have numerous 
adverse effects, they may have lot-to-lot variability, and they are becoming 
increasingly less effective because of the emergence of drug-resistant parasites.  
Alternative treatment regimens with acceptable cure rates are pentamidine, 
paromomycin, interferon-gamma plus antimony, and amphotericin B (and less 
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toxic variations, e.g. liposomal amphotericin B, amphotericin B lipid complex, and 
amphotericin B colloidal dispersion). 
Prevention: leishmaniasis is preventable by avoiding contact with the vector. The 
sandfly is most active from dawn to dusk, it is small enough to fit through standard 
mosquito netting, it makes no audible noise, and it is a relatively poor 
flyer.Effective prevention may be achieved by avoiding nighttime outdoor 
activities, by using topical insecticides (e.g. diethyltoluamide [DEET]) on exposed 
skin surfaces, by using insecticide-impregnated clothing (permethrin stays in or on 
the material for many washings), by using fine mesh mosquito netting treated with 
permethrin, and by sleeping with a fan on. 
Protective immunity after medical treatment or infection is 97-98% effective 
against disease caused by the same species of Leishmania. Deliberate scarification 
of the extremities with material from human lesions was once practiced to prevent 
scarring that may result from a later natural infection of the face. 
The treatment of infected persons and elimination of diseased reservoir vertebrates 
can reduce the source of infections. 
Prognosis.In well-nourished individuals with intact immune systems, recovery is 
expected after treatment with the appropriate medication. 
Patient Education.Behavior modification to avoid vector contact, combined with 
insect control measures, significantly diminishes the risk of acquiring infection. 
 
 
12.3. Pediculosis 
 
Background: Pediculosis (i.e. louse infestation) dates back to prehistory. The 
oldest known louse eggs (i.e. nits) are aged approximately 10,000 years (i.e. 
fossils, not viable). Lice are so ubiquitous that terms and phrases such as "lousy," 
"nit-picking," and "going over things with a fine-tooth comb" are part of everyday 
vocabulary.  
Over the last 3 decades, the incidence of pediculosis has risen steadily, making the 
diagnosis and treatment of louse infestation one of the most common tasks in 
general medical practice. This article focuses on the pathophysiology and life cycle 
of 3 prevalent human ectoparasites, (1) Pediculus humanus capitis (i.e. head 
louse), (2) Pediculus humanus corporis (i.e. body louse), and (3) Phthirus pubis 
(i.e. pubic louse). The clinical aspects of presentation, diagnosis, and treatment of 
these ancient and common human pests are also discussed.  
Pathophysiology: Human lice (P. humanus and P. pubis) are found in all countries 
and climates. They belong to the order Anoplura, the sucking lice, and are 
classified as insects. Mammals are the hosts for all Anoplura, and, although lice 
prefer human hosts, P. humanus is also known to live and reproduce on pigs.  
The Anoplura are wingless and have 3 pairs of legs, each ending with a clawlike 
talus for grasping. The size and shape of the claws are adapted to the texture and 
shape of the hairs and/or clothing fibers they grasp. Their bodies are flat and 
covered with tough chitin. Human lice have small anterior mouthparts with 6 
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hooklets that aid their attachment to human skin during feeding. The sucking 
mouthparts retract into the head when the lice are not feeding. In general, lice feed 
approximately 5 times per day for approximately 35-45 minutes each time.  
In each species, the female louse is slightly larger than her male counterpart. The 
life cycle of lice is 30-35 days from egg to adult. Early death is common, resulting 
from gut rupture during feeding or cementing of the female to the hair shaft during 
ovipositioning.  
P. humanus capitis. The average length of the head louse is 1-2 mm. The louse is 
white to gray and has a long, dorsoventrally flattened, segmented abdomen. The 
average life span is 30 days. After incubation of the ova (8-10 d), the nymph molts 
3 times before reaching its adult form (8-10 d later). The female head louse lays as 
many as 10 eggs per 24 hours, usually at night. She positions her ova at the base of 
the hair shaft, close to the scalp, with a predilection for the posterior hairline and 
postauricular areas. The female louse cannot survive for more than 1 day off the 
human head.  
P. humanus corporis. The body louse is larger than the head louse. Body lice 
range in size from 2-4 mm; the female lice are larger than the male lice. The body 
louse is also flat and white to gray with a segmented abdomen. Unlike the head 
louse and the pubic louse, the body louse does not live on the human body. P. 
humanus corporis lives in human clothing, crawling onto the body only to feed, 
which predominantly occurs at night. P. humanus corporis prefers cooler 
temperatures, living and laying its 10-15 eggs per day some distance from the 
human body on the fibers of clothing, mainly close to the seams. The adult female 
body louse, unlike the head louse, can survive as long as 10 days away from the 
human body without a blood meal. The life cycle from nit to death is 
approximately 35 days, with 3 episodes of molting before maturity.  
P. pubis. The pubic louse gets the nickname of "crab" from its shorter, broader 
body (0.8-1.2 mm) and large front claws, which give it a crablike appearance. The 
pubic louse is white to gray, oval, and has a smaller abdomen than the other 2 
forms. The average life cycle is also 35 days, although the period from ova to adult 
(15 d) is slightly longer than that of the other 2 forms. The average female pubic 
louse lays only 1-2 eggs per day. Their large claws enable pubic lice to grasp the 
coarser pubic hairs in the groin, perianal, and axillary areas. Heavy infestation with 
P pubis can also involve the eyelashes, eyebrows, facial hair, and, occasionally, the 
periphery of the scalp. These insects are less mobile than P. humanus and P. 
corporis, mainly resting while attached to human hairs. They cannot survive off 
the human host for more than 1 day.  
Nits. The average nit (i.e. ovum) of the 3 types of lice is 0.8 mm long. The nit 
attaches to the base of the hair shaft or to fibers of clothing with strong, highly 
insoluble cement. The nit is topped with a tough but porous cap known as the 
operculum. This porous sheath allows for gas exchange while the nymph develops 
in the casing. The ova require optimum conditions of 30°C and 70% humidity to 
hatch within the average time frame of 8-10 days; however, the incubation period 
is longer at lower temperatures. Ova do not hatch at temperatures lower than 22°C 
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but can remain alive for as long as 1 month away from the body (i.e. on fomites, 
clothing, brushes).  
Frequency. Pediculosis is extremely common; an estimated 10-12 million 
Americans, a quarter of whom are elementary school children, are infested. 
Hundreds of millions of cases of louse infestation are reported annually worldwide, 
with an apparent increase over the past few decades.  
Mortality/Morbidity. Mortality with pediculosis occurs from the 3 infectious 
vector-borne diseases (i.e. typhus, relapsing fever, trench fever) that are carried by 
P. corporis. The morbidity associated with pediculosis no doubt relates to the 
social stigma attached to any of the 3 types of infestation. Pruritus, bite reactions, 
and secondary skin infections can also cause significant morbidity.  
Sex. Girls are at higher risk of head louse infestation than boys because of social 
behavior (e.g. social acceptance of close physical contact; sharing of hats, combs, 
hair ties). No sexual predilection exists in body or pubic louse infestation; males 
and females are equally likely to become infested.  
Age. In head louse infestation, children aged 3-11 years are most likely to become 
infested because of close contact in classrooms and daycare facilities. Age is not a 
significant risk factor in body louse infestation. P. pubis infestation occurs more 
frequently in people aged 14-40 years who are sexually active.  
Causes. Causative organisms include P. humanus capitis (head louse), P. humanus 
corporis (body louse), and P. pubis (pubic louse).  
Risk factors for infestation with P. humanus capitis.Factors predisposing patients 
to head louse infestation include young age, close crowded living conditions, sex, 
race, and warm weather. The risk of nosocomial transmission is low, unless close 
patient-to-patient contact (e.g. playrooms, institutions) is present.Based on an 11-
year study of the Israel Defense Force, the head lice infestation rate is highest 
during the warmer summer months. 
Risk factors for infestation with P. humanus corporis. The risk factors for body 
louse infestation include the presence of close, crowded living situations (e.g. 
crowded buses and trains).Social circumstances in which the washing and/or 
changing of clothing is not possible are also significant risk factors for body lice. 
P. corporis can also be acquired through the use of bedding or clothing recently 
used by an individual with lice; thus, those individuals at high risk for infestation 
are those who are homeless, those who are impoverished, and people living in 
refugee camps. 
Risk factors for infestation with P. pubis. Risk factors for infestation of the pubic 
louse also include crowded living conditions.Intimate or sexual contact with an 
infested individual is another common risk factor.Because these organisms most 
often are spread through close or intimate contact, P. pubis infestation is classified 
as a sexually transmitted disease (STD). Condom use does not prevent 
transmission of P pubis. Upon diagnosis of pubic lice, concern should be raised 
about the possibility of concomitant STDs. 
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In children, infestation usually is contracted from a parent who is infested and 
rarely is sexually transmitted. In most cases of child infestations, transmission is 
due to shared bed linens and close nonsexual contact. 
History.Infestations are underreported because of the social stigma attached, 
namely the preconceived notion that lice of any kind are related to dirt and/or poor 
personal hygiene.  
P. humanus capitis. In head louse infestations, parents often seek assessment for 
their school-aged children after becoming aware of an outbreak at school.Pruritus 
is the major complaint, and parents may note the lice and nits in the hair of the 
child.The length of time the problem has been present is often valuable information 
because most children are infested with head lice for as long as 2 months before 
their discovery.Areas affected in head louse infestation include the scalp, the back 
of the neck, and postauricular areas. 
P. humanus corporis.Patients infested with P. corporis (generally people of low 
socioeconomic status) complain of nocturnal pruritus, particularly in the axillary, 
truncal, and groin regions. The lice move from the clothing to the body at 
nighttime to feed, causing intense pruritus.The investigating physician should 
inquire about the patient's socioeconomic status and living conditions. 
P. pubis. With pubic louse infestation, involvement with pruritus of the groin, 
axillae, and eyelashes or eyebrows can help to discern P. pubis infestation from 
head or body louse infestation.Adults infested with P. pubis are usually sexually 
active and have groin and body hair involvement.Children have eyelash and 
eyebrow involvement. Parents of children infested with P. pubis should be 
questioned about being infested because the parents are usually the source of 
infestation.Patients may describe associated features such as papules or wheals, 
indicating bite reactions. Patients may have a history of secondary infection after 
excoriation, which may help to confirm the presence of an infestation. 
A diagnosis of any type of pediculosis requires the finding of live specimens of 
lice and/or a viable nit (i.e. one located at the base of the hair shaft <2 mm from the 
scalp). The practitioner should assess the patient's risk factors for infestation (e.g. 
age, sex, race, social and/or economic status, crowded environment). 
Physical.P. humanus capitis.Patients infested with head lice generally present with 
an itchy scalp. The back of the neck and postauricular areas are commonly 
involved.Excoriations may be present, and, if so, secondary infection, (i.e. 
impetigo) should be excluded and, if present, treated.In patients infested with head 
lice, lymphadenopathy in the posterior auricular and cervical nodes is not 
uncommon.Bite reactions manifested as pruritic papules and/or wheals may be 
present, depending on the length of time since the blood meal. Healed bites may 
reappear when new bites occur in other areas.Close inspection of the scalp in 
affected patients may reveal the nits, live lice, and small, dark specks of insect 
feces. True nits can be differentiated from dried hairspray and hair casts by 
attempting to separate the nit from the hair; the hair casts and dried hairspray 
separate easily, while nits remain securely attached. If the physician remains 
unsure, a Wood lamp examination reveals yellow and/or green fluorescence of the 
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lice and their nits.Uncommonly, in patients who are heavily infested and untreated, 
the hair can become tangled with exudates, predisposing the area to fungal 
infection. This results in a malodorous mass known as a plica polonica. Numerous 
lice and nits are found under the matted hair mass. 
P. humanus corporis. Physical examination findings in body louse infestation 
include multiple erythematous papules (bites) located anywhere on the body but 
concentrated in the axillae, groin, and trunk (i.e. those areas most often covered by 
clothing). Thus, the face, feet, and arms are often not affected.Maculae cerulea 
may be present as blue-gray macules, which are actually a discoloration of the skin 
due to the insect's bite. Enzymes in the louse saliva are believed to cause the 
breakdown of human bilirubin to biliverdin, causing the change in skin color 
associated with maculae cerulea. The finding of maculae cerulea is believed to be 
pathognomonic for infestation with lice.The development of secondary infections 
due to excoriations is also possible. The diagnosis of body lice depends on the 
close examination of the patient's clothing for lice, nits, and insect feces. The 
seams of clothing worn on the axillae and groin regions are common sites of 
residence. The number of body lice per host is usually approximately 10, although 
as many as 1000 lice can be present.Body louse infestation is also known as 
vagabond disease, and patients that have infestation for many years can develop a 
condition termed vagabond skin. The skin becomes thickened and darkened after 
years of bites and subsequent rubbing and excoriations.Individuals with P. 
corporis infestation should also be examined for the presence of pubic and head 
lice. Examining the individual for systemic illness that may be related to one of the 
vector-borne diseases associated with P. corporis is also important. 
P. pubis. The primary complaint of patients with pubic lice is pruritus in the 
affected areas. Another clinical feature of pubic louse infestation is the presence of 
pathognomonic maculae cerulea.The groin, axillae, eyebrows, eyelashes and, 
rarely, facial hair, may be sites of infestation. Scalp involvement is rare and is 
usually confined to the marginal areas. In adults, eyelash involvement in the 
absence of genital involvement is rare. Excoriations are common. Because of the 
less-mobile nature of pubic lice, they are more likely to be found on affected areas 
clasping onto the hairs near the skin's surface.Inguinal or axillary 
lymphadenopathy has also been reported with pubic louse infestation. 
Lab Studies. A Wood lamp examination of the area considered to be infested 
shows yellow-green fluorescence of lice and nits.Because the diagnosis of 
infestation requires identification of a live louse and/or a viable nit, examining 
suggestive particles under the microscope confirms the diagnosis.A fine-tooth 
"bug-busting" comb is useful to dislodge eggs and to remove live lice/nymphs. 
Cellulose tape can be applied over an infested area to pick up lice and place them 
on a microscopic slide to be examined. 
Scrapings for a fungal culture can be taken if dermatophyte infection is a 
differential diagnosis. This is useful when the diagnosis is unclear, i.e. no nits or 
lice have been identified. 
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In P. pubis infestation, blood tests and a thorough examination for concomitant 
STDs, including HIV infection, are appropriate if the physician considers the 
individual to be at risk for these conditions. 
Histologic Findings.Histology is rarely required to make a diagnosis. Examination 
of a bite shows intradermal hemorrhage and a deep, wedge-shaped infiltrate with 
many eosinophils and lymphocytes. 
Medical Care. 
P. humanus corporis. Treatment of P. humanus corporis with any pediculicide is 
usually unnecessary because the louse lives on the clothing. Treatment of clothing 
and bed linens includes washing in hot water and drying with high heat. Dry 
cleaning is also effective for killing lice and their nits on clothing. Education about 
hygiene and accessibility to laundering facilities are important in preventing the 
spread of body lice and reinfestation. In cases of heavy pediculosis, treatment of 
the body with a pediculicide shampoo or lotion may be beneficial, especially if 
coexistent head or pubic louse infestation may be present. 
P. humanus capitis and P. pubis. Pediculicides: These include permethrin, lindane, 
malathion, or mercuric oxide ointment. The pyrethroids are neurotoxic to lice; 
however, they are not very effective against developing nits, although they do have 
a residual effect. Lotions appear to be more efficacious than shampoos because of 
their increased contact time with the skin and hair of affected areas. Permethrin is 
available as a 1% solution (Nix) and as a 5% solution (Elimite), and a formulation 
of pyrethrin and piperonyl butoxide (Rid) is available. Permethrins are usually the 
first line of treatment, although resistance to permethrin is an increasingly 
important problem. Lindane (hexachlorocyclohexane, a chlorinated hydrocarbon) 
is in the same pharmacologic class as dichlorodiphenyl trichloroethane (DDT). The 
use of lindane is controversial because of its known CNS toxicity. The compound 
is extremely lipid-soluble and, therefore, is highly permeable to the CNS. Acute 
lindane poisoning has been reported after ingestion of amounts as small as 5 mL or 
50 mg. Kwell (lindane shampoo) has been removed from the Canadian market 
because of the availability of safer alternatives. Malathion (Ovide) is an 
irreversible acetylcholinesterase inhibitor that is specific for insects. The US Food 
and Drug Administration (FDA) recently approved malathion for use against head 
lice in the United States. Malathion is available as a 0.5% and a 1% solution. 
Mercuric oxide ointment is useful in the treatment of eyelash infestation with P 
pubis. Asphyxiants: petrolatum is often used, with good results, for eyelash 
infestation. The petrolatum covers the lice and their nits, preventing respiration. 
The dead lice are removed mechanically, usually with tweezers. 
Specific oral antibiotics: Co-trimoxazole (i.e. trimethoprim and sulfamethoxazole) 
and ivermectin have been found to be effective against head louse infestation when 
taken orally. 
Mechanical removal and shaving. Solvents that help to dissolve the cement away 
from the nit aid in mechanical removal of nits with fine-tooth combs (e.g. 
LiceMeister). Formic acid and plain white vinegar have been shown to be effective 
solvents. In most studies that compare mechanical removal (i.e. wet-combing q2-
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3d for a minimum of 2 weeks) with a pediculicide, mechanical removal alone is 
not as effective.  
Shaving is effective but is usually not necessary or socially acceptable. However, 
in resistant disease, it may be a consideration. 
Prevention. Environmental eradication. Fomites (e.g. pillow cases, linens, towels, 
toys, hats) should be washed in hot water and dried. Fomites should be exposed to 
temperatures exceeding 55°C for at least 5 minutes. Any object that the infested 
child or parent has come into contact with should be washed thoroughly in hot 
water.Another way to administer environmental control is to seal potential fomites 
in plastic bags for at least 2 weeks so that all the nits hatch and die without a blood 
meal.Providing education to children about the sharing of hats, combs, and hair-
ties is also a good idea.Giving children separate areas to store their belongings in 
the classroom may help prevent the spread of lice. Treatment of contacts. The 
treatment of family members, friends, and/or other close contacts is very important 
in helping to prevent further spread of lice and in preventing reinfestation.Patient 
education regarding treatment of contacts is essential. Parents with children who 
are infested should be advised to treat the entire family with a pediculicide and to 
provide environmental fomite control.Education about hygiene and accessibility to 
laundering facilities are important in preventing the spread of body lice and 
reinfestation. 
Patient Education.Education is important with respect to the proper use of the 
chosen pediculicide, nit removal, and environmental control.In cases of school-
wide head louse infestations, all children and their family members should be 
examined for infestation. The preconceived notion that head lice are related to dirt 
and poor personal hygiene should be dispelled. 
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XIII. VIRAL INFECTIONS 
 
 
13.1.Herpes Simplex 
 
Synonyms and related keywords: HSV, herpes genitalis, genital herpes, herpes labialis, 
orolabial herpes, HSV-1, HSV type 1, herpes simplex virus type 1, HSV-2, HSV type 2, herpes 
simplex virus type 2, localized eczema herpeticum, disseminated eczema herpeticum, Kaposi's 
varicelliform eruption. 
 
Background.Herpes simplex viruses (HSVs) are DNA viruses that cause acute 
skin infections and present as grouped vesicles on an erythematous base. Rarely, 
these viruses can cause serious illness and can affect pregnancy, leading to 
significant harm to the fetus. Most infections are recurrent and tend to reappear at 
or near the same location. Herpes labialis is the most common infection caused by 
HSV type 1 (HSV-1), whereas genital herpes is usually caused by HSV type 2 
(HSV-2). Other clinical manifestations of HSV infection are less common.  
Pathophysiology.Intimate contact between a susceptible person (no preantibodies) 
and an individual who is actively shedding the virus is required for HSV infection 
to occur. Contact must involve mucous membranes or open or abraded skin. HSV 
invades and replicates in neurons as well as in epidermal and dermal cells. Virions 
travel from the initial site of infection to the sensory dorsal root ganglion, where 
latency is established. Viral replication in the sensory ganglia leads to recurrent 
clinical outbreaks. These outbreaks can be induced by various stimuli, such as 
trauma, ultraviolet radiation, extremes in temperature, stress, immunosuppression, 
or hormonal fluctuations. Viral shedding, leading to possible transmission, occurs 
during primary infection, during subsequent recurrences, and during periods of 
asymptomatic viral shedding.  
Causes. HSV-1 and HSV-2 are the causative agents of herpes genitalis, herpes 
labialis, herpes gladiatorum, herpes whitlow, herpetic keratoconjunctivitis, eczema 
herpeticum, herpes folliculitis, lumbosacral herpes, disseminated herpes, neonatal 
herpes, and herpes encephalitis. They have also been linked to some cases of 
erythema multiforme. A febrile illness, exposure to ultraviolet light, trauma, upper 
respiratory infection, or emotional stress may trigger recurrent herpes labialis due 
to HSV-1. 
The patient's geographical location, socioeconomic status, and age influence the 
frequency of HSV-1 infections. The highest prevalence of antibodies to HSV-2 
occurs in female prostitutes and male homosexuals. 
Frequency.Internationally, serologic evidence of HSV-1 infection by early 
adulthood is near 70-80%. HSV-2 seroprevalence has been reported to be as high 
as 40% worldwide. More than one third of the world's population has recurrent 
clinical HSV infections.  
Mortality/Morbidity.Severe complications may be associated with herpes 
simplex. This is especially true in females who are pregnant and in individuals 
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with immunosuppression who may develop disseminated infection and 
encephalitis. The most common complication of primary HSV-2 genital infection 
is bacterial superinfection. In women, systemic complications, such as urinary 
retention and aseptic meningitis (seen in up to 25% of women), can occur. The 
associated pain, paresthesia, and discomfort, as well as the psychosocial impact, of 
herpes simplex outbreaks cause significant morbidity to the individuals who are 
affected.  
Individuals co-infected with HSV and HIV and who have herpetic mucosal lesions 
are more likely to transmit HIV during sexual contact. Organ transplant recipients 
and patients with HIV/AIDS may develop herpetic lesions that exhibit an unusual 
morphology. Moreover, patients with Darier disease, severe atopic dermatitis, and 
mycosis fungoides may develop life-threatening disseminated Kaposi varicelliform 
eruption.  
Another serious consequence of HSV is the transmission of the virus to a neonate 
by a mother who is infected. Asymptomatic maternal shedding occurs 
approximately 7% of the time and is responsible for most neonatal HSV infections. 
HSV infections in neonates are most commonly due to HSV-2 and most are 
acquired peripartum, although in utero and postpartum transmission also occur. 
Transmission is estimated to occur at a rate of 1 case in 3500-5000 deliveries in the 
United States. Neonatal infection can cause long-term sequelae and rarely death.  
Sex.The frequency of HSV-1 and HSV-2 antibodies is slightly higher in females 
than in males. However, women are more likely than men to be protected from 
genital HSV infection by the use of barrier methods.  
Age.The frequency of HSV-1 infection in children varies with the socioeconomic 
status. Approximately, one third of children from lower socioeconomic families 
exhibit some evidence of HSV-1 infection by age 5 years. The frequency increases 
to 70-80% by early adolescence/adulthood. In contrast, only 20% of children from 
middle-class families seroconvert. The frequency of infection remains fairly stable 
until the second to third decade of life when it increases to 40-60%. The rate of 
HSV-2 seroconversion is highest in sexually active young adults.  
History.Primary infection with HSVs is clinically more severe than recurrent 
outbreaks. However, most primary HSV-1 and HSV-2 infections are subclinical 
and may never be clinically diagnosed.  
Orolabial herpes. Herpes labialis (e.g. cold sores, fever blisters) is most commonly 
associated with HSV-1 infection. Oral lesions caused by HSV-2 have been 
identified, usually secondary to orogenital contact. Primary HSV-1 infection often 
occurs in childhood and is usually asymptomatic. 
Primary infection: symptoms of primary herpes labialis may include a prodrome of 
fever, followed by a sore throat and mouth and submandibular or cervical 
lymphadenopathy. In children, gingivostomatitis and odynophagia are also 
observed. Painful vesicles develop on the lips, the gingiva, the palate, or the tongue 
and are often associated with erythema and edema. The lesions ulcerate and heal 
after 2-3 weeks. 
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Recurrences: the disease remains dormant for a variable amount of time. Pain, 
burning, itching, or paresthesia usually precedes recurrent vesicular lesions that 
eventually ulcerate or form a crust. The lesions most commonly occur in the 
vermillion border, and symptoms of untreated recurrences last approximately 1 
week. 
Genital herpes: HSV-2 is identified as the most common cause of herpes genitalis. 
However, HSV-1 has been increasingly identified as the causative agent in as 
many as 30% of cases of primary genital herpes infections likely secondary to 
orogenital contact. Recurrent genital herpes infections are almost exclusively 
caused by HSV-2. 
Primary infection: primary herpes genitalis occurs within 2 days to 2 weeks after 
exposure to the virus and has the most severe clinical manifestations. Symptoms of 
the primary episode typically last 2-3 weeks.  
In men, painful, erythematous, vesicular lesions that ulcerate most commonly 
occur on the penis, but they can also occur on the anus and the perineum. In 
women, primary herpes genitalis presents as vesicular/ulcerated lesions on the 
cervix and as painful vesicles on the external genitalia bilaterally. They can also 
occur on the vagina; the perineum; the buttocks; and, at times, the legs in a sacral 
nerve distribution. Associated symptoms include fever, malaise, edema, inguinal 
lymphadenopathy, dysuria, and vaginal or penile discharge.  
Females may also have lumbosacral reticulopathy, and as many as 25% of women 
with primary HSV-2 infections may have associated aseptic meningitis.  
Recurrences: after primary infection, the virus may be latent for months to years 
until a recurrence is triggered. Recurrent clinical outbreaks are milder and often 
preceded by a prodrome of pain, itching, tingling, burning, or paresthesia. 
Individuals who are exposed to HSV and have asymptomatic primary infections 
may experience an initial clinical episode of genital herpes months to years after 
becoming infected. Such an episode is not as severe as a true primary outbreak. 
More than one half of individuals who are HSV-2 seropositive do not experience 
clinically apparent outbreaks. However, these individuals still have episodes of 
viral shedding and can transmit the virus to their sexual partners. 
Other HSV infections 
Localized or disseminated eczema herpeticum is also known as Kaposi 
varicelliform eruption. Caused by HSV-1, eczema herpeticum is a variant of HSV 
infection that commonly develops in patients with atopic dermatitis, burns, or other 
inflammatory skin conditions. Children are most commonly affected. 
Herpes whitlow, vesicular outbreaks on the hands and the digits, was most 
commonly due to infection with HSV-1. It usually occurred in children who 
sucked their thumbs and, prior to the widespread use of gloves, in dental and 
medical health care workers. The occurrence of herpes whitlow due to HSV-2 is 
increasingly recognized, probably due to digital-genital contact. 
Herpes gladiatorum is caused by HSV-1 and is seen as papular or vesicular 
eruptions on the torsos of athletes in sports involving close physical contact 
(classically wrestling). 
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Disseminated HSV infection can occur in females who are pregnant and in 
individuals who are immunocompromised. These patients may present with 
atypical signs and symptoms of HSV, and the condition may be difficult to 
diagnose. 
Neonatal HSV. HSV-2 infection in pregnancy can have devastating effects on the 
fetus. Neonatal HSV usually manifests within the first 2 weeks of life and 
clinically ranges from localized skin, mucosal, or eye infections to encephalitis, 
pneumonitis, disseminated infection, and demise. Factors that increase the risk of 
transmission from mother to baby include the type of genital infection at the time 
of delivery (higher risk with active primary infection), prolonged rupture of 
membranes, vaginal delivery, and an absence of transplacental antibodies. The 
mortality rate is extremely high (>80%) if untreated. 
Herpetic sycosis, a follicular infection with HSV, may present as a 
vesiculopustular eruption on the beard area. This infection often results from 
autoinoculation after shaving through a recurrent herpetic outbreak. 
Physical.Clinical HSV infections appear as clustered vesicles on an erythematous 
base. They often progress to pustular or ulcerated lesions, and they eventually form 
a crust. HSV lesions tend to recur at or near the same location within the 
distribution of a sensory nerve. Systemic symptoms, such as fever, malaise, and 
acute toxicity, may accompany the lesions, especially in primary infections. Each 
condition has associated symptoms and clinical findings (see History above). 
Although HSV infections may occur anywhere on the body, 70-90% of HSV-1 
infections occur above the waist. In contrast, 70-90% of HSV-2 infections occur 
below the waist. 
Physical manifestations of HSV infections in patients who are 
immunocompromised are usually similar to those in healthy patients. However, 
larger lesions or necrotizing ulcers may occur, and widespread areas may be 
involved. 
Neonatal HSV may be difficult to diagnose because, often, no mucocutaneous 
lesions are present on physical examination. Respiratory distress, jaundice, and 
seizures may occur. 
Complications. The most common complication of HSV infections is bacterial 
superinfection. In women with primary HSV-2 infection, aseptic meningitis is also 
common.Significant complications, such as visceral and CNS dissemination and 
long-term sequelae, are rare and occur in patients who are immunocompromised or 
in cases of neonatal HSV.Patients with AIDS who are treated with intravenous 
acyclovir may develop thymidine kinase–negative strains of HSV that are resistant 
to acyclovir. These patients may be successfully treated with intravenous foscarnet 
or topical cidofovir.Babies born to mothers with genital HSV infection should be 
closely monitored for any signs of infection and promptly treated if signs of the 
disease develop. Neonatal HSV infection has a mortality rate of more than 80% if 
untreated and a mortality/significant morbidity rate of approximately 50% even 
when treated. 
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Lab Studies.Detection and typing of HSV can be completed by obtaining a viral 
culture from skin vesicles. Early in the course of recurrent infection, 80-90% of 
viral cultures of untreated lesions are positive, but the false-negative rate increases 
after 48 hours of lesion onset. 
HSV DNA detection is performed in specific instances by polymerase chain 
reaction (PCR). 
The virus may be isolated from cerebrospinal fluid (CSF) (in newborns), stool, 
urine, throat, anogenital mucosa, nasopharynx, and conjunctivae. 
In the office, a Tzanck smear can be performed as a rapid test for the presence of 
multinucleated giant cells, though the findings are not specific for the type of 
herpes virus. A Tzanck smear is prepared by scraping the floor of the herpetic 
vesicle; samples may be stained with either a Wright stain or a Papanicolaou stain. 
Approximately 50% of the results are positive. 
Direct fluorescent antibody testing may be used on air-dried smears, and 
approximately 75% of the results are positive. 
Serologic assays may be useful in identifying organ transplant recipients or 
pregnant women who may be at risk for HSV reactivation. Their use is also 
becoming more common for confirming infection and for testing of partners or 
those with asymptomatic infection. 
Enzyme-linked immunosorbent assays (ELISAs) and several other HSV-1 and 
HSV-2 serologic assays that can detect antibodies against these viruses are 
available. 
A rapid HSV-2 POCKit test is now commercially available and has a high 
sensitivity. Western blot assays are highly sensitive and specific, but they are only 
available for research purposes. 
Immunoperoxidase techniques may be used to distinguish HSV-1 and HSV-2 
antigens in formalin-fixed tissue samples. 
Histologic Findings.Cells infected with HSV demonstrate ballooning and reticular 
epidermal degeneration, acanthosis, and intraepidermal vesicles. Intranuclear 
inclusion bodies, multinucleate giant keratinocytes, and multilocular vesicles may 
also be present. 
Medical Care. Most HSV infections are self-limited. However, antiviral therapy 
shortens the course of the symptoms and may prevent dissemination and 
transmission.Intravenous, oral, and topical antiviral medications are available for 
treatment of HSV and are most effective if used at the onset of symptoms. Oral 
therapy can be given at the time of the episode or as chronic suppressive 
therapy.Treatment of herpes labialis and herpes genitalis generally consists of 
episodic courses of oral acyclovir and prodrugs valacyclovir and famciclovir. Oral 
antiviral medications, acyclovir, valacyclovir, and famciclovir, may be used (off 
label) as therapy for other uncomplicated HSV conditions (e.g. herpes whitlow), 
and the same doses as those used for herpes genitalis treatment are commonly 
recommended.Commercially available topical treatments for herpes are much less 
effective than oral therapy. Complicated HSV infections, cutaneous and/or visceral 
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dissemination, neonatal HSV, and severe infections in those who are 
immunocompromised should promptly be treated with intravenous acyclovir. 
In patients who are immunocompromised and have recurrent HSV infections, 
acyclovir-resistant HSV strains have been identified, and treatment with 
intravenous foscarnet or cidofovir may be used. 
Activity.Avoidance of known triggers of HSV recurrences, such as UV light and 
smoking, may diminish the number of outbreaks experienced by an individual. 
Prevention. HSV viral shedding is greatest during clinically evident outbreaks; 
however, transmission from individuals who are seropositive to their partners who 
are seronegative usually occurs during asymptomatic HSV shedding periods. 
Therefore, preventing transmission requires more than abstaining from intimate 
contact during outbreaks.Barrier methods, such as condoms, only confer 10-15% 
protection against the transmission of genital herpes, as transmission can occur to 
and from uncovered mucocutaneous surfaces or if the integrity of the barrier is 
compromised. Condoms have also been shown to be more effective in protecting 
women than men. 
Various HSV vaccines have been under investigation for the treatment and 
prevention of herpes genitalis, though most have not been shown to be effective.  
Women who are HSV-2 negative should be counseled to abstain from intercourse 
during the third trimester of pregnancy with partners that could be seropositive 
because primary HSV infection during this time places the fetus at highest risk of 
infection. 
The most common approach in attempting to prevent vertical transmission is to 
have women with clinically apparent HSV lesions during labor undergo cesarean 
delivery. However, cesarean delivery does not prevent all cases of neonatal 
infection because in utero infection occurs and antepartum HSV cultures are not a 
good predictor of neonatal infections. 
Use of acyclovir 400 mg PO tid during the third trimester of pregnancy has been 
proven to be safe and effective in preventing neonatal herpes and in eliminating the 
need for cesarean deliveries. 
Prognosis.For most people, HSV infections are temporary and resolve without 
detrimental sequelae; however, recurrence is common.Long-term sequelae (usually 
CNS) are more common with neonatal HSV infection than with other types of 
HSV infection. 
 
 
13.2. Herpes Zoster 
 
Synonyms and related keywords: shingles, zoster 
 
Background.Zoster is a common, predominantly dermal, and neurologic disorder 
caused by the varicella-zoster virus (VZV), a virus morphologically and 
antigenically identical to the virus causing varicella (chickenpox). Difference in 
clinical manifestations between varicella and zoster apparently depends on the 
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immune status of individual patients; those with no prior immunologic exposure to 
varicella virus, most commonly children, develop the clinical syndrome of 
varicella, while those with circulating varicella antibodies develop a localized 
recrudescence, zoster.  
Zoster probably results most often from a failure of the immune system to contain 
latent VZV replication. Whether other factors such as radiation, physical trauma, 
certain medications, other infections, or stress also can trigger zoster has not been 
determined with certainty. Nor is it entirely clear why circulating varicella 
antibodies and cell-mediated immune mechanisms do not prevent recurrent overt 
disease, as is common with most other viral illnesses.  
An inverse correlation appears to exist between the capacity of a host to mount a 
cellular immune response and the incidence of zoster. However, many patients 
with zoster apparently have normal immune systems. In these patients, zoster is 
postulated to occur when VZV antibody titers and cellular immunity drop to levels 
at which they no longer are completely effective in preventing viral invasion. 
Evidence for this hypothesis includes the observation that pediatricians, who 
presumably are reexposed to the varicella virus routinely and thus maintain high 
levels of immunity to VZV, seldom develop zoster.  
Pathophysiology.Zoster most commonly manifests in 1 or more posterior spinal 
ganglia or cranial sensory ganglia, presumably because viral particles have been 
preserved within these ganglia in a dormant state since the original episode of 
varicella. This results in pain and characteristic cutaneous findings along the 
corresponding sensory dermatomes of the involved ganglia. Less often, 
involvement of anterior and posterior horn cells, leptomeninges, and peripheral 
nerves is observed, with consequent muscle weakness or palsy, pleocytosis of 
spinal fluid, and/or sensory loss. Rarely, myelitis, meningitis, encephalitis, or 
visceral involvement may occur.  
Causes.Reactivation of varicella virus that has remained dormant within dorsal 
root ganglia, often for decades after the patient's initial exposure to the virus in the 
form of varicella (chickenpox), causes zoster. Exactly what triggers this 
reactivation has not yet been determined precisely, but likely candidates include 
external reexposure to the virus, acute or chronic disease processes (particularly 
malignancies and infections), medications of various types, and emotional stress. 
More than 1 or all of these factors, plus others, possibly are capable of triggering 
zoster. The reason 1 dorsal root ganglion experiences reactivation of its stored viral 
load preferentially over other ganglia is unclear. 
The cause of PHN also remains a mystery. Rapid initiation of treatment has been 
shown to decrease the incidence of PHN significantly, which can be explained by 
the theory that incessant pain of active zoster sets up a positive feedback loop 
within the thalamus and the cortex, creating a central pain syndrome similar to 
phantom leg pain. Prompt treatment breaks the loop by providing pain-free periods 
early in the disease course. 
Frequency.Internationally, the incidence of zoster has not been well studied, but 
probably it is in the same range of 2-3 cases per 1000 per year.  
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Mortality/Morbidity.Zoster is rarely, if ever, fatal, although in individuals who 
are severely debilitated, zoster may be considered a contributing factor to death. 
Morbidity usually is confined to pain within the affected dermatome, which can be 
severe and can persist well beyond the duration of active disease (postherpetic 
neuralgia [PHN]). Eye involvement (zoster ophthalmicus) can cause temporarily or 
permanently decreased visual acuity or blindness. Complications such as 
secondary infection and meningeal or visceral involvement can produce further 
morbidity in the form of infections and scarring.  
Age.Almost 50% of individuals who live beyond age 80 years can expect to 
develop zoster. Zoster is rare in children and young adults, with the exception of 
younger patients with AIDS, lymphoma, other malignancies, and other immune 
deficiencies, and patients who are recipients of bone marrow and kidney 
transplants. In addition, patients with these associated factors are at greater risk of 
developing zoster regardless of age.  
History.Zoster may begin with a systemic response, e.g. fever, anorexia, and 
lassitude, although symptoms frequently are mild and may not be associated by 
either patient or physician with the classic zoster signs and symptoms that follow. 
Symptoms typically include prodromal sensory phenomena along 1 or more skin 
dermatomes lasting 1-10 days (averaging 48 h), which usually are noted as pain or, 
rarely, paresthesias. Prodromal pain typically is described as muscle or 
toothachelike in origin but may simulate headache, iritis, pleurisy, brachial 
neuritis, cardiac pain, appendicitis or other intraabdominal disease, or sciatica, and 
it can result in incorrect tentative diagnoses. The prodromal interval of pain prior 
to onset of cutaneous findings has been believed to represent spread of viral 
particles along sensory nerves; however, approximately 10% of patients report 
onset of pain and rash simultaneously. 
After the onset of prodromal symptoms, the following signs and symptoms occur:  
Patchy erythema, occasionally accompanied by induration, appears in the 
dermatomal area of involvement.  
Regional lymphadenopathy may appear at this stage or subsequently.  
The classic finding of grouped herpetiform vesicles develops upon the 
erythematous base. At this point, the virus usually has induced significant 
inflammation of the involved sensory nerve causing severe pain, which led 19th-
century French physicians to refer to zoster as "the band of roses from hell."  
Cutaneous findings classically appear unilaterally (for unknown reasons), stopping 
abruptly at the midline of the limit of sensory coverage of the involved dermatome. 
Vesicles initially are clear, but eventually, they cloud, rupture, crust, and involute. 
This evolution often is accelerated greatly by treatment.  
After vesicular involution, remaining erythematous plaques slowly resolve, 
typically without visible sequelae; however, scarring can occur if deeper epidermal 
and dermal layers have been compromised by excoriation, secondary infection, or 
other complications. 
Unfortunately, resolution of the associated pain does not always accompany 
resolution of erythema and vesiculation. The PHN, which usually is confined to the 
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area of original dermatomal involvement, can persist for weeks, months, or years 
and often is severe. The reason some patients with zoster, and not others, 
experience PHN is not understood fully, but patients who are older (>60 y), 
particularly patients who are debilitated or arteriosclerotic, are affected far more 
frequently than patients who are younger. In addition, PHN is observed more 
frequently after cases of herpes zoster ophthalmicus and in instances of upper body 
dermatomal involvement. Other less common postherpetic sequelae include 
hyperesthesia, or more rarely, hypesthesia or anesthesia in the area of involvement. 
The virus that causes zoster is morphologically and antigenically identical to the 
virus causing varicella. Experimentally, varicella has followed dermal inoculation 
with zoster vesicle fluid in individuals without antibodies to the virus. Susceptible 
individuals can contract zoster after exposure to patients with active varicella or 
active zoster. Whether it is possible (and if so, how likely) for individuals with 
varicella antibodies to contract zoster after exposure to the virus is a subject for 
further study and may depend on the existing antibody titer level in each 
individual, as well as the status of that individual's overall immune response. 
Physical.Classic physical findings of zoster include painful grouped herpetiform 
vesicles on an erythematous base confined to the cutaneous surface innervated by a 
single unilateral sensory nerve. Regional lymphadenopathy may be present. 
Vesicles initially are clear but eventually cloud, rupture, crust, and involute. Many 
clinical variations are possible as follows:  
Herpes zoster ophthalmicus (HZO) constitutes 10-15% of zoster cases. HZO 
results from viral invasion of the Gasserian ganglion.  
For unknown reasons, involvement of the ophthalmic branch of the fifth cranial 
nerve (CN; termed CN V1) is 5 times as common as involvement of the maxillary 
(CN V2) or mandibular (CN V3) branches. HZO is recognized easily by vesicular 
and erythematous involvement of the CN V1 dermatome, ipsilateral forehead, and 
upper eyelid. Ipsilateral preauricular and, occasionally, submaxillary nodal 
involvement is a common prodromal event in HZO and often is valued 
equivalently with pain, vesiculation, and erythema in establishing a diagnosis.  
Prodromal lymphadenopathy should not be confused with later reactive 
adenopathy caused by secondary infection of vesicles. Headaches, nausea, and 
vomiting also are common prodrome symptoms. Signs of meningeal irritation may 
be present; therefore, meningitis must be excluded.  
The ophthalmic branch of the fifth CN (with ciliary ganglion) sends branches to 
the tentorium (recurrent nerve of Arnold) and to the third and sixth (and 
occasionally fourth) CNs, which may account for the frequency of meningeal signs 
and, occasionally, the CN III and CN VI nerve palsies associated with HZO. HZO 
requires particularly aggressive treatment and follow-up monitoring because of the 
possibility of involvement of the eye, which occurs in approximately one half of 
patients with HZO. Traditionally, involvement of the nasociliary branch, 
characterized by vesicles at the tip of the nose, has indicated that eye involvement 
is present or imminent (termed the Hutchinson rule). However, in recent years, 
clinicians with extensive experience in the treatment of HZO have disputed this, 
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claiming that eye and nasociliary branch involvement can be present with or 
without distal nasal vesiculation. In the author's experience, eye lesions are rare in 
the absence of distal nose lesions.  
Eye involvement poses a risk to vision in the absence of prompt detection and 
treatment. The presence of orbital edema is an ophthalmologic emergency, and 
patients must be referred immediately for specialized ophthalmic evaluation and 
treatment. Iritis, iridocyclitis, glaucoma, and corneal tissue ulcerations are possible 
in these cases. Involvement of the area below the palpebral fissure alone, without 
upper eyelid or nasal involvement, is considered less likely to result in ocular 
complications since the superior maxillary nerve innervates the lower eyelid.  
Postherpetic complications are more common in HZO than in other manifestations 
of zoster. In particular, PHN is observed in well over one half of patients with 
HZO and can be severe and long lasting. Scarring also is more common, probably 
as a result of severe destructive inflammation. Palsy of the third CN, and 
occasionally of the fourth and sixth CNs, may occur. Rarely, simultaneous 
involvement of other CNs has been reported. The most common of these is seventh 
CN involvement, which may produce facial palsy. 
Zoster of the maxillary branch of the fifth CN (CN V2): involvement is localized 
to the ipsilateral cheek, lower eyelid, side of the nose, upper eyelid, upper teeth, 
mucus membrane of the nose, nasopharynx, tonsils, and roof of the mouth. At 
times, only the oral mucus membrane is involved without skin manifestations. 
Early preeruptive herpetic pain can simulate a severe toothache and result in 
unnecessary oral surgery or dental treatment. 
Zoster of the mandibular branch of the fifth CN (CN V3): areas of involvement 
include the side of the head, external ear and external auditory canal, lower lip, and 
a portion of the oral mucosa. As in other fifth CN branch involvement, prodromal 
pain in affected areas can result in incorrect diagnoses. 
Zoster oticus (also termed geniculate zoster, zoster auris, Ramsay-Hunt syndrome, 
Hunt syndrome): this form of zoster is considered rare but more likely is 
recognized rarely. It often is mistaken for eczema, Méniиre disease, Bell palsy, 
stroke, and abscess of the ear. Classically, it begins with otalgia and herpetiform 
vesicles on the external ear canal with or without features of facial paralysis 
resulting from facial nerve (CN VII) involvement, auditory symptoms (e.g. 
deafness), and vestibular symptoms in variable combinations. The syndrome also 
may result from zoster of ninth or tenth CN origin since the external ear has 
complex innervation by branches of several CNs (CN V, CN VII, CN IX, CN X), 
as well as vertebral nerve C2 and possibly C3. 
Glossopharyngeal and vagal zoster (herpes pharyngis, herpes laryngis): this 
variation of zoster involves the jugular and petrosal ganglia, which are adjacent 
and often involved in some combination; however, individual involvement of both 
ganglia has been observed. Painful vesicular rash typically involves the palate, 
posterior tongue, epiglottis, tonsillar pillars, and, occasionally, the external ear. A 
unilateral distribution can distinguish this variation of zoster from herpes simplex 
and herpangina. 
265 
 
Herpes occipitocollaris (vertebral nerves C2 and C3 involvement): involvement 
includes the posterior scalp, nuchal area, portions of the ear, and portions of the 
lower mandible and anterior neck. Vertebral nerves C2 and C3 often are involved 
together. Branches of vertebral nerves C2 and C3 communicate with the seventh 
and tenth CNs, sometimes causing CN VII and CN X symptoms as well. Nuchal 
and/or scalp involvement occasionally is confused with folliculitis, furunculosis, 
cellulitis, erysipelas, or acne keloidalis nuchae. The painful prodrome can result in 
confusion and misdiagnosis until the classic vesicular rash appears. 
Zoster encephalomyelitis (meningoencephalitis): localized mild leptomeningitis in 
the region of neurologic involvement is more common than generally is recognized 
and often results in pleocytosis (25-50 lymphocytes) in the spinal fluid.  
Zoster myelitis: that VZV can produce encephalomyelitis is well documented. 
More rarely, the myelitis lesion predominates or is the sole feature. The clinical 
picture is one of acute onset of paraplegia resulting from a diffuse involvement of 
the spinal cord. The picture is that associated with acute transverse myelopathy. 
Disseminated zoster: dissemination usually is defined as a generalized eruption of 
more than 10-12 extradermatomal vesicles occurring 7-14 days after the onset of 
classic dermatomal zoster. Disseminated zoster typically is indistinguishable 
clinically from varicella (chickenpox). Patients in whom zoster has disseminated 
must be observed carefully for the development of pneumonitis and encephalitis, 
which can be life threatening. 
Bilateral zoster: on rare occasions, zoster manifests bilaterally. The reason this 
occurs is unknown, as is the reason zoster typically occurs unilaterally. A popular 
superstition among lay people states that "if shingles occurs on both sides and 
meets in the middle, you will die." While some cases of bilateral zoster have been 
reported in patients who are extremely debilitated and in whom bilateral 
presentation cannot be considered a favorable sign, a fatal prognosis is not 
necessarily indicated for all patients. In cases of bilateral zoster, it is not unusual 
for 1 or 2 adjacent dermatomes to be involved. Unlike examples of multiple 
dermatomal involvement in unilateral disease, involvement in adjacent 
dermatomes is not typically a sign of underlying disease (e.g. malignancy). 
Multiple dermatomal involvement: involvement of more than 1 dermatomal 
distribution in unilateral zoster is rare and usually is considered a harbinger of 
significant compromise of the immune system caused by AIDS, malignancy, 
chemotherapy, and other factors. 
Recurrent zoster: recurrences, while rare, are not unheard of and have not been 
shown to represent any specific event. Most reputed cases of recurrent zoster 
involve other entities, usually herpes simplex in a linear distribution. 
Zoster involving the urinary bladder: rarely, zoster involving the dermatomes of 
the buttock area (vertebral nerves L1, L2, S2, S3, S4) may be associated with 
vesicles in the bladder, which can cause severe dysuria and urinary frequency. This 
picture can be mistaken easily for cystitis. If vesicles rupture in the bladder, 
hematuria (another common symptom of cystitis) may occur. Transient bladder 
paralysis resulting from zoster involving the gluteal and sacral regions and lumbar 
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sympathetic segments has been reported, and acute urinary retention is possible if a 
motor component exists. 
Other internal manifestations: vesicular involvement has been reported in 
bronchi, pleural spaces, and the gastrointestinal tract. Zoster pneumonia also has 
been reported. Such involvement frequently is found in individuals with 
significantly compromised immune systems. Pain in these areas, as on the 
cutaneous surface, may be referred pain and does not necessarily indicate the 
presence of vesicles. 
Motor complications: while zoster classically invades only sensory nerves (for 
unknown reasons), viral particles occasionally cross over to the anterior horn of the 
involved ganglion, resulting in motor symptoms. Paresis may be seen in 
extraocular muscles, any area of facial innervation, and anywhere along the spinal 
cord, including the phrenic nerve. Paresis most commonly is observed when 
muscles of an arm or leg are involved; however, this may be because it is detected 
most easily at those locations. Truncal motor involvement may be more common 
than generally is believed, because both physician and patient easily may overlook 
a small area of muscle weakness of the central trunk.  
Motor symptoms can range from weakness to total paralysis, depending on how 
many roots of the involved nerve plexus are affected. While most motor 
involvement (like most sensory involvement) is self-limited, partial or complete 
paresis can persist indefinitely, particularly when CN V, CN VII, phrenic, and 
upper or lower extremity nerves are affected. Paralysis of abdominal musculature 
can cause a hernial bulge. 
Complications.Pain within the affected dermatome can be severe and can persist 
well beyond the duration of active disease (PHN). Eye involvement (zoster 
ophthalmicus) temporarily or permanently can cause decreased visual acuity or 
blindness. Complications such as secondary infection and meningeal or visceral 
involvement can produce further morbidity in the form of infections and 
scarring.Zoster is rarely, if ever, fatal, although in individuals who are severely 
debilitated, zoster may be considered a contributing factor to death. 
Lab Studies.Systemic manifestations are uncommon and usually are confined to 
patients in whom the immune system has been compromised by other disease 
processes or chemotherapy. General laboratory studies and other systemic workup 
are not indicated unless complications or underlying diseases are suggested. A 
small percentage of patients, particularly those with CN involvement, may develop 
headache and neck stiffness, necessitating a spinal tap to exclude meningitis. 
Occasionally, Tzanck preparation, viral culture, direct fluorescence antibody 
(DFA) testing, and/or skin biopsy may be necessary to establish the diagnosis in 
atypical cases. DFA testing is more sensitive than conventional viral cultures 
because of the lability of VZV. 
Zoster is seen approximately 7 times more frequently in patients infected by 
human immunodeficiency virus (HIV); therefore, when clinically indicated, order 
an HIV test. 
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Histologic Findings.Clinical diagnosis almost always can be made. Biopsy is 
reserved for cases difficult to diagnose. On rare occasions when biopsy is 
necessary, histologic findings are similar to those of herpes simplex and varicella 
(chickenpox). Ballooning degeneration and acantholysis of keratinocytes result in 
an intraepidermal vesicle. Multinucleated giant cells with accentuation of nuclear 
material at the periphery of nuclei are characteristic. Underlying leukocytoclastic 
vasculitis often is a prominent finding and helps differentiate zoster from other 
herpetic infections. 
Medical Care.Until recently, treatment of zoster has been frustrating because of a 
fundamental lack of effective antiviral medications; however, this did not prevent 
many clinicians from making the attempt. An enormous number and variety of 
therapeutic approaches to the treatment of zoster have been proposed over the 
years, most of which probably are ineffective. Reports of anecdotal evidence of 
efficacy are difficult to evaluate objectively because of the highly variable and 
self-limited nature of the disease.  
Systemic steroids. Many practitioners have long used oral prednisone and similar 
medications to reduce pain and to decrease the incidence of PHN, presumably by 
reducing inflammation in dorsal root ganglia and involved sensory nerves. While 
never conclusively demonstrated in a double-blind crossover study, some evidence 
exists that steroids are effective in achieving these treatment goals. More study is 
needed.  
A substantial dose (40-60 mg every morning) typically is administered as early as 
possible in the course of the disease and is continued for 1 week, followed by a 
rapid taper over 1-2 weeks.  
Dissemination of viral particles beyond dermatomal limits always has been a 
theoretical concern, but clinically, it almost never is observed in individuals with 
intact immune systems. Typical risks inherent in the use of systemic steroids, such 
as adrenocortical suppression and femoral osteonecrosis, must be kept in mind. 
Systemic antiviral agents. Controversy over use of systemic steroids has been 
rendered all but moot in recent years with the advent of effective antiviral agents. 
Acyclovir and its derivatives (valacyclovir, famciclovir, penciclovir, and 
desciclovir, which is not available in the US) all have been shown to be safe and 
effective in the treatment of active disease and in the prevention of PHN.  
Usually, the earlier antiviral medications are started, the more effective they are in 
shortening the duration of zoster and in preventing or decreasing severity of PHN. 
Ideally, initiate therapy within 72 hours of the onset of symptoms. 
Varicella-zoster vaccine. Since 1995, live attenuated varicella virus vaccine 
(Varivax) has been available in the US and has been up to 99% effective in 
protecting susceptible individuals from varicella infection. It also may prove 
effective in prevention of zoster.  
Varicella-zoster immune globulin. The Centers for Disease Control and 
Prevention (CDC) currently recommend administration of varicella-zoster immune 
globulin (VZIG) to prevent or modify clinical illness in persons with exposure to 
varicella or zoster who are susceptible or immunocompromised. VZIG provides 
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maximum benefit when administered as soon as possible after the presumed 
exposure, but VZIG may be effective if administered as late as 96 hours after 
exposure. Protection after VZIG administration lasts for an average of 
approximately 3 weeks, according to the CDC. 
Management of PHN. Pain associated with zoster usually is the most debilitating 
symptom of the disease. Once established, pain is notoriously difficult to alleviate 
with traditional analgesics, including narcotics.  
Initiation of antiviral therapy as early as possible in the course of acute zoster, and 
definitely within 72 hours of onset, has been shown to be effective in alleviating 
acute pain and preventing PHN in most patients. Once PHN has developed, 
treatment is much more difficult and often impossible.  
Topical capsaicin commonly is recommended; its active ingredient depletes 
neurotransmitters at involved nerve endings. However, the cream must be applied 
at least 5 times per day to be effective, and pain may increase upon application for 
the first few days of therapy as accumulated neurotransmitters are released. Once 
neurotransmitter reserves have been depleted, any resultant pain relief is 
temporary. Tricyclic antidepressants and the anticonvulsant drug gabapentin have 
been used with variable success.  
Consultations.Consultation with the appropriate specialist may be indicated when 
symptoms point toward meningitis (herpes zoster ophthalmicus), dental disease 
(zoster of maxillary branch), ear infections or deafness (Ramsay-Hunt syndrome), 
oropharyngeal infections (zoster pharyngis/laryngis), meningoencephalitis, and 
encephalomyelitis; when motor complications are present; or when the urinary 
bladder, lungs, or gastrointestinal tract are involved.  
Prevention. Since 1995, live attenuated varicella-virus vaccine (Varivax) has been 
available in the US and has been up to 99% effective in protecting susceptible 
individuals from varicella infection. It also may prove effective in prevention of 
zoster.  
Prognosis is excellent, although the pain of PHN, when it occurs, can range in 
intensity from uncomfortable to debilitating. 
 
 
13.3. Molluscum Contagiosum 
 
Backgroun.Descriptions of molluscum contagiosum have been in the medical 
literature since 1817. In 1905, the viral nature of molluscum contagiosum was 
discovered by Juliusburg. It is a cutaneous infection caused by a large DNA 
poxvirus that affects both children and adults. Transmission has been reported by 
direct skin contact and has occurred in wrestlers, patients of a surgeon with a hand 
lesion, and children sharing baths, towels, gymnasium equipment, and benches. 
Autoinoculation also occurs as evidenced by linear arrays of lesions on infected 
individuals.  
Pathophysiology.The virus replicates in the cytoplasm of epithelial cells 
producing cytoplasmic inclusions, and it may cause enlargement of infected cells.  
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Causes.DNA poxvirus, the largest virus known (200 X 300 X 100 nm), causes 
molluscum contagiosum. The inner and outer membranes of the virion surround a 
dumbbell-shaped nucleoid. The genome is a linear duplex DNA with an estimated 
weight of 120-200 megadaltons. Restriction endonuclease analysis of the 
molluscum contagiosum virus (MCV) reveals 2 viral subtypes named MCV 1 and 
MCV 2 with genomes of 185 kilobases (kb) and 195 kb, respectively.MCV 
encodes an antioxidant protein (MC066L), selenoprotein, which functions as a 
scavenger of reactive oxygen metabolites and protects cells from UV or peroxide 
damage. The particular role of this protein is not known because the attempt to 
grow MCV in vitro has not been successful. 
Frequency. Molluscum contagiosum is common in the tropics and subtropics 
probably because of the increased desquamation associated with hydration. 
Epidemiological studies suggest that transmission may be related to poor hygiene 
and climatic factors, such as warmth and humidity.  
History. Most patients are asymptomatic; some complain of pruritus, tenderness, 
and pain.The incubation period ranges from weeks to months (14-50 d). If patients 
have eczema or other diseases altering skin barrier function, molluscum may 
spread more rapidly in affected areas. 
Physical.Physical findings generally are limited to the skin, but cases have 
reported findings on the eyelids and conjunctiva.  
Skin - Primary lesion. Firm, smooth, umbilicated papules, usually 2-6 mm in 
diameter (range 1-15 mm) may be present in groups or widely disseminated on the 
skin and mucosal surfaces. Lesions greater than 15 mm have been described, 
particularly in patients with AIDS.The lesions can be flesh-colored, white, 
translucent, or even yellow in color.The number of lesions varies from 1-20 up to 
hundreds in some reports.Some lesions become confluent to form a plaque.Lesions 
generally are self-limited but can persist for several years. 
Skin – Distribution. In children, lesions mainly on the trunk and extremities.In 
adults, lesions often are located on the lower abdominal wall, inner thighs, pubic 
area, and genitalia.Although rarely found in the mouth or on the palms and soles, 
cases of molluscum contagiosum involving the oral mucosa, including the lips, 
buccal mucosa, hard palate, retromolar pad, and tongue, have been reported. 
Immunocompromised conditions. In some conditions, including sarcoidosis, 
lymphocytic leukemia, congenital immunodeficiency, selective immunoglobulin M 
(IgM) deficiency, thymoma, treatment with prednisone and methotrexate, AIDS, 
malignancy, and atopic dermatitis, multiple widespread, persistent, disfiguring 
lesions can occur, especially on the face and possibly involving the neck and trunk. 
Complications include irritation, inflammation, and secondary infections. Lesions 
on eyelids may be associated with follicular or papillary conjunctivitis. 
Lab Studies. Generally, diagnosis is made on clinical grounds based on 
appearance of the lesions.Identification of characteristic intracytoplasmic inclusion 
bodies in histologic or cytologic preparations is made by hematoxylin and eosin 
(H&E) staining of biopsy sections. 
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Lab: Serum antibodies have been measured by complement fixation, tissue culture 
neutralization, fluorescent antibody, and gel agar diffusion techniques; however, 
they are not well standardized.Smears from scrapings of lesions stained by 
Papanicolaou or Wright, Giemsa, or Gram reveal inclusion bodies.Antigen of 
MCV may be identified by fluorescent antibody technique. 
Other Tests. Electron micrographs of fixed material from papule are taken. 
Sexually active patients also may have other concomitant venereal diseases such as 
syphilis and gonorrhea, so their partners also should be examined to prevent 
reinoculation. 
Histologic Findings. The epidermis is acanthotic and may measure up to 6 times 
the normal thickness. Basal cells are slightly larger and more columnar than 
normal, with dense and granular nuclei. Above the basal keratinocytes are enlarged 
keratinocytes with a deep purple appearance. The molluscum body is the result of a 
virally induced cytoplasmic transformation that begins in the lower cells of the 
epidermis, just above the basal cell layer. Keratinocytes contain multiple Feulgen-
positive intracytoplasmic inclusion bodies (Henderson-Patterson or molluscum 
bodies) containing viral particles that can be identified in the cells of stratum 
spinosum. The viral particles increase in size as they progress up toward the 
granular layer causing compression of the nucleus to the periphery of the infected 
keratinocytes. The core of the down-growth of the central stratum corneum of the 
papules is largely replaced by viral particles. The dermis under the infected lobule 
of epidermis is normal except for occasional inflammation.  
Medical Care.Molluscum contagiosum generally is self-limited and heals after 
several months or years. Any one lesion is present for about 2 months; however, to 
prevent autoinoculation or transmission to close contacts, therapy may be 
beneficial. The common goal of the different treatment methods is the destruction 
of the lesions. Controlled studies have not been completed with the various 
treatments. Commonly used treatments are not approved by the Food and Drug 
Administration (FDA).  
Topical applications. Cantharidin - a single application that may need to be 
repeated once or twice every 3-4 weeks.Tretinoin - cream 0.1% or gel 0.025% 
applied daily. Podophyllin. Trichloroacetic acid. Tincture of iodine. Silver nitrate 
or phenol. Cryotherapy with liquid nitrogen. 
Systemic agents: Griseofulvin, Methisazone, Cimetidine. In immunocompromised 
patients, improvement of lesions was seen in individual cases with the use of 
ritonavir, cidofovir (intravenous and topical), AZT, intralesional interferon alpha, 
and topical injections of streptococcal antigen OK-432. 
Surgical Care.Curettage followed either by light electrodesiccation or by 
application of a caustic agent to cauterize bleeding points has been shown to be an 
effective treatment in children and adults. The topical anesthetic cream EMLA 
(eutectic mixture of local anesthetics) can be applied under occlusion an hour 
before curettage to decrease the discomfort associated with the procedure.  
Prognosis.Molluscum contagiosum is a benign self-limited disease.Treatments are 
effective.Overall, prognosis is excellent. 
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13.4. Genital Warts 
 
Synonyms and related keywords: condyloma acuminatum, GW 
 
Background.Until the 19th century, genital warts (GW) were believed to be a 
form of syphilis or gonorrhea. The viral etiology of warts was established in 1907 
by inoculation of wart filtrates into skin, inducing papillomas at the injection site. 
Today, condyloma acuminatum or GW generally are recognized as benign 
proliferations of the anogenital skin and mucosa that result from infection with 
human papilloma viruses (HPV). The HPV family has at least 78 well-documented 
genotypes. Some believe that the number of HPV types eventually will reach 100 
or more. Despite the generally benign nature of the proliferations, certain types of 
HPV can place patients at a high risk for anogenital cancer.  
Pathophysiology.GW are a result of HPV infection, which is believed to be 
acquired by inoculation of the virus into the epidermis via defects in the epithelium 
(e.g. maceration of the skin). Autoinoculation of virus into opposed lesions is 
common. Spread of HPV infection is usually through skin-associated virus and not 
from blood-borne infection. Probably, cell-mediated immunity (CMI) plays a 
significant role in wart regression; patients with CMI deficiency are particularly 
susceptible to HPV infection and are notoriously difficult to treat.  
Frequency. GW have affected as many as 30 million individuals worldwide.  
Mortality/Morbidity. Although anogenital warts generally are benign, their 
significance is drawn from the increased risk of malignancy secondary to HPV 
infection. Specifically, HPV types 16, 18, 31, 33, and 51 are associated with the 
greatest prevalence of anogenital malignancy. Infectivity of anogenital warts may 
be up to two thirds of sexual contacts. High concordance for the same HPV type 
has been found among sexual partners.  
Age. The highest incidence of GW consistently is found in young adults aged 15-
25 years. This observation tends to hold true even after adjustment for lifetime 
number of sexual partners, which itself is a significant risk factor for HPV 
infection.  
Causes.The definitive cause of anogenital warts is HPV. HPV is part of the 
papovavirus class, which includes SV 40, BK, and JC virus. The HPV capsid lacks 
an envelope, which makes it very stable and resistant to various treatments.No 
serologic typing of HPV is available because of the lack of consistent in vitro 
culture methods.Typing of HPV is according to genotype, which usually is 
determined by molecular hybridization techniques using molecularly cloned HPV 
DNA of known type as the standard.Two HPV are said to be of different types 
when their DNA hybridize (bind) less than 50% as efficiently to each other as to 
themselves.More than 30 types of HPV (of nearly 80 sequenced to date) have been 
found in genital warts. They are very host specific. These viruses do not infect 
laboratory animals and are not susceptible to acyclovir.As a rule, HPV types 
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causing common warts of the skin do not infect moist epithelium and vice 
versa.Multiple clinical associations with unique genotypes of HPV have been 
documented. HPV types and their association with the clinical disease are as 
follows: plantar warts - 1, 2, 4, and 63; common warts - 2, 4, 1, 26, 27, 29, 57, 65, 
and 75-78; meat/poultry/fish handlers - 7, 1-4, 10, and 28; flat warts - 3, 10, 27, 28, 
38, and 49; epidermodysplasia verruciformis - 2, 3, 5, 8, 9, 10, 12, 14, 15, 17, 19, 
20, 21-25, 28, 36-38, 40, 47, and 50;squamous cell carcinoma or actinic keratosis - 
16, 14, 18, 36, and 41; squamous cell carcinoma, keratoacanthoma type - 37, 7, 9, 
16, 29, 35, and 58;squamous cell carcinoma, in immunocompromised - 48 and 60; 
Bowen disease (non-genital) - 16, 2, 3, 5, 16, 18, 20, 26-29, 31, 33, 34, 54, 56, 58, 
61, 62, and 73;melanoma – 38; oral focal epithelial hyperplasia - 13 and 32; oral 
papilloma - 11, 7, 32, 57, 72, and 73; laryngeal papilloma (recurrent respiratory 
papillomatosis) - 6, 11, 2, 16, 30, 40, and 57;conjunctival papillomas and cancer - 
6, 11, and 16; epidermal cyst – 60; condyloma acuminatum - 6, 11, 1-5, 10, 16, 18, 
30, 31, 33, 35, 39-45, 51-59, and 70; giant condyloma of Buschke and Löwenstein 
and other verrucous carcinoma - 6, 11, 57, 72, and 73; Bowenoid papulosis - 16, 
34, 39, 40, 42, and 45; vulvar intraepithelial neoplasia - 56, 59-64, 67, and 71; 
cervical squamous intraepithelial lesions (SIL); low-grade squamous intraepithelial 
lesions (LGSIL) - 6, 11, 16, 18, 26, 27, 30, 31, 33-35, 40, 42-45, 51-58, 61, 62, 67-
69, and 71-74; High-grade squamous intraepithelial lesions (HGSIL) - 16, 18, 6, 
11, 31, 33, 35, 39, 42, 44, 45, 51, 52, 56, 58, 59, 61, 64, 66, and 68; cervical cancer 
- 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. 
History.Warts generally do not become clinically apparent until several months 
after inoculation with HPV.Lesions follow a slow and indolent course and may 
develop by inoculation from opposing surfaces. 
Physical.Anogenital warts consist of pink-to-brown papillomatous papules or 
nodules of the genitalia, perineum, crural folds, and anus.Warts vary in size and 
can form large, exophytic, cauliflowerlike masses. Discrete papules, 1-3 mm in 
size can present on the shaft of the penis. The growth can extend into the vagina, 
urethra, cervix, perirectal epithelium, anus, and rectum. 
Complications. Disease complications can include progression to malignancy and 
transmission to other sexual contacts. In the setting of GW active during a 
pregnancy delivery, there is a small risk of laryngeal papillomatosis.Each 
therapeutic modality carries its own unique set of risks. Risks of individual 
medical options are enumerated above.Expected effects of cryosurgery include 
pain, edema, vesicles, bullae, weeping, and some necrosis. There is a small risk of 
infection, bleeding, abnormal scarring, pigment alteration, paresthesias, and 
alopecia with cryosurgery.Similarly, laser surgery of GW may result in pigment 
alteration, abnormal scarring, and infection. Special care must be taken to prevent 
respiratory infection from the laser plume generated by vaporization of virally 
infected tissue. 
Lab Studies. Diagnosis usually is made clinically; it may be helped by the 
application of acetic acid and biopsy.At the current time, identification of precise 
HPV genotypes is available only in research laboratories by using DNA 
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hybridization techniques. This technique includes Southern blot (highly sensitive 
and also most time consuming), dot blot, and in situ hybridization.Others methods 
include enzyme-linked immunosorbent assay (ELISA) for immunoglobulin G 
(IgG) antibody (Ab) against HPV 16 capsid.Certain screening tests are available 
with a relatively high sensitivity and specificity; they include the following: 
ViraPap, ThinPrep Pap, Hybrid capture II. 
Other Tests. Acetic acid test. Soaking acetic acid into suspicious lesions can 
enhance the degree of suspicion in lesions without classic features.The method 
involves applying a 3-5% acetic acid–moistened gauze pad for 5-10 minutes on 
suspected lesions of the penis, cervix, labia, or perianal area.Inconspicuous, flat, 
genital lesions that might be difficult to assess become visible. Dysplastic and 
neoplastic tissues turn white (acetowhite).False-positive results are common and 
can result from anything that causes parakeratosis (e.g. candidiasis, psoriasis, 
lichen planus, healing epithelium, sebaceous glands).This technique can be 
combined with the use of colposcopy to examine cervical lesions. 
Histologic Findings. Histopathology can elucidate diagnosis in most cases.  
Verrucae consist of acanthotic epidermis with papillomatosis, hyperkeratosis, and 
parakeratosis. Elongated rete ridges may point to the center of the wart and dermal 
capillary vessels may be thrombosed. Koilocytes are indicative of HPV infection. 
These are large keratinocytes with an eccentric, pyknotic nucleus surrounded by a 
perinuclear halo. Anogenital warts lack a granular layer and tend to be more 
papillomatous and vascular than common warts. An electron microscope may 
show viral particles in nuclei. Immunohistochemical staining with the peroxidase-
antiperoxidase technique stains cells infected by viral particles.  
Medical Care. Treatment is aimed at destruction of the warty growths rather than 
elimination of the virus. Subclinical infection probably is lifelong, and there is no 
cure. Most partners are likely to be subclinically infected with HPV, even if they 
do not have exophytic lesions. Use of condoms may reduce transmission of the 
virus to uninfected partners.Standard therapies for GW can remove most warts; 
however, there is no ideal treatment for all warts and all patients.Caustics/acids - 
80-90% bichloroacetic acid (BCA) or trichloroacetic acid (TCA). Podophyllin 
resin - 10-25% or 0.5% podofilox solution or gel (Condylox). Imiquimod 5% 
cream (Aldara) - 3 times per week, up to 4 months. Interferon, intramuscular or 
intralesional injection - 3 million units, 3 times per week for 3 weeks. 
HPV vaccines (not yet available). A variety of prophylactic and therapeutic HPV 
vaccine trials are ongoing and may be of potential future benefit. Notably, a 
vaccine for HPV 16 is currently in a phase II control trial, a TA-GW vaccine is 
underway in a phase II open trial, and a clinical trial for a multivalent vaccine for 
HPV 16/18/31/45/6 is about to start. 
Surgical Care. Cryosurgery is very effective for treating multiple, small, genital 
warts.Warts on the shaft of the penis and vulva respond very well to 
cryotherapy.Cryotherapy of the rectum is painful and less successful.Cryotherapy 
is effective and safe for the mother and fetus when used during the second and 
third trimesters of pregnancy.Electrosurgery is quite effective for a limited number 
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of lesions on the shaft of the penis.Large, unresponsive lesions around the rectum 
or vulva can be treated with scissor excision of the bulk of the mass followed by 
electrocautery of the remaining tissue down to the skin surface.  
Loop electrocautery excisional procedure (LEEP) after colposcopical biopsy has 
become a standard procedure for cervical lesions particularly for the ones with 
neoplastic features. Removal of a very large mass of warts is a painful procedure, 
best performed under either general or spinal anesthesia. 
Carbon dioxide laser is an efficient method of treating primary and recurrent 
anogenital warts because of its precision and rapid healing without 
scarring.Primary cure rates as high as 91% have been reported. Carbon dioxide 
laser is the treatment of choice for pregnant women with extensive lesions or 
lesions that do not respond to TCA. Pulsed-dye laser and other new lasers have 
been used by some with various successful rates.Surgery is indicated particularly 
for large GW or malignant lesions. For recurrent carcinoma, Mohs surgery is a 
good choice. 
Prognosis is good, and most cases of GW are amenable to treatment. Patients who 
are immunosuppressed with GW may represent a special challenge. 
 
 
13.5. Non-genital Warts 
 
Background. Warts are benign proliferations of skin and mucosa caused by 
human papilloma viruses (HPV). Currently, more than 150 types of HPV have 
been identified. Certain HPV types tend to occur at particular anatomic sites; 
however, warts of any HPV type may occur at any site. The primary clinical 
manifestations of HPV include common warts, genital warts, flat warts, and deep 
palmoplantar warts (myrmecia). Less common manifestations of HPV include 
focal epithelial hyperplasia (Heck disease), epidermodysplasia verruciformis, and 
plantar cysts. Warts are transmitted by direct or indirect contact, and predisposing 
factors include disruption to the normal epithelial barrier. Treatment can be 
difficult, with frequent failures and recurrences; however, many warts resolve 
spontaneously within a few years.  
A small subset of HPV types is associated with the development of malignancies, 
including types 6, 11, 16, 18, 31, and 35. Malignant transformation most 
commonly is seen in patients with genital warts and in immunocompromised 
patients. HPV types 5, 8, 20, and 47 have oncogenic potential in patients with 
epidermodysplasia verruciformis.  
Pathophysiology. Warts can affect any area on the skin and mucous membranes. 
Infection is confined to the epithelium and does not result in systemic 
dissemination of the virus. Replication occurs in differentiated epithelial cells in 
the upper level of the epidermis; however, viral particles can be found in the basal 
layer. 
Causes. Warts are caused by HPV, which is a double-stranded, circular, 
supercoiled DNA virus enclosed in an icosahedral capsid and comprising 72 
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capsomers. More than 150 types of HPV have been identified. Common warts - 
HPV types 2 and 4 (most common), followed by types 1, 3, 27, 29, and 57. Deep 
palmoplantar warts (myrmecia) - HPV type 1 (most common), followed by types 
2, 3, 4, 27, 29, and 57. Flat warts - HPV types 3, 10, and 28. Butcher's warts - HPV 
type 7. Focal epithelial hyperplasia (Heck disease) - HPV types 13 and 32. Cystic 
warts - HPV type 60. 
Frequency. Warts are widespread in the worldwide population. Although the 
frequency is unknown, warts are estimated to affect approximately 7-12% of the 
population. In school-aged children, the prevalence is 10-20%. An increased 
frequency also is seen among immunosuppressed patients and meat handlers.  
Mortality/Morbidity. Common warts usually are asymptomatic, but may cause 
cosmetic disfigurement or tenderness. Plantar warts usually are painful, and 
extensive involvement on the sole of the foot may impair ambulation. Malignant 
change in non-genital warts is rare but has been reported and is termed verrucous 
carcinoma. Verrucous carcinoma is considered to be a slow growing, locally 
invasive, well-differentiated squamous cell carcinoma that easily may be mistaken 
for a common wart. It can occur anywhere on the skin but is most common on the 
plantar surface.  
Age. Warts can occur at any age. They are unusual in infancy and early childhood, 
increase in incidence among school-aged children, and peak at 12-16 years.  
History. HPV is spread by direct or indirect contact. It can resist desiccation, 
freezing, and prolonged storage outside of host cells. Autoinoculation also may 
occur, causing local spread of lesions. The incubation period for HPV ranges from 
1-6 months; however, latency periods of up to 3 years or more are suspected.  
Physical 
Common warts: common warts also are termed verruca vulgaris. They appear as 
hard papules with a rough irregular scaly surface. They range from smaller than 1 
mm to larger than 1 cm. They can occur on any part of the body but are seen most 
commonly on the hands and knees. 
Filiform warts: filiform warts are long slender growths, usually seen on the face 
around the lips, eyelids, or nares. 
Deep palmoplantar warts (myrmecia): deep palmoplantar warts also are termed 
myrmecia. They begin as small shiny papules and progress to deep endophytic, 
sharply defined, round lesions with a rough keratotic surface, surrounded by a 
smooth collar of thickened horn. Because they grow deep, they tend to be more 
painful than common warts. Myrmecia warts that occur on the plantar surface 
usually are found on weight-bearing areas, such as the metatarsal head and heel. 
When they occur on the hand, they tend to be subungual or periungual. 
Flat warts: flat warts also are termed plane warts or verruca plana. They are 
characterized as flat or slightly elevated flesh-colored papules that may be smooth 
or slightly hyperkeratotic. They range from 1-5 mm or more, and numbers range 
from a few to hundreds of lesions that may become grouped or confluent. These 
warts may occur anywhere; however, the face, hands, and shins tend to be the most 
common areas. They may appear in a linear distribution as a result of scratching or 
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trauma (Koebner phenomenon). Regression of these lesions may occur, which 
usually is heralded by inflammation. 
Butcher's warts: Butcher's warts are seen in people who frequently handle raw 
meat. Their morphology is similar to common warts, with a higher prevalence of 
hyperproliferative cauliflowerlike lesions. They are seen most commonly on the 
hands. 
Mosaic warts: a mosaic wart is a plaque of closely grouped warts. When the 
surface is pared, the angular outlines of tightly compressed individual warts can be 
seen. These usually are seen on the palms and soles. 
Focal epithelial hyperplasia (Heck disease): focal epithelial hyperplasia, also 
termed Heck disease, is an HPV infection occurring in the oral cavity, usually on 
the lower labial mucosa. It also can be seen on the buccal or gingival mucosa and 
rarely, on the tongue. The lesions appear as multiple flat-topped or dome-shaped 
pink-white papules. They usually are 1-5 mm, with some lesions coalescing into 
plaques. They are seen most frequently in children of American Indian or Eskimo 
descent. 
Cystic warts (plantar epidermoid cysts): a cystic wart appears as a nodule on the 
weight-bearing surface of the sole. The nodule usually is smooth with visible rete 
ridges but may become hyperkeratotic. If the lesion is incised, cheesy material may 
be expressed. The etiology of these lesions is uncertain. One theory is that a cyst 
forms, originating from the eccrine duct, and secondary HPV infection occurs. 
Another theory is that the epidermis infected with HPV becomes implanted into 
the dermis, forming an epidermal inclusion cyst. 
Lab Studies.The diagnosis of warts is made primarily on the basis of clinical 
findings. Immunohistochemical detection of HPV structural proteins may confirm 
the presence of virus in a lesion, but this has a low sensitivity.Viral DNA 
identification using Southern blot hybridization is a more sensitive and specific 
technique used to identify the specific HPV type present in tissue.Polymerase 
chain reaction may be used to amplify viral DNA for testing. Although HPV may 
be detected in younger lesions, it may not be present in older lesions. 
Procedures.Paring of warts may reveal minute black dots, which represent 
thrombosed capillaries.Obtain a biopsy if doubt exists regarding the diagnosis. 
Histologic Findings.Common warts: histopathologic features of common warts 
include digitated epidermal hyperplasia, acanthosis, papillomatosis, compact 
orthokeratosis, hypergranulosis, dilated tortuous capillaries within the dermal 
papillae, and vertical tiers of parakeratotic cells with entrapped red blood cells 
above the tips of the digitations. Elongated rete ridges may point radially toward 
the center of the lesion. In the granular layer, HPV-infected cells may have coarse 
keratohyaline granules and vacuoles surrounding wrinkled-appearing nuclei. 
Koilocytic (vacuolated) cells are pathognomonic for warts.  
Deep palmoplantar warts (myrmecia): deep palmoplantar warts appear similar to 
common warts except that most of the lesion lies deep to the plane of the skin 
surface. This endophytic epidermal growth often has the distinctive feature of 
polygonal, refractile-appearing, eosinophilic, cytoplasmic inclusions composed of 
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keratin filaments, forming ringlike structures. Basophilic nuclear inclusions and 
basophilic parakeratotic cells loaded with virions may be in the upper layers of the 
epidermis.  
Flat warts: flat warts resemble common warts on light microscopy; however, the 
features tend to be muted. Cells with prominent perinuclear vacuolization around 
pyknotic, strongly basophilic, centrally located nuclei may be in the granular layer. 
These may be referred to as "owl's eye cells."  
Butcher's warts: Butcher's warts have prominent acanthosis, hyperkeratosis, and 
papillomatosis. Small vacuolized cells with centrally located shrunken nuclei may 
be seen in clusters within the granular layer rete ridges.  
Filiform warts: filiform warts may appear similar to common warts but tend to 
have prominent papillomatosis.  
Focal epithelial hyperplasia (Heck disease): focal epithelial hyperplasia is 
characterized by a hyperplastic mucosa with thin parakeratotic stratum corneum, 
acanthosis, blunting and anastomosis of rete ridges, and pallor of epidermal cells as 
a result of intracellular edema. Some areas may have prominent keratohyaline 
granules, and some vacuolated cells may be present.  
Cystic warts: a cyst filled with horny material characterizes cystic warts. The wall 
is composed of basal, squamous, and granular cells. Many of the epithelial cells 
may have large nuclei and clear cytoplasm with eosinophilic inclusion bodies. The 
cyst may rupture, resulting in a foreign body granuloma. 
Medical Care.Multiple modalities are available for the treatment of warts, but 
none is uniformly effective. Start with the least painful, least expensive, and least 
time-consuming methods. Reserve the more expensive and invasive procedures for 
refractory extensive warts. Treatment methods are as follows:  
Benign neglect. Providing no treatment at all is certainly safe and cost effective. 
Consider this as an option, since 65% of warts may regress spontaneously within 2 
years. Without treatment, however, patients risk warts that may enlarge or spread 
to other areas. Non-treatment is not recommended for patients with extensive, 
spreading, or symptomatic warts or in warts that have been present for more than 2 
years. 
Topical agents. Salicylic acid is a first-line therapy used to treat warts. Many 
preparations are available over the counter. Therapeutic effects are enhanced by 
removing surface keratin or by occlusion with adhesive plasters. Cure rates from 
70-80% are reported. Salicylic acid is available without a prescription and can be 
applied by the patient at home.  
Several topical agents are available for treating warts that can be applied by trained 
personnel in a physician's office. These include cantharidin, dinitrochlorobenzene, 
dibutyl squaric acid, trichloroacetic acid, and podophyllin.  
Cantharidin is dried extract of the blister beetle, also termed Spanish fly. It causes 
epidermal necrosis and blistering. Use cantharidin with caution because of its 
potential to cause blistering of normal surrounding skin. This treatment may 
require weekly repetition.  
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Dinitrochlorobenzene (DNCB) is a powerful sensitizing agent that induces an 
allergic contact dermatitis that causes local inflammation and an immune response. 
Dibutyl squaric acid is a contact sensitizer. Unlike DNCB, it is not a mutagen, and 
therefore, may be a safer alternative.  
Trichloroacetic acid is a caustic compound that causes immediate superficial tissue 
necrosis. Use it in concentrations up to 80%. It may require weekly applications.  
Podophyllin is a resin extract derived from the May Apple plant that contains 
several cytotoxic compounds. Use with caution, since it has a powerful irritant 
effect. Podophyllin works better on mucosal surfaces, and therefore, is used more 
commonly for treating genital warts. Reportedly, podophyllin has been successful 
in treating persistent plantar warts. 
Several prescription medications have proven beneficial in treating warts. These 
include imiquimod, cidofovir, podophyllotoxin, 5-fluorouracil, and tretinoin.  
Imiquimod is a potent stimulator of proinflammatory cytokine release. Currently, it 
has been approved only for treating genital warts; however, it shows promise in 
treating common warts as well. Cidofovir is an antiviral agent that is a nucleotide 
analog of deoxycytidine monophosphate. It has been used for refractory 
condyloma acuminata and recurrent genital herpes. Podophyllotoxin is a purified 
ingredient of podophyllin. Since it tends to work better on mucosal surfaces, it also 
is used primarily to treat genital warts. 5-Fluorouracil is a topical chemotherapeutic 
agent primarily used to treat actinic keratoses. It is effective in treating warts when 
used under occlusion daily for up to 1 month. Tretinoin is a topical retinoic acid 
that primarily is used to treat acne. It has been successful in treating flat warts. 
Intralesional Injections: when warts are persistent and refractory to topical agents, 
consider intralesional injections of either bleomycin or interferon alpha as an 
alternative. Bleomycin is a cytotoxic polypeptide that inhibits DNA synthesis in 
cells and viruses. The limiting side effects of bleomycin include pain with 
injection, local urticaria, Raynaud phenomenon, and possible tissue necrosis. Used 
periungually, bleomycin may cause nail dystrophy or loss. Reserve bleomycin as a 
third-line treatment when standard therapies have failed.  
Interferon alpha is a naturally occurring cytokine with antiviral, antibacterial, 
anticancer, and immunomodulatory effects. Intralesional administration is more 
effective than systemic administration and is associated only with mild flulike 
symptoms. Treatments may be required for several weeks to months before 
beneficial results are seen. Consider this treatment as third line, and reserve it for 
warts that are resistant to standard treatments. 
Systemic agents: two systemic agents used to treat warts include cimetidine and 
retinoids. Cimetidine is a type-2 histamine receptor antagonist commonly used to 
treat peptic ulcer disease. Because of its immunomodulatory effects, cimetidine 
was considered a possible treatment for warts; however, results have varied.  
Retinoids are synthetic vitamin A analogs that may help with extensive disabling 
hyperkeratotic warts in immunocompromised patients. They may help alleviate 
pain and facilitate the use of other treatments. Retinoids also have helped reduce 
the number of lesions in immunosuppressed renal transplant patients. The limiting 
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side effects include liver function abnormalities, increased serum lipid levels, and 
teratogenicity. 
Alternative treatments: several alternative treatments have been reported as 
successful in treating warts, including adhesiotherapy, hypnosis, hyperthermia, and 
vaccines. Perform adhesiotherapy by applying tape to the wart daily.  
Surgical Care.Cryosurgery: Liquid nitrogen (-196oC) is the most effective method 
of cryosurgery. Apply liquid nitrogen using a cotton bud applicator or cryospray to 
the recommended 1-2 mm rim of normal skin tissue around the wart. Repeat every 
1-4 weeks for approximately 3 months, as needed. Warn patients about pain and 
possible blistering after treatment. Use with caution on the sides of fingers, since it 
can injure underlying structures and nerves. Other side effects may include 
scarring, ulceration, or pigment alteration. Cure rates of 50-80% have been 
reported. Paring the wart, in addition to 2 freeze-thaw cycles, has been a valuable 
adjunct to cryosurgery for plantar warts but not beneficial for hand warts. 
Lasers. Carbon dioxide lasers have successfully treated resistant warts; however, 
the procedure can be painful and leave scarring. A risk of nosocomial infection 
also exists in health care workers, since HPV can be isolated in the plume.  
The flashlamp-pumped pulse dye laser has shown mixed results in treating warts, 
with decreased risk of scarring and transmission of HPV in the smoke plume.  
A study with an erbium: YAG laser revealed no HPV DNA in the smoke plume. 
Electrodesiccation and curettage: Although electrodesiccation and curettage may 
be more effective than cryosurgery, it is painful, more likely to scar, and HPV can 
be isolated from the plume. Surgical excision: avoid using surgical excision in 
most circumstances because of the risks of scarring and recurrence. 
Prognosis. Approximately 65% of warts disappear spontaneously within 2 years. 
When warts resolve on their own, no scarring is seen. However, scarring can occur 
as a result of different treatment methods.Treatment failures and wart recurrences 
are common, more so among immunocompromised patients. Normal appearing 
perilesional skin may harbor HPV, which helps explain recurrences. 
Patient Education. Alert patients to the risk factors for transmission of warts. 
These include trauma or maceration of the skin, frequent wet work involving 
hands, hyperhidrosis of feet, swimming pools, and nail biting.Butchers and 
slaughterhouse workers also are at increased risk for developing warts.Alert 
patients that some warts may require more than one treatment and may be resistant 
to several treatment modalities. In addition, some warts may regress spontaneously 
without treatment. 
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XIV. CONNECTIVE TISSUE DISEASES 
 
14.1. Discoid Lupus Erythematosus 
 
Background.Discoid lupus erythematosus (DLE) is a chronic, scarring, atrophy 
producing, photosensitive dermatosis. DLE may occur in patients with systemic 
lupus erythematosus (SLE), and some patients (<5%) with DLE progress to SLE. 
Some patients also have the lesions of subacute cutaneous lupus erythematosus 
(SCLE), and some may have a malar rash. Patients with DLE rarely fulfill 4 or 
more of the criteria used to classify SLE. Serologic abnormalities are uncommon. 
Therapy with sunscreens, topical corticosteroids, and antimalarials usually is 
effective.  
Pathophysiology.DLE probably occurs in genetically predisposed individuals, but 
the exact genetic connection has not been determined. The pathophysiology of 
DLE is not well understood. It has been suggested that a heat shock protein is 
induced in the keratinocyte following ultraviolet (UV) light exposure or stress. 
Causes.Patients with DLE probably have genetic predisposition; however, the 
precise genetic factors that increase the risk of this disease are unknown. The 
disease usually manifests following UV light exposure, but other triggers or 
inciting factors also must contribute. 
Frequency.Worldwide, the prevalence of SLE ranges from 17-48 cases per 
100,000. The highest prevalence of SLE occurs in persons aged 40-60 years, and is 
approximately 10 times higher in women than in men. Cutaneous lupus 
erythematosus (CLE) presumably occurs 2-3 times more frequently in women than 
in men.  
Mortality/Morbidity.Patients with DLE rarely have clinically significant systemic 
disease. Lesions may produce scarring or atrophy. Scarring alopecia is particularly 
disturbing.  
Age.DLE may occur at any age but most often occurs in persons aged 20-40 years. 
The mean age is approximately 38 years.  
History.Patients may complain of mild pruritus or occasional pain within the 
lesions, but most patients are asymptomatic. Approximately 5% or fewer DLE 
patients have accompanying systemic involvement. Arthralgia or arthritis may 
occur. Patients may manifest any symptom of SLE; therefore, the history should 
include an assessment for symptoms of pleuritis, pericarditis, neurologic 
involvement, and renal involvement. Several cutaneous diseases have been 
reported, perhaps in greater frequency, in patients with DLE.Malignant 
degeneration of chronic lesions of lupus erythematosus (LE) is possible, although 
rare, leading to non-melanoma skin cancer. Dark-skinned individuals may be more 
prone to skin cancer because of the lack of pigmentation within the chronic lesion, 
combined with chronic inflammation and continued sun damage.Mucin deposition 
is a factor in the histopathology of LE. Some patients develop such a massive 
amount of mucin that lesions become raised and assume a different 
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morphology.Porphyria cutanea tarda appears to be overrepresented in LE patients. 
Often, the porphyria is discovered when antimalarials first are administered. 
Lichen planus-like lesions may be part of an overlap between LE and lichen planus 
or may occur as a result of antimalarial therapy.Psoriasis is a common disease, 
although it is not clear whether it is more common in LE patients. 
Physical.DLE lesions frequently are characteristic. The primary lesion is an 
erythematous papule or plaque with slight-to-moderate scaling. As the lesion 
progresses, the scale may thicken and become adherent, and pigmentary changes 
may develop, with hypopigmentation in the central or inactive area and 
hyperpigmentation at the active border. Lesions spread centrifugally and may 
merge. As lesions age, dilation of follicular openings occurs with a keratinous 
plug, termed follicular plugging or patulous follicles. Resolution of the active 
lesion results in atrophy and scarring. At any time, individual lesions may have any 
or all of these features. Early lesions may be difficult to distinguish from SCLE. 
DLE lesions often are photodistributed, but relatively unexposed skin also may be 
affected. The scalp is a common area of involvement, and permanent alopecia may 
result. Patients with DLE often are divided into 2 subsets: localized and 
widespread. Localized DLE occurs when the head and neck only are affected, 
while widespread DLE occurs when other areas are affected, regardless of whether 
disease of the head and neck is seen. Patients with widespread involvement often 
have hematologic and serologic abnormalities, are more likely to develop SLE, and 
are more difficult to treat.Several unusual variants of chronic CLE, other than 
DLE, have been reported. 
Mucosal surfaces may be affected by lesions that appear identical to DLE of the 
skin or by lesions that may simulate lichen planus.Palms and soles may be 
affected, but this occurs in fewer than 2% of patients.DLE lesions may become 
hypertrophic or verrucous. This subset is manifested by wart-like lesions, most 
often on the extensor arms. Hypertrophic lesions of LE must be differentiated from 
warts, keratoacanthomas, or squamous cell carcinoma. These lesions are more 
difficult to treat.Lupus panniculitis is a form of chronic CLE that may be 
accompanied by typical DLE lesions or may occur in patients with SLE. 
Complications.Scarring or atrophy is possible, but treatment of early lesions may 
be preventative.Serious systemic disease is rare, but when it occurs, patients may 
develop life-altering sequelae.Malignant degeneration is rare. Promptly remove 
new growths within burned-out lesions. 
Lab Studies.Serologic testing.Some patients with DLE (approximately 20%) 
manifest a positive antinuclear antibody (ANA) when tested with human 
substrates. HEp-2 cells currently are the most common substrate used in 
commercial labs.Anti-Ro (SS-A) autoantibodies are present in approximately 1-3% 
of patients.Anti-native DNA (double-stranded or nDNA) or anti-Sm antibodies 
usually reflect SLE, and they may occur in some patients (<5%). 
Other laboratory findings.Cytopenias may be present. Elevated sedimentation rate 
may occur in some patients. Rheumatoid factor may be positive. Complement 
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levels may be depressed. Urinalysis may reflect the presence of renal involvement 
with proteinuria. 
Other Tests. Immunopathology. Deposition of immunoglobulin and/or 
complement at the dermal-epidermal junction is a characteristic feature of LE 
referred to in most texts and articles. Tissue may be examined from skin lesions 
(lesional) or normal skin (non-lesional). Non-lesional biopsies may be from 
exposed or non-exposed surfaces. Testing of non-lesional non-exposed skin is 
termed the lupus band test (LBT).The use and interpretation of these tests varies 
according to the biopsy site. Approximately 90% of patients with DLE manifest a 
positive direct immunofluorescence (DIF) test on lesional skin; however, the 
presence of immunoreactants in the basement membrane zone of lesional skin is 
not specific for lupus and can be seen in a variety of inflammatory skin diseases. 
Older lesions or very early lesions may be more likely to be negative on 
immunofluorescence microscopy. Only patients with SLE have a positive LBT, 
defined as the presence of 4 or more immunoreactants in the basement membrane 
zone. LBTs are neither sensitive nor specific and mostly have been replaced by 
advances in serologic testing. 
Histologic Findings.The characteristic histopathologic alterations observed in 
DLE include vacuolar alteration of the basal cell layer, thickening of the basement 
membrane, follicular plugging, hyperkeratosis, atrophy of the epidermis, 
incontinence of pigment, and inflammatory cell infiltrate (usually lymphocytic) in 
a perivascular, periappendiceal, and subepidermal location. Often, an abundance of 
mucin is seen within the dermis. The histopathologic features differ depending 
upon the type and age of the lesion. 
Medical Care.The goals of management are to improve the patient's appearance, 
to control existing lesions and limit scarring, and to prevent the development of 
further lesions. Advise patients that the risk of serious systemic disease is possible, 
although rare. Regular repeat clinical evaluation accompanied by simple laboratory 
studies usually is sufficient to evaluate the possible progression from the primary 
cutaneous disorder to the disorder accompanied by systemic involvement. 
Therapy begins with sun-protective measures, including sunscreens, protective 
clothing, and behavior alteration. Cosmetic measures, such as cover-up makeup or 
wigs, may be suggested for appropriately selected patients. Make-up used for 
camouflage includes Covermark and Dermablend. 
Standard medical therapy includes corticosteroids (topical or intralesional) and 
antimalarials. Antimalarials appear less effective in patients who smoke; however, 
DLE possibly is worse in these patients. Alternative therapies include auranofin, 
thalidomide, oral or topical retinoids, interferon, and immunosuppressive agents. 
Topical corticosteroids are selected for the type of lesion under treatment and for 
the site of involvement. For example, lotions or foams are preferred for the scalp, 
weaker agents are used on the face, and superpotent agents are used for 
hypertrophic lesions. 
Intralesional injection of corticosteroids (typically, this author uses triamcinolone 
acetonide 3 mg/mL) is useful as adjunctive therapy for individual lesions. Potential 
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for atrophy relates to the amount of corticosteroid injected in any one area; 
therefore, dilute concentrations are preferred. In addition, the treating physician 
must take care to limit the total dose of the injections at any given office/clinic 
visit to avoid systemic toxicity from the steroids e.g. if a patient is given 10 mL of 
triamcinolone 3 mg/mL, this means that the patient has received a total of 30 mg, 
and toxicity is the same as if it had been delivered orally or by intramuscular 
injection. 
Among immunosuppressives, methotrexate may be considered, although this 
author has observed no beneficial effects in the small number of patients treated. In 
this author's experience, azathioprine and, recently, mycophenolate mofetil have 
been successful; however, systemic corticosteroids rarely are effective. 
Surgical Care.Excision of burned-out scarred lesions is possible; however, 
reactivation of inactive lesions has been reported in some patients.Laser therapy 
may be useful for lesions with prominent telangiectasias. Reactivation also is a 
consideration with this form of therapy. 
Consultations.Rheumatology - for joint involvement.Nephrology - for renal 
involvement.Internal medicine - to evaluate systemic involvement.Ophthalmology 
- to monitor therapy with hydroxychloroquine or chloroquine. 
Activity.Since chronic CLE is exacerbated by sunlight or other UV exposure, 
advise patients to take precautions, e.g. to limit exposure to sunlight to early 
morning or late afternoon when the sun is less intense. Advise patients to avoid 
artificial light sources such as tanning beds. 
Prognosis.The prognosis of patients with chronic CLE is favorable regarding 
mortality; however, many patients continue to experience pain in their lesions or 
may experience disfigurement from the scars or atrophy that can 
develop.Exacerbation is possible, particularly in the spring and summer. 
 
 
14.2. Morphea 
 
Synonyms and related keywords:localized scleroderma, plaque-type morphea, generalized 
morphea, linear morphea, deep morphea, en coup de sabre, frontoparietal linear morphea, 
progressive hemifacial atrophy, atrophoderma of Pasini and Pierini. 
 
Background.Morphea, also known as localized scleroderma, is a disorder 
characterized by thickening and induration of the skin and subcutaneous tissue due 
to excessive collagen deposition. Morphea subtypes are classified according to 
their clinical presentation and depth of tissue involvement; they include plaque-
type, generalized, linear, and deep varieties. Unlike systemic sclerosis, morphea 
lacks features, such as sclerodactyly, Raynaud phenomenon, and internal organ 
involvement.  
Pathophysiology.Overproduction of collagen by lesional fibroblasts is common to 
all forms of morphea, but the exact mechanism is unknown. Proposed factors 
involved in the pathogenesis include endothelial cell injury, immunologic and 
inflammatory activation, and dysregulation of collagen production. An 
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autoimmune etiology is supported by the frequent presence of autoantibodies in 
patients with morphea. Reports have shown increased levels of circulating 
intercellular adhesion molecule-1, which is important in immune-mediated 
mechanisms, and of various cytokines, such as transforming growth factor-beta, 
which has been shown to induce fibroblasts to reproduce features of scleroderma.  
Causes.The cause of morphea is unknown. Investigations have not uncovered any 
consistent etiologic factors. Different morphea subtypes often coexist in the same 
patient, suggesting that the causative processes are similar.  
Radiation therapy. Morphea may occur at the site of previous supervoltage 
radiation therapy for breast cancer and other cancers, developing from 1 month up 
to 32 years after irradiation. 
Infection or vaccination.Infections, such as Epstein-Barr virus, varicella, measles, 
and borreliosis, have been reported to precede the onset of morphea and have been 
proposed as possible triggers.The most extensive literature focuses on Borrelia 
burgdorferi as a possible etiologic agent of morphea. Although Borrelia antibodies 
have been found in some patients and DNA from the organism has been detected 
in morphea lesions, a definite causal relationship has not been 
established.Morphealike lesions have also been reported to occur after bacillus 
Calmette-Guérin (BCG) and tetanus vaccinations. 
Immunologic causes. Morphea may result from localized autoimmune reactions. 
Recognition of self-antigens by B cells and/or T cells may produce a local 
inflammatory response, ultimately resulting in the release of growth factors and 
other cytokines capable of stimulating fibroblast-driven overproduction of 
collagen. For example, transforming growth factor-beta, which may be secreted by 
activated T cells or tissue macrophages, has been shown to stimulate fibroblasts 
and endothelial cells to reproduce features of scleroderma. 
Trauma. Trauma has been considered a possible precipitating event in morphea, 
but the relationship is not clear. In particular, trauma has been considered as the 
cause of eosinophilic fasciitis. 
Familial causes. A few familial cases of morphea have been reported, most are of 
the disabling pansclerotic morphea of children subtype. No significant HLA 
associations have been recognized. 
Frequency.The incidence rate of morphea has been estimated to be 27 new cases 
per 1 million population per year. The actual incidence of morphea may be higher 
because many cases may not come to medical attention due to the benign nature of 
morphea.  
Mortality/Morbidity.Morphea has a benign prognosis overall, with survival rates 
similar to those of the general population. However, linear and deep morphea 
subtypes can cause considerable morbidity, especially in children when they 
interfere with growth. Deformities such as joint contractures, limb atrophy, and 
facial hemiatrophy result in substantial disability in 25-44% of patients with linear 
and deep morphea.  
Sex.Women are affected about 3 times as often as men for all forms of morphea 
except for linear morphea, which has a more even sexual distribution.  
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Age.Linear morphea tends to affect children and adolescents, with 67% of cases 
occurring before age 18 years. Other morphea subtypes most often develop later in 
life, with a mean age of onset in persons aged 33-38 years and with 75% of cases 
occurring in persons aged 20-50 years.  
History.Morphea is usually asymptomatic, and, most often, the onset of lesions is 
insidious, although they can occasionally develop rapidly.Arthralgias, occasionally 
localized to an affected extremity, are sometimes reported by patients with 
morphea. In patients with deep morphea, arthralgias, arthritis, and myalgias are 
common, and carpal tunnel syndrome may also develop.Patients with en coup de 
sabre lesions of linear morphea can present with seizures, headache, and visual 
changes. 
Physical.Physical findings in morphea are primarily in the skin and underlying 
tissues, with different clinical manifestations and levels of tissue involvement in 
the various subtypes. Although subdivision of morphea is useful with regard to 
differences in epidemiology, anatomical site, and course of disease, recognizing 
that continuous clinical and histologic transitions exist between all the variants 
within the spectrum of morphea is important.  
Plaque-type morphea is the most common and benign morphea subtype and 
includes guttate morphea and keloidal (nodular) morphea variants. These lesions 
are relatively superficial, involving only the dermis and occasionally the superficial 
panniculus. Generalized morphea is a more severe form of the disease, with 
widespread morphea plaques. Linear morphea is the most common morphea 
subtype in children and adolescents and includes the en coup de sabre and 
progressive hemifacial atrophy variants. Linear morphea often qualifies as deep 
morphea in a linear pattern, involving the deep dermis, the subcutaneous tissue, the 
muscle, and the underlying bone. Deep morphea, also referred to as subcutaneous 
morphea or morphea profunda, may involve the deep dermis, the subcutaneous 
tissue, the fascia, the muscle, and even the bone. Variants of deep morphea include 
eosinophilic fasciitis and disabling pansclerotic morphea of children.  
Types of skin lesions.Morphea lesions are characterized as circumscribed 
indurated plaques that are 1-30 cm in diameter. They often begin as poorly defined 
areas of non-pitting edema, with sclerosis developing as the disease progresses. 
The surface becomes smooth and shiny over time, with the loss of hair follicles 
and the inability to sweat. Eventually, over a period of months to years, the skin 
softens and becomes atrophic.  
Guttate morphea lesions are smaller, 2-10 mm in diameter, and superficial, with 
less induration and a sharply demarcated border. Guttate morphea frequently 
coexists with and may look similar to lichen sclerosus et atrophicus; some authors 
believe that the 2 disorders are related or identical.  
Keloidal (nodular) morphea is a rare variant characterized by nodules resembling 
keloids in the presence of typical plaque-type morphea.  
Atrophoderma of Pasini and Pierini may represent an end-stage (burnt-out) form of 
plaque-type morphea. It is characterized by atrophic plaques with well-defined 
cliff-drop borders, without marked inflammation or sclerosis.  
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Bullous morphea is a rare variant characterized by tense subepidermal bullae in the 
presence of plaque-type, linear, or deep morphea. 
Linear morphea is characterized by discrete indurated linear bands. 
Melorheostosis, a dense linear cortical hyperostosis, occurs rarely in affected 
limbs, and calcinosis has been reported to develop within linear lesions.  
Frontoparietal linear morphea, called en coup de sabre, is characterized by a linear, 
atrophic depression suggestive of a stroke from a sword. The lesion may be 
extensive and can even cause hemifacial atrophy.  
Progressive hemifacial atrophy (Parry-Romberg syndrome) may be a form of 
linear morphea. However, unlike en coup de sabre, the primary lesion occurs in the 
subcutaneous tissue, the muscle, and the bone; the dermis is affected only 
secondarily, and the skin is not sclerotic or bound down.  
Deep morphea is characterized by deep, bound-down, sclerotic plaques.  
Eosinophilic fasciitis (Shulman syndrome) involves primarily the fascia and is 
characterized by acute onset of painful, indurated skin with a cobblestone 
appearance and taut swelling of the entire affected extremity caused by increased 
subfascial pressure. A negative vein sign (veins do not protrude normally but 
instead are represented by linear depressions) is typical.  
Disabling pansclerotic morphea of children has generalized involvement that 
extends throughout the tissues from dermis to bone. 
Color of skin lesions.Plaque-type morphea often begins as an area of erythema. In 
early active phases of the disease, a violaceous border (lilac ring) often surrounds 
the indurated area. With disease progression, the center of the lesion gradually 
develops a waxy, ivory color. As lesions eventually involute, an area of 
hypopigmentation and/or hyperpigmentation often remains. In the guttate morphea 
variant, lesions are typically chalk-white or silvery in color. The plaques of 
atrophoderma of Pasini and Pierini are hyperpigmented. In generalized morphea, 
often a silvery color or hyperpigmentation of the involved areas is present. Deep 
morphea lesions are frequently hyperpigmented, but, because of the deeper level of 
inflammation, they lack the color changes typical of plaque-type morphea. 
Shape of skin lesions.Plaque-type morphea lesions are typically oval or (less 
often) round in shape. Linear morphea occurs as a linear band. Deep morphea 
lesions are rather ill defined. 
Palpation of skin lesions.Morphea lesions are typically indurated and hard, but 
guttate morphea lesions are less firm. In linear and deep morphea lesions, fixation 
to underlying structures and extension down to involve muscle or even bone are 
present. 
Arrangement of skin lesions.Plaque-type morphea lesions are most often single or 
few in number, although they may be multiple. Oval plaques on the trunk are 
typically oriented with their long axes in a horizontal, rather than vertical, 
direction. When bilateral, lesions are generally asymmetrical. Guttate morphea 
lesions are multiple. Linear morphea lesions are most often single and unilateral in 
95% of cases. If both the upper extremities and the lower extremities are involved, 
lesions are usually homolateral. The distribution pattern of linear morphea is 
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controversial. Although linear morphea following the lines of Blaschko has been 
described in several recent reports, some authors have stated that it probably does 
not follow the lines of Blaschko; other authors have noted that linear morphea may 
appear to be dermatomal in distribution. Usually, linear morphea lesions occur 
along the length of a limb, but sometimes a band surrounds a limb or a finger, 
resembling ainhum. Deep morphea is characterized by diffuse thickening of 
tissues. Distribution of lesions is often symmetric. 
Areas of distribution.Plaque-type morphea is more common on the trunk than on 
the extremities, and the face is usually spared. Guttate morphea primarily involves 
the neck and the upper part of the trunk. Atrophoderma of Pasini and Pierini 
usually occurs on the back. Generalized morphea occurs when morphea plaques 
become confluent or multiply and affect a significant portion of 3 or more major 
anatomical regions, often involving the upper part of the trunk, the abdomen, the 
buttocks, and the thighs. In a rare variant of almost universal morphea, the whole 
body, from the top of the head to the feet, is involved; unlike diffuse systemic 
scleroderma, patients lack features, such as sclerodactyly or Raynaud phenomenon.  
Linear morphea most often affects the lower extremities, followed in frequency of 
occurrence by the upper extremities, the frontal part of the head, the anterior part 
of the thorax, the abdomen, and the buttocks. En coup de sabre is a variant that 
affects the frontoparietal part of the face or the scalp, most often the paramedian 
part of the forehead. The occurrence of linear morphea on the extremities and the 
head, where the deep fascia is closer to the dermis than on the trunk, probably 
explains the tendency of linear morphea to affect deep structures. Eosinophilic 
fasciitis commonly occurs on 1 or more extremities proximal to the hands and feet. 
Disabling pansclerotic morphea of children begins with the extensor extremities 
and progresses to involve the trunk, the flexor extremities, the face, and the scalp, 
with sparing of the fingertips and the toes. 
Hair and nails.Scalp involvement results in scarring alopecia, as seen in the 
variant known as en coup de sabre. Loss of eyebrows or eyelashes may also occur 
in this variant. Nail dystrophy may occur in linear lesions located on an extremity 
or in pansclerotic morphea. 
General examination.Extensive truncal morphea may result in restricted 
respiration.When linear or deep morphea lesions cross the joint lines, they can 
result in restricted mobility, contractures, and deformity. In children, lesions can 
result in growth impairment and severe atrophy of involved limbs. Signs of carpal 
tunnel syndrome may be evident in patients with deep morphea (especially 
eosinophilic fasciitis).Linear scleroderma may also be associated with vertebral 
column anomalies, particularly spina bifida occulta and scoliosis.Patients with en 
coup de sabre may develop ptosis, ocular muscle dysfunction, uveitis, asymmetry 
of the tongue, and altered dentition. 
Complications.In the linear and deep morphea subtypes, joint contractures, 
subcutaneous atrophy, and growth failure can be deforming and disabling. 
Lab Studies.No diagnostic laboratory tests are available for morphea. CBC 
count. The CBC count is most often in the reference range. Eosinophilia has been 
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found to correlate with disease activity in patients with linear and generalized 
morphea (although this is not a consistent finding) as well as in patients with 
eosinophilic fasciitis and other variants of deep morphea.Eosinophilic fasciitis has 
been associated with anemia and thrombocytopenia. 
Erythrocyte sedimentation rate: This rate is usually in the reference range, but it 
may be elevated in eosinophilic fasciitis. 
Immunoglobulin G and immunoglobulin M: polyclonal increases may occur, 
especially with linear and deep morphea. This finding is correlated with disease 
activity and the development of joint contractures in linear morphea. 
Rheumatoid factor: this factor is positive in 25-41% of patients, especially 
children with linear morphea; titers are correlated with disease severity. 
Autoantibodies (Detection of serum autoantibodies is common in all types of 
morphea). Antinuclear antibody (ANA) test results are positive in 50% of patients 
with plaque-type or generalized morphea and in 67% of those with linear morphea, 
usually with a homogeneous staining pattern.Anti–single-stranded DNA antibody 
test results are positive in 27% of patients with plaque-type morphea, in 75% of 
those with generalized morphea, and in 53% of those with linear morphea; levels 
are correlated with extensive, active disease and joint contractures.Antihistone 
antibodies test results are positive in 42% of patients with morphea and in 87% of 
those with generalized morphea, correlating with the number of plaque-type 
lesions and the total area affected; levels are not correlated with the presence or the 
number of linear lesions.Anticentromere, anti-Scl70, and anti–double-stranded 
DNA antibodies are usually absent, although anticentromere antibodies were found 
in 12% of patients with morphea in one study.Soluble Il-2 receptors: levels may be 
correlated with disease activity. 
Imaging Studies.Radiography may be helpful in selected cases of linear or deep 
morphea where bone involvement is suspected. It may also be helpful in 
monitoring pediatric patients sequentially for potential growth defects.MRI has 
been reported to be useful in diagnosing eosinophilic fasciitis and possibly for 
monitoring the effectiveness of therapy; however, the considerable expense makes 
its routine use impractical.B-mode ultrasonography can measure the skin's 
thickness, which may be correlated with disease activity. 
Procedures.Although diagnosis of morphea can frequently be made based on the 
clinical findings, a biopsy is often useful to confirm the diagnosis and to 
differentiate among the subtypes.For plaque-type and generalized morphea, a deep 
punch biopsy is usually sufficient.For linear and deep morphea, an incisional 
biopsy extending down to muscle is needed. 
Histologic Findings.Cutaneous histologic findings are similar among the morphea 
subtypes and systemic sclerosis, with homogenization of collagen bundles as the 
fundamental process. The depth of involvement is important for subdivision into 
the morphea subtypes. The epidermis can be either normal or atrophic with loss of 
rete ridges. In the early inflammatory stage, a lymphohistiocytic infiltrate, 
perivascular or diffuse, is often present in the reticular dermis and the fibrous 
trabeculae of the subcutaneous tissues; large numbers of plasma cells may also be 
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present. The dermis is typically edematous, with collagen bundle swelling in the 
lower reticular dermis. In the late sclerotic stage, the inflammatory infiltrate 
frequently disappears. Collagen bundles become thick, dense, homogenous, and 
eosinophilic, with collagen changes extending to the upper dermis and possibly 
also involving the panniculus, the fascia, and the muscle. Hair follicles, sweat 
glands, and subcutaneous fat are progressively lost as collagenous material 
accumulates. Direct immunofluorescence microscopy is positive in about one third 
of cases, most frequently with deep morphea. 
Medical Care.No proven effective treatments for morphea exist. Most patients 
with plaque-type morphea experience very gradual (e.g. over 3-5 y) spontaneous 
remission. Therapy with topical or intralesional corticosteroids offers little or 
limited benefit. Treatment with topical calcipotriene may be attempted.Patients 
with generalized, linear, and deep morphea may require more aggressive therapy. 
Physical therapy to preserve range of motion is of utmost importance. Numerous 
therapeutic agents have been used, including systemic corticosteroids, antimalarial 
agents, D-penicillamine, and other anti-inflammatory and immunosuppressive 
agents. However, no large randomized studies of these agents in patients with 
morphea exist.The use of low-dose UV-A phototherapy has produced marked 
clinical improvement of treated morphea lesions. PUVA bath photochemotherapy 
has also been reported to be helpful in patients with plaque-type or linear morphea, 
and PUVA is considered to be one of the best treatment options available.Severe 
cases of morphea with elevated ANA and other autoantibody levels have been 
improved with the use of plasmapheresis. 
Consultations.Referral to a dermatologist is useful to verify the diagnosis and to 
consider treatment measures if involvement of the plaque-type morphea is 
extensive. For the other morphea subtypes, referral to dermatologist is generally 
indicated. 
Prognosis.Plaque-type morphea is a self-limited condition that tends to slowly 
involute with time; the duration of disease activity is on average 3-5 years, 
although it may last as long as 25 years.Linear lesions tend to persist for longer 
than plaque lesions, but often improve over the years. However, linear morphea, 
especially the en coup de sabre subtype, may remit and reactivate, remain 
unchanged, or become more extensive with time. In addition, patients with linear 
lesions may develop limb atrophy and contractures that result in limited movement 
and persistent disability.Disabling pansclerotic morphea of children is a rare, 
aggressive, and mutilating variant of deep morphea that begins before the age of 14 
years and has a disease course of relentless progression and severe disability. 
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XV. DISEASES OF THE ADNEXA 
 
15.1. Acne Vulgaris 
 
Background.Acne vulgaris is a common skin disease that affects 85-100% of 
people at some time during their lives. It is characterized by non-inflammatory 
follicular papules or comedones and by inflammatory papules, pustules, and 
nodules in its more severe forms. Acne vulgaris affects the areas of skin with the 
densest population of sebaceous follicles; these areas include the face, the upper 
part of the chest, and the back.  
Pathophysiology.The pathogenesis of acne vulgaris is multifactorial. Four key 
factors are responsible for the development of an acne lesion: follicular epidermal 
hyperproliferation and hyperkeratinization, excess sebum, Propionibacterium 
acnes, and inflammation. Follicular epidermal hyperproliferation and 
hyperkeratinization appears to be one of the primary events in the development of 
an acne lesion. The follicular epidermis is hyperproliferative; abnormal production 
of keratins 6 and 16 could play a role. Increasing levels of the adrenally derived 
androgen dehydroepiandrosterone sulfate (DHEAS) are correlated with the 
development of the microcomedo, the primary acne lesion; therefore, these levels 
may trigger follicular epidermal hyperproliferation. This hyperproliferation may 
also be stimulated by an alteration in sebum and lipid levels in acne lesions. For 
example, linoleic acid levels are decreased in acne lesions, and the levels 
normalize after successful treatment with isotretinoin.  
Excess sebum is also a key factor in the development of acne vulgaris. The amount 
of sebum produced and the degree and the severity of the acne are strongly 
correlated. Sebum excretion is under hormonal control. Androgens stimulate 
sebocyte differentiation and sebum production, whereas estrogens have an 
inhibitory effect. Sebocytes have nuclear androgen receptors. They also have 5 
alpha reductase enzymes that convert testosterone to the more potent 
dihydrotestosterone. The androgen hormones bind their nuclear receptors and 
stimulate terminal sebocyte differentiation and the production of sebum. Most men 
and women with acne have normal circulating levels of androgen hormones. An 
end-organ hyperresponsiveness to androgens has been hypothesized.  
P. acnes is a microaerophilic organism present in many acne lesions. Although, it 
has not been shown to be present in the earliest lesions of acne, the microcomedo, 
its presence in later lesions is almost certain. P. acnes stimulates inflammation by 
producing proinflammatory mediators that diffuse through the follicle wall. Recent 
studies have shown that P. acnes binds to the toll-like receptor on monocytes and 
neutrophils. Binding of the toll-like receptor then leads to the production of 
multiple proinflammatory cytokines, including interleukin 12 (IL-12), interleukin 8 
(IL-8), and tumor necrosis factor (TNF). Hypersensitivity to P. acnes may also 
explain why some individuals develop inflammatory acne vulgaris.  
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Inflammation may be a primary phenomenon or a secondary phenomenon. Most of 
the evidence to date suggests a secondary inflammatory response to P acnes as 
mentioned above. However, IL-1β expression has been identified in the 
microcomedone, and it may play a role in the development of acne.  
Age.Acne vulgaris may be present in the first few weeks and months of life when a 
newborn is still under the influence of maternal hormones. This acne resolves but 
may recur at the time of adrenarche when androgen hormone levels begin to rise. 
History.Local symptoms may include pain or tenderness.Systemic symptoms are 
most often absent in acne vulgaris.Severe acne with associated systemic signs and 
symptoms is referred to as acne fulminans.Acne may have a psychological impact 
on any patient, regardless of the severity or the grade of the disease. 
Physical.Acne vulgaris is characterized by comedones, papules, pustules, and 
nodules in a sebaceous distribution. The face may be the only involved skin 
surface, but the chest, the back, and the upper arms are often involved. In 
comedonal acne, no inflammatory lesions are present. Mild inflammatory acne is 
characterized by inflammatory papules and comedones.Moderate inflammatory 
acne has comedones, inflammatory papules, and pustules.Nodulocystic acne is 
characterized by comedones, inflammatory lesions, and large nodules greater than 
5 mm in diameter. Scarring is often evident. 
Cause.An external cause is seldom identifiable in acne vulgaris. Some cosmetic 
agents and hair pomades may worsen acne. Medications that can promote acne 
include steroids, lithium, some antiepileptics, and iodides.Congenital adrenal 
hyperplasia, polycystic ovary syndrome, and other endocrine disorders with excess 
androgens may trigger the development of acne vulgaris.Acne vulgaris may also be 
influenced by genetic factors. 
Lab Studies.The diagnosis of acne vulgaris is a clinical diagnosis. In a female 
patient with dysmenorrhea or hirsutism, a hormonal evaluation should be 
considered. Patients with evidence of virilization should have total testosterone and 
DHEAS levels assessed. Patients with evidence of Cushing disease should have a 
24-hour urine cortisol determination.In female patients with anovulation and 
hyperandrogenism, polycystic ovarian syndrome is likely. Laboratory studies in 
this condition should include an assessment of serum lipid levels.Skin lesion 
cultures to rule out gram-negative folliculitis are warranted when no response to 
treatment occurs or when improvement is not maintained. 
Histologic Findings.The microcomedo is characterized by a dilated follicle with a 
plug of loosely arranged keratin. With progression of the disease, the follicular 
opening becomes dilated, and an open comedo results. The follicular wall thins, 
and it may rupture. Inflammation and bacteria may be evident, with or without 
follicular rupture. Follicular rupture is accompanied by a foreign body reaction. 
Dense inflammation into and throughout the dermis may be associated with 
fibrosis and scarring. 
Medical Care.Treatment should be directed toward the known pathogenic factors 
involved in acne. These include follicular hyperproliferation, excess sebum, P. 
acnes, and inflammation. The grade and the severity of the acne help in 
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determining which of the following treatments, alone or in combination, is most 
appropriate.  
Topical treatments.Topical retinoids are comedolytic and anti-inflammatory. They 
cause epidermal differentiation and, thus, normalize follicular hyperproliferation 
and hyperkeratinization. Topical retinoids reduce the numbers of microcomedones, 
comedones, and inflammatory lesions. They may be used alone or in combination 
with other acne medications. The most commonly prescribed topical retinoids 
include adapalene, tazarotene, and tretinoin. These retinoids should be applied 
once daily to clean, dry skin, but they may need to be applied less frequently if 
irritation occurs. Skin irritation with peeling and redness may be associated with 
the use of topical retinoids. The use of mild, nondrying cleansers and non-
comedogenic moisturizers may help reduce this irritation. Alternate-day dosing 
may be used if irritation persists. Topical retinoids thin the stratum corneum, and 
they have been associated with sun sensitivity. Instruct patients about sun 
protection.  
Topical antibiotics are mainly used for their role against P. acnes. They may also 
have anti-inflammatory properties. Topical antibiotics are not comedolytic, and 
bacterial resistance may develop to any of these agents. The development of 
resistance is lessened if topical antibiotics are used in combination with benzoyl 
peroxide. Commonly prescribed topical antibiotics include erythromycin and 
clindamycin alone or in combination with benzoyl peroxide. Clindamycin and 
erythromycin are available in a variety of topical agents. They may be applied once 
or twice a day. Gels and solutions may be more irritating than creams or lotions.  
Benzoyl peroxide products are also effective against P. acnes, and bacterial 
resistance to benzoyl peroxide has not been reported. Benzoyl peroxides are 
available over the counter and by prescription in a variety of topical forms, 
including soaps, washes, lotions, creams, and gels. Benzoyl peroxides may be used 
once or twice a day. These agents may cause a true allergic contact dermatitis. 
More often, an irritant contact dermatitis develops especially if used with tretinoin 
or when accompanied by aggressive washing methods. 
Systemic treatments.Systemic antibiotics are a mainstay in the treatment of acne 
vulgaris. These agents have anti-inflammatory properties, and they are effective 
against P. acnes. The tetracycline group of antibiotics is commonly prescribed for 
acne. The more lipophilic antibiotics, such as minocycline, are generally more 
effective than tetracycline. Greater efficacy may also be due to less P acnes 
resistance to minocycline. However, P. acnes resistance is becoming more 
common with all classes of antibiotics currently used to treat acne vulgaris. P. 
acnes resistance to erythromycin has greatly reduced its usefulness in the treatment 
of acne. Other antibiotics, including trimethoprim, alone or in combination with 
sulfamethoxazole, and azithromycin, are reportedly helpful. Bacterial resistance to 
these systemic agents may be reduced by combining them with topical retinoids 
and/or topical benzoyl peroxide. Prescribing different topical and systemic 
antibiotics may predispose to antibiotic resistance. 
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Some hormonal therapies may be effective in the treatment of acne vulgaris. Oral 
contraceptives increase sex hormone binding globulin, resulting in an overall 
decrease in circulating free testosterone. Combination birth control pills have 
shown efficacy in the treatment of acne vulgaris. Spironolactone may also be used 
in the treatment of acne vulgaris. Spironolactone binds the androgen receptor and 
reduces androgen production. Adverse effects include dizziness, breast tenderness, 
and dysmenorrhea. Dysmenorrhea may be lessened by coadministration with an 
oral contraceptive. Periodic evaluation of blood pressure and potassium levels is 
appropriate. Pregnancy must be avoided while on spironolactone because of the 
risk of feminization of the male fetus. 
Isotretinoin is a systemic retinoid that is highly effective in the treatment of severe, 
recalcitrant acne vulgaris. It causes normalization of epidermal differentiation, 
depresses sebum excretion by 70%, is anti-inflammatory, and even reduces the 
presence of P. acnes. Isotretinoin therapy should be initiated at a dose of 0.5 
mg/kg/d for 4 weeks and increased as tolerated until a cumulative dose of 120-150 
mg/kg is achieved. An alternate regimen is 1 mg/kg/d for 20 weeks. 
Coadministration with steroids at the onset of therapy may be useful in severe 
cases. Isotretinoin is a teratogen, and pregnancy must be avoided. Contraception 
counseling is mandatory, and 2 negative pregnancy test results are required prior to 
the initiation of therapy. Baseline laboratory examination should also include 
cholesterol and triglyceride assessment and a complete blood count. Pregnancy 
tests should be repeated monthly, and other laboratory tests should be rechecked 
after 6-8 weeks of therapy. Associated mood changes and depression during 
treatment have been reported. Although the cause is not clear, patients should be 
informed of this potential effect.  
The patient is considered at high risk for abnormal healing and development of 
excessive granulation tissue following procedures. Many dermatologists delay 
elective procedures, such as dermabrasion or laser resurfacing, for up to a year 
after completion of therapy. Other procedures to be avoided during therapy include 
tattoos, piercings, leg waxing, and other epilation procedures. 
Prognosis.In male patients, acne generally clears by early adulthood. Female 
patients frequently have adult acne. The overall prognosis for persons with acne is 
good. However, acne can result in long-lasting psychosocial impairment and 
physical scarring. 
 
 
15. 2. Rosacea 
 
Background.Rosacea is a common condition characterized by symptoms of facial 
flushing and a spectrum of clinical signs, including erythema, telangiectasia, 
coarseness of skin, and an inflammatory papulopustular eruption resembling acne.  
Pathophysiology.Rosacea affects the central flush/blush areas of the face (i.e. 
forehead, nose, cheeks, chin), although ocular disease and extrafacial lesions are 
well-recognized features. Vascular lability, manifested clinically as intermittent 
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facial flushing, is a central feature of the disease, probably related to the local 
release of vasoactive substances. A number of dietary triggers (e.g. hot drinks, 
alcohol, spicy foods) and environmental triggers (e.g. temperature changes) are 
well recognized. Permanent telangiectasia may result.  
Sebaceous hyperplasia, fibrosis, and lymphedema characterize more severe forms 
of the disease. An etiologic role has been proposed for Demodex species (mites 
that normally inhabit human hair follicles). Demodectic folliculitis and blepharitis 
have been described, and Demodex mites appear in greater numbers in persons 
with rosacea, but evidence for a central role in the pathogenesis of rosacea is 
lacking. Unlike acne, seborrhea is not a prominent feature, and the pathogenesis of 
the inflammatory papules and pustules is not clear.  
History.Patients are likely to have a background of facial flushing, often dating to 
childhood or the early teens. In adult life, flushing may be increasingly precipitated 
by hot drinks, heat, emotion, and other causes of rapid body temperature changes. 
Some patients report flushing with alcohol, which is not specific.The symptoms 
are usually intermittent but can progressively lead to permanently flushed skin. 
The latter may be described as high color and is associated with the development 
of permanent telangiectasia.A few individuals report a gritty quality of the eyes 
and facial edema. 
Physical.The disease consists of a spectrum of symptoms and signs, with most 
patients failing to develop every stage of disease. Variable erythema and 
telangiectasia are seen over the cheeks and the forehead. Inflammatory papules and 
pustules may be predominantly observed over the nose, the forehead, and the 
cheeks. Extrafacial involvement uncommonly occurs over the neck and the upper 
part of the chest. Prominence of sebaceous glands may be noted with the 
development of thickened and disfigured noses (rhinophyma) in extreme cases. 
Unlike acne, patients generally do not report greasiness of the skin; instead, they 
may experience drying and peeling. The absence of comedones is another helpful 
distinguishing feature. Ocular lymphoedema may be prominent but is mostly 
uncommon. The condition generally does not produce scarring. Rhinophyma may 
occur as an isolated entity without other symptoms or signs of rosacea. It can be 
disfiguring and therefore distressing for patients. Some authorities consider 
rhinophyma to represent a different disease process.Lymphoedema may be marked 
periorbitally, and, on occasion, it is the presenting complaint.Symptoms of ocular 
rosacea may be accompanied by conjunctival injection, and rarely, chalazion and 
episcleritis may occur.Rosacea fulminans (pyoderma faciale) is fortunately a rare 
complication manifested by the development of nodules and abscesses with sinus 
tract formation accompanied by systemic signs.Both seborrhea and seborrheic 
dermatitis/blepharitis are not uncommonly observed in patients with rosacea. The 
reasons for these associations are not well understood.A rare caseating 
granulomatous variant of rosacea (acne agminata/lupus miliaris disseminatus 
faciei) can present with inflammatory erythematous or flesh-colored papules 
distributed symmetrically across the upper part of the face, particularly around the 
eyes and the nose. The lesions tend to be discrete, and surrounding erythema is not 
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a marked feature but may be present. This pattern of rosacea is sometimes 
associated with scarring and may be resistant to conventional treatment. 
Complications.Rosacea keratitis and keratoconjunctivitis sicca are recognized 
complications.Rosacea fulminans is a rare complication. Scarring generally does 
not occur. 
Procedures.A skin biopsy is sometimes performed to exclude diseases, such as 
lupus or sarcoidosis. 
Histologic Findings.The histologic features of rosacea depend on the stage of 
disease. Non-pustular lesions show a nonspecific perivascular and perifollicular 
lymphohistiocytic infiltrate, accompanied by occasional multinucleated cells, 
plasma cells, neutrophils, and eosinophils. Papulopustular lesions show more 
pronounced granulomatous inflammation and sometimes perifollicular abscesses. 
Demodex folliculorum may be abundant in nearby follicles. The histologic features 
of acne agminata are striking, demonstrating caseating granulomata with negative 
stains for mycobacteria and fungi. 
Medical Care.Systemic tetracycline in doses ranging from 250 mg daily to 500 
mg tid is usually effective in treating acneiform lesions, with improvement evident 
within 2-4 months after commencement of therapy. Tetracycline should generally 
be taken on an empty stomach with water only. Tetracyclines can produce 
esophageal irritation and ulceration, and bedtime doses should be avoided, 
especially in patients with gastroesophageal reflux. Alternatives include 
erythromycin 500 mg bid, minocycline 50-100 mg, or doxycycline 50-100 mg 
daily to bid. Erythema responds poorly. Empirical trials of medication may reveal 
spontaneous remission after 18-36 months. The condition takes a chronic course in 
many individuals.Topical metronidazole is helpful for mild disease and as adjuvant 
to systemic therapy.Topical and systemic corticosteroids are relatively 
contraindicated, except as a short course in rosacea fulminans. Flares of rosacea or 
a rosacea-like dermatitis are commonly seen in patients who have been applying 
potent topical corticosteroids to facial skin. Topical keratolytics (e.g. benzoyl 
peroxide, azelaic acid) offer limited symptomatic control of inflammatory pustules.  
Courses of isotretinoin (0.5-1 mg/kg/d) for 4 months may be helpful for 
recalcitrant disease, but recurrence is common. Long-term, low-dose isotretinoin 
therapy may be suitable for selected patients. Isotretinoin is teratogenic and has 
adverse effects on serum lipid profiles. Ocular rosacea may respond to topical 
fusidic acid or systemic tetracycline for at least 3 months. Some patients find that 
regular facial massage reduces lymphoedema. Rosacea fulminans is treated with 
moderately high doses of prednisolone (30-60 mg daily) followed by oral 
isotretinoin.  
Surgical Care.Permanent telangiectasia may be treated by electrosurgery or the 
585-nm pulsed dye laser. However, facial erythema is not improved, and new 
telangiectases develop with the passage of time. Cosmetic improvement of 
rhinophyma may be produced by mechanical dermabrasion, carbon dioxide laser 
peel, and surgical shave techniques.  
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Prognosis.In most patients who receive treatment, a stable state is reached with 
variable residual symptomatology.The disease takes a chronic relapsing or 
progressive course for some patients. 
Patient Education.Patients should be advised to avoid known exacerbating 
factors, such as hot drinks, alcohol, and extremes of temperature, and they should 
be encouraged to use a non-comedogenic, high-factor sunscreen when exposed to 
sunlight and wind. 
 
 
15.3. Alopecia Areata 
 
Background.Alopecia areata (AA) is a recurrent non-scarring type of hair loss that 
can affect any hair-bearing area. Clinically, AA can present with many different 
patterns. Although medically benign, AA can cause tremendous emotional and 
psychosocial stress in affected patients and their families.  
Pathophysiology.The pathophysiology of alopecia areata remains unknown. The 
most widely accepted hypothesis is that AA is a T-cell mediated autoimmune 
condition that is most likely to occur in genetically predisposed individuals.  
Autoimmunity. Much evidence supports the hypothesis that AA is an autoimmune 
condition. The process appears to be T-cell mediated, but antibodies directed to 
hair follicle structures also have been found in AA patients with increased 
frequency compared to control subjects. Using immunofluorescence, antibodies to 
anagen phase hair follicles were found in as many as 90% of patients with AA 
compared to fewer than 37% of control subjects. The autoantibody response is 
heterogeneous and targets multiple structures of the anagen phase hair follicle. The 
outer root sheath is the structure targeted most frequently, followed by the inner 
root sheath, the matrix, and the hair shaft. Whether these antibodies play a direct 
role in the pathogenesis or whether they are an epiphenomenon is not known yet.  
Histologically, lesional biopsies of AA show a perifollicular lymphocytic infiltrate 
around anagen phase hair follicles. The infiltrate consists mostly of T-helper cells 
and, to a lesser extent, T-suppressor cells. CD4+ and CD8+ lymphocytes likely play 
a prominent role because the depletion of these T-cell subtypes results in complete 
or partial regrowth of hair in the Dundee experimental bald rat (DEBR) model of 
AA. The animals subsequently lose hair again once the T-cell population is replete. 
The fact that not all animals experience complete regrowth suggests that other 
mechanisms likely are involved. Total numbers of circulating T lymphocytes have 
been reported with both decreased and normal levels.  
Recent studies in humans also reinforce the hypothesis of autoimmunity. Studies 
have shown that hair regrows when affected scalp is transplanted onto SCID 
(severe combined immunodeficiency) mice that are devoid of immune cells. 
Autologous T lymphocytes isolated from affected scalp were cultured with hair 
follicle homogenates and autologous antigen-presenting cells. Following initial 
regrowth, injection of the T lymphocytes into the grafts resulted in loss of regrown 
hairs. Injections of autologous T lymphocytes that were not cultured with follicle 
homogenates did not trigger hair loss.  
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A similar experiment on nude (congenitally athymic) mice failed to trigger hair 
loss in regrown patches of AA after serum from affected patients was injected 
intravenously into the mice. However, the same study showed that mice injected 
with AA serum showed an increased deposition of immunoglobulin and 
complement in hair follicles of both grafted and non-grafted skin compared to mice 
injected with control serum, which showed no deposition.  
In addition, it has been shown that AA can be induced using transfer of grafts from 
AA-affected mice onto normal mice. Transfer of grafts from normal mice to AA-
affected mice similarly resulted in hair loss in the grafts. In conclusion, certain 
factors within the hair follicles, and possibly, in the surrounding milieu, trigger an 
autoimmune reaction. Adding or subtracting immunologic factors profoundly 
modifies the outcome of hair growth.  
Clinical evidence favoring autoimmunity suggests that AA is associated with other 
autoimmune conditions, the most significant of which are thyroid diseases and 
vitiligo.  
In conclusion, the beneficial effect of T-cell subtype depletion on hair growth, the 
detection of autoantibodies, the ability to transfer AA from affected animals to 
nonaffected animals, and the induction of remission by grafting affected areas onto 
immunosuppressed animals are evidence in favor of an autoimmune phenomenon.  
Genetics. Many factors favor a genetic predisposition for AA. The frequency of 
positive family history for AA in affected patients has been estimated to be 10-
20% compared to 1.7% in control subjects. The incidence is higher in patients with 
more severe disease (16-18%) compared to patients with localized AA (7-13%). 
Reports of AA occurring in twins also are of interest. No correlation has been 
found between the degree of involvement of AA and the type of AA seen in 
relatives.  
Several genes have been studied and a large amount of research has focused on 
human leukocyte antigen. Two studies demonstrated that human leukocyte antigen 
DQ3 (DQB1*03) was found in more than 80% of patients with AA, which 
suggests that it can be a marker for general susceptibility to AA. The studies also 
found that HLA DQ7 (DQB1*0301) and human leukocyte antigen DR4 
(DRB1*0401) were present significantly more in patients with alopecia totalis 
(AT) and alopecia universalis (AU).  
Another gene of interest is the interleukin-1 receptor antagonist gene, which may 
correlate with disease severity. Finally, the high association of Down syndrome 
with AA suggests the involvement of a gene located on chromosome 21.  
In summary, genetic factors are likely to play an important role in determining 
susceptibility and disease severity. AA is likely to be the result of polygenic 
defects rather than a single gene defect. The role of environmental factors in 
initiating or triggering the condition is yet to be determined.  
Cytokines. Interleukin 1 and tumor necrosis factor were shown to be potent 
inhibitors of hair growth in vitro. Subsequent microscopic examination of these 
cultured hair follicles showed morphologic changes similar to those seen in AA.  
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Innervation and vasculature. Another area of interest concerns the modification 
of perifollicular nerves. The fact that patients with AA occasionally complain of 
itching or pain on affected areas raises the possibility of alterations in the 
peripheral nervous system. Circulating levels of the neuropeptide calcitonin gene-
related peptide (CGRP) were decreased in 3 patients with AA compared to control 
subjects. CGRP has multiple effects on the immune system, including chemotaxis 
and inhibition of Langerhans cell antigen presentation and inhibition of mitogen-
stimulated T-lymphocyte proliferation.  
Viral etiology. Other hypotheses have been proposed to explain the 
pathophysiology of AA, but more evidence is needed to support them. AA was 
believed to possibly have an infectious origin, but no microbial agent has been 
isolated consistently in patients. Many efforts have been made to isolate 
cytomegalovirus, but most studies have been negative.  
Frequency.Prevalence in the general population is 0.1-0.2%. The lifetime risk of 
developing AA is estimated to be 1.7%. AA is responsible for 0.7-3% of patients 
seen by dermatologists.  
Mortality/Morbidity: AA is a benign condition and most patients are 
asymptomatic; however, it can cause emotional and psychosocial stress in affected 
individuals. Self-consciousness concerning personal appearance can become 
important. Openly addressing these issues with patients is important in helping 
them cope with the condition.  
Age.AA can occur at any age from birth to the late decades of life. Congenital 
cases have been reported. Peak incidence appears to occur from age 15-29 years. 
History.The natural history of AA is unpredictable. Extreme variations in duration 
and extent of the disease occur from patient to patient. AA most often is 
asymptomatic, but some patients (14%) experience a burning sensation or pruritus 
in the affected area.The condition usually is localized when it first appears. Of 
patients with AA, 80% have only a single patch, 12.5% have 2 patches, and 7.7% 
have multiple patches. No correlation exists between the number of patches at 
onset and subsequent severity.AA most often affects the scalp (66.8-95%); 
however, it can affect any hair-bearing area. The beard is affected in 28% (males), 
eyebrows in 3.8%, and extremities in 1.3% of patients (see). More than one area 
can be affected at once. 
Localized AA: episodes of localized (<50% involvement) patchy AA usually are 
self-limited; spontaneous regrowth occurs in most patients within a few months, 
with or without treatment.Extensive AA: Extensive (>50% involvement) forms of 
AA are less common. AT or AU were reported to occur at some point in 7% of 
patients; AA involving more than 40% hair loss is seen in 11%. The proportion of 
patients with AT appears to decrease with every decade of life.In 30% of patients 
with AT, complete hair loss occurred within 6 months after onset of disease. The 
natural evolution of AT is unpredictable, but recurrences of AA (not necessarily 
AT) are expected. 
Associated conditions. Because some of the entities associated with AA occur 
uncommonly in the general population, a large number of patients with AA need to 
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be examined to confirm whether an increased prevalence of these conditions exists 
among patients with AA. Unfortunately, most studies are performed on small 
groups; therefore, the data should be interpreted carefully.Atopic dermatitis is seen 
in 9-26% of patients with AA. In the general population, the prevalence of atopic 
dermatitis in children in temperate developed countries varies from 5-20%. In 
adults, the prevalence decreases to 2-10%. Some authors have found atopy to be a 
poor prognostic factor for AA.Vitiligo is seen with an incidence varying from 1.8-
3% compared to 0.3% in control subjects.Thyroid disease: Clinically evident 
thyroid disease was found in 0.85% of 1700 patients with AA. The prevalence of 
thyroid disease determined on a clinical or laboratory basis varies among studies 
from 0.85-14.7%. The incidence of thyroid disease in control subjects is estimated 
to be 0.17-2%. The presence of microsomal antibodies is found in 3.3-16% of 
patients. Antibodies can be found with or without signs or symptoms of thyroid 
disease, but patients with positive autoantibodies have a higher incidence of 
functional abnormalities found on thyroid-releasing hormone tests (26% vs 2.8%). 
The incidence of thyroid microsomal and thyroglobulin antibodies in control 
subjects is 7%. Other studies have not supported these results. A study in 100 
patients with AA failed to find an increased incidence of circulating autoantibodies 
including mitochondrial and thyroglobulin antibodies.Collagen vascular diseases 
have been found in 0.6-2% of patients with AA, while the incidence in control 
subjects was 0.17%. The incidence of AA in 39 patients with lupus erythematous 
was 10% in a study by Werth et al, in contrast to 0.42% of general dermatologic 
patients.Diabetes mellitus was found to be more common in control subjects 
(1.4%) than in patients with AA (0.4%). The occurrence of AA may protect against 
the appearance of insulin-dependent diabetes mellitus. However, the incidence of 
type I diabetes mellitus was significantly higher in relatives of patients with AA 
compared to the general population.Down syndrome: AA is seen in 6-8.8% of 
patients with Down syndrome, but only 0.1% of patients with AA have Down 
syndrome. The high frequency of AA in patients with Down syndrome suggests 
that a genetic linkage for AA may exist on chromosome 21.Emotional stress and 
psychiatric disease: Anxiety, personality disorders, depression, and paranoid 
disorders are seen with increased incidence varying from 17-22% of patients, and 
the lifetime prevalence of psychiatric disorders was estimated to be 74% in patients 
with AA. Psychiatric problems are seen in both children and adults. No association 
has been made between the severity of the psychiatric disorder and that of AA. 
Stressful life events within the 6-month period preceding episodes of AA were 
significantly higher in patients with AA compared to patients with androgenetic 
alopecia or tinea capitis. Major stress factors (e.g. death in family) were reported in 
12% of patients.Others associations: Pernicious anemia, myasthenia gravis, 
ulcerative colitis, lichen planus, and Candida endocrinopathy syndrome also have 
been associated with AA in some studies. 
Precipitating factors. A precipitating factor can be found in 15.1% of patients 
with AA. Major life events, febrile illnesses, drugs, pregnancy, trauma, and many 
other events have been reported, but no clear conclusions can be drawn. Despite 
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these findings, most patients with AA fail to report a triggering factor preceding 
episodes of hair loss. 
Causes.The true cause of AA remains unknown. The exact role of possible factors 
needs to be clarified (see Pathophysiology). No known risk factors exist for AA, 
except positive family history.The exact role of stressful events remains unclear, 
but they most likely trigger a condition already present in susceptible individuals, 
rather than acting as the true primary cause. 
Physical.Presence of smooth slightly erythematous (peach color) or normal-
colored alopecic patches is characteristic.Presence of exclamation point hairs (i.e. 
hairs tapered near proximal end) is pathognomonic but is not always 
found.Positive pull test at the periphery of a plaque usually indicates that the 
disease is active, and further hair loss can be expected.Hair loss on other hair-
bearing areas also favors the diagnosis. The most common presentation is the 
appearance of 1 or many round-to-oval denuded patches.No epidermal changes are 
associated with the hair loss. 
AA can be classified according to its pattern. Hair loss most often is localized and 
patchy. Reticular pattern occurs when hair loss is more extensive and the patches 
coalesce.Ophiasis pattern occurs when the hair loss is localized to the sides and 
lower back of the scalp.Conversely, sisaipho (ophiasis spelled backwards) pattern 
occurs when hair loss spares the sides and back of the head.AT occurs with 100% 
hair loss on the scalp. AU occurs with complete loss of hair on all hair-bearing 
areas. AA usually is focal; however, it can be diffuse, thereby mimicking telogen 
effluvium (TE) or the type of androgenetic alopecia seen in women. Nail 
involvement is as follows: nail involvement is found in 6.8-49.4% of patients and 
most commonly is seen in patients with severe forms of AA.Pitting is the most 
common finding. Several other abnormalities have been reported (e.g. 
trachyonychia, Beau lines, onychorrhexis, onychomadesis, koilonychia, 
leukonychia, red lunulae).Fingernails predominantly are affected. 
Procedures.Diagnosis usually can be made on clinical grounds; a scalp biopsy 
seldom is needed, but can be helpful when clinical diagnosis is less certain. 
Histologic Findings.A histologic diagnosis of AA can be made when 
characteristic features are present. Horizontal sections usually are preferred to 
vertical sections, since they allow examination of multiple hair follicles at different 
levels. The most characteristic feature is a peribulbar lymphocytic infiltrate, which 
is described as appearing similar to a swarm of bees. The infiltrate often is sparse 
and usually involves only a few of the affected hairs in a biopsy specimen. 
Occasionally, no inflammation is found, which can result in diagnostic difficulties. 
A significant decrease in terminal hairs is associated with an increase in vellus 
hairs, with a ratio of 1.1:1 (normal is 7:1). Other helpful findings include pigment 
incontinence in the hair bulb and follicular stellae.  
A shift occurs in the anagen-telogen ratio, which is not specific. The normal ratio 
is approximately 90% anagen phase to 10% telogen phase hair follicles; in AA, 
73% of hairs were found to be in the anagen phase and 27% in the telogen phase. 
In long-standing cases of AA, the percentage of telogen phase hairs can approach 
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100%. Degenerative changes of the hair matrix can be found but are uncommon. 
Eosinophils may be present in fibrous tracts and near hair bulbs. 
Medical Care.Treatment is not mandatory because the condition is benign, and 
spontaneous remissions and recurrences are common. Treatments used are 
believed to stimulate hair growth, but no evidence exists that they influence the 
ultimate natural course of the disease. Treatment modalities usually are considered 
first according to the extent of hair loss and the patient's age.  
Assessment of the efficacy of a treatment must be considered with care, since the 
condition is highly unpredictable in presentation, evolution, and response to 
treatment. Little data exist regarding the natural evolution of the condition. For 
example, in patients with less than 40% scalp involvement, a study showed no 
benefit with treatment (minoxidil 1% and topical immunotherapy) over placebo. 
The high spontaneous remission rate makes it difficult to assess clearly the true 
efficacy of a therapy unless appropriate controls with placebo treatment are 
studied. For patients with extensive AA (>40% hair loss), little data exist on the 
natural evolution. The rate of spontaneous remission appears to be less than in 
patients with less than 40% involvement. The relapse rate is high in patients with 
severe forms of AA. Patients with AT/AU usually have a poorer prognosis, and 
treatment failure is seen in most patients with any therapy.  
Since AA is believed to be an autoimmune condition, different immunomodulators 
have been used to treat this condition. Additional treatment options for AA include 
minoxidil and other treatment modalities.  
Corticosteroids.Intralesional steroids: Few studies are available regarding the 
efficacy of intralesional steroids, but they are used widely in the treatment of AA. 
Intralesional steroids are the first-line treatment in localized conditions. Topical 
steroids: Fluocinolone acetonide cream 0.2% (Synalar HP) twice per day induced a 
satisfactory-to-excellent response in 61% of patients, which was maintained in 
71% of patients. Betamethasone dipropionate cream 0.05% (Diprosone) showed 
similar efficacy. Treatment must be continued for a minimum of 3 months before 
regrowth can be expected, and maintenance therapy often is necessary.  
Prednisone: the use of systemic steroids for the treatment of AA is under much 
debate. Some authors support a beneficial role of systemic steroids in halting the 
progression of AA, but many others have had poor results with this form of 
therapy. Some benefit was shown using minoxidil 2% solution applied twice per 
day following a 6-week taper of prednisone, but the relapse rate remained at a 
minimum of 50% at 4 months in the treated group.  
Topical immunotherapy: Topical immunotherapy is defined as the induction and 
periodic elicitation of an allergic contact dermatitis by topical application of potent 
contact allergens. Commonly used agents for immunotherapy include squaric acid 
dibutylester (SADBE) and diphencyprone (DPCP). These 2 sensitizers are not 
present in the natural or industrial environment. Dinitrochlorobenzene (DNCB) has 
become less popular as a result of reports that it is mutagenic in the Ames assay (a 
bacterial assay). Cosmetically acceptable regrowth with topical immunotherapy in 
patients with severe AA (>50% involvement) varies from 22-68%. Most studies 
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have a success rate of 30-50%.  Topical immunotherapy has been used for almost 
20 years; no serious adverse effects have been reported. The mechanism of action 
of topical immunotherapy is unknown.  
Psoralen plus UV-A. Many studies have been performed regarding the efficacy of 
psoralen plus UV-A (PUVA) in the treatment of AA, and the initial response rate 
varies from 20-73%. The relapse rate unfortunately is high (50-88%). Most 
patients relapse within a few months (mean 4-8 months) after treatment is stopped. 
Both systemic and topical PUVA therapies have been used. The number of 
treatments required for regrowth varies, but 20-40 treatments usually are sufficient 
in most cases. A younger age at onset, a longer duration of disease, and the 
presence of AT or AU appear to indicate a poorer outcome. 
Cyclosporine. Cyclosporine has been used both topically and systemically in the 
treatment of AA. Topical cyclosporine has not proven to be effective in severe AA, 
since no patient (0 of 10) showed benefit with application of a 10% cyclosporin A 
(CsA) solution twice per day for 12 months.  
Minoxidil. Minoxidil appears to be effective in the treatment of AA in patients 
with extensive disease (50-99% hair loss). Response rates in that group vary from 
8-45%. Minoxidil was of little benefit in patients with AT/AU. The 5% solution 
appears to be more effective.  
Other treatment modalities. Many other modalities have been reported to have 
variable response rates in small studies. These include nitrogen mustard, massage 
and relaxation, isoprinosine, acupuncture, and aromatherapy among others. The 
efficacy of these treatments needs to be demonstrated in larger placebo-controlled 
trials before they can be recommended. 
Prevention.AA is highly unpredictable. No treatment is effective in preventing or 
halting progression of the condition. No trigger can be found to explain disease 
exacerbation in most patients. 
Prognosis.The natural history of AA is unpredictable. Most patients have only a 
few focal areas of alopecia, and spontaneous regrowth usually occurs within 1 
year.Probably, less than 10% of patients experience extensive alopecia, and less 
than 1% have AU.Patients with extensive long-standing conditions are less likely 
to experience significant long-lasting regrowth.Adverse prognosis factors include 
nail abnormalities, atopy, onset at a young age, and severe forms of AA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
303 
 
XVI. DISEASES OF THE VESSELS 
 
16.1. Erythema Induratum (Nodular Vasculitis) 
 
Synonyms and related keywords: Tuberculosis-associated erythema induratum, 
Erythema induratum of Bazin 
 
Background.In 1861, Bazin gave the name erythema induratum to a nodular 
eruption that occurred on the lower legs of young women with tuberculosis. In 
1945, Montgomery et al, while fully acknowledging the existence of tuberculosis-
associated erythema induratum, coined the term nodular vasculitis to describe 
chronic inflammatory nodules of the legs that showed histopathologic changes 
similar to those of erythema induratum, that is, vasculitis of the larger vessels and 
panniculitis. Erythema induratum and nodular vasculitis had been considered the 
same disease entity for a long time. However, nodular vasculitis is now considered 
a multifactorial syndrome of lobular panniculitis in which tuberculosis may or may 
not be one of a multitude of etiologic components. Therefore, erythema 
induratum/nodular vasculitis complex is classified into 2 variants. Erythema 
induratum of Bazin type and nodular vasculitis or erythema induratum of Whitfield 
type. Bazin type is related with tuberculous origin, but Whitfield type is not.  
Pathophysiology.The morphologic, molecular, and clinical data suggest that 
erythema induratum and nodular vasculitis represent a common inflammatory 
pathway, that is, a hypersensitivity reaction to endogenous or exogenous antigens. 
One such antigen is the tubercle bacillus. Patients with erythema induratum have a 
positive tuberculin skin test result and a marked increase in their peripheral T 
lymphocyte response to purified protein derivative (PPD) of tuberculin, which can 
cause a delayed-type hypersensitivity reaction.  
Causes.Erythema induratum/nodular vasculitis complex is a multifactorial 
disorder. Mycobacterium tuberculosis and delayed-type hypersensitivity are 
considered etiologic factors for erythema induratum of Bazin type. Recently, 
hepatitis C virus has been suggested, but a direct relationship remains unclear. M. 
tuberculosis is the cause of erythema induratum. The cause is unknown in cases of 
nodular vasculitis with a negative tuberculin skin test reaction. 
Mortality/Morbidity.To date, no fatal cases of erythema induratum have been 
reported. However, the chronic, recurrent, painful nodules and resultant scarring 
can be a source of significant morbidity.  
Sex.Erythema induratum shows female predominance, and lower extremities are 
the most common sites in both male and female patients; however, it also may 
occur in other areas.  
Age.Erythema induratum most commonly affects women aged 20-30 years. The 
condition is more common in young women than in other people, but it may occur 
later in life.  
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History.A past or present history of tuberculosis at an extracutaneous site occurs 
in about 50% of patients.Pulmonary tuberculosis is most common. Tuberculous 
cervical lymphadenitis is the next most common finding. Tender, erythematous 
nodules are present on the lower legs. The nodules have a chronic, recurrent 
course. The lesions heal with ulcerations or depressed scars. Leg edema may be 
present. 
Physical.Crops of small, tender, erythematous nodules may be observed. 
Commons sites are the calves, although the shins are also sometimes involved. 
Uncommonly, the trunk, buttocks, thighs, and arms can be involved.The nodules 
are concentrated on the lower third of the legs, especially around the 
ankles.Lesions may ulcerate with bluish borders, which may be precipitated by 
cold weather. These irregular and shallow ulcerations can result in permanent 
scarring and hyperpigmentation of the lesions. 
Complications.Inadequately treated or untreated erythema induratum may result in 
prolonged disease, persistent ulcerations, and complications due to coexistent 
systemic tuberculosis. 
Lab Studies.A complete blood cell count may be performed. The erythrocyte 
sedimentation rate may be increased. 
Imaging Studies.Chest radiography may be performed. Search for evidence of 
active or previous infection. 
Other Tests.Polymerase chain reaction provides rapid and sensitive detection of 
M. tuberculosis in formalin-fixed, paraffin-embedded specimens. Polymerase 
chain reaction can be applied to differentiating nodular vasculitis from erythema 
induratum of Bazin because the demonstration of mycobacteria emerges as the 
only reliable criterion in erythema induratum of Bazin type. 
Procedures.Some patients are highly sensitive to tuberculin PPD. Patients should 
be tested with a 1:10,000 dilution Mantoux test.An excisional biopsy containing 
adequate subcutaneous fat is recommended. Special stains for bacterial, fungal, and 
acid-fast organisms, as well as tissue for culture of these organisms, are generally 
obtained. 
Histologic Findings.Findings consist of a mixed septal and lobular granulomatous 
panniculitis with neutrophilic vasculitis. Caseationl-ike necrosis may also be seen. 
The histologic features are not specific; they vary depending on the age of the 
lesion undergoing biopsy and the overlap with other forms of panniculitis. 
Vasculitis is not always identified and is not a requisite for the diagnosis. The 
presence of both septal granulomatous inflammation and lobular granulomatous 
inflammation is, nonetheless, characteristic of erythema induratum and contrasts 
with erythema nodosum (primarily septal) and polyarteritis nodosa (medium vessel 
vasculitis with minimal lobular inflammation). 
Medical Care.Erythema induratum of Bazin is treated with antituberculous 
therapy. Antituberculosis monotherapy has been abandoned because of high 
resistance; a multidrug combination regimen is more widely accepted.Bed rest with 
systemic steroids may be indicated. Potassium iodide is sometimes applied, with 
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high efficacy; however, this therapy requires caution when used in children or in 
patients with thyroid disease. 
Prognosis.The prognosis is good if treated properly. 
 
16.2. Henoch-Schönlein Purpura (Anaphylactoid Purpura) 
 
Background.Henoch-Schönlein purpura (HSP) is an immunoglobulin (Ig) A-
mediated small-vessel vasculitis that predominantly affects children but also is 
seen in adults. HSP is a subset of necrotizing vasculitis characterized by fibrinoid 
destruction of blood vessels and leukocytoclasis. Clinical manifestations primarily 
include palpable purpura, arthralgia or arthritis, abdominal pain, gastrointestinal 
(GI) bleeding, and nephritis. The most serious long-term complication from HSP is 
progressive renal failure, which occurs in 1-2% of patients.  
Heberden first described the disease in 1801 in a 5-year-old child with abdominal 
pain, hematuria, hematochezia, and purpura of the legs. In 1837, Johann Schönlein 
described a syndrome of purpura associated with joint pain and urinary precipitates 
in children. Eduard Henoch, a student of Schönlein's, further associated abdominal 
pain and renal involvement with the syndrome. Frank proposed the term 
"anaphylactoid purpura" in 1915. This followed from the reasoning that the 
pathogenesis likely involved a hypersensitivity reaction to an inciting agent.  
Two major classification systems are used to make a diagnosis of HSP. The first, 
from the American College of Rheumatology, requires two or more of the 
following to be present: (1) Patient age younger than 20 years; (2) Palpable 
purpura; (3) Abdominal pain or GI bleeding; (4) Extravascular or perivascular 
granulocytes on biopsy. The second classification system is from the Chapel Hill 
Consensus Group, primarily uses nonclinical criteria, and requires only the 
presence of small-vessel vasculitis with IgA deposition.  
Two additional sets of criteria have been suggested for the diagnosis of HSP. 
Helander et al proposed that three or more of the following be present: (1) Direct 
immunofluorescence (DIF) results consistent with vascular IgA deposition;(2) 
Patient age younger than 20 years; (3) GI involvement; (4) Upper respiratory 
infection tract (URI) prodrome; (5) Mesangioproliferative glomerulonephritis with 
or without IgA deposition. Michel et al. proposed criteria to differentiate HSP from 
hypersensitivity vasculitis, requiring three or more of the following be present to 
diagnose HSP: (1) Palpable purpura; (2) Bowel angina; (3) GI bleeding; (4) 
Hematuria; (5) Patient age of onset younger than 20 years; (6) No medications as a 
precipitating agent. 
Pathophysiology.The etiology of HSP is unknown but involves the vascular 
deposition of IgA immune complexes. More specifically, the immune complexes 
are composed of IgA1 and IgA2 and are produced by peripheral B lymphocytes. 
These complexes likely are formed in response to an inciting factor. The 
circulating complexes become insoluble, are deposited in the walls of small vessels 
(arteries, capillaries, venules), and activate complement, most likely by the 
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alternative pathway (based on the presence of C3 and properdin and the absence of 
the first component of complement in most biopsies).  
Polymorphonuclear leukocytes are recruited by chemotactic factors and cause 
inflammation and necrosis of vessel walls with concomitant thrombosis. This leads 
to extravasation of erythrocytes from hemorrhage in the affected organs and is 
manifested histologically as leukocytoclastic vasculitis.  
Histology of involved skin reveals polymorphonuclear cells or cell fragments 
around small dermal blood vessels. Immune complexes containing IgA and C3 
have been found in skin, kidneys, intestinal mucosa, and joints, which are the 
major organ sites involved in HSP.  
Clinical manifestations of HSP reflect small-vessel injury. Abdominal pain, 
present in as many as 65% of patients, is secondary to vasculitis-induced 
submucosal and subserosal hemorrhage and edema, with thrombosis of the 
microvasculature in the gut. Hematuria and proteinuria occur in HSP-associated 
nephritis. Renal manifestations range from minimal change to severe crescentic 
glomerulonephritis.  
Etiology is secondary to the mesangial deposition of IgA predominantly, but IgG, 
IgM, C3, and properdin deposition also may occur. These deposits also can occur 
in the subendothelial and subepithelial glomerular spaces. Many believe that both 
HSP nephritis and IgA nephropathy (Berger disease), which are the most common 
causes of glomerulonephritis in the world, are different clinical presentations of the 
same disease process. Dermatologic manifestations occur secondary to immune 
complex deposition (IgA, C3) in vessels of the papillary dermis, resulting in vessel 
injury, extravasation of RBCs, and clinically observable palpable purpura. This 
tends to occur in dependent body regions, such as the lower legs, buttocks, back, 
and abdomen.  
As many as 50% of occurrences in pediatric patients are preceded by a URI, and a 
recent study in adults demonstrated that 40% of patients had an antecedent URI. 
Several agents have been implicated, including group A streptococci, varicella, 
hepatitis B, Epstein-Barr virus, parvovirus B19, Mycoplasma, Campylobacter, and 
Yersinia. Less commonly, other factors have been associated as inciting agents in 
the development of HSP. These include drugs, malignancy, foods, pregnancy, 
familial Mediterranean fever, and exposure to cold. HSP also has been reported 
following vaccinations for typhoid, measles, yellow fever, and cholera.  
Frequency.In the US, 75% of HSP occurrences are in children aged 2-14 years. 
The incidence in this age group is 14 per 100,000 population.  
Mortality/Morbidity.Most morbidity and mortality in this disease results from 
glomerulonephritis and its associated acute and chronic renal manifestations. At a 
minimum, transient hematuria occurs in 90% of patients. Renal insufficiency 
occurs in fewer than 2% of patients, and end-stage renal failure occurs in fewer 
than 1%. HSP accounts for 3-15% of children entering dialysis programs.  
Age.Most patients (75%) are children aged 2-14 years. The median age of onset is 
4-5 years. Although one of the criteria for the diagnosis of HSP as published by the 
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American College of Rheumatology is "age less than 20 years," the disease can 
occur from infancy to the ninth decade.  
History.The presenting history varies with each patient. The hallmark of the 
disease is the characteristic palpable purpura, which is seen in almost 100% of 
patients. HSP tends to occur on the buttocks and upper thighs in younger children 
and on the feet, ankles, and lower legs of older children and adults. Patients often 
present with low-grade fever and malaise in addition to more specific symptoms. 
Purpura may be the presenting sign. As many as 50% of children present with 
symptoms other than purpura. The eruption often is preceded by arthralgia or 
arthritis, abdominal pain, or testicular swelling. Although it may be present 
initially, renal disease often develops up to 3 months after initial presentation.  
Joint symptoms: Arthralgia or arthritis is the presenting complaint in 25% of 
patients and occurs at some point in 60-75% of patients. Ankles and knees are 
affected most commonly, although any joint may be involved. 
Abdominal pain: Abdominal pain with concomitant hematochezia is the second 
most frequent symptom, is observed in 50-65% of patients, and is the presenting 
complaint in 10-15%. Pain tends to be sharp or colicky, and surgical consultation 
may be indicated to exclude a surgical abdomen. Indeed, as many as 6% of patients 
require surgery as a result of complications such as intussusception, bowel wall 
perforation, or infarction. Gastric hemorrhage with hematemesis, hydrops of the 
gallbladder, appendicitis, and pancreatitis also has been reported. 
Renal involvement.An incidence of renal involvement of 10-60% has been 
reported, and the extent of glomerular injury mostly determines the long-term 
morbidity and mortality of HSP. The presence of glomerular crescents on renal 
biopsy correlates with a poor prognosis. HSP nephritis usually presents as 
macroscopic hematuria and proteinuria lasting days to weeks. These may be 
accompanied by increased plasma creatinine and/or hypertension, followed by 
microscopic hematuria, which may last months to years. Gross hematuria may 
occur years after the initial illness with relapses of purpura, often following a URI. 
Of those patients with renal involvement, as many as 10% may develop chronic 
renal failure and end-stage renal disease. However, fewer than 1% of patients with 
HSP suffer this poor prognosis. 
Disease recurrence: Disease recurrence occurs throughout weeks to months in 
adults and children. In the large pediatric study by Allen et al, children older than 2 
years had a recurrence rate of 50%, while those younger than 2 years had a less 
than 25% chance of recurrence. The primary differences between children and 
adults, according to one study of 57 adults with HSP, are the chronicity and 
severity of the eruption in the latter population. Bullae and ulcers are more 
common in adults, and cutaneous exacerbations may be seen for 6 months or 
longer. 
Other signs and symptoms: Less common manifestations of HSP include testicular 
pain and swelling, hepatosplenomegaly, central or peripheral nervous system 
involvement (seizures or mononeuropathies, respectively), headache, and rarely, 
myocardial infarction or pulmonary hemorrhage. 
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Physical.A full physical examination is indicated, since HSP can affect many 
organ systems. Skin - The primary lesion. An eruption may begin as erythematous 
macular or urticarial lesions, progressing to blanching papules, and later, to 
palpable purpura, usually 2-10 mm in diameter. However, bullae, vesicles, 
petechiae, and ecchymotic, necrotic, ulcerative, or target-ike lesions also may 
occur. Subcutaneous edema is common in children younger than 3 years. 
Skin – Distribution.Lesions typically are symmetric and tend to be distributed in 
dependent body areas, such as the ankles and lower legs in older children and 
adults, and the back, buttocks, upper extremities, and upper thighs in young 
children, since these regions tend to be dependent in the latter group. The face, 
palms, soles, and mucous membranes usually are spared, except in infants, in 
whom facial involvement may not be uncommon. The subcutaneous edema 
prominent in young children involves the scalp, periorbital regions, hands, feet, 
and scrotal area.Lesions usually occur in crops and may fade over several days. 
Recurrences tend to occur in the same sites as previous lesions. 
Skin: Color as seen in the areas of purpura progresses from red to purple, then 
becomes rust-colored or brown before fading. 
Heart: Cardiac tamponade and myocardial infarction rarely have been reported 
with HSP.Lungs: Although seldom a manifestation of HSP, pulmonary 
hemorrhage has been reported. When present, it is a poor prognostic sign with a 
50% mortality rate. One pediatric study showed that 95% of patients with active 
disease had impaired diffusion capacity of carbon monoxide, which was readily 
reversible once the syndrome resolved.Abdomen: Pain secondary to vasculitic 
involvement of small mesenteric or bowel mucosal vessels is common. Examine 
the abdomen for a palpable mass, which may indicate intussusception. Pancreatitis, 
gallbladder hydrops, appendicitis, and massive gastric hemorrhage also have been 
reported.Scrotum/testicles: Testicular involvement has varied in reports from 4-
38%. Testicular pain may be so intense that it mimics torsion.Extremities: 
Arthralgia and arthritis are common, primarily affecting the ankles and knees, 
although any joint may be involved. Periarticular inflammation is 
common.Neurologic: Headaches, seizures, and mononeuropathies rarely have been 
reported with HSP. Perform a careful neurologic examination for focal deficits. 
Complications: Renal involvement, chronic renal failure. 
Lab Studies.Urinalysis: Since renal failure and end-stage renal disease are the 
most serious long-term sequelae of this disease, initial and repeated urinalyses 
(UA) are crucial for appropriate monitoring of disease progression and resolution. 
Proteinuria and microscopic hematuria are the most common abnormalities on UA. 
Since renal involvement may follow the appearance of purpura for up to 3 months, 
perform UA monthly for several months after presentation.Serum electrolytes: 
Creatinine and blood urea nitrogen measurements indicate HSP-associated acute or 
chronic renal failure. Electrolyte imbalance may exist if significant diarrhea, GI 
bleeding, or hematemesis is seen.Antistreptolysin-O antibody titer: URIs with 
streptococcal species have been implicated as predisposing factors in as many as 
50% of patients.Serum IgA level: The level often is elevated in HSP, although this 
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is not a specific test for the disease.Antinuclear antibody test: Systemic lupus 
erythematosus is in the differential diagnosis for HSP.Rheumatoid factor: IgA 
rheumatoid factor has been reported in patients with HSP. In addition, rheumatoid 
arthritis is in the differential diagnosis for patients presenting with significant joint 
complaints. 
CBC with differential: Perform a CBC to determine etiology when a suggestion of 
underlying infection exists (e.g. pandemia with bacterial infection) and to exclude 
thrombocytopenia as a cause of purpura.Coagulation studies: Perform 
prothrombin time (PT) and partial thromboplastin time (aPTT) to exclude a 
bleeding diathesis.Liver function tests and hepatitis serologies: Hepatitis B has 
been reported in association with HSP.Direct immunofluorescence (DIF): Perform 
DIF for IgA on biopsy sections to demonstrate the predominance of IgA deposited 
in vessel walls of affected tissues. Perilesional skin adjacent to cutaneous lesions 
also may demonstrate IgA deposits. Renal biopsy specimens demonstrate 
mesangial IgA deposition in a granular pattern, often with C3, IgG, or IgM. This 
test is both sensitive and specific for HSP.Stool culture and guaiac: With 
appropriate history of GI complaints, a stool culture may be useful to search for 
Yersinia or Campylobacter species. Always search for occult GI bleeding when 
HSP is suspected.Serum markers of inflammation: ESR and CRP often are 
elevated in HSP. Renal biopsy: Renal insufficiency with nephrotic range 
proteinuria (>3.5 g protein/24 h) justifies renal biopsy. DIF for IgA reveals 
granular mesangial IgA deposition. 
Imaging Studies.Ultrasound: Ultrasound is indicated if abdominal pain is present 
to exclude intussusception, bowel wall edema, thickening, or perforation. This 
modality also is useful to evaluate acute testicular pain to exclude torsion. 
Chest x-ray: Chest x-ray excludes pulmonary nodules or hilar adenopathy 
suggestive of malignancy (primary or metastatic) or lymphoma, which have been 
associated with HSP. 
Procedures.Skin biopsy: Biopsy early skin lesions for routine histology and DIF 
to confirm diagnosis or when diagnosis is in question.Renal biopsy: Perform renal 
biopsy when renal insufficiency with nephrotic range proteinuria is seen. Perform 
DIF for IgA deposits.Esophagogastroduodenoscopy: Upper GI endoscopy is 
indicated in patients with HSP when epigastric pain, melena, or hematemesis is 
present. Esophagogastroduodenoscopy (EGD) often demonstrates intensely red 
raised lesions, multiple ulcers, or diffuse erosive lesions. The duodenum frequently 
is involved.Colonoscopy: Colonoscopy is indicated when severe rectal bleeding 
exists. The appearance of the lesions is similar to that described for EGD. 
Histologic Findings.Leukocytoclastic vasculitis is the predominant finding in 
affected tissues. Skin biopsy demonstrates fibrinoid necrosis of arteriolar and 
venular walls in the superficial dermis, with neutrophilic infiltration of the walls 
and perivascular regions. Associated fragments of inflammatory cells with nuclear 
debris are seen. Products of lysosomal enzyme digestion, as well as erythrocytes 
from hemorrhage, are extravasated. DIF shows IgA deposition in affected blood 
vessels. IgM, C3, and properdin also may be seen. Note that immune complex 
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deposition occurs before chemotactants attract neutrophils, which then causes 
vascular injury. Once necrosis occurs, immune complexes disappear.  
Mucosal biopsy from affected GI tissue shows histopathology identical to that seen 
in the skin. Biopsy of affected renal tissue shows a spectrum of glomerular disease 
from minimal change to severe crescentic glomerulonephritis. IgA, C3, fibrin, 
properdin and to some extent IgG and IgM, are seen as granular mesangial deposits 
on DIF. If severe disease is present, deposits also may be seen in the 
subendothelial and subepithelial spaces.  
Medical Care.HSP usually is self-limited and treatment primarily is supportive to 
assure adequate hydration and replace excessive blood loss. Search for and treat 
underlying or predisposing factors. Controversies concerning the use of 
corticosteroid and other therapies in the treatment of HSP exist, since no 
randomized, double-blind, placebo-controlled trials support their use. Some 
retrospective studies have shown that steroids can relieve abdominal pain and GI 
bleeding if administered within the first 24-48 hours. Other studies demonstrated 
no difference between patients treated with steroids and those treated with 
placebos. Some studies also have suggested that corticosteroid therapy may 
prevent the onset of delayed-HSP nephritis or lessen the severity of glomerular 
injury.  
The presence of nephrotic-range proteinuria and hematuria are associated with a 
15% risk of renal failure, and the presence of more than 50% glomerular crescents 
on renal biopsy is associated with 50% renal failure over a 10-year period. Because 
of the potentially severe sequelae in these patients, initiate corticosteroid therapy 
when nephrotic-range proteinuria with hematuria is seen or when biopsy 
demonstrates glomerular crescents. One uncontrolled study showed the benefit of 
combination therapy in severe HSP nephritis with methylprednisolone, 
cyclophosphamide, and dipyridamole. Dapsone, azathioprine, and IV 
immunoglobulin therapies have been tried with varying success, as has 
plasmapheresis. Non-steroidal anti-inflammatory drugs (NSAIDs) may be used to 
treat arthralgia associated with HSP. Oral corticosteroids may be of benefit in 
treating painful subcutaneous edema.  
Consultations.Dermatology - for diagnosis when a cutaneous eruption is the 
presenting symptom of HSP.Gastroenterology - for possible EGD or colonoscopy 
when hematemesis, melena, or hematochezia is present.Surgery - for evaluation 
when abdominal pain is the presenting symptom and severity mimics that of an 
acute abdomen.Nephrology - for evaluation, diagnosis, and management of the 
renal complications of HSP. 
Prognosis.Prognosis is excellent, except when progressive renal failure and end-
stage renal disease develop. Perform monthly UA both in patients who have signs 
or symptoms of nephritis (to monitor progression versus resolution) and in patients 
who have no evidence of nephritis (may develop signs of renal involvement 
months after initial presentation).The syndrome resolves after 4-6 weeks in most 
patients, although as many as 50% have a recurrence. 
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16.3. Hypersensitivity Vasculitis (Leukocytoclastic Vasculitis) 
 
Background.Leukocytoclastic vasculitis (LCV) is a histopathologic term 
commonly used to denote a small-vessel vasculitis. Many possible causes exist for 
this condition, but a cause is not found in as many as 50% of patients.  
The disorder may be localized to the skin, or it may manifest in other organs. The 
internal organs most commonly affected include the gastrointestinal tract or the 
kidneys. Joints are also commonly affected. The prognosis is good when no 
internal involvement is present. The disorder may be acute or chronic.  
Pathophysiology.In the past, circulating immune complexes were believed to 
cause LCV. Although immune complexes are involved in the pathogenesis of 
LCV, other autoantibodies cause disease manifestations, such as antineutrophil 
cytoplasmic antibody (ANCA), other inflammatory mediators, and local factors 
that involve the endothelial cells and other adhesion molecules. The exact 
mechanisms remain to be elucidated.  
Frequency.Hypersensitivity vasculitis reportedly has an incidence of 10-30 cases 
per million people per year.  
Mortality/Morbidity.The prognosis of LCV is generally good, but mortality is 
possible if the kidneys, the gastrointestinal tract, the lungs, the heart, or the central 
nervous system are involved. Chronic cutaneous disease may involve ulceration or 
painful bouts of purpura. Some patients alter their lives because of recurrent 
purpuric eruptions.  
Age.LCV may occur at any age. In children, LCV may be called Henoch-
Schönlein purpura. This condition may also occur in adults. Another form of 
vasculitis that is reported in infancy is acute hemorrhagic edema.  
History.Patients with vasculitis of their skin may complain of itching, a burning 
sensation, or pain, or they may have asymptomatic lesions.Vasculitis of the skin 
may occur in the absence of any systemic disease. Vasculitis may manifest as an 
eruption only, or it may occur in conjunction with collagen vascular disorders, 
paraproteinemia, ingestants (drugs or foods), infections, or malignancy (rare).Elicit 
information about possible systemic manifestations from patients. Inquire about 
the presence or the absence of fever, arthralgia, arthritis, myalgia, abdominal pain, 
diarrhea, hematochezia, cough, hemoptysis, sinusitis, paresthesia, weakness, and 
hematuria. 
Obtain information about symptoms of an associated disorder. Determine the 
patient's history of intravenous drug use, hepatitis, transfusion, and travel, along 
with symptoms or a history of inflammatory bowel disease and collagen vascular 
disorder, particularly rheumatoid arthritis, lupus erythematosus, or Sjögren 
syndrome. 
Physical.Palpable purpura is the most common manifestation of cutaneous 
vasculitis, but other manifestations may occur. Palpable purpura is the most 
frequent presentation of small-vessel vasculitis. Lesions are usually round and 1-3 
mm in diameter. Lesions may coalesce to form plaques; they may ulcerate in some 
instances.Retiform lesions were associated with immunoglobulin A (IgA)–related 
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immune complex disease in one study; however, this result has not been validated 
in subsequent studies.Palpable purpura is most frequently observed on the legs, but 
any surface can be involved. Purpuric lesions are sometimes barely 
palpable.Urticarial lesions may occur in some patients; rarely, this type of lesion 
can predate purpuric lesions.Urticarial lesions are of a different character than 
routine urticaria, tending to be of longer duration (often >24 h) and tending to 
resolve with some residual pigmentation or ecchymosis. Patients complain of a 
burning sensation rather than itching.To determine the duration of individual 
lesions, encircle several lesions and ask the patient to observe them periodically 
and note when they resolve or when they change shape and when a lesion is 
outside the encircled area. 
Patients with hypocomplementemic urticarial vasculitis may develop chronic 
obstructive pulmonary disease; carefully examine the heart and the lungs.Livedo 
reticularis is a rare manifestation of small-vessel vasculitis. It is more frequent in 
patients with occlusive or inflammatory disease of medium-sized vessels.Nodular 
lesions may occur in some patients with small-vessel vasculitis. Ulceration is more 
common in vasculitis that affects larger vessels, but it may complicate intense 
purpura.Perform a careful physical examination in patients with vasculitis, 
including specific observation of cardiopulmonary, musculoskeletal, and 
gastrointestinal systems. 
Causes.Between one third and one half of cutaneous vasculitis cases are 
idiopathic; the remainder have a variety of causes.Antibiotics are the most 
common drugs that can cause cutaneous vasculitis, particularly beta-lactams. Non-
steroidal anti-inflammatory drugs and diuretics also frequently cause vasculitis. 
However, almost all drugs are potential causes.Various infections may be 
associated with vasculitis. Upper respiratory tract infections (particularly beta-
hemolytic streptococcal infection) and viral hepatitis are most often implicated. 
HIV infection may also be associated with some cases of cutaneous vasculitis. 
Ascertaining whether a drug (e.g. antibiotic) or an infection (e.g. upper respiratory 
infection) is responsible for the disease is impossible because the occurrence of 
vasculitis postdates infection and the drug used to treat the infection. 
Foods or food additives may cause vasculitis. Hepatitis C is a regularly recognized 
cause of vasculitis, probably through the presence of cryoglobulins. Interestingly, 
cryoglobulins were present in roughly 40% of those tested; many patients with 
cryoglobulins (98%) did not have vasculitis despite an abnormal circulating 
paraprotein. Hepatitis B was implicated in some cases of vasculitis in the 
past.Collagen vascular diseases account for 10-15% of cases of vasculitis. In 
particular, rheumatoid arthritis, Sjögren syndrome, and lupus erythematosus may 
have an associated vasculitis. The presence of vasculitis often denotes active 
disease and possibly a poorer prognosis.Inflammatory bowel disease, ulcerative 
colitis, or Crohn colitis may be associated with cutaneous vasculitis. Malignancy 
accounts for less than 1% of cases of cutaneous vasculitis.Perhaps 
lymphoproliferative diseases are more common (particularly hairy cell leukemia); 
however, any type of tumor at any site may possibly be related to cutaneous 
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vasculitis.Effective tumor therapy in some patients has led to resolution of the 
vasculitis.Small-vessel cutaneous vasculitis may be seen uncommonly in patients 
with a larger vessel vasculitis, such as Wegener granulomatosis, polyarteritis 
nodosa, or Churg-Strauss syndrome. 
Lab Studies.Evaluation of patients with vasculitis serves 2 purposes: to determine 
the presence of systemic disease and to identify an associated disorder, which aids 
in predicting the patient's prognosis.No established routine exists, but testing for all 
adult patients includes a complete blood count, an erythrocyte sedimentation rate, a 
urinalysis, and a blood chemistry panel.Obtain stool guaiac or Hematest for 
patients with bowel symptoms even though these tests are not particularly 
reliable.Obtain serologic studies (e.g. antinuclear antibody, ANCA, rheumatoid 
factor) for patients without an obvious disease cause. In children and perhaps in 
some adults, serologic testing for a possible streptococcal infection should be 
considered (Streptozyme or ASO titer).Complement levels, including total 
hemolytic complement (CH100 or CH50), C3 levels, and C4 levels, may be 
obtained for patients suspected of having lupus erythematosus or patients who 
have urticarial vasculitis.Include serum protein electrophoresis, cryoglobulins, and 
hepatitis C antibody in tests for paraproteins for patients without otherwise 
identified disease. 
Hepatitis B was associated with vasculitis in the past; however, it appears that the 
association may have occurred by virtue of co-infection with hepatitis C 
(previously termed non-A, non-B).The measurement of hepatitis B surface antigen 
may not be required in all cases.Cryoglobulins are often not obtained properly; a 
positive rheumatoid factor should suggest the presence of cryoglobulins.Perform 
HIV testing for patients at high risk for infection and possibly for those with 
otherwise unidentifiable cause of disease.Consider obtaining direct 
immunofluorescence microscopy for selected patients. The presence of IgA occurs 
in Henoch-Schönlein purpura. 
Imaging Studies.Chest radiography is part of the routine evaluation. Consider 
performing visceral angiography for patients with a severe vasculitic 
syndrome.Perform cardiac ultrasonography and blood cultures for patients with 
fever and/or a heart murmur. 
Procedures.Perform a skin biopsy of a relatively fresh lesion in most, if not all, 
adult patients. For humanitarian reasons, biopsies are often not performed in 
children with suspected vasculitis.Consider performing a biopsy of muscle or a 
biopsy of visceral organs in patients with severe vasculitic syndromes; however, 
most patients with leukocytoclastic vasculitis of the skin do not require such 
tests.Obtaining a bone marrow sample may be useful if the peripheral smear is 
abnormal. 
Histologic Findings.A skin biopsy sample reveals the presence of vascular and 
perivascular infiltration of polymorphonuclear leukocytes with formation of 
nuclear dust (leukocytoclasis), extravasation of erythrocytes, and fibrinoid necrosis 
of the vessel walls. This process is dynamic; a biopsy sample of a lesion too early 
or too late in its evolution may not reveal these findings.  
314 
 
The picture of leukocytoclastic vasculitis is a pattern that can occur in any 
vasculitic syndrome but may also occur in non-vasculitic diseases (e.g. 
neutrophilic dermatoses), at the base of a biopsy sample of a leg ulceration, or in 
some insect bite reactions. Careful clinical-pathologic correlation is necessary. 
Medical Care.Once a diagnosis of cutaneous small-vessel vasculitis is established 
and the patient is fully evaluated, specific or nonspecific management options may 
be used.Elevation of the legs or compression stockings may be useful because the 
disease often affects dependent areas.Treat the cause in patients with an 
identifiable cause. Removal of a drug thought to be causing the vasculitis may 
result in rapid clearing of the process in up to 2 weeks.Treat chronic disease that 
primarily involves the skin with nontoxic modalities whenever possible; avoid 
using systemic corticosteroids and/or immunosuppressive agents. Colchicine or 
dapsone may be administered for patients with disease of the skin with or without 
joint manifestations.Patients with urticarial lesions may be treated with 
antihistamines (both soporific ones and less sedating agents). Sometimes, a 
combination of these agents is needed to control disease manifestations. Some 
patients have responded to non-steroidal anti-inflammatory agents.Patients with 
severe visceral involvement may require high doses of corticosteroids (1-2 
mg/kg/d) with or without an immunosuppressive agent (e.g. cyclophosphamide, 
azathioprine, methotrexate).  
Surgical Care.Surgical care for patients with vasculitis is rarely needed. Surgical 
care may be appropriate if a tumor is identified as a cause of the process.Surgical 
care may be appropriate if recalcitrant ulceration occurs after control of active 
disease. 
Prognosis.The prognosis of patients with cutaneous vasculitis depends on the 
underlying syndrome or the presence of end-organ dysfunction.Patients with 
disease that primarily affects the skin and/or the joints have a good 
prognosis.Patients with Wegener granulomatosis, polyarteritis nodosa, Churg-
Strauss syndrome, or severe necrotizing vasculitis have a potentially fatal disease. 
Treatments with corticosteroids and/or immunosuppressive/cytotoxic agents often 
save the patient's life. 
 
 
16.4. Kaposi Sarcoma 
 
Background: In 1872, Moritz Kaposi (1837-1902) of Kaposvar, Hungary, a 
dermatology faculty member at the University of Vienna, first described 
idiopathisches multiples Pigmentsarkom der Haut, which has become known as 
Kaposi sarcoma (KS). KS had brownish red–to–bluish red cutaneous nodules that 
tended to enlarge into dome-shaped tumors. Kaposi observed similar neoplasms of 
the mucosa, especially of the larynx, trachea, stomach, liver, and colon. Kaposi's 
original 1872 description of 5 patients is more similar to the KS seen in AIDS (KS-
AIDS) than the KS expected in elderly men of Italian, Jewish, or Mediterranean 
linkage, in whom the disease behavior is benign. Kaposi's original 5 patients died 
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within 2-3 years. Kaposi later updated his data, noting that all of his 16 patients 
were men with a prognosis that remained unfavorable.  
For most of the first 3 quarters of the 20th century, KS was viewed as an indolent 
slowly growing cancer, and patients were expected to die with, rather than of, KS. 
The aggressive course originally noted by Kaposi has become part of the 
devastation of AIDS, especially among men who are homosexual.  
American AIDS was identified relatively recently (1981) in 3 reports of KS as an 
original defining element of AIDS (plus an important editorial and a Centers for 
Disease Control and Prevention Morbidity and Mortality Weekly Report bulletin). 
Two of the reports were from New York City, and 1 was from San Francisco. For 
some time, KS was seen in 30-40% of patients with AIDS, often as the presenting 
sign. The incidence of KS has fallen markedly in recent times, although its 
prevalence has not. The challenge remained to explain the reason patients who are 
homosexual and have AIDS exhibited KS much more commonly than did patients 
with AIDS unassociated with homosexuality, with the exception of small foci of 
homosexuals in isolated midwestern communities.  
The breakthrough came in 1994, when the KS-associated herpes virus (human 
herpesvirus type 8 [HHV-8]) was identified using representational difference 
analysis. HHV-8 has been linked closely with all 4 types of KS, i.e. classic 
(traditional), endemic (African), epidemic (AIDS related), and iatrogenic (related 
to immunosuppression). Since then, much research has shown that HHV-8 appears 
to be necessary to, but not sufficient for, the development of KS.  
Nevertheless, 2 critical questions remain. Is KS a hyperplasia or a neoplasm? Is it 
always multicentric or can it be metastatic as well? The authors favor the latter 
interpretation of both points.  
Pathophysiology.HIV transactivating (tat) gene, cytokine, and HHV-8 stories in 
KS are fascinating. Each begins with a classic study. In 1988, the human 
immunodeficiency virus type 1 (HIV-1) tat gene was introduced into transgenic 
mice, inducing nodules that resembled KS in 33 of 37 males but in none of 15 
females. Therefore, it appeared that HIV could play a direct role in causing KS.  
The second saga was a result of efforts to grow KS cells in culture, requiring a 
long-term growth factor. Conditioned medium from T cells infected with human T-
cell leukemia virus type II (rather than HIV-1 or human T-cell leukemia virus type 
I) best supported the growth and long-term culture of KS cells derived from KS-
AIDS lesions. In 1992, this growth factor proved to be a cytokine previously 
termed oncostatin M, since it had been identified earlier for its inhibitory effects on 
a variety of cancer cells. Another cytokine scatter factor was found in large 
quantities in this medium, inducing endothelial cells to demonstrate a KS tumor 
cell-like phenotype. The importance of oncostatin M, scatter factor, and the tat 
protein has been shown in the pathogenesis of KS.  
Other cytokines, including interleukin 1 (IL-1), tumor necrosis factor, interleukin 6 
(IL-6), and basic fibroblastic growth factor (bFGF), may work synergistically with 
the HIV tat gene product. Scatter factor may be involved both in initiation and in 
maintenance of KS. Scatter factor stimulates endothelial cells to migrate nearby 
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and become factor XIIIa–positive c-Met-expressing spindle-shaped KS cells. The 
cells further expand neovascularization by producing cytokines and promoting 
autocrine-mediated and paracrine-mediated growth of KS cells. The scatter factor 
receptor, c-Met proto-oncogene, is expressed by KS cells; the oncogene int-2 of the 
fibroblast growth factor family also may be evident.  
Herpes-type viruses have been linked with KS for more than 3 decades. A 
landmark study showed short DNA sequences of a unique human herpesvirus in 
KS tissues via a new molecular biological technique termed representational 
difference analysis. They resembled herpesvirus saimiri but proved to be a new 
type of human herpesvirus now termed HHV-8. This virus appears to interact with 
the HIV tat protein, excess levels of basic fibroblast growth factor, scatter factor, 
and IL-6. For example, HHV-8–encoded IL-6 has been found to induce 
endogenous human IL-6 secretion. An HHV-8 oncogene, Kaposin (ORF K12), has 
been characterized; however, additional factors remain to be found. For example, a 
53% prevalence of HHV-8 subtype E in Brazilian Indians does not appear to be 
linked with the development of KS in this population.  
Classic KS is seen in Italy with hot spots being in the Po River Valley, Sardinia, 
and southern Italy. It has been suggested that volcanic soil or birthplace/residency 
in areas abundant with bloodsucking insects may be a risk factor (Ascoli, 2003). A 
survey evaluated the correlation between HHV-8 infection and classic KS 
incidence in northern Sardinia (Santarelli, 2001). It revealed that seroprevalence 
was 35%, within a range of 15.3-46.3% in the five areas. Age was as an important 
risk factor. Subjects aged older than 50 years had a higher seroprevalence to HHV-
8 as compared with younger individuals. A strong direct correlation between 
HHV-8 prevalence and classic KS incidence was also observed.  
KS-associated herpesvirus (KSHV), or human herpesvirus 8 (HHV-8), is the most 
frequent cause of malignancy in patients with AIDS (Moore and Chang, 2003). 
KSHV and related herpesviruses have pirated cellular cDNAs from the host 
genome. Many of the viral regulatory homologs encode proteins that directly 
inhibit host adaptive and innate immunity. Other viral proteins may target 
retinoblastoma protein and p53 control of tumor suppressor pathways, which play 
key effector roles in intracellular immune responses. The immune evasion 
strategies used by KSHV in targeting tumor suppressor pathways activated during 
immune system signaling, may lead to inadvertent cell proliferation and 
tumorigenesis in susceptible hosts.  
Frequency.Four groups are predisposed to KS including (1) older men of 
Mediterranean and Jewish lineage; (2) Africans from areas including Uganda, the 
Congo Republic, Congo (Brazzaville), and Zambia; (3) persons who are 
iatrogenically immunosuppressed; and (4) men who are homosexual. KS 
traditionally is an uncommon disease in middle-aged and elderly European men of 
Mediterranean or Jewish lineage. A similar focus of KS exists in the same age and 
sex groups in Africa. If a crudely calculated incidence of 28 cases of KS per 
100,000 in the Arabian population is correct, KS may be more common among 
Arabians than among Mediterranean people. A previously unrecognized genetic 
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predisposition for KS among Arabians has been suggested. The incidence of KS 
among renal transplant recipients may be as high as 3.5% or higher in regions 
endemic for KS, which is significantly higher than the 0.4% incidence renal 
transplant recipients in the United States and Western Europe.  
Endemic African KS has accounted for 10% of cancers and has been seen in a 
male-to-female ratio of 15:1. The Kampala Cancer Registry, one of the continent's 
first and foremost, has shown a significant alteration in the incidence of KS in the 
era of AIDS. In Uganda, KS has caused almost one half (48.9%) of cancer cases in 
men and 17.9% in women.  
Classic KS in Greece seems to have an older age of onset; lower male-to-female 
ratio; endemic clustering; and disseminated skin disease at diagnosis, often 
accompanied by lymphedema and not unusual visceral or lymph node 
involvement.  
Mortality/Morbidity.Patients with traditional KS tend to die with KS rather than 
of KS. Patients with KS-AIDS usually die from associated opportunistic infections 
or from gastrointestinal KS with hemorrhage. The mean survival rate of patients 
with KS-AIDS has been approximately 15-24 months, although the introduction 
into the United States of apparent immune system reconstitution using highly 
active antiretroviral therapy (HAART) has extended survival substantially. KS also 
may be fatal as a result of gut perforation, cardiac tamponade, massive pulmonary 
obstruction or, rarely, brain metastases.  
In Kaposi's original description, death usually ensued within 3 years and was 
linked to fever, diarrhea, and hemoptysis. Inanition may be an important factor, 
and death may ensue as a result of bulky tumor obstructing the bronchi or larynx.  
Patients with AIDS-related KS often have widespread visceral KS, although KS 
limited to the skin also is common.  
Patients with iatrogenic KS tend to have gut bleeding resulting from KS, although 
termination or reduction of immunosuppression often, but not always, results in 
regression of KS.  
Causes.HHV-8 has been linked convincingly with all 4 types of KS, an association 
that is necessary, but not sufficient, to develop KS; therefore, other factors also are 
important. At this point, immunosuppression appears to be the most significant 
cofactor.  
Race.KS is an uncommon disease of middle-aged and elderly American and 
European men of Mediterranean or Jewish lineage. This propensity also is seen in 
individuals with iatrogenically induced KS but not among persons in the KS-AIDS 
group. KS is rare in American blacks, despite its large foci among blacks in certain 
regions of Africa.  
Sex.Classic KS has an overwhelming male predominance, with a male-to-female 
ratio of approximately 10-15:1. For endemic KS in Central Africa, the male-to-
female ratio is near unity in childhood KS cases but often rises in puberty to 15:1. 
In Corsica and Sardinia (where classic KS is endemic), with the arrival of AIDS, 
the ratio of male-to-female cases has dropped from 10:1 to 3:1. Children of women 
who are HIV-1 seropositive without KS have an aggressive form of childhood 
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HIV-associated KS. A male-to-female ratio of 1.5:1 was observed. A male-to-
female ratio of 1.5:1 also was evident among renal transplant recipients in Arabia.  
Age.Age distribution depends on the type of KS. In the United States and Europe, 
traditional KS has a peak incidence between 40-70 years, with a wide range of up 
to 89 years. Young men with KS-AIDS who are homosexual also show a wide age 
range but tend to be much younger, averaging 20-40 years at age of onset. For 
endemic KS in Uganda, the incidence in boys and girls was approximately the 
same in childhood (birth to 14 y), with a small peak in girls younger than 5 years 
and boys aged 5-9 years. Subsequently, a progressive rise in incidence peaked in 
women aged 25-29 years and in men aged 35-39 years.  
History.KS is a neoplasm that often manifests with multiple vascular nodules in 
the skin and other organs.Although true metastases appear to occur, a multifocal 
origin is most common.The pattern of KS is variable, with a course ranging from 
indolent (only skin manifestations) to fulminant (extensive visceral 
involvement).KS also may arise primarily in the oral mucosa, lymph nodes, and/or 
viscera without skin involvement.KS initially may be evident in any organ of the 
body. Chronic lymphedema may precede KS. 
Although primary penile KS is uncommon in HIV negative men, one should 
consider this possibility when treating nonspecific penile lesions. A minimal penile 
lesion with non-distinctive clinical features may be the exclusive manifestation of 
KS. In addition, it may appear as a skin-colored nodule suggestive of a primary 
squamous cell carcinoma. Clearly, in both cases, histologic evaluation is mandated 
to establish the diagnosis. 
Physical.KS is described in 3 forms including localized nodular, locally 
aggressive, and generalized KS. KS typically occurs in these 3 forms and in 6 
stages including patch, plaque, nodular, exophytic, infiltrative, and 
lymphadenopathic.  
Cutaneous KS usually begins as discrete red or purple patches that are bilaterally 
symmetric and initially tend to involve the lower extremities.Patches become 
elevated, evolving into nodules and plaques. Nodules may be spongy to the touch. 
KS also occurs as a large infiltrating mass or as multiple cone-shaped friable 
tumors. These 2 variants, termed locally aggressive KS, may adhere firmly to 
underlying anatomic structures including bone.Early KS may appear as violaceous 
patches (patch stage KS), which occasionally resemble large junctional 
melanocytic nevi or may appear as irregular-shaped patches similar to the nevus 
flammeus.More commonly, KS is evident as violaceous plaques or nodules on the 
lower extremities. The nodules tend to enlarge into dome-shaped 
tumors.Cutaneous KS rarely may be infiltrative or exophytic. To the authors' 
knowledge, infiltrative KS has not been described outside of Africa. Exophytic KS 
may erode downward into bone.Lymphadenopathic KS may demonstrate skin 
lesions. At times, a Köbner phenomenon appears evident, with nodules at sites of 
trauma. 
A few unusual varieties of KS also exist. Telangiectatic KS is an eruption of pink 
translucent nodules with prominent telangiectasia.Ecchymotic KS appears as 
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periorbital ecchymoses. Histologically, there is a large amount of extravasated red 
blood cells, no evidence of amyloidosis, and a dermis containing foci of 
proliferating moderately atypical spindle cells, vascular slits, erythrophagocytosis, 
and other features of KS.Keloidal KS is evident as somewhat brown-to-violaceous 
keloidal nodules. Histologically, these are KS nodules with a keloidal 
component.Cavernous KS is a rare type of locally aggressive KS characterized by 
cutaneous tumors that histologically resemble cavernous hemangiomas; however, 
the endothelial cells and their nuclei are large and prominent, bulging into the 
cavity.Lymphangioma-like KS is a rare variant in which dilated vascular spaces 
produce a bullous-appearing eruption, typically on the lower legs. The lesions are 
easily compressible and appear clinically to be fluid-filled. The vascular channels 
are lined by banal-appearing endothelial cells permeating the dermis in the absence 
of spindle cell proliferation. 
Lab Studies.Serum glucose levels may reflect an increased incidence of diabetes 
mellitus in patients with classic KS. Ketoacidosis is unusual in these 
patients.Immunohistochemical detection of human herpes virus-8 latent nuclear 
antigen-1 has been claimed as useful in the diagnosis of KS.Hemogram in non-
immunosuppressed patients with KS tends to be within normal limits, but 
occasionally, monocytosis or eosinophilia has been noted. Eosinophilia is seen 
especially in African patients and patients who are homosexual, in whom 
parasitosis may be common.In KS-AIDS, cytopenia of 1 or more cell lines is 
frequent. Anemia, if present, may result from gastrointestinal bleeding or may be 
associated with an autoimmune hemolytic anemia or a hematologic 
malignancy.Assays for HHV-8 have been challenging. At present, no universally 
accepted method exists.Polymerase chain reaction often is used but may have 
false-positive results because of its high susceptibility to contamination.Methods 
based on both lytic and latent-phase viral antigens remain promising. 
Imaging Studies.Computed tomography (CT) may be valuable, especially 
abdominal CT scans in patients with AIDS.In AIDS-related KS, early lymphatic 
and hepatosplenic involvement may be evident.Consider CT-directed fine needle 
aspiration to provide tissue confirmation, since lymphomas and atypical 
mycobacterial and other infections may appear similar.Consider endoscopic and 
conventional radiographic studies; however, these modalities may miss 
gastrointestinal KS, while selective angiography may demonstrate 
KS.Radionucleotide scans may be useful in demonstrating visceral KS and 
associated lymphoma.With lung nodules, the distinction between KS, lymphoma, 
and/or opportunistic infection may be challenging. 
Other Tests.Evaluation for KS should include a complete physical examination 
and a biopsy of suspected lesions including lymph nodes. CT scan used to guide a 
fine needle for tissue specimens appears promising.The cell of origin in KS 
remains a subject of dispute, although the following tests may be useful: 
ultrastructural and immunohistochemical testing favor the endothelial cell.The 
presence of factor VIII–related antigen, human leukocyte antigen DR (HLA-DR), 
von Willebrand factor, and the lectin Ulex europaeus I (which all are markers for 
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endothelial cells) is highly suggestive.Reactivity with 2 monoclonal antibodies 
(EN4 and PAL E) implies that KS is derived from endothelium of lymphatic 
origin; however, KS spindle cells express CD34 antigen, a glycoprotein expressed 
by endothelial cells of small blood vessels (but not those of lymphatic origin). 
Histologic Findings.KS tends to demonstrate increased spindle cells with vascular 
slits and vascular structures with a predominance of endothelial cells. Extravasated 
erythrocytes and hemosiderin-laden macrophages often are evident. Some spindle 
cells may show nuclear pleomorphism. Early KS may resemble granulation tissue 
with a diffuse chronic inflammatory infiltrate and capillaries dilated and increased 
in number. This pattern also is seen in lymph nodes and viscera. Histopathologic 
classification is based on relative contribution of spindle cells, fibrosis, and nuclear 
pleomorphism, sometimes divided into 3 histopathologic forms, which include (1) 
a mixed form with an equal amount of spindle cells, vascular clefts, and capillaries, 
(2) a mononuclear type with 1 cell type predominating, and (3) an anaplastic form 
with cellular pleomorphism and numerous mitotic figures.  
The electron microscopy and immunohistochemical features of KS may be 
important. Staining with CD34, factor VIII–related antigen, the lectin Ulex 
europaeus I, and HLA-DR antigen may be useful to support or confirm the 
diagnosis of KS. The authors prefer CD34 antigen, which is expressed by KS cells, 
and find it helpful in distinguishing KS from pseudo-KS (acroangiodermatitis).  
Medical Care.Since the natural history of KS is variable, assessment of therapy 
may be difficult. Treatment usually is based on the extent of disease and the 
patient's immune status. The optimal therapy of KS-AIDS is yet to be determined. 
The challenge is to treat KS-AIDS effectively without immunocompromising the 
patient further, or better, with reconstitution of the immune system. Management 
modalities for KS include nonintervention, surgical removal of skin nodules or 
severely affected areas (e.g. areas of the extremities, intussuscepted bowel), laser 
surgery, conventional and megavoltage radiotherapy, chemotherapy, 
immunotherapy, antiviral drugs, and cessation of immunosuppressive therapy in 
iatrogenically immunosuppressed patients. Indolent skin tumors in elderly white 
patients may not require specific therapy early in the course of the disease; 
however, systemic vinblastine (or other chemotherapy) attacks both cutaneous and 
visceral lesions.Localized nodular disease may respond well to surgical excision, 
radiotherapy, and intralesional and outpatient low-dose vinblastine chemotherapy. 
The latter combination of local and systemic regimens may be preferable. The 
authors usually inform patients that this is a multicentric disease that has silent gut 
lesions that also may regress with the systemic approach. 
Radiotherapy often produces good therapeutic results with classic nodular KS but 
tends to be only palliative in patients with KS and AIDS. In localized nodular KS, 
conventional radiotherapy is highly effective. Electron-beam radiotherapy, which 
has limited penetration beyond the dermis, may be a good modality for superficial 
lesions. Deeper or unresponsive KS may be treated using standard non–electron-
beam radiation or other options. Initial response to radiotherapy usually is 
complete or demonstrates marked regression of the nodules. The more extensive 
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the involvement, the less responsive it tends to be. Radiotherapy may be more 
effective on new, rather than chronic, lesions and may provide local KS control in 
patients with KS-AIDS.Radioisotope scanning using technetium-99m may detect 
occult KS infiltration in the subcutaneous and muscular tissues and draining lymph 
nodes. This allows improved efficiency of large-field radiotherapy. 
Laser therapy: Argon laser photocoagulation therapy also may be beneficial in 
classic KS lesions.The authors' preference often is the Klein regimen of weekly 
outpatient intravenous vinblastine titered against white cell count levels to avoid 
falling below 4000/L. The authors recommend intralesional injections of 
vinblastine for persistent cutaneous nodules and intraarterial vinblastine in certain 
settings for locally aggressive KS. Systemic vinblastine (3.5-10 mg IV weekly 
with, at times, 1 intralesional injection of 0.1 mg) usually is best for both the 
patient with classic KS and, occasionally, patients with KS-AIDS.  
Although the authors prefer low-dose vinblastine, a number of other 
chemotherapeutic agents may be effective. Drugs with proven efficiency include 
vincristine, vinblastine, dacarbazine, doxorubicin, and actinomycin D. Alkylating 
agents (e.g. cyclophosphamide, chlorambucil, bleomycin, doxorubicin, etoposide) 
also may be of value. Multiagent intravenous chemotherapy, rather than single 
agent usage, is preferred by some for disseminated aggressive KS. No particular 
combination regimen has been established yet. The combination of doxorubicin, 
bleomycin, vinblastine, and dacarbazine may be effective.  
Alternating vincristine and vinblastine in patients with KS-AIDS can be both 
effective and well tolerated, but leukopenia and a propensity to opportunistic 
infections make aggressive chemotherapy difficult. Patients with KS-AIDS usually 
succumb either to disseminated KS or to an intervening opportunistic infection 
within 3 years of diagnosis, regardless of the form of therapy (except with HAART 
therapy). All of these therapies (except low-dose vinblastine) are significantly 
immunosuppressive and, perhaps, accelerate the disease. Combining chemotherapy 
for KS with chemotherapy for HIV is an attractive option. Interferon also may be 
used in this way. Thus, the combination of zidovudine, interferon, and low-dose 
intravenous vinblastine may be used for patients with KS-AIDS.  
In iatrogenic KS, cessation of immunosuppressive therapy may be the most 
effective treatment. Patients on immunosuppressive therapy, specifically 
corticosteroids and cytotoxic drugs, may have partial or complete regression when 
therapy is discontinued. If possible, immunosuppressive medication doses should 
be reduced or discontinued before beginning specific therapy for iatrogenic KS.  
In some patients, KS-AIDS may resolve clinically with the use of HAART. 
Antiviral therapy with foscarnet may not only reduce progression of KS in 
patients, but may lower its occurrence substantially in patients with HIV disease.  
Consultations.Treating patients with advanced KS often requires a team approach. 
Medical oncologists often administer systemic chemotherapy. Radiation 
oncologists tend to favor radiotherapy options. Infectious diseases/HIV specialists 
may be needed for HIV and opportunistic infections. 
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Prevention.Reducing the HHV-8 infection rate prevents KS development. 
Suggestions have been made that some antiherpetic agents, particularly foscarnet, 
may lower the HHV-8 infection rate.Screening transplant recipients for HHV-8 
infection may be beneficial. Use of the highly active anti-HIV therapy HAART 
appears to reduce the risk of developing new KS significantly. 
Complications.The most common complications include secondary malignancy 
and secondary infections. In particular, secondary infection occurs with the KS-
AIDS group of patients. A relatively common clinical concern is to distinguish KS 
from opportunistic infection and lymphoma.In patients with classic KS, lymphoma 
develops in approximately 35%, usually after a number of years.KS may produce 
clinical problems including edema from impaired lymphatic draining (sometimes 
resulting in pain), difficulty ambulating, friability of cutaneous nodules, or 
secondary localized skin infection. 
Prognosis.Clinical classification of KS may be the best prognosticator, comparing 
localized nodular disease, locally aggressive disease, and generalized 
KS.Cutaneous skin testing for anergy may correlate with clinical disease type and 
prognosis.Prognosis appears to correlate with the CD4 count. Localized nodular 
KS has the best prognosis, with few deaths directly attributable to KS.Locally 
aggressive KS has an intermediate prognosis. The authors do not disagree with an 
old African estimate of a 3-year survival rate of 64%. Generalized KS, the form 
seen most commonly in patients with KS-AIDS, has a 3-year survival rate closer to 
0% without therapy. 
 
 
16.5. Pigmented Purpuric Dermatitis 
 
Synonyms and related keywords: capillaritis, benign pigmented purpura, 
pigmented purpuric eruptions, Schamberg disease, progressive pigmentary 
dermatosis, itching purpura of Loewenthal, eczematidlike purpura of Doucas and 
Kapetanakis, pigmented purpuric lichenoid dermatosis of Gougerot and Blum, 
lichen aureus, purpura annularis telangiectoides, purpura annularis telangiectodes, 
Majocchi diseases. 
 
Background.The pigmented purpuric dermatoses are a group of chronic diseases 
of mostly unknown etiology that have a very distinctive clinical appearance. They 
are characterized by extravasation of erythrocytes in the skin with marked 
hemosiderin deposition.  
A number of clinical patterns of pigmented purpuric dermatoses or capillaritis are 
recognized that may represent different presentations of the same disorder; 
however, this generally does not influence the treatment or the prognosis. They all 
show a similar histologic appearance. The term pigmented purpuric dermatoses 
includes Schamberg disease (i.e. progressive pigmentary dermatosis), purpura 
annularis telangiectodes (Majocchi disease), lichen aureus, itching purpura, 
eczematid-like purpura of Doucas and Kapetanakis, and the pigmented purpuric 
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lichenoid dermatosis of Gougerot and Blum. Many consider itching purpura and 
eczematid-like purpura to be variants of Schamberg disease.  
Pathophysiology.The etiology is unknown. Venous hypertension, exercise, and 
gravitational dependency are important cofactors that appear to influence disease 
presentation. Histologically, a perivascular T-cell lymphocytic infiltrate is centered 
on the superficial small blood vessels of the skin, which show signs of endothelial 
cell swelling and narrowing of the lumen. Extravasation of red blood cells with 
marked hemosiderin deposition in macrophages is also found, and a rare 
granulomatous variant of chronic pigmented dermatosis has been reported.  
Frequency.During a 10-month period, the authors' United Kingdom hospital-based 
dermatology practice, which serves a population of 300,000 persons, identified 
only 10 such cases. Five cases were diagnosed as having lichen aureus, and the 
remainder had more extensive capillaritis. In the US: Pigmented purpuric 
dermatoses are uncommon.  
Mortality/Morbidity.Typically, the condition is asymptomatic, but pruritus may 
sometimes be a prominent feature in some cases, especially in patients with itching 
purpura.  
Age.Schamberg disease may occur at any age. Itching purpura and the dermatosis 
of Gougerot and Blum mainly affect middle-aged men. Lichen aureus and 
Majocchi disease are predominantly diseases of children or young adults.  
History.Patients complain about the appearance of their skin. In Schamberg 
disease, irregular plaques and patches of orange-brown pigmentation develop on 
the lower limbs. The lesions are chronic and persist for years. With time, many of 
the lesions tend to extend, but some may spontaneously clear.In itching purpura, 
the lesions are much more extensive, and patients typically complain of severe 
pruritus. 
Physical.The hallmark of a pigmented purpuric dermatosis is its characteristic 
orange-brown, speckled, cayenne pepper–like discoloration. The lower limbs are 
affected in Schamberg disease, whereas itching purpura is characterized by more 
generalized skin involvement.In lichen aureus, the eruption is usually a solitary 
lesion or a localized group of lesions that may affect any part of the body; 
however, the leg is the most commonly affected area. Linear or quadrantic forms 
of lichen aureus have been reported.Majocchi disease is characterized by small 
annular plaques of purpura that contain prominent telangiectasia.Pigmented 
purpura with lichenoid-type skin change is yet another clinical variant, which 
Gougerot and Blum first reported. 
Lab Studies.A complete blood cell count is necessary to exclude 
thrombocytopenia, and coagulation screening helps to exclude other possible 
causes of purpura. 
Imaging Studies.Dermoscopy has been reported to be a useful tool for assisting 
the clinical diagnosis of pigmented purpuric dermatoses. 
Other Tests.Capillary fragility may be assessed by the Hess test. 
Procedures.A skin biopsy helps to confirm the diagnosis of a pigmented purpuric 
eruption and aids in excluding cutaneous T-cell lymphoma, which in its early 
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stages may closely mimic a pigmented purpuric dermatitis both clinically and 
histologically. 
Histologic Findings.Histologically, a perivascular infiltrate of lymphocytes and 
macrophages is centered on the superficial small blood vessels of the skin. Signs of 
endothelial cell swelling and narrowing of lumina may be seen. The infiltrate is 
composed of predominantly CD4+ lymphocytes along with occasional CD1a+ 
dendritic cells. Plasma cells and neutrophils are occasionally present; the latter is 
not uncommon in lesions of itching purpura. Extravasation of red blood cells with 
marked hemosiderin deposition in macrophages is typically seen. However, the 
degree of hemosiderin deposition may be variable, and it can be minimal in early 
lesions of itching purpura.  
Histochemical staining with Perls stain and Fontana-Masson stain, to demonstrate 
iron (hemosiderin) and exclude melanin pigment respectively, may be helpful. 
Hemosiderin deposition in the dermis is more superficial in pigmented purpuric 
dermatitis than that seen in stasis dermatitis, which is a useful differentiating 
feature. Mild epidermal spongiosis and exocytosis of lymphocytes may be seen in 
all variants except lichen aureus, which, in general, tends to show a band-like 
infiltrate separated from the epidermis by a thin rim of uninvolved collagen. 
Medical Care.No medical intervention is of proven benefit for the treatment of the 
pigmented purpuric dermatoses. Pruritus may be alleviated by the use of topical 
corticosteroids and antihistamines.Associated venous stasis should be treated by 
compression hosiery. Prolonged leg dependency should be avoided. 
Prognosis.Many lesions persist or extend with time. Most eventually resolve 
spontaneously. 
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XVII. WORK-RELATED SKIN DISEASES 
 
17.1. Characteristics of Work-Related Skin Diseases 
 
Work-related skin diseases show a wide range of clinical features and originate 
from damaging factors at the work place. In many occupations, the skin is exposed 
to damaging factors like chemicals, biological material and mechanical and 
physical forces. This exposure can cause damage to the skin. The sensitivity of the 
skin to damage and its ability to recover varies from one individual to another. 
Work-related skin diseases develop if the balance between the resistance of the 
skin and the force of damaging factors is disturbed. The severity and course of the 
skin disease is determined by the quality of the skin, the characteristics of the 
damaging factors and the medical treatment. The damage can range from a brief, 
burning sensation to a disabling chronic eczema. Early recognition of the relation 
between the disease and the occupation combined with adequate management that 
focus more on the workplace than on the skin, can prevent chronicity with a poor 
prognosis. 
Work-related skin disease is defined as a disease to with occupational 
exposure is a causal or contributory factor. This definition of the American 
Medical Association in 1939 is still valid today. 
 
Skin Damaging Mechanism 
The dynamic interaction between the chemical, physical and mechanical 
characteristics of the damaging factor(s) and the biological make-up of the skin 
determine the degree of the molecular, histological and anatomical damages of the 
skin, expressed in a range of visible and subjective symptoms. 
The most common work-related skin diseases develop almost unnoticed as an 
accumulation of repeated minor damages caused by a variety of different factors to 
which the skin is exposed simultaneously or one after the other. In the initial stage, 
the damage is invisible to the human eye. This damage triggers the release of 
cytokines and these initiate and orchestrate an inflammatory reaction to restore the 
damage. However, the ongoing damage can exceed the skin’s ability to repair 
itself, and visible skin diseases then appear: erythema, scaling, swelling, vesicles, 
rhagades and papules. 
The skin damage can also be acutely overwhelming, with immediate severe 
damage to inter (cellular) structures, e.g. acute chemical burns with erythema, 
swelling, bullae and necrosis.  
Damage caused by other factors may be focused on certain components of the skin, 
e.g. melanocytes by hydroquinone, resulting in depigmentation, or DNA by 
chronic exposure to UV-light inducing skin malignancies. Skin damage can also 
develop after triggering of the immune system, by layer of the epidermis the 
Langerhans cell plays a central role in the orchestration of this immune response. If 
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sensitization is induced, renewed exposure to the allergen initiates a defense 
response amplified by T-cells and antibodies, creating a severe skin disease in a 
short time (minutes to days). 
Work-related skin diseases are distinguished from other skin diseases by 
characteristics revealed by physical examination combined with the analysis of 
occupation, working conditions and the course of the skin disease. 
 
Physical examination.The clinical features and localization provide important 
arguments for or against a work relation. Pre-existing skin diseases are important 
modifying factors for the development of a work related skin disease. 
Clinical features. The majority of work-related skin diseases occur as dermatitis 
or eczema. The following features may also be observed: erythema, vesicles, 
bullae, fissures, rhagades, edema, papules, urticaria, erosions, pustules, necrosis, 
folliculitis, tumors, prurigo, hyperpigmentation and depigmentation. 
Localization.Work related skin diseases generally appear on the exposed areas of 
skin, which are mainly the uncovered skin parts like hands, wrists, forearms, the 
proximal part of the upper arm, neck, face, eyelids and ears. 
Pre-existing skin condition.Atopy: Atopic dermatitis in flexures of elbow and 
knee, on the lips, hands, neck and face. Dry skin:Dry skin with fine 
scaling.Psoriasis:The typical erythemato-squamous lesion on covered skin, but 
also psoriasis stigmata on the head, in the ears, on the nails and the elbows or 
knees. 
Causes of work - related diseases and risk occupations 
Skin may be damaged by biological or synthetic chemical compounds, by physical 
influences and mechanical forces. The severity of the disease is determined by the 
characteristics of the damaging factors, combined with the type of exposure, such 
as: 
• Concentration or strength 
• Duration of exposure 
• Frequency of exposure 
• Temperature of the damaging factor 
• Temperature of the skin 
• Localization of exposure 
 
The following factors can be viewed upon as possible causes of work-related skin 
diseases:Irritants 
327 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Allergens 
Biological or synthetic chemical compounds may induce type I and type IV 
allergies of the skin. Some allergens occur in many products, exposing individuals 
at home and work, e.g. rubber and nickel. Other allergens are present in products 
with a specific use, e.g. ingredients of permanent wave fluids or adhesives.  Table 
17.1 shows product groups containing type IV allergens 
 
Table 17.1 Product Groups Containing Type IV Allergens 
 
Product Group Allergen 
Adhesives Epoxy resin 
Epoxy hardeners 
Phenol formaldehyde resins 
Acrylates 
Rosin 
Cosmetics Fragrances 
Peru balsam 
Rosin 
Cocamidopropil betaine 
Preservatives 
Metals Nickel 
Cobalt 
Dichromate 
Metal working fluids Preservatives 
emulsifiers 
amines 
Plants Promin (primula) 
Tulipalin-A (alstroemeria-tulip) 
Sesquiterpene lactones (chrysanthemums) 
Plastics Epoxy resin 
Epoxy hardeners 
Di-isocyanates 
Acrylates 
Preservatives Methyldibromoglutaronitrile 
Methylchloroisothiazolinone/metylisothiazolinon 
Acids and alkalis                     Adhesives 
Air flow                                    Animals 
Atmospheric humidity            Cold 
Cosmetics                                  Detergents 
Force of gravity                        Heat 
Meat and fish                            Mechanical forces such as pressure and friction 
Metal working fluids such as cooling fluids and cutting  
Mineral fibers                          Oxidizing and reducing agents 
Paints                                        Pesticides 
Plants, vegetables and fruits   Plastic materials, preservatives 
Rubber                                      Solvents 
UV-light                                    Water 
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Quaternium-15 
Professional hair cosmetics Glycerilthioglycolate 
ammonium persulphate 
4-phenylene diamine 
2,5-diaminotoluenesulphate 
Rubber Thiuram compounds 
Mercapto cmpounds 
Black rubber compounds 
Latex 
 
 
The following occupations are considered to be at risk of work-related skin 
diseases: 
 
Table17.2 Riskoccupations 
 
Industry/Sector Occupation 
Agricultural Frame, flower-, vegetable-and bulb grower, forestry workers 
Animal healthcare Vets and veterinary assistants 
Automobiles Mechanic, sprayer 
Bakeries Baker and confectioner 
Beauty care Hairdressers, beauticians, nail stylists 
Catering and food processing Cook, bartender, cleaner 
Chemical industry Production and laboratory workers 
Cleaners Cleaning workers 
Construction Bricklayer, joint, plaster, carpenter, plumber, painter, floor 
layer, roofer 
Electroplating industry Production workers 
Flower shops, garden centers Florist, gardener 
Food industry Vegetable-, fish-, meat- and fruit-processors, bakers and 
confectioners 
Healthcare Doctor, nurse, paramedic personnel, dental technicians, 
dentists, physiotherapists, laboratory workers, maternity, 
hospital and geriatric nurses 
Homework Housewife/husband, housekeeper 
Laboratories Chemist analyst, laboratory worker 
Metal industry Metalworker, construction worker 
Paint industry Production and laboratory workers 
Pharmaceutical industry Production and laboratory workers 
Photography Laboratory assistant 
Plastics industry Production workers, laboratory assistant 
Printing Printers, lithographers 
Public service Cable layers 
Retail trade Personnel in the meat, fish, vegetable, sandwich and last food 
shops 
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Rubber industry Production and laboratory workers 
Service sector Cleaners, domestic workers, laundry workers 
Slaughterhouse Production workers 
Swimming baths Cleaners 
Textile industry Production workers 
Since the product composition, production methods and working conditions are 
changing the list of risk occupation will never be complete. In the future new risk 
occupations will appear and others disappear. 
Diagnosis 
The diagnosis is the outcome of a process of observing, collecting and interpreting 
facts. These facts are derived from clinical inspection, history, patch testing, 
microscopy, bacterial culture, histopathology and – last but not least – workplace 
inspection. Sometimes a definite diagnosis can be made just with a glance but 
additional investigations are often necessary. 
Work-related skin diseases show a wide range of clinical features. The majority of 
diseases are caused by irritant and/or allergic factors, and are visible as dermatitis 
or eczema. The damaging factors reach the skin directly or by air (airborne). 
Sunlight may play a role in the induction of the disease. The following diagnoses 
of work-related skin diseases can be made: 
 
Table 17.3 Diagnoses 
 
Diagnoses 
Direct contact 
 
Acute irritant contact dermatitis 
Sub-acute irritant contact dermatitis 
Chronic irritant contact dermatitis 
Allergic contact dermatitis 
Atopic dermatitis 
Mechanical contact dermatitis 
Hyperkeratotis dermatitis 
Asteatotic eczema 
Chronic exogenous dermatitis 
Immediate contact reactions 
Mineral fiber contacts dermatitis 
 
Airborne: 
Airborne irritant contact dermatitis 
Airborne allergic contact dermatitis 
Sunlight 
Phototoxic contact dermatitis 
Photoallergic contact dermatitis 
Others: 
Acne 
Rosacea 
Psoriasis vulgaris 
Leukoderma 
Hyperpigmentation 
Infections and parasites 
Skin malignancies 
Chronic venous insufficiency 
 
Table 17.4  DiagnosisNavigator 
 
Duration Clinical feature Subjective 
symptoms 
Diagnosis 
Acute Erythema pain, burning acute contact dermatitis 
Sub-acute Erythema pain, burning, 
itching 
sub-acute contact dermatitis 
phototoxic contact dermatitis 
airborne irritant contact dermatitis 
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infection 
Sub-acute Erythema, bullae pain, burning phototoxic contact dermatitis 
(sub)-acute contact dermatitis 
Sub-acute Erythema, vesicles, 
bullae 
itching, burning immediate contact reaction 
phototoxic contact dermatitis 
Sub-acute Dermatitis/eczema Itching allergic contact dermatitis 
photoallergic contact dermatitis 
airborne allergic contact dermatitis 
airborne irritant contact dermatitis 
Sub-acute 
→ chronic 
Prurigo papules Itching mineral fiber contact dermatitis 
parasitic prurigo 
Chronic Dermatitis/eczema Itching allergic contact dermatitis 
chronic irritant contact dermatitis 
atopic dermatitis 
photoallergic contact dermatitis 
airborne irritant contact dermatitis 
airborne allergic contact dermatitis 
asteatotic eczema 
chronic exogenous eczema 
Chronic Hyperkeratosis, 
fissures, rhagades 
Pain psoriasis 
mechanical contact dermatitis 
allergic contact dermatitis 
chronic irritant contact dermatitis 
 
The diagnosis navigator is based on: 
Durationacute = seconds to hours; sub-acute = hours to days 
chronic = weeks to minutes 
Clinical features: erythema, bullae,vesicles urticaria,dermatitis/eczema,prurigo, 
papules, fissures,rhagades, hyperkeratosis 
Subjective symptoms: pain,burning, itching 
 
Clinical Presentationof Work-Related Skin Diseases 
 
Acute irritant contact dermatitis 
Clinical features: burning and pain at exposure site, followed by symptoms such 
as erythema, bullae, edema, erosions, necrosis and ulcers. The symptoms appear 
only on the exposed skin. 
Localization: mostly on the hands, arms, legs and face 
Pathogenesis: damage to intra- and intercellular components of the skin resulting 
in visible morphological change. Clear dose-effect relationship. The damage may 
deteriorate under the occlusive effect of clothing, gloves and footwear. 
Agents: e. g. chemical and physical agents such as strong alkalis and acids, plastic 
monomers (acrylates), amines, phenolic compounds, ultraviolet light and heat. 
Course: the dermatitis develops within seconds to hours following exposure. 
Erythema, swelling and bullae disappear in one to two weeks, usually without 
scarring. If necrosis develops recovery often takes many weeks, with scarring. 
Excision of the necrosis is sometimes necessary. 
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Subacute irritant contact dermatitis 
Clinical features: mostly erythema, bullae and edema. Necrosis is rare. 
Localization: hands, arms, legs and face 
Pathogenesis: comparable with acute irritant contact dermatitis. However, 
symptoms appear later, after a few hours to days 
Agents:  e.g. di-actyl monomers, phenolic compounds, benzalkonium chloride 
Course: cured within a few weeks. Scarring may develop with necrosis 
Remark: the clinical features are sometimes difficult to distinguish from (acute) 
allergic contact dermatitis 
 
Chronic irritant contact dermatitis 
Synonym: orthogenic eczema or cumulative irritant contact dermatitis 
Clinical features: ranging from slight erythema with scaling to eczematous lesions 
with pronounced rhagades. 
Localization: hands, wrists, arms, feet, sometimes the face. The fingertips, inter-
digital webspace and the dorsal side of the fingers are often affected. 
Pathogenesis: caused by the repetition of the same damaging factor or the 
cumulative effect of a variety of minor damaging factors. In many “wet work” 
occupations the clinically normal skin is damaged at a sub-clinical level by 
exposure to water and detergents. A slight erythema with fine scaling is often the 
first visible lesion. A sudden change in occupational exposure or in clinic 
conditions may push the damage”over the edge” to a frank dermatitis or eczema. 
Agents: e.g.water, soap, detergents, organic solvents, alkalis and acids, fruit and 
vegetable juices; dry, abrasive materials; metalworking fluids, cement, 
disinfectants, skin care products, cosmetics; climate: low absolute humidity, dry air 
flow. 
Course: the lesions develop gradually and can suddenly deteriorate. Time off work 
alone usually gives no rapid cure and the dermatitis tends to a chronic course 
 
Remark: differentiation of an allergic contact dermatitis is sometimes difficult, 
even histology not providing a conclusive answer. Negative allergy tests support 
a diagnosis of chronic irritant contact dermatitis. 
 
Allergic contact dermatitis 
Synonym: contact eczema 
Clinical features:Type IV allergens induce skin diseases with a range of lesions. 
This varies from a few vesicles on one finger, to sharply demarcated patches of 
erythema on the back of the hand and up to an extensive and severe eczema with 
severe edema on the hands, arms and face, itching is often a characteristic 
symptom. 
Localization: the hands, wrists, forearms, eyelids, face, neck and feet. 
Pathogenesis: Type IV allergens are chemical compounds of natural or synthetic 
origin. The onset of induction of sensitization varies from months to years, rarely a 
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few weeks. Exposure to allergen causes skin lesions at the site of contact after 24 
to 72 hours. The allergic reaction can be overwhelming so that skin lesions appear 
outside the place of contact. 
Agents: many thousands of compounds may cause a type IV allergy 
Course: Exacerbations and remissions are the characteristic course, changing to a 
more chronic course after a few months. Exacerbations and remissions then 
gradually disappear. 
Remark: with patch testing, false positive and negative reactions can occur. 
Positive reactions have to be assessed for relevance, because positive test reactions 
often have no direct causal relationship with the skin disease. 
 
Atopic dermatitis 
Clinical features: atopic dermatitis is a highly variable skin disease and often 
influenced by exogenous factors. In most cases atopic hand eczema is more or less 
symmetrically localized on the back of the hands and fingers and often the wrists. 
Patches with erythema, edema, lichenification and dryness, sometimes with 
painful; rhagades on knuckles and wrists, may dominate the appearance. 
Localization: work-related causes of atopic dermatitis affect hands, wrists, 
forearms, neck, face and feet. 
Pathogenesis: develops on the basis of an atopic skin constitution, due to reduced 
quality of the skin barrier and disturbed recovery capacity. Exogenous factors often 
make a contribution to exacerbations and a chronic course. Water in particular, 
usually together with soap and detergents, exacerbates a pre-existing atopic 
dermatitis or induces new lesions. Atopic dermatitis is frequently colonized by 
Staphylococcus aureus. By way of a super-antigen allergic reaction 
Staphylococcus aureus may exacerbate the dermatitis 
Course: chronic, often maintained by damaging factors 
Remark: evaluate the atopic skin constitution with history and physical 
examination. 
 
Mechanical contact dermatitis 
Clinical features: erythema with dry adherent scaling. Tendency to rhagades. 
Localization: fingertips and/or palms 
Pathogenesis: friction, pressure and shearing forces. Handling dry and rough 
materials may induce a circumscribed dermatitis. 
Agents: e.g.handling of paper, cardboard, other dry and slightly abrasive material 
Course: chronic 
 
Hyperkeratotic dermatitis 
Clinical features: symmetrically localized hyperkeratotic and well-demarcated 
lesions. Tendency to fissures and rhagades, no nail dermatitis. 
Localization:center of the palm, sometimes tip of thumb and little finger 
Pathogenesis: unknown. No clear relationship with psoriasis or atopy. Mechanical 
forces are sometimes involved. 
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Course: chronic 
Remark: differentiate from psoriasis vulgaris. 
 
Asteatotic eczema 
Synonym: eczéma craquelé 
Clinical features: chapping skin with cracks on a red background; borders are 
irregular, itching is a dominant feature. 
Localization: dorsal site of the hands, wrists, upper arm and outside the thighs. 
Pathogenesis: asteatotic eczema is a characteristic variant of chronic irritant 
contact dermatitis. 
Agents: e.g.excessive exposure to water and soap (washing hands, showering), 
frequently triggered by climatic changes, particularly when changing to windy bad 
weather conditions. 
 
Chronic exogenous eczema 
Synonym: post-occupational eczema or post traumatic eczema. 
Clinical features:  various from eczematous to psoriasiform. 
Pathogenesis: disturbed regeneration capacity of the skin, leading to a chronic, 
self-perpetuating dermatitis. Often starts as an irritant or allergic contact dermatitis 
with remissions and exacerbations related to exposure. Gradually becomes chronic, 
no longer influenced by exposure. Avoiding of exposure is of no benefit. 
Course: chronic, no clear periods with exacerbations and remissions. 
Remark: notoriously resistant to medical treatment 
 
Immediate contact reactions 
Clinical features:symptoms vary from itching, burning and stinging to erythema 
and urticaria, sometimes with vesicles. Erythema and vesicles may persist and, if 
exposure continues, eczema appears. Sometimes, symptoms occur outside the 
direct contact site, combined with rhinitis, conjunctivitis, asthma and even 
anaphylactic shock. 
Localization: sides of fingers, wrists, forearms and face. 
Pathogenesis:  
1. Immunological immediate contact reactions:  the allergen binds to the IgE on 
the mast cell membrane resulting in the release of vasoactive mediators, e.g. 
histamine. 
2. Non-immunological contact reactions: a direct effect on the blood vessels or 
the release   of vasoactive substances by non-immunological mechanism. 
Agents: 
1. Immunological direct reactions: e.g.: meat, fish, fruit and vegetables, natural 
rubber latex, penicillin, saliva of mammals, wool, gut of pig and sheep. 
2. Non-immunological direct reactions, e.g.: caterpillars, jellyfish, Peru balsam, 
camphor, stinging nettles, seaweed, thyme, cayenne pepper, celery, cinnamon 
compounds 
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Course: symptoms and lesions appear seconds to hours after contact. Spontaneous 
recovery in hours to a day. Repeated exposure can cause a chronic dermatitis with 
an eczematous appearance. 
Remark: prick or scratch tests are indicated if (immunological) immediate 
contact reactions are suspected. Specific RAST is sometimes available. 
Generalized urticaria is normally not caused by damaging factors at the 
workplace. 
 
Mineral fiber contact dermatitis 
Synonym: glass fiber or rockwood dermatitis 
Clinical features: itching is dominant. Small erythematous papules, sometimes 
with petechiae, erosions, urticaria and scratches. 
Localization: uncovered skin by direct exposure. Covered skin by contamination 
and penetration of clothing. 
Pathogenesis: mechanical irritation. 
Agents: glass and rockwood fibers. 
Course: symptoms often disappear spontaneously after a few weeks by hardening, 
even if exposure continues. Work interruption cures the condition after a few 
weeks, but it can quickly relapse. 
Remarks: mineral fiber dermatitis is usually airborne. Family members may also 
develop symptoms caused by contamination of clothing in the washing machine. 
 
Airborne irritant contact dermatitis 
Clinical feature: Itching and burning sensations on the exposed uncovered skin; 
sometimes also on covered skin. Erythema, scaling, sometimes eczematous with 
fissures. 
Localization:  forehead, cheeks, eyelids, ears, jaws, nostrils, lips, neck, uncovered 
parts of the arms. 
Pathogenesis: the agents come into contact with the skin by the air, as gas, vapour, 
droplet, spray or dust. Sunlight does not play a role. Pathogenesis is comparable 
with chronic irritant contact dermatitis. 
Agents: e. g.alkalis and acids, organic solvents, cleaning agents, plastic agents, 
plastic monomers, calcium oxalate and silicon oxide, tropical wood sawdust, plant 
particles, vapour of food components, cement powder, phenolic compounds, 
fertilizer. 
Course: comparable with sub-acute and chronic irritant contact dermatitis. 
 
Airborne allergic contact dermatitis 
Clinical feature: Itching, erythema, edema, papules, vesicles and scaling. Usually 
a red, scaling or eczematous picture.  
Localization: forehead, cheeks, eyelids, ears, jaws, nostrils, lips, neck, uncovered 
parts of the arms. 
Pathogenesis: Type IV allergy. 
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Agents: e. g.  plants (Compositae family [chrysanthemums]), plastic monomers, 
pesticides,animal feed ingredients,tropical wood sawdust, chromium salts (cement 
dust) 
Course: comparable with allergic contact dermatitis  
 
Phototoxic contact dermatitis 
Clinical features: the symptoms mimic sunburn with burning pain, erythema, 
edema, sometimes vesicles and bullae. Onycholysis and hyperpigmantation may 
develop at a later stage. The dermatitis is characterized by sharply demarcated 
erythema, often with blisters, leaving hyperpigmentation. 
Localization: sunlight-exposed skin parts, face, neck, chest, back of the hands and 
arms. Lesions are more pronounced on ears, nose and cheeks. Less on sun-shielded 
parts such as eyelids, upper lips, neck under the chin. Hypo– and 
hyperpigmentation may appear. 
Pathogenesis: some chemical compounds are activated by UV or sunlight. This 
activation includes photochemical reactions in the skin which causes cell damage 
or even cell death. There is a clear relationship between dose and effect. Everyone 
is at risk. The causative agent enters the skin directly or by the blood flow. 
Agents: e.g. plants, such as parsley, bear’s breech, dill, celery, rue (Ruta 
graveolens), skimmia, medication: tetracyclines, furosemide, griseofulvin, 
psoralentar products. 
Course: sub-acute: symptoms appear within a few hours to days. The lesions 
disappear in days to weeks after avoiding contact 
 
Photoallergic contact dermatitis 
Clinical features: erythema, edema, papules, vesicles and eczema.  
Localization: sunlight-exposed skin parts, like the face, neck, chest, back of the 
hands and arms. Lesions are more pronounced on ears, nose and cheeks and less on 
sun-shielded parts such as eyelids, upper lips and neck under the chin. Hypo– and 
hyperpigmentation may appear. 
Pathogenesis: some chemical compounds induce a type IV allergy,under influence 
of UV or sunlight. This allergic reaction is comparable with allergic contact 
dermatitis. The agent enters the skin directly or by the blood flow.  
Agents: e.g. plants: Composite family (chrysanthemum, marigold, 
yarrow);cosmetic ingredients: musk ambrette, cinnamic aldehyde; UV blockers 
(sunscreens);medication: promethazine 
Course: lesions disappear in days to weeks after avoiding contact with the allergen 
 
Acne and rosacea 
Oil acne. Follicular papules and pustules, mainly on thighs and forearms, due to 
cutting oils, metal working fluid, grease and lubricating oils. 
Fast-food acne. Variant of oil acne, mainly in young individuals exposed to 
vapours released by grilling and frying 
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Acne cosmetic. Mainly small non-inflammatory closed comedones, caused by the 
use of cosmetics, affect, for example, actors, fashion models, beauty specialists. 
Acne mechanica. Caused by pressure and friction, e.g. on the back and buttons of 
drivers. 
Chlor acne. Develops in a few weeks after systematic exposure to certain 
polyhalogenated hydrocarbons.Clinical: a range of lesions, e.g. open comedones 
and straw-colored cysts.Main localization: cheeks, behind the ears, on the neck, on 
the buttocks, scrotum and thighs. 
Rosacea. Individuals with telangectasia on the face may experience aggravation 
under hot, humid working conditions. Severe cases may have the appearance of 
rosacea. 
Psoriasis vulgaris 
Clinical features: Characteristic lesions are sharply demarcated with induration, 
erythema and scaling. Psoriasis signs: head, ears elbows, knees, natal cleft and 
nails. 
Pathogenesis: hereditary pre-disposition to the development of an inflammatory 
skin disease with a sub-acute or chronic course. Psoriatic skin lesions have an 
increase in volume of the epidermis by a factor of 4 to 6 and of the mitotic index 
by a factor of 8. The renewal of the epidermis is disturbed with an overproduction 
of normal epidermal cells(hyperkeratosis) and deviant epidermal cells 
(parakeratosis), probably caused by a disturbed interaction between keratinocytes 
and T-lymphocytes. The barrier function of psoriatic skin is reduced and external 
factors, such as shearing and frictional forces, and chemical irritants may induce or 
aggravate psoriasis. 
Course: psoriatic patients have periods when new lesions appear quickly due to 
exogenous and endogenous factors, e.g. infections of the upper respiratory tract, 
stress, medication and skin-damaging factors. This phenomenon is known 
as”endogenous eruption pressure” and is caused by activation of the immune 
system. 
Remarks: the unaffected skin of psoriatic patients may have a reduced skin 
barrier, particularly in periods of increased “endogenous eruption pressure”, 
facilitating skin-damaging factors to cause a dermatitis. 
 
Leukoderma 
Clinical features: depigmented patches 
Localization:fingers, back of the hand, wrists, forearms; may become wore 
widespread. 
Pathogenesis: chemical: cytotoxic effect on the melanocyte. 
Agents: e.g. hydroquinone, monomethylether of hydroquinone, p-tert-butylphenol, 
p-tert-butylcatechol;depigmentation following thermal or chemical burns;post-
inflammation: after severe allergic or irritant contact dermatitis 
Remark: leukoderma caused by a cytotoxic effect of melanocytes, is clinically 
often indistinguishable from idiopathic vitiligo. 
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Hyperpigmentation 
Clinical features: irregular hyperpigmentation, usually sharply demarcated 
Localization: arms, legs, face, sometimes covered skin parts. 
Pathogenesis:Skin burn: chemical or thermal. Post-inflammation:reactive 
hyperpigmentation after allergic or irritant contact dermatitis, reactive 
hyperpigmentation after photoallergic or phototoxic contact dermatitis. 
 
Management of Contact Dermatitis 
 
Contact dermatitis accounts for at least 90% of all cases of work-related skin 
diseases. As far as it is distinguished as a work – related case of dermatitis its 
severity should be assessed. The severity of the disease is classified as follows: 
Grade 1: Slight dermatitis, no negative effect on the work ability 
Grade 2: Moderate dermatitis, affecting the work ability, short sick-leave periods 
may occur 
Grade 3: Severe dermatitis with restricted work ability and high risk of a long 
period of sick-leave 
Reducing the damaging factor(s) is the propriety when dealing with occupational 
dermatitis and medical treatment supports the recovery of the skin. Cases of 
chronic eczema require intense and prolonged medical care. The approach to 
occupational dermatitis should be based on 
•Reduction of exposure to skin damaging factors 
•The use of personal protective equipment 
•Improving the skin barrier and resistance by medical treatment 
While reducing damaging factors targets for the workplace, increasing the 
resistance of the skin implies medical treatment. 
Medical treatment is directed by the severity of the contact dermatitis and 
existence of endogenous factors, No medication should be chosen which contains 
skin irritating ingredients or with a negative effect on the skin barrier. This implies 
avoidance, if possible, of strong topical steroids. The following medication can be 
used: 
Topical steroids. Class I or Class II steroids is cream or ointment, Used 
intermittently to limit side effects. Example: application once or twice a day on 
four successive days followed by a three day break. 
Remark: Topical steroids may reduce the defense capacity of the skin barrier 
against irritants 
 
Tar preparations. The main use of tar preparations is in chronic eczema, atopic 
dermatitis and psoriasis. Tars are not suitable to use in the (sub)-acute forms of 
dermatitis. Each country has different formulations using coal or wood tar 
preparations. 
UV-Light therapy. UVB and PUVA – light therapy is chronic dermatitis or 
eczema. Especially when atopic dermatitis or psoriasis background is involved. 
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Antibiotics. Eczema is easily colonized by bacteria, particularly Staphylococcus 
aureus. In mild cases of infection, local antibiotics can be combined with Class I 
and Class II steroids, Examples: sodium fusidate or mupirocin containing creams. 
More severe cases of infection should be treated with a suitable oral antibiotic. 
Bland. Certain ”bland” creams without specific medicaments may promote the 
healing process by their protective or regenerating effect. The term bland is 
actually untrue in this context. Knowledge about the use of these protective and 
regenerative creams is increasing rapidly. Ingredients like petrolatum, ceramides 
and cholesterol play an important role. The majority of these ointments are 
supplied by producers who specialize in skin care at the workplace. Distribution, 
prescribing and reimbursement regulations differ between countries. 
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XVIII. LYMPHOPROLIFERATIVE DISORDERS 
 
 
18.1. Cutaneous T-Cell Lymphoma 
 
Cutaneous T-cell lymphoma (CTCL) is a term coined in 1979 to describe a group 
of lymphoproliferative disorders characterized by localization of neoplastic T 
lymphocytes to the skin at presentation. The skin is the second most common 
extranodal site for lymphoma; gastrointestinal sites are first. Of all primary 
cutaneous lymphomas, 65% are of the T-cell type. The most common 
immunophenotype is CD4-positive. 
These malignancies arise from a distinctive subset of T lymphocytes that normally 
patrol and home to the skin. Naive T lymphocytes (CD45RA-positive) recirculate 
from peripheral blood to nodes until they are activated by specific antigens that are 
presented by dendritic cells in regional draining nodes.  
Activated/memory T lymphocytes (CD45RO-positive) that express cutaneous 
leukocyte antigen (CLA) gain the ability to enter the skin, cycling among 3 
compartments, i.e. skin, node, and peripheral blood. CLA, a marker for these cells, 
is an adhesion molecule that mediates tethering of the T lymphocyte to endothelial 
cells in cutaneous postcapillary venules via its interaction with E-selectin, found on 
dermal endothelial cells. 
 
Classification 
The groups of clinicopathologic entities that comprise the CTCLs differ widely in 
biologic course, histologic appearance, and, in some cases, immunologic and 
cytogenetic features and response to appropriate treatment.  
CTCLs are defined by an integration of these features by 2 classification systems: 
the European Organization for Research and Treatment of Cancer (EORTC) 
classification for primary cutaneous lymphomas (1997) and the World Health 
Organization (WHO) classification of hematologic malignancies (2000).  
The EORTC classification focuses on primary cutaneous lymphomas, which may 
vary from their nodal counterparts in clinical behavior, prognosis, and appropriate 
therapeutic approaches.  
Unlike the general group of lymphomas, a histologic diagnosis in a case of 
cutaneous lymphoma may not be the final diagnosis but, rather, a differential 
diagnosis requiring clinicopathologic correlation.  
The WHO classification includes cutaneous lymphomas in the general 
classification of lymphoma to facilitate the description of clinicopathologic entities 
in their entirety, reporting common features of disease entities that can present in 
multiple anatomic sites. The WHO classification allows oncologists, 
dermatologists, and pathologist to use a common language.  
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Table 18.1.Comparison of EORTC and WHO-Classifications 
EORTC Classification  Frequency 
Five-Year 
Survival 
Rate 
WHO-Classification 
Indolent Clinical Behavior 
Mycosis fungoides (MF) 40% 89% MF 
MF variants 
– MF with follicular mucinosis 
–  Pagetoid reticulosis 
4% 
<1% 
75% 
MF variants 
  MF-associated follicular 
mucinosis  
  Pagetoid reticulosis 
  Granulomatous slack 
skin  
CTCL, large cell, CD30-positive  10% 
 
100% Primary cutaneous CD30-
positive 
lymphoproliferations 
  Anaplastic large cell 
lymphoma  
Lymphomatoid papulosis 14% 100% Lymphomatoid papulosis  
Aggressive Clinical Behavior  
Sézary syndrome  3% 11% Sézary syndrome  
CTCL, large cell, CD30-negative  8% 15%   Peripheral T-cell 
lymphoma, unspecified 
  Extranodal natural killer 
(NK) T-cell lymphoma, 
nasal type 
Provisional Entities 
CTCL, pleomorphic, small- or 
medium-sized 2% 62%  
Subcutaneous panniculitis-like T-
cell lymphoma  
4%  Subcutaneous panniculitis-
like T-cell lymphoma 
Adapted from Annals of Oncology 2000, 11 Supplement 1  
 
18.1.WHO classification of T-cell and NK-cell lymphomas with frequent or 
constant cutaneous involvement 
 
•Primary cutaneous T-cell lymphomas  
- Mycosis fungoides  
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- Sézary syndrome  
- Primary cutaneous anaplastic large cell lymphoma  
- Subcutaneous panniculitis-like T-cell lymphoma 
 
•Other T-cell or NK cell lymphomas with cutaneous involvement  
- Precursor T-lymphoblastic lymphoma leukemia  
- T-cell prolymphocytic leukemia  
- Aggressive NK cell leukemia  
- NK T-cell lymphoma nasal and nasal-type  
- Angioimmunoblastic T-cell lymphoma  
- Peripheral T-cell lymphoma, unspecified  
- Adult T-cell leukemia lymphoma  
- Systemic anaplastic large cell lymphoma 
 
18.2.Mycosis fungoides/Sézary syndrome 
 
This is the most common CTCL (40%), leading some to use the terms 
synonymously. Variants of MF recognized by EORTC and WHO include follicular 
MF and pagetoid reticulosis (Woringer-Kolopp disease).  
MF-associated follicular mucinosis manifests with follicular papules, patchy 
alopecia, and comedo-like lesions. An infiltration of atypical lymphocytes is 
observed in the epithelium of hair follicles. Treatment with topical treatments may 
not be effective because of the depth of infiltration.  
Pagetoid reticulosis (Woringer-Kolopp disease) manifests with a solitary, 
asymptomatic, well-defined, red, scaly patch or plaque on the extremities that may 
slowly enlarge. A heavy, strictly epidermal infiltrate of atypical lymphocytes is 
observed. The prognosis is excellent, and radiation therapy or surgical excision is 
the treatment of choice.  
 
18.3. Mycosis Fungoides 
 
Background.In 1979, the term cutaneous T-cell lymphoma (CTCL) was coined at 
an international workshop sponsored by the National Cancer Institute. CTCL was 
used to describe a heterogenous group of malignant T-cell lymphomas with 
primary manifestations in the skin. In 1806, the term mycosis fungoides (MF) was 
first used by Alibert, a French dermatologist, when he described a severe disorder 
in which large necrotic tumors resembling mushrooms presented on a patient's 
skin. MF is the most common type of CTCL. Sézary syndrome (SS) is a variant of 
MF, occurring in about 5% of all cases of MF, in which the patient has generalized 
erythroderma and more than 1000 per mm3 atypical T lymphocytes with 
cerebriform nuclei circulating in the peripheral blood.  
Pathophysiology.MF is a malignant lymphoma characterized by the expansion of 
a clone of CD4+ (or helper) memory T cells that frequently lack other normal T-
cell antigens (CD7). These cutaneous lymphocyte antigen (CLA)–positive cells 
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home to the skin, and some also may retain the ability to exit the skin via afferent 
lymphatics. They travel to lymph nodes and then through efferent lymphatics back 
to the blood to join the circulating population of CLA-positive T cells. Then, the 
disease fundamentally becomes a systemic disease, even when the disease appears 
to be in an early stage and limited to the skin.  
Mortality/Morbidity.The overall mortality rate is 0.064 per 100,000 persons; 
however, the mortality rate widely varies depending on the stage of disease at 
diagnosis.  
•Late-stage MF or SS is associated with declining immunocompetence. Death 
most often results from systemic infection, especially with Staphylococcus aureus, 
Pseudomonas aeruginosa, and other organisms. Secondary malignancies, such as 
higher-grade non-Hodgkin lymphoma, Hodgkin disease, colon cancer, and 
cardiopulmonary complications (e.g. high output failure, comorbid 
cardiopulmonary disease) also contribute to mortality.  
Age.The most common age at presentation is 50 years; however, MF also can be 
diagnosed in children and adolescents with apparently similar outcomes.  
History.Skin rash.This may consist of patches, plaques, or tumors, which may 
have a long natural history.The median duration from the onset of skin symptoms 
to diagnosis is 6 years. Early in the course of disease, skin lesions may be 
nonspecific, with a non-diagnostic biopsy result, so confusion with benign 
conditions is common.Obtain repeated biopsies in those patients who have 
progressive chronic dermatosis or whose condition is refractory to topical 
treatments. 
Pruritus, erythroderma. Often, diagnosis is made possible through the 
examination of a non-cutaneous site (e.g. blood, lymph nodes). 
Physical.Skin patch, plaque.Patch phase MF is characterized by flat, usually 
erythematous, macules that may have a fine scale, may be single or multiple, and 
may be pruritic. In dark-skinned individuals, the patches may appear as 
hypopigmented or hyperpigmented areas. As patches become more infiltrative, 
they evolve into palpable plaques.Plaques tend to be raised, demonstrating fine-
scale, well-demarcated, erythematous shapes with irregular borders. Annular or 
serpiginous patterns with central clearing and pruritus are common.Patches and 
plaques may affect any area of the skin, but they often are distributed 
asymmetrically in the areas that a bathing suit would cover (i.e. hips, buttocks, 
groin, lower trunk, axillae, and breasts). When the disease affects the scalp, it often 
is accompanied by alopecia. 
Stage IA disease (as defined by the tumor, node, metastases, blood [TNMB] 
system) is defined as patchy or plaque-like skin disease involving less than 10% of 
the skin surface area (T1 skin disease). 
Stage IB disease is defined as patchy or plaque-like skin disease involving greater 
than or equal to 10% of the skin surface area (T2 skin disease). 
Skin tumors.Patients with evidence or a history of patchy or plaque-like skin 
lesions also can have tumors.Tumors are red-violet nodules that may be dome-
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shaped, exophytic, or ulcerated.Stage IIB disease is defined by the presence of 
tumors (T3 skin lesions). 
Skin erythroderma.Generalized erythroderma often is intensely symptomatic, with 
pruritus and scaling that can be profound. The patients experience thickening of the 
skin folds in the face (leonine facies), hyperkeratosis and fissuring of the palms 
and soles, onychodystrophy, ectropion of the eyelids, and edema. Sun exposure 
may be painful as well as pruritic.Stage III disease is defined by the presence of 
generalized erythroderma. 
Lymph nodes.Extracutaneous involvement is more clinically evident as the stage 
and extent of MF increases.Peripheral lymphadenopathy is the most frequent site 
of extracutaneous involvement in MF.Evaluate palpable lymphadenopathy by 
obtaining a biopsy because the result influences the patient's stage, prognosis, and 
treatment.Stage IVA disease is defined by a lymph node biopsy result 
demonstrating large clusters of atypical cells (i.e.>6 cells [LN3 node]) or showing 
total effacement by atypical cells (LN4 node). 
Liver, lung. Stage IVB disease is defined by the presence of visceral involvement 
(e.g. liver, lung, bone marrow). 
Causes.Various theories implicate occupational or environmental exposures 
(e.g.agent orange), other forms of chronic antigenic stimulation, or viral exposures; 
however, the etiology of MF remains unknown. 
Lab Studies.Consider HIV and human T-cell lymphotrophic virus type I (HTLV-
I) testing. CBC with differential: conduct this test and review the buffy coat smear 
for Sézary cells.Liver-associated enzyme abnormalities and lactate dehydrogenase 
(LDH).LDH is a marker of bulky or biologically aggressive disease. Abnormal 
transaminase values may indicate hepatic involvement. Flow cytometric study of 
the blood (include available T cell–related antibodies): conduct this test to detect a 
circulating malignant clone and to assess immunocompetence by quantifying the 
level of CD8-expressing lymphocytes.Uric acid: perform this study in cases 
involving a bulky disease and/or biologically aggressive disease.Southern blot 
testing of the blood: consider this study if detecting a circulating clone of 
malignant cells in the blood will change medical management. 
Imaging Studies.Chest radiograph.CT scan of the abdomen and pelvis: perform 
this test in patients with advanced disease (stage IIB to stage IVB) or in patients 
with clinically suspected visceral disease. 
Procedures.Skin biopsy.Perform a punch biopsy, which is formalin fixed for light 
microscopy. Use a bisected or second punch biopsy on sodium chloride–soaked 
gauze to allow snap freezing for immunophenotyping and T-cell receptor gene 
rearrangement.Bone marrow examination: Perform this procedure only if the 
patient has proven blood or nodal involvement.Lymph node biopsy: Conduct this 
procedure if the nodes are palpable. 
Histologic Findings.The criteria for diagnosis include the following: (1) A band-
like upper dermal infiltrate of lymphocytes and other inflammatory cells, with no 
grenz zone, is present;(2) Epidermotropism of mononuclear cells occurs. (3) When 
a clear halo surrounds an intraepidermal mononuclear cell singly or in clumps, this 
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is called a Pautrier microabscess. Its presence is suggestive of MF, but it is not 
necessary for diagnosis. (4) Little spongiosis of the epidermis is found.  (5) 
Lymphocytes have nuclei that are hyperchromatic and convoluted or cerebriform. 
Medical Care.Conduct the evaluation and treatment on an outpatient basis 
(usually). Use symptomatic treatments, emollients, or antipruritics in combination 
with specific topical and systemic treatment.  
Topical treatments. Generally, use topical steroids, topical chemotherapy (e.g. 
nitrogen mustard or bischloroethylnitrosourea [BCNU]), ultraviolet B or ultraviolet 
A treatment enhanced with psoralen [PUVA]), or total body electron beam 
radiation in the patch or plaque phase. These modalities also are used in the tumor 
phase combined with systemic modalities (e.g. PUVA plus interferon). 
Systemic treatment.This treatment is for patients who have relapsed or whose 
disease is refractory to topical treatments or who have tumors, erythroderma, or 
nodal or visceral disease.Examples of systemic treatment include the following:  
→Extracorporeal photopheresis (leukapheresis with PUVA treatment for the 
collected white blood cells with reinfusion of treated cells)  
→Recombinant alfa interferon  
→Oral retinoids  
→Fusion toxin treatment  
→Systemic chemotherapy with a variety of single agents  
Combination chemotherapy. This generally is not used because the infectious 
complications and short response duration outweigh the modest response rates 
(compared to other non-Hodgkin lymphomas). Increased survival is not 
demonstrated with the use of combination chemotherapy compared to sequential 
topical agents. 
Bone marrow transplantation. Allogenic transplants are reported in the literature 
as case reports or small groups of patients. 
Complications.Infection, particularly from indwelling IV catheters.High-output 
cardiac failure.Anemia of chronic disorders.Edema.Secondary malignancies (skin 
cancer, melanoma, colon cancer, Hodgkin lymphoma, non-Hodgkin lymphomas). 
Prognosis.MF and SS are incurable conditions in most patients, with the exception 
of those with stage IA disease.Mortality and prognosis are related to stage at 
diagnosis. Patients diagnosed with stage IA disease (patch or plaque skin disease 
limited to <10% of the skin surface area) who undergo treatment, have an overall 
life expectancy similar to the age-, sex-, and race-matched controls.Patients who 
have stage IIB disease with cutaneous tumors or who have stage III disease 
(generalized erythroderma) have a median survival rate of 3.2 and 4-6 years, 
respectively.Patients with extracutaneous disease stage IVA (lymph nodes) or 
stage IVB (viscera) have a survival rate of less than 1.5 years. 
Patient Education.Encourage the use of supportive treatments to decrease pruritus 
and lubricate the skin. Avoid sun exposure and remain in a cool environment. 
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XIX. HEREDITARY DERMATOSES 
 
19.1. Ichthyosis Vulgaris, Hereditary 
 
Background.Hereditary ichthyosis vulgaris ichthyosis vulgaris, members of a 
group of cutaneous disorders of keratinization, appear similar both clinically and 
histologically. The term ichthyosis is derived from the ancient Greek root ichthys, 
meaning fish. Although the resemblance is rather fanciful, it nevertheless conveys 
the characteristic features of these diseases. References to ichthyosis have been 
found in ancient medical texts aged more than 2000 years. Robert Wilan first made 
the most accurate description of ichthyosis in the English literature in 1808. Later 
modifications classified the diseases into hereditary and acquired forms.  
Hereditary ichthyosis vulgaris is an autosomal dominant genetic disorder first 
evident in early childhood. It is the most common form of ichthyosis, accounting 
for more than 95% of ichthyosis cases. It is caused by altered profilaggrin 
expression leading to scaling and desquamation. Visible scales are retained for 
longer periods and sloughed off in clumps. Hereditary ichthyosis is also associated 
with atopy.  
Pathophysiology.Ichthyosis vulgaris is classified as a retention hyperkeratosis. 
The only known molecular marker affected by hereditary ichthyosis vulgaris is 
profilaggrin, a high molecular weight filaggrin precursor. Profilaggrin, synthesized 
in the granular layer of the epidermis, is a major component of keratohyalin 
granules. Through various posttranslational modifications, profilaggrin is 
converted to filaggrin, which aggregates keratin intermediate filaments in the lower 
stratum corneum. Filaggrin is proteolyzed and metabolized, producing free amino 
acids that may play a critical role as water-binding compounds in the upper stratum 
corneum.  
Normal expression of the profilaggrin gene can be first detected in the granular 
layer. In ichthyosis vulgaris, the expression of profilaggrin is absent or reduced in 
the epidermis. This biochemical abnormality correlates with the decreased 
numbers of keratohyalin granules and the clinical severity of the condition. 
Analyses of cultured keratinocytes have shown reduced profilaggrin mRNA. 
Compared with normal amounts, one study found only 50% of the profilaggrin 
mRNA and 10% of the profilaggrin protein present. Research has shown that 
defective posttranscriptional regulation leads to decreased stability of profilaggrin 
mRNA. The underlying molecular mechanisms accounting for this instability have 
yet to be determined. Studies using mouse models are currently underway.  
Frequency.Hereditary ichthyosis vulgaris is a common disease in the United 
States, with a prevalence of approximately 1 case in 300 persons. Because 
symptoms improve with age, the true prevalence is probably higher.Hereditary 
ichthyosis vulgaris is found worldwide, and the prevalence depends on the 
location.  
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Mortality/Morbidity.Children and adolescents with hereditary ichthyosis vulgaris 
may experience some morbidity in terms of cosmesis. Secondary infections may 
occur in fissures of the hands and feet.  
Age.Hereditary ichthyosis vulgaris typically is absent at birth. It appears in most 
patients during the first year of life and in the vast majority by age 5 years. The 
extent of scaling usually intensifies up until puberty and subsequently decreases 
with age.  
History.Although the skin in hereditary ichthyosis vulgaris looks and feels normal 
at birth, it gradually becomes rough and dry in early childhood. 
→Scaling tends to be most prominent on the extensor surfaces of the extremities 
and absent on the flexor surfaces. 
→The diaper area is usually unaffected. 
→The forehead and cheeks may be involved early on, but scaling usually 
diminishes in these areas with age. 
→A notable amelioration of symptoms occurs during the summer months. 
→A family history of hereditary ichthyosis vulgaris may be difficult to ascertain 
because of the varying degrees of penetrance and the general improvement of 
symptoms over time. 
Many hereditary ichthyosis vulgaris patients have associated atopic manifestations 
(e.g. asthma, eczema, hay fever). Atopic conditions can be found in many family 
members, with or without symptoms of ichthyosis vulgaris.  
Physical.Ichthyosis vulgaris is characterized by symmetrical scaling of the skin, 
which varies from barely visible roughness and dryness to strong horny plates. 
Scales are small, fine, irregular, and polygonal in shape, often curling up at the 
edges to give the skin a rough feel.Scales vary in size from 1 mm to 1 cm in 
diameter and range from white to dirty gray to brown. Dark-skinned individuals 
often have darker scales.Different types of scaling may be found in different areas, 
even in the same patient.Most scaling occurs on the extensor surfaces of the 
extremities, with a sharp demarcation between normal flexural folds and the 
surrounding affected areas.The lower extremities generally are more affected than 
the upper extremities. Compared to other sites, the scales overlying the shins are 
thicker, darker, and arranged in a mosaic pattern. Patients often report "lizard skin" 
in these areas during the winter.If the trunk is involved, scaling tends to be more 
pronounced on the back than on the abdomen.Relative sparing of the face is seen, 
most likely because of increased sebaceous secretions, although the cheeks and 
forehead may be involved during early childhood in the hereditary form. Dry 
scaling is often observed uniformly over the scalp. Sparing of the flexural folds 
(e.g. neck, axillae, antecubital and popliteal fossae) is attributed to the relative 
increase in temperature and humidity in these areas. Overall symptoms of 
ichthyosis vulgaris generally improve in the summer months or in warm climates. 
Hyperkeratosis is often present on the palms and soles, causing them to appear 
dirty.Skin creases in these areas are more prominent and can lead to painful 
fissuring, especially during dry weather. Secondary infections at fissure sites are 
common. 
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Keratosis pilaris (follicular hyperkeratosis) occurs on the side of the cheek and 
neck, dorsum of the upper arms, buttocks, and thighs. It consists of spiny 
parafollicular papules that when palpated resemble a cheese grater. Dried skin in 
the central portion is often white and mistaken for pus. Inflammation may or may 
not be present. Keratosis pilaris, which can be present without scaling, may be the 
only finding in family members with hereditary ichthyosis vulgaris.Pruritus can be 
caused by dry skin, even if inflammation is not evident. As a result, itching and 
scratching may lead to erythema in affected areas. 
Causes.Hereditary ichthyosis vulgaris is an autosomal dominant genetic disorder 
first evident in early childhood. 
Procedures.Skin biopsy specimens can be examined under light microscopy and 
electron microscopy. Take biopsy samples from regions of maximal hyperkeratosis 
because areas of mild scaling are less reliable for histopathologic analysis and 
findings may be indistinguishable from those of normal skin. The thickest scales 
are usually found on the anterior aspect of the lower leg. 
Histologic Findings.The histological appearance of both hereditary ichthyosis is 
practically identical. The stratum corneum shows compact hyperkeratosis, 
although some areas can be laminated. Patchy parakeratosis and occasional 
follicular plugging is seen. The granular layer is usually one-layer thick or absent. 
The stratum malpighii is usually intact but has a decreased rete-papillae pattern. 
The eccrine and sebaceous glands, when present, are small, atrophic, and reduced 
in number. Sweat glands and hair follicles are evident. Most patients have a slight, 
perivascular, lymphohistiocytic infiltration in the upper dermis. Ichthyosiform 
sarcoid, a manifestation of acquired ichthyosis in sarcoid patients, has the 
additional presence of multiple non-caseating granulomas in the dermis.  
Ultrastructural studies show reduced or absent keratohyalin granules housed in the 
granular layer. They appear spongy or crumbly, most likely due to defective 
keratohyalin synthesis. The hyperkeratotic portions of the stratum corneum have a 
normal keratin pattern.  
Medical Care.Hereditary ichthyosis vulgaris is a chronic disorder that may 
improve with age but often requires continuous therapy. The main approach to 
treatment of both conditions includes hydration of the skin and application of an 
ointment to prevent evaporation. Hydration promotes desquamation by increasing 
hydrolytic enzyme activity and the susceptibility to mechanical forces. Pliability of 
the stratum corneum is also improved.  
Alpha-hydroxy acids (e.g. lactic, glycolic, or pyruvic acids) are effective for 
hydrating the skin. They work by causing disaggregation of corneocytes in the 
lower levels of the newly forming stratum corneum. Lactic acid is available as a 
12% ammonium lactate lotion, or it can be compounded by prescription in a 
concentration of 5-10% in a suitable vehicle. Twice-daily applications have shown 
to be superior to petrolatum-based creams for controlling of ichthyosis vulgaris. 
Removal of scales can be aided by keratolytics (e.g. salicylic acid), which induce 
corneocyte disaggregation in the upper stratum corneum. A commercially available 
6% salicylic acid gel can be used as needed. 
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Over-the-counter products often contain urea or propylene glycol. Moisturizers 
containing urea in lower strengths (10-20%) produce a more pliable stratum 
corneum by acting as a humectant. Propylene glycol draws water through the 
stratum corneum by establishing a water gradient. Thick skin is then shed 
following hydration. Propylene glycol is a common vehicle in both prescription 
and over-the-counter preparations. 
Topical retinoids (e.g. tretinoin) may be beneficial. They reduce cohesiveness of 
epithelial cells, stimulate mitosis and turnover, and suppress keratin synthesis. 
Tazarotene, a topical receptor-selective retinoid, has also been effective in one 
small trial. 
Prognosis.The prognosis for hereditary ichthyosis vulgaris is excellent. Many 
patients experience improvement of symptoms with age. 
 
 
19.2. Ichthyosis, Lamellar 
 
Synonyms and related keywords: non-bullous congenital ichthyosiform 
erythroderma, non-bullous congenital ichthyosiform erythroderma, autosomal 
recessive ichthyosis, erythrodermic autosomal recessive lamellar ichthyosis. 
 
Background.Lamellar ichthyosis is an autosomal recessive disorder that is 
apparent at birth and is present throughout life. The newborn is born encased in a 
collodion membrane that sheds within 10-14 days. The shedding of the membrane 
reveals generalized scaling with variable redness of the skin. The scaling may be 
fine or plate-like, resembling fish skin. Although the disorder is not life 
threatening, it is quite disfiguring and causes considerable psychological stress to 
affected patients.  
Pathophysiology.Patients with lamellar ichthyosis have accelerated epidermal 
turnover with proliferative hyperkeratosis, in contrast to retention hyperkeratosis. 
This involves a mutation in the gene for transglutaminase 1 (TGM1). The 
transglutaminase 1 enzyme is involved in the formation of the cornified cell 
envelope.  
Causes.Lamellar ichthyosis is an autosomal recessive disorder in almost all cases. 
Genetic linkage studies have been performed on families with classic lamellar 
ichthyosis and show markers on band 14q11 in the region of the TGM1 gene locus. 
An autosomal dominant form of lamellar ichthyosis has been described.  
Mortality/Morbidity.In the neonatal period, following the shedding of the 
collodion membrane, the newborn is at risk for secondary sepsis and 
hypernatremic dehydration. As the child ages, the hyperkeratosis can interfere with 
normal sweat gland function, which can predispose to heat intolerance and possible 
heat shock. Ectropion may result in the inability to fully close the eyelids and can 
cause exposure keratitis. 
Age.The disease is present at birth and continues throughout life. 
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Physical.Newborn period. The newborn presents encased in a tough, film-like 
membrane that fissures when stretched. This collodion membrane is shed by 10-14 
days, revealing generalized erythema and scaling. 
Childhood and adulthood.Skin. The disease is characterized by generalized scales, 
which range from fine and white to thick, dark, and plate-like. The scales are 
arranged in a mosaic pattern resembling fish skin. The lesions involve the entire 
body and are increased in flexural surfaces such as the axilla, groin, antecubital 
fossa, and neck. The individual scales tend to be larger over the legs and, in some 
areas, are centrally attached and raised at the edges. 
Nail abnormalities. These include secondary dystrophy with nail fold 
inflammation, subungual hyperkeratosis, and longitudinal or transverse stippling. 
The nails may grow 2-3 times the normal rate. 
Scalp. Scarring alopecia can result from the overall tightness of skin and the thick 
stratum corneum entrapping hairs. The hair may be thin and fine but, similar to the 
nails, can grow at 2-3 times the normal rate. 
Other findings. The lips and mucous membranes tend to be spared. Other 
associated features are ectropion, eclabium, bilateral conjunctivitis, small and 
deformed ears, and inflexible digits due to taut skin. 
Lab Studies.As a result of the abnormal skin barrier, neonatal sepsis is a 
significant risk in the newborn period. If sepsis is considered, perform a sepsis 
workup. Chemistries and fluids need to be monitored closely because of the high 
incidence of hypernatremia observed. 
Procedures.Skin biopsies can aid in the diagnosis of lamellar ichthyosis. At birth, 
electron microscopy can be used to differentiate a severe collodion baby affected 
by lamellar ichthyosis from a baby affected by harlequin ichthyosis by 
demonstrating the absence of the marginal band. 
Histologic Findings.Skin biopsy results show a normal or thickened granular 
layer, mild-to-moderate hyperkeratosis with increased mitoses, and a perivascular 
lymphocytic infiltrate. In autosomal dominant lamellar ichthyosis, the stratum 
granulosum and stratum corneum are separated by a prominent transforming zone 
and scales contain elevated triglyceride and fatty acid levels, which aids in 
differentiation from autosomal recessive lamellar ichthyosis.  
Surgical Care.Surgery is occasionally necessary for severe ectropion.  
Consultations.Consult a dermatologist for the evaluation and treatment of the 
skin. Consult an ophthalmologist for the evaluation and management of ectropion 
from birth. Consult a genetics counselor for a discussion of the risks of subsequent 
children being affected.  
Activity.A potential for heat intolerance and heat stroke is present; however, with 
proper counseling, activity does not need to be limited. 
Medical Care.This disorder has no cure; therefore, treatment is directed at 
decreasing symptoms. Emollients should be applied after showering or bathing. 
The stratum corneum can absorb 6 times its weight in water, and a heavy 
emollient, such as petrolatum jelly (Vaseline) or water-in-oil preparations (e.g. 
Eucerin) should be applied while the skin is still wet. Alpha-hydroxy acids, such as 
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lactic acid (e.g. Lac-Hydrin), help reduce corneocyte adhesion and decrease the 
thickness of the epidermis. Urea creams can help soften scales. Salicylic acids in 
combination with propylene glycol help to remove dark scaling. Care must be 
taken when using topical salicylates over large areas, especially in children, 
because of reports of systemic salicylate intoxication. Topical retinoic acids (e.g. 
Retin-A) decrease thickened scaling. Antiseptics and antimicrobials can be used 
topically to control odor. Because of the significant long-term adverse effects, 
reserve systemic retinoids for severe disease that is refractory to conventional 
therapy. Newer therapies that have resulted in clinical improvement are Locobase 
fatty cream, which is 5% lactic acid and 20% propylene glycol in a lipophilic 
cream base; topical N-acetylcysteine, which has an antiproliferative effect; 
tazarotene topical 0.05%, a receptor-selective retinoid; and calcipotriol, a synthetic 
derivative of vitamin D-3. 
Transfer the newborn to the neonatal intensive care unit for close monitoring of 
fluids, electrolytes, and signs of sepsis. Manual debridement of the collodion 
membrane is not recommended. 
Prevention.Prenatal diagnosis is controversial. A fetal skin biopsy at 22 weeks 
may aid in prenatal diagnosis. In patients with a known gene locus, DNA linkage 
analysis may be useful. 
Prognosis.Patients with lamellar ichthyosis have normal life spans. 
 
 
19.3. Epidermolytic Hyperkeratosis (Bullous Congenital Ichthyosiform 
Erythroderma) 
 
Synonyms and related keywords: bullous congenital ichthyosiform erythroderma 
Background.Epidermolytic hyperkeratosis (EHK) also is termed bullous 
congenital ichthyosiform erythroderma. EHK is a rare autosomal dominant 
ichthyosis, yet a high frequency of spontaneous mutations (up to 50%) occurs. In 
1902, Brocq first described it as bullous ichthyotic erythroderma to distinguish the 
entity from congenital ichthyotic erythroderma.  
Pathophysiology.The defect is found in the genes for keratin 1 and keratin 10. 
Keratins are divided into 2 classes including basic type II keratins and acidic type I 
keratins. Keratin 1 is one of the basic type II keratins found on chromosome 12; 
keratin 10 is one of the acidic type I keratins found on chromosome 17. Keratins 
form intermediate filaments when both type I and type II keratins are present. This 
combination provides structural stability to keratinocytes. Keratins 1 and 10 are 
coexpressed and are involved in the suprabasilar differentiation of keratinocytes. A 
defect at this level (as in EHK) weakens the structural stability of the 
keratinocytes, causing easy blistering, hyperproliferation, and hyperkeratosis.  
Causes.Defects in genes for keratin 1 and 10 are the cause of EHK. Defects in 
keratin 1 are associated with the PS variants; defects in keratin 10 are associated 
with the NPS variants.  
Frequency.1 case per 200,000-300,000 persons. 
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Mortality/Morbidity.Mortality is possible if sepsis or electrolyte imbalance is not 
treated properly during the neonatal period. Morbidities include recurrent infection, 
sepsis, and electrolyte imbalance, which are possible during the neonatal period.  
Age.EHK is a lifelong condition with an onset at birth or in the neonatal period.  
History.EHK presents at birth or shortly thereafter as erythema, blistering, and/or 
peeling, but symptoms in some patients may ameliorate over time.  
Physica.In 1994, DiGiovanna and Bale separated the various clinical presentations 
of EHK into 2 primary types, including NPS (without severe palm/sole 
hyperkeratosis) and PS (with severe palm/sole hyperkeratosis) based on the 
presence or absence of severe palmoplantar hyperkeratosis. The 2 primary types 
were subdivided further into 3 subtypes each depending on the clinical 
presentations. Some of the subtypes have general involvement, while others are 
localized only.  
NPS subtypes do not have severe palmoplantar involvement. Distinctions between 
the 3 NPS subtypes are based on different clinical presentations.NPS-1 has normal 
palmoplantar surfaces, no digital contractures, a hystrix scale, a generalized skin 
distribution, no history of erythroderma, a positive history of blistering, and 
patients may have abnormal gait.NPS-2 is similar to NPS-1. The only differences 
are a brown scale instead of a hystrix scale and a lack of gait abnormalities.NPS-3 
has no palmoplantar hyperkeratosis, no digital contractures, and is generalized in 
skin distribution similar to NPS-1 and NPS-2. In contrast, the palmoplantar surface 
in NPS-3 is hyperlinear, has minimal scale, and a thin white scale is most 
prominent on the trunk. Erythroderma is mild to moderate. NPS-3 may have gait 
abnormalities similar to NPS-1. 
PS subtypes have severe palmoplantar involvement. The 3 subtypes are 
differentiated based on clinical presentations.PS-1 has smooth palmoplantar 
hyperkeratotic surfaces, no digital contractures, a localized distribution of skin 
involvement (limited flexural involvement, truncal sparing), no erythroderma, a 
localized blistering, and no gait abnormalities.PS-2 has smooth palmoplantar 
hyperkeratotic surfaces but has digital contractures, generalized skin involvement 
with hyperkeratosis most severe over the joints at both flexor and extensor 
surfaces, mild-to-moderate erythroderma, positive blistering, and may have gait 
abnormalities.PS-3 has cerebriform palmoplantar surfaces, no digital contractures, 
a tan scale, generalized skin involvement, no erythroderma, neonatal blistering, 
and no gait abnormalities. 
Complications.Patients are at an increased risk for recurrent infections, and a 
pungent smell can be noted. 
Lab Studies.No general laboratory studies are needed, except if necessary to 
follow chosen therapy or bacterial culture for suspected infection. Keratin defect 
studies can be performed. 
Procedures.Along with clinical presentation and history, biopsies can be 
diagnostic in de novo cases.Keratin studies can be performed.Prenatal diagnosis 
can be made through analysis of chorionic villus sampling, amniotic cells, or fetal 
skin biopsies. 
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Histologic Findings.Hematoxylin and eosin findings are distinctive but not 
unique. Typical findings include marked hyperkeratosis, thick granular layer, 
coarse keratohyaline granules, vacuolar degeneration of the upper dermis. 
Occasionally, deeper granular cells become dense, enlarged, and irregular, and the 
shaped masses appear to be keratohyaline granules. Electron microscopy findings 
show clumping of keratin filaments beginning at the suprabasal layer.  
Medical Care.Correct diagnosis is the first step in this genodermatosis. Genetic 
counseling and prenatal diagnosis also can be offered. Newborns with denuded 
skin are at increased risk for infection, secondary sepsis, and electrolyte imbalance. 
These newborns should be transferred to the neonatal intensive care unit (NICU) to 
be monitored and treated as needed. Since the condition tends to improve with 
time, visits to the physician decrease. Wound care for blistering and aggressive 
moisturization/emollients are important.  
Consultations.Refer patients who are considering conceiving children to a 
geneticist for reproductive concerns and assistance.Prenatal diagnosis can be made 
by ultrastructural analysis and by direct gene sequencing.Prenatal diagnosis of 
EHK can be performed by ultrastructural analysis of fetal skin biopsies and 
amniotic fluid cells. Keratin 1 and keratin 10 are expressed suprabasally as early as 
week 14 of gestation; normal fetal keratinization does not begin until the 24th 
week. To date, keratin filament aggregates have been detected for diagnostic 
purposes in the 19th week of gestation for diagnosis.Chorionic villus sampling can 
diagnose EHK earlier by direct gene sequencing if the familial mutation is known. 
The earliest documented diagnosis by this method is at the 15th week of gestation, 
but the chorionic villus sampling theoretically can be tested as early as the eighth 
week of gestation. 
Diet.No special diet is needed. Reports of improvement have been noted with 
high-dose beta carotene, systemic retinoids, topical retinoids, 10% glycerin, lactic 
acid, alpha-hydroxy acid, calcipotriol, antibacterial soap, and urea. 
Further Inpatient Care.Neonatal patients may need to be transferred to the NICU 
for monitoring of infection, sepsis, electrolyte imbalance, and administration of 
intravenous fluids or antibiotics. 
Prognosis.EHK is a lifelong condition. Some patients may experience 
amelioration of symptoms as they age. 
Patient Education: Educate patients concerning the potential of passing the 
chromosomal defect on to offspring. 
 
 
19.4. Ichthyosis, X-Linked 
 
Synonyms and related keywords: ichthyosis nigricans, x-linked ichthyosis 
Background: In 1965, Wells and Kerr first recognized X-linked ichthyosis (XLI) 
as a distinct entity by studying its characteristics in 81 affected males. XLI is the 
second most common type of ichthyosis and one of the most frequent human 
enzyme deficiency disorders. XLI is a clinically mild genetic disorder of 
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keratinization, with extracutaneous manifestations in some cases. It is caused by a 
steroid sulfatase (STS) deficiency resulting from abnormalities in its coding gene 
(STS). The 2 best-known substrates for this microsomal enzyme are cholesterol 
sulfate (CSO4) and dehydroepiandrosterone sulfate. Approximately 90% of 
patients with XLI have complete or partial deletions of the STS gene. No evidence 
of genotypic-phenotypic correlation has been shown, regardless of the location or 
type of the STS mutation.  
The 2 molecular pathways that may contribute to XLI pathogenesis are (1) excess 
CSO4 producing non-lamellar phase separation in the stratum corneum interstices, 
explaining the barrier abnormality, and (2) the increased CSO4 in the stratum 
corneum interstices sufficiently inhibiting activity to delay CD degradation, 
leading to corneocyte retention.  
Pathophysiology.Retention hyperkeratosis results from the delayed dissolution of 
desmosomes in the stratum corneum. COS4 is a multifunctional sterol metabolite, 
produced in large amounts in squamous keratinizing epithelia. It may be both a 
marker for squamous metaplasia and an inducer of differentiation. STS acts upon 
COS4, which is a product discharged by the Odland bodies of the granular layer. 
Since STS is missing in XLI, it cannot act on COS4, resulting in persistent cellular 
adhesion and reduced normal desquamation. Patients with XLI have a 10-fold 
increase in COS4 levels and a 50% reduction in cholesterol levels. Recent work 
suggests that COS4 accumulation, rather than cholesterol deficiency, is responsible 
for the barrier abnormality.  
Since 1978, a deficiency in the STS enzyme has been known to be responsible for 
the abnormal cutaneous scaling. The STS gene has been mapped to the distal part 
of the short arm of the X chromosome (band Xp22.3). This region escapes X-
chromosome inactivation and has the highest ratio of chromosomal deletions 
among all genetic disorders. Complete or partial deletions have been found in as 
many as 90% of patients. Deletion of the entire STS gene is the most common 
molecular defect found in patients with XLI. The large deletions of the STS gene 
are generated by inaccurate recombination at the STS locus. Additional flanking 
sequences are usually missing as well. The STS gene has 10 exons and spans more 
than 146 kilobases of DNA. Its introns vary considerably in size. It is transcribed 
into messenger RNA and translated into a protein of 561 residues.  
Causes.XLI is a genetic disorder caused by STS deficiency that results from 
abnormalities in its coding gene.  
Frequency.XLI is a relatively common disease, affecting approximately 1 in 6000 
males worldwide, with no geographic or racial variations. The frequency of XLI 
was estimated to be approximately 1.98 cases per 10,000 males, which is similar to 
estimates from other European surveys.  
Mortality/Morbidity.Clinically, XLI is usually a relatively mild eruption that 
rarely can be emotionally challenging for children and adolescents. Most patients 
perceive it as more of an annoyance than a serious medical problem.  
354 
 
Sex.Males are affected overwhelmingly; however, a few female heterozygotes 
have been reported. XLI was described in 3 homozygous women who were 
daughters of a father with the disorder and a mother who was a carrier.  
Age.XLI occurs at birth or in early infancy. It may become more prominent as the 
child ages.  
History.XLI is seen at birth or in the immediate neonatal period. Most typically, 
XLI appears in infancy with scaling on the posterior neck, upper trunk, and 
extensor surfaces of the extremities. The scalp is often involved.In childhood, the 
boy who is affected has a "dirty-face" appearance, with an increase in involvement 
with age. 
Physical.Adherent brown scaling is evident in a widespread distribution that often 
produces a dirty-face appearance.In early childhood, scaling of the scalp, 
preauricular skin, and posterior neck may be prominent.Flexures may be involved, 
but palms and soles are usually spared. As the child ages, the mild scaling evident 
in the first few days of life becomes more evident and assumes a dirty yellow or 
brown color with dark, polygonal, firmly adherent scales.This generalized eruption 
tends to fade on the head but becomes more prominent on the trunk and 
extremities, particularly on the extensor surfaces of the legs.Scaling has a tendency 
to be more noticeable in cold and dry weather, improving in the summer 
months.Hair and nails are normal in XLI. Corneal opacities may be evident with 
slit-lamp examination both of adults who are affected and of women who are 
carriers. The flowerlike opacities in the posterior stroma are common findings. 
Approximately 10% of males who are affected and female carriers have diffuse 
deposits in the posterior capsule or corneal stroma that does not affect vision. 
Cryptorchidism occurs in 20% of patients. A few cases of testicular cancer have 
developed in patients with XLI and cryptorchidism.Central nervous system 
electroencephalographic changes have been noted in a few patients.STS deficiency 
slows the delivery of an infant because of insufficient cervical dilation. A relative 
failure occurs in the response to intravenous oxytocin. Since both are indications 
for cesarean delivery or forceps delivery, an increased perinatal morbidity and 
mortality may occur. 
Syndromes of genetic contiguity have been described. As a result of broader 
chromosomal deletions, they may have XLI and additional phenotypical 
abnormalities, which include short stature, chondrodysplasia punctata, mental 
retardation, and Kallmann syndrome (hypogonadotrophic hypogonadism). 
Lab Studies: Diagnosis of patients with XLI and female carriers is based on 
biochemical and genetic analysis. Genetic analysis currently is the most accurate 
diagnostic method in most patients. XLI can be diagnosed by assaying STS 
activity in the placenta or in the skin fibroblasts, keratinocytes, or lymphocytes of 
patients after birth. Patients show a deficiency of arylsulfatase C, which can be 
demonstrated by biochemical testing. Polymerase chain reaction (PCR) and 
Southern blot testing are useful for the genetic diagnosis of XLI, although a few 
patients with XLI carrying point mutations rather than deletions may be missed. 
PCR is not applicable for carrier detection.XLI can be diagnosed prenatally using 
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fluorescence in situ hybridization. Maternal peripheral blood metaphase spreads 
may display 2 hybridization signals on one of the X chromosomes (1 in the STS 
region [band Xp22.3] and 1 in the centromeric region), but only 1 hybridization 
signal (in the X centromeric region) on the other X chromosome; therefore, one of 
the X chromosomes has a deletion in the band Xp22.3 region, a result consistent 
with the carrier status for STS deficiency and XLI. In metaphase spreads from 
amniotic fluid samples, the X chromosome shows 1 hybridization signal in the 
control region, but no hybridization signal in the STS region. Therefore, the X 
chromosome of this male fetus has a deletion in the STS region, a result consistent 
with XLI. The deficit in placental STS blocks placental steroid synthesis, resulting 
in excretion of maternal urinary steroids in much lower amounts than normal. 
Incorporating unconjugated estriol in maternal serum into the calculation of risk 
increases the yield of screenings performed during pregnancy for detection of fetal 
chromosomal and structural anomalies. 
The differential diagnosis of low and undetectable levels of unconjugated estriol in 
maternal serum includes XLI and serious fetal pathologies (e.g. adrenal 
insufficiency, anencephaly, Down syndrome). To diagnose XLI, examine the urine 
of these pregnant women for low levels of nonhydrolyzed sulfated steroids. 
Histologic Findings.Histologic changes of XLI often are subtle. Biopsy specimens 
from ichthyotic skin with mild scaling may appear normal. Specimens obtained 
from regions of thick scaling (e.g. anterior aspect of legs, extensor aspect of arms) 
show mild-to-moderate compact laminated eosinophilic orthokeratotic 
hyperkeratosis, with a normal or slightly thickened granular layer 3-4 cells thick, 
mild acanthosis, well-preserved rete ridges, and a sparse perivascular and 
periappendageal lymphohistiocytic infiltrate.  
Ultrastructurally, keratohyaline granules are increased in size and number. Normal-
appearing keratinocytes appear linked by desmosomal disks all the way up into the 
stratum corneum, where the anucleated cells have increased numbers of 
melanosomes, which may account for the dark coloration of scaling in XLI.  
Treatment.Topical keratolytics, emollients, and hydrating agents are used to 
reduce scaling.Topical isotretinoin may be beneficial. In a small study, the topical 
receptor-selective retinoid tazarotene was efficacious. 
Surgical Care: In cases with cryptorchidism, consider surgical intervention if 
spontaneous descent has not occurred by age 1 year.  
Consultations.An ophthalmologist may detect corneal opacities. An obstetrician 
should be involved for higher risk delivery in future pregnancies. 
Further Outpatient Care: Address the risk for testicular carcinoma by 
monitoring patients with periodic physical examinations. 
Prognosis: XLI is a clinically mild genetic disorder. Some morbidity may occur in 
terms of cosmesis for adolescent boys. 
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19.5. Keratosis Palmaris et Plantaris 
 
Palmoplantar keratoderma (PPK) constitutes a heterogeneous group of disorders 
characterized by thickening of the palms and the soles of individuals who are 
affected. The condition may be subdivided into hereditary forms, acquired forms, 
and syndromes with PPK as an associated feature.  
Hereditary forms may be localized to the hands and the feet, or they may be 
associated with a more generalized skin disorder. Classification of hereditary PPK 
is frequently confusing, and a simple working classification is outlined below. This 
classification incorporates 3 factors: (1) the specific morphology and distribution 
of the palmoplantar keratosis, (2) the presence of associated cutaneous and non-
cutaneous ectodermal disease in sites other than the palms and the soles, and (3) 
the presence or absence of histologic epidermolysis. A diffuse pattern of PPK 
describes uniform involvement of the palmoplantar surface. Focal keratosis refers 
to localized areas of hyperkeratosis located mainly on pressure points. Punctate 
keratoderma features small, hyperkeratotic papules, spicules, or nodules on the 
palms and the soles.  
 
Diffuse Hereditary PPK without Associated Features 
Diffuse non-epidermolytic PPK 
Synonyms include diffuse NEPPK, Thost-Unna disease, and PPK diffusa 
circumscripta. Diffuse non-epidermolytic palmoplantar keratoderma is inherited in 
an autosomal dominant fashion. It often presents within the first 2 years of life.  
Clinical features include the following:  
•Even, thick, diffuse hyperkeratosis is present over the palms and the soles.  
•Red band at the periphery of the keratosis is frequent.  
•Aberrant keratotic lesions may appear in the dorsum of the hands, the feet, the 
knees, and the elbows.  
•Hyperhidrosis may be present.  
•Nails may be thickened.  
Histologic findings include orthokeratotic hyperkeratosis associated with 
hypergranulosis or normogranulosis and moderate acanthosis. Changes are 
nonspecific and common to many varieties of keratoderma.  
Molecular biology features include linkage to type II keratin locus on band 12q11-
13. K1 gene mutation was reported in a single family.  
Treatmentincludes the following: topical keratolytics, such as 6% salicylic acid in 
white soft paraffin or a gel of 6% salicylic acid in 70% propylene glycol; benzoic 
acid compounds; and oral retinoids.  
 
Diffuse epidermolytic PPK 
Synonyms include diffuse EPPK, Vorner disease, and PPK cum degeneratione 
granulosa. This form is the most common type of hereditary PPK. It is inherited in 
an autosomal dominant fashion. Onset occurs within the first year of life.  
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The clinical features are phenotypically similar to NEPPK.  
Thehistologic features are characterized by epidermolytic hyperkeratosis, which 
differentiates it from NEPPK.  
Molecular biology features include a mutation in the highly conserved 1A rod 
domain segment of the keratin 9 gene on chromosome 17.  
Treatment includes oral retinoids and topical calcipotriol.  
 
Progressive PPK 
Synonyms include PPPK, Greither disease, and PPK trangrediens et progrediens. 
Progressive PPK is inherited in an autosomal dominant fashion. Onset occurs in 
children aged 8-10 years.  
Clinical features include the following:  
•Diffuse PPK extends onto the dorsa of the hands and the feet (trangrediens), with 
characteristic involvement of the Achilles tendon.  
•Hyperhidrosis and intrafamilial phenotypic variation are common.  
•The condition tends to be worse during childhood, static after puberty, and 
improves in the fifth decade of life.  
The histologic features are nonspecific, with orthohyperkeratosis and absence of 
granular cell degeneration.  
 
Palmoplantar keratosis Gamborg-Neilson 
Synonyms include Gamborg-Nielson keratoderma. Palmoplantar keratosis 
Gamborg-Neilson is inherited in an autosomal recessive fashion.  
Clinical features include the following:  
•Severe form of PPK has been delineated in 2 families with 6 patients in Sweden.  
•Thick, diffuse keratoderma with knuckle pads and occasional keratosis on the 
dorsa of the hands has been described.  
•Mutilating changes due to constricting bands surrounding the fingers have also 
been described.  
 
Diffuse Hereditary PPK with Associated Features 
Diffuse PPK is associated with extrapalmoplantar skin involvement in several 
inherited disorders of keratinization. The more common conditions are outlined 
below.  
 
Mal de Meleda 
Synonyms include keratosis extremitatum hereditaria trangrediens et progrediens. 
This condition is rare. The prevalence is 1 case in 100,000 population. Initially, it 
was described in inhabitants of the Adriatic Island of Meleda (Miljet).  
Mal de Meleda is inherited in an autosomal recessive fashion. Onset occurs in 
early infancy.  
Clinical features include the following:  
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•Diffuse, thick keratoderma with a prominent erythematous border that spreads 
onto the dorsa of the hands and the feet  
•Constricting bands around digits resulting in spontaneous amputation  
•May have well-circumscribed psoriasis-like plaques or lichenoid patches on the 
knees and the elbows  
•Hyperhidrosis  
•Periorbital erythema and hyperkeratosis  
•Nail changes (koilonychia, subungual hyperkeratosis)  
•Lingua plicata, syndactyly, hair on the palms and the soles, high arched palate, 
and left-handedness (These are all associated features.)  
Molecular biology features include linkage analyses in 2 large families that have 
shown strong evidence of localization to 8qter.  
Treatment includes oral retinoids.  
 
PPK mutilans Vohwinkel 
Synonyms include mutilating keratoderma, Vohwinkel syndrome, and 
palmoplantar keratoderma mutilans. PPK mutilans Vohwinkel is inherited in an 
autosomal dominant fashion. Onset occurs in infancy.  
Clinical features include the following:  
•This condition presents in infants as a honeycomb-like keratosis of the palms and 
the soles.  
•Later-forming, constricting, fibrous bands appear on the digits and lead to 
progressive strangulation and autoamputation.  
•Starfish-shaped keratosis may occur on the dorsa of the fingers and the knees.  
•Alopecia, deafness, spastic paraplegia, myopathy, ichthyosiform dermatosis, and 
nail abnormalities are associated.  
Molecular biology includes a loricrin gene mutation (1q21).  
Treatment includes oral retinoids.  
 
Mutilating PPK with periorificial keratotic plaques 
Synonyms include Olmsted syndrome. This condition is inherited in an autosomal 
dominant fashion. Onset occurs in the first year of life.  
Clinical features include the following:  
•Symmetric, sharply defined PPK surrounded by erythema with flexion 
deformities of the digits lead to constriction and spontaneous amputation.  
•Periorificial keratosis  
•Onychodystrophy  
•Perianal involvement, variable leukokeratosis  
Treatment includes etretinate and topical tretinoin.  
 
PPK with sclerodactyly 
Synonyms include Huriez syndrome. PPK with sclerodactyly is inherited in an 
autosomal dominant fashion. Onset occurs in infancy.  
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Clinical features include the following: sclerodactyly, diffuse keratoderma more 
marked on the soles than the palms, nail abnormalities, hypohidrosis,associated 
with squamous cell carcinoma. 
Histologic findings include the following:  
•A biopsy sample of keratoderma shows acanthosis, accentuation of the granular 
layer, and orthohyperkeratosis.  
•On electron microscopy, dermoepidermal junctions and desmosomes are normal; 
however, dense bundles of tonofilaments are seen in the epidermal layer. The 
granular layer shows large, coarse, clumped keratohyalin.  
•A biopsy sample of the scleroatrophic area shows similar changes with thinning 
of the elastic fibers.  
 
PPK with periodontitis 
Synonyms include Papillon-Lefèvre syndrome. The frequency of PPK with 
periodontitis is 4 cases per 1 million population. This condition is inherited in an 
autosomal recessive fashion. The male-to-female ratio is equal. Onset occurs in the 
first and fifth year of life.  
Clinical features include the following:  
•Diffuse trangrediens palmoplantar keratosis may be observed.  
•Unless treated, periodontosis results in severe gingivitis and loss of teeth by age 5 
years.  
•Patients exhibit increased susceptibility to infection.  
•This possibly is a disorder of leukocyte function, which accounts for prominent 
gingival and cutaneous infections.  
•Some reports suggest a disturbance in leukocyte motility and bacteriocidal 
function that causes recurrent infections.  
•Scaly, erythematous lesions are often observed over the knees, the elbows, and 
the interphalangeal joints.  
•Hyperhidrosis and malodor may be present. 
Histologic findings include the following:  
•Findings are nonspecific, but evidence of hyperkeratosis with irregular 
parakeratosis and moderate perivascular infiltration exists.  
•Electron microscopic features include lipid-like vacuoles in corneocytes and 
granulocytes, a reduction in tonofilaments, and irregular keratohyalin granules.  
Molecular biology findings include the following:  
•Gene locus is mapped to band 11q14-q21.  
•Cathepsin C gene is of possible importance. 
Treatment includes dental clearance and appropriate antibiotic therapy for 
periodontitis and oral retinoids.  
 
Hidrotic ectodermal dysplasia 
Synonyms include Clouston syndrome. Hidrotic ectodermal dysplasia is inherited 
in an autosomal dominant fashion.  
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Clinical features include the following: diffuse, papillomatous PPK;dystrophy of 
the nails, universal sparsity of hair;sensorineural deafness, polydactyly, syndactyly, 
finger-clubbing, mental retardation, dwarfism, photophobia, and strabismus are 
associated. Biochemically, depletion of hair matrix protein may account for 
clinical features.  
Molecular biology findings: Clouston syndrome is mapped to band 13q11-q12.1.  
Treatment of all types of hereditary and keratodermas is difficult. The most 
known therapeutic options only result in short-term improvement and are 
frequently compounded by unwanted adverse effects. Treatment tends to be 
symptomatic and may vary from simple measures, such as saltwater soaks and 
paring, to topical keratolytics, systemic retinoids, or reconstructive surgery with 
total excision of the hyperkeratotic skin followed by grafting. The mainstays of 
treatment include the following. The use of topical keratolytics is common, 
particularly in patients with limited keratoderma. Examples include 5-10% 
salicylic acid, 10% lactic acid, or 10% urea in a suitable base. Topical retinoids, 
such as tretinoin (0.01% gel and 0.1% cream), are effective, but treatment is often 
limited by skin irritation. Consider potent topical steroids with or without 
keratolytics in dermatosis with an inflammatory component. Treatment with 5% 5-
fluorouracil has produced dramatic results in spiny keratoderma, but its use in 
other keratodermas has not been evaluated. Oral retinoids are effective, especially 
in some hereditary PPKs, such as mal de Meleda, Papillon-Lefèvre syndrome, and 
erythrokeratoderma variabilis. Most hereditary PPKs require long-term treatment. 
Results indicate that acitretin is comparable to etretinate. Intermittent therapy 
should be attempted whenever possible. To limit unacceptable long-term adverse 
effects, the optimal dosage of acitretin in adults is 30-35 mg/d (0.5-1 mg/kg/d for 
adults and 0.5 mg/kg/d for children). Treatment of women of childbearing age 
results in long-term potential teratogenic effects. The maintenance dose can be 
reduced to 25 mg/d. Caution is advised if the patient has an epidermolytic form 
because large erosions may occur with retinoid therapy. Patients should be started 
on a low dose, and the dosage should be carefully increased to avoid flaring the 
disease and/or causing erosions.  
Specific therapies dependent on the PPK type may be used. Psoralens and 
ultraviolet A (PUVA) or re-PUVA (a combination of oral retinoids and PUVA) 
may be indicated in PPK secondary to psoriasis or eczema. Patients with 
oculocutaneous tyrosinemia may benefit from dietary restriction of phenylalanine 
and tyrosine. Improvement has been seen in nonhereditary PPK after oral 1-alpha, 
25-dihydroxyvitamin D-3.  
Regular chiropody, careful selection of footwear, and treatment of fungal 
infections are important. Dermabrasion may permit increased penetration of topical 
agents, and carbon dioxide laser treatment may be beneficial in limited 
keratodermas. For severe and refractory keratoderma, consider surgery. Total 
excision of hyperkeratotic skin followed by grafting has been successful in a 
number of cases. Paraneoplastic keratodermas are generally refractory to local 
treatment and may only respond to the removal of the underlying neoplasm.  
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19.6. Epidermolysis Bullosa 
 
Synonyms and related keywords: epidermolysis bullosa, EB, epidermolysis 
bullosa simplex, EBS, hemidesmosomal epidermolysis bullosa, HEDB, junctional 
epidermolysis bullosa, JEB, dystrophic epidermolysis bullosa, recessive dystrophic 
epidermolysis bullosa, RDEB 
 
Background.Epidermolysis bullosa (EB) is a group of inherited bullous disorders 
characterized by blister formation in response to mechanical trauma. Historically, 
EB subtypes have been classified according to skin morphology. Recent 
discoveries of the molecular basis of EB have resulted in the development of new 
diagnostic tools, including prenatal testing. Based on a better understanding of the 
basement membrane zone (BMZ) and the genes responsible for its components, 
new treatments (e.g. gene therapy) may provide solutions to the skin fragility 
found in patients with EB.  
Pathophysiology.EB is classified into 3 major categories including (1) 
epidermolysis bullosa simplex (EBS; intraepidermal skin separation), (2) 
junctional epidermolysis bullosa (JEB; skin separation in lamina lucida or central 
BMZ), and (3) dystrophic epidermolysis bullosa (DEB; sublamina densa BMZ 
separation). Researchers recently have proposed a new category termed 
hemidesmosomal epidermolysis bullosa (HEB), which produces blistering at the 
hemidesmosomal level in the most superior aspect of the BMZ. EBS usually is 
associated with little or no extracutaneous involvement, while the more severe 
hemidesmosomal, junctional, and dystrophic forms of EB may produce significant 
multiorgan system involvement.  
Frequency.According to the National Epidermolysis Bullosa Registry, the number 
of EB cases in Norway is 54.0 cases per million live births, in Japan are 7.8 cases 
per million live births, and in Croatia are 9.6 cases per million live births.  
Mortality/Morbidity.Infancy is an especially difficult time for EB patients. 
Generalized blistering caused by any subtype may be complicated by infection, 
sepsis, and death. Severe forms of EB increase the mortality risk during infancy. 
Patients with the Herlitz or letalis form of JEB have the highest risk during infancy 
with an estimated mortality rate of 87% during the first year of life. In patients 
with EB that survive childhood, the most common cause of death is metastatic 
squamous cell carcinoma (SCC). This skin cancer occurs specifically in patients 
with recessively inherited epidermolysis bullosa (RDEB) who most commonly are 
aged 15-35 years. In contrast, dominantly inherited EBS and DEB and milder 
forms of JEB may not affect a patient's life expectancy adversely.  
Age.Onset of EB is at birth or shortly after. The exception occurs in mild cases of 
EBS, which may remain undetected until adulthood or occasionally remain 
undiagnosed.  
History.Important general points include age of onset; size, frequency, and 
location of blisters; possible inciting factors; prior diagnostic attempts; prior 
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therapies; and extent of pain or pruritus. In the review of systems, elicit 
information including alteration of growth/development and evidence of mucosal 
involvement, including oral, nasopharyngeal, ocular, genitourinary, GI, or 
respiratory symptoms. Inquire about a family history of blistering disease.  
Physical.Perform a complete physical examination with an emphasis on inspection 
of all skin, as well as conjunctival, oral, and genital mucosae. Evaluate the size, 
location, and character of blisters. Attempt to assess the general level at which 
lesions split. Usually, superficial blisters manifest as crusted erosions, 
intraepidermal blisters are flaccid and may expand under pressure, and intralamina 
lucida blisters are tense and heal with atrophy but no scarring. Sublamina densa 
blisters heal with scarring and milia formation. Assess for involvement of nails, 
hair, or teeth.  
EBS is a collection of keratin disorders characterized by intraepidermal blistering 
with relatively mild internal involvement. Lesions typically heal without scarring. 
Most commonly, these diseases are dominantly inherited, but recessively inherited 
cases have been reported. The more severe EBS subtypes include Koebner, 
Dowling-Meara, and Weber-Cockayne forms. An EBS variant associated with 
mottled pigmentation has been described in several families. 
Mild EBS: Weber-Cockayne subtype is the most common form of EBS. Blisters 
usually are precipitated by a clearly identified traumatic event. They can be mild to 
severe and most frequently occur on the palms and soles. Hyperhidrosis can 
accompany this disorder. 
Severe EBS: Usually, a generalized onset of blisters occurs at or shortly after birth. 
Hands, feet, and extremities are the most common sites of involvement. 
Palmoplantar hyperkeratosis and erosions are common, especially in Koebner 
EBS. Dowling-Meara EBS involves more oral mucosa and manifests with grouped 
herpetiform blisters (hence the term EBS herpetiformis). 
HEB includes 2 rare diseases. The first arises from a disorder of the protein plectin 
(HD1) and is associated with muscular dystrophy. The second arises from a defect 
of the β6γ4 integrin receptor and is associated with pyloric atresia. Each disease 
shows intraepidermal blistering at the most basal aspect of the lower cell layer. 
EB with muscular dystrophy: This condition is characterized initially by variable 
blistering activity, followed by onset of muscular dystrophy later in life. The 
degree of blistering activity does not correlate necessarily with the degree of 
muscular dystrophy. Some patients can present with dental abnormalities. 
EB with pyloric atresia: this condition always is associated with pyloric atresia at 
birth and usually is accompanied by severe generalized blistering. In most patients, 
prognosis is poor despite correction of the pyloric atresia because the internal 
involvement is extensive. While this subtype typically is fatal during infancy, some 
patients with a milder case of the disease have survived into childhood. 
JEB is a collection of diseases characterized by intralamina lucida blistering. 
Primary subtypes include a lethal subtype termed Herlitz or JEB letalis, a nonlethal 
subtype termed JEB mitis, and a generalized benign type termed generalized 
atrophic benign epidermolysis bullosa (GABEB). 
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Lethal JEB: The Herlitz or letalis form of JEB is characterized by generalized 
blistering at birth and arises from an absence or a severe defect in expression of the 
anchoring filament glycoprotein laminin 5. Patients with lethal forms of JEB show 
characteristic periorificial erosions around the mouth, eyes, and nares, often 
accompanied by significant hypertrophic granulation tissue. Multisystemic 
involvement of the corneal, conjunctival, tracheobronchial, oral, pharyngeal, 
esophageal, rectal, and genitourinary mucosae is present. Internal complications of 
the disease include a hoarse cry, cough, and other respiratory difficulties. Patients 
with - Herlitz JEB are at increased risk for death from sepsis or other 
complications secondary to the profound epithelial disadhesion, and usually, they 
do not survive past infancy. 
Non-lethal JEB: Patients with JEB manifesting generalized blistering who survive 
infancy and clinically improve with age have JEB mitis. Usually, these patients do 
not present with the same type of hoarse cry or other significant respiratory 
symptoms as do patients with the Herlitz form. Instead, scalp, nail, and tooth 
abnormalities increasingly may become apparent. Periorificial erosions and 
hypertrophic granulation tissue can be present. Mucous membranes often are 
affected by erosions, resulting in strictures. Some patients with JEB mitis can 
present with blistering localized to the intertriginous regions. 
GABEB: This is a relatively mild subtype characterized by generalized cutaneous 
blistering and presenting at birth. Blistering activity is worsened by increased 
ambient temperature, and blisters heal with a distinctive atrophic appearance. 
Extracutaneous involvement is rare, with the exception of teeth. Hypoplastic 
enamel formation results in significant tooth decay. Nail dystrophies and alopecia 
are other common clinical manifestations. Individuals with GABEB have the 
potential to bear children and have a typical life expectancy. 
DEB is a group of diseases caused by defects of anchoring fibrils. Blisters heal 
followed by dystrophic scarring. Formation of milia (1- to 4-mm white papules) 
results as a consequence of damage to hair follicles. 
Dominantly inherited DEB: The onset of disease usually is at birth or during 
infancy, with generalized blistering as a common presentation. With increasing 
age, an evolution to localized blistering is present. A common variant described by 
Cockayne-Touraine has an acral distribution and minimal oral or tooth 
involvement. Another variant described by Pasini features more extensive 
blistering, scar-like papules on the trunk (termed albopapuloid lesions), and 
involvement of the oral mucosa and teeth. Dystrophic or absent nails are common 
in both of these dominantly inherited DEB variants. 
RDEB: This group of diseases ranges from mild to severe in presentation. A 
localized form, termed RDEB mitis, often involves acral areas and nails but shows 
little mucosal involvement. This subtype also demonstrates clinical manifestations 
similar to the dominantly inherited forms of DEB.  
Severe RDEB, as described by Hallopeau-Siemens, usually shows generalized 
blistering at birth and subsequent extensive dystrophic scarring that is most 
prominent on the acral surfaces. This can produce pseudosyndactyly (mitten-hand 
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deformity) of the hands and feet. Flexion contractures of the extremities are 
increasingly common with age. Nails and teeth also are affected. Involvement of 
internal mucosa can result in esophageal strictures and webs, urethral and anal 
stenosis, phimosis, and corneal scarring. Malabsorption commonly results in a 
mixed anemia resulting from a lack of iron absorption, and overall malnutrition 
may cause failure to thrive. Patients with severe RDEB who survive to childhood 
are at significant risk of developing aggressive SCC in areas of chronic erosions. 
Causes.Many stratified squamous epithelial tissues, such as the skin and oral 
mucosa, contain a complex BMZ. The BMZ is composed of many specialized 
components that combine to form anchoring complexes. At the superior aspect of 
the BMZ, keratin-containing intermediate filaments of the basal cell cytoskeleton 
insert on basal cell plasma membrane condensations termed hemidesmosomes. 
Anchoring filaments extend from the basal cell plasma membrane into the 
extracellular environment and span the lamina lucida, connecting 
hemidesmosomes with the lamina densa. At the most inferior aspect of the BMZ, 
type VII collagen-containing anchoring fibrils extend from the lamina densa into 
the papillary dermis, connecting the lamina densa to anchoring plaques, trapping 
interstitial collagen fibrils. Thus, the cutaneous BMZ connects the extensive basal 
cell cytoskeletal network with the abundant network of interstitial collagen fibrils 
in the dermis.  
Keratin filaments: Keratins 5 and 14 combine to form intermediate filaments in 
basal keratinocytes. Keratins contain a central alpha-helical rod with several non-
helical interruptions, as well as non-helical carboxyterminal and aminoterminal 
regions. The regions of highest conservation between the keratins are located on 
the ends of the keratin rod in the helix boundary motifs. Keratin intermediate 
filaments insert upon electron-dense structures termed hemidesmosomes.  
Complications.SCC: arising in chronic wounds or scars of RDEB, this form of 
SCC is invasive and has high metastatic potential. Other EB subtypes do not show 
a tendency to develop SCC. 
Pseudosyndactyly (mitten-hand deformity). This is a frequent complication in 
patients with RDEB but is rare in other subtypes. In this disorder, skin grows 
around the digits because of repeated blistering and dystrophic healing. Over time, 
the digits are encased in a mitten of skin. Therapeutic surgical approaches are 
available, but the rate of recurrence is high. 
Mucosal complications. Patients with RDEB often have esophageal manifestations. 
Esophageal scarring secondary to repeated blistering and healing results in 
dysphagia from webbing, strictures, or stenosis. These complications are rare in 
patients with EBS but occur in patients with Herlitz and other nonlethal forms of 
JEB and dominantly inherited DEB. No cases of esophageal involvement have 
been reported in the generalized benign atrophic form of JEB. While patients with 
the Herlitz form of JEB have the greatest tendency for tracheolaryngeal 
involvement, RDEB may involve the tracheolaryngeal mucosa as well. 
Lab Studies.Obtain a skin biopsy following a thorough history and physical 
examination. Routine histologic analysis is useful only for excluding other causes 
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of blistering. When EB is suspected, the best approach is to obtain 2 biopsy 
specimens. Analyze one specimen using electron microscopy (EM) and the other 
using immunofluorescent microscopy. 
Evaluate anemia using CBC count with iron studies in patients with severe EB, 
especially RDEB.Evaluate infection using bacterial cultures from poorly healing 
wounds or wounds that appear infected. 
Imaging Studies.Evaluate GI dysfunction: Esophageal strictures associated with 
JEB, DEB, or the pyloric atresia associated with a rare form of JEB can be 
visualized best by an upper GI series or endoscopy. 
Other Tests.Evaluate nutrition using serum albumin, height and weight curves, 
diet diaries, and other analyses of nutrition and growth in patients with severe 
EB.Evaluate contractures by establishing the range of motion of limbs and digits to 
monitor contractures and effectiveness of physical therapy.Routine light 
microscopy can be used only to exclude other causes of blistering and cannot be 
used to make the diagnosis of EB. 
Procedures.Electron microscopy.Obtain a biopsy specimen from a fresh blister. 
The best way to obtain a fresh blister is to induce it in the office by gently rotating 
a pencil eraser back and forth over an area of skin until epidermal separation is 
appreciated. Perform the biopsy at the edge of the blister, sampling both 
unblistered and blistered skin. Place the specimen into the appropriate holding 
medium (check with the laboratory beforehand) and immediately send it for 
transmission EM. EM biopsy holding medium usually contains glutaraldehyde. 
EM is the criterion standard for determining the level of blistering. EM can provide 
additional information on BMZ morphology that can be helpful in making the 
diagnosis. For example, intermediate filament clumping indicates Dowling-Meara 
EBS. Rudimentary hemidesmosomes often are found in JEB subtypes. Absent or 
altered anchoring fibrils often occur in DEB subtypes. 
Immunofluorescent microscopy can provide information on the level of the 
blistering.Obtain a biopsy specimen at the edge of a fresh blister for optimal 
results. Make arrangements with the laboratory before obtaining the specimen, and 
promptly send it for analysis. Zeus-holding medium is used widely for 
immunofluorescent microscopy. 
Immunomapping with antibodies to a hemidesmosomal antigen (e.g. BP230 
obtained from sera of a patient with bullous pemphigus) and an antibody to a 
lamina densa protein (e.g. type IV collagen) can distinguish EBS, JEB, and DEB. 
For example, in EBS, both antigens localize to the floor. In JEB, BP230 localizes 
to the roof of the blister, while type IV collagen localizes to the floor. In DEB, 
both antigens localize to the roof of the blister. 
In addition to providing information about the level of the skin separation, 
immunofluorescent microscopy can be useful in providing an important clue 
regarding the underlying molecular defect.  
DNA mutation analysis: perform mutation analysis after immunofluorescent 
microscopy. This is the final step in elucidating the underlying molecular defect, 
and in most cases, it reduces the number of genes to be screened. DNA is extracted 
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from blood of the patient and family members. Initial mutation screening is 
performed by restriction fragment-length polymorphism analysis, hotspot analysis, 
and finally, direct DNA sequencing. 
Prenatal diagnosis: once the mutations are identified in a family, reliable prenatal 
diagnosis is possible. DNA for prenatal diagnosis can be obtained as a chorionic 
villi sample as early as the ninth week of gestation. Alternatively, amniotic fluid 
drawn after the eleventh week can provide the necessary DNA. Schedule the 
procedure in close conjunction with the diagnostic laboratory that will receive the 
sample. 
Medical Care.Skin involvement is as follows. Wound healing: this process is 
impaired by multiple factors including foreign bodies, bacteria, nutritional 
deficiencies, tissue anoxia, and aging. Exogenous agents contributing to 
impairment of wound healing include glucocorticoids and penicillamine. 
Optimizing wound healing in patients with EB involves controlling all of these 
factors. Patients with Herlitz JEB heal slowly, which may be because of a defect in 
laminin 5 (a protein involved intimately in keratinocyte adhesion and migration). 
Infection.Extensive areas of denuded skin represent loss of the stratum corneum 
barrier to microbial penetration. Accumulation of serum and moisture on the 
surface enhances the growth of bacteria. Patients with severe EB subtypes may 
have immunologic abnormalities, including decreased lymphocyte production or a 
poor nutritional status that lowers resistance to infections. Staphylococcus aureus 
and Streptococcus pyogenes are the usual causative organisms, but gram-negative 
infections with bacteria, such as Pseudomonas aeruginosa, also can occur. Patients 
also have increased susceptibility to developing sepsis. Prevention of infection is 
the preferred strategy. With extensive areas of crusting and denudation, a strict 
wound care regimen should be followed. Such a regimen entails regular whirlpool 
therapy followed by application of topical antibiotics. The wound should be 
covered with semiocclusive nonadherent dressings. Do not apply adhesive tape 
directly to the skin. Self-adhering gauze or tape is a better choice for keeping 
dressings in place. 
Tumors. SCC often arises in chronic cutaneous lesions in patients with EB. SCC 
often occurs at multiple primary sites, which is especially true for patients with 
RDEB. In the non-EB population, cutaneous SCC arises most frequently in sun-
exposed areas and primarily affects individuals with skin types I and II after the 
fourth decade of life. In contrast, the distribution of cutaneous SCC in patients with 
RDEB is different. In RDEB, SCC affects all skin types, does not show a 
predilection for sun-exposed sites, and peak incidence begins to increase 
dramatically in the second and third decades of life.Careful surveillance of non-
healing areas is important.  
GI management. The most disabling complication is esophageal lesions, which are 
found in Hallopeau-Siemens and inverse RDEB subtypes, Dowling-Meara, letalis 
EBS subtypes, and all JEB forms except localized and progressiva/neurotropica. 
These lesions are managed in several ways. One medical approach is to use 
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phenytoin and oral steroid elixirs to reduce the symptoms of dysphagia. In 
addition, if oral candidiasis is present, an anticandidal medication is helpful. 
Eye lesions. Patients with EBS, particularly those with the Weber-Cockayne and 
Dowling-Meara subtypes, can experience recurrent blepharitis in 1 or both eyes 
along with bullous lesions of the conjunctivae. Patients with JEB and Hallopeau-
Siemens DEB can experience corneal ulcerations, corneal scarring, obliteration of 
tear ducts, and eyelid lesions. Cicatricial conjunctivitis also can occur in patients 
with the RDEB Hallopeau-Siemens subtype. Corneal erosions are treated 
supportively with application of antibiotic ointment and use of cycloplegic agents 
to reduce ciliary spasm and provide comfort. Avoid using tape to patch the eye 
because of frequent blistering of the skin under the adhesive. Chronic blepharitis 
can result in cicatricial ectropion and exposure keratitis. Moisture chambers and 
ocular lubricants are used commonly for management. This disorder also has been 
treated with full-thickness skin grafting to the upper eyelid; however, complete 
correction is difficult to obtain. 
Oral care. Good dental hygiene is essential for patients with EB, and regular visits 
to the dentist are recommended. If possible, a dentist familiar with EB should be 
consulted. Despite their best efforts, many patients with JEB and DEB develop 
dental caries because of enamel defects. In addition, significant oral mucosal 
involvement can accompany severe forms of JEB and DEB. Avoid harsh 
mouthwashes containing alcohol. Normal saline rinses can help gently clean the 
mucosal surfaces.  
Surgical Care.GI management: Esophageal dilation has been helpful in relieving 
strictures. Removal of esophageal strictures by colonic interposition has proved 
effective in cases of advanced disease. Gastrostomy tube insertion has been 
effective in providing nutrition to individuals with esophageal strictures. 
Surgical restoration of the hand. Mitten deformity of the hand occurs frequently in 
patients with the Hallopeau-Siemens DEB subtype. Repeated episodes of blistering 
and scarring eventually result in fusion of the web spaces. As a result, fine 
manipulative skills and digital prehension are lost. Surgical procedures can correct 
this deformity, but a high rate of recurrence is seen with mitten pseudosyndactyly. 
Typically, the dominant hand has earlier recurrence. Recurrence appears to be 
delayed by the prolonged use of splinting in the interphalangeal spaces at night. 
Surgical excision of SCC. Invasive aggressive SCC is a particularly troubling 
complication of RDEB. When detected, excision of the carcinoma is indicated. 
Both Mohs and non-Mohs surgical approaches have been used. 
Skin equivalents: Artificial skin grafts, such as Apligraf (Organogenesis Inc, 
Canton, Mass), have been useful in facilitating healing of erosions in EB and in 
improving the overall quality of life of patients. While the short-term effects of 
Apligraf have been studied carefully, the long-term effects and the persistence of 
grafts remain in question. Only 2 of 11 skin samples showed evidence of allograft 
persistence by polymerase chain reaction (a sensitive technique capable of 
detecting a small number of keratinocytes and/or fibroblasts) 6 weeks after 
grafting. Therefore, while Apligraf may represent an effective short-term therapy 
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for treating chronic non-healing wounds in EB, claims that Apligraf offers a long-
term cure for EB remain unsubstantiated. 
Consultations.Genetic counseling.Genetic information provided by mutation 
analyses on EB candidate genes provides an immediate benefit to families of 
patients with EB. Siblings of a patient identified as a proband with recessively 
inherited EB that are considering children often want to know whether they carry 
the mutant allele.Most importantly, prenatal diagnosis of EB in affected families 
currently is a genetic-based protocol, providing that the patient identified as the 
original proband has had mutational analysis or identification of the defective 
gene. Currently, fetal skin biopsies and fetoscopy, with their increased risk of 
pregnancy loss, can be avoided by analyzing either a chorionic villus sample as 
early as 8-10 weeks or amniotic fluid in the second trimester. The development of 
highly informative intragenic and flanking polymorphic DNA markers in EB 
candidate genes, together with rapid screening of genetic hotspots, make genetic 
screening of high-risk pregnancy a viable option. 
Diet.Nutritional management.Increased needs: Extensive cutaneous injury is 
associated with marked alterations in both hemodynamic and metabolic responses, 
requiring increased caloric and protein intake for recovery. The burn patient has 
been studied extensively from both of these perspectives. Studies confirm that the 
development of nutritional deficiencies inhibits successful wound healing and the 
body's return to a normal hemodynamic and metabolic profile. 
Impediments to intake and absorption: oropharyngeal and GI lesions greatly 
threaten the nutritional well being of patients with EB. Complications include oral 
blistering, abnormal esophageal motility, strictures, dysphagia, diarrhea, 
malabsorption, and dental problems. Nutritional assessment taking these factors 
into account is essential for replenishing the malnourished patient. 
Activity.Inactivity as a result of pain and scarring can cause contractures to form. 
Physical therapy can be helpful in reducing limb and hand contractions and in 
maintaining the range of motion. EB is a genetic disease and no drugs are known 
to correct the underlying molecular defects. Prolonged use of steroids is 
contraindicated in the treatment of inherited forms of EB. Steroid-induced 
complications further warrant prohibiting their use. No other drugs, including 
phenytoin and tetracycline, have improved the blistering or epithelial disadhesion 
in EB significantly or consistently. 
Further Inpatient Care.When a patient with EB is hospitalized for severe 
blistering, treat the blisters aggressively with wound and nutritional management. 
Regular whirlpool therapy can help with gentle cleansing and debridement of 
wounds. Whirlpool therapy is a helpful adjunct available in most hospitals and 
assists in the care of inpatients with EB. 
Prevention.Prevention of trauma to the skin reduces blistering. Padding of limbs 
helps reduce unnecessary trauma.A soft mechanical diet helps reduce oral and 
esophageal erosions. 
Prognosis.EB is a lifelong disease. Some subtypes, especially the milder EB 
forms, improve with age. 
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XX. SEXUALLY TRANSMITTED DISEASES 
 
 
20.1. Syphilis 
 
Background.Treponema pallidum is the microaerophilic spirochete that causes 
syphilis, a chronic systemic venereal disease with multiple clinical presentations 
(i.e. the great imitator). Syphilis is characterized by episodes of active disease 
(primary, secondary, tertiary stages) interrupted by periods of latency. Since the 
diagnosis frequently is suspected after examination of skin lesions, dermatologists 
are recognized as experts in the diagnosis and treatment of syphilis. Syphilis is 
transmitted in 2 ways, either from intimate contact with infectious lesions (most 
common) or blood transfusions (blood collected during early syphilis), or it is 
transmitted transplacentally from an infected mother to her fetus.  
Pathophysiology.In acquired syphilis, the organism rapidly penetrates intact 
mucous membranes or microscopic dermal abrasions and, within a few hours, 
enters the lymphatics and blood to produce systemic infection. The central nervous 
system is invaded early in the infection; during the secondary stage, examinations 
demonstrate that more than 30% of patients have abnormal findings in the 
cerebrospinal fluid (CSF). During the first 5-10 years after infection, the disease 
principally involves the meninges and blood vessels, resulting in meningovascular 
neurosyphilis. Later, the parenchyma of the brain and spinal cord are damaged, 
resulting in parenchymatous neurosyphilis.  
Regardless of the stage of disease and location of lesions, 2 histopathologic 
hallmarks of syphilis have been noted including obliterative endarteritis and 
plasma cell–rich mononuclear infiltrates. Endarteritis is caused by the binding of 
spirochetes to endothelial cells, mediated by host fibronectin molecules bound to 
the surface of the spirochetes. The resultant endarteritis heals with scar tissue 
formation.  
The mononuclear infiltrates reflect a delayed-type hypersensitivity response to T. 
pallidum, and in certain individuals with tertiary syphilis, this response by 
sensitized T. lymphocytes and macrophages results in gummatous ulcerations and 
necrosis. Antigens of T. pallidum induce host production of treponemal antibodies 
and nonspecific reagin antibodies. Immunity to syphilis is incomplete. For 
example, host humoral and cellular immune responses may prevent the formation 
of a primary lesion (chancre) on subsequent infections with T. pallidum, but they 
are insufficient to clear the organism. This may be because the outer sheath of the 
spirochete is lacking immunogenic molecules, or it may be because of down-
regulation of helper T-cells of the TH1 class.  
Frequency.Syphilis remains prevalent in many developing countries and in some 
areas of North America, Asia, and Europe, especially Eastern Europe. In some 
regions of Siberia, as of 1999, prevalence was 1300 cases per 100,000 population.  
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Mortality/Morbidity.Although rarely seen by clinicians since the use of penicillin 
became widespread in the 1950s, the primary complications of syphilis in adults 
include neurosyphilis, cardiovascular syphilis, and gumma. Death resulting from 
syphilis continues to occur. One study found that of 113 recorded deaths resulting 
from sexually transmitted diseases, 105 were caused by syphilis, with 
cardiovascular and neurosyphilis accounting for the majority of these deaths. These 
figures have continued to increase since the emergence of the AIDS epidemic, 
since genital ulcer diseases (including syphilis) are cofactors for the sexual 
transmission of HIV. Additionally, untreated patients who are HIV seropositive 
have an increased risk for rapid progression to neurosyphilis and for its 
complications. In addition, patients with HIV are at greater risk for development or 
relapse of early symptomatic neurosyphilis for up to 2 years after treatment with 
intramuscular or intravenous penicillin.  
Congenital syphilis is the most serious outcome of syphilis in women. It has been 
shown that a higher proportion of infants are affected if the mother has untreated 
secondary syphilis, compared to untreated early latent syphilis. Since T. pallidum 
does not invade the placental tissue or the fetus until the fifth month of gestation, 
syphilis causes late abortion, stillbirth, or death soon after delivery in more than 
40% of untreated maternal infections. Neonatal mortality usually results from 
pulmonary hemorrhage, bacterial superinfection, or fulminant hepatitis.  
Sex.The male-to-female ratio has increased over the past 3 years, largely due to the 
increased rate of disease among men who have sex with other men. In 2003, it was 
approximately 5:1.  
Age.The incidence of syphilis peaks at age 15-34 years.  
History.Primary syphilis occurs within 3 weeks of contact with an infected 
individual. Patients usually present with a solitary red papule that rapidly forms a 
painless non-bleeding ulcer or chancre. The chancre usually heals within 4-8 
weeks, with or without therapy. 
Secondary syphilis usually presents with a cutaneous eruption within 2-10 weeks 
after the primary chancre and is most florid 3-4 months after infection. The 
eruption may be subtle; 25% of patients may be unaware of skin changes. 
Mild constitutional symptoms of malaise, headache, anorexia, nausea, aching pains 
in the bones, and fatigue often are present, as well as fever and neck stiffness. 
A small number of patients develop acute syphilitic meningitis and present with 
headache, neck stiffness, facial numbness or weakness, and deafness. 
The lesions of benign tertiary syphilis usually develop within 3-10 years of 
infection. The typical lesion is a gumma, and patient complaints usually are 
secondary to bone pain, which is described as a deep boring pain characteristically 
worse at night. Trauma may predispose a specific site to gumma involvement.CNS 
involvement may occur, with presenting symptoms representative of the area 
affected, i.e. brain involvement (headache, dizziness, mood disturbance, neck 
stiffness, blurred vision) and spinal cord involvement (bulbar symptoms, weakness 
and wasting of shoulder girdle and arm muscles, incontinence, impotence).  
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Some patients may present up to 20 years after infection with behavioral changes 
and other signs of dementia, which is indicative of neurosyphilis. 
A small percentage of infants infected in utero may have a latent form of infection 
that becomes apparent during childhood and, in some cases, during adult life. The 
earliest symptom that occurs prior to age 2 years is rhinitis (snuffles), soon 
followed by cutaneous lesions. After age 2 years, parents may note problems with 
the child's hearing and language development and with vision. Facial and dental 
abnormalities may be noted. 
Physical.Primary syphilis.The primary lesion (chancre) occurs on the penis or 
scrotum of 70% of men with syphilis and on the vulva, cervix, or perineum of 
more than 50% of women with syphilis. The primary lesion usually is a single 
ulcerated lesion with a surrounding red areola. The edge and base of the ulcer have 
a cartilaginous (button-like) consistency on palpation. The lesion is highly 
infectious; when abraded, it exudes a clear serum containing numerous T. pallidum 
organisms. Extragenital chancres occur most commonly above the neck, typically 
affecting the lips or oral cavity. The regional lymph nodes usually enlarge 
painlessly and are firm, discrete, and non-tender. 
Secondary syphilis.The protean manifestations of the secondary stage usually 
include localized or diffuse symmetric mucocutaneous lesions and generalized 
non-tender lymphadenopathy. The healing primary chancre may remain present in 
15-25% of patients.Initial lesions are bilaterally symmetric, pale red to pink (in 
light-skinned persons) or pigmented (in dark-skinned persons), discrete, round 
macules that measure 5-10 mm in diameter and are distributed on the trunk and 
proximal extremities. After several days or weeks, red papular lesions 3-10 mm in 
diameter appear. These lesions often become necrotic and are distributed widely 
with frequent involvement of the palms and soles.Tiny papular follicular syphilids 
involving hair follicles may result in patchy alopecia. In addition to the classic 
moth-eaten alopecia, a diffuse alopecia also has been reported.In 10% of patients, 
highly infectious papules develop at the mucocutaneous junctions and, in moist 
intertriginous skin, become hypertrophic and dull pink or gray (condyloma 
lata).From 10-15% of patients with secondary syphilis develop superficial mucosal 
erosions on the palate, pharynx, larynx, glans penis, vulva, or in the anal canal and 
rectum. These mucous patches are circular silver-gray erosions with a red areola. 
Ocular abnormalities, such as iritis, are a rare clinical finding, although anterior 
uveitis has been reported in 5-10% of patients with secondary syphilis. 
Less common findings include periostitis, arthralgias, meningitis, nephritis, 
hepatitis, and ulcerative colitis. 
Tertiary syphilis.Gummas may be identified on the skin, in the mouth, and in the 
upper respiratory tract. They appear most commonly on the leg just below the 
knee. Gummas may be multiple or diffuse but usually are solitary lesions that 
range from less than 1 cm to several centimeters in diameter. Cutaneous gummas 
are indurated, nodular, papulosquamous or ulcerative lesions that form 
characteristic circles or arcs with peripheral hyperpigmentation.The most common 
clinical finding on cardiovascular examination is a diastolic murmur with a 
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tambour quality, secondary to aortic dilation with valvular insufficiency. 
Symptomatic neurosyphilis produces various clinical syndromes that develop in 
approximately 5% of patients with syphilis who remain untreated. The most 
common presentation of meningovascular syphilis (diffuse inflammation of the pia 
and arachnoid along with widespread arterial involvement) is an indolent stroke 
syndrome involving the middle cerebral artery. Cranial nerve palsies and pupillary 
abnormalities occur with basilar meningitis. Argyll Robertson pupil, which occurs 
almost exclusively in neurosyphilis, is a small irregular pupil that reacts normally 
to accommodation but not to light. Tabes dorsalis presents with signs of 
demyelination of the posterior columns, dorsal roots, and dorsal root ganglia (e.g. 
ataxic wide-based gait and foot slap, areflexia and loss of position, deep pain and 
temperature sensations). Deep ulcers of the feet can result from loss of pain 
sensation.Rare findings include iritis, with possible adhesion of the iris to the 
anterior lens, producing a fixed pupil (not to be confused with Argyll Robertson 
pupil). 
Congenital syphilis. The manifestations of untreated congenital syphilis can be 
divided into those that are expressed prior to age 2 years (early) or after age 2 years 
(late). 
Early manifestations 
Early signs and symptoms include development of a diffuse rash, characterized by 
extensive sloughing of the epithelium, particularly on the palms, soles, and skin 
around the mouth and anus. A compilation of early clinical presentations of 
congenital syphilis in 9 studies involving a total of 212 infants included abnormal 
bone radiographs (61%), hepatomegaly (51%), splenomegaly (49%), petechiae 
(41%), other skin rashes (35%), anemia (34%), lymphadenopathy (32%), jaundice 
(30%), pseudoparalysis (28%), and snuffles (23%). A classic mucocutaneous sign 
is depressed linear scars radiating from the orifice of the mouth and termed 
rhagades (Parrot lines). 
Late manifestations 
Late signs and symptoms are rare and, if encountered, usually involve 
complications including interstitial keratitis, cranial nerve VIII deafness, corneal 
opacities, and/or recurrent arthropathy.  
The clinical manifestations of untreated congenital neurosyphilis present in 25% of 
patients older than age 6 years and correspond to those of adult neurosyphilis.  
Gummatous periostitis occurs in patients aged 5-20 years and tends to cause 
destructive lesions of the palate and nasal septum (saddle nose).  
Dental abnormalities may be evident, such as centrally notched and widely spaced, 
peg-shaped, upper central incisors (Hutchinson teeth) and sixth-year molars with 
multiple poorly developed cusps (mulberry molars).  
Peculiar bone findings include frontal bossing of Parrot and Higoumenakia sign, 
which is unilateral irregular enlargement of the sternoclavicular portion of the 
clavicle secondary to periostitis. 
Lab Studies.In suspected acquired syphilis, perform non-treponemal serology 
screening using Venereal Disease Research Laboratory (VDRL), rapid plasma 
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reagin (RPR), or the recently developed ICE Syphilis recombinant antigen test. 
Then, test sera yielding a positive or equivocal reaction by the fluorescent 
treponemal antibody-absorption (FTA-ABS), quantitative VDRL/RPR, and 
microhemagglutination assay Treponema pallidum (MHA-TP) tests. 
Dark-field microscopy is essential in evaluating moist cutaneous lesions, such as 
the chancre of primary syphilis or the condyloma lata of secondary syphilis. When 
dark-field microscopy is not available, direct immunofluorescence staining of fixed 
smears (direct fluorescent antibody Treponema pallidum [DFA-TP]) is an option. 
Both procedures detect the causative organism at a rate of approximately 85-92%. 
For evaluation of infants with suspected congenital syphilis, the 19S 
immunoglobulin M FTA-ABS serology test or the Captia Syphilis-M test currently 
is recommended. Every pregnant woman should undergo a non-treponemal test at 
her first prenatal visit, and women at high risk of exposure should have a repeat 
test in the third trimester and again at delivery. 
Imaging Studies.Radiologic abnormal findings commonly seen with advanced 
gummas of bone include periostitis, destructive osteitis, or sclerosing osteitis. 
For cardiovascular complications of tertiary syphilis, linear calcification of the 
ascending aorta on chest films suggests asymptomatic syphilitic 
aortitis.Angiography may be useful to distinguish between abdominal aneurysms 
of syphilitic versus arteriosclerotic origin since 10% of syphilitic aneurysms occur 
superior to the renal arteries, while arteriosclerotic abdominal aneurysms usually 
are found inferior to the renal arteries. 
Other Tests.Echocardiogram and ECG may help confirm cardiovascular syphilis. 
Procedures.Biopsy may be necessary to differentiate gummas from coincidental 
granulomatous conditions.Lumbar puncture for CSF examination is indicated in 
the following situations: neurologic signs or symptoms, treatment failure or plans 
to administer treatment other than penicillin, a serum reagin titer of greater than or 
equal to 1:32, seropositive HIV, and other changes indicative of active syphilis 
(e.g. gumma, aortitis). Additionally, the only means by which the occurrence of 
asymptomatic neurosyphilis in latent syphilis can be excluded is via CSF 
examination. 
Medical Care.Penicillin remains the mainstay of treatment and the standard by 
which other modes of therapy are judged (see Table 20.1). Penicillin use is the 
only therapy used widely for neurosyphilis, congenital syphilis, or syphilis during 
pregnancy. Rarely, T. pallidum has been found to persist following adequate 
penicillin therapy; however, there is no indication that the organism has acquired 
resistance to penicillin.In patients with allergy to penicillin, skin testing and 
desensitization are recommended. Make every effort to document penicillin allergy 
before choosing an alternative treatment because the efficacy of alternative 
regimens is questionable in all stages of syphilis. Many treatment failures have 
been reported.Tetracycline, erythromycin, and ceftriaxone have shown 
antitreponemal activity in clinical trials; however, they currently are recommended 
only as alternative treatment regimens in patients allergic to penicillin. 
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Table 20.1 Treatment of Syphilis in Europe (2014 European guidelines on the 
management of syphilis) 
 
Early syphilis (Primary and Early latent, i.e. acquired ≤1 year previously) 
First line therapy option 
Benzathine penicillin G (BPG) 2.4 million units intramuscularly (IM) 
(one injection of 2.4 million units or 1.2 million units in each buttock) on day 1[Ib;A] 
Penicillin allergy or parenteral treatment refused 
Doxycycline 200 mg daily (either 100 mg twice daily or as a single 200 mg dose) orally for 14 
days [III;B) 
or azithromycin 2 g orally single dose [I;B] 
Late latent (i.e. acquired > 1 year previously or unknown duration), cardiovascular and 
gummatous syphilis 
First line therapy option 
Benzathine penicillin G (BPG) 2.4 million units IM (one injection of 2.4 million units or 1.2 
million units in each buttock) weekly on day 1, 8 and 15 [III;B] 
Penicillin allergy or parenteral treatment refused 
Desensitization to penicillin 
ordoxycycline 200 mg daily (either 100 mg twice daily or as a single 200 mg dose) orally during 
21-28 days [III;B] 
Neurosyphilis, ocular and auricular syphilis 
First line therapy option 
Benzyl penicillin 18-24 million units IV daily, as 3-4 million units every 4 h during 10-14 days 
[III;B] 
Second line therapy option ( if hospitalization and IV benzyl penicillin is impossible) 
Ceftriaxone 1-2 g IV daily during 10-14 days [III;B] 
Procaine penicillin 1.2-2.4 million units IM daily AND probenicid 500 mg four times daily, both 
during 10-14 days [IIb;B] 
Penicillin allergy 
Desensitization to penicillin followed by the first line regimen [III;B] 
Syphilis in pregnancy 
Pregnant women should be treated with the first line therapy option appropriate for the stage of 
syphilis and if allergic to penicillin should be desensitized. 
Syphilis in HIV 
Treatment should be given as for non-HIV infected patients, although there are very few data on 
the use of second line options 
 
Consultations are necessary depending on the specific complications and organ 
systems affected. 
Further Outpatient Care.Patients with treated primary or secondary 
syphilis.Perform quantitative VDRL testing at 1, 3, 6, and 12 months following 
treatment.If the VDRL titer of 1:8 or more fails to fall at least 4 fold within 12 
months or if the titer starts to rise, consider more intensive retreatment, and 
examine the CSF.If all clinical and serologic examinations remain satisfactory for 
2 years following treatment, the patient can be reassured that cure is complete, and 
no further follow-up care is needed. 
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Patients with latent syphilis.Perform quantitative reagin testing for up to 2 years. 
Schedule annual follow-up visits for an indefinite period of time for patients with 
persistently positive serologic tests. 
Patients with benign tertiary or cardiovascular syphilis: patients should be 
observed by the physician for the rest of their lives to monitor for complications. 
Patients with neurosyphilis (both symptomatic and asymptomatic): Examine the 
CSF (cell count, protein, reagin titer) every 3-6 months for 3 years or until CSF 
findings return to normal. 
Prognosis.For patients diagnosed with primary, or secondary syphilis (without 
auditory/neurologic/ocular involvement), the prognosis is good following 
appropriate treatment.For patients diagnosed with tertiary syphilis, overall 
prognosis depends on the duration and extent of disease activity, along with prior 
attempts to treat the disease. For example, prognosis for advanced symptomatic 
disease in cardiovascular syphilis is poor, unless it is treated with high doses of 
intravenous penicillin. In contrast, in patients with neurosyphilis complicated by 
optic atrophy and blindness, the ability to regain vision remains poor despite 
attempts with high-dose penicillin. 
For patients who are pregnant and have early syphilis, it is likely that the mother 
will deliver a child not infected by syphilis (assuming the mother was treated 
appropriately). 
 
 
20.2. Gonococcal Infections 
 
Background.Gonorrhea (also called “the clap”), caused by Neisseria 
gonorrhoeae, is a public health problem and is the most common reportable 
infectious disease. Gonorrhea is most frequently spread during sexual contact; 
however, it can also be transmitted from the mother's genital tract to the newborn 
during birth to cause ophthalmia neonatorum and systemic neonatal infection. The 
incubation period is usually 2-8 days.  
In women, the cervix is the most common site of infection, resulting in 
endocervicitis and urethritis, which can be complicated by pelvic inflammatory 
disease (PID). In men, infection causes anterior urethritis.  
Pathophysiology.N. gonorrhoeae is a gram-negative, intracellular, aerobic 
diplococcus. It mainly affects host columnar or cuboidal epithelium. Several 
factors influence the manner in which gonococci mediate their virulence and 
pathogenicity. Pili help in attachment of gonococci to mucosal surfaces and also 
contribute to resistance by preventing ingestion and killing by neutrophils. Outer 
membrane proteins such as opacity-associated (Opa) proteins increase adherence 
between gonococci (forming opaque colonies on culture media) and also increase 
adherence to phagocytes. Plasmid-mediated production of TEM-1–type beta-
lactamase (penicillinase) also contributes to virulence.  
Gonococci attach to the host mucosal cell (with the help of pili and Opa proteins) 
and then penetrate through and between cells into the subepithelial space. A typical 
host response is characterized by invasion with neutrophils, followed by epithelial 
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sloughing, formation of submucosal microabscesses, and purulent discharge. If left 
untreated, macrophages and lymphocyte infiltration replace the neutrophils. Some 
strains cause an asymptomatic infection, leading to an asymptomatic carrier state 
in persons of either sex.  
Frequency.Disease rates are unknown for most developing countries. In much of 
Western Europe, rates approximate those in the United States. The incidence is 
substantially lower in most European countries, and indigenous gonorrhea has 
virtually been eliminated in Sweden. The highest incidence of gonorrhea and its 
complications occurs in developing countries. The median prevalence of gonorrhea 
in unselected populations of pregnant women has been estimated to be 10% in 
Africa, 5% in Latin America, and 4% in Asia.  
Mortality/Morbidity.The major complication of gonococcal infections in women 
is tubal scarring and infertility. The incidence of involuntary infertility is estimated 
at 15% after one attack of PID and approximately 50-80% after 3 attacks. The 
incidence of ectopic pregnancy is increased from 7-fold to 10-fold in women with 
previous salpingitis, with resultant increased fetal and maternal mortality rates. 
Failure to diagnose PID can result in acute morbidity, including tuboovarian 
abscess, endometritis, or Fitz-Hugh and Curtis syndrome (perihepatitis), and the 
chronic sequelae noted earlier. Women may also develop gonococcal urethritis or 
infection of periurethral (Skene) glands or Bartholin glands. 
Infertility may be more common after chlamydial PID than after gonococcal PID, 
presumably because the more acute inflammatory signs associated with gonorrhea 
prompt women to seek diagnosis and treatment sooner. 
Urethral stricture caused by gonorrhea in men is less common than previously 
believed; some strictures in the preantibiotic era likely resulted from treatment by 
urethral irrigation using caustic compounds rather than from the gonorrhea itself. 
Sex.Symptomatic disease occurs more predominantly in males than in females. An 
asymptomatic carrier state can occur in both sexes but is believed to occur more 
frequently in females than in males.Serious sequelae are much more common in 
women than in men. PID in women may lead to ectopic pregnancy or infertility, 
and women are more likely than men to develop disseminated gonococcal infection 
(DGI). 
Age.In the United States, the highest rates of gonorrhea are found in young (15-30 
years) unmarried persons and in groups of low educational and socioeconomic 
status. Infection in children is a marker for child sexual abuse. 
History.In all patients presenting with possible STDs, the history should include 
past history of STDs (including HIV and viral hepatitis), known symptoms of 
STDs in current or past partners, type of contraception, and any history of sexual 
assault. In women, the history should also include the date of the last menstrual 
period and the details of parity, including any history of ectopic pregnancies.  
Female genitourinary tract 
The most common site of gonococcal infection in women is the endocervix (80-
90%), followed by the urethra (80%), rectum (40%), and pharynx (10-20%).Major 
symptoms include vaginal discharge, dyspareunia, and mild lower abdominal 
377 
 
pain.When gonococcal cervicitis is either asymptomatic or unrecognized, the 
patient may progress to PID, often in proximity to a menstrual period. PID may 
also be asymptomatic or silent. Symptoms of PID include the following: increased 
vaginal discharge or purulent urethral discharge;dysuria (usually without urgency 
or frequency);lower abdominal pain, usually bilateral; cervical motion tenderness, 
adnexal tenderness,intermenstrual bleeding. Acute perihepatitis (Fitz-Hugh and 
Curtis syndrome) occurs primarily through direct extension of N gonorrhoeae or 
Chlamydia trachomatis from the fallopian tube to the liver capsule and overlying 
peritoneum. 
Male genitourinary tract.In men, urethritis is the major manifestation.Initial 
characteristics are burning upon urination and a serous discharge. A few days later, 
the discharge usually becomes more profuse, purulent, and, at times, blood-tinged. 
Acute epididymitis can also be caused by N gonorrhoeae, especially in men 
younger than 35 years. This is usually unilateral and often occurs in conjunction 
with a urethral exudate. 
Male and female involvement.Both men and women may exhibit gonococcal 
infection of the pharynx, rectum, and eye.Gonococcal pharyngitis is most 
commonly acquired during orogenital contact, with fellatio rather than cunnilingus 
being the more efficient form of oral sex for transmitting disease. Pharyngitis often 
is asymptomatic; however, it may present as exudative pharyngitis with cervical 
lymphadenopathy.Even though positive findings from rectal cultures for gonorrhea 
are noted in up to 40% of women with cervical gonorrhea (a similar percentage 
noted in infected homosexual men), symptoms of proctitis are unusual.Eye 
involvement in adults occurs by autoinoculation of gonococci into the conjunctival 
sac from a primary site of infection such as the genitals. The most common form of 
presentation is a purulent conjunctivitis, which may rapidly progress to 
panophthalmitis and loss of the eye unless promptly treated. 
Neonates.In neonates, bilateral conjunctivitis (ophthalmia neonatorum) often 
follows vaginal delivery from an infected mother. However, transmission to the 
newborn can also occur in utero or in the postpartum period.The symptoms of 
gonococcal conjunctivitis are eye pain, redness, and a purulent discharge. Neonates 
may also acquire pharyngeal, respiratory, or rectal infection or DGI.The organism 
can cause permanent injury to the eye in a very short time; prompt recognition and 
treatment are essential to avoid blindness. Blindness from neonatal gonococcal 
infection is a serious problem in developing countries but is now uncommon in the 
United States and in other countries where neonatal conjunctival prophylaxis with 
antimicrobials is routine. 
Disseminated gonococcal infection.DGI follows 1-2% of mucosal infections and 
occurs because of hematogenous dissemination of gonococci from the primary site. 
The symptoms vary greatly from patient to patient. By the time the symptoms of 
DGI appear, many patients no longer have any localized symptoms of mucosal 
infection.Risk factors are as follows: complement deficiency,female sex: 
disseminated infection may occur more frequently in women because gonorrhea in 
women is often asymptomatic, allowing for dissemination before symptoms occur;  
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menses: in menstruating females, the illness is observed shortly after the end of 
menstruation; pharyngeal infection and pregnancy: these may also be predisposing 
factors to gonococcal bacteremia;the classic presentation of DGI is arthritis 
dermatitis syndrome.  
Joint or tendon pain is the most common presenting complaint in the early stage of 
infection. Many patients with DGI describe migratory polyarthralgia, especially of 
the knees, elbows, and more distal joints, and may also have tenosynovitis. The 
early tenosynovitis most commonly affects the flexor tendon sheaths of the wrist or 
the Achilles tendon (“lovers' heels”). The dermatitis consists of lesions varying 
from maculopapular to pustular, often with a hemorrhagic component. Lesions 
usually number 5-40, are peripherally located, and may be painful before they are 
visible. Fever is common, but the temperature is usually less than 39°C.  
The second stage of DGI is characterized by septic arthritis, by which time the skin 
lesions have disappeared and blood culture results are nearly always negative. The 
knee is the most common site of purulent gonococcal arthritis.  
Rare complications of DGI are gonococcal meningitis and endocarditis. 
Gonococcal meningitis may be clinically indistinguishable from meningococcal 
meningitis upon presentation, although the course of gonococcal meningitis is 
usually less rapid than that of meningococcal meningitis. Gonococcal endocarditis 
is more common in men than in women, with the aortic valve affected most 
commonly. A subacute onset of fever, chills, sweats, and malaise may indicate the 
presence of gonococcal endocarditis. Patients with endocarditis may develop 
atypical chest pain, cough, and dyspnea and may also develop the arthralgias and 
rash typical of DGI. Gonococcal endocarditis can cause severe valvular damage 
and death if not recognized and treated rapidly. 
Physical.Patients may have the typical signs and symptoms of gonococcal 
diseases, especially in the genital tract. Sometimes however, patients may have no 
localized signs or symptoms.  
Female genitourinary tract.Mucopurulent or purulent cervical discharge.Vaginal 
discharge or bleeding; vulvovaginitis in children.Lower abdominal tenderness with 
or without rebound tenderness.Adnexal tenderness (associated with ascending 
infection).Cervical motion tenderness (associated with ascending infection). 
Fever.Upper right abdominal tenderness (with Fitz-Hugh and Curtis syndrome). 
Male genitourinary tract.Mucopurulent or purulent urethral discharge.Unilateral 
epididymal tenderness and edema.Penile edema without other overt inflammatory 
signs.Urethral stricture.Rectal: mucopurulent or purulent discharge with or without 
rectal bleeding,mucopurulent exudate and inflammatory in the rectal mucosa. 
Eyes: purulent conjunctivitis is usually bilateral in ophthalmia neonatorum but 
most often is unilateral when caused by secondary self-inoculation. 
Disseminated gonococcal infection - patients with DGI may present with any of 
the following nonspecific findings: fever (usually < 39°C); polyarthralgia with 
pain; oligoarthritis. 
Skin lesion are characteristically few in number and are mostly found on the distal 
extremities as small papulopustular lesions with an erythematous periphery. 
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Causes.Gonococcal infection usually follows mucosal inoculation during vaginal, 
anal, or oral sexual contact or perinatally.  
Sexual contact.The risk of transmission of N gonorrhoeae from an infected woman 
to the urethra of her male partner is approximately 20% per episode of vaginal 
intercourse and rises to 60-80% after 4 or more exposures.In contrast, the risk of 
male-to-female transmission approximates 50-70% per contact, with little evidence 
of increased risk with more sexual exposures.Transmission through penile-rectal 
contact is fairly efficient. Persons who have unprotected intercourse with new 
partners frequently enough to sustain the infection are defined as core transmitters. 
Neonatal infection may follow conjunctival inoculation during birth or direct 
infection through the scalp at the sites of fetal monitoring electrodes. 
Lab Studies.Laboratory diagnosis of gonococcal infections depends on 
identification of N gonorrhoeae at an infected site. 
Isolation through culture.This is the diagnostic standard and should be used 
whenever practical. A single culture on most selective media has a sensitivity of 
95% or more for urethral specimens from men with symptomatic urethritis and 80-
90% for endocervical infection in women. Simultaneous inoculation on selective 
and nonselective media may provide the highest yield. Although the urethra is 
commonly infected in women with gonorrhea, culturing urethral specimens does 
not materially increase the diagnostic yield except in women who lack cervices 
because of hysterectomy. Patients with possible DGI should have culture samples 
taken from all possible mucosal sites (i.e. pharynx, urethra, cervix, rectum) and 
from blood and synovial fluid. Rectal and pharyngeal specimens are inoculated 
onto selective medium only. When collecting specimens in males, any discharge 
present at the meatus can be easily recovered for examination. If no discharge is 
present at the meatus, urethral material must be recovered by inserting and rotating 
a small swab 2-3 cm into the urethra. A calcium alginate or Rayon swab on a metal 
shaft is recommended. When collecting specimens in women, the exocervix is first 
wiped of exudate. A swab is then placed into the external os and rotated for several 
seconds. However, take care to avoid contact with vaginal mucosa or secretions. 
In patients who may have DGI, all possible mucosal sites should be cultured (e.g. 
pharynx, cervix, urethra, rectum), as should blood and synovial fluid (in cases of 
septic arthritis). Three sets of blood cultures should also be obtained. Specimens 
from any mucosal site should be inoculated immediately in selective media for 
gonorrheal organisms, such as modified Thayer-Martin, or on chocolate agar at 
room temperature, which should be incubated in an enriched carbon dioxide 
environment. The growth of typical oxidase-positive colonies that consist of gram-
negative diplococci strongly suggests gonorrhea. 
Smears with Gram stain. In men, the diagnosis of urethritis can be performed 
using either of 2 methods of Gram staining. The first is via a urine sample. 
Preferably, examine the patient at least 2 hours after micturition or before their first 
morning void. The patient should provide a first-morning void, and the first 10-15 
mL of the urine is saved. The urine is centrifuged so that the sediment may be 
analyzed microscopically under high power or oil immersion. The presence of 10 
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or more polymorphonuclear leukocytes (PMNs) seen under high power is 
suggestive of urethritis. The second method is a Gram stain of urethral exudate. 
The presence of 4 or more PMNs per oil-immersion field is diagnostic for 
urethritis. In symptomatic males, Gram staining of urethral exudate has a 
sensitivity of 90-98% and a specificity of 95-98%. However, in asymptomatic 
males, the sensitivity of the Gram stain is only 60%. Therefore, culture studies are 
recommended if an asymptomatic gonococcal infection is suggested. The presence 
of typical gram-negative intracellular diplococci after Gram stain establishes a 
diagnosis of gonorrhea. If these organisms are not observed, the patient is said to 
have non-gonococcal urethritis. Results are considered equivocal if typical 
morphotypes not associated with neutrophils are present or if cell-associated but 
morphologically atypical organisms are observed. A simple Gram stain is probably 
the method of choice for the detection of gonorrhea in symptomatic males because 
it is much less expensive and much more rapid than the Gen-Probe method. 
In women with positive results from cervical cultures, the Gram stain results from 
the endocervix are 50-60% sensitive and 82-97% specific. Also, the presence of 
more than 10 PMNs per high-power field on an endocervical smear is consistent 
with cervicitis. In women who lack cervices because of hysterectomy, use urethral 
culture to make the diagnosis. 
No available serologic test is sufficiently sensitive and specific to merit use for 
screening or diagnostic purposes. 
Imaging Studies.Ultrasound or CT scan for PID.Pelvic ultrasound or CT scan 
images may show thick dilated fallopian tubes or abscess formation.PID is 
uncommon in pregnancy. Therefore, ultrasound should be used to help rule out 
ectopic pregnancy whenever a pregnant patient has signs and symptoms of 
possible PID.In current practice, vaginal ultrasonography and CT scan help to 
define the cause of pelvic pain syndromes. 
Other Tests.Various tests can be used, if available, to detect the antigen or the 
genome of gonococci in exudates.Fluorescein-conjugated monoclonal antibodies 
for direct fluorescence microscopy can be used to detect antigen. 
Enzyme-linked immunoassays for the detection of gonococcal antigen with 
polyclonal antigonococcal antibodies can also be used. 
Polymerase chain reaction tests for gonococcal DNA amplification can be used, 
although they are quite expensive and do not contribute much in most settings. 
Ligase chain reaction tests for the presence of gonococcal DNA are also becoming 
available. These tests are highly specific and extremely sensitive, but they are 
expensive. 
Histologic Findings.Exudate of PMNs is typical. In PID, loss of ciliated columnar 
epithelium from the fallopian tubes may occur. Tubes, pelvic mesentery, and 
ovaries may be bound together with dense fibrosis and abscess formation. 
Medical Care.The decision to implement antimicrobial therapy should be made 
quickly. The choice of which regimen to use should be based on the clinical 
presentation. Hospitalization is recommended for initial treatment of DGI, purulent 
joint infections, meningitis, and endocarditis. Hospitalization is also recommended 
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for initial treatment of PID cases in the presence of the following factors:  
pregnancy, failure of outpatient treatment, tuboovarian abscess, severe symptoms 
(e.g. severe pain, high fever, persistent nausea and vomiting),immunodeficiency,  
abdominal peritonitis or perihepatitis, uncertain diagnoses, with any possibility of 
ectopic pregnancy or appendicitis masquerading as PID. 
Uncomplicated urethritis, cervicitis, or rectal or pharyngeal infection in 
adults.Effective single-dose regimens currently recommended as initial therapy by 
the US Public Health Service for the treatment of uncomplicated gonorrhea in all 
patients in the United States are (1) ceftriaxone (125 mg IM), (2) cefixime (400 mg 
PO), (3) ciprofloxacin (500 mg PO), or ofloxacin (400 mg PO). The 125-mg 
intramuscular dose of ceftriaxone is fully effective. Ceftriaxone is safe and 
effective in pregnant women, and it probably destroys incubating syphilis. Its 
major drawback is the necessity for intramuscular administration. Studies suggest 
that ciprofloxacin at 250 mg orally is as effective as 500 mg orally, but the 
emergence of less-sensitive strains strongly suggests that the higher dose should be 
used.  
Over the last decade, as fluoroquinolones have become the preferred class of 
antimicrobials for the treatment of gonorrhea, reports of N. gonorrhoeae with 
decreasing susceptibilities and frank resistance have surfaced. Fluoroquinolones 
should also be avoided, if possible, when treating pregnant women and children 
weighing less than 45 kg or adolescents younger than 15 years because of concerns 
of chondrotoxicity with this antimicrobial class. When treating gonococcal 
infections in pregnant women, fluoroquinolones and tetracyclines should not be 
used. Pregnant women should be treated with either ceftriaxone or cefixime.  
Tetracyclines no longer are acceptable therapy for gonorrhea because of the 
prevalence of tetracycline-resistant strains. Because gonococcal infections are 
commonly associated with genital chlamydial infection, most authorities now 
recommend a 7-day course of a tetracycline (usually doxycycline) for all patients 
with gonorrhea as follow-up care to initial ceftriaxone therapy.  
Other therapies include spectinomycin or azithromycin. Spectinomycin at 2 g 
intramuscularly once is effective and can be used in patients allergic to penicillin. 
Azithromycin at 2 g as single dose is also effective; however, its use is limited by 
its cost, adverse gastrointestinal effects, and lack of efficacy in pharyngeal 
infection. 
Therapy for gonococcal arthritis.Use ceftriaxone at 1 g/d IV/IM for a total of 7 
days. Oral therapy may be used initially in carefully selected compliant patients 
with a definite diagnosis and only mild infection. Antibiotics for oral use in this 
situation include cefixime (400 mg bid) or ciprofloxacin (500 mg bid) for 7 days. 
Gonococcal conjunctivitis should be treated with immediate saline irrigation and 
intravenous ceftriaxone.  
For PID therapy for outpatients, use cefoxitin at 2 g IM plus probenecid at 1g PO 
as a single dose or ceftriaxone at 250 mg IM followed by a 14-day oral regimen of 
doxycycline at 100 mg bid. Also, examining and treating all sexual partners of 
women with gonococcal PID is crucial.  
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For hospitalized patients with PID, use cefoxitin at 2 g parenterally every 6 hours 
or cefotetan at 2 g IV every 12 hours plus doxycycline. Alternative regimens are 
available. Again, examining and treating all sexual partners of women with 
gonococcal PID is crucial. 
Surgical Care.Most authorities recommend removal of intrauterine devices in 
women with PID.Examining and treating all sexual partners of women with 
gonococcal PID is crucial.Septic joints should be aspirated, both to make the initial 
diagnosis and to remove inflammatory exudate. Open drainage is rarely indicated, 
except in infections of the hip in children. 
Consultations.A gynecologist should be consulted for patients with severe PID 
and for any pregnant patient with an STD.A pediatrician should be consulted for 
any child with an STD. An ophthalmologist should be consulted for every patient 
with gonococcal conjunctivitis because this disease may progress rapidly and can 
cause permanent loss of vision. 
Further Outpatient Care.Patients with DGI or PID who are treated in an 
outpatient setting must receive follow-up care within 24 hours.Early follow-up care 
and culture with antibiotic sensitivities are indicated for patients with unresolved 
or recurrent symptoms.Follow-up care for test of cure is indicated for all patients 
with pharyngitis treated with spectinomycin because its efficacy is less than 
60%.Instruct patients with uncomplicated cases to follow up with a primary care 
physician or public health provider to reduce the risk of future infection. 
Prevention.Prevention is based on education, mechanical or chemical prophylaxis, 
and early diagnosis and treatment. Condoms offer partial protection.All sexual 
contacts should be treated. Effective antibiotics taken in therapeutic doses 
immediately before or soon after exposure can abort an infection.Preventive 
measures also include attention to partner notification. Patients should be 
encouraged to notify their sexual partners of their exposure and encourage them to 
seek medical care. This is patient referral. If patients are unwilling or unable to 
notify their partners, then the assistance of state and local departments of public 
health can be enlisted. This is provider referral.All infants born to mothers with 
untreated gonococcal infection should be treated prophylactically with a single 
dose of ceftriaxone (25-50 mg/kg IV/IM, not to exceed 125 mg).All neonates 
should undergo prophylaxis for ophthalmia neonatorum with silver nitrate (1%) 
aqueous solution in both eyes once or erythromycin (0.5%) ophthalmic ointment in 
both eyes once. 
Complications.Males.Urethral stricture in adult men is less common than 
previously thought. Some strictures in the preantibiotic era likely resulted from 
treatment by urethral irrigation using caustic compounds rather than from the 
gonorrhea itself.Other complications, such as penile lymphangitis, periurethral 
abscess, acute prostatitis, seminal vesiculitis, and infection of the Tyson and 
Cowper glands, are now rare. 
Females.Tubal scarring and infertility are the major complications. The incidence 
of involuntary infertility is estimated at 15% after one attack of PID and 
approximately 50-80% after 3 attacks.The incidence of ectopic pregnancy is 
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increased from 7-fold to 10-fold in women with previous salpingitis, with resultant 
increased fetal and maternal mortality rates.Failure to diagnose PID can result in 
acute morbidity, including tuboovarian abscess, endometritis, Fitz-Hugh and Curtis 
syndrome (perihepatitis), and other chronic sequelae.Infertility may be more 
common after chlamydial PID than after gonococcal PID, presumably because the 
more acute inflammatory signs associated with gonorrhea prompt women to seek 
diagnosis and treatment sooner. The possible compications are corneal scarring 
after eye infections, destruction of joint articular surfaces, destruction of cardiac 
valves, death from congestive heart failure related to endocarditis or from CNS 
complications of meningitis. 
Prognosis.With adequate early therapy, complete cure and return to normal 
function are the rule. 
 
 
20.3. Chancroid 
 
Synonyms and related keywords: soft chancre, Haemophilus ducreyi, H. ducreyi, sexually 
transmitted disease, STD, genital ulcer 
 
Background.Chancroid is a sexually transmitted genital ulcer disease (GUD) 
caused by the gram-negative bacillus Haemophilus ducreyi. It is characterized by 
the presence of painful ulcers and inflammatory inguinal adenopathy. Chancroid is 
often referred to as a soft chancre because the lesions are usually not indurated. In 
contrast, a syphilitic chancre is non-tender and indurated.  
Pathophysiology.H. ducreyi produces a potent cytolethal distending toxin, which 
is an important virulence factor in the pathogenesis of chancroid, probably 
contributing to both the generation and the slow healing of ulcers.  
Frequency.In developing countries, chancroid is the cause of most GUDs and 
accounts for 10-30% of all sexually transmitted diseases (STDs) in Africa. The 
estimated worldwide incidence exceeds that of syphilis. It is endemic in Africa, 
Southeast Asia, Latin America, and the Caribbean.Chancroid is less common in the 
United States than in developing countries. However, reported cases of chancroid 
in the United States are on the rise in recent years, with about 4,000 cases reported 
annually. Outbreaks of chancroid tend to occur in poor, urban areas.  
Mortality/Morbidity.Chancroid produces painful ulcers on the genitals, often 
(50%) associated with unilateral tender inguinal lymphadenitis (i.e. a bubo). Left 
untreated, the buboes can form fluctuant abscesses that spontaneously rupture, 
resulting in a non-healing ulcer.Recent studies have shown an association between 
chancroid and HIV. H. ducreyiand HIV may be cotransmitted, thereby facilitating 
the spread of HIV. This relationship has been especially significant in the 
heterosexual spread of HIV in Africa. 
Sex.Males develop the disease most often, with a male-to-female ratio of 3-25:1. 
Uncircumcised men develop chancroid more often than circumcised 
men.Chancroid is more common in heterosexual men.Female prostitutes, either 
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having signs of active disease in the form of genital ulcers or being asymptomatic 
carriers, are an important reservoir for infection. 
Age.Chancroid is most prevalent in sexually active and promiscuous males, with a 
mean patient age of 30 years.  
History.After an incubation period of 3-7 days, the patient develops painful, 
erythematous papules at the site of contact. The papules become pustular and then 
rupture, usually forming 1-3 painful ulcers.Men usually have complaints directly 
related to the painful genital lesions or inguinal tenderness. Most females are 
asymptomatic but may present with less obvious symptoms, such as dysuria, 
dyspareunia, vaginal discharge, pain on defecation, or rectal bleeding. 
Constitutional symptoms, such as malaise and low-grade fevers, may be 
present.Most commonly, males report a history of recent contact with a prostitute. 
In addition, men who are infected are less likely to have used condoms and more 
likely to report a history of more than 2 sexual partners in the preceding 3 
months.Intoxication with alcohol and use of cocaine have been reported more 
frequently in men who are infected.Men with chancroid are less likely to be 
circumcised. Oral sex has also been documented in the transmission of chancroid. 
Physical.A small papule is the initial lesion at the site of infection. The papule 
rapidly becomes pustular and eventually ulcerates. The ulcer enlarges, develops 
ragged undermined borders, and is surrounded by a rim of erythema. The border of 
the ulcer is not indurated as in syphilis. A grayish fibrinous membrane covers the 
base of the ulcer. Autoinoculation results in multiple sites of infection in various 
stages of evolution.In men, the most common site of infection is the foreskin, but it 
may also occur less commonly on the shaft, the glans, or the meatus of the penis. 
In women, ulcers most commonly occur on the labia majora, but they may also 
occur on the labia minora, the thighs, the perineum, or the cervix.As many as 50% 
of patients have tender, fixed, inguinal lymphadenopathy, usually unilaterally, that 
when fluctuant is called a bubo and is highly specific for chancroid. 
Complications.Phimosis, balanoposthitis, and rupture of buboes with fistula 
formation and scarring are reported complications. 
Lab Studies.The diagnosis of chancroid based solely on the ulcer's appearance is 
accurate only in 30-50% of cases. In areas of high prevalence, the accuracy for 
clinical diagnosis of chancroid is as high as 80%; however, in areas where the 
disease is less common, the clinical basis for diagnosing chancroid leads to 
overdiagnosis. Considerable overlap exists between the major causes of GUD: 
herpes simplex, syphilis, chancroid, and often co-infection with 2 diseases at the 
same time. Co-infection with syphilis or herpes simplex virus (HSV) occurs in as 
many as 10% of patients. Realizing that no etiology can be found in 25-50% of all 
cases of GUD is important. 
Gram staining may show negative coccobacilli singly, in clusters, or in a school of 
fish pattern.Gram staining of an ulcer specimen has low sensitivity and 
interpretation is hampered by polymicrobial contamination.Stains are not highly 
specific or sensitive, though slides with gram-negative coccobacilli in parallel rows 
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or in a clustered school of fish pattern have been reported to have a sensitivity of 
62% and a specificity of 99% for chancroid. 
Definitive diagnosis requires cultural isolation. Isolating H. ducreyi is difficult. 
Two media are available for culture. Nairobi medium consists of a biplate of (1) 
gonococcal agar base with 2% bovine hemoglobin, 5% fetal calf serum, and 3 
mg/L of vancomycin and (2) Mueller-Hinton agar with 5% chocolatized horse 
blood and vancomycin. Most H. ducreyi organisms are sensitive to vancomycin, 
but some strains are inhibited by its presence. Therefore, negative cultures in the 
setting of high suspicion should prompt screening for vancomycin-sensitive 
organisms.Culture is now the accepted standard for diagnosis in most areas, but, 
even in an experienced laboratory, it is only 60-80% sensitive.Studies have shown 
the culture to be less sensitive in women than in men.Purulent material aspirated 
from intact buboes is almost always sterile. 
PCR amplification by using primers from the 16s ribosomal RNA (rRNA) gene 
may provide a useful alternative to culture for the detection of H. ducreyi. 
Immunofluorescence studies are not sensitive enough. More research is needed. A 
hybridoma-produced monoclonal antibody used as an immunofluorescence reagent 
has shown a sensitivity of 93% in detecting culture-positive chancroid. 
Serologic tests for syphilis include Venereal Disease Research Laboratory (VDRL) 
test, rapid plasma reagin (RPR) test, and a darkfield examination. 
Tests for HSV include a Tzanck smear, direct fluorescence microscopy, and 
culture.Consider tests for other STDs, including hepatitis B, Chlamydia 
trachomatis, gonorrhea, and HIV. 
Histologic Findings.Histologic features from a biopsy sample of a chancroid ulcer 
may be sufficiently distinct to permit a presumptive diagnosis. Lesions show 3 
zones. The most superficial zone is narrow and consists of neutrophils, fibrin, 
erythrocytes, and necrotic tissue. The second zone is wider and contains newly 
formed blood vessels with marked endothelial cell proliferation. The lumina of 
many of these vessels are occluded, leading to thrombosis. The deepest zone is 
composed of a dense infiltrate of plasma cells and lymphoid cells. Ducrey bacilli 
are seldom demonstrable on biopsy samples. 
Medical Care.Local therapy includes topical cleansing, soaks, and measures to 
reduce edema. Patients with non-fluctuant buboes respond well to antibiotics, and 
the lesions do not need to be drained. 
Surgical Care.Fluctuant buboes should be drained under local anesthesia. Insert a 
large-gauge needle into the bubo, passing through normal tissue from the side or 
the top of the lesion, rather than the bottom, thus avoiding continuous dependent 
drainage and fistula formation.Incision and drainage is an effective method for 
treating fluctuant buboes and may be preferable to traditional needle aspiration 
considering the frequency of required repeat aspirations in some studies.If 
circumcision is needed, it should be completed after the patient successfully 
completes treatment with antibiotics. 
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Activity.Patients should refrain from sexual activity until ulcers are healed. 
Untreated chancroid ulcers may persist for 1-3 months. Chancroid ulcers treated 
with the appropriate antibiotic agent resolve within 7-14 days. 
Further Outpatient Care.Patients should receive follow-up care to ensure 
resolution of the disease. Clinical improvement should occur over 7 days, and 
healing should be complete in 2 weeks with appropriate antibiotic therapy. 
Lymphadenopathy may be slow to resolve and may require needle aspiration if a 
significant bubo is present.Because of the highly infectious nature of chancroid, 
routine treatment of contacts of men with chancroid is recommended even if they 
are asymptomatic. All sexual contacts during the 10 days prior to the development 
of the genital lesion should be treated.Empirical treatment of high-risk women has 
been shown to significantly decrease the incidence of disease. 
Prognosis.The prognosis is excellent if chancroid is treated properly and if no co-
infection with HIV is present.As many as 5% of patients have a relapse of their 
disease and usually respond to a repeat course of their original therapy. 
Patient Education.The patient should be strongly advised to avoid sexual contacts 
while the ulcers are open because they are highly infectious and may lead to 
outbreaks.Patients should be advised to avoid prostitutes, to wear condoms, and to 
avoid having multiple partners.Cocaine and alcohol abuse should be addressed 
because both contribute to higher rates of the disease. 
 
 
20.4. Lymphogranuloma Venereum 
 
Background.Lymphogranuloma venereum (LGV) is a sexually transmitted 
chlamydial disease that should be a part of the differential diagnosis for any patient 
presenting with a genital ulcer and/or inguinal lymphadenopathy. Treatment 
involves the use of antibiotics to clear the infection and to prevent tertiary 
sequelae.  
Pathophysiology.Chlamydia trachomatis, an obligate intracellular organism, is the 
causative agent, and serotypes L1, L2, and L3 have been associated with infection. 
While other serotypes of C trachomatis are limited to superficial infection of 
mucous membranes, serotypes L1, L2, and L3 are more invasive and virulent, 
tending to result in systemic disease. The organism travels through the lymphatics 
to multiply within macrophages in regional lymph nodes. Characterization of the 
rate of transmission or the reservoir of C. trachomatis has not been defined clearly, 
although asymptomatic women are believed to be a source of infection.  
LGV occurs in 3 stages, the first of which has an incubation period of anywhere 
from 3 days to 6 weeks (10-14 d average) and is characterized by a painless genital 
papule, which usually disappears after a few days. The onset of the second stage 
occurs 2-6 weeks later and often manifests as unilateral inguinal lymphadenopathy. 
The third stage may occur years after the initial infection and is termed 
genitoanorectal syndrome.  
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Causes.The causal organism is C. trachomatis, serotypes L1, L2, and L3; L2 is the 
most common.Risk factors include the following: unprotected sex, anal 
intercourse, sex with partners in endemic countries, multiple sex partners. 
Other diagnostic considerations: causes of lymphadenopathy include sexually 
transmitted diseases (STDs), such as chancroid, primary and secondary syphilis, 
and granuloma inguinale, and non-venereal diseases, such as cat-scratch disease, 
infectious mononucleosis, tuberculosis, tularemia, brucellosis, bubonic plague, 
lymphoma, and metastatic malignancies. 
Frequency. LGV is most common in Southeast Asia, Africa, Central America, and 
the Caribbean. LGV accounts for 2-10% of genital ulcer disease in India and 
Africa.  
Mortality/Morbidity.Complete cure is achieved by early recognition and 
appropriate antibiotic treatment. Progression to the third stage of the disease can 
result in serious and sometimes permanent sequelae such as genital deformity, 
fistulas, and rectal strictures. Death is rare but may be caused by complete bowel 
obstruction and perforation resulting from a rectal stricture.  
Race.As a cause of rectal strictures, LGV is found more commonly in blacks.  
Sex.LGV is significantly more common in men than in women. Men are more 
likely to present with inguinal lymphadenopathy in the second stage of the disease. 
Women and homosexual men who engage in receptive anal intercourse are more 
likely to present with complications of late disease.  
Age.Peak range is in individuals aged 15-40 years.  
History.The primary stage is characterized by a transient non-painful lesion that 
usually remains unnoticed by the patient; therefore, it is rare for a patient to present 
with the early stage of the disease. Travel and sexual histories are important 
because LGV often is seen in people who have been sexually active in areas where 
the disease is endemic.Male patients tend to present in the second stage with 
painful inguinal lymphadenopathy that usually is unilateral. Constitutional 
symptoms, such as fever, chills, malaise, myalgias, and arthralgias, are common in 
this stage of the disease. Women may complain of lower abdominal or back pain 
because they often have involvement of deep pelvic nodes. Systemic spread 
occasionally can result in arthritis, pneumonitis, hepatitis, or, rarely, perihepatitis. 
The tertiary stage of the disease is termed genitoanorectal syndrome. Women are 
more likely to present in this stage. Symptoms include fever, pain, tenesmus, 
pruritus, and purulent or bloody diarrhea. These symptoms are associated with 
proctocolitis, abscesses, and fistulas. 
Physical.Primary stage.The primary lesion is a small painless papule or 
herpetiform ulcer on the genitalia. The lesion usually heals within a few days; 
therefore, it is identified in only approximately 10% of patients at initial 
presentation. When present, lesions are found most typically on the glans penis or 
vaginal wall. An associated mucopurulent discharge may be present affecting the 
urethra in men and the cervix in women. 
Secondary stage.The most prominent physical finding at the secondary stage is 
unilateral painful inguinal lymphadenopathy.Bilateral lymphadenopathy occurs in 
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less than one third of patients.The nodes most commonly involved are the 
horizontal group of inguinal nodes; however, the vertical inguinal and femoral 
nodes also may be affected.A characteristic physical finding, termed the groove 
sign, occurs in approximately one third of patients. This sign is caused by 
enlargement of the nodes above and below the inguinal ligament.One third of the 
inguinal buboes become fluctuant and rupture, while the remaining two thirds 
involute to form a hard non-suppurative inguinal mass.A 10:1 predominance of 
buboes exists in men compared to women who reach this stage of disease.Women 
often have primary involvement of the rectum, vagina, cervix, or posterior urethra, 
which drain to the deep iliac or perirectal nodes; therefore, only 20-30% have the 
classic finding of inguinal lymphadenopathy. 
Tertiary stage.Physical findings at the tertiary stage include proctocolitis, 
perirectal abscess, fistulas, strictures, and hyperplasia of the intestinal and 
perirectal lymphatics (lymphorrhoids).Chronic infection can result in extensive 
scarring with ischemia and tissue necrosis.The end result can be esthiomene 
(elephantiasis of the female genitalia characterized by fibrotic labial thickening) in 
women or elephantiasis and deformation of the penis in men. 
Complications.Complications usually arise from progression to the third stage of 
LGV. Scarring and local tissue destruction is the rule, with stricture and fistula 
formations and deformation of genitalia. Complete bowel obstruction from rectal 
stricture is possible.Systemic spread occasionally can result in arthritis, 
pneumonitis, hepatitis, or, rarely, perihepatitis.Rare systemic complications include 
pulmonary infection, cardiac involvement, aseptic meningitis, and ocular 
inflammatory disease. 
Lab Studies.Diagnosis is hampered by the difficulty in culturing the organism. 
The best results have been obtained using aspirates from an involved inguinal 
lymph node and from bacterial typing of the culture after growth. Culture requires 
growth in cycloheximide-treated McCoy or HeLa cells, and even under these 
conditions, yields of only 30-50% are reported. 
Serologic tests also are available and produce a strong reaction by complement 
fixation. Tests typically are positive within 2 weeks of disease onset and have a 
sensitivity of 80%. The difficulty is in separating the various serotypes of 
Chlamydia species including those involved in conjunctivitis; however, in the 
appropriate clinical setting, an antibody titer of 1:64 or greater or a 4-fold increase 
in titer is supportive of the diagnosis. Other types of chlamydial infections rarely 
demonstrate a titer of greater than 1:16. Antibody titers do not correlate well with 
clinical severity of the disease. 
Other testing modalities include microimmunofluorescence and polymerase chain 
reaction (PCR). The usefulness of these methods is limited by availability. 
Other Tests.Other testing may include screening for coexistence of other STDs. 
As with all STDs, consider concomitant infections and perform screening tests. 
Necessary procedures may include aspiration of buboes to speed healing and 
relieve discomfort. 
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Histologic Findings in the lymph nodes show focal accumulations of neutrophils 
in necrotic foci in the early stages. Lymphocytic hyperplasia and plasma cell 
infiltration follow. The classic lesion of this disease is the stellate abscess and can 
be identified in lymph node biopsies in secondary and, occasionally, tertiary stage 
disease. 
Medical Care.Recommended treatment (see Table 20.2) is with doxycycline (100 
mg PO bid) or erythromycin (500 mg qid). Continue treatment for 3 weeks, 
combined with aspiration of the lymph nodes if needed. Incision and drainage may 
result in non-healing fistula formation, which can be minimized by draining 
involved lymph nodes from above the inguinal ligament. Symptomatic treatment 
with non-steroidal anti-inflammatory drugs (NSAIDs) and local heat for pain relief 
may be useful adjuncts. 
 
Table 20.2. European guideline on the management of lynphogranulema 
venereum (2013) 
 
Therapy 
1. First line – doxycycline 100 mg twice a day orally for 21 days (IIb;B) 
2.Second line – erythromycin 500 mg four times a day orally for 21 days (III, B) 
Azithromycin in single- or multiple-dose regimen has also been proposed but evidence is lacking 
to currently recommend this drug (IV,C).Doxycycline is contraindicated in pregnancy and 
breastfeeding 
Adjunctive therapy 
1. If fluctuant buboes appear they should be aspirated promptly through healthy adjacent skin 
(IV;C) 
2. Surgical incision of buboes is not usually recommended due to potential complications such as 
chronic sinus formation/ (IV;C) 
3. Patients with residual fibrotic lesions or fistulae do not benefit from further courses of 
antibiotics so surgical repair, including reconstructive genital surgery should be considered  
(IV, C) 
 
Surgical Care.Surgery often is necessary for repair of late complications such as 
fistulas and strictures.  
Consultations.A surgery consult may be necessary for late complications or 
aspiration of fluctuant nodes. 
Prognosis is excellent if LGV is treated early; however, late complications can 
cause significant morbidity. 
 
 
20.5. Granuloma Inguinale (Donovanosis) 
 
Background.Granuloma inguinale (GI) is primarily a sexually transmitted disease 
in which characteristic intracellular inclusions called Donovan bodies may be seen. 
It usually manifests as genital lesions, which are indolent, progressive, ulcerative, 
and granulomatous.  
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Pathophysiology.GI is caused by Calymmatobacterium granulomatis, a gram-
negative pleomorphic bacillus. The mode of transmission is primarily through 
sexual contact, although GI may be obtained through a fecal route or by passage 
through an infected birth canal. It is considered to be only mildly contagious, and 
repeated exposure may be necessary for clinical infection to occur.  
Frequency.GI is endemic in Western New Guinea, the Caribbean, Southern India, 
South Africa, Southeast Asia, Australia, and Brazil. In the US: Fewer than 100 
cases are reported annually, many of which are thought to be due to foreign travel. 
Mortality/Morbidity.Untreated, the disease will most likely not remit, and the 
lesions may continue to expand for years.  
Race.The racial predilection is most likely due to socioeconomic status and living 
conditions rather than a racial susceptibility.  The incidence is higher in blacks than 
in whites in the United States. The incidence is higher in natives than in Europeans 
in Western New Guinea. The incidence is higher in Hindus than in Moslems in 
India.  
Age.The highest incidence occurs in persons aged 20-40 years.  
History.The incubation period may range from 1 week to 3 months.  
Physical.Morphology.Four varieties of skin lesions occur.  
Ulcerovegetative type (most common): these lesions develop from the nodular type 
and consist of large, usually painless, spreading, exuberant ulcers. The ulcers have 
clean, friable bases with distinct, raised, rolled margins. The ulcers are typically 
beefy red in appearance and bleed easily. Autoinoculation is a common feature, 
resulting in lesions on adjacent skin.  
Nodular type: soft, often pruritic, red nodules arise at the site of inoculation and 
eventually ulcerate and present a bright red granulating surface. (A nodule may be 
mistaken for a lymph node [a pseudobubo].)  
Cicatricial type: dry ulcers evolve into cicatricial plaques and may be associated 
with lymphedema.  
Hypertrophic or verrucous type (relatively rare): this proliferative reaction with 
formation of large vegetating masses may resemble genital warts. 
Elephantiasislike swelling of the external genitalia is frequent in later-stage lesions. 
Distribution.In men, lesions may occur on the penis, the scrotum, and/or the 
glans.In women, lesions may occur on the labia minora, the mons veneris, the 
fourchette, and/or the cervix. (Cervical involvement occurs in 10% of cases.) 
Extragenital involvement.Lymphadenopathy does not occur due to GI, but lymph 
node enlargement due to secondary bacterial infection or pseudobuboes may occur. 
Extragenital involvement occurs in 6% of cases.Autoinoculation or direct 
extension may lead to involvement of the oral cavity and the gastrointestinal 
tract.Hematogenous dissemination to the spleen, the lungs, the liver, the bones, and 
the orbits may occur and occasionally results in death. 
Complications.Once the lesions have healed, extensive fibrosis; stricture 
formation; and phimosis, leading to significant deformity and functional disability, 
may occur.Elephantiasis of the genitals may occur secondary to lymphatic 
destruction. Sites of healed lesions are at risk for development of squamous or 
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basal cell carcinomas.GI may also progress to involve extragenital sites with 
potentially fatal systemic spread to the viscera. 
Lab Studies.Although isolation of C. granulomatis has been reported, the 
organism is extremely fastidious and culture is beyond the capability of most 
laboratories. The most effective method of establishing a diagnosis is direct 
visualization of the organisms within the macrophages as bipolar staining, safety 
pin–shaped intracytoplasmic inclusions, known as Donovan bodies. Tissue crush 
preparations are the most reliable method of establishing a diagnosis, although the 
organism can occasionally be visualized in biopsy specimens.Tissue should be 
obtained from the ulcer edge or base via punch biopsy, curettage, or a thin wedge. 
Next, the tissue is crushed between 2 glass slides, separated, and then air dried. A 
Wright-Giemsa or Warthin-Starry stain may be used to demonstrate the Donovan 
bodies.The organisms may be difficult to find in early or secondarily infected 
lesions or in sections stained with hematoxylin and eosin (H&E). Thin, plastic-
embedded sections may allow identification of the rod-shaped encapsulated 
organisms within the macrophages. 
Imaging Studies.If bony involvement is suspected, radiography or other imaging 
studies are indicated. 
Other Tests.Testing for other sexually transmitted diseases is warranted because 
multiple coexisting infections are not uncommon. 
Histologic Findings: The epidermis displays acanthosis at the ulcer edge, with 
pseudoepitheliomatous hyperplasia variably present. A dense dermal infiltrate of 
histiocytes and plasma cells is present, with a scattering of small neutrophilic 
abscesses. The macrophages are large and vacuolated, and they may demonstrate 
intracellular bacilli (i.e. Donovan bodies) when prepared with a Warthin-Starry or 
Wright-Giemsa stain. 
Medical Care.The recommended antibiotic is either trimethoprim-
sulfamethoxazole or doxycycline. Alternatives include ciprofloxacin, 
erythromycin, or azithromycin. The antibiotic should be given for at least a 3-week 
course and then continued until clearing is evident. If the ulcers do not respond 
within the first days of therapy, add an aminoglycoside (gentamicin 1 mg/kg IV 
q8h). Relapse may occur up to 18 months after treatment. Tetracycline is no longer 
recommended because of bacterial resistance. 
Special considerations.Pregnancy is a relative contraindication for the use of 
sulfonamides; thus, the erythromycin regimen is advised. One should strongly 
consider the addition of a parenteral aminoglycoside as well.HIV-associated GI 
may take longer to heal, and the addition of a parenteral aminoglycoside to the 
regimen is also highly recommended. 
Surgical Care.Once healed, disfiguring genital swellings may need to be 
surgically corrected. 
Prognosis.Relapse may occur up to 18 months after treatment. If untreated, the 
lesions may continue to expand for years. 
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20.6. Chlamydial Genitourinary Infections 
 
Background.Chlamydiae are small gram-negative obligate intracellular 
microorganisms that preferentially infect squamocolumnar epithelial cells. 
Chlamydia trachomatis is one of the 4 species (also including Chlamydia 
puerorum, Chlamydia psittaci, and Chlamydia pneumoniae) in the genus 
Chlamydia. C. trachomatis can be differentiated into 18 serovars (serologically 
variant strains) based on monoclonal antibody–based typing assays. Serovars A, B, 
Ba, and C are associated with trachoma (a serious eye disease that can lead to 
blindness), serovars D-K are associated with genital tract infections, and L1-L3 are 
associated with lymphogranuloma venereum ([LGV].  
Pathophysiology.The pathophysiologic mechanisms of chlamydiae are poorly 
understood at best. The initial response to infected epithelial cells is a neutrophilic 
infiltration followed by lymphocytes, macrophages, plasma cells, and eosinophilic 
invasion. The release of cytokines and interferons by the infected epithelial cell 
initializes this inflammatory cascade.  
Infection with chlamydial organisms invokes a humoral cell response, resulting in 
secretory immunoglobulin A (IgA) and circulatory immunoglobulin M (IgM) and 
immunoglobulin G (IgG) antibodies and a cellular immune response. Recent 
studies have implicated a 40-kd major outer membrane protein (MOMP) and a 60-
kd heat-shock protein (Chsp60) in the immunopathologic response, but further 
studies are needed to better understand these cell-mediated immune responses.  
Chlamydiae have a unique biphasic life cycle that is adaptable to both intracellular 
and extracellular environments. In the extracellular milieu, the so-called 
elementary body (EB) is found. EBs are metabolically inactive infectious particles; 
functionally, they are spore-type structures. Onceinside a susceptible host cell, the 
EB prevents phagosome-lysozyme fusion and then undergoes reorganization to 
form a reticulate body (RB).  
The RB synthesizes its own DNA, RNA, and proteins but requires energy in the 
form of adenosine triphosphate (ATP) from the host cell. After a sufficient amount 
of RBs have formed, some transform back into EBs, exiting the cell to infect 
others.  
Frequency. In 1995, the World Health Organization (WHO) estimated 89 million 
cases of C trachomatis infection worldwide. Chlamydia is the most commonly 
reported infectious disease in the United States - estimated at 4 million infections 
annually with prevalence rates of higher than 10% in sexually active adolescent 
females. 
Mortality/Morbidity.Although urogenital carriage of chlamydiae often is 
asymptomatic, the most common manifestation of disease is local mucosal 
inflammation associated with a discharge, urethritis in the male, and 
urethritis/vaginitis/cervicitis in the female. Chlamydia is one of the leading causes 
of pelvic inflammatory disease (PID) and infertility in women. The risk of ectopic 
pregnancy in women who have had PID is 7-10 times greater than that for women 
without a history of PID. In 15% of women who have contracted PID, chronic 
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abdominal pain is a long-term manifestation that most likely is related to pelvic 
adhesions in the ovaries and fallopian tubes.Chlamydial infections increase the risk 
for acquiring HIV infection by increasing genital mucosal inflammation.Pregnant 
women infected with chlamydia can pass the infection on to their infants during 
delivery, which may develop into chlamydial pneumonia or chlamydial 
conjunctivitis. 
Sex.Although the presence of asymptomatic infection with genitourinary 
chlamydiae can differ, acquisition is similar for both sexes.  
Age.Age factors in chlamydial genitourinary infection relate to the age of first 
sexual exposure and the frequency of exposure.  
History.C. trachomatis is a sexually transmitted microorganism responsible for a 
wide spectrum of diseases that include cervicitis, salpingitis, endometritis, 
urethritis, epididymitis, conjunctivitis, and neonatal pneumonia. In contrast to 
gonorrhea infection, most men and women who are infected are asymptomatic, 
and, therefore, diagnosis is delayed until a positive screening result or upon 
discovering a symptomatic partner. Chlamydia has been isolated in approximately 
40-60% of males presenting with non-gonococcal urethritis. Recent 
epidemiological studies indicate a high prevalence rate of asymptomatic men who 
act as a reservoir for chlamydial infections.  
Risk factors: nonwhite race, multiple sexual partners, age younger than 19 years, 
poor socioeconomic conditions, single marital status, non-barrier contraceptive 
use.Neonatal risk: conjunctivitis, neonatal pneumonia. 
 
Physical 
 
Women Men 
- Easily  endocervical bleeding 
- Mucopurulent endocervical discharge 
- Intermenstrual bleeding 
- Cervical discharge 
- Dysuria 
- Abdominal pain 
- Urethral discharge 
- Urinary frequency and/or urgency 
- Dysuria 
- Scrotal pain/tenderness 
- Perineal fullness (related to prostatitis) 
 
Complications.Reiter syndrome, a reactive arthritis secondary to an immune-
mediated response has been associated (among other things) with a primary 
chlamydial infection.It may present as asymmetric polyarthritis, urethritis, 
inflammatory eye disease, mouth ulcers, circinate balanitis, and keratoderma 
blennorrhagica. While the etiology of Reiter syndrome may not be completely 
clear, 2 clear associations are observed. It usually follows an infectious episode, 
and 80% of affected patients are human leucocyte antigen-B27 (HLA-B27)–
positive. Deeper pelvic complications in the female (PID).Potential 
infertility.Spread to the newborn during parturition. 
Lab Studies.Because of the possibility of multiple sexually transmitted infections, 
all patients with any sexually transmitted disease (STD) should be evaluated for 
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chlamydial infection because chlamydial treatment is included in the Centers for 
Disease Control and Prevention (CDC) STD treatment regimens. 
Cytologic diagnosis.This is used mainly for the diagnosis of infant inclusion 
conjunctivitis and in ocular trachoma by the demonstration of intracytoplasmic C. 
trachomatis inclusions in HeLa cells (i.e. continuously cultured carcinoma cell line 
used for tissue cultures).Cytologic diagnosis also is used to evaluate endocervical 
scrapings, but interpretation is difficult and sensitivity and specificity have been 
low. 
Isolation in cell culture.C. trachomatis grows well in a variety of cell lines (e.g. 
McCoy, HeLa cells) that can be maintained in tissue culture.Incubation in tissue 
culture is 40-72 hours, depending on the cell type and specific 
biovar.Intracytoplasmic inclusions can be detected either by Giemsa stains or by 
immunofluorescent staining with monoclonal antibodies.Because of its high 
specificity (100%) and sensitivity, cell culture is the only test that should be used 
to establish the presence or absence of infections in cases with legal implications 
such as rape or sexual abuse. 
Antigen detection and nucleic acid hybridization.By direct fluorescent antibody 
(DFA).By enzyme-linked immunosorbent assay.Detection of chlamydial ribosomal 
RNA (rRNA) by hybridization with a DNA probe. 
Advantage: this is simpler and less expensive. Most studies report sensitivities 
greater than 70% and specificities of 97-99% in populations of men and women 
with a prevalence of infection of 5% or more.  
Disadvantage: it is less sensitive when compared to tissue culture. In low-
prevalence populations (i.e.<5% infected), a highly significant proportion of 
positive test results are false-positive results. Therefore, verification of a positive 
test result is desirable in certain cases. Such verification can be by culture (e.g. a 
second non-culture test that identifies a different chlamydial antigen or nucleic acid 
sequence than the first test), a blocking antibody, or competitive probe. 
Detection of chlamydial genes by DNA amplification tests.Polymerase chain 
reaction (PCR).Ligase chain reaction (LCR).Specific chlamydial rRNA using 
transcription-mediated amplification.Both PCR and LCR detect C trachomatis in 
urine or self-administered vaginal swab specimens with sensitivity comparable to 
that with urogenital swab specimens. 
Serology.Complement fixation test.All patients with LGV or psittacosis have 
complement-fixing antibody titers of greater than 1:16. Fifteen percent of men with 
urethritis and 45% of women with endocervical infection have titers 1:16 or 
greater.Microimmunofluorescence test.This is more sensitive than complement 
fixation test. Results are positive in 99% or more of women with cervicitis and in 
80-90% of men with urethritis. 
Antibody classes.Antichlamydia IgM is uncommon in adults with genital tract 
infection. The prevalence of antichlamydia IgG is high in sexually active adults, 
even in those who do not have an active infection, and it likely is due to past 
infection. A statistically significant association exists between chlamydia-specific 
serum IgA and active disease. The sensitivity, specificity, and predictive values are 
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not high enough to make any serology clinically useful in the diagnosis of active 
disease. Therefore, chlamydial serologies are not recommended for diagnosis of 
genital tract disease.The choice of the most appropriate test depends on the clinical 
setting, the facilities available, and the relative cost. 
Medical Care.Patients should abstain from sexual intercourse for 7 days after 
single-dose therapy or until the end of a longer regimen.Patients also should refrain 
from sexual intercourse until all of their sex partners have been cured.Follow-up 
culture is not recommended after azithromycin or doxycycline therapy, but it may 
be considered in pregnancy after erythromycin or amoxicillin therapy. Non-culture 
tests should be avoided in this circumstance to avoid positive results from 
nonviable organisms. 
Prevention.Individuals who are sexually active should be aware of the risk not 
only of genitourinary chlamydia infection but also of the whole gamut of STDs 
and that the best way of avoiding infection is to practice safe sex. This means using 
appropriate barrier protection (i.e. latex condoms). 
Prognosis.Treatment failures with primary therapies are quite rare. Relapse may 
occur with alternative therapies. Reinfection is very common and is related to non-
treatment of infected sexual partners or acquisition from a new partner. 
 
 
20.7. Trichomoniasis 
 
Background.Trichomoniasis is a sexually transmitted protozoal infection caused 
by Trichomonas vaginalis. Women may be asymptomatic carriers, or they may 
experience a range of symptoms, including a mild fulminant inflammatory disease.  
Pathophysiology.T. vaginalis inhabits the vaginal and urethral tissues. In women, 
T. vaginalis is isolated from the vagina, cervix, urethra, bladder, and Bartholin and 
Skene glands. In men, the organism is isolated from the anterior urethra, external 
genitalia, prostate, epididymis, and semen. Symptoms typically occur after an 
incubation period of 4-28 days. The protozoal pathogen causes direct damage to 
the epithelium, leading to microulcerations.  
Frequency.Trichomoniasis affects approximately 180 million women worldwide. 
The frequency in Europe is similar to that of the United States. In Africa, the 
prevalence may be much higher. Trichomoniasis was present in 65% of pregnant 
women attending an antenatal clinic in South Africa.  
Mortality/Morbidity.Pregnant women infected with T. vaginalis are 30% more 
likely than uninfected women to deliver preterm or to have a low birth weight 
infant. They are 40% more likely to deliver a preterm, low birth weight 
infant.Complications in men include prostatitis, epididymitis, urethral stricture 
disease, and infertility.T. vaginalis infection is highly associated with the presence 
of other STDs, such as gonorrhea, chlamydia, and HIV. Men with coexisting 
symptomatic trichomoniasis and HIV have a 6-fold increase in the concentration of 
HIV in their semen. Theoretically, this confers an increased risk of transmission of 
HIV to their sexual partners. 
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Sex.Symptomatic trichomoniasis occurs more commonly in 
women.Trichomoniasis infection in men is less clinically apparent; 10-50% of 
infected men may be asymptomatic carriers. 
Age.Trichomoniasis is an STD; therefore, it is encountered in sexually active 
adolescents and adults.  
History.Women.Symptoms range from none in women who are asymptomatic 
carriers to a severe pelvic inflammatory disease.Common symptoms are yellow 
vaginal discharge, abnormal vaginal odor, dyspareunia, and vulvar itching.Some 
women may experience dysuria. 
Men.Symptoms range from none in men who are asymptomatic carriers to 
urethritis complicated by prostatitis.The usual incubation period for the 
development of symptomatic disease is 10 days or less.Non-gonococcal urethritis 
is the most typical clinical syndrome in men who are symptomatic.Discharge is 
present in 33-50% of men who are symptomatic and varies from purulent to 
mucoid in character.Most symptomatic infections are intermittent and self-limiting. 
Physical. Women.Purulent or homogenous vaginal discharge and vulvar or vaginal 
erythema are common.Colpitis macularis, or strawberry cervix, describes a diffuse 
or patchy macular erythematous lesion of the cervix. This is a specific sign for 
trichomoniasis but is visible in only 1-2% of cases without the aid of colposcopy. 
With colposcopy, colpitis macularis is detected in up to 45% of cases.Lower 
abdominal tenderness may be present; however, this is described in fewer than 
10% of patients. If this occurs, coexisting salpingitis or an intra-abdominal 
pathology is possible.Coexisting Neisseria gonorrhea infection, candidiasis, and 
bacterial vaginosis are common and may produce a mixed clinical picture. 
Men.The findings on physical examination are generally unremarkable unless the 
infection is complicated. It may be associated with local inflammatory states, 
including balanitis and balanoposthitis.Physical findings of epididymitis and 
prostatitis also may occur. 
Lab Studies.Laboratory studies aid in demonstration of the T. vaginalis organism 
and are used to differentiate the infection from other causes of vaginitis.Bedside 
laboratory studies.The vaginal pH measured on Nitrazine paper is elevated. 
Usually, the pH is above 5.0, and it may be as high as 6.0. Bacterial vaginosis or 
atrophic vaginitis also may cause elevation in the vaginal pH.Upon application of 
10% potassium hydroxide to a vaginal swab sample in the potassium hydroxide 
amine test, a fishy odor is released, which can suggest trichomoniasis or bacterial 
vaginosis. 
Saline microscopic examination.Obtaining a vaginal swab sample for saline wet 
mount evaluation is an easy, valuable, and economical tool for obtaining 
diagnosis.Trichomonads, which are ovoid-shaped parasites, are slightly larger than 
polymorphonuclear lymphocytes (PMNs) and may be identified by their ameboid 
mobility. Trichomonads cause an inflammatory reaction; therefore, a large number 
of PMNs usually are present, and this number correlates with the severity of the 
infection.A saline wet preparation is positive for identifying trichomonads in 
approximately 60% of the cases. 
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Papanicolaou test.Trichomonads may be viewed on Papanicolaou (Pap) test, but 
this test has a sensitivity of only 60-70% when compared to the use of saline 
microscopy.False-positive results are common with this technique. 
Cultures.Incubate the cultures anaerobically.Growth is detected within 48 hours 
and has a sensitivity of 95%.Culture is important in establishing the diagnosis in 
men because the wet preparation findings are often negative. 
Polymerase chain reaction (PCR) methods reportedly have high sensitivity and 
specificity (97% and 98%, respectively). 
Medical Care.Systemic treatment is important to ensure a cure because 
trichomoniasis is an infection of multiple sites (e.g. vaginal epithelium, Skene 
glands, Bartholin glands, urethra).Oral metronidazole is the treatment of choice 
and is demonstrated in multiple studies to be superior in efficacy when compared 
to intravaginal treatment. Treatment failures may require a high-dose 
metronidazole regimen. 
Diet.Instruct the patient to avoid alcohol while taking metronidazole because it 
may cause a disulfiram-like reaction. 
Further Outpatient Care.Sexual partners of infected patients must be treated to 
prevent reinfection.Consider empiric treatment of other STDs that frequently 
coexist with trichomoniasis.Advise the patient to avoid intercourse until therapy is 
complete and the patientand partner are asymptomatic. 
Prevention.Condoms and oral contraceptives may protect against transmission of 
trichomoniasis. 
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